<SEC-DOCUMENT>0000950170-23-009766.txt : 20230324
<SEC-HEADER>0000950170-23-009766.hdr.sgml : 20230324
<ACCEPTANCE-DATETIME>20230324165506
ACCESSION NUMBER:		0000950170-23-009766
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230324
DATE AS OF CHANGE:		20230324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAIA Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001878313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41455
		FILM NUMBER:		23760565

	BUSINESS ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
		BUSINESS PHONE:		312-416-8592

	MAIL ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>maia-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-24T15:52:28.6764+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:maia="http://www.maiabiotechnology.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_32d30681-9f36-4826-9171-c8006f97a233" name="us-gaap:CommitmentsAndContingencies" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6762082b-75c3-405b-b2b0-26f82bc658fb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_82d70279-b727-4e18-b4ca-8c7bda2f0d39" unitRef="U_shares" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e72148a5-95e0-4c93-8975-0a5b223af98e" name="us-gaap:PreferredStockValue" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d4dbe32f-1df1-43a5-8162-239e9214a75a" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" contextRef="C_de81be98-77ce-42a7-8aa0-3c3af1588a89">http://fasb.org/us-gaap/2022#Liabilities</ix:nonNumeric><ix:nonNumeric id="F_5a7219ee-3121-409b-8a87-233effeb520e" name="dei:DocumentFiscalPeriodFocus" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9">FY</ix:nonNumeric><ix:nonFraction id="F_cd9deaf0-1d8f-4cfa-ae75-53003ee3c1ee" name="us-gaap:CommitmentsAndContingencies" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric id="F_78eba3d7-e77c-40a4-a35a-d810414a9501" name="dei:EntityCentralIndexKey" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9">0001878313</ix:nonNumeric><ix:nonFraction id="F_e8f1a25c-5a33-4074-8478-3135ed3b9513" name="us-gaap:PreferredStockValue" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_e0722739-6efe-43f2-8b8c-82b38a8abf92" name="dei:AmendmentFlag" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="maia-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_bd92e2f2-afa8-429c-8e71-c820d8b523b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dddb3b8-9562-481a-8538-c27da39213ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdf96b15-9f52-42b0-af98-607e4a595a5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84f4e80f-cc78-40c3-9fa8-08279e8d87cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:OfferingAndOverallotmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65e57920-9bea-4275-bd59-c0a66b11eb61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:RatchetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d323e1e-91fa-4adc-b0b9-fa95c2a916da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05ed1f6a-7bd5-44e6-a939-0de1e93bb2f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33263a2e-646d-4256-82aa-1223f29184cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ed89264-6427-4629-a39a-d1eb18f5c44a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a3d4bbe-f995-4369-a38d-55c3e19f2acd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0d9ded2-a90c-48e6-a41e-23f182621fc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DgdPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ceb3f2a5-5c4a-48e7-96ef-1bd506bd16cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70eeaef3-d979-4694-830c-aa004fc65cad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfdd4c68-cf69-49c9-921b-9232d6f85520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab7d89f5-c0a9-4cc8-988f-dd865cac4e4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96904691-c19d-41d7-b74c-e304c0e6af45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18f191ce-f487-4a92-a1ad-96c619694078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5aa0a4a7-169f-471d-837f-b409f7c4b858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_514ade27-e387-4d84-83c5-c59113d65690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9fb6a9b-9be5-47bf-a4da-ec226ccb941f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee00796c-ffd3-46f4-93c1-8db0ae1a964e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51ce7740-df5e-458e-9aca-0e98ee73acc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:RatchetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e7436f3-5354-4afa-bd19-4dded9a9e390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a905e51-4f6b-438a-9ff9-32f5ff3fbc1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59d4a5fa-7563-4679-8962-c0917ed9d470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f426df1f-3c59-401e-952f-443722bf8259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e144005c-eb16-4637-a828-601934ff5985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_480dc74f-1404-498f-8b42-20bedaaa1ecf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed9fcd67-e733-47c1-804f-2d29703a3a3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7c6a87c-7d18-4cd1-89df-759036b167f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fdfbd9c-c879-495d-a18d-f5b6252af2fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46d64219-b005-46b4-9a54-af5112c896b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:LeighAnnDurantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cab8d345-5f87-42f4-95e4-921bbed2dd3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faeafa90-e78a-4213-beef-48ac41889fed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77674401-ed32-4efc-bc01-fa0a205bd5c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_704afa9b-4318-432b-94d0-dd9ac96a4003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e1ca0e3-7225-4c0e-aa21-a8c07456a8d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1491750e-595c-458c-b2bc-3af9c7704855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:RatchetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79f9be5c-c6c9-4e62-8570-7a5b4ef49378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da576c98-2bde-4e20-b38d-a9c79bec3a95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5c5e8e4-533d-4dc8-81c1-c4f505de146c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2dbed72-0d93-4962-be44-54187d716c80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77bae37b-9232-4726-80bf-d4346dbdd5c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af4145b4-83cc-4b5a-8c80-2f54f89c9863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68298e68-92ff-4876-a80a-e4764bf1eb5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25edec4e-51a9-4cf7-a863-6a4423d5e981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90df5ec5-d2d5-410c-ae2a-6982581d43c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3cb958a-ca61-46c6-a20f-0990720362c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b89f176d-a5ef-4374-a64e-fbce690b3f42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_093f44a4-068c-4d51-9096-9822ca581146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24d517c1-101e-49f7-858d-15b0bb2079e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95ea31ca-fbf2-45cf-921a-af532996efec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ac28de6-5d6a-4cc2-ac1f-b7f9d7ebb27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a998ab06-ea16-418f-8f43-b74df1888ac3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38807a13-8dd9-4c2d-b8c8-cfc13aebab4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f949a11-176b-4ad1-9d69-a21194d19325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10dbc5ec-42be-4b85-9613-2d111b13181f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6fe62fc-f09a-4c0a-822b-9375cd7875df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4448ed4-2b54-4235-9206-c0b8e343fb1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60690a56-b071-4f7d-a346-3c1b2b2672ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9685ca74-0b09-41fe-a647-8f730fad5ee4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c7dbf97-a62c-4354-b7ac-212c85adff76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbf5e914-0593-48ce-a8d1-7cde11503245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04cf05b4-4370-4979-8fd8-aad3bb1d1cf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dff99c3-0b2d-4940-9d28-68bd8d158e84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PppLoanProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3f721fc-ed4b-48d0-82bf-0755ef0a4134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03e3bd00-bb23-45f7-a4b4-e0c48e0a00f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6992df71-0104-43df-abe1-8e43fcfa0c86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60bc5fdb-609a-4b8d-8539-569a6372e484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08b3f13c-8494-4e8a-bac0-e6e09f3faee0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d8490e1-93cd-41ed-bc23-ad484a70d024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbddc662-f865-4f07-88a7-237f7cbd58b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8de3a275-a1ef-4daa-8115-7bf33cf32d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6b76190-87b3-4e35-a133-5acf6c22a4fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdba1f1c-9953-4f89-8181-9aff72ad45de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_850a921a-9604-4c05-bc2c-f089ad5556e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dd9ecfb-e5be-406a-bca6-0d22818e6d05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e31173a7-a2dc-4f27-be64-82bc649b47d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6039b578-eeec-4f91-947f-34335f15d319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f14d921e-d893-48a9-b93d-6895d30a125f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6171e5f5-549d-4e50-9be8-e0a4a67b59bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3a2c7f8-d558-4863-ba84-7247dacc03ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fed35c89-2357-48b2-9d4e-1962b1feedbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa57afe6-0ae3-4ae8-8716-1ebfc8bf9e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e567c99-be4a-46b9-9a9f-31913733c870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:MAIADrugDevelopmentCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d418fc52-98ec-47f5-95c9-f00cb3c88d3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b86fb584-5f3d-48eb-bd47-338774b042f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dfe66b4-3a5a-4059-86f7-1adc0a69cd08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyOneWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84c3fdea-c2ec-4933-8499-ef4172df40e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">maia:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93dbd88f-ee4a-4a09-9905-9f43b0232942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b0c05a1-2ef5-406c-a235-22c40e3c2880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2369b8a-a97d-441e-a153-ff5a9dd3b27f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8c711ae-2a67-477b-94f2-7ea7a9761789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c20c208-c8e0-40af-b818-86f3f673ef3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c40ba4b1-8a23-45d1-b399-8ff938660566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dc27fee-372c-4000-a17a-fd220345e379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdce226d-2206-4c50-b8bb-8a3e0648506c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0c99f8c-3025-49f9-9ce1-af3347da6e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e133a48-7bca-4524-bf21-ae7de81db87a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_549c2a01-f299-4da3-bbae-8c582a89f09f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_460c12ea-f2c0-4902-aaba-b209608b801a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bfe2412-70aa-498d-b73f-b58ae522d52e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a801211c-4f23-4b06-8cc4-6340d12cffcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9c0194e-ae7a-4f5c-a38a-cbedc013e926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cf26860-1e88-4777-a873-11663c855cc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bda30473-24b2-49f5-aec5-68d7d75fc2b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2e664bd-7357-485e-b4fb-bf293169d186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f508854b-0a5d-48f7-9b76-4f60049b5004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d9234a1-5f51-4764-b7e4-a62ca84ba633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac8db0a5-2d96-4c6b-a190-68c3fc94e6a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35df104b-b405-4915-a247-efcae1451c3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_123bb045-1787-4e92-86ee-97af8a0fc791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-16</xbrli:startDate><xbrli:endDate>2023-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aca59814-cbfd-4366-be06-42a5a0ba6590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82d70279-b727-4e18-b4ca-8c7bda2f0d39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">maia:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f633671-f593-4b41-8b13-f542f6aec2d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd2957a7-98eb-4f84-87e4-b97ec6293ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c664d98-02a0-4f5a-946c-51e9b9611596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_985a2e45-6950-4f45-9fed-bb59ec5581a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf7f6aa9-8e0b-41e9-900f-25e5d88817a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2d52605-606c-4298-a0ed-01a4e1641f08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_139f3834-5a5f-48da-b7b6-95728dcce439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cbd6772-af2d-432e-9e5b-d1b10fd09c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c75159f4-1e2f-4115-964f-af704eb8949f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4e7d396-2e2a-4ecd-bda9-8259234860d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07581902-1fc3-4f0d-9e04-a8dbb844ead0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_349fb6e1-da72-4c3d-8eae-a1f0bc375520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7447a51d-1b53-4834-a837-fd4e4d4818a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-16</xbrli:startDate><xbrli:endDate>2023-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fba4a25-8b91-4e2b-9498-b481e7e735a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandEighteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ad7911b-4b7a-4316-b95d-e54b9310b0df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PppLoanProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d11de7f-4020-4686-9774-064ef0b908c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94951a0e-9218-4969-993f-e925194bc10f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_681b3cde-40ae-48db-9701-970b57fafca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_257832a6-de0c-47b0-b609-38c350dcd89a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3540e61-4c81-4a9e-8519-75d8edfbd550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2703e6a6-9c13-46c2-9da9-deaa17ee8d34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10e99315-c20f-4d44-875f-39b50152cb08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13bf0128-a070-4b47-825e-8161c256c563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7d464db-7209-4119-bc09-50cf74d2d6d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c19f9601-2487-4519-b741-1a2bc336d1b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b94cac1-12b3-47a8-8cee-4ddd38a0ca14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-13</xbrli:startDate><xbrli:endDate>2021-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2767d21-f84d-45dc-805e-c26596b84ec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1c341f2-a782-415b-b128-1db37d526768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6643c0e3-8b98-4c5e-bc38-a4ac458d4842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71ce86d1-a364-40dd-8e50-83d2857961c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34634fe2-cf34-4270-bc4d-2bdee5324351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fd580ec-da61-4243-8bbe-66e3640f920c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80e5dbc0-3203-4a49-8843-3da9d91fc340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6225085e-6353-4624-b82c-bec3de902a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_daea18c7-8f9f-40db-a949-f62882d10b13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4078271a-c8fb-4d34-a59a-234a262797bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a095884-7271-41a9-990e-c05d7154216c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0fc63fe-6219-4ed8-9fd0-353fd3128c57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c159ace3-ffb0-4d4d-8a15-d426dd48bb91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cc4ed46-ee40-4446-afb7-6c466d1a0315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e96f6c1-8fcb-4e45-849b-c83a8f2330e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99f06e4c-f0a7-4618-91e5-f9e6e61a5eb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75c413f9-8ba4-436c-9bf0-776a3437584a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49140d15-f3a7-4a2b-a015-cacc8dec9460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_432d777f-5193-4a7a-bc9c-bd381ee50b47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83947522-5d4a-4233-ab67-fb6efdf06f08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4856ea2-7771-4d18-b27e-ad041dc17195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1389048c-24c0-4a62-aaa4-a2b74693dfae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b04addab-578d-403a-ac75-910316d401b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8986a13-566d-41de-a913-47e267f84b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d07afd76-c668-4a14-b0f2-d16a7a6bc509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0838c5ab-fead-4553-91e0-e9194daa7208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_538b838f-72d0-42ef-a3b6-35b1fbd33513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d10bf70-b796-41c1-99f6-677d11e3838c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea377e52-e368-402f-8f8d-1865b3d62026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-13</xbrli:startDate><xbrli:endDate>2021-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b52893ed-19d1-4467-abfb-baf9e1042428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PppLoanProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bfefa67-16ca-409f-bb23-cdd798adfd46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af7a9610-410c-4458-b075-3916099f847e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:MAIADrugDevelopmentCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10935678-cd01-4042-9bb0-148e441856b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de81be98-77ce-42a7-8aa0-3c3af1588a89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f7aff38-36bd-4981-a8df-ded8085b1fcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea85c9c9-8fa4-44f7-9253-844104dacb55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af796981-4cb4-490f-8a9b-07137ac824a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed6afaaf-47e2-4703-8898-9a173c0212f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c7f2e44-3c3e-49bc-8220-a31f305d9878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fff227d5-244a-4bcb-80ea-d5ce7a3c9fdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba69f1b4-b400-41b9-83cb-6beed2abe583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_960ce175-49b7-4d64-b47c-1ecd446c52b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66a04226-000c-48ad-8295-b5d5efd519ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_311a1cb3-a35e-4309-a95b-0e6e22c3377e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_b4fe6108-af74-46ca-8ef1-45e03a696b6d" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5a7219ee-3121-409b-8a87-233effeb520e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fiscal year</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_59974d73-9209-4eff-bb9b-a553d5d8b115" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_349cbd3b-b6b4-4e80-964c-68e8a48a5a41" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9cbbe513-84c1-491b-9108-ec95124609a1" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_e96c8853-91af-4129-bc25-c10790373a50" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f11ffb3-f55a-47e8-bc35-bc9e6ed3837c" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-41455</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bf19a59a-42f4-4211-a9cf-bf149a980ab6" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA BIOTECHNOLOGY, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a44fd53-4be3-41f9-b73b-60231f8e9dff" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a70872c-6780-44a2-8330-4d9e59e8b061" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83-1495913</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad2e18e9-9b98-464b-a57f-bd29018e4569" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">444 West Lake Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eec1b04c-8f9f-46be-ac8c-5c770c219397" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 1700</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4b6c51cc-97b7-4e34-94d5-f37fba65e569" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chicago</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d6361e0-dcd7-4656-84d0-5b3f4d64b9d3" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IL</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_908e12dc-763b-4b76-bb8c-da782231b5f6" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">06060</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e05d6970-7a9e-44d6-9c13-9b3e70e54db9" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">312</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d74b0ca-6bfa-4340-8ecc-95df2c151f90" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">416-8592</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      </span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0e46e08-aafe-4ac2-9789-fdf1e32fafe0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55d03134-d0cb-4b9c-ac65-9b733248a93a" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e5a4471-2b51-4124-ad55-034e493b819b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NYSE</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;American</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a92ad95-3d7b-4058-9012-6d5b033c350c" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_315add4e-e167-42a4-be1d-5e46478d7a09" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3db64c4-932c-47eb-8fe1-8c0c4e2125d0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_571b1345-2737-4aa5-b869-ba2a52adc873" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.12%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:1.9pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9b8e5b93-dec5-4864-bebc-8f0f97a93ccb" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_33181da3-9f92-48e6-94f6-e540497c921e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:1.9pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_358bbcf9-ac21-46e2-9c90-da2c07ce36c3" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_c5ca9eb5-49ea-429f-ab63-83e3f1d4c6d9" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityExTransitionPeriod" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_d10ed92c-cb60-48e2-b67b-cdd789a5bd31" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No</span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_0f92bb62-aedb-47de-bfd1-606021b5e67f" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2022, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbf99ce6-0856-4743-a0e6-10f9fa7548ab" contextRef="C_4d10bf70-b796-41c1-99f6-677d11e3838c" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The registrant's shares of common stock commenced trading on  NYSE American on July 28, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 22, 2023 was </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86cf2085-6ca0-4722-a11a-8c55de128a0a" contextRef="C_a2369b8a-a97d-441e-a153-ff5a9dd3b27f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,996,404</ix:nonFraction></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;">&#160;</p>
  <div><ix:nonNumeric id="F_2cb85d0b-a1fd-4c15-8d0e-83205fc6359d" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#x2019;s definitive proxy statement for the annual stockholder meeting to be held in 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K as noted herein. The registrant intends to file its proxy statement within 120 days after its fiscal year end.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.093%;"></td>
    <td style="width:82.824%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9c"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item12"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as &#34;believe,&#34; &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;could,&#34; &#34;would,&#34; &#34;expect,&#34; &#34;objective,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;seek,&#34; &#34;grow,&#34; &#34;target,&#34; &#34;if,&#34; and similar expressions intended to identify forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled &#x201c;Risk Factors&#x201d; set forth in Part I, Item 1A of this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission (the &#34;SEC&#34;). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Annual Report on Form 10-K may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there is substantial doubt regarding our ability to continue as a going concern. We will need substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our drug candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to receive FDA clearance for clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to secure clinical sites, enroll patients, and initiate clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our drug candidates, and other positive results;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success, cost and timing of our development activities, preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and focus of our future clinical trials, and the reporting of data from those trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to commercializing our drug candidates, if approved;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any drug candidates for which we obtain approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain key scientific and clinical personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reliance on third parties to conduct clinical trials of our drug candidates, and for the manufacture of our drug candidates for preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish our own manufacturing facilities domestically;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to expand our drug candidates into additional indications and patient populations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the beneficial characteristics, safety and efficacy of our drug candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments in the United States and other jurisdictions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our drug candidates, and any related restrictions, limitations and/or warnings in the label of any approved drug candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to the further development and manufacturing of our drug candidates, including additional indications for which we may pursue;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> our plans and ability to obtain or protect intellectual property rights;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential claims relating to our intellectual property.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10&#x2011;K. You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">required by law, we do not intend to update any of these forward-looking statements after the date of this Annual Report on Form 10-K or to conform these statements to actual results or revised expectations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because some of these risks and uncertainties cannot be predicted or quantified and may be beyond our control, you should read this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in Delaware in August 2018 as a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. We completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved on March 1, 2022, by the Australian Regulatory Agency - Bellberry Human Research Ethics Committee. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia. In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, Phase 2 clinical trial evaluating THIO in patients with NSCLC. Patients with advanced Non-Small Cell Lung Cancer (NSCLC) will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo&#174; (cemiplimab) manufactured and commercialized by Regeneron. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. Cemiplimab has been approved in the United States and the rest of the world for multiple cancer indications, including NSCLC. In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study. In return, we have granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period. Based on the clinical data we aim to generate by the THIO-101 trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA. In addition, in the Fourth Quarter of 2023, we plan to initiate a Phase 2 clinical trial in multiple solid tumor indications of THIO administered in sequence with Anti-PD-1 or Anti-PD-L1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed an initial public offering on August 1, 2022 and our shares of common stock commenced trading on NYSE<br />American under the ticker symbol &#34;MAIA&#x201d; on July 28, 2022. We sold 2,000,000 shares of common stock at $5 per share for<br />gross proceeds of $10,000,000 in the initial public offering. On August 3, 2022, we sold an additional 300,000 shares of common<br />stock at $5 per share for gross proceeds of $1,500,000 upon the full exercise of the underwriter&#x2019;s overallotment option. After<br />deducting $2,406,170 for cash issuance costs, net proceeds from the initial public offering, including the overallotment, were<br />$9,093,830.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Lead Product Candidate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO (6-thio-dG or 6-thio-2&#x2019;-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, our research team discovered that THIO produced telomere modifications and disruption, which ultimately induced cancer-specific innate and adaptive immune responses against immunologically &#x201c;cold&#x201d; tumors or tumor types that were unresponsive to immune checkpoint inhibitors. This hypothesis was tested and demonstrated in syngeneic and humanized mouse models. THIO administered to mice in low doses and followed by an immune-checkpoint inhibiting agent, such as an anti-PD-1 or anti-PD-L1 compound, induced complete tumor regression with no tumor recurrence during the 14 weeks of observation. Further, no toxicities were reported in the tumor-free mice. These new findings were published in the highly reputable, peer-reviewed research scientific journal, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer Cell </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in July 2020. Based on these recent discoveries, a new therapeutic approach has been designed to advance THIO into a Phase 2 clinical trial (THIO-101) in patients with advanced NSCLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our regulatory strategy includes a planned filing of an Investigational New Drug application (IND) with the U.S. FDA in the near future. This would allow U.S. sites to participate in the THIO-101 NSCLC trial. The human safety data generated in Australia and Europe would constitute the basis of the IND application. Although we plan to rely solely on the safety and efficacy data we generate in our own clinical trials in support of our planned NDA filing, we take added confidence in the potential tolerability of THIO in light of the fact that the THIO doses we plan to test represent a range of 4 to 40 times lower than the maximum tolerated dose tested in the earlier clinical trials sponsored by the National Cancer Institute in the 1970s. The planned THIO-101 phase 2 trial is intended to be a proof-of-concept study that may be modified depending on interim results to include both primary and secondary endpoints and be consistent with previously approved cancer treatments. In September 2022, we submitted a pre-IND meeting request to FDA to discuss, among other elements, the existing non-clinical and clinical data to support the conduct of our planned THIO-101 phase 2 trial under an IND to include patients from the United States. MAIA received feedback in-line with the proposed plans from the FDA regarding its manufacturing, preclinical and clinical development plan. MAIA also obtained guidance from the FDA on the assessment of its safety and efficacy in the THIO-101 Phase 2 trial that will be incorporated in the U.S. IND application. MAIA plans to file its U.S. IND in the first half of 2023 and commence enrolling patients in the U.S. in the second half of 2023. Based on the clinical data we aim to generate in the THIO-101 study and assuming THIO achieves its intended clinical effect with a manageable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety profile at one of the doses tested in the study, we expect to seek early FDA guidance and agreement for using this clinical trial as basis for requesting an accelerated approval. The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology will still be required to conduct studies to confirm the anticipated clinical benefit. These studies are known as confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. The FDA&#x2019;s accelerated approval pathway, even if initially granted, does not guarantee an accelerated review or marketing approval by the FDA. The THIO-101 study protocol may need to be amended to increase the number of patients enrolled, undergo modification of the statistical analysis or change in the trial design and/or primary endpoints.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Science--Driven Telomere Targeting Approach</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomeres are regions of repetitive DNA nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes in cells. THIO&#x2019;s mechanism of action comprises telomere targeting and induction of anti-cancer immunogenicity. The enzyme telomerase recognizes THIO&#x2019;s metabolite formed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in situ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and incorporates it into the structure of the cancer cell&#x2019;s telomeres, creating a faulty structure, which breaks apart the telomere spatial structure. As a result, the THIO-modified telomeric structure unwinds, recognized as DNA damage, and the cancer cells die. We believe THIO transforms &#x201c;cold&#x201d; tumors into &#x201c;hot&#x201d; tumors rendering them responsive to immunotherapy (checkpoint inhibitors) and this process takes place promptly within 24 to 72 hours. We also believe we can improve the immunotherapy efficacy and we can restore the immunotherapy efficacy in patients who have progressed or developed resistance to prior immunotherapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomere maintenance is a fundamental biologic process for cell proliferation and resilience in cancer cells, and thus represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in a majority of human cancer cells (over 85% in the aggregate), across various tumor types. In contrast, its activity is detected in less than 1% of normal cells. THIO has only been shown to be active in cancer cells that are telomerase positive (TERT+) and actively dividing. Cancer cells are constantly telomerase positive due to an uncontrolled division process, while a relatively small number of normal cells are telomerase positive only transiently. Therefore, THIO activity is expected to be highly specific to cancer cells versus normal cells. Cancer-specific disturbance of telomeric structure, mediated by telomerase, is likely to lead to disruption in the cell cycle, followed by a very rapid and telomere-length independent cell death. THIO was observed in preliminary in vitro and in vivo studies to induce cancer-specific telomere disruption, by using the enzyme telomerase which differentiates THIO from all other available cancer therapies currently in clinical use. We are also currently developing potential next-generation small molecule telomere modifying agents with the goal of identifying additional proprietary drug candidates, across multiple cancer types.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Second Generation Molecule Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our THIO program drives our development pipeline of second-generation telomere targeting agents. We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with increased anticancer activity. This program may also allow us to strengthen our patent portfolio. Our current 2nd-generation pipeline of potential telomere-targeting agents includes seven compounds that have successfully undergone </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inhibitory testing in five cancer models. The data from those studies showed a significantly lower 50% inhibitory concentration (IC50) for those compounds compared to THIO, as reflected in the following figure:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.19%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:8.294%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:8.743%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.376%;"></td>
    <td style="width:12.354%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:8.638%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:10.238%;"></td>
    <td style="width:1.005%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="21" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IC50, &#xb5;M</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cell Lines</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compound ID</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MC38</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LLC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hep55- 1C</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">H2081</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HEK293</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO(6 thio dG)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.92</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compound #5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.34</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.34</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.02</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compound #6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.34</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.34</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compound #11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.36</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.44</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.63</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compound #12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.84</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.77</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.61</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IC50 is the half maximal inhibitory concentration, and it is a measure of the potency of a substance in inhibiting a specific biological or biochemical function, such as cell proliferation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cell lines: MC38, LLC, Hep55-1C, H2081,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and HEK293 are Non-Small Cell Lung Carcinoma, Colorectal, Hepatocellular carcinoma, Small Cell Lung Carcinoma, and Immortalized Human Kidney cell line, respectively. *- Data unavailable</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The figures below represent dose-response curves from which IC50 values were derived for second generation compounds #5 (X97848), and #12 (X97855) in HEK293 cells:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_0.jpg" alt="img118615358_0.jpg" style="width:307px;height:206px;" /><img src="img118615358_1.jpg" alt="img118615358_1.jpg" style="width:310px;height:208px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The graph below demonstrates the dose response curves for our number five next generation compound, designated as 6S-dG-dimer, in ovarian cancer-derived cell line CoC1/DDP, in comparison with cisplatin (current standard of care in this setting). The corresponding IC50 values are shown next to the plot.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_2.jpg" alt="img118615358_2.jpg" style="width:624px;height:252px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In mid-January 2023, MAIA nominated one lead new molecular entity candidate (designated as MAIA-2021-20) and one back-up new molecular entity candidate (MAIA-2022-12) for further advancement into preclinical GLP-toxicity and other studies, and may advance one of these candidates into human clinical trials upon completion of the required preclinical evaluations. MAIA also has filed a broad provisional patent application covering the composition of matter for the new telomere-targeting molecules in the fourth quarter of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create a second generation of THIO-like compounds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,103,125,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OUR PIPELINE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,103,125,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pipeline includes several potential targeted immuno-oncology candidates for relapsed and refractory cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_3.jpg" alt="img118615358_3.jpg" style="width:589px;height:282px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pipeline products are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved in the sought-after indication or will meet the developmental milestones set forth above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules. Our initial focus is to efficiently advance our Phase 2 clinical program with THIO in sequential combination with cemiplimab. Ultimately, our goal would be to position THIO as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer. To date, THIO has never been tested in clinical trials in combination with any check-point inhibitor. The key elements of our strategy are to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance our existing clinical programs, including seeking accelerated approval for THIO in NSCLC as a tumor mass-reducing and simultaneously immune system priming agent administered in advance of the immune-activating agent, cemiplimab for treatment of advanced NSCLC, and ultimately, as a cancer treatment foundation in multiple indications and geographies. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Broaden the clinical development of THIO by exploring synergistic administration prior to other standard-of care immune-therapies including cell therapy. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Develop a franchise of telomere-targeting cancer treatments.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leverage our regulatory strategy to acquire additional human data faster outside U.S. for other cancer indications. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selectively enter into strategic collaborations with pharmaceutical and biotechnology companies that have immune activating therapies.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expand our existing intellectual property portfolio.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will face certain challenges in implementing our business strategy including, among others, the fact that earlier development of THIO was not commercially pursued. Even if THIO successfully advances through clinical studies and towards approval for use, we may face early competition from generic alternatives to THIO after expiration of any applicable regulatory exclusivities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Market Opportunity and Unmet Medical Need</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most cancer cells are telomerase positive (TERT+), including 73% to 100% of primary human cancers dependent upon tumor type, indicating a significant potential therapeutic utilization for THIO across most of the tumor types. We believe successful targeting of telomeres in TERT+ cancers may represent a significant potential for broad therapeutic utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.954%;"></td>
    <td style="width:1.769%;"></td>
    <td style="width:9.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.759%;"></td>
    <td style="width:34.759%;"></td>
    <td style="width:1.759%;"></td>
    <td style="width:9.0%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor Type</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERT(+)</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor Type</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERT(+)</span></p></td>
    <td style="background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Small Cell Lung Cancer (NSCLC)</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pancreatic Cancer</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Colorectal (CRC)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82-89%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Small Cell Lung Cancer (SCLC)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hepatocellular Carcinoma (HCC)</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79-86%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ovarian Cancer</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Breast Cancer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Renal Cell Carcinoma (RCC)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prostate Cancer</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Glioblastoma Multiforme (GBM)</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bladder Cancer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neuroblastoma</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">head &amp; Neck Squamous Cell Carcinoma (HNSCC)</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">`86%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lymphoma (high grade)</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gastric Cancer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chronic Myeloid Leukemia (CML)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Melanoma</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83-86%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chronic Lymphocytic Leukemia (CLL)</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">`57%</span></p></td>
    <td style="background-color:rgba(235,236,235,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cervical Cancer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acute Myeloid Leukemia (AML)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sources: A Survey of Telomerase Activity in Human Cancer &#x2013; JW Shay, S Bacchetti &#x2013; European Journal of Cancer, 33,5,787-791, 1997. Telomerase Active in Human Liver Tissues; H Tahara, et al; Cancer Research 55, 2734-2736 1995; Highly /aggressive Metastatic Melanoma Cell Unable to Maintain Telomere Length; N Viceconte et al; Cell Reports 2017; and Clinical Relevance of Telomerase Status and Telomerase Activity in Colorectal Cancer; T Femandez et al; PLOS one 2016</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial development program will focus on Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC) and Small Cell Lung Cancer (SCLC) in areas of clear unmet need and/or areas with deficient immunotherapy effect within each tumor type. Each tumor type and area of unmet or undermet needs represent significant clinical and commercial opportunity. We believe that THIO offers a desirable profile with significant commercial potential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.861%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.944%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.944%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.944%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.944%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.944%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor Type</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incidence</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 (M)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prevalence</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 (M)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mortality</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 (M)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 ($B)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 ($B)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Small Cell Lung Cancer</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Breast</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prostate</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.8</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Colorectal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liver</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Small Cell Lung Cancer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sources: WHO; Global Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below reflects the current market for check-point inhibitors because there is no current market for THIO-like molecules. The years in the indication columns on the table below signify the timing of FDA approval in the US for the clinical indications of interest. Because the key element of our strategy is to develop THIO to work in combination with check-point inhibitors, if THIO is eventually approved by the FDA for use in conjunction with check-point inhibitors, this table provides a high-level understanding of the potential market for THIO in that combination. There is no assurance, however, that any potential market for THIO would follow the current landscape for checkpoint inhibitor franchises.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current Landscape of Checkpoint Inhibitor Franchises</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.544%;"></td>
    <td style="width:17.519%;"></td>
    <td style="width:9.459%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:8.644%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:6.698%;"></td>
    <td style="width:6.096%;"></td>
    <td style="width:7.041%;"></td>
    <td style="width:13.999%;"></td>
   </tr>
   <tr style="height:17.2pt;">
    <td rowspan="2" style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug</span></p></td>
    <td rowspan="2" style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</span></p></td>
    <td rowspan="2" style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($B)</span></p></td>
    <td rowspan="2" style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td rowspan="2" style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indications</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(tumor</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">types)</span></p></td>
    <td rowspan="2" style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NSCLC</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCLC</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRC</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HCC</span></p></td>
   </tr>
   <tr style="height:17.15pt;">
    <td colspan="4" style="background-color:rgba(29,66,88,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(247,248,249,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year of FDA Approval</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.544%;"></td>
    <td style="width:17.519%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:8.458%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:7.643%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:6.698%;"></td>
    <td style="width:6.096%;"></td>
    <td style="width:7.041%;"></td>
    <td style="width:13.999%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KEYTRUDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(pembrolizumab)</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Merck</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.2</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2015</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017</span></p></td>
    <td style="border-top:0.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OPDIVO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(nivolumab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BMS / Ono</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2015</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TECENTRIQ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(atezolizumab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Genentech / Roche</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2016</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IMFINZI</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(durvalumab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AstraZeneca</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TYVYT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(sintilimab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eli Lilly / Innovent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIBTAYO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(cemiplimab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regeneron</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BAVENCIO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(avelumab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pfizer / Merck AG</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TBD </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(tislelizumab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Novartis / BeiGene</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JEMPERLI </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(dostarlimab)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.25pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;border-right:0.25pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Source: BioMed Tracker 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to obtain, maintain and enforce patent protection wherever appropriate for our product candidates, formulations, processes, methods and any other proprietary technologies, and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our practice is to actively seek to obtain, where appropriate, intellectual property protection for our current product candidates and any future product candidates, proprietary information, and proprietary technology through a combination of patents, protection of proprietary know-how and trade secrets, and contractual arrangements, both in the United States and abroad. However, full patent protection may not provide us with complete protection against competitors who may seek to circumvent our intellectual property. Our success will depend on the skills, knowledge, experience and know-how of our management research and development personnel, as well as that of our advisors, consultants, and other contractors. To help protect our proprietary know-how that is not patentable, we seek to put in place appropriate internal policies for the management of confidential information requiring all our employees, consultants, advisors, and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information, and which will require disclosure and assignment to us of the ideas, developments, discoveries, and inventions important to our business. See &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors &#x2013; Risks Related to our Intellectual Property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file for patents, both directly and in collaboration with our licensing partners, in the United States with counterparts in certain countries in Europe and certain key market countries in the rest of the world, thereby covering the major pharmaceutical markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 8, 2020, we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center (collectively, UTSW). Pursuant to the amended and restated agreement, which we refer to as the UTSW1 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following patent families, which are generally directed to methods of using THIO and are owned and/or controlled by UTSW:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:6.935%;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title / PCT Application Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947), issued in the US, MX, NZ and RU (all method of use) pending in BR, CA, CN, EP, HK and SG.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6-Thio-2'-Deoxyguanosine (6-Thio-dG) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells / <br />PCT/US2017/34706 (WO2017/205756), pending in the US (method of use)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors / <br />PCT/US2019/023596 (WO2019/183482), pending in the US (method of use)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675), pending in the US (method of use)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and (2) a non-exclusive worldwide license to develop and commercialize related technology rights. The UTSW1 Agreement includes an exclusive license to US patent no. 10,463,685 (expires April 8, 2034), and pending US patent application nos. 16/450,430 (having an earliest expiration of March 23, 2037, if a patent is granted), 16/304,538 (having an earliest expiration of May 26, 2037, if a patent is granted), and 16/982,979 (having an earliest expiration of March 22, 2039, if a patent is granted). All patents are method of use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 23, 2020, we entered into a second agreement with UTSW, which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights. Pursuant this second</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">license with UTSW, which we refer to as the UTSW2 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent family:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:6.935%;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title / PCT Application Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090, pending in the US and PCT (method of use)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and (2) a non-exclusive worldwide license to develop and commercialize related technology rights. The UTSW2 Agreement includes an exclusive license to pending US patent application no. 17/200,539 (having an earliest expiration of March 12, 2041, if a patent is granted). This patent is generally directed to methods of using THIO in combination with immune checkpoint inhibitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property acquisition and protection strategy, to adapt to competition or to seize potential opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Team</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled an experienced management team with deep research, development, and commercialization experience in the areas of telomere-related science, immunotherapy, and across a vast array of oncology indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Key Team highlights:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our team is led by our Co-founder, Chief Executive Officer and President Vlad Vitoc. He is an M.D. and M.B.A. with over 22 years of experience in the Pharmaceuticals and Biotechnology industries. He has served on leadership teams in various oncology companies and business units and has a track record of success at Bayer Pharmaceuticals, Astellas Pharma Inc., Cephalon Inc. and Incyte Corporation, including development and commercialization of major oncology brands, organizational capability building, talent recruiting and development, and functional leadership. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Chief Medical Officer and Head of Development, Mihail Obrocea, M.D., is a former practicing academic medical hematologist/oncologist and experienced pharmaceutical physician executive that brings over 20 years of successful cancer drug development track record from Juno Therapeutics Inc. (acquired by Celgene/BMS), Pharmacyclics Inc., AbbVie Bio Corp., Mannkind Corp., MedImmune, Inc. and Pfizer, Inc., among others. His experience includes clinical development of cell therapies (CAR-T), cancer vaccines, antibodies, and antibody drug conjugates (ADCs) and small molecules across a wide range of tumor types and clinical indications.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Chief Scientific Officer, Sergei M. Gryaznov, is a Ph.D. who is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. He is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO&#x2019;s telomere targeting activity.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Chief Financial Officer, Joseph F. McGuire has served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. (&#x201c;Avadim&#x201d;). Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have engaged the following advisors, who are leading, internationally recognized experts in oncology, telomeres and telomerase research, to be a part of our Scientific Advisory Board (&#x201c;SAB&#x201d;), which provides independent non-binding scientific advice to our management team in the roles detailed below under each member&#x2019;s name:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tom Gajewski, M.D., Ph.D. &#x2013; Professor of Cancer Immunotherapy (University of Chicago)</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of the key pioneers in cancer immunotherapies and accomplished in the field</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Key investigator on all phase 2 and phase 3 trials in Melanoma (with Keytruda&#174;, Opdivo&#174;, etc.)</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Past president of the Society for Immunotherapy of Cancer (SITC)</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR)</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Serves as an editor for Cancer Research and Journal for Immunotherapy of Cancer</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On our SAB, will cover translational research for all cancers, for clinical development</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tudor Ciuleanu, M.D., Ph.D. &#x2013; Professor of Oncology (University of Medicine and Pharmacy, Cluj-Napoca, Romania)</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Top Key Opinion Leader (KOL) in NSCLC and CRC in Europe</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Key investigator in more than 90 phase 3 and phase 2 clinical trials, including most immune therapy agents</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of the best published clinical investigators (appears in most references in the National Comprehensive Cancer Network (NCCN) guidelines)</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President of Romanian Federation of Cancer Societies</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Editor for the Journal of Clinical Oncology (JCO), Romanian edition</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On our SAB, will lead clinical activities in Europe across tumor types &#x2013; NSCLC, CRC, Gastric, HCC, Head and Neck, Urological cancers, and Lymphomas</span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jerry Shay, Ph.D. &#x2013; Professor and Vice Chairman of the Department of Cell Biology (University of Texas Southwestern)</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of the world leaders in the study of telomeres and telomerase</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scientific co-founder of the research supporting our lead program THIO and an integral advisor to the program</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Highly influential biomedical researcher with over 30 issued patents and more than 500 peer reviewed publications</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Southland Financial Corporation Distinguished Chair in Geriatric Research and a Distinguish Professor at University of Texas Southwestern, having received the University of Texas Regent&#x2019;s Outstanding Teaching Award and the Minnie Steven Piper Foundation Professor Award</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Awarded the Eunice Kennedy Shriver NIH Alliance Pioneer Award in 2017</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On our SAB, Dr. Shay will provide scientific leadership as the THIO co-inventor and a worldwide recognized expert in the science of telomeres and telomerase in cancer. Dr. Shay serves as the Chairman of the SAB.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Ashley, M.D., Ph.D. &#x2013; Professor of Neuro-Oncology (Duke University)</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Top KOL in pediatric and adult neuro-oncology</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expert in translational research and clinical development</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expert in immuno-oncology, having developed and clinically tested dendritic cell vaccines and other immuno-therapeutics</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal investigator of a number of important national and international studies, both clinical and pre-clinical</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Former Director of two major cancer centers, The Royal Children&#x2019;s Hospital Melbourne and Andrew Love Cancer Centre &#x2013; Barwon Health</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On our SAB, will assist in translational research in Brain Cancers for clinical development</span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gunnur Dikmen, M.D., Ph.D. &#x2013; Professor at Hacettepe University Medical Faculty, Department of Medical Biochemistry, as well as the director of the Hacettepe University hospital&#x2019;s emergency laboratory. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Broad range of experimental and clinical experience in molecular &amp; cell biology and clinical biochemistry, translating research results from bench to bedside and from academia to clinical laboratory to mentor the next generation of multidisciplinary research projects by providing new therapeutic approaches for cancer and telomere related diseases.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expert in the biology of telomeres and telomerase in the treatment of cancer.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under her capacity as Secretary-General of the Turkish Biochemical Society, organized various important national and international courses and congresses.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On our SAB, will assist in preclinical and translational research, across tumor types.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adam Yopp, M.D. &#x2013;Associate Professor and Division Chief of Surgical Oncology and Colorectal Surgery, at Harold C. Simmons NCI-designated Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completed a fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center focusing on upper GI and hepatopancreatobiliary malignancy and joined UT Southwestern in 2009.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director of the Liver Tumor Program at UTSW and both his research and clinical interests are focused on the delivery   of care in patients with primary liver cancer.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Much-recognized key opinion leader in liver cancer.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On our SAB, will assist with developing THIO for the treatment of liver cancer.</span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our SAB is primarily compensated by way of the grant of stock options as determined by the Company as appropriate in recognition of the specific services or areas of expertise of each member.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also supported by a seasoned board of directors, whose members have significant entrepreneurial skills in company building and corporate financing as well as decades of collective leadership and board experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Telomere Targeting Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Targeting Telomeres via Telomerase Leads to Cancer Cell Death</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.417%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:35.581%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomeres are regions of repetitive nucleotide sequences that are associated with specialized proteins at the ends of linear chromosomes, that represent a critical key therapeutic target for cancer. Telomeres are often depicted in imagery like the end of a shoelace.</span></p><div style="margin-left:0.33958333333333335in;text-indent:0.0pt;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.552459393356607%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maintenance of telomeres is essential for unlimited cellular proliferation and confers immortality in cancer cells. Telomeres in human cells consist of double-stranded and single-stranded repeats of the sequence TTAGGG, which terminate in a single-stranded 3&#xb4;- extension overhang of the G-rich strand. Their major function is to cap and protect the ends of chromosomes and thus to provide genetic stability. This capping function is mediated by a special architecture in which the 3&#xb4;- overhang participates with telomere-binding proteins in a large loop structure called T-loop. The image on the right reflects the general location of telomeres as the end-cap of the chromosomes, which are located in the nucleus of the cell.</span></div></div></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adapted from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Transcendental Meditation and lifestyle modification increase telomerase</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, December 6, 2015.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img118615358_4.jpg" alt="img118615358_4.jpg" style="width:221px;height:216px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The most successful anti-cancer drugs in the market today typically interfere with only one of the specific capabilities or &#x201c;hallmarks&#x201d; cancer cells use for tumor growth and progression. In contrast, our lead drug candidate, THIO, targets two major hallmark pathways:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Targeting cancer cell </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">telomeric</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> DNA structure and functional integrity; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activating the immune system that turns immunologically &#x201c;cold&#x201d; tumors into &#x201c;hot&#x201d; tumors that are responsive to therapy. THIO synergizes with immune activating agents, like checkpoint inhibitors, for the potential to attack and destroy tumors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The chart below reflects the many different methods by which successful anti-cancer drugs might prevent tumor growth and where THIO stands in relation to the other approaches.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_5.jpg" alt="img118615358_5.jpg" style="width:619px;height:325px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ch Pipeline - PLANNED STUDIES 2022 2023 2024 2025 THIOLung Cancer Colorectal Cancer Other Solid Tumors Ph 2 THIO-101 NSCLC-2L+US Accelerated approval (projected) Ph 3 TERT+ NSCLC-2L+ Ph 3 NSCLC-1LPh 2 THIO-102 TERT+ CRC-3L+ Pivotal. Ph 2 Ph 3 MSS CRC-1LPh 2 Basket TERT+ Tumors L3+Ph 3 Pivotal TBDSCLC HCC GBM Melanoma Pancreatic Ovarian Breast Prostate Ph 3 Pivotal TBD Preclinical US Potential IND</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adapted from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cell 2011, Volume 144, Issue 5, Pages 646-674</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (DOI:10.1016/j.cell.2011.02.013)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Role of the Enzyme Telomerase</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Telomerase</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is a ribonucleoprotein enzyme (reverse transcriptase) that synthesizes telomere repeats from the beginning, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">de novo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In human cells, the telomerase holoenzyme consists of a high-molecular-weight complex with a template region-containing RNA subunit, hTR, and a protein component, the catalytic subunit human telomerase reverse transcriptase (hTERT). In most normal somatic cells, telomerase activity is absent and telomere repeats are lost with cell division and with aging. Telomerase is especially important in fetal tissues, reproductive cells and other tissues where extensive cell proliferation is necessary. However, most adult normal tissues are telomerase silent. Telomere attrition, beyond a certain threshold, results in the uncapping of chromosome ends, which subsequently induces DNA damage and onset of replicative senescence. In contrast, about 73% to 100% of all cancer cells in most tumor types have detectable telomerase activity, which leads to the stabilization of telomeres and allows for unlimited growth potential along with disease progression. Successful targeting of telomerase positive (TERT+) cancers represents a significant potential for therapeutic utilization in almost all tumor types.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since most cancer cells are reliant on telomerase for their survival, and telomerase is undetectable or only transiently present at low levels in normal cells, telomeres of cancer cells and telomerase are attractive targets for the development of new cancer therapeutics. &#x201c;Proof of Principle&#x201d; for validation of telomere structural integrity-targeting as a therapeutic concept was demonstrated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in human tumor cells using dominant negative mutant forms of hTERT. In these experiments, telomerase activity was abolished, which was associated with continuous telomere shortening, subsequently leading to the cancer cells death. Research has also indicated that cancer cell specific anti-telomeres and anti-telomerase therapies may have fewer side effects than more traditional treatments, such as chemotherapy or radiotherapy. This has made anti-cancer therapies based on telomerase inhibition an area of interest in medicine. However, attempts to directly target telomerase in clinical trials have not yet produced an approved drug, as these efforts have encountered material limitations primarily due to increased toxicities that may result from the long lag period between initiation of anti-telomerase treatment and its therapeutic effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Differentiated Activity of THIO, a Telomere-Targeting Agent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO (6-thio-2&#x2019;-deoxyguanosine or 6-thio-dG) is a small molecule telomere targeting agent that uses the enzyme telomerase for DNA integration predominantly in the telomeric structure. Based on pre-clinical studies, THIO&#x2019;s telomere targeting activity is believed to be primarily cancer-specific in tumor cells with active telomerase, but not in normal cells. Based on our extensive review of publicly-available information, to our knowledge THIO&#x2019;s direct telomere targeting action utilizing telomerase is different from other commercially available cancer therapies and those currently in publicly disclosed clinical trials. Telomeres, along with the enzyme</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The statements above are not intended to give any indication that THIO has been proven effective or that it will receive regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In non-clinical studies, published initially in 2014 along with subsequent studies, THIO was found to be converted, in cells, into the substrate recognized by telomerase, and then incorporated into telomeres of the cancer cells. Once incorporated, THIO compromised the cancer cell&#x2019;s telomere structure and function, leading to &#x201c;uncapping&#x201d; of the telomeres, induction of DNA damage responses, and rapid cancer cell death. These profound structural modifications of cancer cell telomeres were irreparable. In both </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">studies, THIO showed a very prompt effect, causing telomere uncapping and leading to cancer cell death</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, independent</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the initial tumor telomere length.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_6.jpg" alt="img118615358_6.jpg" style="width:594px;height:315px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The above graphic represents an established method of action from previously conducted research in rodents that forms the scientific rationale for further clinical studies, but has not yet been tested in humans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, further non-clinical research in syngeneic and humanized mouse models of telomerase-expressing cancers uncovered previously unknown telomere targeting activity of THIO specifically resulting from its breakdown of cancer cells. The THIO-containing DNA fragments, resulting from THIO telomere disruption, are packed into micronuclei and are released from the treated cancer cell into the blood stream, which enhances immune responses. An immune response was observed, attributed to stimulation of the cGAS/STING pathways in the host APCs (Dendritic Cells, pDCs), as well as activation of NK cells and CD 8+ and CD 4+ lymphocytes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the same time as the T-cells activation, THIO treatment reduced levels of myeloid-derived suppressor cells (MDSCs) in the tumor micro-environment (TME), which is considered important for an anticancer immune response. While THIO activated CD8+ T cells, it also increased the total number of CD8+ T cells and upregulated PD-1 expression in the CD8+ T cells on per cell basis in the mouse model. This research demonstrated how the THIO-produced telomere stress may have the potential to increase innate sensing and adaptive anti-tumor immunity. In short, this immune system stimulation and TME remodeling proceeded in a specific antigen-dependent manner and induced adaptive immune responses that eradicated remaining cancer cells </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The above noted recent studies in a humanized mouse model also supported the hypothesis that sequential administration of THIO followed by an anti-PD-L1type of checkpoint inhibitor may overcome resistance to checkpoint blockade in advanced cancer models, suggesting that the combination therapy could benefit PD-L1-resistant patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Administration of low doses of THIO, aimed to activate the immune system via THIO-induced telomeric DNA modification, followed by checkpoint inhibitor therapy (anti-PD-L1 or anti-PD1), eliminated advanced tumors in preclinical models with confirmation of cancer cell type specific immune memory. This potential for THIO to induce immune memory, if confirmed in human clinical trials, would be a distinct feature of THIO&#x2019;s mechanism of action, offering the possibility that the immune system may continue to be active against the cancer cells over extended periods of time, potentially reducing the need for additional treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These pre-clinical results provided the basis for our new clinical therapeutic strategy for sequentially administering THIO as a telomere-targeted agent first, to activate the immune system against the specific cancer, followed by immunotherapy or other immune-activating therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Limitations of Other Therapeutic Approaches</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In contrast to THIO, which targets telomeres, a challenge for the potential clinical application of pharmaceutically useful telomerase inhibitors (e.g., Imetelstat), is the therapeutic window (the range of dosage of a drug or of its concentration in a bodily system that provides safe effective therapy) and the often-observed delay between initiation of treatment and phenotypic response (called the &#x201c;lag period&#x201d;). Since the antiproliferative effect of any direct telomerase inhibitor is dependent on the telomere length of any given tumor cell, clinical response will be delayed until the telomeres become critically short, and thus can no longer protect the chromosomes, and as a result, the cancer cell dies. This requires a significant number of cell divisions to become apparent, and treatment may have to be given continuously for weeks to months, potentially in conjunction with other treatment modalities, to achieve an appropriate level of efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO: A Telomere Targeting Agent</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO (6-thio-2&#x2019;-deoxyguanosine) is a synthetically-modified small molecule nucleoside that was originally designed to be an improved chemotherapy drug developed to work around purine analog resistance, which was standard-of-care therapy in the 1970s. Sponsored by the National Cancer Institute, THIO was extensively investigated in at least 19 clinical trials with over 600 cancer patient subjects (adult and pediatric) treated, both as monotherapy or in combination with other commonly used standard agents of the time. See &#x201c;THIO Clinical Trials&#x201d; below for more information about these trials. A traditional treatment strategy was used where patients were treated to maximum tolerated dose (MTD), a common approach for cancer therapy drug development. Although study results were promising, development was abandoned in favor of other therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The previous human experience presents significant limitations as it dates to the 1970s and early 1980s when the implementation of ICH Good Clinical Practices was not yet in effect. The published studies did not disclose certain data points in line with the current ICH Good Clinical Practices, such as efficacy endpoints and serious adverse events, whether those endpoints were reached, whether the data was found to be statistically significant and serious adverse events. Further, we do not know whether those prior studies were powered for statistical significance in the way our planned studies will be powered, based generally on the results of these prior human studies, we believe that THIO has a well-established safety profile, which we intend to independently demonstrate through our own clinical studies. Moreover, all prior studies were conducted primarily in heavily pre-treated, refractory patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further detailed analysis of the body of prior THIO research indicates researchers were not aware of three key factors, which if they had been known at the time, may have impacted the decision to cease development. These factors have only been discovered since 2014 (with the most recent in 2019), as illustrated in the following graphic:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO&#x2019;s detailed telomere targeting mechanism and resulting immune activation. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At high drug exposure (MTD), THIO can be immunosuppressive.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proper administration of THIO to activate the immune system followed by immunotherapy to achieve best response. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomeres are vital DNA-structures discovered by Jack Szostak&#x2019;s laboratory, for which he received the Nobel Prize in 2009, which are present at the ends of each chromosome which protect the genome from degradation, unnecessary recombination, repair, and interchromosomal fusion. Telomeres, along with the enzyme telomerase, are both crucial for the survival of cancer cells. Telomerase was discovered by Elizabeth Blackburn and Carol Greider, who shared the Nobel Prize with Jack Szostak in 2009.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO is believed to selectively target telomerase positive (TERT+) cancer cells, where the enzyme is activated, versus normal cells. 73% to 100% of primary human cancers are TERT+ dependent upon tumor type, indicating a significant potential therapeutic utilization for THIO in almost all tumor types. THIO&#x2019;s cancer-specific disturbance of telomeric structure by telomerase leads to disruption in the cell cycle, followed by rapid cell death. Based on extensive review of publicly-available information, THIO&#x2019;s direct telomere targeting action utilizing telomerase is different from other commercially available cancer therapies and those currently in publicly disclosed clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, the MAIA research team showed that in mouse models THIO-produced telomere modification and disruption induced cancer-specific innate and adaptive immune response against immunologically &#x201c;cold&#x201d; or unresponsive tumor types. When THIO was administered at low doses, in syngeneic and humanized mouse models of telomerase-expressing cancers, followed by a break to allow for the activation of the immune system against the specific cancer, then followed by a standard-of-care immunotherapy agent like a check point inhibitor (CPI), either PD-1 or PD-L1, complete tumor regression was observed, with no observed toxicities. These effects have been replicated in multiple preclinical models, utilizing all leading checkpoint inhibitors or radiation therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on these studies, we hypothesized that THIO, administered in advance of immune-activating therapies (e.g., checkpoint inhibitors, radiation therapy, etc.), at dose levels significantly lower than the levels evaluated in previous clinical trials, will &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">prime&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the tumor environment and initiate an overall anti-tumor immune response. This represents an entirely new therapeutic approach for THIO and forms the basis for the new clinical strategy for planned future trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Preclinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following summarizes the relevant preclinical studies. Extensive preclinical studies have been performed to validate THIO&#x2019;s primary mechanism of action: targeting telomeres directly and causing cancer cell death via telomerase-mediated DNA damage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To our knowledge, THIO alone has shown significant telomere targeting activity in numerous non-small cell lung cancer (NSCLC) and multiple other cancer-based cell lines </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including but not limited to small cell lung cancer (SCLC), melanoma, colorectal cancer (CRC), glioblastoma multiforme (GBM), diffuse intrinsic pontine glioma (DIPG), neuroblastoma, pancreatic, hepatocellular carcinoma (HCC), as well as head and neck cancer, breast cancer and prostate cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: in summary, EC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> values (the concentrations at which half of the total number of cancer cells are dead) were approximately 0.4 &#xb5;M to 1.5 &#xb5;M. THIO was not cytotoxic in normal, untransformed telomerase-negative cells at concentrations up to 100 &#xb5;M.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: in summary, the doses that resulted in cancer cell death were in the range of 2.5 - 5.0 mg/kg, depending on the tumor type and the schedule of the drug administration ranging from 1 to 3 days per cycle.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma, and in May 2022, the FDA granted ODD to THIO for the treatment of small cell lung cancer. The FDA&#x2019;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO in Sequential Administration in Advance of Checkpoint Inhibitors (CPIs) Therapy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, THIO, at 3 mg/kg/dose, (which corresponds to a 20 mg/patient/day low-dose), administered followed by a one-day break, followed by an immune checkpoint inhibitor (either anti-programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) products), resulted in complete tumor regression in NSCLC and CRC syngeneic mouse tumor models.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At this low dose, THIO was able to transform immunologically &#x201c;cold&#x2019; tumors, (tumors that do not respond to the CPI treatment), into immunologically &#x201c;hot&#x201d; tumors, which then responded well to the following sequential treatment with a CPI. These potent anti-tumor phenotypic effects were also accompanied by the efficient induction of the tumor-specific CD8+ cells, as well as CD4+, and natural killer (NK)-cells (Mender, 2020b).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These responses were achieved through telomerase-dependent and cancer cell specific activation of a) DNA damage responses, and b) cGAS/STING pathways by THIO. This body of research represents the basis for the new immune-activation treatment strategy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following represents key highlights from THIO preclinical research:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO has been tested in multiple preclinical studies evaluating various tumor types </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> including in lung, colorectal, prostate, breast, ovarian, head and neck, brain, melanoma, and liver cancer. THIO has also been tested in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mouse models of lung, colorectal, brain, melanoma, liver and brain cancers. In the below graphic, the left panel depicts cancer cell colony formation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> assay results conducted with various types of telomerase positive cancers, namely prostate, breast, ovarian, colon, brain, head and neck. In the control column, cancer cells grew. In the second column, with the telomerase inhibitor BIBR, the cancer cells also grew. In the third column, in which the telomere targeting agent THIO was administered at a concentration of 2.5&#xb5;M, cancer cell growth was visibly inhibited. In the fourth column, in which THIO was administered at a concentration of 5&#xb5;M, cancer cells were also visibly inhibited. The same concentrations of THIO were also administered </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in rodent models (mice), caring tumors, derived from either brain, or liver, or melanoma, or neuroblastoma, or colorectal cancer cells were treated with THIO (at 2 mg/kg to 5 mg/kg doses), significant reduction in tumor masses resulting from the treatment with THIO was observed. Note that THIO&#x2019;s activity seen in preclinical models has yet to be demonstrated in humans.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_7.jpg" alt="img118615358_7.jpg" style="width:160px;height:190px;" /><img src="img118615358_8.jpg" alt="img118615358_8.jpg" style="width:446px;height:159px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO demonstrated potential to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">selectively</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cause cancer cell death with active enzyme telomerase versus normal cells</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The below graphic illustrates formation of telomeric damage foci (TIFs) in telomerase activity-positive cancer cells, but not in normal non-cancerous cells, resulting from application of THIO. These data indicate molecular mechanism of THIO that targets telomeric DNA of cancer cells through their telomerase enzymatic activity. At the same time, normal cells, that are devoid of telomerase activity, are not affected by THIO. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_9.jpg" alt="img118615358_9.jpg" style="width:598px;height:233px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(128,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mender I. et al., Cancer Discovery (2015)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*TIF &#x2013; telomere damages induced foci</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*TRF2 &#x2013; protein associated with telomeres</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Gamma-H2AX &#x2013; protein associated with induction of DNA damage</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*CRC &#x2013; colorectal cancer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*hTERT &#x2013; protein components of telomerase enzyme</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO, as a single agent, showed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> telomere targeting activity in cancer cells that are resistant to tyrosine kinase inhibitors (TKIs), checkpoint inhibitors, IL-2, IFN&#x3b1;, YERVOY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ipilimumab) and a host of chemotherapies. The below graphic, in NSCLC and Melanoma models respectively, demonstrates in vivo telomere targeting activity of THIO in mice models of lung cancer, derived from PERC16 cells, and melanoma derived from WM4265 cells. Both cell lines are resistant to multiple standard-of-care drug compounds, as listed in the Figure legends.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_10.jpg" alt="img118615358_10.jpg" style="width:583px;height:235px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*i.p. &#x2013; intraperitoneal injection</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*IL-2 &#x2013; cytokine interleukin 2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*IFN-a &#x2013; interferon alfa</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO was observed to penetrate the blood-brain barrier and inhibits tumor growth, inducing in-tumor telomere dysfunction and cancer cell death, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> models of difficult to treat pediatric brain cancer, where no therapy exists. In the below graphic, this is shown through presence of Caspase-3 enzyme which is associated with cell death. Sengupta, S. et al. Induced telomere damage to treat telomerase expressing therapy-resistant pediatric brain tumors. Mol Cancer Therapeutics, 17(7): 1504-1514, 2018.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_11.jpg" alt="img118615358_11.jpg" style="width:279px;height:215px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img118615358_12.jpg" alt="img118615358_12.jpg" style="width:293px;height:214px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*TIF &#x2013; telomere damage induced foci</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*MB004 &#x2013; brain cancer cell line</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO transformed &#x201c;cold&#x201d; tumors into &#x201c;hot&#x201d; tumors that were responsive to immunotherapy. THIO utilized a telomere targeting pathway that synergized with checkpoint inhibitors and other immune-activating therapies. The tumor-specific immune activation, resulting from THIO&#x2019;s primary mode of action, overcame resistance to current check point inhibitor (CPI) standard-of-care therapy, as illustrated in the following Colorectal Cancer model. The below graphic demonstrates telomere targeting activity of THIO alone, and in sequential combination with immune checkpoint inhibitor (anti-PD-L1 compound, atezolizumab), in mice model of colorectal cancer, derived from MC-38 cells. Two doses of THIO are shown to control tumor growth while anti-PD-L1 agent. Sequential administration of THIO (2 days), followed by administration of the anti-PD-L1 agent, demonstrates disappearance of tumor cells.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_13.jpg" alt="img118615358_13.jpg" style="width:624px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunological memory was observed in mouse models, where the immune system continued to be active against the specific treated tumor cell type for 100 days post-tumor inoculation. The below graphic demonstrates that the tumor-free animals that were treated with the sequential combination of THIO and anti-PD-L1 compound were followed for 70 days, with no observed tumor recurrence. Subsequently, animals were re-challenged with 10 times more MC38 cancer cells. Cancer growth was not observed in these animals, demonstrating induction of anti-tumor-protecting memory after sequential administration of THIO and anti-PD-L1 agent; ref: Mender, I., et al. Telomere stress potentiates STING-dependent anti-tumor immunity. Cancer Cell, 38,3, 400-411.E6, September 14, 2020.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_14.jpg" alt="img118615358_14.jpg" style="width:624px;height:238px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, due to the cGAS/STING activation caused by THIO, telomere targeting activity was observed in numerous preclinical tumor models when THIO was administered followed by immune activating therapy such as immune checkpoint inhibitors (anti-PD-L1 or anti-PD-1 antibody). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A summary of the pharmacological aspects of the investigational product and, where appropriate, its significant metabolites studied in animals, should be included. Such a summary should incorporate studies that assess potential therapeutic activity (e.g. efficacy models, receptor binding, and specificity) as well as those that assess safety (e.g., special studies to assess pharmacological actions other than the intended therapeutic effect(s)). The results of all relevant nonclinical pharmacology, toxicology, pharmacokinetic, and investigational product metabolism studies should be provided in summary form. This summary should address the methodology used, the results, and a discussion of the relevance of the findings to the investigated therapeutic and the possible unfavourable and unintended effects in humans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is therefore hypothesized that THIO, administered in advance of immune-activating therapies (e.g., checkpoint inhibitors, radiation therapy, etc.), at dose levels significantly lower than the levels evaluated in previous clinical trials, will &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">prime&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the tumor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">environment and initiate an overall anti-tumor immune response. If confirmed through additional clinical studies, this could represent an entirely new therapeutic approach for THIO and form the basis for the new clinical strategy for planned future trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Clinical Trials</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to rely solely upon our self-generated clinical safety and efficacy data, if favorable, in support of our anticipated NDA filing for THIO. However, THIO, as a compound, was the subject of investigation in numerous clinical trials in the 1970s to the early-80s in a variety of solid tumors and hematological malignancies. The compound was evaluated in at least nineteen (19) Phase 1 to Phase 3 clinical trials with over 600 patients treated by major cancer institutions and cancer cooperative groups. THIO was studied in combination with common agents in use at the time, including methyl-CCNU or mitomycin, two widely used alkylating agents to treat a variety of cancers and leukemias. Studies utilizing THIO as a single agent have been published in peer-reviewed journals. As part of the existing data base of clinical experience with the drug, we expect to reference the older NCI studies in the public domain as well as reference NCI&#x2019;s original IND filing in support of an IND filing, pursuant to FDA regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the THIO single agent peer-reviewed published data available from the previous clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:8.176%;"></td>
    <td style="width:20.519%;"></td>
    <td style="width:20.38%;"></td>
    <td style="width:11.12%;"></td>
    <td style="width:20.843%;"></td>
    <td style="width:18.963%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Study</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor Type</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regimen/Dose Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluable Subjects</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observed Adverse Events</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Responses</span></p></td>
   </tr>
   <tr style="height:88.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C76-92</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric Acute Leukemia who received prior</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6-mercaptopurine (6-MP) or 6-thioguanine</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO 200 to 2,250 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;given every 12 hours for 3 doses every 2 weeks</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maximum tolerated dose (MTD) was determined to be 1,750 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">given every 12 hours for 3 doses every 2 weeks</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reversible urate nephropathy, elevations of liver enzymes, nausea and vomiting, alopecia, and skin reactions</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Therapeutic Responses observed in 6/23 (26%) patients comprised of</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 complete responses and 4 partial responses</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Source: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Higgins, G. R., Jamin, D. C., Shore, N. A., Momparler, R., Hartman, G. and Siegel, S. E. (1985). &#x201c;Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.&#x201d; Cancer Treat Rep 69(6): 699-701t</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 &#x2013; Single Agent Studies</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:8.731%;"></td>
    <td style="width:17.583%;"></td>
    <td style="width:20.083%;"></td>
    <td style="width:8.861%;"></td>
    <td style="width:11.222%;"></td>
    <td style="width:9.602%;"></td>
    <td style="width:9.741%;"></td>
    <td style="width:14.176%;"></td>
   </tr>
   <tr style="height:22.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Protocol</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor Type</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regimen/Dose</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluable</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subjects</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ORR</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Overall</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Response)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PR</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Partial</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Response)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CR</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Complete</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Response)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse Events</span></p></td>
   </tr>
   <tr style="height:14.95pt;">
    <td rowspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEG-248</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Patients</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27 (23%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11 (9%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16 (14%)</span></p></td>
    <td rowspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leukopenia</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thrombocytopenia</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Skin rash</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alopecia (reversible)</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nausea and vomiting</span></p></td>
   </tr>
   <tr style="height:3.7pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acute Myelocytic Leukemia (AML)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (24%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (6%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (18%)</span></p></td>
   </tr>
   <tr style="height:3.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 (20%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6 (12%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (8%)</span></p></td>
   </tr>
   <tr style="height:13.9pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blastic transformation of chronic myelogenous leukemai (BTL)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (27%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (27%)</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6 (23%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (12%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (12%)</span></p></td>
   </tr>
   <tr style="height:3.7pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acute Lymphocytic Leukemia (ALL)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50%)</span></p></td>
   </tr>
   <tr style="height:3.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (20%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (10%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (10%)</span></p></td>
   </tr>
   <tr style="height:21.55pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EST 4273 (ECOG)</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Colorectal</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(prior 5-FU chemotherapy)</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO 100 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;daily for 5 days every 3 weeks</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vs</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MeCCNU 175 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">every 8 weeks</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leukopenia, thrombocytopenia, nausea and vomiting</span></p></td>
   </tr>
   <tr style="height:13.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 (9%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 (9%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Omura, G. A., Vogler, W. R., Smalley, R. V., Maldonado, N., Broun, G. O., Knospe, W. H., et al. (1977b). &#x201c;Phase II Study of beta-2'-deoxythioguanosine in adult acute leukemia. (Study SEG-248)&#x201d; Cancer Treat Rep 61(7): 1379-1381 Douglass, H. O., Jr., Lavin, P. T., Woll, J., Conroy, J. F. and Carbone, P. (1978). &#x201c;Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea: A Phase II-III study of the Eastern Cooperative Oncology Group (EST 4273).&#x201d; Cancer 42(6): 2538-2545</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The previous human experience presents significant limitations as it dates to the 1970s and early 1980s when the implementation of ICH Good Clinical Practices was not yet in effect. The published studies did not disclose certain data points in line with the current ICH Good Clinical Practices, such as efficacy endpoints and serious adverse events. , whether those endpoints were reached, whether the data was found to be statistically significant and serious adverse events. Further, we do not know whether those prior studies were powered for statistical significance in the way our planned studies will be powered. Based generally on the results of these prior</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">human studies, we believe that THIO has a well-established safety profile, which we intend to independently demonstrate through our own clinical studies. Moreover, all prior studies were conducted primarily in heavily pre-treated, refractory patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding these limitations, the available data provides substantial information on the clinical experience with and clinical profile of THIO with an exposure exceeding 600 subjects (adult and pediatric) at doses significantly higher than those intended for investigation in the current program and new treatment strategy. All studies were conducted in heavily pre-treated/refractory patients, most of whom were pre-treated with other standards of care including chemotherapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, THIO has not received marketing approval in any country; therefore, there is no marketing experience to be reported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The planned clinical trials will assess a novel THIO therapeutic strategy: - evaluate the safety and efficacy of low potentially immunogenic doses of THIO administered to activate the immune system against the tumor to be treated, followed by standard-of-care immunotherapy (checkpoint inhibitor) or other immune activating therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Developmental Initiatives and Objectives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the existing data regarding pre-clinical information on THIO, we believe it is possible to enter the next human clinical study in the near term with the new low dose immunogenic approach with THIO. We plan to approach the FDA to request a modified toxicity requirement to allow us a reduced time and expenditure to IND in the United States, however, the FDA may not grant such request. We are currently working with experts to evaluate the extent and quality of the existing data supporting THIO and had a pre-IND meeting with the FDA for guidance in 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 and 3 Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary short-term objective is to assess this approach in a Proof-of-Concept study outlined below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This first study is a dose-finding, Phase 2 clinical trial evaluating both safety and efficacy of THIO sequenced with cemiplimab in patients with advanced non-small lung cancer (NSCLC) who progressed or showed no clinical benefit to first line treatment containing an immune checkpoint inhibitor. This trial, designated as THIO-101 study is our first human clinical trial to test the immune system activation demonstrated in preclinical animal models: lower doses of THIO administered prior to a checkpoint inhibitor treatment reverses drug resistance, enhance and prolong immune responses in patients with advanced lung cancer who did not respond or progressed after a prior cancer treatment which contained another immune checkpoint inhibitor.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial design has two primary objectives: (1) safety of THIO administered as a priming immune system agent prior to cemiplimab administration and (2) clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. The study is ongoing in Australia and Europe and we expect will be followed by the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following chart sets forth the design of the THIO-101 trial:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img118615358_15.jpg" alt="img118615358_15.jpg" style="width:624px;height:153px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This &#x201c;dose-finding&#x201d; trial will assess the safety, mechanism of activity, and immune system activation of four THIO doses tested out in separate arms administered in parallel. Each dosing arm will be further evaluated for efficacy based on Overall Response Rate (ORR), Duration of Response (DoR) and Progression Free Survival (PFS) to determine to optimal (safe and effective) dose of THIO administered in sequence with cemiplimab. Additional patients may be recruited for further clinical evaluation in any of the THIO arms based on safety and clinical benefit. Each arm of the trial will enroll a minimum of 22 and up to 41 evaluable patients. Subsequently, we expect to target earlier lines of therapy (1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> line) in pivotal Phase 3 confirmatory studies in NSCLC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we submitted a pre-IND meeting request to FDA to discuss, among other elements, the existing non-clinical and clinical data to support the conduct of our planned THIO-101 phase 2 trial under an IND to include patients from the United States. FDA&#x2019;s November 2022 feedback indicated that our protocol generally sounds reasonable, subject to certain modifications to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">protocol and requests for additional information. We intend to incorporate FDA&#x2019;s feedback and provide the requested information as part of our IND submission to FDA, which we anticipate filing in the near future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In an effort to obtain FDA and/or EMEA approval of THIO in combination with other standard of care approved cancer immunotherapies, we will have to conduct head-to-head studies which will compare standard of care treatment alone to standard of care treatment combined with THIO. In such studies, we would have to show that THIO added to standard of care therapies adds a significant treatment benefit by slowing down tumor progression and increasing the overall survival of the cancer patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are actively evaluating other regulatory strategies and pathways that have the potential to accelerate and/or expand the study of THIO administered in sequence with an immune-checkpoint inhibitor in other solid tumor indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event THIO demonstrates early clinical efficacy, we plan to expand our clinical development program in multiple tumor types and assess several regulatory approval pathways utilizing our other development programs. The clinical development plan includes the initiation of an additional &#x201c;basket trial&#x201d; in multiple cancer types. This study uses a special design which allows different cancer indications to be studied under the same single trial umbrella. Some of the indications considered are:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hepatocellular carcinomas (HCC)</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">small-cell lung cancer (SCLC)</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">melanoma </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">breast cancer</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pancreatic cancer </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">glioblastoma multiforme (GBM)</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ovarian cancer</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prostate cancer</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ultimately, we envision positioning THIO as the foundational priming treatment for all immune-activating agents over time based upon THIO&#x2019;s tumor-specific immune-activation approach that enables key clinical strategies that could dramatically expand the immunotherapy market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Generation of Telomere Targeting Agents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through the same mechanism of action as THIO, such as targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover compositionally new compounds with potentially improved specificity towards cancer cells relative to normal cells, and to assess telomere targeting activity in comparison with THIO. This program may also allow us to strengthen our patent portfolio. Although the program is in early stages and we may not be able to identify suitable compounds, we believe we will be able to create or discover a second generation of THIO-like compounds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Collaborations and Key Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Through our licensing agreements with The University of Texas Southwestern Medical Center (&#x201c;UTSW&#x201d;), we have commercial rights to certain U.S. patents, as well as their foreign counterparts, for the use of THIO in treating telomerase-expressing lung and colon cancer cells. We are currently using this technology to study a treatment regimen comprising the use of THIO treatment followed by cemiplimab (Regeneron) treatment in NSCLC. In addition, we have licensed a number of pending U.S. and foreign patent applications from UTSW directed to other indications, and we are continuing to pursue discussions with several companies to develop other treatment regimens using THIO for additional cancer indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we entered into a Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc. (REGN) to supply cemiplimab for the THIO-101 study. Regeneron will contribute the drug supply without cost, which represents a significant direct cost savings for our program. In exchange, Regeneron will receive development exclusivity for NSCLC indication during the study period, which means that MAIA cannot study THIO in NSCLC with any other PD-1 antagonist (a product sub-class of immune checkpoint inhibitors). All other tumor types remain open, and we are in discussions with other pharmaceutical companies to evaluate additional agreements that may be appropriate to support the expanded development of THIO. The supply agreement will remain in force until all of the obligations of the parties&#x2019; related to the studies contemplated by the agreement are completed, or until terminated by either party. The agreement may be terminated in the event of unsafe use of cemiplimab, material breach, regulatory action or corruption.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our management believes that strong partnership interest will develop from other pharmaceutical companies who have checkpoint inhibitor franchises or those with cancer immunotherapy interest. We expect to continue discussions with several</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companies that have expressed interest and plan to expand discussions to capitalize on these opportunities. The checkpoint inhibitor market is large, and our goal is to ultimately position THIO as the foundational priming treatment to be used prior to all checkpoint inhibitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The University of Texas Southwestern Medical Center License Agreement 1</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 8, 2020, we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center (collectively, UTSW). Pursuant to the amended and restated agreement, which we refer to as the UTSW1 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent families generally directed to methods of using THIO (below) and (2) a non-exclusive worldwide license to develop and commercialize related technology rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:6.667%;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title / PCT Application Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6-Thio-2'-Deoxyguanosine (6-Thio-dG) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells / <br />PCT/US2017/34706 (WO2017/205756)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors / <br />PCT/US2019/023596 (WO2019/183482)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the UTSW1 Agreement, we agreed to pay UTSW a minimal license fee, deferred license fees, milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with UTSW, see the section entitled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Intellectual Property &#x2014;License Agreement 1 with The Board of Regents of The University of Texas System</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The University of Texas Southwestern Medical Center</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d; The UTSW1 Agreement includes an exclusive license to US patent no. 10,463,685 (expires April 8, 2034), and pending US patent application nos. 16/450,430 (having an earliest expiration of March 23, 2037, if a patent is granted), 16/304,538 (having an earliest expiration of May 26, 2037, if a patent is granted), and 16/982,979 (having an earliest expiration of March 22, 2039, if a patent is granted).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The University of Texas Southwestern Medical Center License Agreement 2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 23, 2020, we entered into a second agreement with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights. Pursuant this second license with UTSW, which we refer to as the UTSW2 Agreement, we obtained (1) an exclusive, worldwide license to develop and commercialize the following UTSW patent family (below) and (2) a non-exclusive worldwide license to develop and commercialize related technology rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:6.667%;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title / PCT Application Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the UTSW2 Agreement, we agreed to pay UTSW a minimal license fee, deferred license fees, milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with UTSW, see the section entitled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Intellectual Property &#x2014;License Agreement 2 with The Board of Regents of The University of Texas System</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> /</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The University of Texas Southwestern Medical Center</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d; The UTSW2 Agreement includes an exclusive license to pending US patent application no. 17/200,539 (having an earliest expiration of March 12, 2041, if a patent is granted).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement 1 with The Board of Regents of The University of Texas System /The University of Texas Southwestern Medical Center</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 8, 2020 (the &#x201c;Effective Date&#x201d;), we entered into an amended and restated agreement (of our prior November 29, 2018 agreement) with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, (collectively, UTSW) to develop and commercialize certain UTSW owned and/or controlled patents and related technology directed to methods of using THIO (&#x201c;the UTSW1 Agreement&#x201d;). The license is exclusive as to worldwide Patent Rights for all uses in the Field, which is defined as all therapeutic, prophylactic and diagnostic fields of use for all indications, including</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">discovery and development uses. The license is sublicensable with prior UTSW written approval consistent with the terms of UTSW1 Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW1 Agreement includes an exclusive license to the &#x201c;Patent Rights&#x201d; of the worldwide patent families including all provisional applications and any divisionals, continuations, continuations-in-part and foreign counterpart applications that are entitled to claim priority thereto, and any patents resulting therefrom, of the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:6.667%;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title / PCT Application Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telomerase Mediated Telomere Altering Compounds / PCT/US2014/33330 (WO2014/168947)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6-Thio-2'-Deoxyguanosine (6-Thio-dG) Results in Telomerase Dependent Telomere Dysfunction and Cell Death in Various Models of Therapy-Resistant Cancer Cells /PCT/US2017/34706 (WO2017/205756)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of 6-thio-dG to Treat Therapy-Resistant Telomerase positive Pediatric Brain Tumors /PCT/US2019/023596 (WO2019/183482)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of Drug Resistant Proliferative Diseases with Telomerase Mediated Telomere Altering Compounds / PCT/US2017/023858 (WO/2017/165675)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW1 Agreement also grants the Company a non-exclusive worldwide license under the Technology Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field, wherein Technology Rights means Licensor&#x2019;s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by Inventors at UTSW which are necessary or reasonably useful for practicing Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW1 Agreement also grants the Company the first right to negotiate an exclusive license under any patent rights covering or claiming any improvement, which is any patentable invention and is conceived or reduced to practice solely by Dr. Jerry Shay or those under his direct supervision at UTSW within 3 years of the Effective Date, under certain conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the UTSW1 Agreement begins on the Effective Date and continue until the earliest of: (i) termination pursuant to the UTSW1 Agreement, (ii) the last date of expiration or termination of the Patent Rights; or (iii) if Technology Rights are licensed and no Patent Rights are applicable, twenty (20) years after the Effective Date. The Company may terminate the UTSW1 Agreement for convenience, at any time prior by providing ninety (90) days&#x2019; written notice to UTSW. UTSW may terminate the UTSW1 Agreement if the Company (i) becomes in arrears in any payments due, and fails to make the required payment within 30 days after delivery of written notice from UTSW, (ii) is in breach of any material non-payment provision, and does not cure such breach within 60 days after delivery of written notice, (iii) UTSW delivers notice to the Company of three or more actual breaches in any 12-month period, even in the event that the Company cures such breaches in the allowed period, (iv) becomes insolvent or bankrupt, then termination is immediate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UTSW and/or the co-owners of certain patents have reserved the right to publish the scientific findings related to the Patent Rights and use and to permit other academic institutions to use the licensed subject matter for teaching, research, education, and other education-related, non-commercial purposes. The Patent Rights are also subject to any rights of the United States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government-funded or non-profit entity-funded research.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the UTSW1 Agreement, the Company paid to UTSW a nominal one-time upfront license fee. The Company is also obligated to pay all accrued patent expenses as well as ongoing patent expenses on a scheduled basis tied to Company fund-raising through Series A funding until Company has reimbursed all patent expenses. In the event that the Company assigns the agreement to a third party, the Company is obligated to pay UTSW an assignment fee in the mid-six figures within 15 days of such assignment. The agreement cannot be assigned without UTSW&#x2019;s consent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the UTSW1 Agreement, the Company is obligated to use diligent efforts to bring licensed products to market through a funded, ongoing and active research and development, manufacturing, regulatory, marketing or sales program (all as commercially reasonable) and provide semi-annual reports to UTSW on its progress. The Company is also obligated to pay agreed upon milestone payments to UTSW. Failure of the Company to fulfill these obligations may be treated as a material breach by UTSW.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The only milestones that require payments under the UTSW1 Agreement include: (i) first commercial sale in the U.S. of licensed product for treating an oncology indications ; (ii) first commercial sale in the U.S. of licensed product for treating a non-oncology indications; (iii) first time aggregate Net Sales (as defined in the UTSW1 Agreement) of licensed product for treating an oncology indications exceeds low-nine figure sales in a contract year; (iv) first time aggregate Net Sales of licensed product for treating a non-oncology indications exceeds low nine-figure sales in a contract year; (v) first time aggregate Net Sales of licensed product for treating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an oncology indications exceeds low ten-figure sales in a contract year; (vi) first time aggregate Net Sales of licensed product for treating a non-oncology indications exceeds low ten-figure sales in a contract year. There are no milestone payments required on any development or regulatory milestones. The only required milestone payments under the UTSW1 Agreement related to commercial sales milestones, and the aggregate amount of milestone fees payable pursuant to the UTSW1 Agreement will not exceed $112 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in UTSW1 Agreement) and dependent on whether Net Sales are greater than or less than/equal to low ten figures of sales, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by a certain percentage. The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW1 Agreement) in each country. In the event that the Company or its sublicensee challenges the Patent Rights, then the Company will be obligated to pay multiples of the applicable royalty rate of the Net Sales and, should the outcome of such challenge determine that any claim of the Patent Rights challenged is both valid and infringed then the Company will pay royalties at the rate of multiples of the applicable royalty rate of the Net Sales sold thereafter and reimburse UTSW for all fees and costs associated with defending such challenge, including attorney&#x2019;s fees and expert fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW1 Agreement also contains an anti-stacking provision pursuant to which in the event the Company or its sublicensee pays royalties or other payments to a third party who owns or controls intellectual property deemed necessary to develop, manufacture, have manufactured, distribute, have distributed, use, lease, loan, import, offer for sale and/or sell any licensed products and licensed services, the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a certain percentage of the royalty obligation in any contract year. In the event that the payment to the third party who owns or controls intellectual property deemed necessary to extend or expand the franchise or exclusivity of a previously launched licensed product (e.g., such as a new formulation as a second generation product containing the same compound as the previously launched Licensed Product), then the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced below a certain percentage of the royalty obligation in any contract year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UTSW maintains direct control over the prosecution and maintenance activities of the Patent Rights, and the Company is obligated to reimburse past and ongoing patent expenses as noted above. UTSW will permit the Company to comment on submissions to government patent agencies, during prosecution and will consider the Company&#x2019;s comments, but UTSW retained control over all final decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW1 Agreement contains a representation that UTSW has the rights and authority to grant to Company the licensed rights and is to its knowledge unaware of any third-party infringer or any infringement of third-party intellectual property rights. The UTSW1 Agreement also requires the Company to indemnify UTSW and other related parties against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs and expenses arising out of any product the Company produces under the UTSW1 Agreement, and requires the Company, beginning with the earlier of the first clinical trial or commercial sale or other commercialization, to obtain liability insurance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will have the first and sole right but not the obligation, at its own expense, to initiate an infringement suit or other appropriate actions against third party infringers and monetary recovery received therefrom, after the Company is reimbursed for expenses in enforcing the Patent Rights, is shared between the Company and UTSW pursuant to a good faith negotiation between the parties at that time. If the Company does not file suit within six months after a written request by UTSW, then UTSW may bring suit to enforce any Patent Right and retain all recoveries from such enforcement. If UTSW pursues such infringement action, it may, as part of the resolution of such efforts, grant nonexclusive license rights to the alleged infringer notwithstanding Licensee&#x2019;s exclusive license rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the terms of the UTSW1 Agreement, on April 24, 2020 Company sublicensed all Company rights and obligations under the UTSW1 Agreement to Company affiliate THIO Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement 2 with The Board of Regents of The University of Texas System /The University of Texas Southwestern Medical Center</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 23, 2020 (the &#x201c;Effective Date&#x201d;), we entered into a second agreement with The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center, (collectively, UTSW), which set forth the agreement between the parties pursuant to the Company exercising its option rights in the UTSW1 Agreement and obtaining additional license rights (&#x201c;the UTSW2 Agreement&#x201d;). The license is exclusive as to worldwide Patent Rights for all uses in the Field,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which is defined as all therapeutic, prophylactic and diagnostic fields of use for all indications, including discovery and development uses. The license is sublicensable with prior UTSW written approval consistent with the terms of UTSW2 Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW2 Agreement includes an exclusive license to the &#x201c;Patent Rights&#x201d; of the worldwide patent family including all provisional applications and any divisionals, continuations, continuations-in-part and foreign counterpart applications that are entitled to claim priority thereto, and any patents resulting therefrom, of the following</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:6.667%;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title / PCT Application Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sequential Treatment of Cancers Using 6-Thio-dG and Checkpoint Inhibitors / PCT/US2021/022090</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW2 Agreement also grants the Company a non-exclusive worldwide license under the Technology Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field, wherein Technology Rights means UTSW&#x2019;s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by inventors at UTSW which are necessary or reasonably useful for practicing Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the UTSW2 Agreement are similar in many respects to those set forth in the UTSW1 Agreement. Pursuant to the UTSW2 Agreement, the Company paid to UTSW a nominal one-time upfront license fee. The UTSW2 Agreement recognizes the accrual of low five-figures in patent expenses relative to the Patent Rights of this agreement and provides for deferral of this fee and related ongoing patent expense fees on a schedule connected to the Company&#x2019;s fundraising through Series A funding. Once the Company has raised mid seven-figures, the patent expense fees are be paid in full for all patent expenses incurred by UTSW for the Company&#x2019;s licensed technologies which accrued between December 12, 2019, and the date at which the mid seven-figures has been raised. Until the Company has reimbursed all patent expenses it is obligated to report its fundraising progress to UTSW on a quarterly basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The milestone payments are the same as in the UTSW1 Agreement wherein the milestone fees are based solely on commercial sales milestones and are payable one time only, regardless of the number of licensed products or licensed services developed and regardless of the number of indications or patient sub-populations treated with a licensed product(s) and regardless of whether the licensed products or licensed services developed are within the rights granted by the UTSW1 Agreement or the UTSW2 Agreement. In other words, there are no milestone payments required on any development, or regulatory milestones under the UTSW1 Agreement or the UTSW2 Agreement. The only required milestone payment under the UTSW1 Agreement or the UTSW2 Agreement relate to commercial sales milestones and the aggregate amount of milestone fees payable pursuant to the UTSW1 Agreement or the UTSW2 Agreement will not exceed $112 million. In the event the Company assigns the UTSW2 Agreement to a third party, the Company is obligated to pay UTSW low six-figures within 15 days of such assignment, which is cumulative of the UTSW1 Agreement assignment fee, such that if both agreements are assigned to a third party, a total of high six-figures would be owed to UTSW. The agreement cannot be assigned without UTSW&#x2019;s consent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. There are mid-single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in UTSW2 Agreement) and dependent on whether Net Sales are greater than or less than/equal to low ten-figures in sales, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by a certain percentage. The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (10) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. In the event that the Company or its sublicensee challenges the Patent Rights, then the Company will be obligated to pay multiple times the applicable royalty rate of the Net Sales and, should the outcome of such challenge determine that any claim of the Patent Rights challenged is both valid and infringed then the Company will pay royalties at the rate of multiple times the applicable royalty rate of the Net Sales sold thereafter and reimburse UTSW for all fees and costs associated with defending such challenge, including attorney&#x2019;s fees and expert fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UTSW2 Agreement also contains an anti-stacking provision pursuant to which in the event the Company or its sublicensee pays royalties or other payments to a third party who owns or controls intellectual property deemed necessary to develop, manufacture, have manufactured, distribute, have distributed, use, lease, loan, import, offer for sale and/or sell any licensed products and licensed services, the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party. However, such adjustment in royalty payments to UTSW may not be reduced by more than a minimum percentage of the royalty obligation in any contract year. In the event that the payment to the third party who owns or controls intellectual property deemed necessary to extend or expand the franchise or exclusivity of a previously launched licensed product (e.g., such as a new formulation as a second-generation product containing the same compound as the previously launched Licensed Product), then the Company may reduce payments to UTSW by a certain percentage of the royalty, milestone or other payments paid to such third party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, such adjustment in royalty payments to UTSW may not be reduced by more than a certain percentage obligation in any contract year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the development and reporting obligations as the UTSW1 Agreement and as with the UTSW1 Agreement, UTSW has reserved the right to publish the scientific findings related to the Patent Rights and use and to permit other academic institutions to use the licensed subject matter for teaching, research, education, and other educationally related, non-commercial purposes. The Patent Rights are also subject to any rights of the United States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government-funded or non-profit entity-funded research.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The obligations and rights as to patent prosecution and defense of the Patent Rights are the same as those for the UTSW1 Agreement. The term and termination provisions of the UTSW2 Agreement is the same as the UTSW1 Agreement, however in the event that the UTSW1 Agreement is terminated for any reason, or expires, then the UTSW2 Agreement likewise is terminated or deemed to have expired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The above description of UTSW1 Agreement and UTSW2 Agreement is just a summary and readers are referred to UTSW1 Agreement and UTSW2 Agreement, which are attached hereto as Exhibits 10.2 and 10.3 respectively, for a full and complete description of the patent expenses, milestone payments, fees and royalties payable by MAIA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our intellectual property, including the intellectual property licensed under UTSW1 and UTSW2, has been conceived or developed through government-funded research and thus may be subject to federal regulations providing for certain rights for the U.S. government or imposing certain obligations on us, such as a license to the U.S. government under such intellectual property, &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers. See Risks Relating to Our Intellectual Property - Intellectual property discovered through government funded programs may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology industry is characterized by a rapid evolution of technologies, significant competition and strong defense of intellectual property. While we believe that our platforms, technology, knowledge, experience, and scientific resources provide us with unique competitive advantages, we expect to face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. For example, current competitors in the non-small lung cancer indication are Merck, Regeneron, Eli Lilly and Roche. There are also many other large and small companies developing products for this indication. Key product features that, if approved, would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors also include large pharmaceutical and biotechnology companies, which may be developing therapeutic candidates with mechanisms similar to our compounds or targeting the same clinical indications as our therapeutic candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our therapeutic candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These early stage and more established competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">those we are developing. Any pharmaceutical candidate that we develop must be approved by the United States Food and Drug Administration, or FDA, before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before it may be legally marketed in foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates biopharmaceutical products under the Federal Food, Drug, and Cosmetic Act and the Public Health Services Act, or PHSA, and implementing regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Approval Processes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of an Investigational New Drug Application, or an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance of several phases of adequate and well-controlled human clinical trials according to the FDA&#x2019;s current good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug or biologic for its intended use;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of a New Drug Application, or an NDA, for a new drug product, or a Biologics License Application, or a BLA, for a new biological product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA&#x2019;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s or biologic&#x2019;s identity, strength, quality and purity;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or BLA; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA or BLA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions brought by the FDA and the Department of Justice, or DOJ, or other governmental entities, any of which could have a material adverse effect on us. These sanctions could include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of an approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seizures or administrative detention of product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">total or partial suspension of production or distribution; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions, fines, disgorgement, or civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources. There can be no certainty that approvals will be granted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a biopharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the drug or biological candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted in accordance with the FDA&#x2019;s good clinical practices requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials prior to approval are typically conducted in three sequential Phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1. The drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients having the specific disease.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2. The drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials, which usually involve more subjects than earlier trials, are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA or BLA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA by the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug or biological candidate and, among other things, must include methods for testing the identity, strength, quality and purity of the final drug or biologic. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews for completeness all NDAs and BLAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA or BLA for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the NDA or BLA submission is accepted for filing, the FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. In addition to its own review, the FDA may refer applications for novel drug or biological products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advisory committee, but it considers such recommendations carefully when making decisions. During the approval process, the FDA also will determine whether special marketing conditions or restrictions under a risk evaluation and mitigation strategy, or REMS, are necessary to assure the safe use of the drug or biologic. If the FDA concludes that a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is to be manufactured, and may also inspect facilities that provide raw materials for use in the product. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical trial sites to assure their compliance with cGCP during the conduct of studies of the subject drug. If during the review of the application the FDA identifies questions or concerns regarding the application, data, manufacturing process or manufacturing facilities, it may issue a deficiency letter which the sponsor must adequately address to the FDA&#x2019;s satisfaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NDA or BLA review and approval process is lengthy and difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA or BLA does not, in its submitted form, satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA will issue a &#x201c;complete response letter&#x201d; (CRL) if the agency decides not to approve the NDA or BLA. The complete response letter usually describes the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter will typically include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product receives regulatory approval, the approval may be for more limited conditions of use than the sponsor had proposed, such as limitations to specific diseases or subsets of a disease, limited patient populations, second-line or third-line use limitations, limited dosages or other limitations which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which may involve clinical trials designed to further assess a product&#x2019;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Companion Diagnostics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many drugs for cancer indications involving patient-specific genetic mutations or biomarkers are approved by FDA with limitations that the specific genetic mutation must be confirmed in each patient by use of an FDA-approved diagnostic test, commonly referred to as a &#x201c;companion diagnostic.&#x201d; The FDA issued a final guidance document in July 2014 addressing agency policy in relation to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. The FDA has also issued a Guidance, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (2016), which is &#x201c;is intended to be a practical guide to assist therapeutic product sponsors and IVD sponsors in developing a therapeutic product and an accompanying IVD companion diagnostic,&#x201d; and a Guidance, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2020), which &#x201c;describes considerations for the development and labeling of in vitro companion diagnostic devices (referred to as &#x201c;companion diagnostics&#x201d; herein) to support the indicated uses of multiple drug or biological oncology products, when appropriate.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As stated in its Guidance, the FDA may decide that it is appropriate to approve such a product without an approved or cleared </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. To date, no product targeting TERT+ cancer patients has been approved by FDA, and the applicability to THIO of FDA&#x2019;s Companion Diagnostics Guidance and policy is yet to be determined. If a companion diagnostic is required to be developed and approved in order to receive approval of THIO, the cost and length of time to fully develop and receive approval (if at all) of THIO may both be increased, as described in more detail in the section </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors &#x2013; Risks Relating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">to Government Regulation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because the FDA&#x2019;s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has a Fast-Track program that is intended to expedite or facilitate the process for reviewing new drug and biological products that meet certain criteria. Specifically, new drug and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Under a Fast Track designation, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if (i) the sponsor provides a schedule for the submission of the sections of the NDA or BLA, (ii) the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and (iii) the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product submitted to the FDA for marketing approval, including those submitted under a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or the new product has the potential to offer a significant improvement in the treatment, diagnosis or prevention of a disease compared with marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of accelerated approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies to confirm the safety and efficacy for the approved indication. Failure to conduct such studies or conducting such studies that do not establish the required safety and efficacy may result in revocation of the original accelerated approval. In addition, the FDA currently requires as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch or subsequent marketing of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process, and even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Hatch-Waxman Amendments and Generic Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orange Book Listing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a drug product is approved under an NDA, the product is listed in the FDA&#x2019;s publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; commonly known as the Orange Book. An NDA-approved drug product will be designated in the Orange Book as a Reference Listed Drug (RLD). Sponsors of approved NDA&#x2019;s are required to list with the FDA patents whose claims cover the product&#x2019;s active ingredient, formulation, or an approved method of using the drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Term Extensions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&#x2019;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ANDA Approval Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hatch-Waxman Amendments established an abbreviated FDA approval process for generic drugs that are shown to be pharmaceutically equivalent and bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application, or ANDA, with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. Drugs approved in this way are commonly referred to as &#x201c;generic equivalents&#x201d; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Section 505(b)(2) NDA Approval Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments to the FDCA and enables the applicant to rely, in part, on the FDA&#x2019;s previous approval of a similar product, and/or published literature, in support of its application. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&#x2019;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section 505(b)(2) applicant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANDA and 505(b)(2) products may be significantly less costly to bring to market than the reference listed drug, and companies that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ANDA and 505(b)(2) NDA Patent Certification Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If an ANDA is submitted to FDA with a Paragraph IV Certification, the generic applicant must also provide a &#x201c;Paragraph IV Notification&#x201d; to the holder of the NDA for the RLD and to the owner of the listed patent(s) being challenged by the ANDA applicant, providing a detailed written statement of the bases for the ANDA applicant&#x2019;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent infringement lawsuit against the ANDA applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA will be automatically stayed for 30 months, or until 7-1/2 years after the NDA approval if the generic application was filed between 4 years and 5 years after the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed. The applicant may, in certain circumstances, elect to submit a &#x201c;section viii&#x201d; statement with respect to a listed method of use patent, certifying that the proposed generic labeling does not contain (or carves out) any language that would infringe a method of use patented listed in the Orange Book for the RLD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ANDA or Section 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulatory Exclusivities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Chemical Entity (NCE) Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hatch-Waxman amendments provides a period of five years of non-patent marketing exclusivity for the first approved drug containing a new chemical entity (&#x201c;NCE&#x201d;) as an active ingredient. An NCE is an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &#x201c;active moiety&#x201d; is defined as the molecule or ion responsible for the drug substance&#x2019;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA or 505(b)(2) NDA seeking approval of a product that contains the same active moiety, except that the FDA may accept such</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an application for filing after four years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five years after approval of the reference drug, the 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7-1/2 years after the approval of the reference drug NDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Clinical Trial (3-Year) Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular indication or condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application or supplemental application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Orphan Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to a therapeutic candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a product or therapeutic candidate for this type of disease or condition will be recovered from sales in the United States for that product or therapeutic candidate. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product or therapeutic candidate that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the approved product is entitled to orphan product exclusivity, which means that the FDA may not approve any other marketing applications for the same drug for the same indication, except under limited circumstances, for seven years. Orphan product exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA, or if our therapeutic candidate is determined to be contained within a competitor&#x2019;s approved drug for the same indication or disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, an orphan drug credit is available for qualifying costs incurred between the date the FDA designates a drug as an orphan drug and the date the FDA approves the drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor conducts pediatric research and submits new clinical information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to support a label change for pediatric use; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#x2019;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following approval of a new drug or biologic product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, continuing cGMP compliance, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#x201c;off-label use&#x201d;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">new NDA or a NDA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an NDA or BLA approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product or therapeutic reaches the market. Later discovery of previously unknown problems with a product or therapeutic candidate, including adverse events of unanticipated severity or frequency, may result in in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved application, or suspension or revocation of product approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, a therapeutic candidate manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cGMP compliance requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">record-keeping requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reporting of adverse experiences with the therapeutic candidate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing the FDA with updated safety and efficacy information; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">therapeutic sampling and distribution requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in-patient populations that are not described in the product&#x2019;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Therapeutic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, foreign regulatory agencies, and some state agencies for compliance with cGMPs and other laws. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any noncompliance with cGMP requirements. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA or BLA applicant and any third-party manufacturers involved in producing the approved product. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of quality control and quality assurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act, or the DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10&#x2010;year period that is expected to culminate in November 2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulation Outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. It also is not yet clear how the United Kingdom&#x2019;s recent withdrawal from the European Union will affect the approval of medicinal products in the United Kingdom. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under European Union regulatory systems, a company can consider applying for marketing authorization in several European Union member states by submitting its marketing authorization application(s) under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The centralized procedure is compulsory for medicines derived from biotechnology, orphan medicinal products, or those medicines with an active substance not authorized in the European Union on or before May 20, 2004 intended to treat acquired immune deficiency syndrome, cancer, neurodegenerative disorders or diabetes and optional for those medicines containing a new active substance not authorized in the European Union on or before May 20, 2004, medicines which are highly innovative, or medicines to which the granting of a marketing authorization under the centralized procedure would be in the interest of patients at the European Union-level. The decentralized procedure provides for recognition by European Union national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for marketing authorization is submitted simultaneously to the national authorities of several European Union member states, one of them being chosen as the &#x201c;Reference Member State,&#x201d; and the remaining being the &#x201c;Concerned Member States.&#x201d; The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labeling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the marketing authorization on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder is unable to supply sufficient quantity of the medicinal product, or the marketing authorization holder has given its consent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Coverage, Pricing and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. In the U.S., third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic and biosimilar products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement for the pharmaceutical or biological products apply to companion diagnostics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, in some foreign countries, the proposed pricing for a product and therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, therapeutic candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product and therapeutic candidates. For example, in the United States, the system for FDA to collect and expend user fees paid by manufacturers of drugs, biologics, and medical devices must be reauthorized by statute every five years, and since 1992, each reauthorization legislation has included, to greater or lesser degrees, various other changes to the FDA&#x2019;s regulatory systems and procedures. The current legislative authority for FDA user fees expires in September 2022, and by that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. The expected 2022 reauthorization may include new legal provisions that could significantly impact our business in ways that cannot be predicted at this time. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of reducing drug prices, containing healthcare costs more generally, improving quality and/or expanding access.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted in March 2010 and has had a significant impact on the health care industry in the U.S. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA and we expect there may be additional challenges and amendments to the ACA in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which was signed into law on March 27, 2020, and was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, on December 20, 2019, the Further Consolidated Appropriations Act for 2020 became law (P.L. 116-94), which includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the &#x201c;CREATES Act.&#x201d; The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#x201c;commercially reasonable, market-based terms.&#x201d; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. While the Trump administration put forward various proposals and executive orders aimed at reducing drug prices, the Biden administration is likely to pursue its own proposals going forward. In August 2021, President Biden announced his support for legislative proposals to grant Medicare the power to negotiate lower drug prices, for pharmaceutical companies to face penalties if they raise prices faster than inflation, and to impose a new cap on how much Medicare recipients have to spend on medications. Such proposals may be included in upcoming legislation in Congress, but the outcome of such proposals remains uncertain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we research, and, if approved, market, sell and distribute our therapeutic candidates. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, physician sunshine and drug pricing transparency laws and regulations such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government uses these laws, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other allegedly unlawful sales and marketing practices; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, includes federal, civil and criminal provisions that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Physician Payments Sunshine Act, among other things, imposes requirements on manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to HHS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors and, beginning in 2022 for payments and other transfers of value provided in the previous year, certain advanced non-physician health care practitioners), teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations impose specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#x2019;s privacy and security standards directly applicable to &#x201c;business associates,&#x201d; defined as independent contractors or agents of covered entities, which include certain healthcare providers, health plans, and healthcare clearinghouses, that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws which require the registration of pharmaceutical sales representatives; and state laws and non-United States laws and regulations (particularly European Union laws regarding personal data relating to individuals based in Europe) that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not own or operate manufacturing facilities to produce any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for all our required raw materials, Active Pharmaceutical Ingredient (API), and finished products for our preclinical and clinical trials and if and when applicable, commercialization. We currently employ internal resources to manage our manufacturing relationships with these third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#x2019;s current good manufacturing practices, or cGMP, regulations. cGMP regulations require, among other things, quality control and quality assurance as well as corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulations - Environmental<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to various environmental laws of federal, state and local governments and foreign governments at various levels. Compliance with existing laws has not had a material adverse effect on our capital expenditures, competitive position, financial condition or results of operations, and management does not believe it will have such an impact in the current fiscal year. However, we cannot predict the impact of unforeseen environmental contingencies or new or changed laws or regulations on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had a total of 18 full-time employees which includes one employee employed by our Romanian subsidiary. We believe that we maintain a satisfactory working relationship with our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations. None of our employees is represented by a labor union.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Engagement, Talent Development &amp; Benefits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, and opportunities for equity ownership.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diversity, Inclusion, and Culture</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in Delaware in August 2018, and we have operations in Chicago, Illinois, with some of our team members setup virtually and working remotely in California, Nevada and Florida, among others. Our principal executive office is located at 444 West Lake Street, Suite 1700, Chicago, IL 60606, and our phone number is (312) 416-8592. In July 2021, we established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various preclinical and clinical activities for the development of our product candidates. In April 2022, we established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of our product candidates. Our website address is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.MAIABiotech.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The information contained on our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider any information contained on, or that can be accessed through, our website as part of this Annual Report on Form 10-K or in deciding whether to purchase our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implications of Being an Emerging Growth Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements, and registration statements; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If some investors find our common stock less attractive as a result of these exemptions, there may be a less active trading market for our common stock and the price of our common stock may be more volatile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933 (the &#x201c;Securities Act&#x201d;) for complying with new or revised</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to emerging growth company will have the meaning associated with it in the JOBS Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implications of Being a Smaller Reporting Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we are a &#x201c;smaller reporting company&#x201d; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held by non-affiliates equals or exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates equals or exceeds $700 million as of the end of that year&#x2019;s second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Risk Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of the material risks to our business, together with the information contained elsewhere in this Annual Report on Form 10-K, before you make a decision to invest in our common stock. Please note that the risks highlighted here are not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial condition and operating results may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary Risk Factors</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred losses since our inception and anticipate that we will continue to incur increasing losses for the foreseeable future.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are heavily dependent on the success of THIO, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which could delay or prevent the start of clinical trials for our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for THIO or any other candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market opportunities for THIO, if approved, may be smaller than we anticipate.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain FDA approval for our IND application for the planned THIO phase 2 trial, our clinical development of THIO may be significantly delayed and our business may be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain FDA approval for THIO or any other candidates in the United States, we may never obtain approval for or commercialize THIO or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A variety of risks associated with operating internationally could materially adversely affect our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations (&#x201c;CROs&#x201d;), consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of THIO and intend to rely on CMOs for the production of commercial supply of THIO, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend on license agreements with the University of Texas Southwestern, or UTSW, to permit us to use patents and patent applications, as well as to exploit specific technological know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have been granted licenses of use to patent applications. There can be no assurance that any of the patent applications that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be limited.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property rights do not address all potential threats to our competitive advantage.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The price of our common stock may be volatile and you could lose all or part of your investment. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may, in the future, issue additional capital stock, which would reduce investors&#x2019; percent of ownership and may dilute our share value.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our shares of common stock are currently listed on NYSE American. If we are unable to maintain listing of our securities on NYSE American or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $15,769,279 and $12,578,211 for the years ended December 31, 2022 and 2021, respectively.  As of  December 31, 2022, we had an accumulated deficit of $44,207,272. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to incur significant additional operating losses for the next several years, at least, as we advance THIO and any other candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other candidates, if approved. The costs of advancing candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enroll our Phase 2 trial, or conduct clinical trials for any other indications or other candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish sales, marketing, distribution, and compliance infrastructures to commercialize our drug, if approved, and for any other candidates for which we may obtain marketing approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional clinical, scientific and commercial personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our development and planned future commercialization efforts, as well as to support our transition to a public reporting company; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license or invent other candidates or technologies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our ability to successfully develop, commercialize and license any candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#x201c;&#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and &#x201c;&#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to Commercialization</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of THIO and launch and commercialize THIO, if we receive regulatory approval. We will require additional capital for the further development and potential commercialization of THIO and may also need to raise additional funds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sooner to pursue a more accelerated development of THIO. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our cash reserves as December 31, 2022 of $10.95 million and current financial condition as of the date of this Annual Report on Form 10-K, there is substantial doubt about our ability to continue as a going concern. (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See &#x2014;  Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#x2014;  Capital Resources &#x2014;  Our Ability to Continue as a Going Concern&#x201d; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further information.) Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to the:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for THIO or any other future candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;clinical development plans we establish for THIO and any other future candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;number and characteristics of candidates that we discover or in-license and develop;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;effects of competing technological and market developments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;costs and timing of the implementation of commercial-scale manufacturing activities; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, to fund our current or future operating plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate candidate development or future commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in Delaware and began our operations in August 2018. Our operations to date have been limited to financing and staffing our company, licensing candidates, conducting preclinical studies, manufacturing clinical supply, and preparing for clinical studies of THIO. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are heavily dependent on the success of THIO, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any products that have gained regulatory approval. Currently, our lead clinical stage candidate is THIO. As a result, our business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize THIO in a timely manner. We cannot commercialize THIO in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize THIO outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of THIO for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that THIO is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. Even if we were to successfully obtain approval of THIO from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for THIO in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for THIO, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize THIO, we may not be able to earn sufficient revenue to continue our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may face future business disruption and related risks resulting from the outbreak of the coronavirus (COVID-19) or from another pandemic, epidemic or outbreak of an infectious disease, any of which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease like the outbreak of COVID-19. For example, as a result of measures imposed by the governments in regions affected by COVID-19 businesses and schools have been suspended due to quarantines or &#x201c;stay at home&#x201d; orders intended to contain this outbreak. The spread of COVID-19 from China to other countries has resulted in the Director General of the World Health Organization declaring the outbreak of COVID-19 as a Public Health Emergency of International Concern (PHEIC), based on the advice of the Emergency Committee under the International Health Regulations (2005). In March 2020, and subsequently, various international travel restrictions were imposed and modified between the US and foreign countries and such restrictions may continue, be reimposed, or be expanded or otherwise further modified for the foreseeable future. COVID-19 continues to spread globally, including with the advent of the new &#x201c;Delta&#x201d; variant throughout 2021. The COVID-19 outbreak has impacted international stock markets, which continue to reflect the uncertainty associated with the slow-down in global economies and the reduced levels of international travel experienced since the beginning of January 2020. We continue to assess our business plans and the impact COVID-19 may have on our ability to advance the development of our drug candidates, including delays in starting or completing clinical trials, or to raise financing to support the development of our drug candidates, but no assurances can be given that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in particular. One of our initial clinical studies is taking place in Australia, which previously imposed one of the strictest COVID-19-related measures, including lock-downs, and may do so again in the future. While we have not currently experienced any potential delays or increased costs as a result of these measures, we may do so in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators and out-license partners&#x2019; ability to perform preclinical studies and clinical trials. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent to which the coronavirus impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, THIO and our other compounds may not have favorable results in later preclinical and clinical studies or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory approval to commence and continue to conduct a trial;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining Institutional Review Board, or IRB, approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside the United States;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">having patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold by regulatory authorities, or IRBs, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical sites deviating from trial protocol, failing to adequately enroll study subjects, committing fraud or other violations of regulatory requirements, or dropping out of a trial, which can render data from that site unusable in support of regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing patient safety concerns that arise during the course of a trial;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adding a sufficient number of clinical trial sites; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing sufficient quantities of THIO for use in clinical trials.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#x201c;&#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immuno-oncology agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products. Because all of our product candidates are derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived likelihood that our other product candidates will experience similar failures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#x2019; approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a biologics license application (BLA) or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we develop our product candidates and initiate clinical trials of our additional product candidates, serious adverse events, or SAEs, undesirable side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Should we observe SAEs in our clinical trials or identify other undesirable side effects or other unexpected findings depending on their severity, our trials could be delayed or even stopped and our development programs may be halted entirely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our product candidates initially show promise in early clinical trials, the side effects of biological products are frequently only detectable after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined to be attributed to our product candidate, we may be required to develop a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or ADA caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#x201c;boxed&#x201d; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to change the way a product is administered or conduct additional clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product may become less competitive, and our reputation may suffer;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may decide to remove the product from the marketplace; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim, topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and treatment continues and more patient data become available. Adverse differences between previous preliminary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#x2019;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the global COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to design such product candidates with the properties that we desire; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for THIO or any other candidates, our business will be substantially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for THIO or any other candidates. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of a NDA from the FDA. Our ability to obtain approval by the FDA or other regulatory authorities can be adversely impacted for various reasons including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a candidate is safe and effective for its proposed indication;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our candidates, or other products containing the active ingredient in our candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that a candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our development candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may inspect and find deficiencies at the clinical trial sites we use to conduct our clinical studies; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize a candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The planned THIO-101 phase 2 trial is intended to be a proof-of-concept trial that may be expanded depending on interim results and includes both primary and secondary endpoints consistent with previously approved medicines. If THIO achieves its intended effects and does not exhibit unacceptable safety risks, we plan to seek accelerated approval of THIO based on positive results of the expanded phase 2 THIO-101 trial, followed by full approval based on the results of a single phase 3 clinical study, as opposed to the traditional approach of conducting two or more phase 3 studies. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA. A single-study approach is permissible in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certain circumstances, particularly in oncology, but such circumstances are exceptional and FDA may not agree with that proposed approach, and thus we may be required to conduct two phase 3 trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the adequacy of the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate, and more particularly:</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if our NDA does not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if the FDA determines that it has insufficient information to determine whether such drug is safe for use under such conditions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if based on information we submit and any other information before the FDA, the FDA determines there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if the FDA determines that our labeling is false or misleading in any particular way.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of drugs that enter clinical development, only a small percentage successfully complete the regulatory approval processes and are approved and commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market THIO or any other candidates, which would significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the FDA or an applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, the FDA or foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, or may require warnings, other safety-related labeling information, or impose post-market safety requirements, including distribution restrictions, that negatively impact the commercial potential of the drug. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the nature of the trial protocol;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the existing body of safety and efficacy data with respect to the product candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competing clinical trials being conducted by other companies or institutions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain patient consents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in enrollment and completion of studies due to the COVID 19 pandemic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for THIO are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Serious adverse events or undesirable side effects caused by THIO or any other candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. THIO has been previously evaluated in at least 19 clinical studies both as monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies. A classic treatment strategy was used where patients were treated to maximum tolerated dose (MTD). Dose-limiting reversible toxicities were mainly hematologic (leukopenia, thrombocytopenia), gastrointestinal (nausea, vomiting) and generalized skin rashes; increases in blood urea nitrogen, creatinine, aspartate aminotransferase, alanine transaminase, and bilirubin were also recorded (Douglass, 1979; Gagliano, 1981; Higgins, 1985)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The available data provides substantial information on the safety profile of THIO in over 600 subjects (adult and pediatric) at doses significantly higher than those intended for investigation in the current program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If unacceptable side effects arise in the development of our candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our development candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw approvals of such product;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a &#x201c;black box&#x201d; warning or contraindication;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product may become less competitive; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market opportunities for THIO, if approved, may be smaller than we anticipate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to initially seek approval for THIO for use as a priming treatment in combination with the immune check point inhibitor cemiplimab in non-small cell lung cancer (&#x201c;NSCLC&#x201d;) in the United States. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and primary and secondary market research, and may prove to be incorrect. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have never obtained marketing approval for a development candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our development candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our development candidates or may conclude after review of our data that our application is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">insufficient to obtain marketing approval of our development candidates. If the FDA does not accept or approve our NDAs for our development candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our development candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO is active in cells that are telomerase positive (TERT+). The status of a tumor as being TERT+ can only be established by use of an in vitro test of the tumor cells. While experimental versions of such tests currently exist, none to date have received FDA approval. Under current FDA Guidances, for drugs and therapeutic biologics where the use of a specific diagnostic test is essential for the safe and effective use of the therapeutic product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test, the FDA generally will not approve the therapeutic product if a relevant &#x201c;companion diagnostic&#x201d; test is not also approved or cleared for the appropriate indication. As stated in its Guidances, the FDA may decide that it is appropriate to approve such a therapeutic product without an approved or cleared </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic device. Although the vast majority of cancers are TERT+, the FDA may determine that THIO can only be approved (if at all) for patients whose cancer has been confirmed to be TERT+ through use of an FDA-approved companion diagnostic. If the FDA were to take such a position, the development and potential approval and commercialization of THIO would take longer, be more expensive, and could become impractical.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval for THIO or any other candidates in the United States, we may never obtain approval for or commercialize THIO or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for THIO or any development candidate, we will still face extensive and ongoing regulatory requirements and obligations and any development candidates, if approved, may face future development and regulatory difficulties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on manufacturing such products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the labeling or marketing of products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning letters or untitled letters;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of the products from the market;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recall of products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the FDA&#x2019;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek a Breakthrough Therapy designation for THIO from the FDA. However, we might not seek such designation or be granted the designation by the FDA if sought, and even if we are granted the designation, it may not lead to a faster development or regulatory review or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek a Breakthrough Therapy designation for THIO or one or more of our other candidates. Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). For purposes of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer to findings that suggest an effect on IMM or serious symptoms. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for fast track designation (under a separate request), priority review, or accelerated approval, if supported by clinical data at the time the NDA is submitted to the FDA. FDA encourages a Breakthrough Therapy designation request to be submitted, and received by FDA, no later than the end-of-phase-2 meetings. Even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designation as a Breakthrough Therapy is within the discretion of the FDA both at the time of the submission of such a request, and during FDA&#x2019;s review of the drug and supporting data. Even if we believe that one of our candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation or may grant such a designation and subsequently rescind the designation prior to approval. Even if we receive and maintain Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use of THIO or any other candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impairment of our business reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of participants from our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant costs to defend the litigation;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">distraction of management&#x2019;s attention from our primary business;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to commercialize THIO or any other product candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased market demand for any product; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The product liability insurance coverage we plan to acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We intend to acquire insurance coverage to include larger clinical studies, different countries and the potential sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If THIO is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research; seek patent protection; and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may, among other things:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe effects;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain quicker regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement more effective approaches to sales and marketing; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">form more advantageous strategic alliances.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than THIO. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval for THIO, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may face early generic competition for THIO or our other products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmaceutical companies developing novel products face intense competition from generic drug manufacturers who aggressively seek to challenge patents and non-patent exclusivities for branded products, and who are able to use much less-onerous product development and FDA approval pathways for their generic products. The active ingredient of THIO was extensively tested as early as the 1970s and we intend to rely in part on the clinical data previously developed for the drug in support of an NDA for THIO. Generic drug applicants and other competitors may be able to similarly rely upon the prior clinical data in support of efforts to gain approval of competing products using the same active ingredient as THIO. If one or more such competitors complete development and seek and obtain regulatory approval before we do, our ability to obtain approval of and market THIO may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the FDA&#x2019;s generic drug approval processes, described in more detail in the section titled &#x201c;Hatch-Waxman and Generic Competition,&#x201d; we believe that THIO, if approved before any other application for a drug containing the same active ingredient, may be eligible for a five-year regulatory exclusivity period known as new chemical entity, or NCE Exclusivity, which would delay FDA review and approval of a competing product application that relies in whole or in part upon the FDA&#x2019;s approval of THIO, but such exclusivity is only determined by the FDA after a drug is approved and the FDA may determine that THIO is not eligible for NCE Exclusivity, or that approval of THIO must be delayed due to another applicant&#x2019;s relevant exclusivity. A new drug may, upon approval of its initial NDA or approval of supplemental NDAs, qualify for a three-year exclusivity period during which no generic version could be approved for the specific conditions of use covered by such exclusivity. Three-year exclusivity does not prevent FDA approval of another drug with the same active ingredient for a different indication or other conditions of use not protected by the exclusivity. Even if a competing version of THIO was approved with a different indication or condition of use, physicians would be free to prescribe such drug for uses that are covered by our regulatory exclusivity, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as THIO, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when a comparable alternative drug, an equivalent generic drug, a biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as alternatives to less expensive drugs and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If THIO or any candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectiveness of sales and marketing efforts;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to offer our products for sale at competitive prices;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any restrictions on the use of our product together with other medications.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any infrastructure for the sales, marketing or distribution of THIO, or compliance functions related to such activities, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial, compliance, and other non-technical capabilities or make arrangements with third parties to perform these services. We expect to build a focused sales, distribution and marketing infrastructure to market THIO, if approved, in the United States, with expected licenses in other countries and regions, including large markets such as Japan and Europe. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, oversee the compliance of sales and marketing functions, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, distribution and compliance capabilities could delay any product launch, which would adversely impact the commercialization of that product. For example, if the commercial launch of THIO for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our product candidates on our own include, but are not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe our products; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#x2019;s strategic interest in a product and such collaborator&#x2019;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of THIO, if approved, for certain markets overseas; however, we cannot assure you that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of THIO, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for THIO we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for THIO at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A variety of risks associated with operating internationally could materially adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of our product candidates and in April 2022, we established a wholly owned Romanian subsidiary, MAIA BIOTECHNOLOGY ROMANIA S.R.L. to conduct various preclinical and clinical activities for the development of our product candidates. Additionally, our business strategy includes potentially expanding further internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional potentially relevant third-party patent rights;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limits in our ability to penetrate international markets;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expansion of the Russian military invasion of Ukraine;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certain expenses including, among others, expenses for travel, translation and insurance; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations (&#x201c;CROs&#x201d;), consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our employees and independent contractors, including principal investigators, clinical trial sites, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of THIO and intend to rely on CMOs for the production of commercial supply of THIO, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of THIO and any candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of THIO drug substance to enable us to complete our clinical trials, and we have also engaged a CMO to provide clinical and commercial supply of the drug product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMOs. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#x2019;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We intend to continue to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 2 trials of THIO. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our CROs will be required to comply with the good laboratory practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#x2019;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our development candidates, if approved, and may affect the prices we may set.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, has substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#x201c;transfers of value&#x201d; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;extension of a manufacturer&#x2019;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;expansion of the entities eligible for discounts under the Public Health Service program; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x200b;a licensure framework for follow on biologic products.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">qui tam</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#x201c;any request or demand&#x201d; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we conduct clinical trial programs or enter into research collaborations in the European Economic Area, or EEA, we may be subject to the General Data Protection regulation, or GDPR. The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the EEA/European Union, or EU, to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The United Kingdom has implemented its own version of the GDPR, which contains similar requirements. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#x2019; or service providers&#x2019; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent legislation may materially adversely affect our financial condition, results of operations and cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently enacted U.S. tax legislation has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. Many of these changes are effective immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and Internal Revenue Service, or the IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reduction of the corporate tax rate under the legislation may cause a reduction in the economic benefit of deferred tax assets available to us. Furthermore, under the legislation, although the treatment of tax losses generated before December 31, 2017, has generally not changed, tax losses generated in calendar year 2018 and beyond will only be able to offset 80% of taxable income. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going-forward basis. We intend to work with our tax advisors and auditors to determine the full</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend on license agreements with the University of Texas Southwestern, or UTSW, to permit us to use patents and patent applications, as well as to exploit specific technological know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to license agreements with UTSW under which we were granted rights to patents and patent applications, as well as proprietary technologies, that are important and necessary to our business. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents, as well as the exploitation of proprietary technology, are subject to the continuation of, and our compliance with, the terms of our license agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our license agreements impose upon us various diligence, payment and other obligations, including the following:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our obligation to pay UTSW various milestone payments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our obligation to pay UTSW royalties based on net sales; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our obligation to pay UTSW fees associated with the prosecution, maintenance, or filing of the patents and patent applications we have licensed.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with any of our obligations under the license agreements, or we are subject to a bankruptcy or dissolution, UTSW may have the right to terminate their respective license agreements, in which event we would not be able to market any product candidates covered by the licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently own any patents, and we are heavily reliant upon licenses from UTSW to certain patent rights that are important or necessary to the development of our technology and product candidates. As a result, we may be limited in our ability to prevent competitors from developing and commercializing competitive products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not control the prosecution, maintenance, or filing of the patents and patent applications that are licensed to us under the license agreements. Thus, these patents and patent applications were not drafted by us or our attorneys, and we do not directly control the prosecution of these patents and patent applications. We cannot be certain that drafting or prosecution of the patents and patent applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents. UTSW directly controls the preparation, filing and prosecution of patent applications, and is responsible for maintaining the patents, covering technology that we license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with the obligations under our license agreement, including as a result of COVID-19 impacting our operations or due to lack of funds, or if we use the licensed intellectual property in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreement is terminated, we may not be able to develop, manufacture, market or sell the product candidates covered by our agreement. Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputes may arise regarding intellectual property subject to, and any of our rights and obligations under, any license or other strategic agreement, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which our technology and processes infringe, misappropriate or violate the intellectual property of the licensor that is not subject to the license agreement;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sublicensing of patent and other rights to third parties under any such agreement or collaborative relationships;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#x2019;s rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to seek alternative options, such as developing new product candidates with design-around technologies, which may require more time and investment, or abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have been granted licenses of use to patent applications. There can be no assurance that any of the patent applications that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have been granted licenses of use to patent applications in many countries worldwide. These applications cover a range of treatment methods. Unless and until the pending patent applications are issued, their protective scope is impossible to determine. It is also impossible to predict whether or how many of the patent applications will result in issued patents. Even if pending applications are issued, they may be issued with coverage significantly narrower than what is currently sought.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our proprietary position for our product candidates currently depends in part upon licenses to patents protecting methods of use, which may not prevent a competitor or other third party from using the same product candidate for another use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Composition of matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to be the favored form of intellectual property protection for pharmaceutical products, as such patents generally provide protection without regard to any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect the use of a product for the specified method. These types of patent claims do not prevent a competitor or other third party from making and marketing an identical API for an indication that is outside the scope of the method claims. Moreover, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no assurance that all the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents further cover THIO or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to any patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of Supreme Court Cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#x201c;law of nature.&#x201d; Further, publications of discoveries in scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. While various extensions may be available, the life of a patent is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become subject to third parties&#x2019; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly and/or time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to third-party claims including infringement, interference, or derivation proceedings before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that the third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defending such claims would cause us to incur substantial expenses and, if unsuccessful, could cause us to pay substantial damages if we are found to be infringing a third party&#x2019;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#x2019; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot guarantee that any of our or our licensors&#x2019; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (AIA) which was passed in September 2011, resulted in significant changes to the U.S. patent system.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#x201c;first-to-file&#x201d; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#x2019; patent applications and the enforcement or defense of our or our licensors&#x2019; issued patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#x2019; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#x2019; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#x2019; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries having similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a non-expired patent which claims a human drug product, a method of using the product, or a method of manufacturing the product, as compensation for effective patent term lost during product development and the FDA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory review process. Moreover, only one patent may be extended covering the drug product and the total patent term including the extension cannot exceed 14 years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO (referred to as Patent Term Adjustment, or PTA). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may develop, acquire, or license intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as march-in rights). If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, some of our intellectual property, including the intellectual property licensed from the University of Texas Southwestern Medical Center was funded in whole or in part by the United States government, the United States government has certain rights to such patent rights and technology, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes and march-in rights, and impose certain reporting and domestic manufacturing requirements. These rights may permit the United States government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to United States industry. In addition, our rights in such inventions are and may be subject to certain requirements to manufacture products embodying such inventions in the United States. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make products that are similar to THIO or our future product candidates but that are not covered by the claims of the patents that we own or license from others;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ownership of our patents or patent applications may be challenged by third parties; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture THIO and any future product candidates, and we expect to collaborate with third parties on the development of THIO and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for any other of our product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any proprietary name we propose to use with our clinical-stage product candidates or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. The EMA may also object to our proposed proprietary product name that infringes the existing rights of third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of THIO or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize THIO or our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. At this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize THIO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#x2019; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our proprietary information may be lost, or we may suffer security breaches.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, damage to our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Employees, Managing Our Growth and Our Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on the development, regulatory, commercialization and business development expertise of Vlad Vitoc and Mihail Obrocea, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize product candidates will be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business and operations would suffer in the event of system failures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of THIO or any other product candidate could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Relating to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An active, liquid trading market for our common stock may not develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock was listed and began trading on the NYSE American on July 28, 2022 under the symbol &#x201c;MAIA.&#x201d; Prior to the listing, there was no public market for our common stock.  An active trading market for shares of our common stock may never develop or be sustained. If an active trading market does not develop, you may have difficulty selling any of our shares that you purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The price of our common stock may be volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities markets worldwide have experienced in the past, and are likely to experience in the future, significant price and volume fluctuations. This market volatility, as well as general economic, market, or political conditions could reduce the market price of our common stock regardless of our results of operations. The trading price of our common stock has been and is likely to continue to be volatile and could be subject to wide price fluctuations in response to various factors including, among other things, the risk factors described herein and other factors beyond our control. Factors affecting the trading price of our common stock could include, but are not limited to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the broader stock market; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in our quarterly results of operations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments in our industry in general; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse results or delays in clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to commercialize our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including without limitation the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of expenses related to future product candidates or clinical development programs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to achieve product development goals in the timeframe we announce;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuance of new, negative or changed securities analysts' reports or recommendations or estimates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales, or anticipated sales, of our stock, including sales by our officers, directors and significant stockholders;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions or departures of key personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or political developments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the public's response to press releases or other public announcements by us or third parties, including our filings with the SEC;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements, media reports or other public forum comments related to litigation, claims or reputational charges against us;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">guidance, if any, that we provide to the public, any changes in this guidance, or our failure to meet this guidance;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development and sustainability of an active trading market for our common stock; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investor perceptions of the investment opportunity associated with our common stock relative to other investment alternatives;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other events or factors, including those resulting from system failures and disruptions, earthquakes, hurricanes, war, acts of terrorism, global outbreaks or pandemic, other natural disasters or responses to these events;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting principles;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">litigation and governmental investigations; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changing economic conditions. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other factors may cause the market price and demand for shares of our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the past, when the market price of a stock has been volatile, holders of that stock sometimes have instituted securities class action litigation against the company that issued the stock following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. Securities litigation against us, regardless of the merits or outcome, could result in substantial costs and divert the time and attention of our management from our business, which could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales of our common stock, or the perception in the public markets that these sales may occur, could cause the market price for our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the time of this date of this Annual Report on Form 10-K, 632,703 shares of common stock are reserved for issuance under our 2021 Equity Incentive Plan. We cannot predict the effect, if any, that market sales of shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Sales of substantial amounts of shares of our common stock in the public market, or the perception that those sales will occur, could cause the market price of our common stock to decline. Of the shares of common stock outstanding, 8,350,367 are restricted securities within the meaning of Rule 144 under the Securities Act and subject to certain restrictions on resale. Restricted securities may be sold in the public market only if they are registered under the Securities Act, or are sold pursuant to an exemption from registration such as Rule 144 or Rule 701.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, each of our officers, directors, and certain of our stockholders agreed in connection with our initial public offering, which was consummated on August 1, 2022, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of the prospectus in our initial public offering, without the prior written consent of the representative. Certain of our other stockholders, who are not insiders, have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 12 months after the date of the prospectus, without the prior written consent of the representative. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144. Following the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. As a result of our current dividend policy, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it. Any future determination to declare and pay cash dividends will be at the discretion of our board of directors and will depend on, among other things, our financial condition, results of operations, cash requirements, contractual restrictions and such other factors as our board of directors deems relevant. Our ability to declare and pay dividends to our stockholders is subject to certain laws, regulations, and policies, including minimum capital requirements and, as a Delaware corporation, we are subject to certain restrictions on dividends under the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;). Under the DGCL, our board of directors may not authorize payment of a dividend unless it is either paid out of our surplus, as calculated in accordance with the DGCL, or if we do not have a surplus, it is paid out of our net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Our ability to pay dividends depends on our receipt of cash dividends from our operating subsidiaries, which may further restrict our ability to pay dividends as a result of the laws of their jurisdiction of organization or agreements of our subsidiaries, including agreements governing our indebtedness. For more information, see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividend Policy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case, to the fullest extent permitted by Delaware law. Pursuant to our amended and restated bylaws and the DGCL, our directors will not be liable to the Company or any stockholders for damages for any breach of fiduciary duty, except (i) acts that breach his or her duty of loyalty to the Company or its stockholders; (ii) acts or omissions without good faith or involving intentional misconduct or knowing violation of the law; (iii) pursuant to Section 174 of the DGCL regarding director liability for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unlawful payment of a dividend or unlawful stock purchase or redemption; or (iv) for any transaction from which the director derived an improper personal benefit. In addition, we have entered into indemnification agreements with each of our executive officers and directors. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under the DGCL. The bylaws also require us, if so requested, to advance expenses that such director or officer incurred in defending or investigating a threatened or pending action, suit or proceeding, provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may, in the future, issue additional capital stock, which would reduce investors&#x2019; percent of ownership and may dilute our share value.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have the right to raise additional capital or incur borrowings from third parties to finance our business. We may also implement public or private mergers, business combinations, business acquisitions and similar transactions pursuant to which it would issue substantial additional capital stock to outside parties, causing substantial dilution in the ownership of the Company by our existing stockholders. Our Board of Directors has the authority, without the consent of any of the stockholders, to cause us to issue more shares of common stock and/or preferred stock at such price and on such terms and conditions as are determined by the Board of Directors in its sole discretion. The issuance of additional shares of capital stock by us will dilute your ownership percentage in the Company and could impair our ability to raise capital in the future through the sale of equity securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain stockholders who are also officers and directors of the Company may have significant control over our management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our directors and executive officers own as of March 22, 2022, an aggregate of 3,581,804 shares of our common stock, which constitutes 32.5% of our issued and outstanding common stock. As a result, our directors and executive officers may have a significant influence on our affairs and management, as well as on all matters requiring stockholder approval, including electing and removing members of our Board of Directors, causing us to engage in transactions with affiliated entities, causing or restricting our sale or merger, and certain other matters. Such concentration of ownership and control could have the effect of delaying, deferring or preventing a change in control of us even when such a change of control would be in the best interests of our stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover protections in our amended and restated certificate of incorporation and our amended and restated bylaws, or our contractual obligations may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions contained in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of the DGCL, could delay or make it more difficult to remove incumbent directors or could impede a merger, takeover or other business combination involving us or the replacement of our management, or discourage a potential investor from making a tender offer for our common stock, which, under certain circumstances, could reduce the market value of our common stock, even if it would benefit our stockholders. Among other things, these provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">do not permit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delegate the sole power of a majority of the board of directors to fix the number of directors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide the power to our board of directors to fill any vacancy on our board of directors, whether such vacancy occurs as a result of an increase in the number of directors or otherwise;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">generally limit stockholders ability to call special meetings of stockholders and generally prohibit stockholder action to be taken by written consent; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, agents or other stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (i) derivative action or proceeding brought on our behalf, (ii) action asserting a claim of breach of a fiduciary duty or other wrongdoing by any current or former director, officer, employee, agent or stockholder to us or our stockholders, (iii) any action or proceeding asserting a claim against us or any current or former director, officer or other employee of the company, arising out of or pursuant to arising under any provision of the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware, except for, as to each of (i) through (iv) above, any action as to which the Court of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chancery of the State of Delaware determines that there is an indispensable party not subject to the personal jurisdiction of the Court of Chancery of the State of Delaware (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery of the State of Delaware within ten (10) days following such determination), in which case the United States District Court for the District of Delaware or other state courts of the State of Delaware, as applicable, shall, to the fullest extent permitted by law, be the sole and exclusive forum for any such claims. However, the exclusive forum provisions shall not apply to suits brought to enforce a duty or liability created by the Securities Act, the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) or any other claim for which the federal courts have exclusive jurisdiction, for which the federal district courts of the District of Delaware shall be the sole and exclusive forum unless the Company consents in writing to the selection of an alternative forum. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in any shares of our capital stock shall be deemed to have notice of and consented to the forum provision in our amended and restated bylaws. This choice of forum provision may limit a stockholder's ability to bring a claim in a different judicial forum, including one that it may find favorable or convenient for a specified class of disputes with us or our directors, officers, other stockholders, or employees, which may discourage such lawsuits, make them more difficult or expensive to pursue, and result in outcomes that are less favorable to such stockholders than outcomes that may have been attainable in other jurisdictions. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies' certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are considered a &#x201c;smaller reporting company&#x201d; and are exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rule 12b-2 of the Exchange Act defines a &#x201c;smaller reporting company&#x201d; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Had a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated offering price of the shares; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the case of an issuer who had annual revenue of less than $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a &#x201c;smaller reporting company&#x201d; we are not required and may not include a Compensation Discussion and Analysis section in our proxy statements; we provide only 3 years of business development information; provide fewer years of selected data; and have other &#x201c;scaled&#x201d; disclosure requirements that are less comprehensive than issuers that are not &#x201c;smaller reporting companies&#x201d; which could make our stock less attractive to potential investors, which could make it more difficult for you to sell your shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are considered an &#x201c;emerging growth company,&#x201d; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially impact reporting of our financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant volatility to our reported or expected financial performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Under standards established by the Public Company Accounting Oversight Board (&#x201c;PCAOB&#x201d;) and the Exchange Act, a deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB and Rule 12b-2 of the Exchange Act define a material weakness as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting for the first fiscal year beginning after the effective date of our IPO and in each year thereafter. Our auditors will also need to attest to the effectiveness of our internal control over financial reporting upon  losing our Emerging Growth Company status and becoming an accelerated filer or a large accelerated filer. If we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected, and we could become subject to litigation or investigations by the stock exchange on which our common stock are listed, the SEC or other regulatory authorities, which could require additional financial and management resources and could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting requirements of the Exchange Act, which is necessary to maintain our public company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy in which event you could lose your entire investment in our Company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon becoming a public company, we are required to comply with the SEC&#x2019;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our controls over financial reporting. Although we are required to disclose changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal controls over financial reporting pursuant to Section 404 until the year following our first annual report</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">required to be filed with the SEC. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting, as well as a statement that our independent registered public accounting firm has issued an opinion on the effectiveness of our internal control over financial reporting, provided that our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the Securities and Exchange Commission, or SEC, following the later of the date we are deemed to be an &#x201c;accelerated filer&#x201d; or a &#x201c;large accelerated filer,&#x201d; each as defined in the Exchange Act, or the date we are no longer an emerging growth company, as defined in the JOBS Act. We could be an emerging growth company for up to five years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified deficiencies in our internal control that we consider to be material weaknesses in our internal control over financial reporting which existed as of December 31, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did not maintain an effective control environment as there was an insufficient complement of personnel within the finance and accounting function with appropriate degree of knowledge, experience and training in the application of U.S. generally accepted accounting principles (&#x201c;U.S. GAAP). These factors contributed to the following additional material weaknesses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We failed to design, implement and maintain effective controls regarding:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks associated with segregation of duties.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks associated with accounting for non-recurring complex transactions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we work towards remediating these material weaknesses, we will design and implement controls to properly account for non-recurring complex transactions in accordance with U.S. generally accepted accounting principles. In addition, we will design, document, and consistently perform control activities in the identified areas which are currently lacking. To assist us in the remediation and performance of remediated controls we hired a Corporate Controller, and we will continue to utilize an accounting and financial reporting advisory firm with significant experience with publicly held companies to assist our management in evaluating the accounting treatment for complex transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley, and we may be unable to accurately report our financial results, or report them within the timeframes required by law or stock exchange regulations. We cannot assure that our existing material weakness will be remediated or that additional material weaknesses will not exist or otherwise be discovered, any of which could adversely affect our reputation, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unanticipated changes in the insurance market or factors affecting self-insurance reserve estimates could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use a combination of insurance and self-insurance coverage to provide for potential liabilities for workers' compensation, general liability, property losses, auto liability, directors and officers liability, pharmacy liability and employee health care benefits. However, there are types of losses we may incur but against which we cannot be insured or which we believe are not economically reasonable to insure, such as losses due to acts of war, employee and certain other crime, certain wage and hour and other employment-related claims, including class actions, actions based on certain customer protection laws, certain cyber events and some natural and other disasters or similar events. If we incur these losses and they are material, our business could suffer. Liabilities associated with the risks that are retained by us are determined, based in part, by considering historical claims experience, severity factors, inflation, and other actuarial assumptions. Our determination of the risk we retain is subject to a high degree of variability related to, among other things, future interest and inflation rates, future economic conditions, litigation trends and benefit-level changes. Any deviation of actual claims and other expenses related to these and other risks in excess of our assumptions, estimates, and historical trends, may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets. Additionally, Russia&#x2019;s prior annexation of Crimea, recent recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in Ukraine have led to sanctions and other penalties being levied by the United States, European Union and other countries against Russia, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People&#x2019;s Republic, and the so-called Luhansk People&#x2019;s Republic, including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telecommunication (SWIFT) payment system. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past led and may in the future lead to market-wide liquidity problems. On March 10 and March 12, 2023, the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) took control and was appointed receiver of Silicon Valley Bank (&#x201c;SVB&#x201d;) and Signature Bank, respectively, after each bank was unable to continue its operations. We are unable to predict the extent or nature of the impacts of the failures of SVB and Signature Bank and related circumstances at this time. Similarly, we cannot predict the impact that the high market volatility and instability of the banking sector more broadly could have on economic activity and our business in particular. The failure of other banks and financial institutions and measures taken, or not taken, by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not hold any of our funds at SVB or Signature Bank, if the financial institutions with which we do business enter receivership or become insolvent in the future, there is no guarantee that the Department of the Treasury, the Federal Reserve and the FDIC will intercede to provide us and other depositors with access to balances in excess of the $250,000 FDIC insurance limit, that we would be able to access our existing cash, cash equivalents and investments, that we would be able to maintain any required letters of credit or other credit support arrangements, or that we would be able to adequately fund our business for a prolonged period of time or at all, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, if any parties with which we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#x2019; ability to continue to fund their business and perform their obligations to us could be adversely affected, which, in turn, could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Unresolved Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Properties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our headquarters is in Chicago, Illinois where we currently lease office space with approximately 124 square feet under a six month lease starting in October 2022, under which we currently pay $3,000 per month. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms. Additionally, we intend to maintain our business model designed to leverage virtual technology to minimize brick and mortar facilities while optimizing our ability to attract top talented employees that may reside in any geography.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Legal Proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the date of the Annual Report on Form 10-K, we are not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Mine Safety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information and Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is traded on NYSE American under the symbol &#x201c;MAIA&#x201d;. As of March 22, 2023, 10,996,404 shares of the Company&#x2019;s common stock were issued and outstanding and were owned by approximately 136 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, we issued and sold 263,729 shares of our common stock with an aggregate principal<br />amount of approximately $2.4 million.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Between April 22, 2022 and May 3, 2022, warrant holders exercised warrants, resulting in the issuance of 153,000 shares of<br />common stock for proceeds of approximately $275,400.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />In May 2022, we issued and sold 11,111 shares of our common stock with an aggregate principal amount of approximately<br />$0.1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2022, we entered into an agreement with FORCE Family Office, LLC (&#x201c;Force&#x201d;) for the provision of investor<br />relations services from January 16, 2023 through July 16, 2023, pursuant to which we issued 18,000 shares of common stock on January 16, 2023. Pursuant to the agreement, we also agreed to issue an additional 18,000 shares of common stock on April 16, 2023 unless the agreement is terminated beforehand.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue 22,500 shares of common stock on March 8, 2023 and an additional 22,500 shares of common stock every ninety days after the execution date of the contract until termination of the agreement.  The term of the agreement extends for 180 days, and renews automatically until we provide written notice prior to the end of the term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Between January 1, 2021 and August 1, 2022, we granted to our employees, officers, directors and other persons who provide<br />services to us options to purchase up to 2,634,513 shares of common stock under the 2018 Stock Option Plan and the Amended and<br />Restated 2020 Stock Option Plan, at a weighted average exercise price of $3.21 per share. In addition, we issued to certain persons who provided services to us and in conjunction with convertible notes, warrants to purchase up to 769,865 shares of our common stock at a weighted average exercise price of $6.04 per share, which expire at various dates through September 2028 and vested upon issuance.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No underwriters were involved in the foregoing issuances of securities. The securities described above were issued to investors<br />in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the<br />Securities Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipient of securities in the transactions described above represented that it was an accredited investor and was acquiring the securities for their own account for investment purposes only, and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. [Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion together with our financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that are based on our current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. See &#x201c;Cautionary Note Regarding Forward-Looking Statements.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biotechnology company engaged in the discovery, development and commercialization of therapies targeting cancer. Our initial disease target is lung cancer, a serious medical condition with an incidence of over 235,000 new cases in the US in 2021, representing 12.4% of all cancers, and over 131,000 deaths, or 21.7% of all cancers. Worldwide, lung cancer incidence is over 2,200,000 per year (ranking second only after breast cancer), and mortality over 1,800,000 (ranking first). Specifically, we are targeting Non-Small Cell Lung Cancer (NSCLC), which represents 85% of all lung cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We accomplished the following key milestones:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2018, we in-licensed THIO from University of Texas Southwestern, in Dallas. The patent license is global and exclusive for the duration of the patients&#x2019; lives.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we completed a common stock seed round in the amount of $2 million.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we generated the first data for THIO demonstrating complete regression with no recurrence when administered in advance of atezolizumab (TecentriQ&#174;; Genentech), in colorectal and lung cancer preclinical models.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the First Quarter 2020, we filed a provisional patent application for THIO in sequential combination with checkpoint inhibitors, covering all tumor types. The patent was allowed in the US in the First Quarter 2021 and expires in 2041.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the First Quarter 2021, we entered into a Drug Supply Agreement with Regeneron Pharmaceuticals, Inc. Under this agreement, Regeneron will provide cemiplimab (LIBTAYO; anti-PD-1 checkpoint inhibitor) at no charge for the THIO-101 trials, testing THIO administration for immune activation followed by cemiplimab in NSCLC. This drug supply agreement replaces direct drug purchase expense that we would be otherwise required to incur. In exchange, Regeneron received development exclusivity in NSCLC for the duration of the trial which is expected to be two years, meaning we cannot conduct trials in NSCLC with another checkpoint inhibitor during the time of the trial. All other areas of study and development in any other tumor types remain open.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the First Quarter 2021, we initiated our clinical supply manufacturing (CMC) under Good Manufacturing Practices (GMP) conditions to provide clinical supply for THIO-101 and other development needs.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Second Quarter 2021, we completed a convertible note funding round in the amount of approximately $8 million.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Third Quarter 2021 and Fourth Quarter 2021, we sold common shares of MAIA for total proceeds of approximately $6.2 million. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the First Quarter 2022, we completed the Crossover Round for total proceeds of approximately $2.4 million. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the First Quarter 2022, THIO received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the THIO-101 Phase 2 clinical study.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO for the treatment of hepatocellular carcinoma, and in May 2022, the FDA granted ODD to THIO for the treatment of small-cell lung cancer. The FDA&#x2019;s Office of Orphan Products Development may grant orphan designation status to drugs and biologics that are intended for the treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, we completed the Additional Round for total proceeds of approximately $99,999. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, we entered into a research and collaboration agreement with the Nationwide Children&#x2019;s Hospital to evaluate the potential of THIO in combination with current standard-of-care therapies for brain cancer. The organizations is conducting preclinical studies to assess the efficacy and safety of THIO in combination with radiotherapy and immune checkpoint inhibitors in vitro and in vivo models.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, we completed our selection process for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia. We have also submitted a similar application to conduct the same Phase 2 study in Europe.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 28, 2022, the Company&#x2019;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold 2,000,000 shares of common stock at $5.00 per share for net proceeds of $10,000,000 in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5.00 per share when the underwriter exercised the overallotment for net proceeds of $1,500,000 prior to deducting underwriting discounts, commissions, and other offering expenses. We believe we have raised sufficient capital to fund the THIO-101 lead-in and preliminary efficacy of the phase 2 THIO-101 trial. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, MAIA&#x2019;s Phase 2 clinical trial. THIO-101 is a critical component of THIO&#x2019;s clinical development process and it is of the utmost importance that we collaborate with leading cancer institutes in Australia and now in Europe, for a target total of 30 clinical trial sites in six countries.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational telomere-targeting agent, in patients with advanced non-small cell lung cancer (NSCLC).</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the first week of March 2023, the first two patients were dosed in Europe in MAIA&#x2019;s Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Following regulatory clearances in Hungary, Poland, and Bulgaria, five clinical sites have been activated in these three European countries.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of the COVID-19 Pandemic on Our Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 Outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our initial clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of the War in Ukraine on Our Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The short and long-term implications of Russia&#x2019;s invasion of Ukraine are difficult to predict at this time. The imposition of sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations. Because of the highly uncertain and dynamic nature of these events, the Company terminated any planned research activities in Russia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Operations Overview and Analysis For the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.829%;"></td>
    <td style="width:1.617%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.617%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.617%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.617%;"></td>
    <td style="width:14.864%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollars</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percentage</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development <br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,933,314</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,496,796</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,436,518</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative <br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,143,527</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,289,831</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,853,696</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratchet share expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,099,360</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,099,360</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating costs and expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,176,201</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,786,627</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,389,574</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,176,201</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7,786,627</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8,389,574</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,967</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(827,539</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">820,572</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(99)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,870</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,012</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(142</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Australian research and<br />&#160;&#160;&#160;&#160;&#160;development incentives</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313,625</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,666</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,959</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">618%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paycheck protection program loan forgiveness</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,500</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(62,500</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of embedded <br />&#160;&#160;&#160;&#160;&#160;features</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(203,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of warrant <br />&#160;&#160;&#160;&#160;&#160;liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98,394</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,546,280</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,644,674</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(106)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of <br />&#160;&#160;&#160;&#160;&#160;convertible notes and convertible <br />&#160;&#160;&#160;&#160;&#160;notes, related parties</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,322,943</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,322,943</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406,922</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,791,584</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,198,506</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(108)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15,769,279</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12,578,211</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,191,068</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to noncontrolling <br />&#160;&#160;&#160;&#160;&#160;interests</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(74,331</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,331</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deemed dividend on warrant <br />&#160;&#160;&#160;&#160;modifications</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(450,578</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(450,578</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to MAIA<br />&#160;&#160;&#160;&#160;Biotechnology, Inc. shareholders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,219,857</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12,503,880</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,715,977</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses increased by approximately $5,437,000 or 155%, from approximately $3,497,000 for the year ended December 31, 2021 to approximately $8,933,000 for the year ended December 31, 2022. The increase was primarily related to an increase in payroll and bonus expense of approximately $2,244,000 related to increased headcount of nine additional employees during the fiscal year 2022, the increase in clinical expenses related to the clinical trial startup of THIO of approximately $1,979,000, an increase in Scientific pre-clinical research of approximately $1,127,000, an increase in professional fees of approximately $18,000, and an increase in other expenses related to research and development of approximately $116,000 offset by a decrease in stock based compensation costs of approximately $47,000 related to employee options granted during fiscal year 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses increased by approximately $1,854,000 or 43% from approximately $4,290,000 for the year ended December 31, 2021 to approximately $6,144,000 for the year ended December 31, 2022. The increase was primarily attributable to the increased costs to create additional infrastructure to support our operations as a public company. Increases included an increases in payroll and bonus expense of approximately $929,000 related to the increase in head count over the same period last</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year, the approximate increase in other expenses of $896,000 and an increase of approximately $358,000 in professional fees offset by decrease in stock based compensation expense of approximately $329,000 primarily due to the 2021 expense related to founder's stock-based compensation expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ratchet Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratchet expense increased by approximately $1,099,000 or 100% for the year ended December 31, 2022 due to the issuance of ratchet shares to certain private investors that purchased shares of our common stock prior to our initial public offering.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other income (expense), net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net increased approximately $5,199,000 from other expense of approximately $4,792,000 for the year ended December 31, 2021 to other income of approximately $407,000 for the year ended December 31, 2022. The increase in other income (expense), net was primarily the result of a loss on extinguishment of convertible notes and convertible notes of approximately $2,323,000 in 2021, approximately $1,645,000 of expense for the change in fair value of the warrant liability, the change in the fair value of bifurcated embedded feature of $203,000, expense related to approximately $828,000 of interest for convertible notes for the year ended December 31, 2021, and other income increased by approximately $270,000 of income related to the Australian research and development incentives for the year ended December 31, 2022 offset by a decrease in other income of approximated $63,000 for the paycheck protection loan forgiveness for the year ended December 31, 2021 and offset by the approximate $7,000 of interest expense for the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents selected financial information and statistics as of and for the years ended December 31, 2022 and 2021:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.415%;"></td>
    <td style="width:1.165%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.661999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.631%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.128%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Data:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,950,927</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,574,592</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Working capital </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,539,131</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,526,499</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,022,040</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,327,199</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued bonus</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,094,582</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384,750</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,271</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,507,793</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,181,203</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We define working capital as current assets less current liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Ability to Continue as a Going Concern</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our available cash totaled approximately $10,951,000 which represented an increase of approximately $376,000 compared to December 31, 2021. As of December 31, 2022, we had working capital of approximately $8,539,000 which represents an increase of approximately $13,000 compared to December 31, 2021. We have generated no revenues as of December 31, 2022. The Company&#x2019;s current operating plan indicates that it will continue to incur losses from operations and generate negative cash flows from operating activities given ongoing expenditures related to the completion of its ongoing clinical trials and the Company&#x2019;s lack of revenue generating activities. Based on the Company&#x2019;s cash reserves as December 31, 2022 of $10.95 million and current financial condition as of the date of the Annual Report on Form 10-K, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To meet the Company&#x2019;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after these financial statements are issued.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sale of Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, the Company sold 263,729 shares of common stock at $9 per share for gross proceeds of $2,373,561 before transaction costs and expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Between April 22, 2022 and May 3, 2022, warrant holders exercised warrants, resulting in the issuance of 153,000 shares of common stock for proceeds of approximately $275,400.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 19, 2022, the Company sold 11,111 shares of common stock at $9.00 per share for gross proceeds of $99,999 with no transaction costs. On August 1, 2022, the Company sold 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000 in an initial public offering. On August 3, 2022, the Company sold an additional 300,000 shares of common stock at $5 per share for gross proceeds of $1,500,000 per the overallotment option for the underwriter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to raise additional capital to fund our operations, to develop and commercialize THIO, and to develop, acquire or in-license other products. We may seek to fund our operations through public equity, private equity, or debt financings, as well as other sources. We cannot make any assurances that additional financings will be available to us and, if available, on acceptable terms or at all. This could negatively impact our business and operations and could also lead to the reduction of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ended December 31, 2022 and 2021</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.491%;"></td>
    <td style="width:1.647%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.016%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.638%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.209999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash flows used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(11,655,725</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,122,896</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash flows provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,036,790</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,033,731</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of foreign currency exchange rate changes on cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,430</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">376,635</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,910,835</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, net cash used in operating activities was approximately $11,657,000, which consisted of a consolidated net loss of approximately $15,769,000 offset by non-cash charges of approximately $3,320,000 which primarily includes approximately $2,319,000 in stock-based compensation, approximately $1,099,000 of expense related to the ratchet share issuance, offset by a gain of approximately $98,000 related to the changes in fair value of the warrant liability. Total changes in operating assets and liabilities of approximately $793,000 were primarily driven by an approximate $211,000 increase in accounts payable, and an approximate $1,027,000 increase in accrued expenses and an approximate $440,000 decrease in deferred offering costs offset by an approximate $111,000 decrease in deferred compensation, an approximate increase of $269,000 in Australian research and development incentives receivable and an approximate $505,000 increase in prepaid expenses and other current assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021, net cash used in operating activities was approximately $4,123,000, which consisted of a consolidated net loss of approximately $12,578,000 offset by non-cash charges of approximately $7,330,000 which primarily includes approximately $2,723,000 in stock-based compensation, a loss of approximately $203,000 related to the change in fair value of embedded features related to convertible notes, a loss of approximately $1,546,000 related to the changes in the fair value of the warrant liability, and amortization of debt discount on convertible notes of approximately $597,000, offset by a gain from forgiveness of Payroll Protection Plan loan of approximately $63,000. Total changes in operating assets and liabilities of approximately $1,126,000 were primarily driven by an approximate $806,000 increase in accounts payable, and an approximate $1,261,000 increase in accrued expenses, offset by an approximate $7,000 decrease in related party payables, an approximate $15,000 increase in prepaid expenses and other current assets, an approximate $264,000 increase in deferred compensation, and an approximate $652,000 increase in deferred offering costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2022  was approximately 12,037,000 consisted primarily of gross proceeds from the sale of common stock in the initial public offering of approximately $11,500,000, net proceeds from issuance of common stock of approximately of $2,474,000 in a crossover round, and proceeds from issuance of common stock upon exercise of warrants of approximately $385,000 and stock options of approximately $84,000 offset by approximately $2,406,000 of the offering costs paid in the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2021 was approximately $14,034,000 which consisted primarily of proceeds from issuance of convertible notes totaling approximately $7,369,000, collections of subscriptions receivable of approximately $322,000 for MAIA, proceeds from issuance of common stock (net of transaction costs) of approximately $5,742,000, proceeds from the paycheck protection program loan totaling $63,000, proceeds from exercise of warrants of approximately $529,000 for MAIA, and proceeds from exercise of stock options of approximately $9,000 for MAIA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s discussion and analysis of our financial condition and results of our operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of stock options and warrants and accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. We define our critical accounting policies as those accounting principles that require it to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 1 to our financial statements, we believe the following are the critical accounting policies used in the preparation of its financial statements that require significant estimates and judgments.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock-based awards are classified as equity (restricted stock awards, and stock options, and warrants). We recognize related stock-based compensation expense based on the grant date fair value of the awards. The fair value of restricted stock awards is based on the trading value of the Company's common stock. We estimate the fair value of stock options and warrants using the Black-Scholes-Merton valuation model which requires the use of subjective assumptions that could materially impact the estimation of fair value and related compensation expense to be recognized. One of these assumptions include the expected volatility of our stock price. Developing this assumption requires the use of judgment. The Company lacks company-specific historical and implied volatility information. Therefore, we estimate our expected stock volatility based on the historical volatility of a publicly traded set of peer companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Two of the assumptions used in the Black-Scholes-Merton valuation model are historical volatility and fair value of common stock. Historical volatility is subject to uncertainty due to changes in the market over time. The fair value of our common stock is subject to uncertainty due to the possibility of changes in the results of our clinical trials, which could impact the fair value of our common stock. The total expense related to stock options is material to our financial statements on an annual basis, and significant fluctuations in the volatility assumption or the fair value of our common stock could result in material changes in related compensation expense to be recognized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepaid and Accrued Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our prepaid and accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our prepaid and accrued research and development expenses as of each balance sheet date in our financial statements based on facts and circumstances<br />known to us at the time. We confirm the accuracy of estimates with the service providers and make adjustments if necessary. Examples of estimated prepaid and accrued research and development expenses include expenses for:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Research Organizations (CROs) in connection with clinical studies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investigative sites in connection with clinical studies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vendors in connection with preclinical development activities; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vendors related to product manufacturing, development and distribution of clinical materials.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base our expenses related to clinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. The scope of services under these contracts can be modified and some of the agreements may be canceled by either party upon written notice. There may be instances in which</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study<br />milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed we may report amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates and the amount actually incurred.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required by this Item.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning on page F-2 are the consolidated financial statements with applicable notes and the related Report of Independent Registered Public Accounting Firm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Controls and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Evaluation of our Disclosure Controls and Procedures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision of and with the participation of our management, including our Chief Executive Officer, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual Report. The term &#x201c;disclosure controls and procedures,&#x201d; as set forth in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive<br />Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective at the<br />reasonable assurance level due to material weaknesses in internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company noted 1) insufficient segregation of duties within the Company&#x2019;s control activities and procedures throughout the year, and 2) an insufficient level of detail to identify all relevant risks of material misstatement including the risks associated with the accounting treatment and financial reporting of non-recurring complex transactions. These factors contributed to a material weaknesses in the application U.S. GAAP to effectively evaluate the accounting treatment for certain non-recurring complex transactions during the quarter ended September 30, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the material weaknesses described above have not yet been fully remediated as of December 31, 2022, our management is committed to remediating identified control deficiencies, fostering continuous improvement in our internal controls and enhancing our overall internal controls environment. Our management believes that these actions, when fully implemented, will remediate the material weaknesses we have identified and strengthen our internal control over financial reporting. Our remediation efforts are ongoing and additional initiatives may be necessary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we work towards remediating these material weaknesses, we will design and implement controls to properly address the risks associated with segregation of duties and to account for non-recurring complex transactions in accordance with U.S. GAAP. To assist us in the remediation and performance of remediated controls we hired a Corporate Controller, and we will expand the nature and extent of our review of technical accounting treatment internally and continue to utilize an accounting and financial reporting advisory firm with significant experience with publicly held companies to assist our management in evaluating the accounting treatment for complex transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley, and we may be unable to accurately report our financial results, or report them within the timeframes required by law or stock exchange regulations. We cannot assure that our existing material weakness will be remediated or that additional material weaknesses will not exist or otherwise be discovered, any of which could adversely affect our reputation, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We monitor our internal control over financial reporting on a continuous basis. During the year ended December 31, 2021, we identified a material weakness in our internal control over financial reporting related valuation of our common stock, the calculation of earnings per share in accordance with U.S. GAAP, the reconciliation of significant account balances, and authorization over cash disbursements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have refined our entity-level controls to ensure that they adequately address above material weaknesses and the focal points of the COSO framework as they relate to our business and organization, the precision, sufficiency, review and approval of the reconciliation and review of significant account balances, authorization over cash disbursements, and Stock-based compensation or valuation of common stock calculations to address these material weaknesses. We have determined these material weaknesses have been remediated.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In addition to the measures taken in response to the material weakness defined above, there were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, during the period ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Controls Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include a report of management&#x2019;s assessment regarding internal control over<br />financial reporting or an attestation report of our independent registered public accounting firm due to a transition period<br />established by rules of the SEC for newly public companies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Other Information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9c"><span id="toc_page"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PA</span><span id="part_ii"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RT III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Directors, Executive Officers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code of Business Conduct and Ethics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a code of business conduct and ethics that applies to all our employees, officers and directors, including those officers responsible for financial reporting. Our code of business conduct and ethics is available on the investor relations section of our website. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual<br />meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by<br />reference.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Executive Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual<br />meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by<br />reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item12"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual<br />meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by<br />reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual<br />meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by<br />reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Principal Accounting Fees and Services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in our definitive proxy statement with respect to our 2023 annual<br />meeting of stockholders to be filed not later than 120 days after the end of the 2022 fiscal year, and is incorporated herein by<br />reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Exhibits, Financial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(1) Financial Statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements required by this item are submitted in a separate section beginning on page F2 of this Annual Report on Form10-K.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(2) Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The Exhibit Index is incorporated herein by reference.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:91.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022027256/maia-ex31_8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of MAIA Biotechnology, Inc</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022027256/maia-ex32_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of MAIA Biotechnology, Inc.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Registrant&#x2019;s Securities.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022027256/maia-ex11_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Representative&#x2019;s Warrant (Included in Exhibit 10.19)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex42_16.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Warrant</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex41_27.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen certificate representing shares of common stock</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022027256/maia-ex101_10.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex101_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement, dated as of September 16, 2022, between the Company and Vlad Vitoc.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex102_8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement, dated as of September 16, 2022, between the Company and Mihail Obrocea.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex103_9.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement, dated as of September 16, 2022, between the Company and Sergei Gryaznov.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022032061/maia-ex104_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement, dated as of September 16, 2022, between the Company and Joseph McGuire.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6&#134;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022021928/maia-ex101_313.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply and Non-Exclusive License Agreement between the Company and Regeneron Pharmaceuticals, Inc. dated February 1, 2021.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7&#134;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022021928/maia-ex102_238.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent &amp; Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center dated December 8, 2020.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8&#134;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022021928/maia-ex103_239.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent &amp; Technology License Agreement between the Company and The Board of Regents of The University of Texas System on behalf of The University of Texas Southwestern Medical Center dated December 23, 2020.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex108_15.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. 2018 Stock Option Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex109_22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. Amended &amp; Restated 2020 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(5)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022027287/maia-ex993_36.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. 2021 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(6)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1011_13.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Director Stock Option Award under Amended &amp; Restated 2020 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(6)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1012_12.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Compensatory Management Stock Option Award Agreement under Amended &amp; Restated 2020 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(6)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1013_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Consulting Stock Option Award Agreement under Amended &amp; Restated 2020 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(6)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022024583/maia-ex1014_128.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Employee Stock Option Award Agreement under Amended &amp; Restated 2020 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(7)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000095017022017637/maia-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Incentive Stock Option Award under 2021 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(7)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000095017022017637/maia-ex10_5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Non-qualified Stock Option Award under 2021 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(7)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000095017022017637/maia-ex10_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Director and Consultant Non-qualified Stock Option Award under 2021 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022027256/maia-ex11_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Underwriting Agreement dated as of July 27, 2022 between the Company and ThinkEquity, LLC</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(8)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022038110/maia-ex161_46.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter from EisnerAmper LLP regarding the change in the Registrant&#x2019;s certifying accountant, dated November 21, 2022.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1878313/000156459022014036/maia-ex211_10.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries of the Registrant.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="maia-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="maia-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="maia-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="maia-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)           Filed as an exhibit to the registrant&#x2019;s Current Report on Form 8-K filed with the SEC on August 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2)           Filed as an exhibit to the registrant&#x2019;s Current Report on Form 8-K filed with the SEC on September 21, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3)           Filed as an exhibit to the registrant&#x2019;s Registration Statement on Form S-1 filed with the SEC on May 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4)           Filed as an exhibit to the registrant&#x2019;s Registration Statement on Form S-1 filed with the SEC on April 11, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(5)           Filed as an exhibit to the registrant&#x2019;s Registration Statement on Form S-8 filed with the SEC on August 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6)           Filed as an exhibit to the registrant&#x2019;s Registration Statement on Form S-1 filed with the SEC on June 29, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7)           Filed as an exhibit to the registrant&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on August 22, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8)           Filed as an exhibit to the registrant&#x2019;s Current Report on Form 8-K filed with the SEC on November 22, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#x201c;[***]&#x201d;) because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or confidential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated: March 24, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.509%;"></td>
    <td style="width:6.056%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:43.417%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA BIOTECHNOLOGY, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vlad Vitoc</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vlad Vitoc</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Chairman</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:42.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:28.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vlad Vitoc</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman and Chief Executive Officer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vlad Vitoc</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joseph F. McGuire</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joseph F. McGuire</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Steven Chaouki</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Steven Chaouki</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ramiro Guerrero</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ramiro Guerrero</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Louie Ngar Yee</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Louie Ngar Yee</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Cristian Luput</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cristian Luput</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Stan V. Smith</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stan V. Smith</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jean-Manass&#xe9; Theag&#xe8;ne</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jean-Manass&#xe9; Theag&#xe8;ne</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:95.0%;"></td>
    <td style="width:5.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (Grant Thornton, LLP PCAOB ID </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e42fca6-b08e-4a5f-8555-8a3dab888a42" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">248</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered_pub_ea"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (EisnerAmper, LLP PCAOB ID </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09ebc1ba-8842-4014-8919-683d78a40f58" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">274</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in</span></a><a href="#stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemt"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board of Directors and Stockholders</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion on the financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">balance sheet of MAIA Biotechnology, Inc. (a Delaware corporation)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2022, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#x2019; equity, and cash flows for the year then ended, and the related notes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as of December 31, 2022, and the results of its</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operations and its</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going concern</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred recurring losses, has negative cash flows from operations, and has an accumulated deficit of $44,207,272 as of December 31, 2022. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis for opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_21874969-d62c-465f-a206-428a5b2e1dbe" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GRANT THORNTON LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4fb6a1f1-99f1-4a3f-a72e-7c693235fb8c" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Charlotte, North Carolina</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered_pub_ea"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Board of Directors and Stockholders of</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheet of MAIA Biotechnology, Inc. and Subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2021, and the related consolidated statements of operations, changes in stockholders&#x2019; equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ EisnerAmper LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor from 2021 to 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4b9bddd9-2d67-42ca-b28e-9a2ba44e61aa" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EISNERAMPER LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09bea1fc-ff08-4e45-bb67-54a543c4a1e3" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Iselin, New Jersey</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 8, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.687%;"></td>
    <td style="width:0.066%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.066%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.686%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14f301cc-d65a-4417-809d-2d17f702482b" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:Cash" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,950,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7628c8f8-36e1-4cb3-ae66-790f1089dc2a" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:Cash" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,574,292</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96bb75f4-3ef9-4bf6-bb80-e9de3fa7966e" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">554,321</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92105fa0-c2fb-4d36-9093-64b910fc8e0c" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">54,537</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Australia research and development incentives receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8392966a-9755-4eb8-9178-db5aef1cb894" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="maia:ResearchAndDevelopmentIncentivesReceivable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">302,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_303fd690-be56-4244-a9df-d3728a69cb33" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="maia:ResearchAndDevelopmentIncentivesReceivable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">43,666</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72823109-f19c-458a-9538-13adc3965052" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,808,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49011899-aa86-4d77-9432-cd4f0105743e" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,672,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5341b6bf-5ad8-4339-a196-7fdd93c3841c" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">211,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75eae16d-bf4a-4c12-ae5c-db987320807c" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">651,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efe8db27-eed6-4e47-9304-acfda0094ca4" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_805482ad-2920-47ee-8273-72b9dd781521" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ee5c0d1-5572-4a9f-b83a-d2d7d2fe614c" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,022,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b5f0993-aa93-4dba-9c94-d80967059ab1" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,327,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5c51c78-e8d7-4f3a-84b0-b7383a1f1ac2" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,165,505</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68fbe41d-742c-4189-8529-b67e5d28fc0b" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">960,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fb7cbce-ed9e-47fc-a3b1-4e4e0a7a86ea" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,103,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1683486f-43b3-4db6-a7d4-23a516175d59" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,185,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b79f88cc-1f8c-4cc3-99bb-84b14db75218" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,268,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db4ff37c-1030-4c30-9480-2e261239d71f" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,145,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97c7f475-ff10-4bd9-addd-6074c8e1951b" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="maia:WarrantLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_769793e7-b39d-45d2-9ddf-19563cf30540" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:Liabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,514,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_362c739e-c21b-436b-8c23-92e62270287b" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:Liabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,145,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_32d30681-9f36-4826-9171-c8006f97a233;"><span style="-sec-ix-hidden:F_cd9deaf0-1d8f-4cfa-ae75-53003ee3c1ee;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 5)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7086fd7b-89cb-4774-b59d-599ae6f5b4cb" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c3dc6846-0de6-4bb8-96b9-4a5e796255fc" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c59099a6-b7a2-49b2-a7d4-d0e835a0bf43" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d351eba-aa6c-4c97-b03d-2ae5ddfa4ae3" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;authorized at December 31, 2022 and December 31, 2021 respectively,<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a79fb31-dfec-43cf-9806-9bd914cc8160" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4316cc74-04fd-4604-a39e-1722c2231a60" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fa54f89f-98a8-4537-8286-26488af9cd2f" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ee96ebd2-e862-4140-ac6d-bd3fa5f54154" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e8f1a25c-5a33-4074-8478-3135ed3b9513;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e72148a5-95e0-4c93-8975-0a5b223af98e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d3d71ba-6f36-4311-94aa-7495cd25ff63" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_292c9f3a-ca4d-4958-a263-32db50dda459" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbc29414-56d5-4634-a80e-49eb6f4fb056" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdd7a213-678e-4277-8e52-64ab3b560edf" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;authorized at December 31, 2022 and December 31, 2021 respectively,<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c06ea33e-1cec-4546-b4ce-37da836a3ab8" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_421afbd7-3c8f-4b4f-b685-96be7f40b547" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,955,904</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_856d9fe2-dd7e-421e-960a-e81cb801d4e4" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fb472338-c106-4c82-9a58-995af339fb82" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,584,980</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022<br />&#160;&#160;&#160;and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe9fe187-5b68-4a95-9b02-fedf61c7e8fe" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,096</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8e99eb0-d98a-4a3d-8c13-630ab6d54f57" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f8d36bc-8368-4bc4-ba5e-0fa59267f04d" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">52,729,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fd19ade-749d-48a0-bd63-642c9ec7ee94" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">37,618,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14f30d37-2108-4277-a0b1-a2ec152d3196" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d052c01d-489e-4e92-a104-5999ec3fbc65" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">28,437,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c6e8d35-3b7d-4ac6-916e-1338fbc1ab72" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fa2fbf4-e64e-4de0-a695-c0191a738d0b" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,507,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c61f36e0-cabf-463b-9303-9d5f8933d300" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d8328b3-357f-4dfe-bc56-f58828e70423" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,022,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7224f1d2-95c0-4de0-8d48-8dec0a14c297" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,327,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See the accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Inc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.044%;"></td>
    <td style="width:1.874%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.254%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.573%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.254%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f34723b9-00ec-4521-a85f-7d1438d0aa19" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,933,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b409c12c-4672-41a0-9421-79e0e5d18c35" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,496,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6404fc98-3717-493c-8364-74464377db29" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,143,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40079c1b-d068-4eea-97e9-7eecb6b3eb9d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">4,289,831</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ratchet share expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13b8b8e3-e8d2-437b-aa4e-607efab8ea3e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:RatchetShareExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e71719df-5663-4581-a612-ddff68ed89a1" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:OperatingExpenses" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">16,176,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44c45550-f196-46d8-b536-3c7eee219c6d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:OperatingExpenses" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,786,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01606826-129c-4128-b4a8-79380f479b4c" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">16,176,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fa072ad-9843-4475-8b5d-3c7618f798b2" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">7,786,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d517654b-ddfa-414a-bd13-53107b1b300b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e53b2ee-405c-437d-8265-c3a7d4707d2c" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">827,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d63f5966-aead-4d06-b2b0-3dd6fdac8c9d" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,870</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05b52244-30f1-4b3f-b219-2b1994efadd3" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Australian research and development<br />&#160;&#160;&#160;incentives</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13776d33-4291-41d1-bf18-d0eac92827ea" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:AustralianResearchAndDevelopmentIncentives" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">313,625</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1409e2e-b901-4219-8231-177900a0fab1" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:AustralianResearchAndDevelopmentIncentives" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">43,666</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paycheck protection program loan forgiveness</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cda4f4f-c5b4-49fd-a5a4-6fb910a4d66a" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of embedded<br />&#160;&#160;&#160;features</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6803fa8-9851-4f65-9364-d5a9acb3a184" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ChangeInFairValueOfEmbeddedFeatures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_500280db-7292-4385-a684-b4064c4cbccd" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">98,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b967a28-d509-478a-b1fc-b450a4cc42da" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,546,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of convertible<br />&#160;&#160;&#160;notes and convertible notes, related parties</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37c844d9-f610-49c6-b473-f236363a7d69" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">2,322,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa0a7d1f-920e-484f-82f7-04d5b005c4ef" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">406,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_920f8722-0b7f-40ef-895f-c613b5f31c32" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">4,791,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_704b8c81-cc12-464e-af62-37ea75682066" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea13727c-49da-425f-9cb5-f887db58863d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,578,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to noncontrolling<br />&#160;&#160;&#160;&#160;&#160;interests</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ba0f4fe-f009-4b83-8c7a-60c3239550a4" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">74,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deemed dividend on warrant<br />&#160;&#160;&#160;&#160;&#160;modification</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deb7a039-10dc-420b-a39a-50673acc60ca" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:DeemedDividendOnWarrantModification" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">450,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to MAIA Biotechnology, Inc.<br />&#160;&#160;&#160;shareholders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e914b60a-9807-438c-9bcb-76ee41f5d766" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">16,219,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83d63238-a6e0-460c-85a3-d8b0ae4e87a3" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f8917f2-ec6c-46c4-b0df-80c4d50b668c" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_1ae67414-266e-4fd3-8868-3d776f837edc" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.75</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24e0ea83-1506-4f8d-bd30-eaaec0e231f9" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_98e048bc-9347-4500-94f5-5dc35257d6ec" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.37</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding basic and<br />&#160;&#160;&#160;diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1942f0c2-8fef-4c33-b0d4-bd06d4a000c3" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c280a5ac-637a-416e-b82f-014a7ccecb2f" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,276,761</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baf693da-c476-48f2-9287-2ce8f890aa66" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_a88819e6-70d1-455a-8fc6-b78ae7740251" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,278,435</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.161%;"></td>
    <td style="width:1.878%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.093%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.58%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.287%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_709357e7-d504-46be-a8be-272878920bba" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">16,219,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aeb47211-a7ab-49bc-9850-49ee267d4843" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Foreign currency translation adjustment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ba20b2c-5e36-4eef-8082-33ac0cc04160" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01bc07eb-0cac-4820-a1f6-f3f308a78c87" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">16,235,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6752ef7-b801-4d1e-8720-54ddd09c5429" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biote</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">chnology, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the Year ended December 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.251%;"></td>
    <td style="width:1.053%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.506%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.053%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.8649999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.053%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.979%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.053%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.992%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.053%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.493%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.053%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.256%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.122%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.097000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:4.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:4.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:4.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:4.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid-In Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77a2ac6e-050c-4e97-b40a-1486eafd4501" contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,584,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d274170f-e0a2-49c5-9993-9240fc3061c0" contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_913ba90f-88a8-4379-a4a2-0aaaaa2d2cf5" contextRef="C_5c7dbf97-a62c-4354-b7ac-212c85adff76" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">37,618,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef657e56-8f40-4d1f-bf11-3c0a32afb2d2" contextRef="C_94951a0e-9218-4969-993f-e925194bc10f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">28,437,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_833635eb-5d0f-4193-aca7-65a674be8ad6" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdfc882b-a00a-410b-bfd6-70a85092f75a" contextRef="C_35df104b-b405-4915-a247-efcae1451c3e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">46,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35c981b2-3d1d-4a51-9232-f1d923c67383" contextRef="C_35df104b-b405-4915-a247-efcae1451c3e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_522223b3-0dd8-4d63-a45b-792187068ca3" contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">83,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf0afe18-943a-4dcd-9905-0e4dbc399243" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon exercise of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a3e5006-22cc-4e1c-a32f-338bfbb47eb3" contextRef="C_35df104b-b405-4915-a247-efcae1451c3e" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">529,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b271d5c7-bfa8-4c17-b5dc-591d1cbe1d82" contextRef="C_35df104b-b405-4915-a247-efcae1451c3e" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81480d35-1bd5-4d84-8dcf-23dc191320e1" contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">385,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c0c3e20-f958-4ce2-ad93-4e80c6018231" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">385,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33bd0cbb-301e-46f5-bed0-5b73e36e1801" contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_404329db-f21f-406e-9faf-bf05984612db" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares in connection with equity<br />&#160;&#160;&#160;financing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1956f7d7-5c23-4f64-b5be-a6882a825fd7" contextRef="C_35df104b-b405-4915-a247-efcae1451c3e" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">274,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_859a719e-94e7-4d2d-b9d3-6bcf6e1c3428" contextRef="C_35df104b-b405-4915-a247-efcae1451c3e" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01df092b-dd01-4e9e-a9f3-e1caea97442c" contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,473,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21df3802-f25b-4c22-aa81-83a309393b63" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,473,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares in connection with initial public<br />&#160;&#160;&#160;offering, net of $</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f860467-2956-48be-ba9b-cf9e5861311a" contextRef="C_f426df1f-3c59-401e-952f-443722bf8259" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,749,905</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;issuance cost</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8861ef67-fafd-4d1f-9ada-f44569eb578d" contextRef="C_460c12ea-f2c0-4902-aaba-b209608b801a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,300,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aed9066-25dd-4ab2-b3ae-a0478164424d" contextRef="C_460c12ea-f2c0-4902-aaba-b209608b801a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3949b4b8-b6ee-41a2-87ef-40a06f21fe8a" contextRef="C_8de3a275-a1ef-4daa-8115-7bf33cf32d56" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,749,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf0c0223-5f2c-4985-a549-fdb9465a4c7a" contextRef="C_f426df1f-3c59-401e-952f-443722bf8259" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,750,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Issuance of ratchet shares</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0726d7bb-6059-4e75-899a-00fdda1cb299" contextRef="C_1491750e-595c-458c-b2bc-3af9c7704855" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">219,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4075a33f-0613-46de-9d7b-6bdc845a3737" contextRef="C_1491750e-595c-458c-b2bc-3af9c7704855" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47c3ac9b-feea-4424-91e3-a4f838e4e8d8" contextRef="C_51ce7740-df5e-458e-9aca-0e98ee73acc3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,099,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa41890c-43ca-4d73-bb08-af58be90daa6" contextRef="C_65e57920-9bea-4275-bd59-c0a66b11eb61" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Modification of warrant in equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5915eecb-083a-44d6-84fb-31e812329e1b" contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e" name="maia:ModificationOfWarrantInEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">450,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e6a64ed-1dc6-499e-bab9-753784010988" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ModificationOfWarrantInEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">450,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deemed dividend on modification of warrant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a8ae2dc-661c-4f43-8e39-9d970a623ebd" contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e" name="maia:AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">450,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2bf839d-0cbd-40eb-a0c0-1defb1c5c845" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">450,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6881932-9a13-4633-8904-9bde9ecbd100" contextRef="C_b7c6a87c-7d18-4cd1-89df-759036b167f7" name="maia:ForeignCurrencyTranslationAdjustment" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f890b370-26a7-4933-8d38-292dcabab374" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ForeignCurrencyTranslationAdjustment" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_235130d4-fb7c-4638-afea-d013ea2f65c7" contextRef="C_e4448ed4-2b54-4235-9206-c0b8e343fb1b" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad904153-6935-41e7-9ee3-ef59b16cceed" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bdfdb74-552c-4f13-8c10-4472ac16a09c" contextRef="C_bd92e2f2-afa8-429c-8e71-c820d8b523b9" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,955,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed3decfd-9af3-4b65-a11d-53e3c5718ad1" contextRef="C_bd92e2f2-afa8-429c-8e71-c820d8b523b9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,096</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b9c2b17-00e0-4f72-bd35-3865759aaa4b" contextRef="C_71ce86d1-a364-40dd-8e50-83d2857961c7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">52,729,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1468ecf-a045-422b-8b9d-4b51a996e457" contextRef="C_4a905e51-4f6b-438a-9ff9-32f5ff3fbc1a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c9839e6-7c91-4ea6-9f21-8a68e40abf87" contextRef="C_fed35c89-2357-48b2-9d4e-1962b1feedbe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3d235c2-33ba-44dc-b95d-ce5c7e8fd905" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,507,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the Year ended December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.605%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.3639999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.701%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.4929999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.719%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.579000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.36%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.0920000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.798%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.16%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.53%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:4.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:4.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:4.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:4.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid-In Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subscription Receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total MAIA Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncontrolling Interest</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' (Deficit) Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_690af3e6-4ab8-4a6d-b444-e35c5ac9f112" contextRef="C_c40ba4b1-8a23-45d1-b399-8ff938660566" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,433,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f663eee-f006-4656-b846-12b4f038cb4d" contextRef="C_c40ba4b1-8a23-45d1-b399-8ff938660566" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d3e39e0-1502-4ed6-99b7-c008c0da2690" contextRef="C_0fdfbd9c-c879-495d-a18d-f5b6252af2fe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,599,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3aa41aa-4107-419a-8281-d12e224160b2" contextRef="C_03e3bd00-bb23-45f7-a4b4-e0c48e0a00f2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,934,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c0f64fe-dcfa-4ccc-83cf-f0220ddb6fa5" contextRef="C_77674401-ed32-4efc-bc01-fa0a205bd5c3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">2,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f960c69c-b5d8-417d-a4a6-08b01eeda5bd" contextRef="C_b2767d21-f84d-45dc-805e-c26596b84ec5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">3,336,087</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42da24f7-539e-4e3e-a676-e3a59c41aa4c" contextRef="C_6ed89264-6427-4629-a39a-d1eb18f5c44a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,719,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b387ffe-d5d1-4ff8-ac5d-0526e1afe0ef" contextRef="C_7bfe2412-70aa-498d-b73f-b58ae522d52e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">1,616,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_335d61ec-2804-4540-a31f-d1b6999f2ea7" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ad49371-eda7-4a19-9c98-ea3091ab9dd6" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99fdaaad-3b34-4d9c-b7f3-9604be2126df" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fd67a4f-ad62-4bdc-bb70-beda5758a599" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed0619bd-4d3d-49f5-b375-b81c71b4cea3" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon exercise of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_514f39c8-c2fd-41eb-8ee2-d6f37f7a3800" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">283,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_183577c6-88d9-4ee1-a2e1-be9efcf774f4" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96b891d2-2fc9-4e13-9f23-a3692cc04272" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">529,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e74b59b1-f525-43f7-b29a-81bd64b0036b" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">529,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aadadf06-bbd9-495e-bdef-840b0b08729f" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">529,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of restricted common shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ece7d5f1-ccf7-4e1d-94ca-9b6794e04037" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef8ae72d-b8a0-4aa2-b134-c3af6cb7ad1e" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f6a46b4-7457-4226-b6f6-58c733040326" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">27,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95142a14-db07-4257-998e-cba4465055ac" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">27,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfd39494-6a6d-422a-b566-38df9cc25dd5" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">27,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancellation of restricted common shares</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7469c0b9-e4c1-4b80-b9ba-16c277da5ea1" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2487bb5e-a058-4edc-a9f2-496b015f31bf" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2533e7e6-da0a-4e01-b2ec-36ffa0cca281" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6af05c6b-c3bc-4ff8-b5a5-a68e77b4640e" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense - MAIA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26c5028f-4301-4fc6-902f-4ba78e333f03" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,428,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_358e0a01-bf0b-4227-9776-03c306d5d40d" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,428,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97eca392-6bd7-4f4f-8a0c-06c86f7e0924" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,428,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense - DGD</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2454aa8-f346-4893-a597-bda0fff254d5" contextRef="C_514ade27-e387-4d84-83c5-c59113d65690" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">161,460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bffe88a1-c697-46a2-83b6-aacb5bef42ba" contextRef="C_af4145b4-83cc-4b5a-8c80-2f54f89c9863" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">161,460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense - THIO</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04315021-1b39-47ef-9385-7002c54e92a9" contextRef="C_38807a13-8dd9-4c2d-b8c8-cfc13aebab4d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">104,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa82fe00-8620-480b-8b9e-f61b61b941fc" contextRef="C_10e99315-c20f-4d44-875f-39b50152cb08" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">104,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of stock options to satisfy accrued bonus</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b470d4f-9efa-4753-825f-99ddf179c2bf" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:IssuanceOfStockOptionsToSatisfyAccruedBonus" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_391c523a-372c-4ff8-b0a6-62ec50ae066b" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:IssuanceOfStockOptionsToSatisfyAccruedBonus" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a7c8029-a9af-4550-965d-1f719516c1a2" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:IssuanceOfStockOptionsToSatisfyAccruedBonus" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of stock options to satisfy deferred compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_828ba255-d2b0-486b-afab-e547db3c45a9" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1989d0ff-70e2-4b4d-b413-3f9f33c8b9c9" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e5d4d40-2dd7-4b5f-bcb1-40b31d8a8751" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon conversion of convertible notes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29b31bca-30ed-43f8-b74e-efbf6832694b" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,375,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38d43c41-ba5f-4a14-ac73-7cd7d2f2403f" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">138</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6245257-fad5-4657-82c7-2a928e1cdb1e" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,001,136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b90447d2-aeb4-4579-8e22-31e8cbd6dc51" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,001,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cba83c85-88f9-496c-96ea-41a22ddd4e65" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,001,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon conversion of SAFE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f19d846c-34d4-4cd5-bff0-63d1cce3822e" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="maia:StockIssuedDuringPeriodSharesConversionOfSafe" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,208</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2df22ab6-3802-430a-87c8-5c559cd84ff4" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:StockIssuedDuringPeriodValueConversionOfSafe" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aee09bff-bafd-4ecb-a7ec-ce1bda78d59a" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:StockIssuedDuringPeriodValueConversionOfSafe" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef1e64e-4f5b-4a80-93df-9c86985e6966" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:StockIssuedDuringPeriodValueConversionOfSafe" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares in connection with Equity Financing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_196a921d-3ecb-4439-a92e-42c26016db35" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">772,563</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5e31c75-ea66-4a30-98ea-b415b49bcf9d" contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eb611af-8621-4b25-8b16-5ce735a8cd6a" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,180,426</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9792af37-f592-446a-b2c1-0a901eac4986" contextRef="C_3dc27fee-372c-4000-a17a-fd220345e379" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">320,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a768d15a-4370-4317-b109-5135b85eb8b2" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,860,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8031fe96-b5f7-4730-83c0-515fd6ad4675" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,860,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receipt of stock subscription receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b98c692b-b81b-4a5c-85ed-fc36f25f950b" contextRef="C_3dc27fee-372c-4000-a17a-fd220345e379" name="maia:ReceiptOfStockSubscriptionReceivable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e02677a-5c28-42d9-9142-01d94183ff05" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:ReceiptOfStockSubscriptionReceivable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a348f9ed-1a24-418c-b4f0-88436046e73e" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ReceiptOfStockSubscriptionReceivable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction costs incurred in connection with Equity Financing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c88ec77-6f41-4fd3-b362-ca94bd4bf0d8" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:TransactionCostsIncurredInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">118,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d324967f-f41b-40d8-a07f-9afb5074274e" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:TransactionCostsIncurredInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">118,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b99e091-2e21-48b9-b141-b16916fdeac7" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:TransactionCostsIncurredInConnectionWithEquityFinancing" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">118,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e00fb27-bc66-405a-9695-6edc3035f248" contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0" name="maia:ReclassificationOfWarrantLiabilityToEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8548124-0d71-44ec-8c1b-02f3ab71181b" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="maia:ReclassificationOfWarrantLiabilityToEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e06a9f18-d35f-4844-8f2d-2dcf9d5b3840" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ReclassificationOfWarrantLiabilityToEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of restricted common shares to founder pursuant to<br />&#160;&#160;&#160;THIO Merger Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55311164-e211-4adf-a2f9-7703a6d7994a" contextRef="C_08b3f13c-8494-4e8a-bac0-e6e09f3faee0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">700,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_545d46b4-ae0d-47a7-9aed-959f4dd5b93f" contextRef="C_08b3f13c-8494-4e8a-bac0-e6e09f3faee0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84274583-3313-47d3-af87-3930d0a68665" contextRef="C_07581902-1fc3-4f0d-9e04-a8dbb844ead0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dissolution of DGD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2885bd2-578f-4acc-b2de-a47b37237a45" contextRef="C_aca59814-cbfd-4366-be06-42a5a0ba6590" name="maia:DissolutionOfFirm" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,098,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a78933b-20ae-4359-ad30-5e791d0c9d47" contextRef="C_681b3cde-40ae-48db-9701-970b57fafca8" name="maia:DissolutionOfFirm" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,098,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ca9634e-a0cb-4169-9cbc-9ead0f6feb20" contextRef="C_514ade27-e387-4d84-83c5-c59113d65690" name="maia:DissolutionOfFirm" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">1,098,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dissolution of THIO pursuant to Merger Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e110b48-a767-42a2-bfbc-366003d64ad2" contextRef="C_07581902-1fc3-4f0d-9e04-a8dbb844ead0" name="maia:DissolutionOfFirm" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">813,805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02f762a4-8aa6-4bb9-9460-0d4cce066801" contextRef="C_25edec4e-51a9-4cf7-a863-6a4423d5e981" name="maia:DissolutionOfFirm" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">813,805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9887b18b-205a-4403-8c80-4f7baa46abcf" contextRef="C_6f7aff38-36bd-4981-a8df-ded8085b1fcf" name="maia:DissolutionOfFirm" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">813,805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_193aac89-c9ad-4bff-bbe9-44a4e477238e" contextRef="C_e8c711ae-2a67-477b-94f2-7ea7a9761789" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44d57f24-82b7-486c-bb27-a65743d13dab" contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,503,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3cd41ab-a1a3-4d65-b720-9cbed5832654" contextRef="C_f3cb958a-ca61-46c6-a20f-0990720362c8" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">74,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eec3805-b9c5-4913-a6f6-316c93bdc5d3" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,578,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60aed006-e876-49ff-b197-26cd3abc618c" contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,584,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bdf2cb0-4a94-4bcb-a0fc-a115db45a795" contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d60ab972-c7ed-41f3-a455-0344b7dfdd38" contextRef="C_5c7dbf97-a62c-4354-b7ac-212c85adff76" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">37,618,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_647b97f8-09a9-4b2a-bde6-83117dae3088" contextRef="C_94951a0e-9218-4969-993f-e925194bc10f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">28,437,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaf6c8ec-5315-4092-af38-60ba9cc71bbe" contextRef="C_f2dbed72-0d93-4962-be44-54187d716c80" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ce6c939-b492-4913-9869-f89e8096bf5f" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,181,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.932%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="7" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss, including noncontrolling interests</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40c899f2-c058-4cd8-b61a-65c52ccde4e6" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">15,769,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8017482-efde-4d8f-bba4-bd648ebd9b41" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">12,578,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55179c89-589f-4f2a-80e4-709d5e31da32" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be73a2aa-e27f-4d12-b2c7-de294e635ac3" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,722,893</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Loss on extinguishment of convertible notes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07e5ca9f-c060-4c9a-b60f-6ae7e8416bcf" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">2,322,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Gain from forgiveness of Paycheck Protection Program loan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43468b6f-ada8-48b8-bfee-6c072ec2484a" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of embedded features</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10fb4960-df2a-4d05-a978-4147971190c2" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ChangeInFairValueOfEmbeddedFeatures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of ratchet shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9bfeaaa-0a6e-4bac-9d8f-eabfa481d859" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:IssuanceOfRatchetShares" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4184c83-cbf6-4596-8361-c7a9957673cc" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">98,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96ab9175-a6c1-42ec-9390-d07cf98bff54" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,546,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Amortization of debt discount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1992bd7-1968-45b1-ba86-caa95ccd3847" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">596,953</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d11e4937-eeec-4b0a-9a8c-fe8b2ca88dbe" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">505,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f33061f-017f-40c5-9240-80f54ca3a8e9" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Deferred offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32f88675-3933-48ae-bca7-e3ed21890b8e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:IncreaseDecreaseInDeferredOfferingCost" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">440,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c4dc9df-69f1-477f-9a25-d8c1ac6b4b8a" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:IncreaseDecreaseInDeferredOfferingCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">651,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Australia research and development incentives receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a131682-a7f9-4de8-b5e4-2df8e4fc49b0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">269,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba9cb1f8-527a-4e45-a621-db1c5e091699" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dd2bf44-ea5b-4fc6-be50-d028a161da8d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d707eb39-cb60-4324-bec4-664f605ccf85" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">211,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9f724dd-821a-4e20-875f-563da6efa209" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">805,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a027e358-2f3c-47ca-8a21-ed4bb7c12796" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">915,742</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b24f67-b7ae-4355-925a-d62d6044e42a" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">997,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to related parties</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8f4d904-b228-4dae-89f7-d4402d1ce64d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">7,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1590181-6d43-4f1b-a67d-1a29f9ce3c91" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">11,655,725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7a9175f-c9f1-44ca-89a4-b994a6bab110" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">4,122,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of convertible notes, warrants, and embedded conversion <br />&#160;&#160;&#160;&#160;&#160;features</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7196ce5d-bf07-483a-8791-f9c1e0f07cca" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,369,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from Paycheck Protection Program loan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a5dba36-e006-42bb-9cf3-810f6017142d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ProceedsFromPaycheckProtectionProgramLoan" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collections of subscriptions receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff77f683-56f2-4ee6-ba78-837e23d7c7c1" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ProceedsFromCollectionOfSubscriptionReceivable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">322,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock, net of transaction<br />&#160;&#160;&#160;&#160;&#160;costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d43e3dff-9b15-4b72-8405-363949b4d298" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,473,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfdf0aff-2aae-411b-9abe-22ca7fec0e75" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,742,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e94b2f38-dbb7-4b19-9cb8-00946d56bfd5" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_538d6974-aeb0-42cf-90c3-12002cd990d2" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_070ca82b-cf0c-47c8-b4a9-6f3cd8f421ad" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">385,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_544fead4-0d44-4cf1-bfeb-f2f8332564ac" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">529,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of common stock in initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1a242a2-8214-41ca-9119-0aed1325cbc2" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,500,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of initial public offering transaction costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67f74ede-239c-454c-a094-de3dbe759d24" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:PaymentOfInitialPublicOfferingTransactionCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,406,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment on loan payable to officer</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04b313bd-0a26-47a9-bd2f-8ff68e40e0f1" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dc56187-582e-4ccb-bdac-4c9d50caba6e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,036,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06957346-9542-4028-9752-8be7e1c68234" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">14,033,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net effect of foreign currency exchange on cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e52c1f3-3afe-4feb-a307-a4aecd5d57f2" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">4,430</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase in cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_052d0a4b-b0ed-4a32-9d55-1f8a24de571d" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">376,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28e291e2-8510-4a37-a1ea-613ac6eac62a" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,910,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0414b4dd-7b81-46d8-98a2-81eb0f66625a" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,574,292</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a4d6c18-e697-40c2-a43b-ad5f01c5e948" contextRef="C_7bfe2412-70aa-498d-b73f-b58ae522d52e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">663,457</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash at end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_080e43f3-f059-476c-a97c-18a81da6bd24" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,950,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae56162a-52bb-4db2-b934-5f994bc50c48" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,574,292</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of convertible notes and accrued interest into MAIA common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a63c07fc-8619-44e6-b42d-f7d1bf02a3a0" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,249,587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of SAFE into MAIA common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd3e1a2a-302a-4787-ac8e-b2fa2aed5e44" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued for accrued bonus</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a69124a-3a9e-4631-8f69-3c14a5e825b0" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:OptionsIssuedForAccruedBonus" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued for deferred compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f304c49-5003-48f9-a253-20a18fd868c7" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:OptionsIssuedForDeferredCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">285,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5feb1b64-b6ec-4af6-aea6-25b381195e36" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ReclassificationOfWarrantLiabilityToEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of convertible note for payment on loan to officer</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ddc8dc1-128a-419f-9baf-e1f15d3b8812" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">21,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Previously paid issuance costs in connection with the initial public offering</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1121277-42aa-48b3-aa5d-6eb75600e7e2" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">651,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants issued to underwriters in connection with the initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28fd4bf9-18e1-406c-82f0-b9f84fa99126" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">343,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemt"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, In</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d7c03aa9-7d7a-4eb7-8cbe-00ec9f4e0600" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6941be2b-9b58-46c9-b092-1671953fdc39" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business, Organization, and Principles of Consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#x201c;the Company&#x201d;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#x201c;MAIA&#x201d;) was incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_712dcaa8-7bcb-48d6-9fe0-6daed58715e8" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fdefd89b-6f29-4b6d-8b60-9aebe38cabac" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 3, 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Therapeutics, Inc. (&#x201c;THIO&#x201d;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c00f411a-4f0a-4159-9f81-149c0a5a3646" contextRef="C_cfdd4c68-cf69-49c9-921b-9232d6f85520" name="us-gaap:MinorityInterestOwnershipPercentageByParent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">93.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f504a4f4-eb1e-4944-b9e4-6712990eb177" contextRef="C_cfdd4c68-cf69-49c9-921b-9232d6f85520" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">6.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a08271c3-ef07-41c3-a903-f6781ed82f8c" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:StockholdersEquityNoteStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">minority stockholder of THIO received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30e44824-e779-4c3b-b401-7c0c7fdfdeb5" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> share of MAIA common stock for each share of THIO common stock owned prior to the merger.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DGD Pharmaceuticals Corporation (&#x201c;DGD&#x201d;), incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_42b846dc-8b49-4c95-9fc6-e6a88944b9dc" contextRef="C_c0d9ded2-a90c-48e6-a41e-23f182621fc1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb50e893-5ea8-4511-a162-e1708256879a" contextRef="C_c0d9ded2-a90c-48e6-a41e-23f182621fc1" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2019</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Drug Development Corporation (&#x201c;MAIA DD&#x201d;) incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0ed3a71-01e9-4c79-b6fd-a8af4bb7fce6" contextRef="C_af7a9610-410c-4458-b075-3916099f847e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Texas</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_845c26a8-af37-4a83-a12a-4a7c6b1ca8b6" contextRef="C_af7a9610-410c-4458-b075-3916099f847e" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 10, 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4443b1ae-845f-47c1-ade2-ca8fbad857ff" contextRef="C_8e567c99-be4a-46b9-9a9f-31913733c870" name="us-gaap:MinorityInterestOwnershipPercentageByParent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</span></div></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_43888924-a46e-496b-8bfb-6062731fad0b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company had working capital of&#x2009;$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c8f3d5d-d8ab-4d7c-a7bf-39f9cb6b47b3" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="maia:WorkingCapital" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,539,131</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95f49ea5-bff2-468f-8661-8cf132a0c5f6" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9189528-9559-483b-b7c2-8ce44d6ef5e7" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:Cash" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,950,927</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and current liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c45c252-9182-4805-afb1-d4cd73bba61b" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,268,906</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a5103a6-faab-418c-bd7d-445db59e44d6" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:Revenues" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32aad0c4-10b0-4bcf-a142-e80c85f48323" contextRef="C_850a921a-9604-4c05-bc2c-f089ad5556e7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">263,729</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0cb5fac-32fd-4204-8468-9660f625fa5d" contextRef="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_888dc44c-53f0-40f4-9801-51d8654b3a62" contextRef="C_850a921a-9604-4c05-bc2c-f089ad5556e7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,373,561</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before transaction costs and expenses. During May 2022, the company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2026c25d-f3bb-4e74-a071-5aeabda71ae2" contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2da3828-cf79-409f-a685-dd6c8ff84f9b" contextRef="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbdf9d8f-83a4-4c35-9f3d-4aac653d1fd6" contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">99,999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol &#34;MAIA.&#x201d; The Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b04d12ae-3164-4d61-b6c9-48843c3a5af0" contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ecf3a31-2c04-49e0-8815-9e5e8a1f982f" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7cc1c9-e230-4756-b5a3-3c278a86e458" contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the initial public offering. On August 3, 2022, the Company sold an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce761fd4-3601-4438-90fb-bba93a7d8f0b" contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cfd06a0-c677-47dd-ab6d-85b9f1cc1e36" contextRef="C_5aa0a4a7-169f-471d-837f-b409f7c4b858" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_500adcc1-4ee5-4681-8261-1cbdd45284ce" contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per the overallotment option for the underwriter. After deducting $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05c83a74-7018-4021-81cc-6fc71745244a" contextRef="C_84f4e80f-cc78-40c3-9fa8-08279e8d87cf" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,406,170</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for cash issuance costs, net proceeds from the offering and overallotment were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66b48779-49a8-4fc4-88cf-41e8b9d1ff4e" contextRef="C_84f4e80f-cc78-40c3-9fa8-08279e8d87cf" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,093,830</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3b82862f-ffc6-4837-b400-06f61429d2f3" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:GoingConcernConsiderationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern Considerations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a60f7ff0-023e-4f44-81fb-e0ae9381897a" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">44,207,272</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the Company&#x2019;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73571a4b-6202-46a0-9c43-f32ef89ab338" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,951</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,000 million in cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">meet the Company&#x2019;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after these financial statements are issued.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_58430710-2f88-4bb4-99c8-a6c467098529" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of the COVID-19 Pandemic on our Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 Outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_39a41108-4351-4189-90df-7962afac4a5b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d; or &#x201c;GAAP&#x201d;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da394fec-7fc8-4cc4-911c-f189061995c4" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s Chief Executive Officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_859dd0fa-7cbd-4a83-898b-c15275aed45b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#x2019;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_68b08aca-6ac0-4955-909d-8342f00b96c0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:CertainRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4a6b99e8-e1fe-4d3d-b8a9-8f9a86698991" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">financial statements of the Company&#x2019;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">period </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#x2019; equity as accumulated other comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3d06ce08-c38a-41a8-b513-720534d949ed" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#x2019;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_25e38661-c118-47a3-9ac9-1344d3eccc90" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f199ea1c-306d-4f81-b21b-9a3c2855e4c3" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8b68aced-a961-4909-b17a-a2bac6170c0a" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash equivalents as of December 31, 2022 and 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c51e4401-2d5d-4e1d-8e98-98932ab7a485" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#x201c;Accounting Standards Codification (ASC) Topic 820&#x201d;, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc6da17b-9d85-4f5f-a77b-2c0f52bb8153" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_767ac5eb-9c57-41e8-bdd7-5de7c1451d45" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s research and development expenses consist primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#x2019;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#x2019;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c79ece20-5513-4924-a170-b782eabd4820" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ResearchAndDevelopmentIncentivePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Incentive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8448df0d-6e77-4ca8-afc5-eb7b5fbcbcb6" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7415af44-84f1-4029-bfa3-b8ce5e7b0bb1" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#x2019;s role at the Company.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ea81fa28-db2d-4e49-857c-a3d0437a30be" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:CommonStockWarrantsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), depending on the specific terms of the warrant agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When warrants are issued for services to non-employees, under ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ca6713d-a4da-48b1-8b64-2bddaef2c07a" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13f26a74-b327-4112-909a-f00e69514791" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5261e74d-24fd-46f2-85e0-9bfa276f53a7" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6976f445-af5d-4b10-9648-ed53d5e2baf9" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.772%;"></td>
          <td style="width:1.171%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.741%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.171%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.144%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a84988ea-f6ff-4106-8513-eaeb41369a8b" contextRef="C_0f633671-f593-4b41-8b13-f542f6aec2d1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,545,628</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2630f16-f119-4e6a-8a1e-82d46fac2f6b" contextRef="C_6171e5f5-549d-4e50-9be8-e0a4a67b59bf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,797,185</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0f378d0-937d-4f45-b098-b273e33d8da8" contextRef="C_af796981-4cb4-490f-8a9b-07137ac824a9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">796,985</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff3c8f1d-4061-4351-bc43-4cd4587ba5a4" contextRef="C_3dddb3b8-9562-481a-8538-c27da39213ed" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,311,117</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a68dd44-baf0-46ef-8c2e-66037ad67314" contextRef="C_84c3fdea-c2ec-4933-8499-ef4172df40e8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">58,333</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_49ee0a3c-1c0c-4bba-a37a-fe2898531064" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Standards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a0b2792f-605a-4763-8395-d49240ea0dd1" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:LessorLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASU No. 2016-02</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as amended, Leases (&#x201c;Topic 842&#x201d;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_39488108-13a6-4758-a518-3dc778070850" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> this new standard as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9968103a-0f7a-43e9-ab8c-d4e00fd9c771" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#x2019;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e9650a3-2cec-41df-8098-65a46e19b11e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. RELATED PARTY TRANSACTIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Consulting Services</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leigh-Ann Durant, a former member of the Company&#x2019;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_596bfa7f-839a-4b7a-a3ad-eb4ca3126792" contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86" name="maia:ConsultingServices" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">88,994</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2eab590f-c43c-4b8c-a48c-2605611c5ab2" contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86" name="maia:CashPaidForServicesProvided" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">34,560</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued her options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3df4509c-7292-4bcd-b730-5a995c7408d7" contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86" name="maia:OptionsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,964</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccef2470-a7f6-4310-b7d8-fd2473b2ed4d" contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86" name="maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">54,434</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the year ended December 31, 2021.  Ms. Durant was no longer considered a related party in 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baf60086-991b-4848-8afb-e1cdac24c683" contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938" name="maia:ConsultingServices" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">4,700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74fceb7a-ad79-47da-aee8-4d723ed5c886" contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938" name="maia:CashPaidForServicesProvided" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,350</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued him options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f763a464-7ef5-4182-aa57-d129e65e6c56" contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938" name="maia:OptionsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">184</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_735eae9b-25d2-4043-b5e6-883005a781f2" contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938" name="maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19b5414d-1654-4eb2-9e15-81490ca5a926" contextRef="C_bf7f6aa9-8e0b-41e9-900f-25e5d88817a5" name="maia:RemainingConsultingServicesSettled" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,250</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for services provided in fiscal 2021 were settled in March, 2022 for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_343e85b5-ca9b-43be-a042-04fa9ee5eb5d" contextRef="C_bf7f6aa9-8e0b-41e9-900f-25e5d88817a5" name="maia:OptionsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">226</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options issued to Mr. Vitoc. The Company also issued him a convertible note in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f016484c-49cd-4a78-8247-38bef33b169b" contextRef="C_bdba1f1c-9953-4f89-8181-9aff72ad45de" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during April 2021, which was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1c58b82-4dba-477d-8579-e071d9be3c45" contextRef="C_a801211c-4f23-4b06-8cc4-6340d12cffcd" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,557</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock on September 30, 2021 at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_002f7c0f-5448-4aac-b039-c8a4857aeb20" contextRef="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and also received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be25cb53-cccc-4fc3-9357-82c8040b1952" contextRef="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,278</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants to purchase shares of common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9c208ee-3204-4830-8a8f-ee2a0d565e7f" contextRef="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.  In 2022, Mr. Vitoc provided consulting services to the Company through July 2022 for which the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a91f80-eaff-408e-b636-13e2a749ef0b" contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db" name="maia:ConsultingServices" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">36,900</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for services provided during the year ended December 31, 2022.  The Company paid Mr. Vitoc $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b1ff8dc-1464-44b3-9d8b-e513d9855736" contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db" name="maia:CashPaidForServicesProvided" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">19,950</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued him options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c43b786-6e43-4c20-8f72-ffbc326deb78" contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db" name="maia:OptionsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,690</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6520c97a-b06e-4b20-bffa-68d9362b2c96" contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db" name="maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue" unitRef="U_USD" scale="0" decimals="3" format="ixt:numdotdecimal">19.950</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In August 2022, Mr. Vitoc became an employee of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CEO Loan Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's chief executive officer lent the Company a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73241a87-8d8e-4b5e-bdfa-d71b76f5017d" contextRef="C_480dc74f-1404-498f-8b42-20bedaaa1ecf" name="us-gaap:UnsecuredDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_13cbd84f-c86e-4564-9422-0ed746867b10" contextRef="C_bda30473-24b2-49f5-aec5-68d7d75fc2b2" name="us-gaap:UnsecuredDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in August and September of 2018. These amounts, were unsecured, had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6aa764c6-5434-4df3-a070-32af21227d3d" contextRef="C_480dc74f-1404-498f-8b42-20bedaaa1ecf" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c085bd34-a54c-4fd0-8505-8d0f24039517" contextRef="C_bda30473-24b2-49f5-aec5-68d7d75fc2b2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stated interest rate, and no stated repayment terms. The Company repaid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c8c3fd-82a0-44d3-9330-cc30736772fe" contextRef="C_549c2a01-f299-4da3-bbae-8c582a89f09f" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,633</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the loan to the CEO during 2020 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_214a574e-f461-47d8-95f4-815c4f817f05" contextRef="C_77bae37b-9232-4726-80bf-d4346dbdd5c3" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">367</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4f16322-e044-4a21-9ef9-7528a0ef0e6c" contextRef="C_34634fe2-cf34-4270-bc4d-2bdee5324351" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">21,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The convertible note issued to the CEO was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2af026fb-b2db-4bd8-9149-9bbd2e9b0250" contextRef="C_49140d15-f3a7-4a2b-a015-cacc8dec9460" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,621</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock on September 30, 2021 at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c80ed0e8-af0b-4ca5-822a-f22ce17fe9e0" contextRef="C_a998ab06-ea16-418f-8f43-b74df1888ac3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.  No further notes to the CEO were incurred in the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2b460b92-ee95-4f89-a614-8f8f0433ee5b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.  ACCRUED EXPENSES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_15fefff6-2c57-4b19-95e7-59e657eaef30" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, accrued expenses consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.486%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.15%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.607%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.139%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bonus</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77015284-3df0-4555-9fe0-9d5d2400265c" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,094,582</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffb02229-4b81-42f2-9bf3-232e3eecbeef" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">384,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional  fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fb8b345-0e6e-41c5-916f-e81be8660779" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">332,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_573ad3b0-c884-4429-9e21-fe5146310edd" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">380,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9286b44d-869c-435a-a995-bb6b0a031a8d" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="maia:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">516,961</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_534b1b7c-45a3-4cd8-801d-f0da631a8523" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="maia:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">268,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred compensation to former officers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c65f39f6-a573-4dda-a70c-794eec0edcd2" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">111,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3aad42d8-24f9-45f6-9311-8461b883864b" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">159,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9fa01bb-2913-4369-87a0-e96348a73100" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">41,157</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_848a32a2-46fa-4809-97e5-7d192627eb63" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,103,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f471f32-385a-4e82-8c78-92cd19d4b195" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,185,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Compensation Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de56b5ef-a1e5-4f30-950a-ee22965f2b8f" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85862c8a-63b2-49b6-b669-ca46cf9c1745" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">111,271</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2b8fe5a-a91e-4bf9-ab7f-c3b93692f0cc" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredCompensationLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">193,379</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in deferred compensation. The Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31ccd9a6-d45d-4e4e-83a1-a9dca5ecc402" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:CashPaidToSettleAPortionOfDeferredCompensationBalance" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">457,749</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efa5c812-a3f8-44ac-8a7b-9d71d1a69774" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">268,769</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6bca42c-fc42-48e0-9114-7f93ccd9b858" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">296,264</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb7b9df9-b74d-4010-bcbe-29ea16999b1e" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">743,167</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The fair value of the options issued in excess of the deferred compensation balance settled totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_033d5a41-3560-44b2-8eff-f9cbc8eec8ec" contextRef="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,846</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Bonus</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, the Company accrued $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d433b901-2021-496a-94bc-d0158ceca053" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,094,582</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1824941-ed67-43ac-bd46-216fd07f7c32" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">384,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4603f5ff-e1db-42e2-ae4f-6abe42ebd5b6" contextRef="C_c3a2c7f8-d558-4863-ba84-7247dacc03ae" name="maia:IssuanceOfStockOptionsToSettleAccruedBonusBalance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">713,536</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6898de32-58ca-42c3-ae57-9930812119fd" contextRef="C_c3a2c7f8-d558-4863-ba84-7247dacc03ae" name="maia:FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">786,531</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The fair value of the options issued in excess of the accrued bonus balance totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_befb9f07-e7bf-4948-a593-b9bf9cca0bae" contextRef="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e" name="maia:StockBasedCompensationExpenseRelatedToAccruedBonusBalance" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,531</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August of 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_01b6bcba-0912-4fca-95d7-438c9db09210" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:PaycheckProtectionProgramTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. PAYCHECK PROTECTION PROGRAM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 31, 2021, the Company received a second PPP Loan in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_258780c0-d05b-45fa-87c5-d353825d48ed" contextRef="C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb54d257-2b6b-44ae-ac0a-3771ed1ea7c6" contextRef="C_b52893ed-19d1-4467-abfb-baf9e1042428" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.98</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum. The term of the PPP Loan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_377cf83d-530d-49a3-b2ea-b972ffe2220a" contextRef="C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65ba1a34-ba69-4372-826c-91d3af586aa0" contextRef="C_0ad7911b-4b7a-4316-b95d-e54b9310b0df" name="maia:ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and the Company recorded a gain on extinguishment totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce5aed9d-b171-4d20-81f8-181170d1db25" contextRef="C_0ad7911b-4b7a-4316-b95d-e54b9310b0df" name="us-gaap:ExtinguishmentOfDebtAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11a0579b-95cf-4c7f-8ab8-032d13960127" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. CONVERTIBLE NOTES PAYABLE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes Payable issued in 2019</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, the Company issued a Convertible Promissory Note totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b0f6934-a888-48f6-8b8d-b3f8737d1453" contextRef="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to one individual (the &#34;2019 Convertible Note&#34;). The 2019 Convertible Note bore interest at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d83ded9f-bf23-4ebf-a0a8-54e2cd6ce22d" contextRef="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, was unsecured, with a scheduled maturity date of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e25f9cc-5f17-4ff8-87b6-c03eaf0dec9e" contextRef="C_f14d921e-d893-48a9-b93d-6895d30a125f" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5254954-fdd3-451b-9497-440914647f74" contextRef="C_8a3d4bbe-f995-4369-a38d-55c3e19f2acd" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (before any transaction related expenses and costs). The conversion price will be set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2ad1b6b-b902-4382-8481-c75fcd47fb02" contextRef="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e" name="maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the preferred stock issued in the aforementioned Equity Financing.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Put Feature</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the terms related to the Equity Financing conversion, (the &#x201c;Embedded Put Feature&#x201d;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense on the 2019 Convertible Note totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a4700b7-b634-4827-8a7e-98601e6a7f93" contextRef="C_96904691-c19d-41d7-b74c-e304c0e6af45" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6461d2d9-df78-4f12-8150-179cd1e92640" contextRef="C_2cc4ed46-ee40-4446-afb7-6c466d1a0315" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">607</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44c276ed-889f-4f85-b44b-1e83411e188c" contextRef="C_a3f721fc-ed4b-48d0-82bf-0755ef0a4134" name="maia:Debtdiscountandvalueofembeddedputfeature" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at issuance. The balance of the debt discount was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d61826d7-7692-429b-bb46-18d8fcf73901" contextRef="C_6643c0e3-8b98-4c5e-bc38-a4ac458d4842" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c1bab52e-ec9a-4d54-9006-dd870159c8e8" contextRef="C_c159ace3-ffb0-4d4d-8a15-d426dd48bb91" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022 and 2021. During the year ended December 31, 2022 and 2021, amortization of debt discount amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_371e7ef0-2cc5-4c41-8115-b23365544d92" contextRef="C_96904691-c19d-41d7-b74c-e304c0e6af45" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e25abed6-2345-4ad3-acf1-22af00e26a28" contextRef="C_2cc4ed46-ee40-4446-afb7-6c466d1a0315" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">310</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes Payable issued in 2020</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2020, the Company issued Convertible Promissory Notes totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73c6c54b-f3c0-42fe-8bcc-e88678edde59" contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">610,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to various investors or holders, including $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6513fff-a5c9-4f84-a769-3e10974c036f" contextRef="C_f508854b-0a5d-48f7-9b76-4f60049b5004" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">110,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Convertible Promissory Notes to related parties (collectively, the &#34;2020 Convertible Notes&#34;) throughout fiscal 2020. The 2020 Convertible Notes bore interest at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f37ba5b-89ad-468e-a879-35539fef9f2b" contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, was unsecured, with a scheduled maturity date of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6175bfa-f390-4ad4-a1f3-ac8c8661c875" contextRef="C_fdf96b15-9f52-42b0-af98-607e4a595a5f" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 31, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fbc9350-f7bd-4a6b-934d-c9eb0ecd7bec" contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc" name="maia:MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3986e94a-01ed-417d-8b32-bbf5219ccc85" contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc" name="maia:PercentageOfVotingPowerDefiningChangeOfControl" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued on conversion shall be shares of the Company&#x2019;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Prices</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conversion price is set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b46fbdd4-2cef-4b2d-9a2a-2ad5b3fc7d81" contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc" name="maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Put Features</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#x201c;Embedded Put Features&#x201d;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95379e22-0b6e-400d-9b3d-e1cc3c663e98" contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">131,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at issuance of the 2020 Convertible Notes (see Note 8). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maturity Date</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense on the 2020 Convertible Notes totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aec36a74-a4ec-488b-acd2-653f8f184f06" contextRef="C_b7d464db-7209-4119-bc09-50cf74d2d6d7" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">27,375</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b17f26ac-d880-4c86-91ec-556c5a9e82fb" contextRef="C_fdf96b15-9f52-42b0-af98-607e4a595a5f" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,523</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discounts on the 2020 Convertible Notes totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_173f4c5f-181c-44a7-8ead-012d9d980fd3" contextRef="C_8c20c208-c8e0-40af-b818-86f3f673ef3b" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d9d0a37-0090-4756-b9f3-bae3c7e13a69" contextRef="C_ed9fcd67-e733-47c1-804f-2d29703a3a3f" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022 and 2021, respectively.  During the year ended December 31, 2021 amortization of debt discounts amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b26534d3-634f-425b-96c4-aab4f9a4f73f" contextRef="C_b7d464db-7209-4119-bc09-50cf74d2d6d7" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">83,608</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2ef0a19-2ddc-4c15-97c8-9643d31b9b8c" contextRef="C_66a04226-000c-48ad-8295-b5d5efd519ea" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amortization of debt discounts for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4fd64e4f-32b4-4735-954d-7ca394fc52bf" contextRef="C_3c664d98-02a0-4f5a-946c-51e9b9611596" name="maia:WarrantDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e44bf063-e1c0-4750-9b67-a31082b1ec5f" contextRef="C_3e133a48-7bca-4524-bf21-ae7de81db87a" name="maia:PercentageOfIssuableUponConversionOfExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d25ac70-ee25-496e-b6f1-491e67bf2782" contextRef="C_3e133a48-7bca-4524-bf21-ae7de81db87a" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">65,660</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 8) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes Payable issued in 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the  year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d4245de-99b3-4a13-b0c6-7b551b1d2eba" contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,390,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to various investors or holders, including $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14a1f9f2-89cd-4d1c-ab47-7c01ff679364" contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4" name="maia:ConvertiblePromissoryNotesToRelatedParties" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,863,300</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Convertible Promissory Notes to related parties (collectively, the &#34;2021 Convertible Notes&#34;) which included a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47656c38-12a3-4f8a-af4c-02200049966f" contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4" name="maia:ConvertiblePromissoryNotesToSettleLoan" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">21,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c023fc70-328e-41ff-88e1-bc73840d7062" contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f86a5e57-8e4b-46b5-a8e2-7c01aec272eb" contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued on conversion shall be shares of the Company&#x2019;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Prices</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conversion price was set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42a18ac7-c67e-47f6-a0ab-235ad00b9c1f" contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad" name="maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Put Features</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#x201c;Embedded Put Features&#x201d;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3717b9c2-ec71-4a56-9612-7a8240ee20ec" contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,821,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at issuance of the 2021 Convertible Notes (see Note 6). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maturity Date</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense on the 2021 Convertible Notes totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4045dc20-a06e-4970-8e78-a8336a3932ef" contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">199,049</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a5348bc-d8d3-4471-8058-1b71981edb7e" contextRef="C_b2d52605-606c-4298-a0ed-01a4e1641f08" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, amortization of debt discounts amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ec786bf-4e7d-4a20-a8cb-99b646486aec" contextRef="C_6039b578-eeec-4f91-947f-34335f15d319" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97e3b61c-8fdd-4be2-82e1-dd446ca524e9" contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">513,035</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_98ba0428-ae97-41c3-8acc-f7f616f98bd9" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:WarrantDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad7c2a0a-d882-49e7-9694-350cc5598584" contextRef="C_6dfe66b4-3a5a-4059-86f7-1adc0a69cd08" name="maia:PercentageOfIssuableUponConversionOfExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_573565bd-aab0-409f-ac71-4a7398b72156" contextRef="C_6dfe66b4-3a5a-4059-86f7-1adc0a69cd08" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">320,460</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 6) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion of Convertible Notes Upon Equity Financing</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e833ad2-1809-4525-8fdb-72952b46e545" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company converted all $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d7a507d-7072-4f83-b1e6-f120434ac038" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,010,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its outstanding principal and all accrued and unpaid interest of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_361ca525-78fd-48ac-83d6-bb7b6dc6b85f" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:DebtConversionOriginalDebtAmount1" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">240,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the Company&#x2019;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aa83ae9-fcc3-4c7c-8219-7a1f6ddf7807" contextRef="C_24d517c1-101e-49f7-858d-15b0bb2079e8" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,375,228</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock on September 30, 2021 at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3da067bb-e417-4cb5-b869-6b516086f54c" contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83321fa2-1934-40f7-bcf7-d8edc7e9af21" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million loss on extinguishment, upon conversion, year ended December 31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65eabf8b-fa28-40fd-9454-1bc4c14901ff" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021 there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afa217b0-648a-46da-a5a7-515b33c99316" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="maia:ConvertibleNotesOutstanding" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Convertible Notes outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bdc0945-b31c-48bb-a828-57936537c082" contextRef="C_24d517c1-101e-49f7-858d-15b0bb2079e8" name="maia:CommonSharesUponExerciseOfWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">686,489</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0aa619c-3604-498e-af3f-4c6ac782d074" contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expire at various dates throughout fiscal 2028.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e149df82-4c04-4d39-8812-628d27fcb99f" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:WarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,504</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of these warrants have been exercised.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c1961a4-ce4f-4d8c-88a0-47265b81fc04" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:SimpleAgreementForFutureEquityDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. SIMPLE AGREEMENT FOR FUTURE EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, the Company issued a simple agreement for future equity (&#34;SAFE Agreement&#34;) for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f92b655b-1468-425d-bdd9-99cae650ef19" contextRef="C_a8986a13-566d-41de-a913-47e267f84b74" name="maia:SimpleAgreementForFutureEquityIssued" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. 'The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The conversion price will be set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c33fc1f8-e5c0-4528-8cae-af07b1d40fc8" contextRef="C_a8986a13-566d-41de-a913-47e267f84b74" name="maia:PercentageOfConversionPrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_163f0547-0830-4853-a137-6d0a93aa5025" contextRef="C_c4856ea2-7771-4d18-b27e-ad041dc17195" name="maia:SimpleAgreementForFutureEquityIssued" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14fab763-b878-438a-a52c-1c8fa5ca27f3" contextRef="C_c4856ea2-7771-4d18-b27e-ad041dc17195" name="maia:NumberOfCommonSharesConvertedUnderSAFEAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,208</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock on September 30, 2021. The price of the common shares issued in the equity financing was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e51fd561-eb05-4f33-b1fe-579fae2c0fef" contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">8.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. 'The conversion price was equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c11be71-a9a5-4d29-8a4d-02121fac964b" contextRef="C_c4856ea2-7771-4d18-b27e-ad041dc17195" name="maia:PercentageOfConversionPrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37a3a06d-381d-4f81-9c33-b5a550304ad1" contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">8.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e7c2c1a-08d0-43c2-a9d7-f491391f0cb3" contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978" name="maia:CommonStockConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span><span><ix:nonNumeric id="F_8fd4cba7-689d-4b89-8ede-7da17b541f9a" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_8fd4cba7-689d-4b89-8ede-7da17b541f9a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  FAIR VALUE OF FINANCIAL LIABILITIES</span></ix:nonNumeric></span></p>
  <div><ix:continuation id="F_8fd4cba7-689d-4b89-8ede-7da17b541f9a_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a563e2c-0ec7-4039-84ba-5eec71d1cd50" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" escape="true" continuedAt="F_0a563e2c-0ec7-4039-84ba-5eec71d1cd50_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.057%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.657%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.041%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d4dbe32f-1df1-43a5-8162-239e9214a75a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, beginning of period</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cf16a17-3e04-4d91-b2fd-e7dcb77d92ab" contextRef="C_05ed1f6a-7bd5-44e6-a939-0de1e93bb2f6" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">127,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liability on convertible notes payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa2475a4-3536-49a5-be37-478de53ac8fa" contextRef="C_8f949a11-176b-4ad1-9d69-a21194d19325" name="maia:DerivativeLiabilityOnConvertibleNotesPayable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,821,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss (Gain) on fair value of embedded features</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5361efb-c1e3-47f9-b65e-236aacfdb0bb" contextRef="C_8f949a11-176b-4ad1-9d69-a21194d19325" name="maia:ChangeInFairValueOfEmbeddedFeatures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extinguishment of derivative liability in connection with debt conversion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5deb2e57-de1f-4090-806a-fca38ee6bc1a" contextRef="C_8f949a11-176b-4ad1-9d69-a21194d19325" name="maia:ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">3,151,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, end of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#x2019;s income reflected the volatility in these estimate and assumption changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14e85319-2096-410b-a276-fcf6b4452342" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ChangeInFairValueOfEmbeddedFeatures" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">203,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3b13176-d165-469b-af32-b5ac67dc985f" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%; the probability of an equity financing was estimated to be approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5304e90-7c9a-4582-8b15-606030fcdc4b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ProbabilityPercentageOfEquityFinancing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%; and the probability of default, change in control or dissolution was estimated to be approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e18cc68d-1175-4b79-a56d-c9a31b0bb228" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ProbabilityPercentageOfDefaultChangeInControlOrDissolution" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_755c524a-f22b-42e5-a015-02722a5b4722" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.627%;"></td>
        <td style="width:1.225%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.027%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.216%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.027%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.216%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.027%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.216%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.42%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_206b118d-2865-445c-bfd6-783049287951" contextRef="C_a0c99f8c-3025-49f9-9ce1-af3347da6e53" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be7fa11e-a4bb-4c82-96cc-a5b5b6e037fc" contextRef="C_432d777f-5193-4a7a-bc9c-bd381ee50b47" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8110ece4-a894-4a7b-80a8-ebd61f8baf2b" contextRef="C_a0c99f8c-3025-49f9-9ce1-af3347da6e53" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4f0ef3d-4f26-44ff-ae63-c1a3627054aa" contextRef="C_432d777f-5193-4a7a-bc9c-bd381ee50b47" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aec52d1-1b5b-4eb9-9585-e8e6314f9de5" contextRef="C_349fb6e1-da72-4c3d-8eae-a1f0bc375520" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrant liabilities measured at fair value on a recurring basis at December 31, 2021. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_0a563e2c-0ec7-4039-84ba-5eec71d1cd50_1" continuedAt="F_0a563e2c-0ec7-4039-84ba-5eec71d1cd50_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):</span></ix:continuation></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_0a563e2c-0ec7-4039-84ba-5eec71d1cd50_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.818%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.012%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, beginning of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fba62493-ef2c-416e-9fe1-5aa9add1d625" contextRef="C_e4e7d396-2e2a-4ecd-bda9-8259234860d5" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">85,260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e880d73-9d23-4060-b9b0-55e1345a84cd" contextRef="C_da576c98-2bde-4e20-b38d-a9c79bec3a95" name="maia:ChangeInFairValueOfWarrantLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">343,735</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7b5a1a6-71c5-4ed7-b91f-96c813e65fd2" contextRef="C_faeafa90-e78a-4213-beef-48ac41889fed" name="maia:ChangeInFairValueOfWarrantLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">320,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on fair value of warrant liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00f023a6-5d23-4b60-a5b6-9d324db21cc2" contextRef="C_da576c98-2bde-4e20-b38d-a9c79bec3a95" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">98,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4fa1458-27b7-4a94-b904-686d228bd98e" contextRef="C_faeafa90-e78a-4213-beef-48ac41889fed" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,546,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7145722-e27d-45bb-a9dc-0375bb378aea" contextRef="C_faeafa90-e78a-4213-beef-48ac41889fed" name="maia:ReclassificationOfWarrantLiabilityToEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">1,952,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, end of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fecf7308-7f65-4588-b4fb-f017195eb876" contextRef="C_432d777f-5193-4a7a-bc9c-bd381ee50b47" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0f482d48-5895-4951-8338-e43510ff1b96" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.  STOCKHOLDERS&#x2019; EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the Company&#x2019;s initial public offering, the Company&#x2019;s shareholders agreement terminated pursuant to its terms. In connection with the closing of the Company&#x2019;s initial public offering, the Company amended and restated its Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate of Incorporation&#x201d;) and amended and restated its Bylaws (the &#x201c;Amended and Restated Bylaws&#x201d;). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022 and became effective on that date, and among other things, increased the authorized number of common stock to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75f9c32b-ef86-4d36-8bcd-6ca63fa5ae0e" contextRef="C_e31173a7-a2dc-4f27-be64-82bc649b47d4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and decreased the authorized number of preferred stock to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_471b72b6-5763-42d6-9f1a-b0f76d271466" contextRef="C_e31173a7-a2dc-4f27-be64-82bc649b47d4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of MAIA Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5b67bc1-da9e-49cd-a02b-cba524bca075" contextRef="C_93dbd88f-ee4a-4a09-9905-9f43b0232942" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">263,729</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06eace70-5eec-484d-84a6-c608dd18b139" contextRef="C_ac8db0a5-2d96-4c6b-a190-68c3fc94e6a5" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af156fa3-a944-4462-b091-55e5841941ad" contextRef="C_850a921a-9604-4c05-bc2c-f089ad5556e7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,373,561</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b32ab68-4828-45c4-99d7-6bc121f8af2d" contextRef="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c" name="maia:TransactionCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transaction costs. During May 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2219d4b-f7ef-4bb2-8417-fe08b9780fd9" contextRef="C_46d64219-b005-46b4-9a54-af5112c896b0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44a9531d-f4d9-4d83-b3ff-e939c8ef24f9" contextRef="C_ab7d89f5-c0a9-4cc8-988f-dd865cac4e4b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a79a5eed-015a-4b4f-a66f-5949ff1049fe" contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">99,999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_114a7c0c-99c7-441a-8edd-bda9003d96b3" contextRef="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c" name="maia:TransactionCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transaction costs. The Company issued these shareholders additional shares upon the closing of the Company's initial public offering such that the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9eccd9e-a8f3-4950-b24c-af6bb882124e" contextRef="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> price per share they paid was equal to the price per share in the Company's initial public offering of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6668fb6-abdc-4845-a20e-37c0699f9d92" contextRef="C_95ea31ca-fbf2-45cf-921a-af532996efec" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The number of Ratchet Shares were calculated using the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3d46989-4d4c-4d97-9060-1f21bdf3e85d" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share price in the Company's initial public offering and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a92750b0-0d99-4527-98b2-5d7e0f493784" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">219,872</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were issued on August 1, 2022 to the investors in the Recent Private Rounds. The Ratchet shares were determined to be a freestanding instrument that was classified as a liability when the right was granted and subsequently reclassified to equity when shares were issued. The Ratchet Shares were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10a75e88-1495-4acb-984c-a99a8cea1a93" contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,099,360</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd33ea19-8159-404c-8202-b10cfa01c418" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> price of the initial public offering and were recorded as expense included in operating expense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 28, 2022 the Company&#x2019;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf6eac49-63d0-40c3-8cfb-3ea02a65b0df" contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b322b08c-a2da-43a6-93a1-42e984605870" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e791bab6-ce7c-47b1-8cbc-b1c6cd7f07a4" contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6" name="maia:ProceedsFromCommonStockNetOfIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84eede3d-1184-42eb-a8f9-f1f11b41bca9" contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37e509c6-1498-4fa1-a5bb-fd8503a666ca" contextRef="C_5aa0a4a7-169f-471d-837f-b409f7c4b858" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share when the underwriter exercised the overallotment for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c708fcea-0c8a-450a-84bf-f104de69da28" contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583" name="maia:ProceedsFromCommonStockNetOfIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to deducting underwriting discounts, commissions, and other offering expenses. After deducting the underwriting discount and other offering expenses payable by the Company, the total net proceeds for the initial public offering and the overallotment were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9bf0a56-f94e-48eb-a07a-09b67028f516" contextRef="C_a1c341f2-a782-415b-b128-1db37d526768" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, MAIA recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdaf46f7-a5f0-4490-91e5-5697f302865d" contextRef="C_fff227d5-244a-4bcb-80ea-d5ce7a3c9fdc" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">202,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of stock compensation expense related to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a02df7bb-deb2-4b6e-9cbe-c589709634db" contextRef="C_5e1ca0e3-7225-4c0e-aa21-a8c07456a8d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">112,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of MAIA&#x2019;s restricted shares granted to the founders. On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_426be2c1-0a10-4233-ab8c-bbcc2f336f2d" contextRef="C_8b94cac1-12b3-47a8-8cee-4ddd38a0ca14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">612,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> fully vested THIO restricted shares were canceled and the founder was issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f89c9d5-5cbb-4a41-87f5-cc0a2e7165d2" contextRef="C_ea377e52-e368-402f-8f8d-1865b3d62026" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">612,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> MAIA </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restricted shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in accordance with the founder's original award, the founder was also issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ab02fce-7b86-41f4-ac71-36efcd581d35" contextRef="C_fff227d5-244a-4bcb-80ea-d5ce7a3c9fdc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> MAIA restricted shares which vested ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6a0f1ee-332b-4e5a-9f69-a2a96e9b508b" contextRef="C_c0fc63fe-6219-4ed8-9fd0-353fd3128c57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unvested shares as of December 31, 2022 related to the founder's restricted shares. During the 12 months ended December 31, 2022, MAIA recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_961fd52f-2ab7-499e-890c-158155724a7a" contextRef="C_4ac28de6-5d6a-4cc2-ac1f-b7f9d7ebb27a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">52,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of expense related to  restricted stock for the year ended 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0bd47fcb-85d2-4812-b92e-5a8f6d200a6e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.072%;"></td>
        <td style="width:1.159%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.023%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.616%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.131%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Grant<br />Date Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cdf0774-e42f-4e84-820d-5b58fbf8186f" contextRef="C_cab8d345-5f87-42f4-95e4-921bbed2dd3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">58,333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbe2af3b-050a-477f-8bfc-817101b0271c" contextRef="C_cab8d345-5f87-42f4-95e4-921bbed2dd3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fe48750-be17-4f3f-926f-ca3855a292ab" contextRef="C_8cbd6772-af2d-432e-9e5b-d1b10fd09c8e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">58,333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8875ade-3b35-4aa5-b625-60345b971c7c" contextRef="C_8cbd6772-af2d-432e-9e5b-d1b10fd09c8e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the  holders&#x2019; warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#x2019;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only to be exercisable, in whole or in part, during the exercise period ending on the earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30562ac4-269d-4670-ae81-5ba99386c034" contextRef="C_139f3834-5a5f-48da-b7b6-95728dcce439" name="maia:WarrantModificationValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">144,497</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86d07e04-fe0a-4083-b005-242515ca2ab4" contextRef="C_e6b76190-87b3-4e35-a133-5acf6c22a4fb" name="maia:DeemedDividendOnWarrantModification" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">450,578</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was treated as a deemed dividend and is reflected as &#x201c;Deemed dividend on warrant modification&#x201d; in the accompanying statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January 2022, warrants were exercised, resulting in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1ea0eca-8dd5-4782-9401-989e89e6ef97" contextRef="C_1dd9ecfb-e5be-406a-bca6-0d22818e6d05" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of MAIA common stock for proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b848203-6e75-44f8-b8ec-1f1a921c37af" contextRef="C_1dd9ecfb-e5be-406a-bca6-0d22818e6d05" name="maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">110,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During May 2022, warrants were exercised, resulting in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56ea522d-ad69-43f0-8499-eac6dc92aa2e" contextRef="C_46d64219-b005-46b4-9a54-af5112c896b0" name="maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">153,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30b31cd1-5fe9-4d07-bfb0-36da696b6071" contextRef="C_46d64219-b005-46b4-9a54-af5112c896b0" name="maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">275,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Another </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8c7ac5f-9566-47b2-a17a-26f5d66e528c" contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc" name="maia:WarrantsExercisedShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">394,501</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants were exercised with a cashless exercise assuming the fair market value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0fb0fcb-77e4-454e-9240-a58952575403" contextRef="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c" name="maia:CashlessExerciseAtFairMarketValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share resulting in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fcaf46c-8531-4915-be5f-983d707eeb48" contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc" name="maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">315,601</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the closing of the initial public offering, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eed5ba67-7fc4-4367-a180-5110d493272e" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="maia:NumberOfWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,520</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63619d43-2c39-471b-8f95-98e28faf7923" contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share expired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the closing of the Company&#x2019;s initial public offering, the Company issued warrants to purchase an aggregate of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_587cca78-b107-4c39-91df-9a43e9cfae97" contextRef="C_d2e664bd-7357-485e-b4fb-bf293169d186" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock to the Representative or its designees, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9196cc1-293b-46c5-93e2-13b0150ea8b0" contextRef="C_e31173a7-a2dc-4f27-be64-82bc649b47d4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">6.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (the &#x201c;Representative&#x2019;s Warrants&#x201d;). The Representative&#x2019;s Warrants are exercisable beginning on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0bbd05bd-748e-4046-96d1-19bfc1376e58" contextRef="C_5e96f6c1-8fcb-4e45-849b-c83a8f2330e8" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 23, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_67762d1d-5cd7-4b4e-a136-414653585ecc" contextRef="C_5e96f6c1-8fcb-4e45-849b-c83a8f2330e8" name="maia:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 27, 2027</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pursuant to the terms and conditions of the Representative&#x2019;s Warrants.  On August 3, concurrently with the full exercise of the Underwriter&#x2019;s over-allotment option, the Company issued additional warrants to purchase an aggregate of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cea7433e-4c33-414e-8b99-6d7e2b822a12" contextRef="C_b86fb584-5f3d-48eb-bd47-338774b042f1" name="maia:ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock to the Representative or its designees on the same terms. The warrants are not indexed to the Company&#x2019;s own stock and therefore meet the definition of a derivative liability. The warrants are liability classified instruments and were initially recorded as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18652f0d-797c-48aa-8cb3-0010cc526d98" contextRef="C_79f9be5c-c6c9-4e62-8570-7a5b4ef49378" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">343,735</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was the value determined using the Black-Scholes method using a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd63b4cb-9b62-48b5-b553-49fb1eacb521" contextRef="C_10935678-cd01-4042-9bb0-148e441856b3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a590dcfd-a598-4138-bfa8-ab091f18627b" contextRef="C_10935678-cd01-4042-9bb0-148e441856b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fdcc822-fb28-45e8-ab30-1a81b4168528" contextRef="C_10935678-cd01-4042-9bb0-148e441856b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As of December 31, 2022 the Company remeasured the warrant liability resulting in a value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a65e813-1f77-4727-b3a4-ed12a2b5363f" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">245,341</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The gain on remeasurement of the warrant liability in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f227a48f-84c4-4a81-8461-88289ee2aba3" contextRef="C_d3540e61-4c81-4a9e-8519-75d8edfbd550" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">98,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was included in other income. Only the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ff5e1d4-076d-402f-b79d-4b9cb74309cf" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">115,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants issued in 2022 are classified as a liability, all other outstanding warrants are equity classified.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa1a4e3c-cdf8-40ee-85f6-7af3e47a1e39" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ScheduleOfWarrantExercisedTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.425%;"></td>
        <td style="width:1.005%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.994%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.183%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.994%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants<br />Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term in<br />Years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb56761c-784f-4978-8cdd-3098c37d720a" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,311,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f913669-7c30-4804-8899-a0802ffadb53" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="maia:ClassOfWarrantsWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_29a49034-3126-4239-b6a1-e71f090d0276" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.30</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b796ca08-e5f5-4cb7-b312-28ae0c02b664" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">115,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de8ccaa0-79fb-491f-94d0-43cdce90d3fd" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsWeightedAverageExercisePriceIssued" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_757bc6cc-2c50-4530-9275-90389eb3e1a3" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">608,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54710dc8-701b-4c92-a844-4a1e3eb22e58" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsWeightedAverageExercisePriceExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30f3b6cb-a053-4fab-be0a-809ddccc75b0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsExpired" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,520</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63755577-5a8c-493b-9406-754e8adfac21" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsWeightedAverageExercisePriceExpired" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcb743a9-9c86-46ac-ba34-d43ed285e148" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">796,985</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b76e56d-de77-4adb-ad49-9528bca1dbe8" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="maia:ClassOfWarrantsWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47014a67-b835-4090-9d56-dbef911497fe" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.16</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bcdc4fd8-9b41-473f-a1ec-19431c7c7ffa" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.0%;"></td>
        <td style="width:2.0%;"></td>
        <td style="width:14.5%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.88%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06b045d2-0144-48d5-84f1-fb03d2f4118f" contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02adfaaf-589a-4892-b918-078d546e65e6" contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff44f904-af7f-4afb-a982-9b09777ded4b" contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3b98777-4166-4779-af68-60cfdc864e5a" contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73a58959-2fcf-4761-8f2a-0a2eb4644dd7" contextRef="C_33263a2e-646d-4256-82aa-1223f29184cd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_43016640-5052-4934-b799-ce72d2163dd1" contextRef="C_83947522-5d4a-4233-ab67-fb6efdf06f08" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8434b71b-de04-4abf-83f7-43de347a3171" contextRef="C_538b838f-72d0-42ef-a3b6-35b1fbd33513" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d3bbaa0-f31f-4209-b3cd-34da1a979b75" contextRef="C_0cf26860-1e88-4777-a873-11663c855cc6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_378f8421-9d3d-420c-b85a-b6587bf3a7d2" contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">78</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_700da138-b929-420a-94c9-78b5bd9ddbba" contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">92</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bcf7e38-b7f6-4553-a2d4-e9522c360681" contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">81</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d43bee8-f410-4224-a610-eaa6da7effa7" contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">106</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. Stock Award Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the &#x201c;MAIA 2018 Plan&#x201d;). MAIA&#x2019;s board of directors administers the MAIA Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf7f8cb4-43d3-448a-956b-0fb3f8f18d00" contextRef="C_7fba4a25-8b91-4e2b-9498-b481e7e735a2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding in the plan of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#x201c;MAIA 2020 Plan&#x2019;&#x2019;), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dd597cd-e3f3-487a-8df2-16c9c7676cd5" contextRef="C_6992df71-0104-43df-abe1-8e43fcfa0c86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,983,023</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding in the plan as of December 31, 2022. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45de699c-fac0-42fb-aa9b-2defeca9230d" contextRef="C_6992df71-0104-43df-abe1-8e43fcfa0c86" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for future issuance in the MAIA 2018 Plan or the MAIA 2020 Plan .</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 1, 2022 the Company approved the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the &#x201c;MAIA 2021 Plan&#x2019;&#x2019;) with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a3538b8-801d-4560-9607-210f39b03c4f" contextRef="C_70eeaef3-d979-4694-830c-aa004fc65cad" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,909,518</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock reserved for issuance. As of December 31, 2022 there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adb72994-8326-4460-8d80-1f5927d0939d" contextRef="C_e144005c-eb16-4637-a828-601934ff5985" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,271,413</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock available for future issuance under the MAIA 2021 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dd0227c-e550-41b7-b93e-276ade2d9489" contextRef="C_e144005c-eb16-4637-a828-601934ff5985" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">638,105</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding in the MAIA 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options are to be granted with an exercise price which is at least equal to the stock&#x2019;s estimated fair value at the date of grant, and with a contractual term of no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5305b090-9b56-47b8-bfee-0baed9197eb2" contextRef="C_0d8490e1-93cd-41ed-bc23-ad484a70d024" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. In the case of an option granted to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d2a5729-f502-477b-9b59-964efa6e0f3b" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% stockholder, the exercise price shall be generally no less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bc6b8e7-1467-46fa-93d4-fcd93e2d1671" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value per share on the date of grant, and the contractual term shall be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_def16657-a0a1-4721-9a43-f0b61cf42a05" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are canceled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are canceled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company&#x2019;s exercise repurchase rights and various other features of awards granted under the plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7c9202b-66f9-4227-aefb-310e7a9526c0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.822%;"></td>
        <td style="width:0.96%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.292%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.173%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.291%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.972%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.315000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.185%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.991%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options<br />Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term in<br />Years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d05b9c90-e4a5-4833-8a6f-88da994de828" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,797,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93029763-d655-4cc1-aaa1-7487fe2d7bfb" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a68eeac7-23b0-4128-b798-dde37c88f3ec" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.59</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6f0d098-9a8c-482d-8579-720b2b917efd" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">811,831</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62f4a7aa-d395-48f5-8173-b6e16c5a8d52" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d105f066-cd9a-45ca-800a-9bfc9c2da4a0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">46,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d960ee07-929c-4621-8f51-9b51f6a246ae" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled/forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe9b3600-467b-4cd0-a247-e65f55e63368" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,888</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f5adfbb-74c2-45a6-a6e6-19362a6e7c25" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a380c0e-dee3-4c98-b898-bbdeee8a9cd7" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,545,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8d46f70-10e8-437f-81bd-63d4c8ecfd9b" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f18d9387-775e-4473-aa92-a1d0da653fa4" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.85</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b7c6e33-0a1e-4fb0-9fe9-1d3bc3e707f6" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,773,706</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5fd2c25-bebe-41a6-8666-66fa01d01807" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,449,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87f8987e-8ccf-4050-8986-8c9949b819dc" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_86989026-dbe6-4da6-9a96-4bcf08a0f9f8" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.59</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1f01b7d-9811-4d87-b954-3e8cbba83363" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,804,841</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_458530a7-bc55-470b-9611-73dd5b4ea6aa" contextRef="C_d07afd76-c668-4a14-b0f2-d16a7a6bc509" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.87</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method (&#x201c;OPM&#x201d;) and the Probability-Weighted Expected Return Method (&#x201c;PWERM&#x201d;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, the per share values calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share<br />of the common stock before a discount for lack of marketability is applied. From January 27 to May 31, 2022 the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8665c73a-c706-4db0-9207-a75f921fd949" contextRef="C_d418fc52-98ec-47f5-95c9-f00cb3c88d3c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:numdotdecimal">9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share based on the sale of common stock from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27, 2022 to May 19, 2022. From June 1, 2022 to August 1, 2022 the fair value of the Company's common stock was estimated for financial reporting purpose at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_407dc70b-0238-439c-92c8-75f97479cb41" contextRef="C_1d9234a1-5f51-4764-b7e4-a62ca84ba633" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share based on the price paid in the initial public offering. Following the initial public offering, the fair value of common stock, is based on the closing price of the common stock in the public market.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />During the year ended December 31, 2021, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07d178e0-83d2-441e-99a8-f2e56563e1af" contextRef="C_90df5ec5-d2d5-410c-ae2a-6982581d43c0" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was used. During the period of March 1, 2021 to June 6, 2021, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes based on valuations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e3f491b-7cc0-4cca-aefd-8d8ac009f53b" contextRef="C_960ce175-49b7-4d64-b47c-1ecd446c52b2" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.83</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share in February and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February and April 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair<br />value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to<br />arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value not be necessary to determine the fair value of our common stock.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4b5dc57e-799a-45be-88b8-d427de359a24" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.458%;"></td>
        <td style="width:1.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.113%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.113%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_411d535b-1094-4fae-ac16-4c1b2a1f277c" contextRef="C_13bf0128-a070-4b47-825e-8161c256c563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.14</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9067a81f-e59c-4ab6-bfc8-88a11af085bf" contextRef="C_13bf0128-a070-4b47-825e-8161c256c563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.45</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c7e56e8-cc31-4ab6-8164-818a3af91726" contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.36</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27fcdd10-e0f5-4259-a6f8-110da0bf25f8" contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.27</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_288dec63-9171-46ce-83ce-c97b7ac12cf6" contextRef="C_1389048c-24c0-4a62-aaa4-a2b74693dfae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b202cc94-9c73-4cc8-af85-b4216af6df9a" contextRef="C_6c7f2e44-3c3e-49bc-8220-a31f305d9878" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c37858ed-43c3-4011-9f22-18aa27cd59bc" contextRef="C_68298e68-92ff-4876-a80a-e4764bf1eb5f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4133148-dd6b-4cf6-a93c-f973384997b2" contextRef="C_5dff99c3-0b2d-4940-9d28-68bd8d158e84" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2726f3ac-b340-46f8-ab79-2c378695edeb" contextRef="C_13bf0128-a070-4b47-825e-8161c256c563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">71.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f20cb30f-da61-4444-872f-b47c0832d3ca" contextRef="C_13bf0128-a070-4b47-825e-8161c256c563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">87.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_977942ce-7a01-460a-a9ae-fbbd31dc09cc" contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">71.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5e7dec6-f6e1-43b0-b1da-9ce114725b37" contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair values of stock options issued during the years ended December 31, 2022 and 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ere $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1f55335-ebfb-46d9-867d-7882d6e5c042" contextRef="C_13bf0128-a070-4b47-825e-8161c256c563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a66a9c50-3c09-4621-bc0c-baf34e1fad77" contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.55</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. At December 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72359bb3-8930-46e8-8973-df87901c8b3b" contextRef="C_80e5dbc0-3203-4a49-8843-3da9d91fc340" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,447,367</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which the Company expects to recognize over a weighted average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb272aa7-8305-49d2-831d-301a560f4d83" contextRef="C_13bf0128-a070-4b47-825e-8161c256c563" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.26</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1313009e-c250-4dc1-84b6-f263cf43ffac" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation related to the Company&#x2019;s stock plans are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.288%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.964%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.243%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30ce8a42-a491-4280-9fa4-a35bc2f3850e" contextRef="C_c9fb6a9b-9be5-47bf-a4da-ec226ccb941f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,422,799</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1450a05a-7e62-4970-b1e5-314dea1edcca" contextRef="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,779,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38ac0879-00df-4484-bc7b-eb703e774e86" contextRef="C_daea18c7-8f9f-40db-a949-f62882d10b13" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">896,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1177c0d-5daf-4f43-aeb1-9a4080892589" contextRef="C_60bc5fdb-609a-4b8d-8539-569a6372e484" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">943,708</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35376e46-1afb-4c9a-916f-a8b1e24a8638" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,319,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_531e8c36-e233-43e6-baa3-c7d28bfde939" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,722,893</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_a90eb627-3a86-4319-ae91-6fed774530ca" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:DefinedBenefitPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYEE RETIREMENT PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. The Company will make a safe harbor matching contribution equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5cd50d6-3bc4-4818-acbe-9ea8383af33e" contextRef="C_1bfefa67-16ca-409f-bb23-cdd798adfd46" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of employee salary deferrals that do not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5311da10-a40c-43a8-a424-9fbb4e268b76" contextRef="C_04cf05b4-4370-4979-8fd8-aad3bb1d1cf7" name="maia:DefinedContributionPlanEmployerSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their compensation plus </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb8d3d90-ebb2-407f-9dcd-d27bde915012" contextRef="C_704afa9b-4318-432b-94d0-dd9ac96a4003" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their salary deferrals between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fb1ef39-a34f-47be-9e54-64724d1ec428" contextRef="C_704afa9b-4318-432b-94d0-dd9ac96a4003" name="maia:DefinedContributionPlanEmployerSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bec7b04f-2e0c-479f-b4c3-12840c005c24" contextRef="C_1bfefa67-16ca-409f-bb23-cdd798adfd46" name="maia:DefinedContributionPlanEmployerSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2022 Company match is immaterial. The Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e18f516d-40db-4c58-9638-c42dbdec324a" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.  COMMITMENTS AND CONTINGENCIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent Licensing, Sponsored Research, and Patent &amp; Technology Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (&#x201c;PLA&#x201d;) titled &#x201c;Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology&#x201d; with the University of Texas Southwestern (&#x201c;UTSW&#x201d;) to license patent families for a specific compound (&#x201c;THIO&#x201d;) from UTSW to MAIA. The agreement, as amended, has a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_85f11bb1-31be-4aac-8517-606e11f32141" contextRef="C_c5c5e8e4-533d-4dc8-81c1-c4f505de146c" name="maia:TermOfAgreement" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6dd5ff7-9c2a-45f1-ab12-589504458cad" contextRef="C_9685ca74-0b09-41fe-a647-8f730fad5ee4" name="maia:MilestonePayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06241a4a-46bb-4c8d-8656-c0747d3ea4b4" contextRef="C_99f06e4c-f0a7-4618-91e5-f9e6e61a5eb9" name="maia:MilestonePayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, not to exceed a combined milestone payment total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0228e325-e66d-462d-8cfb-534fa61f0c51" contextRef="C_c5c5e8e4-533d-4dc8-81c1-c4f505de146c" name="maia:CombinedMilestonePaymentsMaximum" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">112,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1245889c-fe96-4fda-89d4-366226912ffb" contextRef="C_7a095884-7271-41a9-990e-c05d7154216c" name="maia:PaymentsDueRelatedToMilestones" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments are due to UTSW related to the milestones. The agreement requires royalties of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80927d7a-e2e1-46f4-8849-97ddf1b71d0a" contextRef="C_aa57afe6-0ae3-4ae8-8716-1ebfc8bf9e47" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84ae2669-899b-473b-9c4e-930783b12b5c" contextRef="C_0838c5ab-fead-4553-91e0-e9194daa7208" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e058eed-e523-4013-b0b3-cf3028b688ae" contextRef="C_60690a56-b071-4f7d-a346-3c1b2b2672ae" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b282adc6-93b9-4efb-8b89-db2380002a5a" contextRef="C_4078271a-c8fb-4d34-a59a-234a262797bb" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on net sales above $1,000,000,000.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also in December 2020, the Company entered into a second license agreement with UTSW titled &#x201c;Patent and Technology License Agreement AGT. NO. L3648 &#x2014; MAIA Biotechnology&#x201d; pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b98ae236-2677-4970-96aa-9b609281d553" contextRef="C_b04addab-578d-403a-ac75-910316d401b0" name="maia:TermOfAgreement" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a146a1b7-a9e9-4a64-a9e7-ac3ad07986cc" contextRef="C_093f44a4-068c-4d51-9096-9822ca581146" name="maia:MilestonePayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33085c93-1e00-488e-967a-b3aa5a93e022" contextRef="C_c75159f4-1e2f-4115-964f-af704eb8949f" name="maia:MilestonePayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, not to exceed a combined milestone payment total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c49b255c-4233-447a-81de-d1d86f17ca4c" contextRef="C_b04addab-578d-403a-ac75-910316d401b0" name="maia:CombinedMilestonePaymentsMaximum" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">112,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2865065-1463-4de6-96ff-ac21524f8804" contextRef="C_7b0c05a1-2ef5-406c-a235-22c40e3c2880" name="maia:PaymentsDueRelatedToMilestones" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments are due to UTSW related to the milestones.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The agreement requires royalties of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48ed8fd1-4476-4a91-b7e6-bf4368d668a5" contextRef="C_bdce226d-2206-4c50-b8bb-8a3e0648506c" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82e531e4-aee3-440a-866d-0fdc4da50f84" contextRef="C_75c413f9-8ba4-436c-9bf0-776a3437584a" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa92c6f8-9987-445c-95ef-776fac99495f" contextRef="C_b89f176d-a5ef-4374-a64e-fbce690b3f42" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30b92c3f-8997-4554-886f-b98d2f24ee2e" contextRef="C_ee00796c-ffd3-46f4-93c1-8db0ae1a964e" name="maia:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on net sales above $1,000,000,000.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54daaeaa-6782-47d1-a5bd-738994fe0c32" contextRef="C_7b0c05a1-2ef5-406c-a235-22c40e3c2880" name="maia:PercentageOfRoyaltyPaymentsOnNetSalesDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f99d982e-029e-4311-8467-7346338e71a0" contextRef="C_b04addab-578d-403a-ac75-910316d401b0" name="maia:ClaimExpirationTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regeneron - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. (&#34;Regeneron&#34;) to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug cemiplimab representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_664e8f86-86b1-45c1-90f2-1e5e885af205" contextRef="C_59d4a5fa-7563-4679-8962-c0917ed9d470" name="maia:TermOfAgreement" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan in the event that patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of December 31, 2022 neither party has terminated the agreement.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span><span><ix:nonNumeric id="F_853197f2-7f98-4661-aaf2-7b200d0c52f0" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_853197f2-7f98-4661-aaf2-7b200d0c52f0_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  INCOME TAXES</span></ix:nonNumeric></span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_853197f2-7f98-4661-aaf2-7b200d0c52f0_1"><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e735d98d-933a-47ea-9be4-a7137214fb2a" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's net deferred tax assets consist of the following components:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.818%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.012%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce206a4c-a644-4d62-a55f-6321fe433aaa" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,294,955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a7b116a-dcb2-425a-8ba4-c0ab6456a01d" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,013,721</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0177259d-be60-4151-9fd1-f292bdbd428c" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,183,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1aa4176-de10-4741-b30b-6b324a43f662" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,800,935</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c009c3f0-da0f-4b49-b53d-fd18efeeef1a" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,499,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_197e30d5-4695-4092-8007-e429f3e10483" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">244,848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa7d5eae-8c39-4a2b-bb63-38683e81cdc3" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">109,673</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8be65f5-e125-45bb-b313-0f40d9a90adb" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a870f8-f61a-43ba-8f3d-c23187b93472" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">102,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3479c65-f28d-47f5-9946-59ddc643b727" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,229,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c1a75af-6e2f-49ac-a1ac-29d948b26c23" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,027,154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d60a8ce-c624-43e0-980e-b33dc1065792" contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,229,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44d0041f-ca81-4917-97ec-29b5f1109893" contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,027,154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company has unused U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c42f2b9-af41-4558-b0f0-94f66ab0dc6d" contextRef="C_2d323e1e-91fa-4adc-b0b9-fa95c2a916da" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_acddcfba-97cb-4310-aa57-2c4d91c9a142" contextRef="C_dbddc662-f865-4f07-88a7-237f7cbd58b3" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.4</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that may be applied against future taxable income. The state NOL carryforwards begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2dae785a-86c2-4049-b432-1ce08650e737" contextRef="C_c19f9601-2487-4519-b741-1a2bc336d1b4" name="maia:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The U.S. federal NOL carryforwards may be carried forward indefinitely, however are limited to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_609bc689-8db4-495c-8250-4305ecb30b84" contextRef="C_2d323e1e-91fa-4adc-b0b9-fa95c2a916da" name="maia:OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent of taxable income. The Company has unused Australian NOL carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bedd9513-1ad8-4802-9e93-18dcf49516cc" contextRef="C_2703e6a6-9c13-46c2-9da9-deaa17ee8d34" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that may be carried forward indefinitely. The Company has unused U.S. federal research and experimentation (&#x201c;R &amp; E&#x201d;) tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_132eac93-77d4-45ff-b064-74daf8b51588" contextRef="C_257832a6-de0c-47b0-b609-38c350dcd89a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a7bacf7d-a851-46e1-bf81-873cbc2a9fb2" contextRef="C_bd2957a7-98eb-4f84-87e4-b97ec6293ef9" name="maia:ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use of the Company&#x2019;s NOL and R &amp; E credit carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#x201c;ownership change,&#x201d; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#x2011;percent stockholders (or certain groups of non&#x2011;five&#x2011;percent stockholders) over a three&#x2011;year period occurs. After such an ownership change, the corporation&#x2019;s use of its pre&#x2011;change NOL carryforwards and other pre&#x2011;change tax attributes to offset its post&#x2011;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an ownership change occurs and if the Company earns net taxable income, the Company&#x2019;s ability to use its pre&#x2011;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#x2019;s state income, franchise, or similar taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 740, &#x201c;Income Taxes,&#x201d; the Company recorded a valuation allowance to fully offset its deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The valuation allowance increased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98104366-49b4-40aa-a78d-0fa009c931c4" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bfa24cd-e9c6-49d8-9706-8f9be4c4ebcc" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022 and 2021, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred a pretax book loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cbf7db3-e939-4733-b6bb-6452acae7a4e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">15.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022, which consisted of a U.S. loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12a0f205-d23f-4cf0-9f09-76e0e533fe0f" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">15.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a foreign loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b96c5962-ff3c-4646-9ca6-588d7bee9152" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company incurred a pretax book loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1cd2821-ab67-446c-a628-5e558102b562" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">12.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021, which consisted of a U.S. loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6503fdb3-6edb-4358-a059-b6415618b37d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a foreign loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43331c00-d793-4ae3-b1e1-6aed118a2aaa" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No provision or benefit for U.S. federal, state, or foreign income taxes has been recorded for the years ended December 31, 2022 and 2021, mainly due to net losses incurred by the Company in all jurisdictions other than Romania, which provides for a tax exemption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e2abd603-2514-4a3b-b9bc-0a7947ee208f" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.021%;"></td>
        <td style="width:1.156%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.156%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.31%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_777e94bf-6351-4a80-a0e7-b62d7db2456e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7cae02-649d-4be9-8050-9d9584fa7f1d" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b04157a4-8353-4c48-a2c2-d11be3bcdc7e" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6f45932-c319-4b9d-8171-1723b79c4ccf" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09ce149e-b52e-41e9-84de-b4e37ad727d2" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_719e798f-2ccb-44fd-8eb4-ffef92cfbbdd" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebaaa20d-d3c1-4158-b48f-6df30b0cd649" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54715b33-7c50-4d4a-ac88-59f411fdd253" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other nondeductible expenses/(nontaxable income)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57dd0fcc-0366-4ac2-9007-06c4c19d7aa1" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bb8ffc9-33d4-46c9-b55a-7da05f611904" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6e0f983-4450-47a0-b92f-06fc57c3bdbf" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdaa0db5-ff34-44be-a891-ee3114864d15" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8832b913-6523-4673-a7a5-0a7e2c2f7c0f" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ff27e45-fc93-4fc2-98dc-174105722b82" contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company files income tax returns in the U.S. federal jurisdiction, several U.S. States, Australia, and Romania. The Company&#x2019;s tax returns since inception remain open to examination by the taxing authorities.</span></p></ix:continuation></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3e6b661-629e-4b40-ba0e-b45c2f085e82" contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUBSEQUENT EVENTS</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 16, 2023, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cd52e78-0bc8-4b7f-80fa-16f43dd2268d" contextRef="C_123bb045-1787-4e92-86ee-97af8a0fc791" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for investor relations services from January 16, 2023 through July 16, 2023. Per the agreement  an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53263e37-9266-49f2-8799-50de51c2f1ed" contextRef="C_7447a51d-1b53-4834-a837-fd4e4d4818a5" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock will be issued on April 16, 2023 if their services are still in place per the contract.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cc42b37-a446-41d8-a8de-48ab1de8b73c" contextRef="C_b6fe62fc-f09a-4c0a-822b-9375cd7875df" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock on March 8, 2023 and an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62121cb7-ff56-4922-bfac-a44e63f692a8" contextRef="C_d9c0194e-ae7a-4f5c-a38a-cbedc013e926" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock every ninety days after the execution date of the contract until termination of the agreement. The term of the agreement extends for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b86be85-622d-48a8-a9e1-bfd5273a975f" contextRef="C_ceb3f2a5-5c4a-48e7-96ef-1bd506bd16cb" name="maia:TermOfAgreement" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and renews automatically until we provide written notice prior to the end of the term.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Options</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From January 1 to March 20, 2023 we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c9b1537-6ca3-42ee-9d4e-924d52e83550" contextRef="C_ea85c9c9-8fa4-44f7-9253-844104dacb55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">638,710</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options at a weighted exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51f38bf3-4559-4b7a-8f48-d72a9db4d9cc" contextRef="C_ea85c9c9-8fa4-44f7-9253-844104dacb55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to employees and consultants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>maia-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF REGISTRANT&#x2019;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a description of the securities of MAIA Biotechnology, Inc. that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), certain provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws. The description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to Delaware law and to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and are incorporated by reference herein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As used herein, the terms &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; and &#x201c;us&#x201d; refer to MAIA Biotechnology, Inc., a Delaware corporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorized Capitalization</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our authorized capital stock consists of 70,000,000 shares of common stock, par value $0.0001 per share and 30,000,000 shares of preferred stock, par value $0.0001 per share of which 10,996,404 shares of common stock and no shares of preferred stock were issued and outstanding as of March 24, 2023.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive on a pro rata basis our net assets available for distribution to stockholders after the payment of all debts and other liabilities, subject to the prior rights of any holders of outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of our amended and restated certificate of incorporation our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that delay, defer, or discourage transactions involving an actual or potential change in control of us or change in our management. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Authorized but Unissued Shares</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Stockholder by Written Consent</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware Anti-Takeover Statute</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to Section 203 of the Delaware General Corporation Law (DGCL), which prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Choice of Forum</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Court of Chancery of the State of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent permitted by law, for: any derivative action or proceeding brought on our behalf&#x37e; any action asserting a breach of fiduciary duty&#x37e; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation, or our bylaws&#x37e; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our bylaws will not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find either choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance Notice Requirements for Stockholder Nominations and Proposals</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#x2019;s intention to bring that business before the meeting. Although our amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Classified Board.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, our board of directors is divided into three staggered classes of directors of the same or nearly the same number and each are assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors are elected for a three-year term to succeed the directors of the same class whose terms are then expiring.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist of one third of our board of directors.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National Securities Exchange Listing</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is listed on NYSE American, or the &#x201c;NYSE American&#x201d;, under the symbol &#x201c;MAIA.&#x201d;.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>maia-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have issued our report dated March 24, 2023, with respect to the consolidated financial statements included in the Annual Report of MAIA Biotechnology, Inc. on Form 10-K for the year ended December 31, 2022.  We consent to the incorporation by reference of said report in the Registration Statements of MAIA Biotechnology, Inc. on Form S-8 (File No. 333-266453).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant Thornton LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Charlotte, North Carolina</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>maia-ex23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consent_of_independent_account_firm_ea"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statement of MAIA Biotechnology, Inc. on Form S-8 (No. 333-266453) of our report dated April 8, 2022, on our audit of the financial statements as of December 31, 2021 and for the year then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 24, 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ EisnerAmper LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EISNERAMPER LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Iselin, New Jersey</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 24, 2023</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>maia-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Vlad Vitoc, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of MAIA Biotechnology, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 24, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Vlad Vitoc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vlad Vitoc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>maia-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Joseph F. McGuire, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of MAIA Biotechnology, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 24, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joseph F. McGuire</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joseph F. McGuire</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>maia-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of MAIA Biotechnology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 24, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Vlad Vitoc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vlad Vitoc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>maia-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of MAIA Biotechnology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 24, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joseph F. McGuire</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joseph F. McGuire</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img118615358_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. 3,# 2(  A$! Q$!_\0
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MTKK5;<H;!&1G!ZB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXB@C34[?[3$H.U?-95(;&<A2,@X'6LS788I_&GAJ.:))$*79VNH8?<3L:Z<
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M+X:GHMC?K&8UN;=)@A.2NY0<9_&KM1*+C)Q>Z&%%%%2 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'R;\8_^2K:W]8?_1,=%'QC_P"2K:W]8?\
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MU9PIZF-HD56^A,;C_@)K=K?$_P 5OOK]^OZB6P4445@,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Y-^,?_)5M;^L/_HF.BCXQ_P#)5M;^L/\
MZ)CHH ]_T*"UN/ACX<COK\VEI_9MN92) F\")3C<>1C&>,=*ZG3H[./3H%L#
M&;38#$8VW*5/.0>]>63)=7/@OPE$EW>6\$6F6LF8-*-RK,8P"I?<!R#C;C/O
M7I'AN V_AVRB+2,P3):2$PL22224R=O7IF@#5HHHH 1E#J58 J1@@]ZQ?^$6
MT\VDMN9+Q@[ATD-TY>'!R!&V<H!V K;HH Y6[LX+#Q9X5M;=-D4<5V%&<_P+
MR3W/?-=57(^*(KV?Q9X;33[N*UN-MT1+)!YHQL7(V[E_/-:PLM>QSK-K_P"
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MPR*&22-@RL#T((X(KDI]-2S\1^%+*5A<;([PLSJ/F8JI)QVY)KL%544*JA5
MP !@"@!:*** "BBB@ HHHH **** "BBB@#S7QI!K0\=:'J$%Y:00V<FY/D;)
MB=D1_,.<8RV<C'%>E5SGBK1OM]A?7/G[-MA)%MVYS\ROGK_L8_&MK3KO[?IE
MK>;-GGPI+MSG;N .,_C6S5Z*?9M?E;]32I)/E2[?JRS1116)F%%%% !1110
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M7BK_ *&>U_\ !6/_ (Y4I6N:5)J2BET5OS.CI"0HR2 /4USO]E>*O^AGM?\
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M$SG:W'N>1@\]>E=-8VL%C86]G:C;;V\:PQKNSA5& ,GKP*Q/[*\5?]#/:_\
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M$O\ T!M)_P#!I)_\CT =%17._P!J>)?^@-I/_@TD_P#D>C^U/$O_ $!M)_\
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1M,K[=J*G7RAG[N>G>B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img118615358_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. 3,# 2(  A$! Q$!_\0
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MP+_R3_PY_P!@RV_]%K704 <__P (+X1_Z%?1O_ &+_XFC_A!?"/_ $*^C?\
M@#%_\37044 <_P#\(+X1_P"A7T;_ , 8O_B:/^$%\(_]"OHW_@#%_P#$UJOJ
M5I'J<>G-+_I4D;2K'@_<!P3GIWK./BFT"7#&SU'="P C^RMNE!.-R#^)?>@"
M/_A!?"/_ $*^C?\ @#%_\31_P@OA'_H5]&_\ 8O_ (FMR">.YMXYXFW1R*&4
M^QJ2@#G_ /A!?"/_ $*^C?\ @#%_\31_P@OA'_H5]&_\ 8O_ (FN@HH Y_\
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M ( Q?_$T?\(+X1_Z%?1O_ &+_P")KH** .?_ .$%\(_]"OHW_@#%_P#$T?\
M""^$?^A7T;_P!B_^)KH** .?_P"$%\(_]"OHW_@#%_\ $T?\(+X1_P"A7T;_
M , 8O_B:Z"B@#G_^$%\(_P#0KZ-_X Q?_$T?\(+X1_Z%?1O_  !B_P#B:Z"B
M@#Y%^*MM!I?Q*U>RT^&.TM8S%L@@4(BYB0G"C@9))_&BI/C)_P E7UOZP_\
MHF.B@#Z6\"_\D_\ #G_8,MO_ $6M=!7$^&?$FFZ/X)\,6UXUT)9=+MB@ALYI
M@W[H=T4C/!XZUUMA?6^IV45Y:NS02 E2R,AX.#E6 (Y!ZB@"S1110!6EM6DO
MH+@, (E<%<=<X_PKGX=)\1JMS//=:9)?>;O@E\N3;MY&UAG@!3QCOSWKJ:*
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M##8O)8*QSC':NUM6N'M8VNHXXIRH\Q(W+JI] Q R/P%8&L?\COX9_P!V[_\
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M5Q>2M'<YBM%4LV47D!B!C\>]=G:SFYM8IV@E@+J&,4P =/8X)&?QH FHHHH
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MK0NP\L C C<%2..Q^E>B>''23P_:2(\#AU+;H)#(C$L22&(7//L* -2BBB@
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M]8?_ $3'10!]+>!?^2?^'/\ L&6W_HM:Z"N?\"_\D_\ #G_8,MO_ $6M=!0
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M.>*HV/B?7YKJRBN]/$"EMUXS6K#R$)&T$^8<$\\\_04^XL]8N[];R;1--:0
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MS[2FXJ"=IZC/I[5A?VCXG_Z ^D?^#27_ .1Z/[1\3_\ 0'TC_P &DO\ \CT
M;']G66(1]CM\0_ZH>4OR?[O''X47&GV=VX>XM89F&/\ 6(&Z=.M8_P#:/B?_
M * ^D?\ @TE_^1Z/[1\3_P#0'TC_ ,&DO_R/0!O&&,XS&AQT^4<4)#'&[NB*
MK/C<0.N.!6#_ &CXG_Z ^D?^#27_ .1Z/[1\3_\ 0'TC_P &DO\ \CT =#17
M/?VCXG_Z ^D?^#27_P"1Z/[1\3_] ?2/_!I+_P#(] '0T5SW]H^)_P#H#Z1_
MX-)?_D>C^T?$_P#T!](_\&DO_P CT =#17/?VCXG_P"@/I'_ (-)?_D>C^T?
M$_\ T!](_P#!I+_\CT =#17/?VCXG_Z ^D?^#27_ .1Z/[1\3_\ 0'TC_P &
MDO\ \CT =#17/?VCXG_Z ^D?^#27_P"1Z/[1\3_] ?2/_!I+_P#(] '0T5SW
M]H^)_P#H#Z1_X-)?_D>C^T?$_P#T!](_\&DO_P CT ?-7QD_Y*OK?UA_]$QT
F5W7C+X1^*/%OBR^USS]'M?M6S]S]IE?;M14Z^4,_=ST[T4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img118615358_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "] =0# 2(  A$! Q$!_\0
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M10!1TR[FNHIQ.$$D,[1$Q@@''?!^M7JS-&_YB/\ U^R?TK3H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-%!HH KZC_P @N[_Z
MXO\ ^@FGVG_'E!_US7^5,U'_ )!=W_UQ?_T$T^T_X\H/^N:_RH FHHHH **@
M:\M5E6)KF$2.NY5+C+#U ]*DBECGB66&1)(VY#(P(/XB@!]%%% !1110 444
M4 <-J5EK6D>+M6U2QT1=8AU6TBA5?.1/*=-PVON_Y9G=G(SWXK)U3PUX@N?%
MQNH[)_->>UDM;^*[Q%8Q(!YT6S(SGYNWS9YQBO3Z* ."\.66NZ%(FAOH$5S;
M+J,MR=2:9 GEN[,&"\MY@W8QC\:K+X/N+.]\16=AIRP:=J5Y98V, #$,&9O7
MU'OFO1J* /+)="UZ\DOM$&CRQ03^(!J0U!Y4\M8A(K\#.[<=N,8[T6&AZ_.]
MMI$NC2VT-OXADU-K^25-AB$K. @!+;CD#H.IKU.BA:?U_78#SSP5X$GLX=-O
M]:N[QKBQFN)+:Q9D\J R._S# R25/<GJ:]#HHH **** "BBB@ HHHH ****
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M "*MS_UT@_\ 1R4 ;]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'J*,CU% "T4F1ZBC(]10 M%)D>HHR/44 +129'J*,CU% "T49'K10 AHH-%
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MR_J!6AIET+[2;.['2>!)/^^E!_K7-4Y9P51*VMG8I=BU1116 PHHHH ****
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M+GVYJQ'X;2&[M[N/2].6>W"B)A+)\NT$#C&"0"1F@#8_L?3/^@?:_P#?I?\
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M %?4?^07=_\ 7%__ $$T^T_X\H/^N:_RIFH_\@N[_P"N+_\ H)I]I_QY0?\
M7-?Y4 >?^(IO!<GB:]M=0\2W.DW<BJ+ZU2Z,$=RH48W9']U@,@@D CM7H%H+
M<6< M-GV;RU\K9]W9CC'MC%<;X\LM0EN[*XLK6]=!%(IDTZ")YO-^7RPQD'^
MKX.<>@S77Z<+D:9:B\""Z$*><$^Z'P-V/;.:%L#W)&N;=)?*:>)9,9V%P#^5
M87C"6.;PE<O%(LB&6'YE.1_KDJ'Q!H U7499C8AA'92!)8BJR/(PVX!/<+G&
M>,FN?U73]:M?!ZJDL=II\=S&7MKBW0SNAF3&6C(56Z] >U 'I%%%% !1110
M5AZP1#X@T&X/>:6#/^_&2/U45N5A^*#Y5K87.,^1?P,?H6VG_P!"IK<VP_\
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M$#Y_49^M;E% &7#IUU;L&ADL(V"[05M",#.<??\ 4DU-Y6J?\_EI_P" S?\
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M,T;_ )B/_7[)_2M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 0T4&B@"OJ/_(+N_\ KB__ *":?:?\>4'_ %S7^5,U'_D%W?\
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M32^9OD,O)WQ+$QZ?W5'XYH ZNVE,]K%,1@R(&QZ9&:EID,2PPQQ)G:BA1GT
MQ3Z& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9HW_ #$?^OV3
M^E:=9FC?\Q'_ *_9/Z5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% "&B@T4 17D33V5Q$F-SQLHSZD8JE!<ZA%;QQG2V)50O\
MKT["M/-&: ,_[9J'_0+;_O\ I1]LU#_H%M_W_2M#-&: ,_[9J'_0+;_O^E'V
MS4/^@6W_ '_2M#-&: ,_[9J'_0+;_O\ I1]LU#_H%M_W_2M#-&: ,_[9J'_0
M+;_O^E'VS4/^@6W_ '_2M#-&: ,_[9J'_0+;_O\ I1]LU#_H%M_W_2M#-&:
M,_[9J'_0+;_O^E'VS4/^@6W_ '_2M#-&: ,_[9J'_0+;_O\ I1]LU#_H%M_W
M_2M#-&: ,_[9?_\ 0+;_ +_I1]LU#_H%M_W_ $K0S1F@#/\ MFH?] MO^_Z4
M?;-0_P"@6W_?]*T,T9H S_MFH?\ 0+;_ +_I1]LU#_H%M_W_ $K0S1F@#/\
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K1FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- "&BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img118615358_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '" ZL# 2(  A$! Q$!_\0
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M^H!Q39;ZT7Q9"AN80PMFC(+C.XNN%^OM3'LH]0U/6K9SM+) 58=48 D$?0T
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M6G>=8WFI:?<O&S2H;J,QKM4YX8 ?7'YU)X<U*Q70["!KRW$VP+Y9D&[.>F*
M-^BBB@"EJUY)8:=)<1(KR*550_3E@.?SJF]_J=C-;_;H+9H)I!%O@=LHQX&0
M1R*?XD&[0YE#%27C&1U'SKS21Z'F>*2ZU"[NEB<.D<C#;N'0\#G% %JSO'N;
MF^B9%46\HC4CN-H//YTEI>O<:A?V[(H6V=54CJV5SS67;:>;S5=5<7MW;XN
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M;Z^6:&S2"W^V2(TC%G/EJH./3)/-/U969M.P"<7:$X'0;6J/6'T_?$NH0RA
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M5+10!&UO"S%FAC)/4E13U544*H  Z "EHH C-O Q),,9)ZDJ*>JJBA54*HZ
M# I:* "DVKNW;1NQC..<4M% "$!@0P!!Z@T%05VD#;C&*6B@!H1%;<%4'&,@
M=J4JK$$J"1T)'2EHH A-K;F;SC!$9?[^P;OSI[Q1R8\R-6QTW#-/HH 8D4<>
M?+C5<]=HQ23017"[9HDD7T=014E% #418U"(H51T"C %.HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **:S8*CU.*=0 4444 %%%% !1110 444A8#O0 M%-WBDW^U #Z*C60E<\4N
M\T /HIF\T;S0 ^BF;_:EW^U #J*0,#WI: "BBB@ HHI,_.1[9H 6BBB@ HHH
MH **** "BBB@ HHIJMEV'I0 ZBBB@ HHHH **** "BBB@ HHI,_/M]LT +11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !17(WWC6ZL#<M+X7U?R("VZ?8NPJI^]G/3 S3+7QS=7
ML<,L'A76'AEP5E5%*D'OG/2@#L:*R(?$$,WBFXT$02":"!9S*2-I![>N>:L:
MUJD>B:-=:E+&\D=NF]D3&3],T 7Z*Q=0U][/1;74H-+N[Q9U5S'  6C4KNR<
MGH.E5O#7BS_A)27ATF\M[4H66YEV[&(.-H(/7_"@#HZ*YS6/%]OINHC3+2RN
MM2U#;O:WM5SY8]6/:H],\9Q76J1Z9J6FWFE7DPS"MRHVR^RL.] '3T45RM]X
MOO+&XN4/A?5Y8H&8>>B+L8#^('/2@#JJ*XRT\>W%_;QW%IX6UB:"3[DJ*I4C
M..N:[('- "T45A^&-=EUZVO998$B-O=R6X"DG(7'/ZT ;E%%% !1110 4444
M %%%% !1110 44C,%4L>@&35/2M5M-:T]+ZQ<O Y(5BI'0X/!H NT444 %%%
M% !1110 44C$*I8] ,U3TG5;36M/COK%R]O(2%8J0>#@\&@"[167H]]J%Z]Z
M+_339+#<-'"2^[SD'1O:M2@ HHHH **,T4 %%%% !11FB@!C_>3_ 'OZ&GTQ
M_O)_O?T-/H ***I-JMHFL)I1<_:W@-P%VG&P'&<_6@"[1TIA?TIO6@!Y<=N:
M:6)I**8@HI0">U+L- #:*?L%+M'I0!"GW!3J='CRQ^-/P/2D,BHJ7 I,"F!'
M14FT>E)L% AE%.V'UI"".U  &-.#COQ3** )::/]:?H*90'_ 'ASZ"D,EHI
M0>E+0 4444 %%%% !1110 4Q/]9)]1_*GTQ/];)]1_*@!]%%% !1110 4444
M %%%% !3?^6O_ :=3?\ EK_P&@!U%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OB[_ )$_6/\
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M5K&03"(?V2NY9% ^\Y&?F/Z4 :WA".UT>Z\2WEZ99[W3)766\+L?.0C=RN<
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M]_\ ?C_Z]+_PLWP]_P!/?_?G_P"O2Y)=@]K#N=B  , 8 I-J[MV!GUQ7'_\
M"S?#_P#T]_\ ?C_Z]'_"S/#_ /T]_P#?G_Z]/DEV#VL.YUSPQ2E3)&CE>5+*
M#BGXS7'?\+,\/_\ 3W_WY_\ KT?\+,\/_P#3W_WY_P#KT<DNP>UAW.P "C
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MMZ7\R-O5]-35-'O-/WF$7,31ETZC(ZUS6GQ^-=)T^#3HK'1[A($$<<WG,@(
MP"5Q_*K7_"?Z)_T\_P#?K_Z]'_"?:)_T\_\ ?JCDEV#V]+^9$_A?0KO3)M1U
M#4IH7O\ 491)*L (CCP,!1GK]:Z$@$$$9!Z@US'_  GVB_\ 3S_WZH_X3W1?
M^GG_ +]4<DNP?6*7\R.E2&*)"D<:(A_A50!7,Z_HFJR:]8:YHS6C7-K"\!@N
MLA&5CG((Z&E_X3W1?^GG_OU2_P#">:-_T\_]^J?)+L'UBE_,BAJFG>+?$MD^
MEWUOIEA8S$":1)&EDV@Y^48Q78)%'%;+!C<BJ$PPSD 8YKGO^$[T;M]I_P"_
M7_UZ;_PG.C^MS_WZ_P#KT<DNP?6*7\R.@V)&L:1HJ*&X51@=Z?@9S@9]<5S3
M>-]'8KS<\'/^J_\ KT\>.-&[_:?^_5')+L+ZQ2_F1T@0$[L#/KCFG%%(P5!
M]17-_P#"=:/_ -//_?JE_P"$YT?_ *>?^_5')+L/ZQ2_F1TM%<U_PG.C_P#3
MS_WZH_X3G1_^GC_OU1R2[!]9I?S(Z6BN:_X3G2/^GC_OU1_PG&D?]/'_ 'ZH
M]G+L+ZS1_F1TM%<U_P )QI'_ $\?]^Z7_A.-(_Z>/^_=')+L'UFC_,CI**YO
M_A-](_Z>/^_='_";Z3_T\?\ ?NCV<NP?6:/\R.AB_P!6/QI]<RGC7250#_2/
M^_=/_P"$VTG_ *>/^_='LY=@^LT?YD='17.?\)MI/_3Q_P!^ZE3Q;IKC.VX'
MUCI<DNPUB*3VDC>HK$_X2K3O^FW_ 'Q1_P )3IW_ $V_[XHY)=A^WI_S&W16
M+_PE.G?]-O\ OBC_ (2C3_\ IM_WQ1R2[![:GW-JBL;_ (2?3_\ IM_WQ1_P
MDVG_ /3;_OBCEEV#VU/N;--'^M/T%9/_  DVG_\ 37_OBFCQ)8;R?WO3'W*.
M678/;4^YM$ ]:C*XK+_X26P_Z:_]\5:MM6LKLA8Y@'/\+<&ERM#56#V99H!Q
M3F [4S-!9*&S2U#FGB0'KUI#'T4W>*-XH =4:?ZV3ZC^5.WBF*X#N?I0!+13
M/,7WH\Q?>@!]%,\U?>CS5]Z 'T4SS5]Z3SE]Z )**C\Y?>CSE]_RH DIO_+4
M_P"[3?.7W_*F^<GF$\]/2@+DU%1>>GO^5'VA/?\ *@+DM%1?:$]_RI/M,?O^
M5%A7)J*A^TQ_[7Y4?:8_]K\J+!<FHJ#[5'_M?E1]JC_VORHL%R>BH/M<7^U^
M5)]KB_VORHL%RQ15?[9%_M?E1]LB_P!K\J+!<L456^VQ?[7Y4?;8?]K\J+!<
MLU@:E-?7NOQ:3:7CV4:6_P!IFFC16=LMM55W @="3QZ5K?;8?]K\JP]1:YMM
M;BU>PMS=_P"C_9Y[?<$8KNW*RD\9R3D&FD*3&WYU;3-*VSW_ )Y^VPI%.%"R
M-&64$/@8SR1QVJ[+JD%E=ZQ+)+<NMI DTD1 VJNTGY.^3CG-9EZ=7U+29#/#
M"D_VJ*:&U5_N(K X9^A8X)Z8'2G7MI<7)UYE10;^T2*$%OX@K @^@R>M5;N3
M?L:5AKWVR_6RGL+FSDEB,T!FVGS$&,G@G!&1P:K6^NQP:78K;I>:A=7!<0QO
MM$CA20S,>% 'K[BG/$YUK2[L >5;6\D<G/(+;<8'?H:RK>SOM,CTJ[BMQ<S6
MBSQRVZN 661MV5)X)&!P<=:+(+LW?[<D:P2:+2KY[EI#%]E*!6##KEB=H7C[
MV<'BJ%]KKW>E136XFM)X]1AMIXGQN0[UW*<<$$'J.QJOJ4FJ:A;6DMS9$QI.
MS36-O<[&9,?)EL@$@\D9Q^54(--U"/3;R);&.-FU*.]AC^T[LJ"I*ECT/R]?
M>A10G)G::C?PZ7I\U[/N\J%=S!1DGV%9_P#PD#P6-Y=7^EW=H+6/S&#;6#K_
M ++*<$^U2:G/]ITJ:*.UBN)'3!@G.$?U4GZ9KFHM+NY]/U>UBAFL+:ZMO+AM
MKBX,V)><L#D[5Z#&?? I)+J5*3OH=<^I1)J5M8E7\VXC:1#C@!<9S^=9-MXL
MCN%M[@Z;>16%Q((4NGV[=Y;:,J#D GC..]5[674+SQ!8WUU8"T@MK>2)@9@[
M,[;>1C^'CK^E9.CK?:MX7T_2A9K':M*)'NC,,&-92V .NXXQZ=\T^5=27)G1
M7?B;R+N\@@TN]NA9$?:7B"X0%=V1DY8X[#FHY-9/]N)/#))-9'2VNA&G\?S#
M! ]<51BN=3AUOQ#'I^GK=&29%5S,$$;^4O+ _P /3IDU<T[1+G2M1TPJ$EMH
M-/\ LDLA?!4@@YQW!Q19(=VS376K61M-6+?(=04O%@=%"[B3Z=0/J:TJX[PA
M98U+4)A(DMI9NUG9,AR-A;>WY$A?^ UV%2U9E1;:NSG?&'BF+PUIH90LE[-D
M01GI[L?85XC?7]UJ=V]W>SO/.YY9CT]AZ#VK8\;:FVJ>++URV8X&\B,=@%X/
MZYK-TH:6;IO[7:[%OLX^RA2V[/OVZUUTX*,;]3AJS<Y6Z%*BNT;2/!R:)'JQ
MFUK[/).8 ,1[MP&>GI6;8:5H^KZW=064EZ+**SDG4S;1(74=#CC%5SHCV;V.
M=I1TI$^;;GOBNAU?2M*T3Q2UC=27C:>D:LS1[3+DIGC/'6J;MH2HMJY@45TO
MBK2M"T8K;6,M^]X524^=M\O8P)[<YZ4O]C:-I%C;2Z]<7;7=S&)4M+0*#&AZ
M%R?6IYU:Y3@[V.9%+6]JFC6']DC6-%N9IK(2"*:.X4"2%CTSC@@U@U2=R)1<
M=Q:6M#1]%N=9G=8F2*"(;I[B0X2)?4G^E7O$VCZ?I0TZ33;B:>"[@\T/+@9Y
MQD# P*3DKV#D?+S&#2UL:'I%O>PW=_J,[P:=9@>:T8!=V/15SWJU<:3I%_H]
MU?Z)+=K)9@-/;W6TDH3C<I'\J'))V&H-JYSPHK;T;0DN[9M2U*8VFE1G!D ^
M>5O[B#N?>H?$>F0Z/K]S86[.\46W:9""W*@\X^M',KV)<&H\QF"E%-)PI/I6
M[X@T%-'DB>WF,\# ([$<I)M#%3^!!%-M7L)1;5S%I:N&Q0: -1WMO^UF#9VQ
MLW9^M79;+2M,$4-^UY/=/$LK"W*JL88 @98'<<$>E+F0<C,8=:=5V2PBEU*&
MUTRX^UB?:(RR[&!/\+#L1WQQ5MX-!MYFM9;B^E=3M>YA"^6#WPIY8>^1FCF%
MR,R*6M6TT=)M<?3WN4=%C=Q- 00P"%AC\AQVK)4Y4'U%%[B::W'4M:HL=/L+
M>"34WN9)YT$BV]OM4HAZ%F.>3UQCI5>^M;2*.&XLKDRPRY!20 21,.S ?H1U
MH4D)P:*=.%-IPID,6EJ6V-J'/VM9V3''DD Y_&M::TT>'3;6](U K<-(H3<F
M5V8]N^:3=AJ-U<Q13A5Z*R@N+'4;N-I56VV&-6P20QQS46G6RWNI6MJS%5FF
M6,D=0"<47)Y7IYE>@5I:78VMUK0T^X:8"24Q(\9'!R1DYJ/[&EUJHL[!9/F?
M8/.(SD9R21T'>GS"Y'N4J4=*U&CT**0P&>^EP<&YC"A/J$/)'XU5O[)]/NC"
MSK(I4/'(O1T/((I)W"4&E<KBEI*N:8M@]XJ:B\T=NW'F1$90^IR.13;L0E=V
M*M.%7]8T>?1[H(Y$D$GS0SK]V1?\:H4)I[!*+B[,6E%6[JR2WTZPN5=BURKE
M@>@PV.*AMC )#]HCDD3:<"-L'..#]*5]!.+3LR,=*6KD=K&VARW1!,RW21#!
M[%23Q]150J0<$$'T(Q3N)Q:$I:L7%E);6]M,V2)T+@;2-N&(P?RJ!58KD*Q
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M@\\CWJR;*19)(RRY2(2D^V ?ZU9>2>:WOUN]VV,?+N'W6W8 %2R@_;+K@_\
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MS:>1;B(QD8(^;GG&,TFIZ)->/J(A:-$FM(88=Q_B1RW/H.E176FZAK4TTEW
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M)Q2BXF!4B9P5&U3N/ ]*M32>=:6UW*HDD$K(^>-X&",U(T\MQIUQ+<D;&($
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MYS^U'G/[46"Y8HJMY[^WY4GVA_;\J+!<M455^T/[?E2?:9/]G\J+!<MTQ?\
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M^5'VV;T7\J+!=&C16=]ME_V?RIZ7S?QJ"/446"Z+U%,CD61=RG(I](84444
M<5\1/$TFC:8EC:/MO+L'YQUCC[D>YZ#\:\;X%=7\1KAYO&ETCGY88XT0>@VY
M_F37/Z=J=UI5R;BS=4D*[260.,?0BNRG&T=#SZTN:>I4W#U%+D>M=U=^)=4B
M\&Z9?I)"+F:ZECD?[/'RJ]!C%4-)^T:KX<\43&'S[N3R&'EQ9;._G  X_"J4
MW:[)<%>R9RE+D <FNH\(:5>Q>)[5[G3KE(0LFYI8&"CY&ZY&*E\ WL\>NM9
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M)>,X_P!6WJ*.;<.7;S,CH.:4$'H16KIY&GZ,^IA$:Y>806Y=0P3"[F;!XSR
M,^M1W&L37MI)%>QQSR<&*8*$:,YY' Y!]#1=W$XI+5F?D#J0*<*WKV\GT&6*
MPL?+B9(4>:7RU9I790W)(/ S@"LN]NUO9$E\A(I=N)3&,+(W]['8XZT)MDRB
MEI?4KT9 ZD4ASCCKBNFO)]0T^.$Z3%MTWR4998X5<,=HW%R0><Y&#0W848WU
M9SE ()QD5K6'E:CJD]W/:Q"*"![AX8QM1RHZ8[ G&:!KUU*VR[2&>V;AH/*5
M0!_LD#*D=J+L7*MVS+[XI:T%5?\ A&YFP,_;% /?&P]Z-(AA>>>XN(Q)%:PM
M,8ST=A@*#[9(HN+DU2* (/<4ZM(:[<RYCO4BN+=@08O+5,>A4@9!%9M"OU)D
MDMF+2@@]"*T]#0/<7&Q(Y+M8";9) "&?(['J0,D"B[U#4&C>WU&$,6'R^;"$
M9#Z@@#_"AMWL/D7+=F;N7U'YTH(/0UT6CZS?SS7"2S(RI:2NH,*<,JY!Z5CW
M>H75^$^TR!]GW<(J_P @*2;O84HQ4;IE<=*-R^H_.G1LT;JZG#*00<=ZW[?6
MK]]&OIFF4RQR1!&\I. 2V>WM3;:V%",9;LY_((ZTO:M:TN)]1DOGG_>R_8V"
MX0 ]1T %0Z9:S_VK9[K>7;YZ9S&<8W"B_<7)=JW4H @=2*45N:-/)%XJ$*%?
M+EN65U*@@C)XY'%5[5OM=U>7UX!-]GB,A0@ .<A5! [9(S]*7,/V6F_4R\@G
MJ*=6G#K-Q+,D=X(Y[9V"O%Y2CCI\I R".U5Y]/FCU"YM(8Y)C#(RY1"3@'J<
M4[]R'!6O'4J8.,X./6EK6TMM2TV=C_9T\UO(-LT+PMAU_+@^]/UG139HE[:K
M(;&;E=ZD-$?[K _SI<RO8KV,N3F73<Q\XZF@=*U/-;2]/M6@"K<W*F5Y"H8A
M,X51GIT)-5[B^-ZD7G1)]H5N9E 4NOH0.,^]-,B4$M&]2H&'J*4D#N*W=7U6
M^M]7NX(641)(55/)4C'ITI\#&T\500PHD:3M%YL6T$ L 67!Z<FES.Q?L5S6
M3ZV.?'(XI:GO9Y+F]EDE8%MQ7(4#@'CI4%4C"2L[(44M(*6F(<B%W"CO6BBA
M%"KT%5+0?.Q]!5P5$C:DM+ES3/\ D*VG_79?YU?><QQW0N-16Y5U95B#LWS9
MX/(XQ65;S-;W$<R@%HV# 'ID4TG<Q)[DFH:NSJC4Y8V-EH[:XEAMWB;S6M5(
ME#]"%R!CTXK+AF:"594QN7D9&1FI5O9%N$FVKN2,1@=L8Q4<$OD3I+Y:R;#G
M:XX/UI),J4DVK%Z=YETP)=R,\TL@DC5VRRKCK[9JC4]Q>"Z+,UM$LCG)D!8G
M]34%"6@3:;T%4D,""01R".U=CH^H&^M29#^]CPK^_H:XT5L^')"M_(G9X^?P
MJ9JZ-L--QG;N=0>:2EI*P/38HZTM(.M*: "DI:2@!#24II#0 'I47\1^E2U&
M?]8?H*8@[TXTTTO:@!**** &F@T&@T"&TAI30: &U3U.&2XTV\ABD:.5X6".
MI(*M@X(Q[U<I </GZ4P9R"ZI/=W>F7Z2NMO;QP+<)N(!:7(.1T)'R_3)J>TU
M&\9$6W=6N=2NIGB,^2D42'&<#KT& ,=:T(?#EG!I5[IZ/-Y5X[.[;OF4G^[Z
M8[5(^BP?8[*"&:6W:R $$T>-R\8.<C!R.M7=&:C(SO[=OL1VRV]N]Z+YK.0;
MBL9(0L&'<#IQ]:9/?3:=J&JW<J+)-%90$QJQ"EB2./;)K2BT2"+[.WFS/+%<
MFZ:1B,RR%2I+<>A[8Z47>BV]Y<7,LLDNVY@$$L8("D Y#>H(HN@M(QY9M3M-
M<GEN#;RW,6F-(JQ!E0X?."">O6K+^)$6[F41C[*EH9EE.>7VA]I]/E(J[:Z1
M]GOOMDU[<74WD^1F;;C;G/8"JP\+V0TV*Q$L^R.?SPY8%B>FWZ8X^E%XBM);
M$,NJO9->W4EI']J2Q@D?#'YF9B I]@>_6HI[R[TW5GNM3,+F#3I)/W 95/S#
MC!SSGC-:]UI-M>2W;S%R+J%874'  4D@CWR?T%0IH<9E>2[N[B\9[=K=O.V@
M%#] .?>A-#:D4]&\0/?Z@EK));3>9$90UNCKY1&/E;=UZ]1Z'BKCW]Z_B!].
MMX8#%'%'+))(Q! 8D$ #J>*L66GR6C@OJ%U<JJ;$24KA1^ &3[FI$L8X]4FU
M ,WFRQ)$5_A 4DC\>:3:N-)V,"TU9X].TV.V2TLA<M*2\Y8QIM)XZ]3]:AM+
MG4;^_P!'G2:,W,]M<$-*F$4;U ^5>HXX^M3WVD2VD5E;VZWLEK LAWVZH\F]
MCT*MQC&><9J_I5A<F2WO;]Y3<6XDCB#A03&Q!&\+QNX[56EB+-NQ1&IZC?)H
MTL)@A:6XEBE4[BK,@8'I_#QGZXJS'K-PVNR63RVD*I+Y:P2JZR2+C[ZM]TY[
M"K T*%+6WABN9XFMYVGCE7;N!8G(Y&,?,13YM(%Q<I)->W+PI.)U@8KM5QTP
M<9QGG&:5T5:1I4445!84444 %%%% !1110 4444 %%%% #XI3%(&'3N/6M56
M# $=#6/6E9MFW7VR*EE(GHHHI%'BGQ)LWMO%\LS?<N8D=#CT&TC]/UKD:]R\
M;>&?^$CT@>0 +ZW)> GC=ZJ3[_SQ7B$L4D$SPS1M'*C%71A@J?0BNRE*\;'G
MUX.,K]SHK_\ Y)YHW_7[/4WANZN++PIXDN+69X9T%OMD0X(R^#BN6W,5"DG:
M.0,\"@,P! 8@'J >M5RZ6(Y];G8^$O$&L7OB6VM[K5+J:%UDW1R29!^1C4?@
M"RNIO$1NHK>1X$BF1Y /E5BIP"?4UR08J<J2#Z@XIR22(/DD=<]=K$4.&]AQ
MJ;7Z'1>&T-K>:EH>H9LY;ZU-N#-\NR3[R@^F:+#P=K(U2-;VS>TMX7#S7$I
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MWR:7_A [S_G]@_[Y-=Y11[:8OJ%#L<'_ ,()>#_E\@_[Y-'_  @EY_S^P?\
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MH,>AJW.MG;Z79V5R]P)"#<N(E4C+?=SD]=H'YUEW-U->2!YF!VC:JA0%4>@
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M3[L\J_X1G6O^@?+^8_QI?^$:UG_H'R_F/\:]2HI^WD+^SJ?=GEO_  C.M?\
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MHH **** "BBB@ HHHH **** "BJ[W]I'?1V3W4"W<JEXX&D =U'4A>I JQ0
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MI"<FHQ_KC_NC^M,1*@[T^D P*6D,**** "BBB@ HHHH *8O^N?Z#^M/J-?\
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M=^(5FD,]S:QVK1'&T*C$@COGFLA_ -NN@V%A::E=VMWI]U+=6=\@4O&\CNS
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M\IVCYEVC+*1V88Z5YE\-8_'J?#[2?["_X1D:>R,4\\3>83N.=^WC.<UK^%=
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M$H-(\6ZYX@CNI9)=6\K?$R@+'L7 P>IS7(#XKW9_YA,'_?X_X4O_  M:[/\
MS"8?^_Q_PH]E/L/V\.YV,7A:&+QU<>*1=2&::R6S,&T;0 V[=GKFM^O,1\5+
ML_\ ,*A_[_'_  I1\4KK_H%0_P#?X_X4>RGV#VT.YU/BOPA!XJGT:6>ZE@.E
MWR7B!%!WLI^Z<]JUM6TJRUS2KG3-1@$UI<H4D0]Q_0CJ#7!?\+0NC_S"H?\
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M2: #%)BEHH *2EI"<4"$)Q3:#10 E*!1BEH *;_%^%+2=\T +2444 %)113
M2BBB@!**** $IO\ $:=28Y)H *2N:U#7=77Q.^C:99V<S+ LVZ>1EX[]/K3[
M+7[Z/68]*UNQBM9YP6MY89-T<F.V3WJN5D<ZN=%257N]1LK!5-Y=P6X;[OF.
M%S3FN[9(%G:XB$+8VR%QM.>F#2L5=$IHIDT\5O&9)Y4B0<%G; J*[O[.P0/>
M74-NK=#(X7-*P7+%%4=1N]FA7EY:2JQ2W>2.1"&&0,@^AJ#P[>S7OANRO+N4
M-+)&6D<@*.IY]!3MI<7,KV-6BJMKJ5C>NR6MY!.Z?>6.0$BG2ZA90&037<$9
MB&Z0-( 5'J:5F.Z+%%16]U;WD(FMIXYHCT>-@PJ%M4T]+L6C7UNMR>D1D&[\
MJ+!=%NBHYYX;6%IKB5(HUZN[8 KGKS7)'\4:);V%Y')8W2N9/+PP8C/?M32;
M$Y)'2T5#=,ZV<[12)'((V*O)]U3C@GVJGIUVT.BVTNIWUM)*1AYT8!';)Q@]
M*5AWU-*BJT6HV4]R]M#>023I]Z-7!8?A5F@+A16)J&HSVWBG2[03!+6:"9YE
M(&#M'!SVQ6G:WUI?(SVES#.JG!,;AL&FT)23=BQ156XU.PM)EAN;VWAE;[J/
M( 3^%32SPP1>;-*D<?'SLP YZ<TK#NB2BHY;B&#9YLJ1[SM3<P&X^@]:BN]1
MLM/"F\NX+<-T\UPN:+!=%FBF1RQ2Q"6.1'C(R'5@01]:KV^J:?=S-#;7MO-*
MOWDCD!(_"BP71K6MP01&YX/0FKU8W3D=:UXVWQJWJ*EEICJ***0SRWXM(PNM
M+D_A*2*/KD5YQ7MGQ"T1]7\-M) I:XM&\Y% Y88^8?ES^%>)]:[*+O&QY^(B
MU.X5W/AK5_[%\&/=.@DMVU,17$9&=\31X8?U_"N&KH([B$?#V>V,J>>=25Q'
MN^8KLZX]*J:NK$4W9W-I]+C\%+J&LATE+_NM(.<[MXSYG_ 0<5E^/BS>+IB<
MLQ@A^I.P5@W5_=7=K;6\\S/%:H4A4_P@G/\ G\*["^.GZC\2H)I;NW-C''%+
M)(7&UMB [<],Y &*FSB[LMM25EY&C;RG2=3T?PS)%*;)[1HKW"':99AG)/3@
MX'XUYY?V;V-Y<64P^>"1HV!]C6]=>._$4UW/+!J<L43R,T<85<*N>!T]*G\0
MPV_B#6;"]M;RTA?4;<-.990JQ2J/F#>F<"B-XO4<VI+3H1>.0/[;M3@?\>$'
M_H-6],N;GPWX3M;VUCE:[U"\67Y%)_<1'IQZG]*/&EC%<7]E<V^I6$R/'#:D
M13AF5@,%B.R^]&O>+;^PU(:?H>HM%I]G$D$?E!2'('+9P<\TEK%) [1DY,S_
M !9IA@\4NMK&?+O]L]NN,9\SM_WUD56O?"NNZ=9R7=YILL5O'@NY92!DX['U
M-:.KZG_;WA.SO;JZ1]5LIVADR0'DC;D-@>AQ7--/,ZE7FE93U#.2#5QYK6(G
MRW;[DTU_=W=C:Z?(Y>WMR?)B51U8\].IK>\2HVF>%=&T:Y?_ $^$R7$D><F%
M6^ZI]#[5H^%].L[/1QJL.HZ7_;$N1 MW,%6V'(W8YRW^-8.N:+/:1M>W.KZ?
M?2328?R+GS)"3GD\=.*5TY6'9J-^Y;\;G9?Z=8K@6UM80^6G8;ADGZT[7"TW
M@OPS=2'=,//BWGDE5;Y1^%6+JUMO%MI8WD&I6-K?PP+;W4-W+Y>=OW74]QBJ
M/B2YM!:Z5H=A<I<Q6",'N!PK2.<MCV%)=$5+J^Y0 U3Q7KD8):XOIL*&  V
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M6G5S'0%)2TE !24II* "BBB@ HHI* "BBB@!****!!24M)3 *2EI*0!1113
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M UG_ -^Q6ZKKJCF>%?1G@5&!Z5[[_P (=X<_Z UG_P!^Z/\ A#O#G_0&L_\
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MSP@4X >@KW;_ (1#P[_T![3_ +]BE_X1'P]_T![3_OV*/;Q[#^K2[GA:\4\
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M.-%)G-% "TE%% !1124 %%%% "4444Q!24M)0 4E+24@"BBDW4P"D)H)S3:
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MQ:C93WLMG%=1/=1<R1*V67Z_F*XG3]5D\)6D]C*&D2>!+G3^,[G<#*?F<_\
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M_P"^7_\ BJ/8S'[>!ZQ17E(^)VL'_ESL?^^7_P#BJ=_PLS5_^?2R_P"^7_\
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MGJS0J2?TK=5^Z.5X7LSYPW+ZBEW\YW\_6OHS^QM+_P"@;9_]^%_PH_L;2_\
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M/45[+_9EA_SY6W_?I?\ "C^S;#_GRMO^_2_X4?6/(?U=]SQT$>HJ0$>M>O\
M]FV/_/E;_P#?I?\ "C^SK'_GSM_^_2_X4?6/(/J[[GEEI=)!;WD; DSP^6".
MQW Y/Y5$"/6O6/[/LO\ GSM_^_0_PH_L^R_Y\[?_ +]C_"A8A+H'L'W/*@1Z
MU(I'K7J7V"S_ .?2#_OV*/L%G_SZ0?\ ?L4_K"[!]7?<\Q!'K4BD>M>E?8;3
M_GU@_P"_8I?L5I_SZP_]^Q3^LKL'U=]SSA!N( !)]!S6SI^@W5V5:53!#W+#
MD_05V,<$,7^KB1/]U0*DJ98EO9#C02W97MK>*T@6&%=J+^OO4M/Q1BN>YO89
M13Z,4 1T5)@>E&!Z4@(Z*DP/2C ]*8$1I*EP/2C ]!0!%14N!Z"C ]!0!%25
M-@>@HP/04@(:*FP/048'H*86(**GP/048'H*+A8@I*L8'H*-H]!1<+%>DJSM
M'H*-H]!1<+%:BK.T>@HVCT%%PL5:*M;1Z#\J-J^@_*BX6*E%6]J_W1^5&U?[
MH_*BX6*E)5S:O]T?E1M7^Z/RHN%BE15W:O\ ='Y4;5_NC\J+A8HFBKVU?[H_
M*C:O]T?E1<+%&DJ_L7^Z/RI-B_W1^5%PL4<TE7]B_P!T?E1L7^Z/RHN%C/HK
M0V+_ '1^5&Q?[H_*BX6,ZBM'8G]U?RHV)_=7\J+BL9M%:6Q/[J_E1L3^ZOY4
M7"QF4AK4V)_<7\J/+3^XOY47"QETE:OEI_<7\J/+3^XOY47#E,K-)FM;RT_N
M+^5'EI_<7\J=PY3()HK7\M/[B_E1Y:?W%_*BX<ID45K^6G]Q?RH\M/[B_E2N
M'*9%%:_EI_<7\J/+3^XOY47#E,BBM?RT_N+^5'EI_<7\J+ARF116OY:?W%_*
MCRT_N+^5%PY3(HK7\M/[B_E1Y:?W%_*BX<ID45K^6G]Q?RH\M/[B_E1<.4R*
M*U_+3^XOY4>6G]Q?RHN'*9%%:_EI_<7\J/+3^XOY47#E,BBM?RT_N+^5'EI_
M<7\J+ARF14D<,DI^53CU/2M,(@.0JC\*=1<.4B@@6%>.6/4U+112*"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img118615358_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'O ?L# 2(  A$! Q$!_\0
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MUU6PD:"\M9!(C*<=#R/H>E?<W@OQI;_$+P9I^N0##3IMF7LD@X85\7ZQ8\$
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M(9KY%\%W@\NW;=TKZ3^'^L*PBY["OK:Z9\#4TG<]K^(5J=5^&>IQJ-[Q()E
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M-='8?\><7TKGQ&R.JD6:6D%+7$= 4444 %%%% !1110 4444 %%%% !1110
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M?K2?Q5Z*V1PRW%IRX]<D\4VE&%4GCK5LA;GF_C'XH:G9^,D\(^$="7Q%X@6
M7%T)IO*@LHS]W>_]X^E;F@^)=2?PA/>>-=/MO"TRL\,R&Y#Q%3P'5_0BN UB
MXO?A'\8M=\3W>E7FI^%O$D$*RWEA&9I;2>,8VNHYVD=Q7/?&B\U?XD:3X/\
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M+"QII61T*R':AJ#S.VX\BLB1B^>*L3*=W&<U%Y>:]-+0"HT9.::8\<5::/\
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MZ?\ \>,7TKEK?"CJI%D4M(*6N,Z HHHH **** "BBB@ HHHH **** "BBB@
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M444QBG[C5T>G_P#'C%]*YP_<-='I_P#QXQ?2N6M\*.JD612T@I:XSH"BBB@
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MTR6RF/\ >*<C^5?6/@7R_EX .?SKX2HDJC1][3ES4U<]!T>U6WA48P0*T:9
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M516:(6J$XJ61AS55WZXZUW\DDSY^KB-!LQ"XQQ4UC;F:7 &:CAM6F8?6NO\
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M:[SXA?$34_V@KX7=P]SHWPWM&/V+3%)635V!XFE](\]%[UP?B34$=MD06.-
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MON:\FOOB9\9/$8:X:30/ MDWW8GS<SJ/]IB0N?I7@?\ PE'BW2[Z6#1=%O\
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M,EU,HVFO0_#/@\X1W7GW%>S%'ED7A7PFK*DC)^E>BV6DQVZ@ <5-INGK;P
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M7 [UZ:75G$VNAO>$=!^U2*[#!^E>OZ/IJ6ENN$ (%8WA711:VZ,>#]*ZM5V
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M<2J-N[->J>#_  UM$;,G.:S_  GX6?Y69?<5Z=I]FMK$H QQ6Y@36\'V< 8
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MC!5,)A?CDHI'P.-CB*NL4[GHG_"K?!O?P]I[?\ _^O1_PJ[P;_T+MA_W[_\
MKUF?\+I\/?\ /KK7_@LD_P */^%T>'O^?76O_!9)_A7K?VCEO_/V/WGAK"XW
M^5FG_P *O\'?]"[8?]^__KT?\*O\&]_#M@/^V?\ ]>LS_A=/AW_GUUK_ ,%D
MG^%'_"Z/#W_/KK7_ (+)/\*/[1RW_G['[Q_5\;_*S3_X5?X,_P"A=L/^^/\
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M?Y6:/_"KO!H_YERP_P"^/_KTO_"K_!O_ $+NG_\ ?'_UZS?^%T^'O^?36O\
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M+MQN!/6M:F:4'"-JJOZG-3P,U-IPT/<O$.@^$_"FBWVKZE:K!96Z[Y) ,Y[
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M\">'YHXW_LI4+JOR'@CCIBOGQ_VC-!\,^,M=U7P]+/?6&M>7)+#=V$T;P2H
M,YQR,=J[YOVN/ ?V)RMUJ9OO*.,Z9*$\S'TZ9JEF='_GXOO%]1>W(;6C7'@3
M7/'6K>%;2S4ZIIR*\V5PC^H5NY'<5T]WX*\,V5I<7,MA&D,,;22,3@!0,FOE
M#PYXS\&>%=;T+Q':^)==GUV.[DGU%9]/E^SR)(?WBJ-N>!TS7I?Q-_:.\%>-
MO"=UHNGZGJED+R01W,O]FS!DAS\VWC[V*/[4I]*J^\/J/]P[709/"/CKP'=^
M(-"L/+A_>1@2H4=&4]Q^M8%C>^&K7PU96VJ:&_B75]0E9;?3(XP[RA>I(/
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M!2_\- V6/^1/\2#V^P"N@\Q_>CS']:/]0<!_S\D+_6C$?RHY_P#X7_8[L_\
M"'^) ?\ KP'^%"_'ZP&<>#_$@!'_ #X#G]*Z#SG/>CS)/6C_ %!R_P#Y^2'_
M *T8G^5'/?\ "_[''_(G^).O3[ ,4?\ "_['OX0\2$^OV 5T/F/[T>;)ZT?Z
M@X#_ )^2#_6C$_RHY[_A?UB.1X/\2?\ @ *#\?K%O^90\2'O_P > _PKH?,?
MUH\U_6G_ *@X#^>0?ZT8G^5'/_\ #0%CT_X0_P 28_Z\!0/C]8XP/"'B3_P
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M_P! 7Q%_X+V_PKWG_A!X_P"^W_?1I#X'3^^W_?1I/&3']4I]CP?_ (7YHO\
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6 3CK730KM4"O(DSUX*R):***Q-#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img118615358_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_5.jpg
M_]C_X  02D9)1@ ! 0$ JP"K  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ([!$$# 2(  A$! Q$!_\0
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MRC?WYQ7JGY6/W<F@2=*AW_YQ1NH F\REW_C4&^C=0!-YE&_ S4._WI=_0]:
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MT\RW?XT;AZ5'NI-P/:K.,EW4;A4>ZC<*8$FZC=46ZDW4AV'[^*7?46[T-+N
MI@/W4NZHMU+NI 2;OPI-PJ/?3=U,"7=2;ZCW^U+OI#)-U'F5%NHW>U R7=SD
M4FZF;Z9N-,"7?2;JCW4;J0$NZDW5'NHWTP)-U&ZH]U&ZD!+NIFZH]U&Z@"3?
M[4>8>E1[J-Q]* )-U&ZHM_:C<: )=U&ZH]V:"U $N_M29]*CW=J/>@"3=1NJ
M/-+0 _=Q3=U-IIH DW9I,TW%&V@!V:/2F9HH ?2[JBW=J-U $NZC-1]Z-W-
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M+'E^+WOU1+^TYH0D?0?$T,$D*W4/V>5)1M93C>FY?[WW_P#OFNGO_!-_X^^
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M,@_^+H_X9]\>_P#0!'X7D'_Q='M(?S!]5K_R2_\  9'G^?;]:7=_L_K7?_\
M#/OC[OH/_DW!_P#%TG_#/WC['_(!_P#)N#_X[1[2/\P?5:_\DO\ P&1P.?\
M9X^M&?\ 9KO/^&??'O\ T <_]OD'_P 71_PS[X]_Z /_ )-P?_%T>TC_ #!]
M5K_R2_\  9' 9/\ =_6C.?X?UKO_ /AGWQ__ - '_P FX/\ X[2_\,_^/_\
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M>TCW']6K_P C^X\YW>_Z4;O]K]*]&_X9M^(W_0M?^3UM_P#':/\ AF_XC_\
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MZ*/*3^Z*=10 WRT_NBCRT_NBG44 -\M?[HH\M/[HIU% #?+3^Z*/*3^[3J*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:O1X_NUYG\"+CR/"^HZ"^!/H.HW%DRJNW]VS>;"?^_4J?E4/XSGDOWL7Y/\
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M+_G\M_\ OZO^-']J67_/W!_W]7_&@"U157^U++_G\@_[^K_C1_:EE_S]P?\
M?U?\: +5%5?[5LO^?RW_ ._J_P"-']JV7_/Y;_\ ?U?\: +5%5?[5LO^?RW_
M ._J_P"-']JV7_/Y;_\ ?U?\: +5%5?[5LO^?RW_ ._J_P"-']JV7_/Y;_\
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M_P"A-T?_ ,!%_P *</@1\.>_@W1Q_P!NB_X5Z JE:?S1R1["]C2_E7W'G_\
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M&BBBI.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\M4'FR[=0A_>H=^UGM)V7:FUNBKU%S\5;RZNTT[6]%:PUBR\1V^DR)INL2M
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M_P#'66J.N%_JU3M>/_MQZ71114G(%%%% !1110 4444 %%%% !1110 4444
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M=_=1?]M:]22+RUZ5S/P_\ 6/P]T>6TM9)+JXN96N;R_NOFGNYV^])(W<FNL
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MJ+PN&/3K7CUYH&K_  =U*XU+PW9/K'A.>1I;K08R//LF;[TEH6)W*22WD_\
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M9HS\UM9X!FF/]WY<JO\ M,M>@:1I=OHVFVMC9QK%:VL:Q0HO "@8"US7P_\
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MC]M'-=NJ6UM-<-_=C7=_Z#7N/P^\,:U)^S;\6+7^Q[\W=S GD6_V63=+\O\
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M\6?^#^[_ /BZ].R?6CZG]*7,^X?6Z_\ .>9?\*-TG_H9/%?_ (/[O_XNF_\
M"B])Y_XJ3Q9C_L/W?_Q=>GY_VOTI.?[WZ4<S[A];K_SGF=M\!_"<F#J*7^NY
MZQZQJ%S=I_WQ(Y7_ ,=KO]+TNST:QBLK&UALK2-=J06\:QHH_P!E5Z5>4ACP
M:5OKBAW>YG4KU:W\25Q:***1B%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)*CI[?>Q3:I$DJ]*6
MBBI&%%%% PHHHH **** (&8X!S7EWQ7^%&K>-V34?#7C+6O"^N6Y5H_*O)6L
MY=O19(-VW_/S*U>H\%?:FA!V;]*J+<7=%1G*,N:)\TQ_M.:S\,8YM'^*WAZ>
MQU6&%FM=2TX;K74F7[JI_=9O_P!K;7K'P9^+%G\7/A_:>(;=5BG(\JZM@^[R
M)U.&3^3#_99:ROC=\#;7XY:9IEE?:[>Z=:V,K3B&U5&664KM#-N_N_-_WTU?
M(?Q@T:[_ &5;?4/"WAGQK-?7'B>TVWME]D6-K:+=_K=_F_>;]XOW?N[O]FNK
MEHU(::3.NK4PRH.;]V9M_M%?&+5_CWX[3X:>!I6ET".Y\J::%LI>2JWSRLW_
M #PB.3_=^7=_<KR7QWXET_PUHLO@CP?)OT.&3_B9:E_'J]RO\7^S O\ #%_P
M+^*NIL?">J^"= 3P9X?58O&&JV/V[Q+?-)Y7]FZ>R;D@9W^ZNWYI?^ K\VVN
MQT/]FVQT/P[H5Y-'X?\ $\VLRJ@NM0U2:QB194W1+:_*OFLR_-N^;_=KKPZI
M47S5#;+L/"C_ +3B?BE\,>Q\P#ZUW7P6^+%_\'?&4&KVQ:XL9/W-_9[ODG@;
M[W_ OXEKI_C!^SW/\/=1OVTC5(]7LX8/MC6DRM%?P6V[;YK1,J[EW;EW+_P)
M:\>YKVXRIXJGY'U7-2Q5,^COCW\-[/PUJ=CXK\.LMUX2\0)]IM9(5_=Q2$;B
MN/[K9W+_ ,"6O.='T2_\1:E'8:792WUW(VT)"N[_ /9_WJ]Z_9'\.ZU\0?A[
MK'AOQ1ICW?@:9-]E=S'#1S[OF$ _N_Q;ONJU?4W@?X8^'_ASI0L=#L([5/E\
MR;&9)6_O.W\1K\_Q.76KR]X_(<=D"^N24)6@>86_P%F\>_#?P]I'CN?RM2TP
M(/M&G/EMJKLV[F']W;N_O;:K?"_P;\)2NI?9-'MX;G3=9DT.9M;17E-Y&RKL
M3>[??W*R[?O*U>X:]I?_  D&@7NGK?75@US&T8N[&3RIX6/\:-V9:_,WP[X)
M\=^"_P!O#PGH?C35+[6%FUPZC:WUPNV/4%6%E6Y55^7=MB56_B^6NATXK6Q[
M4,+1^+DO+N?IY9Z/:V$(CM;>*WB_NQ(%7\A5]8U4=*5,8XIU;&UDMB"2WCD5
ME= 4_P!JO(?B5X&^%%U8Z^/$?A_1KF?2]-DU>[CC@6*[6V7<3*K+M;_EFWS;
MOO+7LG/K7Y[?\%*],UZ/X@?#Q_#,EY_:?B*RN]!:VL6;==KYL+>0RC[ZL91\
MK?+_ #7"=.G+6432$I1>AUVN?L)>&?'WA'3/$/@:]U'PTVH6D=XFFZVOFJJ2
M)N1&_BC==QW?,U?*WQ0^"_B[X.ZI]D\2:8\,7_+*_@&ZUG_W9/\ V7[U?IK\
M!_!/B/P1X#LX?&'B*_\ %'B>["SZC=74^^**9E&8H%^55C3!^ZOS?>KN=<T'
M3_$>E76FZK9PZA872>5-;7$>^.1?1EKSJN7PFO<T9Z5''U:;][WC\D/@Q\+;
M[XP>/[#PY82>1')NEN[K'^H@7[S_ .]_"O\ M,M>]_';QS8R+8> ?"H^R>#O
M#@6"-%.[[3(.K,W\7.[_ 'FW;J]Y\>?">'X+_"WQ'#\+-&\K4M5F$ERRONG2
M'^)8F;YFV_PIG^)J^(_]="&0?**]7*\"L/S5):L_0>',/2Q]66,J/X?AC_[<
M.C^8[FK?\)^*'\.WT\9ACU'2;Z/R+_3+A<Q7,?\ [*R_PM_"U2^$/#MEJS3Z
MEK5\NF:!9,OF73#=YTGRMY*JK;F9EW-\O]VIEUCP:K16Z^']2%G'(I^VQW,?
MGR;6;YFC\O;_ !;67<OW?O5[\I1/ML7B*-:,L)*E[2/VBA>R:E^S]XZT7QAX
M)U)YM(U"-KBPDE7=YD&[][:S_P .Y?XE_P!QE_V?T2^$OQ.TKXP>!K+Q%I1V
M^</+N+1I,O;S+]^-OIV_O*5;O7PW]AM?"<S>%==N3<>"?$<:W27$]NT4]F^-
MJ7.UOF5E8_-_"RUR/@?Q7XC^!WCC7?"-UJS:#9:HW]GZC=+"94@5C\EU$NY?
M^6;;E;=]UO[U<%2G=W1^"9CEO]FXF-I?N)_#+L?8>H?M@>&[/7M>TT6=WJ!L
MW2&P-FGF-?2='51CC:W&3UJ31?"/Q*^+FH0ZSXLUF[\&:''\]KH6CS&&X<'_
M )[2+AO\_=6LWP9^QOIV@ZIINMV_C'4)KFVD6>&2UMXHE/J.=WRM]:^BI@RA
M8T;9)SM;&<^M82Y?^79ZN-KY?A7RY;[W]Z7_ +:GM?\ KE)+&U%C:Q6\;2NL
M2[0TTK2O_P "9CN:K7/]ZF<T>M9V/F"7YO6G4RGU((****!A1110 4444 1.
MN33:F;[M0U2))5-.IJ]Z=4C"BBB@85P7Q9_X]- _[#5I_P"AUWM<%\6/^/30
M/^PU:?\ H8JH[F-;X&=WN&T>E<CKWC*?2_$":3:V<,TWDK.S7-T8<J6VXC^1
MMS>WRUUP VX[5ROC#PE<^*HWMQ?1164T9CDBEM1(PS_%&V]=K?7=2TOJ.IS<
MON;F;J7Q#;3];ETF;3&;5!-&+>%9N)HF&?.SMX5=K ]>GO6=:_%^&;SE&F;;
MB+45L#&UQR5+LOF?=_V&^6NFD\*AO$MEJYO& M;1[00E-VX,RMNW?\!%<U-\
M(89_[.<:F8KBSO7NC,EOS*K2^88V^;U_BK1<GVCEJ?6=>3]/Z_X8++XP->:7
M?WRV5@1:QR2-:IJ6ZY&QBOS1^5\O2KLGQ,DL3=1:CI2Q3PP0S(MO<>8LGF-L
M5=S(N&W<5'#\-;^/P_=:&=:MVT^:.5!_H!$J[V)^]YFT_>_NT]/A-:00ZA#;
M3QVMM=K$PBAM54131])%]^!Q[4O<)_VG^K%O4?%6JZ7I-S=WFA(BVA5I!;WA
ME0QM]YE.P,S+_=VC_>J_X9\2)XFCN9X(/+LHI6CMYR^?/ X9@/[N[-9.G^ Y
M+35-6OI]1MWFU" 0R?9;+R!GYOG/SMN;YOTK?\-:'_PC^AV.F"?[4MI$L9?8
M$W8Z<=JA\MCIA[3F5]OE_7_#&_1112.@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (/I2TE/7]*L
MDDHHHJ"@HHHH **** "BBB@"&BDI:LDYSQEXDL/ GA74=?U*3;9:;;O/)_M;
M?X5_VF^[7YR^#]=E\7>,?%7Q=\3JMPNC%;R"TE_U4]XS;;6#_:5=N[Y?X8O]
MJO=/^"@'Q'EM=/T/P)928EOV^VWJ[NL2MMB3_@3[F_[9+7@7Q=N5\)Z)X<^&
M]O!'%_8,7VK5&79^_P!0E56EW-_%Y2_NMW^PU=6%H^UG8O#4?KF)C#I$W?V?
M-:75?&?C75?$LGVO3+C1;F?6/-5F:1&DC^[M;^]_X[71_$I_#-K\1?%#>.-,
MU35;&YLK?_A%;K369;/9Y2;?(VLJ[=VW;MW+\K5X-X;\5:IX0U+^T-*NVM;A
MHVBD^1662-OO*RM\K+_O5] >$?VF([SP_96FHZK!X(GTIU?RM-T=;N*]B5=J
MQ*K?ZB3;\NZO4Q%"49\\(Z'V&(HRC4YHFA;[[/X!K::ZDB>,O[%U![1;]7:Z
MBL?/7?YN[YEC9?\ 5_+_ +M<Q^R_^S8WQ6U!=>UQ3%X6MI-I7.UKR1?X5_V?
M[W_?-7-#\6:]^TY\1O\ A'M/L8="T.Y3RK^XL8Q)=BR5MVR2=OF;YO\ QYOX
MJ]S^+GQVD_9T\/>(=%7PA<:-H^FZ9_Q3>N*OFV%Y<>5E;:0*/W,F_=MW?>VU
MPU*T\/&5/[4CSZU:6'CR1^*1](:?I]MIMG#9VEO';6D*^7'#"H5$7^Z!5VN+
M^$GQ*TSXN_#W0O%NCDFRU2W6?RV?<T#]'B;_ &E;<O\ P&NTKS#YX*Y[6/!>
MB^(M:T?5M0TZWN=1T>5IK"Z:/]Y;LRLKE6_VE:NAJI=:E!8Q[[F:.W3^]-(J
MB@"W166WB32X[6*Z;4;002ML27SEV,WINS5Z&X2>)9(RKJW=&S0!-6+>^&-+
MU+7-/UBZL(9]2T]98[2XDCW/"LNWS-OINV+^5;5% !1110!%)\JY;FOE#]IS
M]G5M0^T>,O"MIF__ -;>65O&/](XYD5>[]?E_B_WOO?55U=16]NTLSK'$!EF
M8\"ODCP9^VE>_$7Q!XQT7P-X?'C/58]86'1;2%GM8?[.5%5[NYG9=J(TF[:/
MO-O5=M5&HZ3NCTLOQE? 5XXBB>;_  @TO1=>L_"UGK,22Z?!KY-];R3%EQ-$
MZQ;EV_NU\V%%VLS;MW^U7HOQJ^$^D> =;@N?"<\/A^ZUVQGM8/+F,*K<1M%(
MGEO_ ,L]RJ\?R[?O+6?\>/#<OP;\0'6=/@\_PAKV1J&E2;C")@P9SM^[\V!\
MQ^[EMM><:A>>&/B%,LVI^,=5TC[.GR0Z@&OX(_W>YEC^96^5OE^;=]W^*NY7
MFN=/0_0J<9X^M'&4Y2C1E_V]_P"2_P"(X'7]+U?3;YI-;L[^VN'X+WR.6?\
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M,4F6V^M>1.#B['X/0JIQY&]4;F/44I!YR*YK5O'^@Z+J#V-[JEM!<QX+Q/(
MR\;A5_6_$FF^';-+F_O([6&1MJ/,V U3J='M(:^]L:N3U' ^M3_05@:5XJTS
M6]-FU"TO89[2W+++*C95-HW-4.C^/M!UZ^^Q6.JVMS<,-RQQR9;'TI!SQTUW
M.EVYP32_6N7U;X@Z!H-\UE?:K:VUS'@O%+( PRNX?I5S6/$VE^'[&*[OKZ&U
MMYCB.65L*W&?Y4#YXZZ[&X/:DV_G6+I/B33=?L'O;&\ANK:)BLDL;952!G_"
MJFD>/M"U^^^Q66J6MS<L-RQQOEL>N* YXZ:[G2[1P3UI?7-<OJWQ!T#0;YK*
M]U6UMKF/&^*60!AE=P_2KFL>)M+\/V,=Y?7T-K;S'$<DC85N_% <\-==C9;.
MWBHOH/UK,T7Q-I7B"QDN[&^AN;>$XDDB?*KQG^59^C^/M!UZ_P#L5EJEM<W+
M?,L<4@+4:B]I'37<Z//3(YJ?GG(KE=8\?:#H%]]CO=4M;6Y4;FCE<!JT-6\3
M:;H6GQWE]>0VUM*RK'+*V%8D9'Z4![2.NNQM?A2\=JQ-&\3:5X@LI+NQOH;J
MWA.))(FRJ\9_E5'2OB!H&NWZV-EJMK<W4GW(HI 6.%W''X4#YX::[G3#)X;K
M7#?%=5%GX?)_Z#=I_P"AUJZMX]T'P_?"RO=5MK6X4;FCE?#8^E<#\>()[JQT
M'4[+5&MK5KE%_P!9MB)/S1R?\!YJH_$CFQ%50I3E'6Q['SQBE^@KGO"NMZ?J
MVBQ/8ZDNI1VH\J6XW[V9@/XCZU!I/Q"T'7+];*RU6UN;F3[D44@+'"[CQ]*D
MZ/:0TUW.IVYP31ZYKF=8\?:#X?OOL5[JEM;7(&YHY),-CZ5:U+Q1IFBZ;%J%
MU?0V]G.5$4\C85LC(_,4#YXZZ[&Y]*-HYQUK%T3Q-I?B2"2;3[V&ZCA.V1HG
MSM/O5'2_B#H&NWZV-EJMK<W,GW(HI 6/R[C^E <\=-=SJ-HXSUH_E7-ZUXZT
M/P[>)::AJ=M:7&W?Y<K@-M]:MZEXCTW1],34KJ\BALI-NR=VPC;NG/O0'/'7
M78V/ITI0H'(K%T7Q-IGB2WDGT^^ANHX3MD:)\[3[U2TOX@^']<OA9V>K6D]S
M)]R-)06;Z"@.>.FNYU%%)N^;'>EI%A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%87BOQ58^#
M].6[NS)))(XAM[6W7=-<2'[J(O\ $QH W:QM4\6:)H;;=3UK3[!O[MU<I$?_
M !YJY2+POX@\:;+CQ5J$ND6;?=T+2)RGR^D]POS.?]PJM;VE?#OPSH<>RRT#
M3X<C!?[,K.?]YV^9OQ- ] _X69X0_P"AJT3_ ,&,/_Q5'_"S?!__ $-6B?\
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M^%_PI/\ A'=*'33;,?\ ;!/\*-0,O_A9GA#_ *&O1/\ P8P__%4?\+,\'_\
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MI8%9=S?P^:O_ 'S7U[^RIXX?Q]\#/#EW<-OO;.+^S[ABVYF:$[59O]IE"/\
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ML9/LMG?0,^J-]F$-P[H&GF\@>3M*'/RM7;?#7Q1>^+/"%GK&HK;+/=22E%M
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MON.IHHHKR#V HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 044^3[U,JR2>BD7[M+4%!1110 4444 %%%% $%%%%62?!
M?[:/AVX^&GQP\.>/]-C\M+]HIG95^4W-LR_>_P!Y?*_[Y:O&/''A3P-HOQ<N
MK?5-#OAH7B:2+5-$O;'4(M.B6VN5W;9/-C:,+$S,O\.W;7Z#?M)?"U/BS\*-
M6TI4WZG OVS3_P"\+A/NK_P+YE_X%7Y_Z1?7WCKX0W.F074EIXH\ .VMZ++;
M_)/]FW;KJ-67;]UMDZ_Q?(U=^#J\LN6YQR7LZC\S,\=7WPP\#WRZ?HOPWOM3
M:=%:WO?$>K3)YB9V^8L$'E-M;;\NYE9EPVWYJW?B%\'K.;X777BC2?",WA^[
MLVMGVVJW/^F12,Z^:T$KRM OW=J[MVU&9MJRI7"6?[2WQ*TWS6MO$GV>64[I
M+B*QMEEE;^\TGE;FKKU_:6\=:'II\.>)=0URWN[25KZ6:>>3[?<S,J[8M\G_
M ![1>4_\*[O^^OE^BE1Q$'%+?_$S9)W=]_5G2_L(_'(^!_B$WA'5)F;1O$4B
MI!N;Y8+O^%O^!_=_WMM>I_MKZ#XF\=:EXCMO"=UXVL?^$=TK^U-4O&OY;;0?
M*CB:3RHXE3]_.RX^[\J_Q>WQ7\0?%%IXT\::IKMAI"Z#:WD@E6PADW+&=J[C
MN_VFRW_ J_0[]C_]I2Q^,GA=/"?BB>&3Q=;0M$T5P,_VE J?ZW^ZS?WE_P"!
M?Q5Y6:8-R_VF,=]S6G)[M&M^PQ\ A\&?A!;W^IQR)XG\2+'J&H"=-LD*;?W4
M#>ZJWS?[3-7TM2#I2UX&Q>XUT$BX89%<SXF\ :1XLM(;:\BE2&%66-;:9XE
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 9)4=3-\PJ&J1)*M.J.I*D:"BBB@84444 %%%% $'
MZTOZTE%62,925YKX(_:I^'FH?!'XLZ;\2O#40@LK^[\V5,?NH[O^-64?PRKN
M;_ONM_\ :\_:!N;Z:RT;X5>*]8N?$&DF:;5UT!/,MH[=5^9I9%Z,C+_#\OWM
M_P##3?V2/A#KWQ?^'?B#7OB9K^N:]I6L0FQTRRU+4)Y41%^]=*K-][>,*?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IK#'-.I#R*!$-2(W:F4Z/K5,1)11
M14E!1110 4=!2'I7G7Q=7XC7FA_9/AW)H%CJ$P*OJ.MS2_N/^N<2Q.K-[L<#
M^ZU-:NPBO\5OCQX/^#.A_P!H^)M56UD9?W%C%\]S<_[D?U!^;[O^U7B7]D_%
M;]JL;]5:Z^%7PU<_+80MG5=2CQ_'_<7_ #M;[U=[\*/V5M'\%ZV?%GBJ_F\=
M>.Y6\V36=3&Y;=N?]1'_  ]O_9=H^6O=?+VHV!G\:Z/:4\.OW?O2[_Y(-SC/
MAS\)?"?PL\/?V-X:T2WT^S=?WWR[I;C_ &I7;YG/7[U=5HVDV6A:5::=IUM'
M9V%G$L$%O"NU(XU7:JK[ 5>VFE7]V.OZ5SRDWJV"/+OCU\"]*^./@]M,O-MI
MJEMNET_4%7YH)3Z_WD;^)>]?G_J.G?V&UQ\+/BK:364-I*S:=K.W=+I4C?==
M/^>MHW\2_P# E^:OU24[AD?G7F/QQ^!>@?'#P]]AU-!;:G"K-8ZE$O[VV?\
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MKS=^W;\T7^U7KCD9'?%8NC^&['1;S4KJVBE6ZU"<7%S)+-+*7?:%&-S-M4#
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M\Q1MW9P#Z5YDZ/++WZO+'_P'[7^+_MT[Z=>\?=IWE]_Z'G&F_$#6+W[!/+J
M@OI%M/L^EJD>+]9 OFRXV;OEW-]QMJ[?FKJ-,U;5(_AC/K$^I37=_+8/=+))
M%$@B81DC:JK]/O;JL^'OB;HNOVDM[')]DLX8%N&FNI(Q&JLS+EF5FV\J?O8K
M1U'Q+X<O-,6VNM8L&M=30Q1!KI5%PK?*0C;OF_X#2IQ<HRE&O\7PE5I>]R^Q
MY=?Z1PUEXPU:^F-I9>(I+^V>>U1M2A@A9X9)"_FP?<V_+M7^'<N_YJAU;QUK
M5D^H(FL.VHP2749TQX(MT4,<3M%<'"[OFVJV[[GS[=M>C)XP\-PZ>MR-:T\6
M"MY(N#=)Y6X?P;MWWJ>?&GAY8[F0:UI_EVVWSW^U)MBW?=W'/R_C2E1?+_'_
M *_\"#VRYK^Q_K_P$\_FU_7K"_NA)KLUS%:S6/[N6VA'G+<.JLK;4_AYV[?^
M!;ZQ-:\9:OJGAR_1=;F:[;3YIKZU@BB5],E5EVQ?<W+NRRY;YOEW+MKTN\^(
M6@V<R6\6HVT]Q+;/=PQ1SQ_O8UZE69@OKW_A;^[6HOB32VO'M!J%J+Q(_.DM
MO.7S%3^^RYSM]Z4J2FI1C6_F_KXC2-?V;C*5'^O_  $\\@OKZ[\326>G:W)'
M#//\U_;16[RSJ+2-E9F\K:W7\O:LJ'QIJ.M:YH%M=ZM]D^T0V=PT"7,-LDFY
M S%OF69F9ONK'\O9J]:TG7]-UP2'3=0M=0\MMCM:S+)M;T;:>*I77@W2=0U-
MKZ>&=IW=))(UNYEBD9<;6:-7V-]U?O+_  U4L)4ERRI5/M<Q"Q--:3I_9M_P
M3I';'&*R]:UBQT*RDO-2N8[6VC^_+*VU13->\06GAO1[G4[Z3R;6W7?(]<AX
M=\,7?BJ\A\1>*(SYZMYMCI,G,5FO\+,O\4O^U_#GBO1K5I1E[.G\1P4Z<6O:
M5/A'P^.O$'B2-F\/>&F:W;[E]K$QM8F_VECV-(R_55JRNE^/[@;IM>T6U8#[
MD.FNZ_\ ?32UVJ1*O0Y_"I'5CT;'X5DJ$IK]Y.7_ *3_ .DFGUA1?[N"7X_F
M<5_9'CW'_(RZ/_X*'_\ C]']D>/O^ADT?_P4O_\ 'Z[?:?6DVGUJOJL?YI?^
M!2%]9E_+'_P%?Y'$_P!D>/O^ADT?_P %+_\ Q^C^R?'O_0R:/_X*7_\ C]=O
MM/K2;3ZT?58_S2_\"D'UF7\L?_ 5_D<3_9'CWOXDT?\ \%+_ /Q^C^Q_'N/^
M1ET?_P %+_\ Q^NWVGU_2C:?6CZK'^:7_@4@^LR_EC_X"O\ (XC^Q_'W_0R:
M/_X*7_\ C]']C^/?^ADT?_P4/_\ 'Z[?:3WHVG/6CZK'^:7_ (%(/K,OY8_^
M K_(XC^Q_'W_ $,NC_\ @I?_ ./T?V1X]_Z&71__  4/_P#'Z[?!]:,'U_2C
MZK'^:7_@4@^LR_EC_P" K_(XC^R?'W_0R:/_ ."E_P#X_1_8_C[_ *&71\?]
M@E__ (_7;[3ZTFT^M'U6/\TO_ I!]9E_+'_P%?Y'#,WQ!TT[BNB:]$H^YF2R
ME;_T8M2Z/\2+*XU!-+U>TN/#^KR?ZNUO@,3?]<I%RLGX5V$;%H\@?-65KWAK
M3_%6G266IVL=S W57&<-_>'H:GV=2FOW4O\ P+^N8/:TYO\ >1^[^K&UPU.K
MSCPMJU_X7\01^&M8N)+VVG#/I>I3??D5?O02?]-%_O?Q+[UZ/711JJK&YC4I
M^S=@HHHK<S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QOP'#_PG7QI\9>*Y_GL_
M#[CPSI2?PJZJDM[+]6=XH_\ MWKV)%*J!7D_[-,GG_#66\?B>\U[6IYO][^T
M[I?_ &45ZOO^4'O5U?CY7TT ?1114 -/W32]N*\/^,?C/4M'^)'AS1H_$7B/
M0M+N]*O+N7_A&M$34IY)XY;=5W+]EN65-LK_ ,*\[?F[5Q7C_P"/GB/P5X9\
M$IJVMZ;X;\1IIS:[K%IJ+0PRWT$3HOV5$E^[+*K.VU/F5HMM9J6O]>?_ ,B6
MHMGU-17S1\4_BYJ&G^,=?CT_QCKFE6D6A:?>:)!I.C17EK<W=R]PJ+/*UK+Y
M2R,L"KNDC^\WUI/&GC_QJOBCQ/86VL>(K/Q!I^FV,NGZ)H>AK?6$]W)"[-'/
M/]DD\M&D7;N:6/Y>:KF0N5GTOBAL8YK@O&?B0:-?>"([JTFEGU#4VM_]'OI(
M5A<6EQ+EE3_7+^ZV[6^7YMW\%>6:]\=-<\2?"W6YIM%7PU-JG@R\\0Z3>:?J
MSSRHL<2;M_[J+RW5IH]NUFZ_PT[E1IN7+YGTAW%+7AK_ !7O_MD>B^(M -GJ
M%MJ&C;/[.UN7:\=Y*\4<CNL<;$JT3[HFW*W]YJR? /Q2U[2?#&GQ>(-/^W:7
MJVH:O9VFK+JTKW1EBENY525/*_=+Y<#*KI*VW:ORKVF4E&+D1'WCZ(HKYYT/
MXXZMI:WM]=:/!'X0TSPAIVNHIU26ZO\ ,RR[49I(L2,639N:3^'?N8LRIT&L
M_&[7/#\SZ1JOA.SM_$K3:>D%G;ZPTEK)%=W#0(_G_9U961D;<OE_[K-5O1V%
MK:Y[-17E6D_%C59/B)'X7U70+32BS+ )9-2;?/-Y'FLUNKP(L\/WEWJ^_P"1
MLQ+M;'JM ;!1110!Y1^T-HEQ)X#;Q/I4>[7?"DRZY9,H^9A%S/%_VT@\U/\
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ME?YG>T445W'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D/P+;^P]5^(/A*7"SZ
M/XAGO(5'\5M>_P"E1-_WU),G_;.O6SM45XY\7+:X^'/BNP^*6G6TUS;6=O\
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M:ZNDC59D6VW12,KI]WS%569MS,@1MG_A>DWAY=:34=/GNVCDU/\ L]Y;J/\
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MR^*6OR_X)=HHHKT#C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPCY_XM[H?_@,*/W/=_=_P1V/5O,%1M,D:DL=JCJ37EO_  RO\)/^B>Z'_P"
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M#_C1S8C^2/\ X$__ )$.7#?SR_\  5_\D=Q17#_\*8\$?]"Q8_\ ?!_QI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_ASS7<8#*..*16'0/^E25U1BHJR/&J5)U7><KA1115&84444 %%%% !1110
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MGQ._Z*Y_Y;5K_P#%52/A?XVZ+ODL/'?A;Q(O\-KK7A^2U)]C-!/U_P!KR_\
M@->Q446"YXM:_M 7'A;4(-+^*'AFX\!SS2>5!K2S_;-$N6S\H^UJJ^2S8/RS
MI'_P*O:%8.H93D'H:HZKI-GKFFW%AJ-I#?6-S&T4]K<(LD4JGJK*W#"O#=.A
MG_9G\5:=I,MU-<_"?69UL[$W4K2MX=NVPL4.]O\ ETD^ZN[_ %;?+]UJ-@W/
MH&BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A1OP_\ ^A1T?_P$7_"D_P"%&_#_ /Z%'1__  $7_"CFJ?RARX3^>7_@*_\
MDCLO[2M_^?F/_OM:7^TK?_GYB_[[%<;_ ,*-^'__ $*.C_\ @(O^%)_PHWX?
M_P#0HZ/_ . B_P"%'-5_E#EPG\\O_ 5_\D=BVJ6L8RUQ$/\ @8KE=:^,'@_0
M9A;W6N6\EZ1E;*U#3W#?[L<89C^51?\ "C?A^#_R)^C_ (VB'^E=#H7A/1?#
M,/EZ/I-CI<?]RSMTB_\ 011^]Z!_LD?YI?='_P"2/.)=/\1_%QD@O;6X\*>$
MQ_K+9I-M_?*?X6V_ZF/C[OWF_P!FO4=*TNTTC3X;&R@CMK2W18XH8AM55'0
M>E6HY#P=^]?7&*>VYE(/WNU:*'*[F=:NZJY$N6*Z$M%%%6<H4444 >1^./A+
MJ=GXJN?'?P[O;?1?&$T:QW]E=!CIVMHOW$N47[LB]$G3YESAMR_+573?VF=!
MTN2+3?B)8W/POUQOE,?B [;&5L?\L+X?N)%_X$K?[->S5!>6<&H6[07,,=Q
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M?\:\[_X9>^$'_1,O"G_@H@_^)H_X9>^$'_1,O"G_ (*(/_B:-0T/1/[7L?\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img118615358_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_6.jpg
M_]C_X  02D9)1@ ! 0$ L "P  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )!!$$# 2(  A$! Q$!_\0
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M*I>X&T/&<>H[&NQQ:E-)GE5*T*<</.I&]UKH=9#\3_"U]/?V6M>$+.PMLO\
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M]Z4J4)))]"XXVO%27-\6YZ[H_P"T=J.CZ6NG0^'-)6U_CCYVN /3'6N:\/\
MQ8U?PSKU[J&G065O:WLA>73MA\H>PXKAO,%'F#WJ8T8QOYFDLQQ4K+GM;8]4
MG_:"UA+.X@TK1-*T"2Y;][<V*?.PQSV'>N<\#?$S4O =]=WT%O#>W%Y_K_.8
MCGUZ5QQF%+Y@]:4:%.*M84LPQ,W&4I_#L7;K49+JXO)<F(7<C/-$I^1MW/Y
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M_P# *2D_X0OQ+_T -3_"SE_^)I^TB+ZI7_D,GWS1O-:__"$^)?\ H7M4_P#
M*7_XFC_A"?$O'_$@U3/_ %XR_P#Q-+VD0^IU_P"0R?XJ3=6G_P (3XC_ .@!
MJW_@')_\34G_  A7B7'_ " -6_\  *3_ .)H]I$?U.O_ "&1O-&_\JU_^$*\
M2_\ 0O:M_P" 4O\ \31_P@_B7/\ R+VIC_MSE_\ B:/:1#ZG7_D,;<U.WUJ?
M\(3XD_Z%_5/_   D_P#B:/\ A!_$O_0O:M_X!2__ !-'M(A]3K_R&3N_.BM;
M_A"_$O3^P=5_\ Y/_B:#X(\2?]"]JW_@!)_\31[2/\X?4Z_\AD;C2;N]:_\
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M_$T>TB/ZG7_D,3S#_>YHQ6W_ ,(+XG_Z%S5O_ "3_P"(IG_"#>)O^A<U;_P
ME_\ B:/:1_F#ZG7_ )#(\PT>9Z\UK_\ ""^*!_S+FK9_Z\)/_B:3_A!/%'_0
MO:Q_X 2?_$T>TB'U2O\ R&-SS_A2;C_=Q6W_ ,(-XG'_ #+>L?\ @!)_\333
MX&\3[O\ D7-8_P# "3_XFCVD?Y@^J5_Y#&_X#1M%;'_""^)_^A<UC_P D_\
MB:/^$%\3\_\ %.:QG_KPD_\ B:/:1_F#ZI7_ )#(]*-O:M?_ (07Q3Q_Q3>J
M_P#@!)_\31_P@OB?_H6M8_\  "3_ .)H]I'^8/JE?^0Q_7YN*;N/ _&MK_A
M_$__ $+FL?\ @!)_\31_P@7B?_H7-8_\ )/_ (FCVD?YA_5,1_(8HD.:?O\
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M(UK'_@!)_P#$TO\ P@/BIL_\4UK7_@!)_P#$T>TB+ZG7_D,3?^=/\S.36O\
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MX 2?_$T>TB/ZG7_D.?W.,T?-70?\*[\5]_#6L?\ @!+_ /$T?\*[\6?]"QK
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M]EB_N"C[+%_<%344 0_98O[@I/L</]RIZ* (?LL7]RC[+%_<%344 0?8X_\
M:_.E^RQ?W!4U% $/V2+^X*0V<1_AJ>B@"'[+'_=H^RQ?W:FHH @^QQ_[7YTO
MV2'^X*FHH A^RQ\_+1]DB_N5-10!#]EB_N"C[+%_<J:B@"'[)%_<H^R1?W*F
MHH A^RQ?W:;]ABSG!_.K%% $/V6/^[BC[+%_<%344 1?98O[@I/LD7]RIJ*
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MH_L>P_Y\K;_ORO\ A0!<HJG_ &18_P#/E;_]^E_PH_L>P_Y\;?\ []+_ (4
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M'; _E5:K-]_Q]-GT%5CCG'ZT '\Z/TH!Z4=Z ';J;T[T49SUH &H]:*3CZ4
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MD1F]E&2/:OS9^"<WBG]H_P"-FN:_J_Q7G\-#1=3@>VTUY]J7<(D?]T@S@C"
M<?WZZ3]J;QSKGQ2_:<TGX::5X^;PKX6$"YO[*Y B2;'S%W4^OKTJ^5KE3W8=
M9>1^@.",;@5.,[6X(^HH]S]:Y7X>Z;'X,^'.C6-]K\6M)I]FJ2:Y-,,7&"?G
M+$XZ>_8ULZ7XDT?7O,.EZO8ZIY?WOL5RDNWT! /%/1["-'M2"H[J[@L;:6XN
MYXK6"/AY9W"*O?DFJFE>(M(UY7;2]6L=3\O[XLYUD*_7!XJ5KL!H[2<$#(Z?
MS_P-)ZCK7SG\6_VO;/X<_&/PSX.M(--U:RU9@M_J37:@61W!1NP<# )S7L'C
M#XN>"O /AF'Q'K_B;3[#0KA@L-^)1)'*QZ!2N<T:6OT#K8ZM:7V_E572=6M-
M>TNUU'3[B.\L;N,307$1RLB'D,*M4 &1]:/PP:/6G=NN: &T<=>]'TI>O>@!
M,FKVD_\ +2J/OBKVDXQ+]?\ &@#1HHHH **** "BBB@#Q']LC/\ PSUXM],6
MO_I7#7YJ5^EG[8W_ ";QXM^MK_Z505^:=>W@OX;/G\P^-!24M%>D>2&:0G;2
MCVI"<<4#$W&DHI,4A"]*/TH],T5708M-8X^E!/K2,>E(0G3ISFEQ\M)2YZ4D
M]4#V/L__ ()\Y/A_QLH'_+>+KT^ZU?*_A..6X^+6C01AC/-JZXC0D<!_TQ7L
M/[*'[0'A3X*Z7XDM_$JWS-J,L;QBSMFE&T*P.<=.M=CI/QX_9W\%ZE<:YX>\
M'7XUYB9%D>TD!+^NYR0OX5Y;E.E6<E$]F,:=2@HN1Z!^TA>(WQJ^"L&Q/M*Z
MFDS\98IN"\'ZFN=_::/F?M,?"$G/WHP=IX/[V2OG_4_CY/XV^/&@>./$<<EM
MIFFWT,J6MO\ O&@A1PQ50.I.*[/XQ?M">$O'OQA\ ^*-+&H#2]#*&[$]L4DX
M=C\BG[W#"E"BZ?L;]M3M]O!W9WG[<GQ/\6^#?%V@Z+H6O76BZ;<6<DTOV&0Q
M/)(6V@%ASC!Z5W7@1=,\%_LIV5V_B1_"=O<6:S7.LVT'G2))(-S$#!^;<3S[
M5\R_M5?&3P]\9O&6CZMX<6[\BTLV@D^VP&([RV00#VQ73? ?]J31O"/@>3P3
MX\TJ75M V>7'/!'YA"?W&3KUSS[UG&C+V%_M&,JT772O[IZ7%\</ADGP4U7P
MOKGQ/O/&LD\#(NH7]A+YNYAA%)V8ZXQFM.'4;KX5?L3VE_X>G33]0^PPRO<1
MCE))?FD8'UR>#VKQ[XC?&KX0Q_#K4?"GP_\ !36ZZ@=[7-U T9@?LXWDL2#V
MSBG? _\ :@T#PU\.KGP#\0-&EU+PUL9(7A0S,R,=QC91S@$G!J/8S2NEH:.O
M3<M6<3JW[3'Q%U;X:VFAWMTSV32$MKLT?[^X;JH$IZ,#T(-?37BCQSXAM_V+
M;'Q!;ZW>P:\UO"TFH).RS ECD%_2O%OC'^T5X(U/X:KX#^'7AHV&C.1ON+RW
MVF)3]X('R0W^U6[\-_VGOA[-\'+3P+\1M&OKV&U 79;PM+', 25)*8P1_2JE
M3;I7Y;:F<*B5;WI75CY6N+B6^N9+JYD:ZFN'\V27^\QZD_C4+?>/.:NZS)93
MZUJ4FG1/!I[2R&TC;@^63\N1V.*I<=AQ7KQ5HI'CSU;?42BE84A.W&:HR&LW
M:F[L=J.IXI&].](!-W-+N/%-],4E2%V.YIA[T[(IOKZTBQ0..M)]TX[4N>*1
MFYYH&-;M7M'[&'_)R_@__M\_](YZ\5DQQWKVC]B__DY;P9_V^?\ I'/6-;^%
M(Z*/\6!^J%%%%?/'TX51TK_D#6/_ %P3_P! J]5+2?\ D"V?_7NG_H(H =11
M10 4444 %%%% 'G7[1A_XL5XZR,C^R9^^/X:^1_V<_ /[0>M_"#0[SP'\0])
M\/\ A:9)#;Z=?0QR2I\Y!^8VLC+G!_BXZXK[2^+/A&\\>?#7Q+X=L)H+>\U2
MQDM8I;D'RU+C&6QSCZ5\N^"?V</VD/AWX9L?#_A[XG>&=-TFT0K#;_8Y91'E
MLD LN<')_.EK9BD]+%O]D#5K;P+\6/&'P\\0Z4C_ ! 8RWM[XB6Y\W[=B0DI
MM*J4'S[Q_>W'@;15?Q)-X'^(WQ4\5MX&^"3?$_7+>?R]<U&\U1-.MXI "!Y;
M2$ABV#D#'3->B?L[_LQ:M\-_&>K^.O&_B*/Q-XTU)7C,ULC)#$CE2Q&[EF.U
M1SP ,"N4T[]DWXC> _B;KFH> ?B/!X?\)ZY>?:[V&6T\VZCR22B C8<9.&."
M*J?O-6)2Y4<A^PC]KT/XS_%'0O[*D\/619IVT4RB5;.1)RBQ>8#AF125)&.@
MKC?%/@77/A7\7/'>K>,O@Q>?%"QUO4'N[#4[42E57)(+- DI1=O!5QGC@5]#
M>"?V8=<^&7[0DWC/PYX@@'A74XG;5K"\#M=W$[*2S[@ O+X<Y[YJKXT^!OQP
MM/%6J7O@3XOK!IFJ77VF2VUZU\YK7@#9$54C& !T'2E))RBWT'&_*TR?X ^*
M_AUKWP3\7VO@#0'\+_9X+B;4=%F4K)#-)&_//)4[&4$@'Y.0*\W_ &/=%U?Q
M9^R/\0=)T&8VNLWE[J%M:2&7;ME,2@+G'R=<>V<U[5\&?V:XOA!X)\5V4>K'
M5O$OB9':_P!2FC"1M*5DVX4<[0TKGWSTJA^SM^SUXC^$OP=\0^#]6\2Q1ZGJ
M5[<SV^JZ&K(]LLBJ%(\P??!!/2F_C;\OU0K:17G^C/DKP_;Z-\*?"(\-_$G]
MG34[]+/='?\ B%O.$:(_*X=$:-L X!5QG;TSDG]!/A+K7AGQ!\.="O/!R+#X
M<:V5+.%4*F)%XV$'D$8YS^N:^<M4_9K^/>KV,OA>]^,-C>^#985MI&N+ M>O
M& -VXD8)./6OH_X4_#;2_A%X!T?PGI#2266G1;!+,<O*Q.69O<DGZ# IJRII
M#=W-OH?+O_!0SPGI%K:^%/$,.F0MKEYJ"6DUSE@TT0QA",XP S'IFKG[66B:
M;\&_V6$T7P7I\>@Z?K>H6\=XMOD[Q(-S@EB3E]H'!KT_]JKX$Z[\=-$\-V6A
M:AI^GRZ;J*W<C:@),,N5^[L&<X!Z^M=O\4_A#I/Q>^&=SX.UMY(H)8D$=U;\
M/!,@^21,]P>Q[$BHL^1P6EVF'V[^1\\?$W]F7X=:7^RG/J=KX<CBU:VT>&]2
M_5B9A,0C%SDXZL>W';D"N9\>^*K_ ,7?\$Z='U#4Y6N;M6MH))IOF,BI/M5N
M?8#\JZF;]E'XR>(-(7P9X@^+5O/X!2-(/+MK0_;)(5P%1B1C&!Z]<5ZA\9OV
M=Y?%G[/,'PR\'W-KID5K]F2"34B[J$C<,<E1DL>OU)HG>2LAQT:N9_[+?P?\
M)6/P[\&>+CHZ3^*18E?[6N&9IL%G&.N ,' P.F*]I\7C_BDM;]/L,_\ Z+:L
MCX1^#KOX??#?0/#M]<Q7=WI]L(99H 1&[9)RN><<]ZW]>L)-4T+4;*%E2:YM
MI(4:3.T,RD GVR:N3NR8KEBC\ZOA3\&9?B5^QE-K>B1"/Q=H&JW%[974?$I4
M10EU##G/&Y?<>]:FM_&6U^-?BO\ 9_OI?FURQO?L6K0/M+)-\H+<^N,_C7U7
M^RC\%=8^ OPM;PQK=_8ZE>&^DN1/8!Q'L9(U (<9S\A_2O)=>_8=U"+]H&T\
M:^&M4TRQ\.?;H[^?3[E93<*X;=((V Q@]L]*2^-/H%1<T7;<YG]M.^OO%7[0
MW@#P;)HLWB?2H[:.]C\/+=K;C49FED#*&;Y1\D8^8]!G!&:QO&?P.^(E]XD\
M,Z]X)^ J_#[5='NQ*;BP\3V5P9X^,#!=-N.<X/.<<U]*_M$?LVVWQO\ [(U6
MPUF?PUXMT8DV&JP+NPN=VQAZ;@#N'(Y]:Y#P/\"_C9=>)M*OO'WQ<6?3=*NE
MGAL="MMGVG:, 2LXY!!(/7J:N%EJRIR<;.*N8O[5<%QX.^+GP:^(XMGCD6_B
MTK4'9LQP*[?*#SC.)IQGV[UY_P#M'>'[WXU?$GXD>)-'NMR?#?2;86/D@.)Y
MF!G;!'I@\^U?5/[0GPHE^,WPOU'PY:745EJ3/'<65S/DQQS(<@L!SC!8<=,@
MUSW[-GP#O?A#\,=3T#Q'J%MJ^K:M<32WMY:;MK*Z[54%^3@9Z^M0NLAVM9H\
M;^+'B2/X^>*/V>_#\$[746I$:QJ&S +!%4L2.V/*EZ]FK[-Z  =*^6?V9?V0
M]<^"OQ(OO$6NZY8ZS90VDMEI44/FF6"-I%*EBPQ]P,#CNYKZFI\W,EI8 HHH
MJ0"BBB@ JRGW5^E5JLI]U?I0!4U?_D$W_P#UQ?\ ]!-7*J:Q_P @F]_ZX/\
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MSD=*XWQ)\"_C7^T]K7@>X^);6?A[0M-0W.HVT=MY4D<OGR+Y*#/[TM&D4F\
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M&-HQ36O4JUMR.3'%>V?L7KG]I?P@/^OS_P!(YZ\4?M7M/[%__)RW@S_M\_\
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M!Y&:*7\<4?PY[4 'O1^E''I2=\T#%]Z#^E'1<9_&CN/6@04< &C!QTR*3]:
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MK][$_5*BBBOGSZ8*I:1_R";#_KBG_H(J[5'1?^0/8?\ 7O'_ .@B@"]1110
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MH$2,P[4C<<U%_%GI0V!0589(59L]3BF=23U/7-.Y-+_+%2%QGUH/O1Y?'6D
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M'B"'))'9@*V=0^*7A:UU:;14\1Z:FN+OBCL9)CD2*GF8DP/E 7YC[4EQ\2-
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M^'9P7^SCR\Y&-W&,_7FO6_F&T9.-N.#QUZ?7BG!R>,Y&<\]:71E\Q\S1V_\
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MT<D39 ;!R.2/>N+7X=V>IQ^+/%/B#6)/#_ARUU9K2&6SMA--<S%F_=I'D @
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M* "BBB@ HHHH **** "BBB@"EJW_ ""K[_KB_P#Z#4CNS\+TIFK_ /()OO\
MK@__ *":D_Y:"J0#_P"+C^__ $J6HN_I\]2T@,:]&+N0_3%0YJS>_P#'P]5L
MT@#OZ4#[U'W:.:  =5HHS[4<]: #WI.?7\J4=*.U &%X[U34=(\%ZSJ6D"%M
M2M;<W,?VA"T>U6!?(!'\&[OUKSV/XT7TWQ&TNS2.S;P=/I0FGO,'SEO"F]4'
M/W<5ZY/;Q75O+;SH)8)D:*1#T9&!!'Y&O'1^S9;Q?#J_\+P^)KR.[N-0%_%K
M'DKYL&.%C5>A4+E?QJ=;.Y3L<QK&K>*?%GB#X7:DD^FV6O7J7TD4[P/)!% S
M?NF\O<"Y,>P]>I-;FH?$?Q)9_#/Q;_;L&D:AKFA:M'823BR!M;H>8 '\DL2I
MP>[&O0;[X;VUQKWA/4H+Q[:+P[;M;06H0,'0HB ;OX<!.WK67KOP@AUG2?%=
M@VKS0#7M0CU)W2%=T&UPP4#^('&,FC:#:)^TC&;Q/X]\9>)=:M_"DNCZ9IFC
MB&%DO[5KA[Z5DW. 0RB%5QC^+UQ7/:A#XOU+XZ:ZWA^]TW1-6_X1NVFF-[;O
M>1_ZTDHBAEX_VC^5=CK'P@U7_A(KW4O#7C2[\+PZH(AJ5FMK'<+,R+M#Q,W,
M3$9R5[G-;FD_#F'2?&MYXB74[FX>XTR/3?)F 9P$)(D,G5FIQ7O*0IW<6D4_
M"OC/5O%'PFF\06]O;1ZV+6X86Z M$]Q%NS@=<,5^[VSUKD[7XW:C>>*_ ]M#
M%:-H=_:(^N3!"9+:XD4^6J\_*NY2#G->D^!_"2>"?#\.E1W<EZL4\DWG,@1F
MWN7VD#T)KSV']G*VM_!OBO0(?$EW$^M7/G6U^L*^;I\>[<L:_P!X!B>3ZTNH
M^B,OQ)\>-3\/^"]/U.<VUM-KFK3V=C=+837 M($5R&>",%Y6S%)]W'4=!DUF
MV?Q\\2+X!\970-MJVJ:*D4MIJTNCW.FVUT'95*-#, 0RDD<,<XKTW7OA;%J7
MAGP_8V.K7&DZQH+++I^KQ(':.;859V0\,&W-E3P0Q%9T_P )M5U_P7KFD^(/
M&MYK5_K)CW:@;5(HH50@@1PK\JY 'UZT=1/8Y#QI\7/%'@&UT'3=6UG35U76
MHFO!JEMH%S<Q6<(CW;/L\1=I&)XW$KUS7;?!?XD77Q TG4C?QM--I]T+87ZV
M$UC%? H'$B13*&3AL%>>5//-7/&/PUN-?;1+_1?$-QX;\0Z/#Y-KJ,<*S(RE
M-C"6%OE?(SC/0UL^#O#=]X=L94U37KKQ'J-Q+YL]Y<J$7. -L<8XC48R *N.
MKD)*W+<\%N(_%9TWX[/JVO6NI:;#)(B6BV#Q%7*?+M<R-\@'4;>377_#7Q%X
MP\-S> M*UR[TK5-&UK2HELX;&U>&>U9+=7PSEB'7:#DX7V%;ES\';J\U?QN_
M_"3R6VB>*XR9=.%@GF038V^:LWWFX_A/'-;H^'4"W'@R1K^0)X9A$2+)&&%S
M^Y$0+?W>!GCN32C\.I4M97/%F_:>U6\U!M3L+J.;34N_('AU/#=_)/*@?;O6
M\5/+#'KC&/?O75:KX\^(6L^+_'-GX>O-&TW3O#<%M<QQZCIKRR7 >W\UXBP<
M;2""-V./2N@M?@WK&D7JV6F>/=2TOP>+@W)T&&!/,7+;C&ES]]8R?X>F,BM[
M3_AK#8^(O'&K#49'E\411PR1^6!]G"0F($'^(X.<FG';4KT*LGQ.2T^#L7CJ
M>S^]IB7ILTDYWM@;0?[NX]?2L:S\8>,_!_BGPJOC&]T:_P!.\1W2V<%OIUFT
M,MC<,I=5+EF$JX5@6PO0<<\=1I_PWL+?X9VW@B\D;4-,CL5L7D("-(!_'QT.
M>:Q/#OPFU:SU[2[[Q)XRN/%5CHS!]*L9+..#R'"[0\CJ,RN%X#-SRWJ:3W%T
M/,_ >M>./#_@'5?$.D7&C?V!I.HW+7.F74#R3W*"3YG$^1Y9P>%VGIUKH_$'
MQ=\0-XIE73]9T3P[I<=K:W5K;Z]8R;=164 _\?0.R+J%Z-C(-7X_V?\ 5+>R
MFT:#Q[>1^%KRYDN=0TMK*-I+@NP9D6;[T:<#@>_K6KXT^#>I>*6GL;7QE<Z9
MX7NXO(NM%DLH[G]UM"[()&&Z$;1_#WYI(E''?$GX^:CHWC#4M$T_4K?03I,<
M3RO)H%YJWVYVC638AA7$?W@ 23ZXK3U#XJ>+O$%U\-[30(;#0KKQ1%=-<_VM
M9RR- 8HRP*H=IYQT;'UKH-5^#^HV^LW&I>#O%]QX.FOH8H-1C2T2Y2Y$:!%=
M0WW'V@#<.>!6M-\,UF\1>#-6;6KR9O#<,\2BX_>279EC9"SR'D8W9Q^%,?4Y
M63XG>(?#>B^*['6FL;KQ/I<L$%D]O;&**[$X01RB/<> QDRH/_+,URGCG]H+
M6-&\1:IH]MJMKI%UHNR*XCD\-WVI#4)MH+!6@4K"I/ ))/.<5Z;XF^$-GXH^
M(F@^*Y=0DMSI8^>Q1 4N67=Y3,>VSS)>.^_VJ#Q!\+-8N/$FHZIX4\9WGA)=
M58-JMI%:)<"=L8\R(O\ ZIB/XEYSCTH*OK8Q9/B1XH\;WGAC2/"\-MX:U35-
M+;6;R?5[62?[+"D@C,?DG822Q')(.#TJ[\!X]0@M_&8U9K9M177+CSFM,['P
M/O*&/''.W/'J:T?$WPKO=2DT74= \47FB>(]+MS9KJD\"WGVB D%EEC?AF)
M.X]ZT_AOX$?P+9ZHEQK,WB&?4KR2]FN;J((V]_O+@=%]!01Y'B=S^T[JO]H3
M:A:SK-917GDKX;B\-WTMS<Q"39N%XJ>6K'[V,$  \UW_ (F^*6O>&/%R>&);
M:VEU/Q$5;PU-Y>Q,8S(DXSG*#DGC/2K=G\&]9T>^>UTKQ]J6F>$I+E[I]%C@
M0S!G;<RK<_?5"?X1QBK>O?!FT\47>J:AJ>IRW&LS-'_9VH+$%;2U0Y01@=3G
MJ3U[T%HY_5;?Q>W[1?A:!/$5C'ITFDSR2V:Z>^& >(2 'S,;F8@J<':.,'.0
MSP/\0O&.O>%];\5ZGJ?AZSTBU-Q!!9O;O& R-@223[CQC^$+DGZUU^I_#[5[
MSQIX9\2VWBDVMWI=M):WL;6$<@U!7*%CS_JCE!]WH"15:Q^#=C;_  UU+P;-
MJ5Q/:7DKRK=! KQ%GW# '!P?SHELB8Z.YY_\.?V@-0U'7K^PU34;;Q# FE2Z
MG'=6VAW6E>48V ,>)AB4$$G>IXV].:[#P;KGQ$N[6P\2:R^BW'AZ\M3=3Z7:
MP-%<V";"XQ,6(F;'&"JC/>HM+^"^NQZ]8:IK_CN7Q%]GM)M-GM'TV*&&>U<<
M)M7[K@@?..2,CO5SPK\)-8\/W5I;7OCF^U;PMI\/D6>B-;)$=FW9MFF'S3+M
M.,-2D-'F.A_M-ZMJ6KV&H12+?V%U<!!X;M_#E\L\<9;;N%Z4\MF[XX!]:-86
M*+P?\>@ K?\ %11DG!*L1';9^IYKTK1?@_K6@W=G9V_C[45\'6<OFV^@+;HK
MCG<(VN!\S1Y_A/;BHK[X&O??\+ @'B5X[#Q9<+>_9S9HQLK@!!O#=7'[M?E/
M'%- S8\,^*KV3QE<^'W$(T^QT6UNHB$*R;F3D$],<= *\SB\57_CK4_@9KFI
MI"MY<:C?.[6Z%(\B-E "DDC&!P:[J_\ A+K\E_INJ:7XYETC6H[-+#4KR/3H
MG2^B7H5C/$3>C+TJI8_ 5M+T'P%8Z?XGGAN_"5Y+=17TUJDINUDR)%=3P"0<
M!NHZT1*5CC/&7[0.I^%O%UV(M>TK4+"UOEMI=(L=&N9SM+!26OP/*60 Y*G@
M$8SWKMH_%'C'Q%\3O$6B6-YI5CX?TE(9#YUDT\]RDD.XIN#@*03][!%4=6^
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M?XR>&'_::F\9F:YD\/20^0+HVI,L<ABVB98V'\)_E1XD\=^%-6^%NJ:#J/Q
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MVC5/^ UH''<TF31'G_&OESJ.ATW_ (\(<_W:M56T[_CQA_W:LUYW4[@HHHH
M**** "BBB@ HHHH **** "BBB@"GK'_()O?^N+_^@FI6^\.YJ+6/^03>_P#7
M!_\ T$U*W7^E4@'+]X_[U2U&N-Q_WOZ5)4B1E7V?M;8]!_*JA_*K5]_Q]/UZ
M"H#[#_"@8WO[T>GK1Z]Z3^+[N: '_I3?>C% YH  ?:@_RHY^@IW>@"*XFCMX
MY))9$CC1=Q=V"J!WR>WXUSGA?XF>$O&TEW'X>\1:=K<EGG[2MA.LI@P>=X'3
M\:3XEW-_IOP_\0SV6GKJUU#:%A:NF]9LN!N*]RHR<=\5\]^#?$4%_P#%3PA=
M?\)CJ'BR&;3+VT'VC0TLK>UG,1Q OEPQY]/GW#WI;Z%-:'OVF_%SP3K>O0Z+
MIWBO2;[59L^5:P7:-(^#@X4')Y#?]\FF^-OBEX9\ /\ 9-8US2]/UB:%Y+2S
MO[E8I)R!D*H/WA]*\:T#0TM?V>O!CK8O;7$>NB0-';;)06OY0QVA<K\N>??K
M6KJ/B/P_X"\0_$^P\4VCQ:IK<LDUDRZ>\POK8QD1HC*I&X=,,0,T>1"ZGKG@
MOQ8/$7@C3-?NXTLEN+4W$P4_)&-Q&3Z# SFHM+^*'A#6X+^;3_$FF7L5A&);
MN2WN%=8$(R&8@\"N9\&V;K^SK:0/"=YT27$,D)#9(?"E/7&.*\]\1>'[V3]F
M/X=Q6*W.G16#6%UJ)L[5))H(5Y:3RG!#%3SC!IR=K)"A)ZW/;O#'Q$\,^--'
MFU/0=>T_5K"#B:YM+E7CB/HS X'%'A+XB^%O'T]S#X<\0:=K4MLQ$RV=PKF/
MMDX/'->"Z;<)<VOC7Q1HWB'5OB9J$>DQVN[4M"MK.VE_>CY-L<$32L@R^U@1
MP*SO"/B5=6^+FA26WC34O%AO]#O=/AEFT1+&&WN"/E@4Q0Q].V[./[U.)9]#
MV7Q.\):EXFE\-VOB/39_$$6?,TQ;E?/0#J2O7'/ZUR?@;X\:!X@O+K3=;U32
M=%U\ZG<V%OIS7062:.)RBLJGKG':N8^$_BKP>FA^%_!USI%X?%>FW9:;3/[/
M=9;2?>^Z9I" NT@@Y#-]Y1CKC!L=%B;X$^.Y3I^Z\;Q-<W*LMN5E=_M/^L&!
MGH3R*E_#<#W3Q1\1O"O@>]M;/Q!XATW1KJ[D\NWAO+A8VF8_PJ">3[5/XF\=
M>'?!.GP:AXBUJST/3YFV1W-],L2/D\;23SD<^U?.WB>231/B3XKEUWQIK'A.
MVUFUM%LTMM%M[^/4D\DAT#R02,K9(X+*,FMW2&TGX4>)/!.K^(CJ">'H/#Z6
M-C?ZA8;IK6<RR,Z3+"IPY1HUP!@;*I)IM@];'K/PS^("^/K'5;V,6SVEK?M;
M6TMI+O29!_%GWIUK\0M)TFPO=0U_Q#H<%M;ZB]E]IAGQ$G (BE+ 8D&<X'8B
MN7_9YN+2[TGQ5=V5G+9V%UKLTT'G6YA+H?XPOH?PKRZ'36GTX1R63R+_ ,+&
M=RK6[]!''AAQT]SD5$FTP6Q[>WQL^'\.DV>I-XRT5+"ZF-M%</>)LEE'WD4Y
MY(]!6UX@\>>'?"MK;W.LZU9:9;7"F2&:ZE$:R(!EF4GJ ,$UYY8^'-/;XQ?%
M6?\ LR-#/I5LDDI@P)08#GD#DYXX-<+X7LFF3]G3[79R3K +W<\D#-Y+>7QN
MW D9X SCI5,I0=KGL[?&;P*L.E2MXNT58M4R;-_ML96?!Q\ISS74?VI:?VJ-
M,:ZA6_,8F^SM( _EDD!\>A(KPVW\.6<>F?&]4TY%$M]\O^C8,C"($$?+S\W=
M>]6]+\7:?\/?''AG6/$33:=8:CX:M;:*X6UDD#SJ<LC[%)W'=D9]#2EHR$[Z
M'J5UX_\ #5CHL>L7&MV4&ERNT:74DRJC.O5<^O%'AGQYX=\::;-J.@ZU8ZM8
MPMLDNK2=7BC."2&<<#'O7SMHMO\ VM\'?AONL97C;Q09?)NK=R47S"0S(>0.
M_-=5\3O#M[?:Y\6+71+.5+B\TBU<I;P)^_VL^X*"NR1BI88?/)%'0IJSL>N>
M%_B1X5\;7E]:Z!X@T_5[JQQ]JAL[A9'@/HX!RI^M.\7?$3POX$2T;Q'K^GZ(
MMV<0->SK&)/8$GD^U>(_#1-.\1_$3PS=P^.O$/BJ[T6WD58)= M+"*Q5D4%)
M9([>,GE3\JEA73^)/$FA^ ?C3KFJ>+8I(;'4],BMK'43:/<1D C?;_(K%21S
MR />GTN2MSTCQ-X^\,^#-)35-?UVQT;37"E+N\N%CC8-T(8GOVK#\;?$J/1-
M-\,7VD?9M9L=:U%+,3>:=GEL,[XR.M>/>,V@T/Q;X?\ $<&L:U\-_"(T<0V%
MU#HL%X89/,8NDL<D4QCR"N-@&>YXINH:?:^%OA?X2U*+4-5O=,E\5)>/?:G8
M+"ZHV?F6"! L:-U^51[BD5YGL^@_$V.XO/&PUIK+2-.\.WGV1;Z:8(NS&0SL
M> <9K=\)^-] \>:8=1\.ZQ9:U9*QC>>QF61%8'!&1Q7@MS)H^J7GQ6TO4+C4
M[.3^V[?489+"Q,TL:Y!BGVNI1T##)')P.E=[\$_%TGC+5_$TL36.K6.8Q'X@
ML]/>R:Z8)RLB,!N9>FX "J)9ZQSSSP#Q[^]&ZAF 5>C-CD_TI%^[G%(8M&[\
M:#1[4/40C<T=>].^]]?6D]Z-P KQUH"]:!A>G6C=V/6@ P1THQ03SFBC8!,^
MM(R[EVYQ_GM3J-O%"TV %D==Q5F3)XVG^?J::L87.WY0PYQST.<_CWIWUZT=
M: #CTJ]I/60U2Z^U7M)^[(/>@#0HHHH **** "BBB@#P_P#;*_Y-U\5^F;3_
M -+(*_-"OTN_;*_Y-U\5_6T_]+(*_-$=Z]G!?"SY_,/C0>8*A]*DDZ5'7HGD
MBKWKL-2_Y([X7_[#NJ_^B-.KDAUKKM2_Y)#X:_[#NJ_^B-.K.?QP.F/PS.0%
M,;\10YI?XO45H8E[P_I9\0>(]+TP2-$U[=):LZ@8"D]:]2^(&N> ]!\1>)O"
M+>#;>&STQ&LK74[=Y3?"Z10=\AW;"I).0%R 17D5K<36DT5Q!(T,\3B1)%ZJ
MP/!KT;6/CE>:Q_:=T?#&A0^(+ZW\FZUH1NTLJX"LWED;58@#+#FLJUVERF])
MI7N>E^"_AWHEQ=>']"US0?"^G#5-/WE+K4)I=99RA(D4JJQ*.!A2.E<IIMKX
M<\#_  *T[7[KPAI_B35Y];FLI)=0>1=T* L NQQSQUK,T_\ :'O=+UK2]<N?
M!^@ZAK^GVBV:ZI,9/,EA"XV%!P&P< ]:Y3Q!\2+G7/!]KX9BTRSL=+M]1EU6
M(6K.71I%*^7ENPS7-R5'L=2G ]:UKX>^$/#_ (V\6^(9=*$VAZ;X?M]7AT5R
MQB$\P7",5;<4!;H"#[USWP]TWP=\8/&7A^UFT&'PY=VL-Q-JL&GNRV-S'& R
M ;B[(?F^<Y. .E<[;_'36/\ A*)-9;3K":.XTN/1[O3>3!=VZ* /,[@\#D5%
M;?&W4]'U+09O#FAZ5X9AT5I7@LK2-I$D,@ D$CMRX8 <'TK10FEJB.:,GH=/
MXVT[P3J/@369#/X1T[Q!9S(VGKX6N+J;SHR^#'-YJ[?^!!@?:F?'^/P]X/NM
M,\.Z-X2TNS>;2;6[FU'$TETSL ?W9,@51_O*:X[7_B='K'AN_P!%TKPEH?A^
MROKH75XVFQO)),X.<[F'RC/8<5E?$+X@7_Q(UNTU*_M[>UEMK."R LR6!\H8
MYS[5G&,EN.<H=#N[>'P]\+_ACX0UF_\ #-CXCU?Q%/)<RR:B9)$AMT)!2)4=
M/F/.6)./2MWPIX2\&3>$O$WC2RL=*CM!J:V.F6'C"[E2SMU:-9'.Z%=[$EL#
M=@;0.:\]\/?%J71?"]GX?U;P[I?B?2[.[:\L%U,NALW/)V,G521]T\5.OQNU
M6?\ M^'6M&T?6]%UMUDNM'FA:"VW* J%"HRN%51QZ4Y*3V"+CU/6/!^D^%;/
MXP:5<^&+C36:\T&_-_9:1+++:VTRP/E8VD4$J0<]^G6N4\O1W^"_P^'B"X^R
M:'_PDMU]LG'\$6Y=WX8KE[/XX:EIOC+3?$-MH&BV]O96;V$6DV\;I;>2R%"I
M?&2V">3S55?C%/!X;L]$3PUH_DV%^^H6;RAY?(=S\RE&&'4].:RY)W-_:P3T
M.U^+_A6WM?"-]?Z?X,T&'3/M8^PZ]X:OY)(H;5ON"X5R6;<.^%YS7@[=J[_7
MOB_/JGAW6-#TKPSI?AB'6)TEU%K%I7-RR'*\-PB@_P (XK@F KHI)I:G)6DI
M.Z$'0'K0U!..,TE;F C?=]Z:Q-*Q_P YIFXT )FE_2BF;NW4T#L.H/UI-Q]:
M3.14#&,?FQ39/NGFI"O>H_\ &@!O/.**-_\ DTS(W9H ;3Z;3J"R/TKV_P#8
MK_Y.<\%?[UY_Z13UXAUQ7M_[%'_)SO@SK_R^?^D<]8UOX1M1_B1/U:HHHKP3
MZ0*HZ1_R"=/Y_P"6*?\ H%7JI:/_ ,@BPY_Y81_^@B@"[1110 4444 %9NM_
M\>Z?[XK2K-UW_CU7/]ZJCN3+8QE_'->:^(/$6L&WNH/['N]4N%U546%;:58K
M9%E>6"565?WO^JBW?W6;YMM>EX'YU!++';QS23LL,,:[F9FV;5KLD<<??.9T
MNXN=4T[1EUBTV:A/)*TD/E?PQ;MG_M*MJ30;&9MQMHS_ , KQ2;]I?1M6\92
MV?@WP]K7CRZAC:V6?1HD6RB;=\^^XEVI_"OS5K:M\7OB+X>TVXU34OAE;VFF
MVJ>9)++XE@WHO^YY6W_QZN:.(B>O_9N)^U[O_;QW/C34=$\!^&[_ %N[LE>&
MU3Y5B7YI&9]J1+_O,RU\/_%3XS:_XRGNHKZ]9;5F_P"0;:MMM8O]G;_RU_WI
M:Z/XU?M5KXX@M=&OO#VH>%XHI?/#7K;_ #Y=FU?N?*NW<W^5KQ"ZWW,GFJ^_
M<WWZ^BRNG0K<TYD5L!7PO\>!BWTDMU)NE;?\WS5GS0YK9FA_BQ5;[,TTB1*O
M\6ROJ8GB8K$<L>4S]-T@ZC<\.J*OSLSM7TI\$?A>UO/:ZK/;-"TB[+.VE7:_
MS?>E;^[\OW?]EW_O5Q7PM\$RR:[8)*O^KE6]G^7[JQ/O7_OJ7;_WS+7U!KVJ
MQ?#7P0=958YM9O)?LMCO3Y%;8S>:_P#LJJ[O]KY5_BKY_'XGFE["!CA:?/[T
MCP#]IO0VT+QI<6S?)YMM!.O^ZR[/_0E:O#MK>77=^.=<N_$6L3W%W=S7UU(V
MZ2ZG;<TC5RK6W\)KU,+3E&E",SKQ$N6/*4(8W^T1.W]ZOL#]DO4E75M0L91\
MGE07J_\ ;3=$W_HC_P ?KY/L;-Y;Z)5_O?W:^I_V<[%K?Q%<3+]Q8H+-_P#:
MVH\O_M=?^^:YLVY?91/'P<I2K2/KMC^['%+'TQ1'OVY?\S2>M?)GNG1:;_R#
MX?\ =JU5>Q_X\HN_RU8K@>YUA1110 4444 %%%% !1110 4444 %%%% %+6/
M^03?\?\ +%__ $&I2/FX_6H]6_Y!5]Q_RQ?_ -!-#<GGBJ0$\8VD]?O5+42=
M3_O5+4B1E7W_ !]-]!5?KTY%6+[_ (^VX["JO3KTH&'X_E1BCG-)[T +GCKQ
M1].E)QUI_?I0 P?2CVI?TH[>M  "<$G[Z_ZOTZ=Z3:NT )&!][;Y:XW=^WZ]
M:7J31_.D.XBY#L2J9QA6 Y]>G3KS2>6DAC:558K_  % P]B">13J#038&VA1
MM9FDZ\@8Z\C'I0QVQX4 E2<(5&T#L*!UHY[4]Q];B1*(]@4*J#YBBH%&X]Q@
M?2D\F-+?:B*)!R/D51NS[#\Z<#28I[ -6-6^<QHDIZE%'&/1NO7^0IWEIN92
M<0X #*H#>IS]30.6Z4[GI4M75@&S(DLD?RJ4#9/F(I*^ZYZ&AHU=@'"R0XR?
M,4,<^H!XI?\ /6BF A7J0Q1L8&T!1]<"E^[G9@#8,#:/O=\_7UZT4=Z35QC=
MG";0%VGG'4#T'K^-+M5<;%Y ZX'/M[#Z4N:3]*87=K"@#>">O0L ,X]/>FO$
MK1>5M38IRF44X]#R.*=0OOQ1N(:L:^8S9" MD*JC'_UJ5=RQ@!@,$X0 8(SD
M9/7K2G\Z#][@4NEAMW=QVV,9,:B$L<L8T49'I4;(&;#!7CQD>8@8EO4YI_8T
MTYIB&^7YRH)\/S\V5# ^V#VI&5W4*5C(SR,95?H",9J2C\:!@RJKDQ]]P)90
M&QCCD>]$8$4910L:G/R1H%4?@*#GK1_D4"$QN/H .*%[=Z*=0 GZT?A3NV!S
M3?Y4 &?ES24O_ J0N><B@8O6DI:!WXH$)QGFESTHSVQ0M !Z]Z7=GBDZ<8HS
M[T +WX-)CTI/K2\DGZT '&/?I5[2?^6M4?UJ_I/_ "U^M &A1110 4444 %%
M%% 'B'[9G_)NOBKZVG_I9!7YG^U?I?\ MC?\FZ^+>_-I_P"E4%?F:<5[&"_A
MG@9A\:&9H/W:/XQ1W]:]4\R!)_#76ZL/^+.^&O\ L.ZK_P"B-.KDJZO5/^2.
M>&N?^8[JO_HC3JQJ?% UC\,SCQS2\T?K16AB,IE/%,]Z %_A]Z3)/?-&>U&:
M!![4SK2_P^]-Q[TAC^/3FF?Q8ZBAO:F<_A4B#FEI#3=QH- [T44>U(8<EL^G
MM1STHIG:@ Z<FF\T4GX4 )S]:3)SGK3QGUJ'Z5!0%2>AS1(OIQ0_4YYI.XS3
M /YTUOK3_6H_X: '<'Z4VD:EZ]Z0#6IIIU-W>M!8[O3'QWIX]J;0 T_>%>V_
ML3_\G/>#/^WS_P!(YZ\/D/(%>X?L1C_C)SP9_P!OG_I%<5E4_A2.BC_$B?JY
M1117@'T052T?_D$V''_+!/\ T$5=JEHO_('L/^N$?_H(H NT444 %%%% !69
MKW_'JGKO%:=9NN_\>J?[XJH_$B9;'+ZQJEGH>DW5_?S1V=A;1-<37$S;4B5?
MXZ\,\.^&=4_:'6#Q+XRN+JQ\%S2M+I?A-?W:3Q?PSWC?>DW?>\K[OW*T/BK8
MS_$[XJ>'/A\)67P[9VIUW78U;_CY19=MK W^RSJS-_N5[7Y8C)WG]VM3_%E_
M=/0C+ZA1C*'\27_DIRTFIZ1X#\,W]ZT,-II5M)M@M;6+;]W]TD2+_M,NW;_M
MU\J?%/XK:IXHO'>[G^56W0643;X+;_XIO]K_ +XVUT7Q*\:R^(G^T,[?98]R
MVD6[Y%_OR_[TK;_F_P">6W_:W>07=O%-(S2+\_\ ?KYG_6S#83%RI^RYHQ/J
M\%PKB<9AO;U9^](Y;4=^I,_G)YR-]Y'6N0O]/E\,^;=Z?N>U1MT]E_L_WEKN
MM0@:W.3UK(F/5=OS]J_5\'6PV=8;ZUAI'QN,Q6)R&M]5Q/PF5'MO(XF@;>LJ
M;U9:['POX*E^U11+'OOY_P#4(Z_=_P"FK?[*?_8USG@'2&TOQ-=6TT;36[P?
M;+2W_O-OV^4O_ F7_ONOK'X>^ T$4&FVT49EVK]IN(HMOGM_%*W_ (]2J9C+
MV7+]H\/$8&/UGFA+FI?%$O\ PT^'4*I%:6,'DV\7^LF9?GE;^\[_ ,35P_[2
M7B))O$T^G6TF^TTB/[!%M;_EJVR65O\ T!?^V5?1VH7EA\)_",]_,/M$WW8;
M=6VO<RM]U5_S\JH[?PU\2>-+IKJZE0R>=++++/.R?Q2RN\KM_P!]-7!@*?/5
MYCMIQ.*>'S&=MM031+6NT/>J=PF5Z8K[*)X^.K>Z6_!BQ/XCM5D7?%N^:OKW
M]G/0UETF"=OOVOFQ3O\ WI5E=97_ .!2[V_X%7RM\/-%DU+7HF16^7^*OK;]
MG&X_T.XV?\>]U//<1_\ 7*2=F5_^^=M?/YM+WHG)E?PR/=,XY]:*, \]:>&[
MXKYP^@-_3?\ CQA_W:M56T[_ (\8?]VK->>]SK"BBB@ HHHH **** "BBB@
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M=:G>-SY=K TM>Q:O^SI\1T^%NB6Z^%;I[FUU34+J>W62)I5CE@LT1MN[Y_\
M52_]\U]CZ%H7@S]FOX;O)D6.G6B@W5^\?[RYD]6]2?TZ5P6@?ME:#?\ B"WL
M-6\/:OH-A<2".TU2[B BGR>#DC//UKQI8F<Y7B>U#"QIQM*1\#ZEI]WI-]+9
M7UM-8743;);>XB\IE_WEJJ^?QK](_P!HKX&:9\8/!\]W9PHOB2TMFDL+M%^>
M7(SY3_WE;_QWK7YN2;HY/FKT:-;VD;'F8BE*B[HCY^M/I80K20F<R>2' DVD
M;@OJGO\ 6O4=/\!_#W4O NJ>*O[;\70VUC<1VLL)@MFF+-_=.,;:VE)1W,(Q
MYCROIC%+79:KX*TL?#U_%>F7>H21-K!L(K>YMEW[0F[<VP8J-O VFVGPZT;Q
M7?W=]$EYJTMC-9QPCS%15#%H]PQSGOZ5FZL$KLT]G+H<7C'J#1[UZ[XE^"=A
M#\3=#\(>&-5O[Z]O+>.[ENM4BC6&*%E+9^4?P*"3FHM(^%_@GQ?K]WX:\+>+
MM5N/$<,;_8GU"TB6TOI(P6<(RC<N<<9I*<7J@]C(\G&,4=!6IX=\*:MXK\16
MVAZ9: ZQ=R-#'9L<%77._GZ@UU]U^SWX^MXVF.G6!@C9HIYX=3B>*T9>HE8<
M1_C5>TC\0>SE.7*><+\O48H[UU&J?#7Q3H_BBST"XTEO[9OO+>V@LI!-',K+
ME'1A\K)MSENE6]6^#OB;1Q9O=0Z;+:7-X+$W5IJ"3Q0S-QY<KJ<19]3WH]I$
M?LY'%M[=:3GM7J7CCX ZWX:\8:;H6D7$.O7%];130-]JB649B5G\Q1]T+G&[
MN #65;_"G5=%\1>&5UF"WET35+Y;9-1TN_6X@D;=\T>Y?N-[5'M(A[.1P.!3
M=OM7J?Q%^ OB+PSKOBN;3+"V;0=)E:3[-#?K)<VUN3\K/%G.,=2W2L;0_@GX
MR\3:7:7^GZ=;&VO(VDL[>YOHXKF95ZM$AY<'_9JO:1#V<CA:;@^G->CZ;X!T
MZ3X+ZUXCNK6:/7++7+?3HT\UD558,71AGK\M=!IO[/>J>)M:\86TMK:^#Y]#
MT_[4FFR:JLI+<'YF?D*0<[N@Z5,JD.I<:<F>+N"?K28Z5VWA[X.>+?%6FQWM
MG:Z<MG<7!M[>2ZU%+8W<B<NL&\YD[?=X-86E^#=<UKQ6OARVLF_MXR&W^QW3
M!/F'52#T.*M2C/0)0E%7,2C&.:WT^'WB"3PIK'B(::QT;2+C[+>W)D!,,G/[
MO;WZ?@:U(O@UXMN;PV;V-M9_Z$FHB6]NXX(HX'&09'.-I/'!K-2B[BE&4;'$
ML#GUIO/I787'PE\5V_BO3_#KZ4LVJZF@FM%M94E@N%V_ZU)!\I4=S[5!XL^&
MNO\ @FPLKW5K6U;3KS=%#=:?>)>1/(#RI=>C#T-/FB/V<CEN=M-Q3\=J/6J,
M[C**5NE,H*#]:.:4=:4T 0,#N'85[A^Q/_R<YX,_[?/_ $BGKQ-NAKVO]B3_
M ).>\&#_ *_/_2*XK*KI2D;4?XL3]7:***\ ^D"J>C_\@FQ_ZX)_Z"*N52T?
M_D$6'_7"/_T$4 7:*** "BBB@!BMNK.UK/DIMZ[J\H^('QS_ +!U_P#X1_1(
MK6\U-.;IKN27$/\ =54C1F;_ 'OE7_:W<5Y_K7QU\9:W]D72[C2K>V\]HI;B
M*VE5]W]U?,^5F_V$W-M^:O+J9C0I2Y9&WU>I..AT_P .]MQ\<OBU.Q_>QMI5
MDKC^[]E\W_T*5J[[Q->-I?AK6KJ!U26.TE97=OX]ORU\Y_#?XLQ>&?CQKUMX
MJO;>%_$NGVDL%["W^C^?!YL3)N_A^1U^\D>W;\RK7<>&?#MI\6/&VNZGK\DE
MYI^G7+P6EFLO[K;YLL2-_>7Y8U;Y=FYI6W?PUT4\5&<.6G\4CNS"C*-2,I?#
MRQ_])B> >+/*62-+9]]I%%$L&S[FW9\M<E)-MKWCXI_"]O#<ER\-NQT7=NMK
MY/NQ*W_+*7^[L_A9_EV[?FW?>\CF\$76WSI"J6GWO.=UV_\ ?5?BN)PE3!5Y
M4Z\=3]ORK,\-BL)&49')3>;>,\,?SM)6SH/@<>9$MS!)=W[1>:MC$R;]G]]M
MWW5KK=#T$;8ETR-;R5F_X_9E_P!'B3^^G_/7_@/R_P"U7H?AWPSY;_9+.*29
MY&W3RLVYY6_OM_E:_3N$98W"^UDH\L)'Y;QI7P&92I1C/FE$\NF\,S:7\0/A
M_/*T+W;2WD7V>W3Y(O\ 17;Y7^\W^]_XZM?6GPW\+OIEO]LGBV2R_=WUYI9^
M%[.^_:&\+:5&OG/X=TJZU#4'^_Y4LX6.W5O]K8)6KU;XE>-5\&^'_P#1WC_M
M2Y_=V:,NY%_O2O\ [*__ !*_Q5]="7/*<O[Q\IBJ?+3H4H?R_P#MTCQ;]I3Q
M1)<>)KJW27]UI\"VL:;O^6LJI*S_ /?+1+_P!J^<)MS-N:NN\9:HNI7C+%))
M+\WFR2RMO:5OXF9F_BKEYD5/X:^VP-/DI'F5JGLHE"4=:HRQLS)%6I<#;\W2
MI/#VG/J>JQ1*N_Y_X%KUOL\Q\9BJTJLN6)WO@;PO%>1BPGC_ -$>V6XG7;_K
M]SRKL;_9_=?-_>_W=V[ZE^$^@R6<+7<L>S=]W;7B_P /4@7QU-8RQLDNY;*!
MG7Y)_+WL^W_:65I5_P" 5]5V<*QVL2JNQ%7.TU\-B:G-4D?58>G[*G").,T-
MZXI!^M+_ -L\5SG1]LZ+3_\ CQB^E6:K:?\ \>,7^[5FO.ZG<%%%% !1110
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M&U9[F43NBWMTL:R!MP>-!*%C.2>4"_E766?A'1["ZU6X@L%2?5%1+U_,=OM
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M$;DNE:&Z=0LJ2,!\O0C Z>M8_@FUL-!^#NK^.-1O]:N]9NC<VIN%O2'*^=M
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MR)=O_CU>25:T75[O0=5L]4L)&M[RSF6>"5?X65]Z5V2CSQY#SZ<N649'ZO\
MC3_A'H_#=[<>*$M;G1X<O*MX@,0P>"0>&/H:^;M>DU/]J+Q)HEIIE@-#^'6@
MS9&HWQ53>GCA ?3':NNT/QMX/_:V^'/_  CUUJ,FE:JZAKW3HY@LRLO4H?XH
M_P#:K)/["?A"..)8?$/B)/+D69HTNRJ-SGIT(KP(_NW[Q]/+]Y'W3Z0T^W2U
MLX((PPBB0(HD.3@# _E7Y)^+;B"Y\6:U/:,KVLM].T#)]S:TK[*^VOVAOVB-
M*^&_@V;P?X;U)=2\1/;FS::-]XLHP,,SO_STQ_#7P9ST->EA*<HMS/)QDXR2
MA$8?KTKTKP_J5E'^S[XPLI+F!+V35+1TM6D4.ZC=D@9Z5YLPIK-CD%5;U;H:
M[I1YMSS8R:V/6M$\>:AX1^ JQ:)KG]GZJWB!I)8K>6/S&B$?<,#QGT%3>*/$
ME_X_^"/A6RO-<BU7Q VMSJ$N[F*-U0J-H).U5&<\MBO)FTVY@M8KPPW$<,Q9
M$G:,".4@X.&Z$BJTL9;*(O.W;Y;<*#ZD^M8RI1G'E-XU97U/I+QMJ^G>%?CY
MH>KZIJ-B^@76CII4U[8WD4WEN\)BD.V-B1M+=3C-8/P_\!P_"GXA#Q9K?B71
M)?#VBM)<6\]EJ$4LM\"I$8CA1BP/3.X"O"8?+\US"-@< 8C (R!SG/K1#&NY
M1^[!VXVI@[1GMFIC3Y5RENMRNYZ5\"]:MO\ A?>@:K>RI8PW&H37C/,VU(U=
M9"-S=NOZU=TK5+2/X9?&2S;4HXY+[4X)(X!<#=<8=LD#/(KRB95?,;KP3G:I
M[]@::S+R^3U =@O(/8>]5[*+7+<RC4E&^FY](>$?'VC:'XD^%TU]J%K;Q?\
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M-]_UQ?\ ]!-3,.?<5#K7_('OO^N$G_H)J9N3ZYJD XYSS_?J6HT[_P"\:DI
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M(!V[T#\,4E+^- !C\J*/2CZ4  '/2KVD_P#+0YSS5'MSUJ]I'27ZT :-%%%
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M^C"]*2U1V.H_#SP#J'B3QQX5\/V&M6NN:#:SW-C=7E^LT<_E,I=6CV#:=F_
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MU!XRT'X:VFIZ[X<TN;7+76+&86MCJ=Y.LD%_,&VLIA"@QCKSDU@Z?\3KG1O
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M%I;VJ<9V32*////W0*S;_P"/4^IGQTD^BQ+#XCTR#2K:..;$>GPQ<(H4@[\
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M/IT>G/=S2::I)2S:3]U&PZL@[%JKM2T<J6PM;WN;L/Q"\6V-M;6L'BC6(K>
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M_D?_ (+[;_XBC^S;S_G^C^]_T#X/_B:],_X9#\$_\^Z?]^__ +*@?LA^"O\
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M$ #+=,=Z $STI.Q(YI>A(Z?6G=^ : &'C^'BE^IS3OYTFWM0 W^(4=:*7^=
M!_P*CUI,"G9 H 2CU[48W<>E*W^<4 )1^E+C.<#(')Q2>] "<+BE-%%  :"/
M2E"G;D*0.YQ29H .*./2CUSTH4%F  R3^- !^)-%'X\T9_2@ HZ]*&[CO1P:
M #M[4<Y-!P.GX4GX<T +Q_C1VI%_WJ7- "?I2]^*/7^M'K0 <'&:,&CCZ4=\
M&@ [5>TD?ZWZU1]JT-*^[)ZY']: +]%%% !1110 4444 >'?MG_\FX^+.?\
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M% !1110 4444 >)_M,>"7\0> Y=;L5VZ_P"%Y5UK3)-VW]Y#\S1M_LNFY?\
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M7:_'[Q!=:-IGB/\ X01H/"CSK87LMQ=XNK>9I F1%_$@8@Y]*ZO0O ^J:?\
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M31]2U_5)K?0]26RL;U$$U\5<';'N;J20/F-6UHF)79[R ^[!CR.67<NU6')
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MAF:&(?O7C0D(?]HX^7\:6"*XU"0Q6L4US<OUCMXS(Q7I]P#..U>\:/#X0@^
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M_2.>EA/]X@=N=_\ (LQ'^&7_ *2?J51117WA_+84444 %%%% %+6/^03??\
M7%__ $$U*WWOI_A4>L?\@F]_ZXO_ .@FI&/S&J0!'DMGK\U6*KQ_-)S5BD3$
MRK[_ (^G[<"JOTJS??\ 'VWT_I584B@H_A7'6EZ4G/% PHR1VHYI/^ \4"%Z
M8[T=\=:0FEH K7UC;ZII5WI\X8072/'+SR5;@X_.N>C^&NA1^!8O",MJUWHD
M<?EK#*V67#;T8-_?5N0?:NK'S': 2>F *SK'Q%I&J:A<V-EJVGWM_:G%Q:VU
MU')+#R!\Z*Q*]1U]:770>MT<EX9^#.B^&;ZXO)-2UKQ!--;M:"36[]KAK>%A
M@I$,#:#Z4SPW\$-#\.^(K75$U37;Z.S.ZRT[4-0,]E9-C&Z&,@;3CW/Z5UT?
MB31[C6'TF+5]/EU5,[]/2[C:X7'7,8;</RI-4\3:+H; :EK.FZ<6.T+>7D41
M)/089A3%\+/%O G[-\-YHLP\376NZ8DNIW,]SH=KJ&VROXVEW*T\(^\2/1AC
M%>C>+OA+HWC*:TN1>:IX>U*" 6B7VA77V2809SY3, <IZ^M=9?:C::;8O?7E
MY;V=DB[VNKB=8X@IZ,7)"X]\T66K6&H:6NH6M_:W5@R[Q>P3H\)4=3Y@.W ^
MM+[-QOR.3A^$'AN/1='TU8KJ.'2[T7\#+-B5YAQOE?'S$]ZUK[P/I&I>(M2U
M6Y@EN+F_M!97,<DI\AXL'*@#!!Y]:T=)U_2M>LWNM,U2QU*TC8H\]G=1S1HP
MZAF5B ?K18:]I>K3R06.J6-]/%_K([6ZCE=/<A22*N*ON!QWA7X)Z'X6UJ'4
MDU'7=5^SJRV-GJU^;BWT]2,%84P-O'')/%4%_9W\+PZTUY%>:X-,-Q]K7PY_
M:+?V4)LD[Q#C(.><AOPKO[[Q%I&F:E:Z?>ZMI]EJ%U_J+2XNXXYIO]U&8,WX
M"EUCQ!I7AN)'UC5;'28Y#M1[^YC@#'T&\C-0!Q?B;X'Z!XFUJ>_?4M>TQ+L
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M/^(K#7CKWB;5=7M(VA>[U/4C</<PDG$4A*C* DX&.];W@+X>V/P\_M)=.O\
M5;NVO;EKG[)?W?F0V['^&)<?*OM74TN?YTNC1%M4S@_&/P9T7Q=K#:H;_6=!
MU.6-8;N\T&^-L;R)>D<W!W+^%.U#X/:#>6OAV&WDU'1_^$?G^T6+:7=F-AG&
MY9&(.\-_$.]=UU_PH(XHZ6'UN<-+\%_#$FGFQ:*[-N-7775 GY^UJV0<X^[S
MT_6NA3PK9CQ>WB8M*VK/:?8"V_$?E;MP^3''US6P,T+[4P.)E^$F@W&A'2'%
MT+-M1&K#]]\PN-P;!X^[D"M*Q\ Z5I]]XCO(4F$_B M]OS*<-N79A>.,"NC_
M )4M*W]?UZ <#X@^">AZWH^AV$-]K&BS:)E;#4M&O?LUY&A^^GF8/#<@C'(X
MJI8? /PWI>C^(])@N]:>QUY5%XLE[G:Z@?OD./ED. 2>03GBO2>W%'>J X#5
M/@OHVK^&=*TRYU/7S>:4/]!UY-1*ZI!D;3B;;SD<=*DT_P""OABU\)WOANY2
M\U6SU!_.N[_4+AIKN>7.0[/Q\P/.0/PKNQVH_P *FP'G/ACX&Z/X8\36'B Z
MQX@UO6+..:WBNM:U$SL(I"I(/RC(&P8KJ7\'Z<_C2#Q:Z2MK<-HUFK9^38?4
M>M;IZ4=.<4WJ.YY]XL^"&@^+-8NM4.HZWHEU=A%OCHMX;<:BJ# 6<8((P O&
M.!6S!\-]#L]:T+5+6V>TN-%MVM+&..4^7'&X^8'.2?\ $UU%!''6@1S,?P^T
MB*P\3VH2X$?B.2:6^428),BE6VM_#P3^=8FN?!'0M:L_#\=OJ.NZ#=:);1V=
MK?Z1J)M[GR%51Y3/M.5PHSQS7H/K12>H[GFVF_L_^%=)L3I\$^J_8!J<>L16
M\EWOCCN4).\9'\1))^M=+IO@+2M+NO$5W;+.D_B @WVZ7(X4I\O'7!KI.<4?
MJ*;U7*%];G'V?PIT*U;PJP^U!O#)<:?NE!&&!!W\?,<$T6_PKT.R\)ZAX;@6
MY&EWT[SS%ILR;BX?@XZ945V5-/!/:DU<#YT^,GPZUS5O'D%VF@^*M3TV*VCM
M[*Y\):G#;NBHO_+?S5.6SC!7%>I?!_3?$VF^$UB\37%Y--YK&UBU283WL4).
M56>4<._N.*[GHWI2=>,TUHK '&XTO7GO2?6E]>X_6@09J]I/_+3C^[5'T]:O
M:3C$GKF@#1HHHH **** "BBB@#P[]M#/_#./BS_MT_\ 2R"OS#:OT\_;0_Y-
MQ\5_]NG_ *605^8/Z5[&!_AL\#,/C0OXT/3Z97I'G">H-=EJW'P=\,?]A_5?
M_1&G5QQ^X>:Z_5/^2.>&/^P[JO\ Z(TZL:GQ0-(_#,XJD_E3Q36Q5D;@Z[=K
MIR^X,5/1E!Z5]*:?\</ LWC'PCXLO/$'B.R.BV"VLOANSA86RN%*[E(<*1SG
M!4\]Z^:>J@=O>@L&Y=LXXRW&/IZU-2"G%79<)>S=T>J^*OB%X<G^%OB7PWI=
MS=7-SJ&O_P!IV\]W:>2IA*X._P"8_-G\ZVM+^-^A:/XB\'S-!>7NF0:!)H>J
MP,@B<K([%S&><X!4]J\/W;,N&#!^"&XW?C3!MC9E7Y@3EEYYX]?P'Y5"IP2L
M:>UD^A[ ?%'P_P#"?PJ\9^&/#VL:OJ>K:XR+:O>::+:&-%;=M8;WR0.-Q//H
M*P/@MXZTCP'X@UF[UG[0;6ZTNXM(S%%R)64 #KTS7GN\(2KLL8<#YA\P08Z$
M_P!*-H*@XYZE6)^<<DL/3MQ40IPBFF5*<W)-'IGA/Q=X:OOA1J/@GQ9?W^D-
M_:*ZC8ZA868N<MA@T;1EEQP1SD_2N\7XX>#;'XR>%->T_P#M*7P_I6@R:7NE
MM@)VE*,-Q7=]W)_^M7SJRI,P7(D?;D G:2N<YX^E(H$F_:-RD[MI'4>F?6FX
M1Z,.=\KDT>B>#_'VF>'? /CW2YO.?4=8N(+FQ\N/='\DLCX<Y&#RO^-=1XB\
M8_"SQ_K5KXKUU]675A9+#?: EIF"XN%38K?:-V5!X.-I^M>(EA(54;=N?EC)
MQL;Z]33F8;F9\/G D;H<XH<(MWN5&<XQL>FZ-XR\+7/P1USPGJ-]>:%?2:M_
M:-F(;;[5%@+M$6[*[1VS@UVDWQ\\*W/BK3TN[.[FT&Z\,1Z!J7[O$T#C!#IS
MAAE01FOGLL=H"LF1P,-R%^G>K\F@7W_"._VP$CDTIIA'E;A/.,@&03%G?CCT
MQFB<(R2$JDHZ]STN;QQX1\&^ 7\->$+_ %/7IM1U*"YOM0U"S%N4BB;*IY>X
M[L<_-D?2M:X^,WAN3]I"]\;*]XVA2120QDQ#<Q-L\?*_[QZY]*\/>168HY)=
M>6(/<\XXIK-^["$A4!R!^()_E^E3[..XU4D;7A/Q,WA3QWI/B& %WL]02YVL
MAW%0V[;C/IZU[]-^T?X+;XQ1W4D&I'X:C35LGLU@&_SA)YV_&?[X%?,SR<,P
M8*V2_(P#Q@=:U-8\(:QX9TW3-2O[)K>RU:(W%C<%P?.B'#'\ZJK!2DK,(SG9
MR/3?"OQHTK_A+O'O_"2/J5MHGBAF)N].D87%H X:(@*5)Y !4$<$\UC>)O$7
M@G3;7PY;Z-JOB'Q)=6%^EW?ZMJ32+E0P(1(6D8# [Y->:J!M [4H X'X4O9H
M?M6>U7WQPTRW_:2U'QO:6MQ<:)>.\3QL3%/Y;QE6=2#P0"2/<"L7Q?X@\ P^
M&]6ATGQ%XO\ $^LZA*&M4U-Y+>"RA#;B&4R/YA]^..U>6LH;)/? -'8^YR?K
MZT>SC8(UI*XQ>F:*=^%,[UHMK&*OU(V]*9CY:<WWC3*10'A:&]Z6BD6,S3OX
MJ*;[4@%_BKW/]A__ ).@\&?]OG_I%<5X;_%7N/[$7_)T'@K_ +?/_2.>E4_A
M2+H_Q(GZQ4445X!]"%4M%_Y ]A_UPC_]!%7:I:/_ ,@FP_ZX)_Z"* +M%%%
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MES1)J4IT9<M1$M%%%>F8E/6/^03??]<'_P#035H9]!^=5-9_Y ]]_P!<)/\
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MV/ZBO?-5\'Z#KUK9VNI:+87]M92++:PW%NKI XX#("."/:HQX*\/?VG>W_\
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M!]"%4]'_ .039?\ 7!/_ $$5<JEHY_XE-A_UP3_T$4 7:*** "BBB@ HHHH
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M_BQ/UAHHHKP3Z$*IZ1_R";'_ *X)_P"@BKE4](_Y!-E_UP3_ -!% %RBBB@
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MK0 >M&WV_6C\*=^M #?848Q[>E+SMYI* #IZ@U>TD?ZP_P!:HX[5H:5TE^M
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M:EW=@@5>I). ![DGBNFG^$/CZUCDEE\%:U!'&OFLTT 7:G]XG./TK'\-,?\
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M]<$_]!%7*I:/_P @FP_ZX)_Z"* +M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ,!4KFF[C_"*<<XKFO$_BZR\+K&;KS'D?A8XADFN/$8BC
MA:7M:\N6)<8RJ2Y8E6T\727IN+Q;*3^Q[>>Z@EOA(-R/ S+*WE]?+#1,O\3;
MOX-OS54N/'[Z;I5I?WND7$,%\UM%9K'(LK2R3OM2)O[K_P![^'_:KB5\7:2M
M^)$AU!K-+F6\73VDC^SF63=O;[FYOO2-M9MNYO\ =K.GU+1;S3H;2[75KJ&W
M6!;4O<1*UHT$BR1.NU?O;U3[^[[G^]N^6_UPR+_G_P#^E'I_V7C?^?1ZK-XG
MOX;ZTTLZ1_Q-[H2R1K]H3R#%'Y6^7S/O;?WJI]W=N_AV_-5*^^(3:;J^DV$V
ME7<;W1B^UMOC_P! \UF2#S?F_P"6DBL@V[NE<"/$VG_:H;X2ZQ_:D<DDGV\S
MP;V5E16CV[?+V_NHOEVK]S=]ZJ;7/AF;3]1@N=.O+NZO5^:^N&B>Z@;;MW1-
MM^5]W[S_ 'F:I_UPR/\ Y_\ _I0?V7C?^?1ZOHOCJSUGQ-J.CHC0S6ZL\,C$
M?Z2B/Y4K+_USD^1OJM=1,,KPN?QKQSPBWA0:EH0MK>6PU+3V=$NG55ENPR%7
M\]E'S[FPW^\JUZ^L<B_=/%?28+,,-F%/VN%GS1//JT:E"7+5C8% C0,!QZ=:
M@NKB"&-'E=8P[;5W-CYFKGM:^(NDZ3JDEE<"4R1CYGQPM<==+'KWCNYUBXT]
MO%NC-I<=C9V\'ELMK([OY^Z.5UVF5&B^;^[%M_WHIYE@JM:6'A5CSQ^R5*C4
MC'GE'W3V2BO)_#NO:KI'ABVU274K1M!L&:V:WO5=[O[- YB>667?\TWR^8R^
M7_L?>^:NQT/Q7%J]R]DUM>V&H&/SU@OXC&TL6XKN7]/]I=R[J]8YSIZ*** "
MBBB@ HHHH IZQ_R";W_K@_\ Z":LQ[MOS'FJVL?\@F^_ZX/_ .@FK= "T444
M 9-]_P ?3_A_*JWJ:L7O-Y)]!_*JX_"@ /YUG^(-%MO$>D7FFW2"2WNHWB;;
M5_K1[547*,N:(2CS1Y3XNU[1?$_PKU2X@$EUIZ2R%8[FU;RUG0' .5SR1SCJ
M/2M6U^.&N6O@J[T"26[GO)W8?VA+=;G /4!OI7UI?6=MJ5NUM=PQW=O+]Z*5
M=RM6'#\./"]G<+-#H&GI*OW7^S+7T,<VI587K4_>/ 66U*+O1F?/_P $?A1=
M:]K5GKE^CKI=L1+&TBY:=_X<'NN>_O7U)VH4+&-JKA:7MQTKR<9BI8RIS2/5
MPV'6&C:(YNC'@;1G.0,?C4;6\?G"4P0O.JY#21*)&/KN8<_@:J:_-';>']3N
M)81<QPV[RF+."^%)QGM7C.D?&*\M_#G@/3?"7@NW>7Q%!<3PV4ET4BMBCL#N
M<GG)&:X(VO8ZG=)7/<6C2165U1@W5&0%>>HP1C]*%1(XQ&D<:1@8V(@"X],
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MH5CW'N!DXK+169\*"Q)P% R23T KJ=<^$OC7PUHK:MJ?AF_LK!=F9Y4X0/\
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MBBBO!/H0JEH__()L/^N"?^@BKM4]'_Y!-C_UP3_T$4 7**** "BBB@ HHHH
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M\\P*92R=O6D/L*!B^],?/U^E'I4=04=5\*=0T_2?B?X7O-6=8],AOHS<,RY
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M4=.*7^='WL4P$5>"/SYI5XV]BO HZ4>G]: %4!"S#@MUII565A_">HI1VHH
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M>_\ 0<\4?^!%K_\ &*^J]M&/>E[:H'U>E_*?*G_#NGX>_P#0>\3_ /@1;?\
MQBC_ (=T_#O_ *#_ (H'_;Q;?_&*^JZ6G[:K_,'U>E_*?*?_  [G^'?_ $'_
M !1_X$6W_P 8I/\ AW-\._\ H/\ BC_P(MO_ (Q7U92T>VJ_S#]A2_E/E/\
MX=R_#K_H/^*#_P!O%M_\CTW_ (=Q_#G_ *#_ (I_\"+;_P",5]68/K^E'/\
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M?WOTH]I/N+V-/^4^3O\ AVW\-3_S,'BC_P ";7_Y'IW_  [;^&__ $,'BO\
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M^^8__B*/L,W_ $$+G_OF+_XBKE% %/[#-_T$+C_OF+_XBC[#-_T$+C_OF/\
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M +-C[LU']FQ_WF_.KE% %/\ LV/^\U']FQ_WF_.KE% %3^S8_P"\U)_9L?\
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img118615358_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &S 6X# 2(  A$! Q$!_\0
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M!!!Z$4M !114<D\4./-E1,]-S 9H DHJ-)X9,>7*C9SC:P.<4HEC8@"1"22
M PY(ZT /HIHD1G9 ZEUZJ#R*=0 4444 %%%% !1110 4444 %%%% !0:*#0
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MYE4YP#P<\GK3:U?D)/1,]DU2_L=3\,W%S97D%Q;$8\V&0.O!YY'%>1^(]?\
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M8V\^5MJE<G.  6YI(/&'B_3KN&TU.#2;^XU'3Y;NP2R9EVNB[@CECT.<9]:
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M,*]5^/2.=)T>15R$G<GVX%>;C=<;3+A\#/'589Y'7I6[I>"@._D<*/2L!<,
MP[\BK^F726\Y,G(KW9KFCH8Q>I?N[UQ*%5"%SU]:F59Y[=608C;)7':I)9X7
M1#@'G(]J+B_7[$ZJ51AP"O6N1IM))&ICWL*QMU4@\9%;_P )>/B;!SUMWS^5
M<W-)YC%MV?7/>NL^#EE+<^.S?H#Y,,;*2?<8%9Y@^7"M2[,4/B/34:/^W-74
M@EO/ ''3BKZJ&!)8<^E95Q*8/%%SO;Y9F*C(Z$=*UE(PJL,?2OC;:7.L=M;J
MIP>PJ)F</SG\*G+I&IR>!WIH>.1,@YSW%(=Q&0$ DXQ5:Y>..)U;)!4Y..!5
MDGHHYQ6;K5S]GT]D"Y>8^6H'OWIQ0BS89/PUG&<G9(!^?%.L%5-/ME3[HB7\
M\5<TZW6'P68B?DYQ],BLW3&,<3VA;YH&V\]QV-(:-%.!TI3Q2*XX%.8 \YJ1
MC1UJ*681-\RDKZBINAIC$#D]!UI@4-04R7>F[?O"Z4_AWKNJX=)EEU>"12#'
M PR?]IC@?I7<4A,****!!0:*#0 4444 %%%% !1110!SWB;0I]3O-%U&R,8O
M-,O!*N\X#1L-LB_7:?TKG-$^&%@-1OK_ %RU2:X;4Y;N$),VQE)RF]>A(KT2
MBA: ]=#*M?#FF6B:FBP;X]3E::Z20[@[,,'CTP*R]*^'?AC1_M7V;3]_VF(P
M,)Y&DVQ'_EFN3\J^PKJ:* .;TSP+H6EFY:.":9IX3;,US.TI6$_\LU)/"^U5
M%^&GAM+6RMUAN@EFCQH1=.&:-NL;$')7VKKZ* .9@\!Z%;+H_EPS!M(!6U;S
MCD*3DJW]Y?8TRP\!Z'H6H3ZKI-D5O=CF"-YF,4;-R=JDX7)ZXKJ:* .-L_#W
M]@_#LZ9=%9IR&DN6'1I'?<Q_,_I7D7BG06R&0?,O^J;^\/[IKWW7HVET:X16
MC5B!@R-M4<CJ:XV70C=0&.6:S<-U'G+73A<3*A4YD3**DCP105?9("&4X93Q
MBM2TB0EGC/..A-=_J'@"*X=E6\L'XXS<*&7\<UB77@'4+1 ;76-,<G[RS7*#
M ^N:^IIYI2J17-H<WLFF<]<+)O53(,XS@'K6->W05C&.7)Z#GFNO/PYU^]D#
M'4],V'J8[I#C]:Z_PW\-=(TJ5)KF\M+J['.&F4@&IK9G1I0]W5@J3;U,OX8>
M$I;*XBUG4$Q)(X\E&'(YZUZ=XZTFWUK1A97 &'SM/]TXZU L#QSP;+BT!$J@
MKYPZ9Z#WK6\0123?94C>)3N;(D<+GCMZU\O6Q-2I5]KU.J,4M#Y=U/3+OP[J
M$EG?(53.5<#@CV]JB7) =&!!YR*^@]9\+V6L61BU(VC*!PYE *^^:\PU#X<I
M:W).E>(=-*>CW<8_K7T.!S5.*C,YYTM;HY--[$ ,<GM5IX));4-N/'7/2MB/
MP9K"$YUC0\$8S]LC_P :M6'@&2<XU3Q)IBQ9^XEVF#^1KLJ9A2C=H4:;ZG%V
MUO<ZO>K86"-)(YP2O05] ?#_ $"+P]'#:J 9BI:5O4U!X>\+Z1I=OC2I[&5O
MXI5F5C71:9;RQ:Q'F6W9=A)59 6_*OG<PQ\L0^5:(WA!1,W7['[9+<%%_>!N
MW'3O56QU%(5%O>MMG[,>C_\ UZVI$66[N2;ZUXD(QN.5]C5"_M=+<!;O4+)'
MZ#+UY\6VK&A:&22I0,C#\Z>(PHV@ #MBN?$NGV!*IXILH@.BM+N'Y&D?4[2=
M=K>+=-'^XVTT[2["T->\NX+%-\S[<_PC[Q^@K+M4GU&Y^UW:; O$:?W1_C3H
M8M#$WFR:W932$8#M+DG_  K7,,!A4Q7]H$Q\IWG%*5TM@T+[2!/"TS #:N0!
M[9KG79BR7-L<S(,;?^>J^GUK86-;_P &7,45_;.&++YZL=@.>YQ619:/<6Z8
MDU*Q8=L.?\*A#+=G=172G:V)!]Y&X(_"KJ>A'XUG26UD[J9M2L@X&-ZR$,/Q
MH\RWAXC\169'_34AC3>H&FRGL#6?=W>-T-OAYB.3GY4'J:;OLYE(D\0VTG'W
M$?8/TYI@M;>9?+BU*P"_W$<\_7CFEJ%RO9(JWD"HV461<L?XVSUKT2N!>Q2V
MNK9GU.R1?-4 %SECGH.*[ZD@84444Q!0:*#0 4444 %%%% !1110 4444 %%
M%% !117BNN>._$-KJ_B=HO%.DV*:5<%+?3[BW#27  !P#G//3I0![517G+^)
M?$WB;6;;1M#FM=(F338;^\FN(3*0TG2-5R,8YR35_5I_&6G^#DEN-2TNVO8'
M9KR^2W>11".A6/NQXXH>@+4W_%*>9X<NUQG(''XBO)-7U..P@=4(55&'<=_8
M5V5CK^H:]\(EU:]:$7DJ'<T/W2 ^ <?PDCDCM7DFN7*,-C-N4$@#/7WKTLOP
MZJSLS*I.R,F^UNZNF*P_N(O]GJ?J:S$&)=[G<>Y8YS3WX!(_"HCS@GK7UL*-
M."LD<O,V:$>H- 08E"$?W3BM[3-=6X8)<$[L\..H^M<D,TZ)S',KCMP:PK82
MG.-DK#C-H]CT6X%QJ5I%.5,HE1DD[.,C]:] \5O%#;0S2[0L98[CVXKQOPA=
M?:M0LH&/*3HR'/\ M#BNW^-%_+:Z'8V\3%?M,C*Q![ "OF*F%OB%374ZE/W;
MGF'BKQ7<ZS=-:VCF.S0XX_BKFEM$(SL!;OFIUCVC %3I"V,GI7T^'H4Z$%%'
M+*3D[E+[*A'W%_ 4R2T3'W /H*T1"">AJ.1-C8/2MUR,6HS2]4O= NUGMGP!
MU7L17O/P_P!7M=>E6]B51,(BKCNM>!.%/&.*[SX+2RQ>-Y[<,?*:U9BO;.17
MCYI@X.FZBW1M2F[V9W_B"_2PN;ILC>7.!_6N0^S7&IR&XF<I">A_B;Z>@K1U
ML-J/BJZ@?F..0E_IFK1V(H4# Q@8["O#A"VILV9::;9PEMMK'G^^XW&G&P@9
M#NAB/_ !6B(]_)[=*1E'3I6O,(Y^;1(Q\]J3$W]PGY6-2Z1K$EA<?9I]Q4-A
ME;^'_P"M6PT1V^Q[UC:Q9#RA=KS+']X?WEHLI+4#U"R,3>$9&B50A+' ''6N
M3OKUF80PY)/&!WK6T&9F^&TC[B<%L$^F:S-+@!C-RV-S_=SV%<35FT6AD&D*
M</<MO?KM!X'^-7?LMNBX$$8'^[5CO@"D<<4T#*<EC:3J5,*9]0,&LRZTZ6R_
M?0L7C'7^\M:A)CDQS@FK1 QGVZ4V(I:3=1WMQ!%,%9UD4@D>]>EUY0+?['KE
MKY?"/*I ';YAFO5ZB2*"BBBI *#10: "BBB@ HHHH **** "BL'Q)KTFDSZ3
M96L:27NI7:P1J_14 W.WX*/UK,_X6?X8&IFP>YN$D6Y:TDD:W;RXY < ,_09
M/3UH6H'8T5S$/CW0IM:O=*$EPLUB9/M4C0D10[!DEGZ#(Z>M,TKXB^&M6^U&
M&]>$6T1G8W,31;X1UD3(^9?<4 =57*:3X%L+'7=9U2\BM;V6_N_M,9EMU+0<
M8V@G-0R?$C1SH^I7T$5XTME;_:/LSV[+))&?NNH[H?6HK/XE:6_AG3=5NK>]
M6:]B:06L5LS2!5^^V/[@_O=Z/Z_K[@M<L:[X/O[G7_[>T#63I6HR0"WG+0"9
M)8P<C*GH0>],N?"GB"71K*./Q;<C5K:9I3=O I20-P4:/H5';TIC_$C36\4Z
M1I%K!<7$&HVWVA+N.)B@!.!SV'7)[5:L?'NBZUJ$^EZ7<LUYL?[-)+"RPSLO
M78Y&& /7% &3?Z O@_X9:G;BX:[GD=KB>9E"^9([@L0HX4>PKP:_F:2[8GH.
M!7OE_KJ^)OA1/J+1B*61/+FB_N2*^UA^8KP"\1H[QPW [5])D=M;_P!;'-7*
MI8YS^E,R<U(XS30M?0,Y[@#Q3PA-+&H9@#5HQ[1S2; V?"-U]G\1::"0JFZC
M'/?) KTGXW@&PT;/_/:3^0KR;1F'_"1:0I'_ "_0G_Q\5ZW\;?\ CPT?I_KI
M/Y"O#Q,4L=3?J;Q?[MGD<(&!QDU=C4,P]*H*2 #FKL)/!'6O6JIF<1HE5IGC
M$9&WOV-1SP@KGO5IY-PQQBJTL@VY+5E&]RF9SC#<UWGP=7_BO7/_ $YO_,5P
MTF"V:[CX.D_\)ZX_Z='_ )BHS&WU6?H33^-'3S\Z]J\NT9^TLN?84_.[ YR*
M;=%%U_58AG)G9J?&#WZU\PGH=0_&0!TII7&0.34@Z5&R9;=G%9ZCN1G !R3G
MTJ"=0]NZD9#*0:G= &S@U6O9!'9RR'C8I-:Q)-OPZY'PHFQV9U'TW8J>)-D*
M(!C:HQ1X5A+?#!E8#+,[8_X%FG1'?$K>HKEG\3+Z$BD>E(R[OI1TIDCD+Q0D
M UXP1@]J$R1UI8@2NXTB+AB>U-@5[I0;FQ;N+E.?QKTBO/S&LEY:(1DB96_6
MO0*SD-!1114C"@T4&@ HHHH **** "BBB@#B_&4#P>*O"&L$$V]M>R02X&=O
MFIM5O;D 9]ZXG2] U_Q'8>(='MOL,>E7&O2M//)N\Z,*X8[1C#9QP<C%>TLJ
MN,,H8>A&:1(TCSL15R<G QDT+3^O0'_7XG"1>!+B?1?%^F74T<*ZS<L\,L9W
M%5VJ%W?B.E4XO!GB/5KRWN-<_LB+^S["2SMHX4:1)RZ[2T@.,+@?=%>DT4 >
M7:!\.]6L!JD0F6QLKK3WM5LA=-<)YC#[ZE@"B_[/-1W/@KQ=?:%HNG3W44$-
MK9O:SQ6=VT66QA'+;<L,=4XKU6BC^OS_ ,P/--'\$Z]IB^&2?L;&ST^73KU?
M-/RJ[9WH<<GCH<56\)_#Z]\-:A9RZE%8-9Z2LC1W@N)6D<<X/ED[4XSG&<UZ
MI2$!E*L 0>"#WHN]PZ6/,]#T^5_A1?33*8FU*XEO%1OX%>3*C\L'\:\NUO3,
ML3C:P/6OH;Q.4C\-W9; 0*/;'(KRR_LHKI!\R[B.#ZUZ&!Q3H2TV,YQYD>6-
M;LAY!S2&$A22.E=3=Z68IB/EX_A)K U2=('$+%8SC/)'-?44,4JCT.64&BB.
M*>T[!<'\ZK&\@'_+13^(K1T?0-3\13!;9 L.>9"> *WJUJ=./--DJ+9=\'6$
M^K^+=.$2G;!<1NS=@ P->W?%71GUC081$/WT+,Z?D*QO"^AV7AF&VC21-YE0
M/*?XF)KN?$DJ(EM&S ,[,%![\5\GB\:YUU4CT.N,+1L?,:LR$JX(8'#*>H-3
MK.RKA:] \6>"1?2-?:<52;J\9Z/7F]TLEC.8KI?)<'&UB*^BPN,I8B.^IS3@
MXLL>:Q!X.3UJ)O?-0I=1%@!-'R>NZG3R1"3:LH<GHJFNMN,-62KL:S_*3V'>
MO2?@MI-PWB"?5G!6+R6C3(ZY(KG/#W@F\U9TGOL06@YVYY85[)X7^QV6I1Z?
M R*1"2L8ZX'>O"S7,(RBZ4-3>E3UNS \10-::[/=H/E9R&(J&*42!63E2,YS
MU]JZ/4(DN[JY0QNP\QE/RFN;GTJ]T^1I+9&="<[2IKQJ<UU-K$Y8<8ZTO\.2
M,U5BO3G$MI<*V.2L9(_E2O?Q#.+:Z/\ VQ;_  K2R$*9AOY-8NJ3-=SI:099
M<@N1W]JT)&O[T>7!:2Q ]RAW8_*M'2]!%BOFS(YEZ_=)Q2=110TCH-*M7L_
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M7G.L>*O -^S/=:-J2R9QF)T!-<CJ&J7WB#4F+DJK=6/(4>@I\<%O:/@1))R
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MF)9B%Y],#'X5Y.[/>ZE-?R[C&"5BXZ8KW7QY;QZ+\,-1M])M$CCMX%6&",8
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MCHV1!#$ID.] %(R*BO8E91Y;C<.6QZ5HEE&3G)QT[8K*=X9;MI(R#(  0!C
MYZUI3;;&4@KJZE7VE3U J/Q!:BXT\:A&NV>T(<8ZE?XA4LV[>-@)5NU2R3(^
MFW*M\Q$+ KZ<=ZUG'2X'3Z9*K_#:65#E2&/ZBL7P]"9+*2[9B'N22A(Y51P*
MM>''DD^#\A8?-Y;@ ?6K.GJJ:?;)'C:(QT^E<,UJ)%A%*H 23@<D]Z<%W'/2
MG#GK1W-2,AD7%-0Y'7ITITQP#GTJI;LY8Y'?BJ4= ,P0BQ\66R#Y8KME< =
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M/:M-- TZ%"IMO,XY,C%B:OE0]2[)I=[<*1-KEGM_NQ2!<_CUJ./PZ^QE@NK
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M@Q</<_$>XD94YLV'RC&,$5QNN:G:SVMK#:*<A,OE<$M_6O4_@KX<?3)6U"Z
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MWN:O:A;F[\77HD^:*&9I&'J>PJPD;S7!9\E ?D]17B4XI*[.DJO,50)!''"
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MZM]-A_K7I=><6+I-XRL4QCR#DD_WF'3\J]'K1D3W"BBBD0%!HH- !1110 A
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M[$'/X"O4*\TTSP]X@C\2Z?<SV/EVD,N6(E4[1@]LUZ731G/<****9(4&B@T
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MHQ6S10!SPT*_MK%+6TO8RC1LLRS1Y4ECDLH'?D\5&N@ZC!?0RQ75O+%;QK'
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img118615358_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? ;X# 2(  A$! Q$!_\0
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M4+/<7UV2(^@&"#P*1K"FY:O1%S11B*8>DF*TZR]$!$$P8Y(?DUJ4S)A1110
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M$/VB$OFW+RL>7+#!J:74;&"/S)KVWC3)&YY5 R#@\D]CQ]:+G4;&S*"ZO+>
MR<H)957=],GF@!OD33G_ $AP$_YYIW^IJTJA5"J  .@%!8!2Q/ &<UAW%[+.
MYPQ1.R@XI7-(4W/8W:*PK>^E@<;F+)W!.:W 0P!'0\T7"=-PW%HHHIF844$@
M#).!3%FC<X612?0&@+#Z*** "BBB@ JHW^CWJN/N3<-_O=JMUG7]Y;F!T#DL
MO(*C."*!J+>QHT51@U6VGC#!FZ<_*:G%[;'_ );+^/% FK;D]%,$T3=)$/\
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M4OCV2Q^W#^SKF^%JUY-,X:./RH8)BC8&?F/''<XYQ7<(XD177[K $4 <7=^
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M*,<GJ: $EACF7;(H(J&V9DD>W=MVS!4GN*L$@ DG %5K;,T\EQC"D;4]P.]
M!CRM0P/NRKDCW%6JJY\W4./NQ+@GW-6J "BBB@ HHHH **** "BBB@ HHHH
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M59L84EN,'D'KBMZN&_X5I:B2P/\ :=P8[/R\*\:-RDQE&TD?)DMAL=0!7<T
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MU8@MU@4\[G/WF/4T 5#(7M[:9SN"/\_\JT:KFRA:3?@\G)7/!/TJQ0 4444
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img118615358_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I E8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WMY-C8QFF
M^?\ [/ZTD_WQ]*BH F\__9_6CS_]G]:AHH F\_\ V?UH\_\ V?UJ&B@";S_]
MG]://_V?UJ&B@";S_P#9_6E$Q/1"?I4%>*?M$7MW96/AXVMU/ 6DG#>5(4SP
MG7'6@#W/S&_YYFCS&_YYFOA3^W=8_P"@K??^!#_XT?V[K'_05OO_  (?_&@#
M[K\QO^>9H\QO^>9KX4_MW6/^@K??^!#_ .-']NZQ_P!!6^_\"'_QH ^Z_,;_
M )YFCS&_YYFOA3^W=8_Z"M]_X$/_ (T?V[K'_05OO_ A_P#&@#[K\QO^>9H\
MQO\ GF:^%/[=UC_H*WW_ ($/_C1_;NL?]!6^_P# A_\ &@#[K\QO^>9H\QO^
M>9KX4_MW6/\ H*WW_@0_^-']NZQ_T%;[_P "'_QH ^Z_,;_GF:/,;_GF:^%/
M[=UC_H*WW_@0_P#C1_;NL?\ 05OO_ A_\: /NOS&_P">9I#,1U0BOA7^W=8_
MZ"M]_P"!#_XU]'_ *ZN+SP'>275Q+/(-1<!I7+$#RX^,F@#UKS_]G]://_V?
MUJ&B@";S_P#9_6CS_P#9_6H:* )O/_V?UH\__9_6H:* )O/_ -G]://_ -G]
M:AHH F\__9_6CS_]G]:AHH F\_\ V?UH\_\ V?UJ&B@";S_]G]://_V?UJ&B
M@";S_P#9_6CS_P#9_6H:* )O/_V?UH\__9_6H:* )O/_ -G]://_ -G]:AHH
M F\__9_6CS_]G]:AHH F\_\ V?UH\_\ V?UJ&B@";S_]G]://_V?UJ&B@";S
M_P#9_6CS_P#9_6H:* )O/_V?UH\__9_6H:* )O/_ -G]://_ -G]:AHH F\_
M_9_6CS_]G]:AHH F\_\ V?UH\_\ V?UJ&B@";S_]G]://_V?UJ&B@";S_P#9
M_6CS_P#9_6H:* )O/_V?UH\__9_6H:* )O/_ -G]://_ -G]:AHH F\__9_6
MCS_]G]:AHH F\_\ V?UH\_\ V?UJ&B@";S_]G]://_V?UJ&B@"TC;USC%%-A
M_P!7^-% #)_OCZ5YQXJ\<ZKH'B>XT^*VB>R\NT2.?86,4TLA&'Y^ZR*^#V('
MK7H\_P!\?2N/OO$UNGC;_A&SIEK+(\4,KS32@%P2Q "[#N*[2>2.O% &0OC7
M4SK>S[3I[1R:G<Z?_9@C/VB!(U<B9FW9(^0$C&,,,&L.T^(?BF;POJ5WMM/M
M\=E97%LD]L(RSSR!?E4.=\>#PW!SP16LOQ(TXZG82_V!$LU_;6KO,9%$NV=R
M@7.WY@N,G+#BK-MX[TN;Q!>:9+HL"QZ>+I'EC99'BCMSDLR;1M0E?EY/.* ,
MFU^*-_?:/K=]#%"K&:VAT>-HF8L9=P)<#)8#8[<#HM;^@>.TU;4-*2XEM;6"
MZTMIY5F8(RW*2B-T&X]CNXZU4E\<P:9I[WEWX8CM)EM(;^T19(SOB>18P2RK
M\C+Y@R,'AC@]:M:3XDTGQ#/IBR:!:F6[O;F .RI($>)=[."5!(;W />@#MZ*
MYV3QC9Q^.8_"YB8S/#O\_>,"4J7$6.NXH"V:R+/XASWVD:Q>Q:$4ETN+SY;6
M6["2",;BVY2N58;>F"#GAJ .YKPW]I'_ (\/#G_76X_E'7?:AX\N-*_L@7FB
M&/\ M",2%S=@1QAF "ARH4O@[L$KQT)-<%^TD,6/AT?]-;C^4= 'S[1110 4
M44HQ@YSGM0 E%.12[!%4LS<*!ZU)/;S6-X\%S$4FB;:\;CH1V-*ZO85UL0T]
M(I'5V1&94&6(&=HSC)IN,TZ,\D%RBD8.._M^=#'9O1#**DB1'+!W*G:2F%SN
M;L/;ZT,B^6A4N7.=P*\ ^Q[\47%<CHHHIC"OIK]GG_DG][_V$G_]%QU\RU]-
M?L\_\D_O?^PD_P#Z+CH ]9HHHH **** "B@ GI001U% !1110 4444 %%%+@
M^AH 2BBB@ HHHH ***,'TH **,&C!H ***,<9H **** "BBB@ HHHH ****
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M/<1>2S73K(#&3G;T&[)ZELDX&30!RZ^,_$5PDT4*:;%+;07L\DDJ;Q*(/+P
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M0.P':@!U%%% !1110!8A_P!7^-%$/^K_ !HH 9/]\?2HJEG^^/I45 !1110
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M738[>.-YV,L4JE6)E)7Y1SRI_#;BNCHHH **** "BBB@ HHHH **** +$/\
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MW=K8LRI";BV:-K@MT\I3RX]Q6LWB72!XDC\/B[5M3>%IS"O/EH #ES_"2#D
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MCL^\L")"BL$P3PQ8Y/6O2Z**9+MT"BBB@04444 %%%% %B'_ %?XT40_ZO\
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MV==3R0QB02!D56R0".58$$<GKT.#VK*N])LM/\9^%I((1]H\NXA>X;F214@
M&YNYX% '74444 %%%% !1110 4444 %%%% !1110 451U35K/1[99[V1D1FV
M+M7))^E7(W66-)$.Y'4,I]0>E #J*** "BBB@ HHIDLL<$3RS2)'$@+.[L J
M@=22>@H ?167_P )+H'_ $'M*_\  V/_ .*I?^$DT'_H.Z7_ .!D?_Q5.S T
MZY_7/$%[8ZK!I>EZ;%>WCVLEXXFN1 BQ(RJ<-@_,2W&< =S5T>)-!) &NZ62
M>WVR/_&LO6#X*\0B,:I?Z1<^2&"G[<JD*WWE)5@2IP,J>#BBS"Y7N?&L\.H7
M!72E;2[.\@L;JX-R/-664)C:@&&53(@)SSSCI5;2_B$VLZN^CVFFHFI+)=((
MYYBJLL1PC@A3\K?,,XX*D5=DA\"3ZM'J;76C&[B*,&%Z@7*#",4#;25' )&1
M4MN_@JSO;>\@OM'CN8%E$4HO4RHE8LX^]R"Q)YZ9.,468&#<?$J\L_#FDZO=
MZ790+J33% ]TY2-(U)RQ6,G)((Z8Z<U<N?']U%:S7D>A'[/8V5O>:DLUR$DA
M$H)"HN"&( ).2,].M:,;^"8K>R@2^T;R;)9$MT-ZA"+("'&"W(()'.:IOI_P
M[D%H'N=&86L:11 Z@"-B'**PW_.%/(#9Q19@=!HFL?VRNH,(/*%G?2VGWL[]
MF/F]LYZ5IUR]K)X*L=5GU.VU73(KN=V>5AJ8VLS?>)3?MR?7%:G_  DWA_\
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MSHK$+(!VR/PK7K*'B7P\H &NZ2 . !>1<?\ CU+_ ,)-X?\ ^@]I7_@;'_\
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MFMHY)8&@D906B9@Q0^A(R#^%24=1D<BB@ HHHH *P/'/_)/_ !'_ -@V?_T
MUOU@>.?^2?\ B/\ [!L__H!H ^+ :<,DX%-J1!@&NFC%S=N@F2(BXZ\THV>8
MH?.W/S$>GM0')5OE!Z#=Z4LC+Y2)L4,,G>IY;/8_2NZ=2*BHQ1G<L7JVGGR-
M9B18"?W8E(+;??'>F_9IX80WE!UG3()&2HSC/M4ERENDPGLXKA;9@ AE(R'
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M%$/^K_&BL1C)_OCZ5%4L_P!\?2HJ "BBB@ HHHH **** "OGW]I'_D)^'O\
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MFF?YI#GMZGFJVTA58D8/2N:E*S\Q17F#<YP,"HC4S'Y*A-&*25C1'U'^S_\
M\DW_ .XA+_Z"E?,E[_Q_W'_75OYFOIO]G_\ Y)O_ -Q"7_T%*^9;T?Z?<?\
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M_,<V\KYFC)^20CI6B+73X+V"8'S$9@^R,\(O=?K65(1D6D;JT44A(F  S_\
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MJ@#5FLK2Y<//:PRL!@,\88X_&H'T;2I0!)IEDX'(#VZG^8JC]J\5?] ?2/\
MP8O_ /&J/M7BK_H#Z1_X,7_^-4 6_P#A']$_Z VF_P#@)'_A1_PC^B?] ;3?
M_ 2/_"LO4-7\4:=IUQ>OH6G3+ A<QPW\C.V.P'E<FK/VKQ5_T!](_P#!B_\
M\:H T%TC3$4*FFV:J.@6!0!^E3P6UO; BW@BB#<D1H%S^59'VKQ5_P! ?2/_
M  8O_P#&J/M7BK_H#Z1_X,7_ /C5 &Y16']J\5?] ?2/_!B__P :IK7OBM>F
MA:8_^[J+<?G&*"H0<W9?BTOS-::PLKB0R36=O(YZL\0)_,BL[4/">@ZHL:WF
MEP.(R2NS,>,_[I&?QJ#^T/%?_0O:?_X,O_L*/[0\5_\ 0O:?_P"#+_["E<V^
MK3[Q_P# H_YE=OASX1==KZ+&R]<&:0C_ -"I?^%=^$_^@.O_ '_E_P#BJ2]U
MSQ186IN)/#=HZAD7;%?EFRS!1P$Z9//H,U8_M#Q7G_D7M/\ _!E_]A1</JT^
M\?\ P*/^9H6^A:3:V\<$.FVHCC4*H,88@?4\G\:N06\%LA2WACB4G)$:!03^
M%8?]H>*_^A>T_P#\&7_V%']H>*_^A>T__P &7_V%%P^K3[Q_\"C_ )G045@K
M>^*GSG0],3_>U%N?RC-.^U>*O^@/I'_@Q?\ ^-4S&<7!V?X._P"1N5@>.?\
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M82%=2"V2>E:8=7;'9LL6BVXT&:66^B\QIE46A4ER.[@]!Z53NW25]R#: ,
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M75=>CC:T1DC^S7T*@AB"<YSZ4 ?)5*BEW51C+' R<"OHK_A2_P ./^ADG_\
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M#55P/UK?VZOH-<USYN,[7<\?VF4A0 F['114[26]M<F.!RZ8QYF.OX5]$?\
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M9CZDGDU%7I0344I.[("O;/V</^0]KO\ UZ1_^AUXG7MG[.'_ "'==_Z](_\
MT.J ^CX?]7^-%$/^K_&B@!LH8N" >E<-??"/P5J5_<7UWH9DN;B1I97^T2C<
MS'). V!R:[^B@#SG_A2W@+_H '_P*F_^*H_X4MX"_P"@ ?\ P*F_^*KT:B@#
MSG_A2W@+_H '_P "IO\ XJC_ (4MX"_Z !_\"IO_ (JO1J* /.?^%+> O^@
M?_ J;_XJC_A2W@+_ * !_P# J;_XJO1J* /.?^%+> O^@ ?_  *F_P#BJ/\
MA2W@+_H '_P*F_\ BJ]&HH \Y_X4MX"_Z !_\"IO_BJ/^%+> O\ H '_ ,"I
MO_BJ]&HH \Y_X4MX"_Z !_\  J;_ .*H_P"%+> O^@ ?_ J;_P"*KT:B@#SG
M_A2W@+_H '_P*F_^*H_X4MX"_P"@ ?\ P*F_^*KT:B@#SG_A2W@+_H '_P "
MIO\ XJC_ (4MX"_Z !_\"IO_ (JO1J* /.?^%+> O^@ ?_ J;_XJC_A2W@+_
M * !_P# J;_XJO1J* /.?^%+> O^@ ?_  *F_P#BJ/\ A2W@+_H '_P*F_\
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M .!4W_Q5>C44 ><_\*6\!?\ 0 /_ (%3?_%4?\*6\!?]  _^!4W_ ,57HU%
M'G/_  I;P%_T #_X%3?_ !5'_"EO 7_0 /\ X%3?_%5Z-10!YS_PI;P%_P!
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*3D8YHI]% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img118615358_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K D<# 2(  A$! Q$!_\0
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M!2'BN5:4DG_=+>^1ZTOB'P;J>K>*M0UBVDV/!!:26$4C@V]Q/$TA*RIU(PP
M/;=D<BNOAUS37C@:6YAM9+EV6**>5%=R&V\#//([>U3IJFGR7ILDO[5KL9S
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M)(%9LG X]SP/4\4 >,76K>(VU/P,TVF:J-*M7L4@\H*4NW:'+NQ+9R.  1C
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MU2X:W\ME"M!((VD(D';A?QR#T- '"3>*M9U/0-:@N-8/FPQPSFXM(E\N)?M
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MV<3&,[89&FEE(7@D(/,4#O\ +4\_@?4KB'4=/+:6MM=/=2#4#&S78,RD8'
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MT#Q@,K;=W\7IQN.>E/7XAWURCW-II,'V3R[,1F:X*N9;H+L!PI 52W+9^@H
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M 3-%OVGR\'J<=/<5H#XEZ!-=64%D+R^-W!'<!K6 OY:.VU2PZ]000 2,<XH
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M48DF6(!W'NV,FK-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9M3CM96T^2,2*C20.<2AE9BZ9/W4QANO.>E=:T$,CI(\2,Z?=9E!(^AH%O"
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M1S"0W#Q"1C+,GRC8IRJA4YVKG S3];F\1'PCX935+6$[KS3S=323$3+)]H7
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M<HK/EUO38=333I+R-;MQD1G/Y$] ?8G/-0Y-ZL<8]$C0HHIDDT40S)*B?[S
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MN;A/\:U-J_W1^5<QXOUO2M*.FVVH122//<+-"L;HF#$RMDEB!U*\=\T :?\
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M4O\ GO:_]^6_^*HV:E_SWM?^_+?_ !5 %RBJ>S4O^>]K_P!^6_\ BJ-FI?\
M/>U_[\M_\50!<HJGLU+_ )[VO_?EO_BJ9&-59,O):(V3QY3'C/'\5 %^BJ>S
M4O\ GO:_]^6_^*HV:E_SWM?^_+?_ !5 %RBJ>S4O^>]K_P!^6_\ BJ-FI?\
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M<L((&NE+ A6$<N[=C86()0<!0O!.:]&HH !G SUHHHH **** "BBB@ HHHH
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MR,N"JLQRI[XYKUFB@"AHFG/I&AV6G27373VT*Q&9D"%\#&<#@5?HHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img118615358_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #7 1<# 2(  A$! Q$!_\0
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M6\4<B'S#;%H"-JI-L7+,V&+)AL\>U=>RJZE6 92,$$9!%"J$4*H 4#  ' %
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M[@;B@'7U]^F>*;)#*W[Z%7D92KIDX^GYCK5I\17!G#A<'!0=,YY!/XUH(A'
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=U.*6BB@ I 021W%%% "T444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img118615358_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 24# 2(  A$! Q$!_\0
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M=JC*C ^7('08'Y4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC*6JSM(#N<Q$[AC:<A@1U/\ ",T67<.:78Z^:Z@@DACED57G?9&IZLV"<#\
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MH7+*2%VES\I'3/:KFI&<>(6,XUDIB+[&+'=Y9.3OWX^3Z^9QC[O-:']M7_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!116$LUWXBT[4(TCDT]4N9;:&839:55&QG_=L"OS[QC.?DR"I(*@&[167H.F
MWNE:>+>^U.74)0(P)9!@_+$B$\DGYF1G.3U<CG&3J4 %%9FH^)-"T>X6WU/6
MM.L9V0.L=S=)$Q7)&0&(.,@\^QJG_P )UX1_Z&K0_P#P81?_ !5 &_17FO\
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M$<YP1@]*]K^'YS^SSXR_ZZW'_HF.O(X-/@+Q>;?1Q(\7F,Q*';@'(P')S]W
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M!)QCGKW/%7-3\(Z?JVI2W\\MPLLMLUL0C+@*002,J3G!Z9QWQFI_^$2\-_\
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C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img118615358_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYZK^5 #Z*9^\]5_*C]YZK^5 #Z*9^\]5_*C]YZK^5 #Z*9^\]5_*C]YZK^5
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M,_@#C(KI:\\\>V.BV.LV>M7FF'4+ZZ M8%EDA2*%D#NLFZ7"@@,W&<-QP<4
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M&PN9H)XK?5I-0D22'<LBL\C;,$_]-!S[5#<?#ZUFNKA8S;V^GSWOVAK:&'8
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M#6EZC://<:JWF7#*JQNTF\JO)(]N<5T-94KS_>25GV[?\.;5K0_=Q=UW[_\
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MET./2[.%;)%$>^6"&+=-L&!Y@*%7]>1UYXKIJ*L@H:1I5KH.CP:=:;A;VZD
MN<DY)))]R235Y6#*&!R",@U!?7,-I9R2SR"-,8W'ID]*33[F&ZLHY()!(@ 7
M</4=:S]I'GY+ZVN7R/DYK:%FBBBM" HHHH **** "BBB@ K@_B'J.HVT4216
M\T%FF&>^$MD$+'(V$7!X/0Y%=Y7EWQ8O)[.2PNITLTLK1O.CF9XI9-Y5D8&V
ME($@P1C:VX'M0!W'A.S73_"FF6JQS1K' H"S2([#ZLGRG_@/'I2>*M6O]$T&
M;4-/LH[MX07D621E"H 23\JL2>,  =Z9X,@M+;P9I$-B]P]JML@C:XCV2$8[
MK_#].U6]:T.TUZS6VNVN$".)$DMYVB=6P1PRD'H2/QH XN?XI&WG2:32E_LT
M0Q>=(MP&D6:2V:X55 &&4*FTMGJ?2NB\(>);GQ#!>)?64=I>6CQATBE\Q"LD
M2RH02!SM< \=0::OP_\ #27D%PNGX$,"VZP^:WE%0AC!*9P6",R[CS@UH:!X
M<TWPU9R6VG1R!9'WN\LK2.Q"A1EF). JJ .P H U6=5ZFF^:GK^E/HH 9YJ>
MOZ4>:GK^E/HH 9YJ>OZ4>:GK^E/HH 9YJ>OZ4>:GK^E/HH 9YJ>OZ4>:GK^E
M/HH 9YJ>OZ4>:GK^E/HH 9YJ>OZ4>:GK^E/HH 9YJ>OZ4>:GK^E/KG+KQ4+3
MQ =-DM3Y8(!E4ECRN?N@<UG4JPII.;M?0UI49U6U!7MJ=!YJ>OZ5S/C*\OX[
M>RATFX=+J6; 2,X9A@^O8>M6[OQ*86ABATR[>6=ML*R*$W'Z'G [G%94_A;5
M=3+3WUQ;I<NV3(NYB%[(!P H_4]:B5;2\$V_ZZ[%0H>]:HU%?UTW+VGN=&L4
MA(:\UJ[ DF!.26QC+'LHZ?RK2L+)8)6N[J7[1?.,-)M.%']U!V'\^]2:3I46
MEVBQK\\Q \V4\ER!_+T%7ZJ,7*TI[]NW_!%*:BG"GMW[_P# &>:GK^E'FIZ_
MI3Z*U,1GFIZ_I1YJ>OZ4^B@!JNK=#0Z+)&T;C*L""#W!IU-DD6*)Y'.$0%F/
MH!0%[:F+/X2TB>5)/(:/;_"CD _6JGB/PDFHZ#<66EI:VTTK1EC-'O1U5PQ4
MYSC..N.*K:IX]MK._@AM(5N87 +R[BNW)QT(YXYJ]J?BE(M(O+O1XXM0FM(S
M-)"\C0CRP"20Q4\\=*PA"BI7BE<2Q_M?W?M+V\_ZN<9;_"2X73K>"XN[*6>V
MM(K>"4Q,?+*7;3DKGD90[?\ ZU:.A_#>ZTQU1M3%K"EK/;))IH\J7#W E5LD
M$ X&T\5)_P +-CL8=/DURQAL!?Z=)?PD7)D! V%$SM'+!_PQWI+;XES7WD6]
MGHIDU"Z:W2V@:Y"JQEM_/8LVW@(N>Q)]*W&/M_AG;+!K<MS.;C4+R6Z>UFDD
M<I!YR% Q3.W?@G+ 9.:72O FJ&XCNM7UHP7$%C#I\!TG,1$4;;B69\DECC(P
M!@5T?AK7SK]C<O+:-:7=G<O:74!<.$D3&=K#[P(((.!UK:H XS0_#.MZ9_:.
MGW,NEW&DW=U<W*_NW,P:5RZ@Y^7@G]*WO#.DR:%X7TO2995EDL[:.!I%& Q5
M0,BM6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YVVTGP_X0N]8UHO
M#9G4ITFNI97"J&X4#/8%CGZL:T5U_2'G\A=2M3+Y[VVP2C/FHNYDQ_> Y(]*
MM;[2\\R+=#/Y;;9$R&VGK@CL:=]FMPV[R(MVXOG8,[B,$_7'>@#%N?''A6S6
M!KGQ#IL2W$0FA+W*CS$)(##GD9!&?8U!_P +%\%_]#3I/_@6G^-;CZ;82! ]
ME;,$&U0T2G:/0<=*;_9&F_\ 0.M/^_*_X4 <?;^)_ -OXAN=83Q1I'FS1A=O
MVI,*>YZ]3@?E6M_PL7P7_P!#3I/_ (%I_C6I)9Z)%#YTEMIZ1;MN]D0+G.,9
M]<\5-_9&F?\ 0.M/^_*_X4DDMB8PC'X4<I8>+/ .G7U]=P>)])$EVX=_]*3C
MCH.?7)_&M'_A8O@O_H:=)_\  M/\:UAI^CF-9!9V)1R K"-,,3TP<5)_9&F_
M] ZT_P"_*_X4));!&*BK1,7_ (6+X+_Z&G2?_ M/\:/^%B^"_P#H:=)_\"T_
MQK:_LC3?^@=:?]^5_P */[(TW_H'6G_?E?\ "F4<[?>.O ]_92VLOBG2=DBX
MR+I./0]:?;^/O!%M;QP1>)]("1J% ^U)V_&MUM+TI"H:QLE+'"YA49/H./8T
MQ+#1I)GA2TL&ECQO01H67/3([5/)'FY[:[%<SY>6^AE?\+%\%_\ 0TZ3_P"!
M:?XT?\+%\%_]#3I/_@6G^-;7]D:;_P! ZT_[\K_A1_9&F_\ 0.M/^_*_X51)
MS]UX]\$7EK+;R^*-)*2*5/\ I2?XTEIX\\#V5I%;1>*-)V1J%'^E)S[]:WVT
MS25=4:QL@S9V@Q)DXZXXJ&"WT&Y<I!#ILKCDK&L;']*GDCS<]M=BN9\O+?0Y
MV7XM>"HM:ATUM<MF,L>];A'#0@Y(VLX^Z>,\\<]:[565U#*P96&00<@BL27P
M=X=GUJ'5Y='M'O88_+B=HP0@R3D+TSSUQFMJ-TD0/&RLAZ%3D&J)'4444 %%
M%% !1110 5R7BB[T/P[J]AK6H:']IFF)MWOXK8S26R@%EX"D@$\<8ZUUM<%\
M4(;:>QTL3RP.ZW+&.QN+2:YBNCL8$-'%\QV@[@>@(H [6QO8M1L8;R 2"*90
MZB2-D;'NK $?C5BL7PC;?8_".E6_VB>X\NW5?-GB:-VP.ZM\R_0\XQ3_ !'K
M%QH>E->VVGF]*G+@SK"D: %F=W;@  >_)% &O17 'XJ6220R2Z5=16+01O+<
M.RAHI)(&G6,IU/R(>>F2*W_"GB<^);>Z,MA)875LZ+) \@DP'C61"&''*N/H
M<B@#H**0LJ]2!]32>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]
M]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]
M]?SH =14-Q=16UM+.S K&I8\CG Z5SJ^*/[3M9#:C[#$G^NN[@C$8]AGEO05
ME.M&#47N^AK"C.:<ELMV:U]J+K/]AL$6:](R<_<B']YS_3J:YO\ MZ/1]?ET
MQ-/EOM2D(!N"X!D8KD #^%1^@J_9/<7$'D:.AL[1CE[ZY&99CW95/)/NWY5J
M6&D:=I[&5%66Y8[GN9COD8^I8_THC!M\T]_R_KN$II+EAM^?]=A-+TM[>1[Z
M^D$^HS##R#[L:_W$]%'Z]36I3?,3^^OYT>8G]]?SK4R'44WS$_OK^='F)_?7
M\Z '44WS$_OK^=5;[5++38/-NIU0'A5'+.?10.2?I0W83:BKLN45QL5GK=_X
MEBU7S7M-/+J?LLLY#;0,<J.!GKBNP\Q/[Z_G4QE?H9TJCG>ZM^HZBD#*W1@?
MH:;,TBP2-"@>4*2B,VT,<< GM5+4U!HHW8,R*Q'0D9J.]M(K^PN;*?=Y5Q$T
M3[3@[6!!P?H:\[\0:K\1UUBT%AI2PVY5?,2!EF1CNYRY4%>/;WK<UF;Q#<^'
M-5>ZB_L=K:V>XAN+*\$CEU4D*04QCCFNRM@I4J:FY1=^TDW_ %Z7(C--VL:*
M^$=+1K1AY^;736TR/,G_ "Q;:#G_ &OD'-9Z_#G0TMA%"][#(C0-%<1W!66%
MH8O*0JW;Y.#G(.3Q7(KKGB73H]$6SNKC5'O/#LVH3BZN$CVN1$=X(3G;N.%]
M^M4+3Q=K%Q#:Q7^O3V=A/+8)=Z@ @-NKV?F'YB"$WR8&X],]JXRSUG0]"L_#
M^GFTLO-8/(TTLLSEY)9&.6=V/4FM*N'\*>([T^%+Z^E2]UR&VOY;>SGMXE,M
MW & 5^JJV,D;A@$+FK7AW7=?U#7[RTN=.:328RQCU%X6MB&W?ZO8Q)?'3>N
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M52P8J"R]"1R*9Y$0F\WRD\S^_M&?SJ2B@".6W@GQYT,<F.F]0<?G3@BJ254
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img118615358_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[RYD$,LNZ-?M&/- &.AQG'N:XK_A:VJ+%?3FQ@VQI<^1'*C1L&6[2"/S.?E
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M>#REODP9R-Q,S-O;?(V[DX'&* /1**** "BBB@ HHHH **** "BBB@ HHHH
MQO$W[S3(K4=;JZBA_ L"?T!K9K%U3]_XAT:VZA&EN&'^ZNT?JU;5 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!2UBVEO-$O[6'!EFMY(TR<#<5('\Z\;TGX2:]8:AI\
MTAMV@LI;&:&(3<1-F,W1''K'QZYKV75KTZ;HU]?K&93;6\DPC'\6U2<?CBN
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MV*6UXP>XC6( .0<@GZ'D>G:MVB@#)_X1?0OM5A=?V3:"?3T$=HXB&85'0+Z
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M$31GR7<$)*C-RH."!SB@#K**@L;R'4;"WO;8LT$\:R1EE*DJ1D'!Y''K4]
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M_P"+[*/M;6LDQ^K$*/T!H VJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M/Q)I#%<EW^VQC>QZG[U6KWQ)X4O[*:TF\0Z08Y4*-_IL7?\ X%4O_"%^%?\
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M2!Z^M;*?ZQ?K3:<G^L7ZT 6J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M]OSJQ10!7\E_;\Z58F#@G'!J>B@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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<.@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img118615358_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118615358_15.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %?!98# 2(  A$! Q$!_\0
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MW1;G4K6\L=5BMT+M':R,7('7:,8.!SC.>U=1\*])MM>^"?B*PO-1ATBUFO\
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MWX94*KC&=V2<8/3D\ :WQ$\4:<OP8TRZ;0+9X+^-8K>URNRT9XGVNOR]5[8
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M])-+9]>SV9Y!(ICD93U4XIM>L^#[K2=8L_'6MZIH6FL;.*WDAMX;?;$K@L
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MKT_:0[GP_P!3Q'_/M_<SE**ZO_A5WB?_ *!G_DQ%_P#%T?\ "KO$_P#T#/\
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M YQQ5;QWXI\*7WPOTWP_H-[.9-/O/,6*[B822K^\#/NQM&2^[!(X[#I7)?\
M"KO$_P#T#/\ R8B_^+H_X5=XG_Z!G_DQ%_\ %UC[*ES<W-UN>A]<QWL?9.CT
MY;V=[?E^!O?'+QAI7C+Q!I]SI%W]K@AM/+9O+=,-O8D88#VK1NO%7AKQ%\'=
M-T.]U5[#5=-+S);BW=_-=5D"+N P 2PY/N*Y#_A5WB?_ *!G_DQ%_P#%T?\
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MR[I87MHK5!U&UOO%LG_ZV/FO?\*6UO\ Y^M/_P"_DG_Q%'_"EM;_ .?K3_\
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M3^W9_$4GAV[ND7[58R6$EQMD4!25=, @@#W[]\"A_P *6UO_ )^M/_[^2?\
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M\-:E\*K7PWJ&OWGAN[MY6WO;0R,)D+,2#L!RI#G(./F'<#F/QQXZ\,ZQX/\
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M^+&@ZO+/<3Z=IMN+.2_D3]Y/\CJ9B@&1R_3K@?A6/_PI;6_^?K3_ /OY)_\
M$4?\*6UO_GZT_P#[^2?_ !%:N-)O61PQECHI*-*UFGUU:\KV^Y(EL]5T'P_H
MGC;3;;61J"ZA%;_9)A;21>85<E@00=N,]3U_DGP[\3:79>%]>T2]U2;P]<WS
M1R1ZI!"TA*J1F,A?FQUZ'^(_0Q_\*6UO_GZT_P#[^2?_ !%'_"EM;_Y^M/\
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M_P!"?IO_ 'P?\:/^&>?AO_T)^F_]\'_&CW@_<^96_P"&C_AK_P!#;9?]\O\
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M]F3Q'K.H:MJ'P[\47-_?W$EU<3>>Z;Y78L[;1>@#))X  YQ7L/\ PRG\+/\
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M:_#'P]I]M>P7OA>QFMKR2Y1%CD9UA \LAB2/W;?> ZBOK/\ X93^%G_0K_\
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MF22222:['_A1WPYZ?\(#X8_\$UO_ /$5FZU-.UF=<<)4E%/F1XQ_PU1\+?\
MH:E_\ ;K_P"-4?\ #5'PM_Z&I?\ P!NO_C5>T?\ "C?AS_T(/AC_ ,$UO_\
M$4?\*-^'/_0@^&/_  36_P#\11[>GV97U.K_ #(\7_X:H^%O_0U+_P" -U_\
M:H_X:H^%O_0U+_X W7_QJO:/^%&_#G_H0?#'_@FM_P#XBC_A1OPY_P"A!\,?
M^":W_P#B*/;4^S#ZG5_F1XO_ ,-4?"W_ *&I?_ &Z_\ C5:OA?\ : \ ^-->
MM-&T;Q M[J5T6$,'V2X3=M4L?F:,+PJGJ>U>I?\ "C?AS_T(/AC_ ,$]O_\
M$5\U_$3PIHOA#]M;X?V6A:18Z+9R:.TK6^GVR01M(1> L50 9(51D^@'I6E.
M<*CLDS&K0J48\S:/=M<URQ\-Z>]]J,_V:U5@K2;6;D\ 8 SR?:N;_P"%Q>#_
M /H,K_X#S?\ Q%5OCHO_ !;V[_Z[1?\ H0KT7P;\/?"USX0T.>?PUH\LLEC
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M_P""^'_XFCVP?4X'E/\ PN+P?_T&5_\  >;_ .(H_P"%Q>#_ /H,K_X#S?\
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M=_\ !K;_ /Q=<=X^_9]^!/PS\+W>OZ_X=%I86^!\NHWC/(Y/RQHOG<L?Z$G
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M_"CZPOY/S#ZE_??X'Q[_ ,-%?$;_ *(/XG_*X_\ D6C_ (:*^(W_ $0?Q/\
ME<?_ "+7V%^%'X4?6%_+^8?4O[[_  /CW_AHOXB_]$'\3_E<?_(M=/\ !3X\
M77Q:UO7]*O/#$OAJ[T?8LT,]T9'WEF4HRF-"A!7I7TU_*OC7]G__ ).&^-?'
M_,5E_P#2F>M8351/W=CEK471<?>O<^C-IHVFG[31M-(@9M-?(DG[?GER,O\
MP@F=IQ_R&/\ [GKZ^VFOR'N/]?)_O'^=95)..QV8>G&=^8^N?^&__P#J1/\
MRL?_ '/1_P -_P#_ %(G_E8_^YZ^0Z*RYY'9]7I]CZ\_X;__ .I$_P#*Q_\
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M *&*]A\"_P#(D^'_ /L'6_\ Z+6O(/CU_P DYN_^NT7_ *%7K_@7_D2?#_\
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MX*'[PKGO^$3_ &F?^BB>'/\ P&C_ /D.MIT_:1BDR:-;V,I<R>I]/T5\P?\
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M=)_O'^=?K[7Y!3_ZZ3_>/\ZPJ=#OPO491116)WA1110 4444 %%%% !1110
M4444 ?1_["7_ "5C5?\ L#R?^CH:^[J^$OV$?^2LZK_V!Y/_ $=#7WA733^$
M\K$?&,HI]%:'-8913Z* L%%+M-&TT:@UH?)'B#_D/:E_U\R?^AFL^M#Q!_R'
MM2_Z^9/_ $,UGU]#'X4?C=3^*_4^E[KX3Z9XJ^$>FG3]/M;76C8PW$=Q#"B/
M+((P=K-QG=D\D\$@]J\X^ .@V6K>.;ZSU:PANTBL9"8+N$.%<21C[K#@CD>W
M->AZYXTF\!^#?AUJ:9:W\F&*YC4 EXFA7<!TYX!'3D#M72Z'X,M[?XC-XNTH
MI)IFK::QD:/ 42EHV5AZ[UR>G523UKPE4E&$E+9['Z5+!T:^)I5*2]Z%N9=T
MUHSQSX._#[3O&7C/53J,8ET_3R6^R@E0[%B%''\( /'^[VXK>LOB+X%NO$S:
M/J'@6QTJT:4VYNIH8T>,YQEUV#9@]3NXKBO =]XGT?QAJ6I>&M/?4'A:1+F/
MRRR%"Q.#CH?ER,<Y'X5Z/8_&;P;X^N+:Q\2>'E@FF)A$TR+.D><@?/@.N2>H
M'&<Y'6NBK&3FV]5;H]CRL#.E&BH1:A)R?Q1NI:[7Z'E_C3P?IT?CZ'2?"][;
MZA9WSQ_9O*F$JQ,[;2C,,]#SZ[2,YZGT;Q)'X*^"MG9Z3+H$7B?69HQ--)=H
MN,9(W98,%R0<*HZ+SV)KS>"=.^&?QP\-FW<II5ZS&%)"6,;LK($SU(RR8)]?
M;-<S^T19S6WQ)GED_P!7<6\4D7.?E *X_-3^=4I>VE"#>EOO,YTW@:-?$1@E
M4YK=TE:^GJ;GB:+P'XZ\!W&L:='9^&M;M5;;:>8D1D91N*;!@."#PP&<X]"*
M3X9>'=+U'X,^++ZZTZUN;V#[5Y5S+"K21XMU(PQ&1@\\5YEIO@O6M8T&\UFS
ML&GTVS+"><.HV;5#'C.3@$'BO7OA+_R0GQG_ -O?_I,E.JO9PM&5]2<#4>*Q
M//5I*+Y'TW\SP:O2_@S\-;3QI<WNI:PQ31=/ \SYM@E;J06[*!R>1U%>:5[W
M\%X6U+X.^,+"V_>WDAN%2%3\QW6ZA>/<@_D:Z<1)QIZ=3Q\GH4Z^+M45[)NW
M>R*,/Q1^'KZTMDW@JSCTEF\K^T&@C,@'3>4VYQWSNSCMGBN)^*_AG0_#VO1M
MX=U&VO=.N5+"&"X$S0.,94X)P"",9YZ^E<5&C2LJ(I=V.T*HR22<  >I-;'B
MCP9K7@R>"+6+%K-IE+1$NK*P& <%21W'YCU%*%*-.:M+<*^-JXJA-5*::3TD
ME;E\M.YBU['^SS_S'_\ MW_]J5XY7LG[/&?^*@Q_T[_^U:K$?PV3DO\ OT/G
M^1[%7RCX2LOBO\9/B5\2=/\ #_C]M#L_#VK20)#<+D>6TTZHJX7HHB[^HKZO
MVFO#/V/?^2N?'O\ [#B?^E%[7DJ3C"4D?IZ@IU(P?]:$/_#/'QV_Z*U;_P#?
MMO\ XBC_ (9X^.W_ $5JW_[]M_\ $5]7T5S?6:GE]QZ'U.EY_>SY0_X9X^.W
M_16K?_OVW_Q%'_#/'QV_Z*U;_P#?MO\ XBOJ^BCZS/R^X/J=+S^]GRA_PSQ\
M=O\ HK5O_P!^V_\ B*/^&>/CM_T5JW_[]M_\17U?11]9GY?<'U.EY_>SY0_X
M9X^.W_16K?\ []M_\11_PSQ\=O\ HK5O_P!^V_\ B*^KZ*/K,_+[@^ITO/[V
M?*'_  SQ\=O^BM6__?MO_B*/^&>/CM_T5JW_ ._;?_$5]7T4?69^7W!]3I>?
MWL^4/^&>/CM_T5JW_P"_;?\ Q%'_  SQ\=O^BM6__?MO_B*^KZ*/K,_+[@^I
MTO/[V?*'_#/'QV_Z*U;_ /?MO_B*/^&>/CM_T5JW_P"_;?\ Q%?5]%'UF?E]
MP?4Z7G][/E#_ (9X^.W_ $5JW_[]M_\ $4?\,\?';_HK5O\ ]^V_^(KZOHH^
MLS\ON#ZG2\_O9\H?\,\?';_HK5O_ -^V_P#B*/\ AGCX[?\ 16K?_OVW_P 1
M7U?11]9GY?<'U.EY_>SX=U2+XI?"7XS> =!\1^.VUVUUJZ4O' N$*!PI5LKW
MSVKT[]K3_DW_ ,5?]NO_ *50UA_M/9_X:4^#7_78_P#HU:W/VM,_\,^^*O\
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M /V#K?\ ]%K653=%8?X3=HHHK([ HHHH **** "BBB@ HHHH **** "BBB@
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M^+'Q#M?A=X%U+7[@++-$OEVEL6 -Q<-Q'&.<G)Y..0H8]JQ/AO\ \E#\??\
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M "37/6_QZ^,'CCX<^)?%VE?\(WH^F>&[UEF*6\C2WBH%9H@KLX VL&+#!.0
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M5_M6L_%J/Q%:"&15L9O#-O;H9"I".S1N&(5B#M!&<8R,YH \*U%M4TWXEO\
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M >K_ !T\5>/]#L]$T[X>Z%'J.JZM=&VEU*ZC9[;38\ >;(%.1RP.<$ (V0>
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M ?)_[3__ "<K\&?^NQ_]&K6]^UK_ ,F^>*_^W3_TKAK!_:>_Y.6^#'_78_\
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M6?DV/CO3OM\?W?[6TY527ZO%PK<]T*\#[IK+F6UST52DU<]#_:K'_%>?!O\
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M?CM_R1GQO_V![G_T4:JG\:,JG\.1PO[)'_)OOA;ZW7_I7-7L'^>E>0_LC?\
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MNE/1'DSB^9V.[_STJKJB_P#$KO/^N+_R-<=_POKX<?\ 0[:)_P"!J5POP_\
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MPEZGA87_ )&$_P#"OS9YU\3]/D\<?%70/"EU<20Z/]E:\E6%MK,V7&>A'\
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M</=17GWQL^%FE:AH7PO\"V[26.FKJ#6<$T1Q)$R64QCDR",L'56Z\D'UKO\
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MZZ&TCS\5O#U_0]D_X4S\/_\ H1?#7_@HM_\ XBD/P9^'Y4_\4-X;'_<(M_\
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M &[_ /M6O%Z]J_9O&?\ A(?^W?\ ]JURXG^$SW,E_P!^I_/\F>S[37R'X/\
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M>?#?_DG_ (;_ .P=;_\ HM:X;XRC'PWUCZ1?^CDKN?AO_P D_P##?_8.M_\
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M>O\ HE5I_P!_C_\ '*/^%S?'K_HE5I_W^/\ \<JI_P * ^-__17#_P!_)O\
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MP.3C'&<UY%^S#9ZMI^L?$^VUW6)-?U:/Q"5N-0D39YK>1%T7)VJ!P%'"@ #
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M]BZC_P ^%U_WY;_"JYEW,_95/Y64:*O?V+J/_/A=?]^6_P */[%U'_GPNO\
MORW^%',NX>RJ?RLHT5>_L74?^?"Z_P"_+?X4?V+J/_/A=?\ ?EO\*.9=P]E4
M_E91HJ]_8NH_\^%U_P!^6_PH_L74?^?"Z_[\M_A1S+N'LJG\K*-%7O[%U'_G
MPNO^_+?X4?V+J/\ SX77_?EO\*.9=P]E4_E91HJ]_8NH_P#/A=?]^6_PH_L7
M4?\ GPNO^_+?X4<R[A[*I_*RC7M?[-W_ #,7_;O_ .U:\B_L74?^?"Z_[\M_
MA7LG[.MC<6?_  D/VBWE@W?9]OF(5SCS<XR.V1^=<V):]D[,]O):<XXZFVFM
M_P CV2BG45X=S]3L-HIU%%PL-HIU%%PL-HIU%%PL-HIU%%PL-HIU%%PL-HIU
M%%PL-HIU%%PL-HIU%%PL-HIU%%PL-KQ[]KO_ )-W\6?]NG_I7#7L=>._M>?\
MF[^+/^W3_P!*X:TIOWT95%[DO0]!^%6BV?B3]GOPAI.HP_:-/O\ PQ:6MS#O
M9?,C>U177<I!&5)&0<\\5S/_  QA\'/^A0/_ (,[S_X]7:_ [_DB_@'_ + %
MA_Z3I7;=:Y'.49/E=CT8TX3A'F5SRGPG^RW\,?!'B&RUS1/#7V+5;)S)!<?;
M[J38Q!4G:\I4\$]1WKU?%)S2FLW*4G>3N:QA&"M%6/EKQK^UMXBUKX@ZEX ^
M&7@UM7\1V5S-:R7.J3(D0:%V60J@8#;\O#-(O7[O:O-= ^&OC?X\_&;7O!?Q
M6\::@4T.UAO;FPTJ15@+/&K1J@VB-642C+>6V<,,\[J^@?B?^R'\/OB9?7.I
MM97&@ZY<2F>74=*D\LR2<DEXR"A)8[B0H8G^+K7C=O\  WXU_ 'QA>^*_".I
M6?Q#:ZMUM[I=0W?:9HE4;=R.^?E"J%"2D\ 8QQ7HPG3Y;0T=NO\ F>54A5YT
MZFJOT[>A]I#C KY-^+7_ "?7\.?^P&W\KZOK+TKY.^+/_)]GPX_[ ;?RO:YL
M/\;]&=>*^!>J/0?V@O\ DFMW_P!=X?\ T,5ZGX%_Y$GP_P#]@ZW_ /1:UY=^
MT)_R36[_ .N\/_H0KU'P+_R)/A__ +!UO_Z+6LJFYK1^$WJ***S.@**** "B
MBB@ HHHH **** "BBB@ HHHH **** $[FO#O'W_)RGA'_L&2?^@W->X]S7AW
MC[_DY7PC_P!@Q_\ T&YJH[D3^%FK\9/^2:ZQ](O_ $<E=S\-_P#DG_AO_L'6
M_P#Z+6N)^,W_ "376?I#_P"CDKMOAO\ \D_\-_\ 8.M__1:UUU/X2]3PL-_O
M\_\ "OS9YM\>/$WBO1=0MH-.DO+'P^T"M=7UE!N96+D$;\C:0-N.5SD\UYC#
MIOA>[\2>$6L-3NM<N[R_0:F-0BQDETZ@@Y!RV?F;ZU]*>,OB!H?@:&%M8N_)
M:?/E1*C.SXZX '3D=:X3Q%H?PQ\:>&YO$,DMO8VY8J;ZU)AD$F<E2F/F<^A4
MD@Y'4&MJ-3EBDXM>:/+S#!JK6E*-52:UY9/9+7373[CUBQL[?3[6*WM(8X+>
M-=J11*%51Z #I5@]S7"?!=[5O -F+&>YNK)99EADNU"R;!(V 0"1QT_H,X'=
MG[IKSY+EFT?5X>HJE&,[6NCP?X6_\E"^('_7\W_HZ6O4J\M^%?/Q$^(/_7\W
M_HV6O5*[ZOQ?=^1X&6_P/G+\V>&_'[3[CP'XA\/_ !9TN.21]%(L=<MX 2US
MILC $XW#+1LVX#N2"3A*]GT_4+;5K"VO;.>.YL[F-9H9XF#)(C ,K*1U!!'3
MBG:GIMKK&G75A>P)<V5U$T$\,@RLD;*592/0@G\Z^>_AC\3-+^ L?B7P!XZU
M<6$'AV83:/>W>YGO=/E8F,( N9'0DJ0HXY X0UA>QZ]N96*_[67_ "/GP9_[
M#O\ [5MZ^FJ^3OVA/%5EXWU7X#:]IPD%CJ&KK/")E"OM,MOC< 3S7UC55O@@
M/"Z3FGY?D+7RC^V%\$_!>B?#OQ!XSLM&\GQ+<7D4DM[]JG;<TD@#G87V<@GH
MM?5U>5?M-> ]9^)/PCU'0M MEN]2FG@=(GE6,$+("QW,0. #WKE/0//M:^"?
M@OX?_L_^)]?T#1OL&K7WAADN+C[5/+O#QJ[#:[E1EE!R!VKC]$^.45K^S#)X
M9_X0CQG(Y\-SV7]J1Z2#8?-"Z^;YN_\ U8SDMCH*^@_''@_5-:^!.H^&K2!9
M-8FT7[$D)D"@R^6%V[B<8R.N:RM%\ ZU9?LRR>#I;95UX^')]/%OYJE?/:%U
M5=^=O+$<YQ0!\PZ[_P FC_!W_L8G_P#1]S7I6M>&[3XX_M>:SX=\6>;?^'/"
M^E)-9Z:LS)&TCK 6+X/.3*Q.",[(P<@8,.J_ 'QK=?L]?#CPK'ID1UO1M9:[
MO(/M40"1F6=@0V[:3B1>A[UV'Q2^$OC;0/BJ/B=\,_L-[J]Q:BTU/1]0;:MT
MH"J"K%@,;4CXW+@Q@Y.2* .)^,W@?2?V>?B9\/?&'@B!M#2_U :?J>GVLK&*
MYA8H2 A)&"N[/;(C(&1FOK"^MFOK&>".XELWEC9%N(-OF1$@@.NX$;@3GD$<
M#BOFW2?A?\3?C)\2O#?B3XH66F^'-'\-2>?9Z182+*\\VY6!8AW&"43.6Z(
M%^8M7T9KFF-K6B:AIZW=SI[7=O);B[LWV30;U*AXV[,N<@^H% 'Q!\3?A)X>
M^$'B+P/I&FC4M&UE=7CFN_B-J2RK9*&=V2/JT9D QGA1^[!;AF*WOCMXBM?$
M_P"TYJFB>)?#>L^-]*T734CTSP_HK2@O-)%%*\C[#N P[Y9.?DB!X%=7K/P2
M^-?C;P_:?#OQ'K.D77A6WNEN9?$LDTL][<(&+!#O;<6 ?H5'W0-Y'7L/B1\(
M_&_A;XICXC?# :;>ZC=6"Z=J.E:JQ F50BJZMN'&(X^-RD>6.6W$4 >+>,_%
MFAZ)^R"UGX$U'6AIM]X@&GWUGKDBM<668VE>!"B@!&,:MQG/F/GDL!WFG>!]
M*^!_[67@;2/",4FG:3K>CS1W]L97F\YE69MQ+DX.Z.(_+C[ON:TF_9-UC7_@
MSXAT?7-6LF\9:SK+:_Y\(<6L-Q@@(3C)!5Y,D+P7X#;>=CX<_"KX@^)/B]IO
MC_XDG3+*ZT.Q>PL+/27)\]B'4RR#++@B63H0<[> !@@'&:;^T7\7O%?P]\2^
M+=+TKPM;:7X=NY([F259]]PJA#LC3>>5!RS%AG<,<@YUI?VA/B9I]OX(\8ZG
MHN@V7@CQ)?6]D+.%I9KV)7/^L9LJN6"NZXSQ@'GFKGP[^"?B[P_^SS\1?"M[
MI\<6MZQ>W<UG +F-@ZO%$JDL&P.4;J:O>,O@[XIUCX&?"_PW:V,;ZOH>HZ?<
M7T)N(P(TBBD60AMV&(+#H>] %[Q)\5OB'XJ^,6L^"_AW:Z#%!H%O%+?W^O"4
MI)(X5@BF,Y'#8^[_  /STK6_9Y^,7B3XJ:AXTM?$FE66CW.AWXLUM;3>6C.7
M#+(Q8AB"@&0 /:O+O&&MZC\/?VFO$D_@?Q!X:;4M6M8%U72?$4DEK':L$C*R
MB0A5<!65L([-^\D^0[<C<_8OANY=0^*.H7-]%K N-=*G5+<8BNY 7+R)_LG>
MK=>C"@#Z;KA?CM_R1GQO_P!@>Y_]%&NZKA?CM_R1GQO_ -@>Y_\ 11JZ?QHR
MJ?PY''?LA?\ )O/A7ZW?_I7-7L=>._L@_P#)N_A7ZW?_ *5S5[)755?OL\RD
MOW<?0\:_:^_Y-U\6_2U_]*X:Z_X*_P#)&_ G_8"L?_2=*Y']K_\ Y-U\7?2U
M_P#2N&NP^"G_ "1OP+_V ;'_ -)TK&_O&_V#LJ_'"3[[?6OV1K\;I/\ 6-]:
MB9O0ZB4445F=04444 %%%% !1110 4444 ?I5^Q[_P F[^%?K=_^E<U>S5XW
M^QW_ ,FZ^%/K=_\ I7-7LU=">B/.DO>8VJFK?\@J]_ZXO_(U=JKJW_(+O/\
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M=A**7_/2C_/2@.5=A**7_/2C_/2@.5=A**7_ #TH_P ]* Y?(2BE_P ]*/\
M/2@=A**7_/2C_/2@+"44O^>E'^>E 6$HI?\ /2C_ #TH"PE%+_GI1_GI0%A*
M*7_/2C_/2@+"44O^>E'^>E 6$HI?\]*/\]* L)12_P">E'^>E 6$HI?\]*/\
M]* L)7CG[7O_ ";OXL_[=/\ TKAKV3_/2O'?VOO^3=?%O_;I_P"E<-72_B+U
M,JGP2]#TSX&_\D6\ _\ 8 L/_2=*[>N(^!O_ "1;P#_V +#_ -)TKMZXY_$S
MTZ?P(6BBBI- HHHH 1NE?)_Q8_Y/L^''_8#;^5[7U@>E?)_Q7_Y/N^''_8#;
M^5]73A_C^3.+%_ O5'HG[0O_ "3.[_Z^(?\ T,5ZAX%_Y$GP]_V#K?\ ]%K7
MF'[0R_\ %L[O_KO#_P"ABO3_  +_ ,B3X>_[!UO_ .BUK*>YM1^$W:***S-P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 3N:\/\ 'G_)RWA#_L&2?^@W
M->X=S7A_CS_DY;PA_P!@Q_\ T&YJH[D3^%FQ\:/^2:ZQ_P!L?_1R5VOPV_Y)
M_P"&_P#L'6__ *+6N+^-&?\ A6FL_2'_ -')7:?#?_DG_AS_ +!UO_Z+6NNI
M_"7J>'A_^1A+_ OS9YMXZ_L<_'?1SKCV@T^/2RW^G,HB#;I<9W<9^O\ 2N+\
M-^'?"&O>//$*ZMK-K:>'K.Z:2SLA=+%#,7)R5.1\H"K]W_9YP.?=?$_PQ\-^
M,M02^U?3OM=RD8B63SY$P@)(&%8#J361_P *#\#?] 4_^!D__P 75PQ$(QM=
M[6.#$99B*E9S48./-?5O72UGH=?H,VES:5 =&DM9-.4;(OL3*8@ <8&WCBM$
M_=-9OAWP[I_A72X].TN#[-91DE8M[/C)))RQ)ZFM,_=-<#M?0^IIJ2@E)6?E
ML>$_"G_DHGQ!_P"OYO\ T=+7JM>5?"G_ )*)\0?^OYO_ $=+7JW^>E>A5^+[
MOR/G\M_@?.7YLK:A;R7EC/!#<R64LB,JW,*J7B)! =0X*Y!_O*1QTK\W_P!I
M3X,^/O _B*76O$U_<^*M/N6Q'KWS,H^8XCD7/[D\\*#MYPI.#C]*?\]*AOK&
MWU*SGM+N"*[M)T:*6"9 Z2(P(964C!!!/!%<[5SUH2<7L?#VL3_:/ /[,SYS
MC4=O_?-Q"/Z5]TU\J?M(>%],\&^(/@AH^CVPL]-MM=80VZEF"!IX&(!)SC+'
MO7U75U/@@/#_ ,2;] HHHKF.X**** "LF3Q9HD"VS2:QI\8NKEK& M<Q@37
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MH?#GAC2/"&EQZ;HFFVNE6$?*V]I$L:9P,L<=6X')Y-:=% !7"_';_DC/C?\
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MEHHN FVC;2T47 3;1MI:*+@)MHVTM%%P$VT;:6BBX";:-M+11<!-M&VEHHN
MFVC;2T47 3;1MI:*+@)MHVTM%%P$VT;:6BBX";:\<_; '_&.OBW_ +=/_2N"
MO9*\F_:JTB_U[X">*+'3+*XU&]E^R^7;6D+2ROBZB8X51DX )X'8UI2?OHRJ
M_!*W8[_X&G_BRW@'_L 6'_I.E=O[U\<^!_VG_'O@OP5X?\/_ /"C_$5Y_96G
MV]C]HW7">;Y<:INV_93C.W.,GKUK<_X;$\>_]$&\0_\ ?ZX_^1*B6'J-O3\4
M;0Q5)12;_!GU717RI_PV+X]_Z(-XA_[_ %Q_\B4?\-B^/?\ H@WB'_O]<?\
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MVC;4C&;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;:
M&;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M
M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;:
M &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-
MM/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;
M: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:
M-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT
M;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;
M:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/V
MT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &
M;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/
MVT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;:
M&;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M
M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;:
M &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-
MM/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;: &;:-M/VT;
3: &;:-M/VT;: &;:*?MHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>maia-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-24T15:52:29.5995+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="maia-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="maia-20221231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:href="maia-20221231.xsd#DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:href="maia-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="maia_WarrantLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="maia_ResearchAndDevelopmentIncentivesReceivable" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantLiabilityNoncurrent" xlink:label="maia_WarrantLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndDevelopmentIncentivesReceivable" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_InterestExpense" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="maia_DeemedDividendOnWarrantModification" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="maia_AustralianResearchAndDevelopmentIncentives" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="maia_RatchetShareExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendOnWarrantModification" xlink:label="maia_DeemedDividendOnWarrantModification"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AustralianResearchAndDevelopmentIncentives" xlink:label="maia_AustralianResearchAndDevelopmentIncentives"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RatchetShareExpense" xlink:label="maia_RatchetShareExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="maia_ProceedsFromPaycheckProtectionProgramLoan" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="maia_ProceedsFromCollectionOfSubscriptionReceivable" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_IssuanceOfRatchetShares" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="maia_PaymentOfInitialPublicOfferingTransactionCosts" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="8" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="maia_IncreaseDecreaseInDeferredOfferingCost" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="13" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="15" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="18" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfRatchetShares" xlink:label="maia_IssuanceOfRatchetShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IncreaseDecreaseInDeferredOfferingCost" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="maia_AccruedResearchAndDevelopmentCostsCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>maia-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-24T15:52:29.3957+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantDescription" xlink:label="maia_WarrantDescription"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesUptoOneBillionMember" xlink:label="maia_NetSalesUptoOneBillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonStockConversionPrice" xlink:label="maia_CommonStockConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OperatingLossCarryforwardsExpirationYear" xlink:label="maia_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_SimpleAgreementForFutureEquityIssued" xlink:label="maia_SimpleAgreementForFutureEquityIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RestrictedCommonStockAwardMember" xlink:label="maia_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsIssuedForDeferredCompensation" xlink:label="maia_OptionsIssuedForDeferredCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RegeneronPharmaceuticalsIncMember" xlink:label="maia_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ThioMergerAgreementMember" xlink:label="maia_ThioMergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonStockWarrantsPolicyTextBlock" xlink:label="maia_CommonStockWarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UniversityOfTexasEuropeanMember" xlink:label="maia_UniversityOfTexasEuropeanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOMember" xlink:label="maia_THIOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsExercised" xlink:label="maia_ClassOfWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" xlink:label="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfFoundersTerminated" xlink:label="maia_NumberOfFoundersTerminated"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OfferingAndOverallotmentMember" xlink:label="maia_OfferingAndOverallotmentMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantValue" xlink:label="maia_WarrantValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyOneWarrantsMember" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantLiabilityNoncurrent" xlink:label="maia_WarrantLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_Debtdiscountandvalueofembeddedputfeature" xlink:label="maia_Debtdiscountandvalueofembeddedputfeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsToPurchaseSharesOfCommonStock" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MAIADrugDevelopmentCorporationMember" xlink:label="maia_MAIADrugDevelopmentCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashlessExerciseAtFairMarketValuePerShare" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DGDMember" xlink:label="maia_DGDMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PatentAndTechnologyLicenseAgreementMember" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendDeclared" xlink:label="maia_DeemedDividendDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesUptoOneMillionMember" xlink:label="maia_NetSalesUptoOneMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DefinedContributionPlanEmployerSalary" xlink:label="maia_DefinedContributionPlanEmployerSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RelatedPartyMember" xlink:label="maia_RelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesAboveOneBillionMember" xlink:label="maia_NetSalesAboveOneBillionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UnvestedRestrictedStockAwardsMember" xlink:label="maia_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_FounderMember" xlink:label="maia_FounderMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsIssued" xlink:label="maia_ClassOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchProgramExpenditures" xlink:label="maia_ResearchProgramExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PppLoanProgramMember" xlink:label="maia_PppLoanProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UniversityOfTexasSouthwesternMember" xlink:label="maia_UniversityOfTexasSouthwesternMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MilestonePayment" xlink:label="maia_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CombinedMilestonePaymentsMaximum" xlink:label="maia_CombinedMilestonePaymentsMaximum"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaymentsDueRelatedToMilestones" xlink:label="maia_PaymentsDueRelatedToMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantOneMember" xlink:label="maia_WarrantOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashPaidForServicesProvided" xlink:label="maia_CashPaidForServicesProvided"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertiblePromissoryNotesToRelatedParties" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_LeighAnnDurantMember" xlink:label="maia_LeighAnnDurantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfFoundersToWhomSharesGranted" xlink:label="maia_NumberOfFoundersToWhomSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsExpired" xlink:label="maia_ClassOfWarrantsExpired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" xlink:label="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertiblePromissoryNotesToSettleLoan" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantModificationValue" xlink:label="maia_WarrantModificationValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_SubscriptionReceivableForIssuanceOfCommonStock" xlink:label="maia_SubscriptionReceivableForIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_LiquidityPolicyTextBlock" xlink:label="maia_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ModificationOfWarrantInEquity" xlink:label="maia_ModificationOfWarrantInEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsExercised" xlink:label="maia_WarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsExercisedShares" xlink:label="maia_WarrantsExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsIssuedForAccruedBonus" xlink:label="maia_OptionsIssuedForAccruedBonus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightOutstandingAndExercisable" xlink:label="maia_ClassOfWarrantOrRightOutstandingAndExercisable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_BlackSholesMethodMember" xlink:label="maia_BlackSholesMethodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_The401KPlanMember" xlink:label="maia_The401KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfEquityFinancing" xlink:label="maia_ProbabilityPercentageOfEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertibleNotesOutstanding" xlink:label="maia_ConvertibleNotesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AustralianResearchAndDevelopmentIncentives" xlink:label="maia_AustralianResearchAndDevelopmentIncentives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_SimpleAgreementForFutureEquityDisclosureTextBlock" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfRatchetShares" xlink:label="maia_IssuanceOfRatchetShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TransactionCosts" xlink:label="maia_TransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RaduVitocMember" xlink:label="maia_RaduVitocMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" xlink:label="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOTherapeuticsIncMember" xlink:label="maia_THIOTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConsultingServices" xlink:label="maia_ConsultingServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ForeignCurrencyTranslationAdjustment" xlink:label="maia_ForeignCurrencyTranslationAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfWarrantsIssued" xlink:label="maia_NumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfDirectorsToWhomSharesGranted" xlink:label="maia_NumberOfDirectorsToWhomSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfWarrantsExercised" xlink:label="maia_NumberOfWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MaiaDrugDevelopmentCorporationMaiaDdMember" xlink:label="maia_MaiaDrugDevelopmentCorporationMaiaDdMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaycheckProtectionProgramTextBlock" xlink:label="maia_PaycheckProtectionProgramTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" xlink:label="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DissolutionOfFirm" xlink:label="maia_DissolutionOfFirm"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantTwoMember" xlink:label="maia_WarrantTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfWarrantLiability" xlink:label="maia_ChangeInFairValueOfWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClaimExpirationTerm" xlink:label="maia_ClaimExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReceiptOfStockSubscriptionReceivable" xlink:label="maia_ReceiptOfStockSubscriptionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendOnWarrantModification" xlink:label="maia_DeemedDividendOnWarrantModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" xlink:label="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" xlink:label="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RatchetMember" xlink:label="maia_RatchetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExpirationOfPatentRightsPeriod" xlink:label="maia_ExpirationOfPatentRightsPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndDevelopmentIncentivesReceivable" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RemainingConsultingServicesSettled" xlink:label="maia_RemainingConsultingServicesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfStockCompensationExpenseRecognized" xlink:label="maia_PercentageOfStockCompensationExpenseRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IncreaseDecreaseInDeferredOfferingCost" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TermOfAgreement" xlink:label="maia_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RatchetShareExpense" xlink:label="maia_RatchetShareExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ScheduleOfWarrantExercisedTableTextBlock" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GoingConcernConsiderationsPolicyTextBlock" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandEighteenStockOptionPlanMember" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DgdPharmaceuticalsCorporationMember" xlink:label="maia_DgdPharmaceuticalsCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UnrelatedThirdPartiesMember" xlink:label="maia_UnrelatedThirdPartiesMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyWarrantsMember" xlink:label="maia_TwoThousandAndTwentyWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MoneyChannelNycIncMember" xlink:label="maia_MoneyChannelNycIncMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WorkingCapital" xlink:label="maia_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfConversionPrice" xlink:label="maia_PercentageOfConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Certain risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certain Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to MAIA Biotechnology, Inc. shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impact of the COVID-19 pandemic on operations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impact of the COVID-19 Pandemic on Operations [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of the COVID-19 Pandemic on our Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt conversion, original debt, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Original Debt, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesUptoOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales upto one billion.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesUptoOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Upto One Billion [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesUptoOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales up to $1,000,000,000</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonStockConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonStockConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonStockConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock conversion price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with equity financing, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with Equity Financing shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares In Connection With Equity Financing Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid to settle a portion of deferred compensation balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid to settle a Portion of Deferred Compensation Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid to settle a portion of deferred compensation balance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares upon exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SimpleAgreementForFutureEquityIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simple agreement for future equity issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SimpleAgreementForFutureEquityIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreement for Future Equity Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SimpleAgreementForFutureEquityIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple agreement for future equity issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RestrictedCommonStockAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RestrictedCommonStockAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Common Stock Award [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RestrictedCommonStockAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted common stock award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsIssuedForDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued for deferred compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsIssuedForDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued For Deferred Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsIssuedForDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued for deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RegeneronPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron pharmaceuticals inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RegeneronPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RegeneronPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right additional purchase aggregate of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Additional Purchase Aggregate of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or right additional purchase aggregate of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Unvested balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Unvested balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ThioMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">THIO Merger Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ThioMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">THIO Merger Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ThioMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">THIO Merger Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UniversityOfTexasEuropeanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of texas european.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UniversityOfTexasEuropeanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of Texas European [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UniversityOfTexasEuropeanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University Of Texas European</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Retirement Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issuable upon Exercise of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">THIO.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">T H I O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">T H I O</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">THIO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 27 to May 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January twenty seven to may thirty one two thousand twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Twenty Seven To May Thirty One Two Thousand Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credits, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Experimentation Tax Credits Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Experimentation Tax Credits Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">(Gain) loss on fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain on remeasurement of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability percentage of default, change in control or dissolution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Probability Percentage of Default, Change in Control or Dissolution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Probability percentage of default, change in control or dissolution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 27 to June 30, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January twenty seven to june thirty two thousand twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Twenty Seven To June Thirty Two Thousand Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfFoundersTerminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of founders terminated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfFoundersTerminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Founders Terminated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfFoundersTerminated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of founders terminated.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability, bifurcated put contained in convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Subsidiary Or Equity Method Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Subsidiary Or Equity Method Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OfferingAndOverallotmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering and Overallotment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OfferingAndOverallotmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering and Overallotment Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OfferingAndOverallotmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering and overallotment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability, Defined Benefit Plan, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation to former officers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with Equity Financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares In Connection With Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_Debtdiscountandvalueofembeddedputfeature_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and value of embedded put feature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_Debtdiscountandvalueofembeddedputfeature_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DebtDiscountAndValueOfEmbeddedPutFeature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_Debtdiscountandvalueofembeddedputfeature_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Discount And Value Of Embedded Put Feature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current cash reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options to Purchase Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Due to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due to Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital shares, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units, Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MAIA Drug Development Corporation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M A I A Drug Development Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA DD</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MAIADrugDevelopmentCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MAIA Drug Development Corporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Short-Term Debt [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense related to accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based Compensation Expense Related to Accrued Bonus Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based compensation expense related to accrued bonus balance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise at fair market value per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise At Fair Market Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise at fair market value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancellation of restricted common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancellation of restricted common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from collection of subscription receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collection Of Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collections of subscriptions receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DGDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DGD.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DGDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">D G D [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DGDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">D G D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DGDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DGD</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled/forfeited, Options Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Cancelled/forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent and technology license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent And Technology License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent and Technology License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck protection program loan forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain from forgiveness of Paycheck Protection Program loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss from Forgiveness of Paycheck Protection Program Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) from forgiveness of Paycheck Protection Program loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash issuance cost, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Related Party Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on loan payable to officer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency translation adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of voting power defining change of control</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Voting Power Defining Change Of Control</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Voting Power Defining Change Of Control</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from convertible debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes, warrants, and embedded conversion features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of outstanding principal and interest written off amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Outstanding Principal and Interest Written Off Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishment of outstanding principal and interest written off amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Converted shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of convertible notes, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend declared.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend Declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesUptoOneMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales upto one million.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesUptoOneMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Upto One Million [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesUptoOneMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales up to $1,000,000</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of derivative liabilities related to convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probability of the convertible notes maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probability Of The Convertible Notes Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probability of the convertible notes maturity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DefinedContributionPlanEmployerSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee salary deferrals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DefinedContributionPlanEmployerSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DefinedContributionPlanEmployerSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employer alary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 30,000,000 and 70,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively,0 shares issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense - MAIA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability on convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability on Convertible Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability on convertible notes payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesAboveOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales above one billion.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesAboveOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Above One Billion [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NetSalesAboveOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales above $1,000,000,000</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions used in Calculating Value of Warrants Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share-based payment award, warrants, valuation assumptions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price, exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative liability on convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and derivative liability at the issuance date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Outstanding, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock or Unit Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income Expense Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional incremental stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued bonus expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Promissory Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Convertible Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one convertible promissory note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible notes and accrued interest into common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Convertible Notes and Accrued interest into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes and accrued interest into MAIA common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchProgramExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research program expenditures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchProgramExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Program Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchProgramExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research program expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 1, 2021 to February 28, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January one two thousand twenty one to february twenty eight two thousand twenty one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January One Two Thousand Twenty One To February Twenty Eight Two Thousand Twenty One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right date from which warrants or rights expire.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Date from which Warrants or Rights Expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or right date from which warrants or rights expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PppLoanProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">P P P Loan Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PppLoanProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PPP Loan Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PppLoanProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PPP loan program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UniversityOfTexasSouthwesternMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of texas southwestern.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UniversityOfTexasSouthwesternMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of Texas Southwestern [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UniversityOfTexasSouthwesternMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UTSW</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 1 to January 26, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January one to january twenty six two thousand twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January One To January Twenty Six Two Thousand Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CombinedMilestonePaymentsMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined milestone payments maximum.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CombinedMilestonePaymentsMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Milestone Payments Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CombinedMilestonePaymentsMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined milestone payment maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentsDueRelatedToMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due related to milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentsDueRelatedToMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Due Related To Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentsDueRelatedToMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due related to milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unsecured Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs incurred in connection with equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Costs Incurred in Connection With Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs incurred in connection with Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashPaidForServicesProvided_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for services provided</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashPaidForServicesProvided_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid for Services Provided</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CashPaidForServicesProvided_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for services provided.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Notes To Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory notes to related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_LeighAnnDurantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ms. Durant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_LeighAnnDurantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leigh-Ann Durant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_LeighAnnDurantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leigh-Ann Durant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfFoundersToWhomSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of founders to whom shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfFoundersToWhomSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Founders to Whom Shares Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfFoundersToWhomSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of founders to whom shares granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants expired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrants Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants Outstanding, Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Warrants to Underwiter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants to Underwiter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants to underwriter in connection with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes to settle loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Notes To Settle Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory notes to settle loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantModificationValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant modification, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantModificationValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Modification Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantModificationValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant modification, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 1, 2021 to June 6, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March one two thousand twenty one to june six two thousand twenty one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March One Two Thousand Twenty One To June Six Two Thousand Twenty One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australia research and development incentives receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Receivables, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Australia research and development incentives receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SubscriptionReceivableForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription receivable for issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SubscriptionReceivableForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Receivable for Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SubscriptionReceivableForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription receivable for issuance of MAIA common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss (Gain) on fair value of embedded features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss (Gain) on fair value of embedded features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of embedded features.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Embedded Features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of embedded features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of embedded features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables From Stockholder [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from Stockholder</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of the conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Conversion Price Percentage Of The Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Debt Conversion Price Percentage Of The Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ModificationOfWarrantInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Modification of warrant in equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ModificationOfWarrantInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Modification Of Warrant In Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ModificationOfWarrantInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of warrant in equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, exercises in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE into MAIA common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares vesting quarterly instalments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Quarterly Instalments, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, vesting quarterly instalments, number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled/forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price expired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense related to deferred compensation balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward limited percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforward Limited Percentage of Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforward limited percentage of taxable income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock options to satisfy accrued bonus.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock Options To Satisfy Accrued Bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock options to satisfy accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Promissory Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Nineteen Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options issued to settle accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Stock Options Issued to Settle Accrued Bonus Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of stock options issued to settle accrued bonus balance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsIssuedForAccruedBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued for accrued bonus.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsIssuedForAccruedBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued For Accrued Bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsIssuedForAccruedBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued for accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightOutstandingAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant outstanding and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightOutstandingAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Outstanding and Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantOrRightOutstandingAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right outstanding and exercisable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_BlackSholesMethodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black sholes method.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_BlackSholesMethodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black Sholes Method [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_BlackSholesMethodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Sholes Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued to underwriters in connection with the initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants issued to underwriters in connection with the initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_The401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401 (K)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_The401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The401 K Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_The401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The401 K Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net effect of foreign currency exchange on cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net effect of foreign currency exchange on cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders shares cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 70,000,000 and 30,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively,10,955,904 and 7,584,980 shares issued and outstanding at December 31,2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights exercisable period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Of Initial Public Offering Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Initial Public Offering Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment of initial public offering transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments additional paid in Capital deemed dividend modification of warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Additional Paid In Capital Deemed Dividend Modification Of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend on modification of warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assumptions, contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of common stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability percentage of equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Probability Percentage of Equity Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Probability percentage of equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions used in Calculating Value of Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock options to satisfy deferred compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock Options To Satisfy Deferred Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock options to satisfy deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from paycheck protection program loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Paycheck Protection Program Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Paycheck Protection Program loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertibleNotesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertibleNotesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConvertibleNotesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AustralianResearchAndDevelopmentIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Australian research and development incentives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AustralianResearchAndDevelopmentIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Australian Research And Development Incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AustralianResearchAndDevelopmentIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australian research and development incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development incentive.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Incentive Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Incentive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of common stock total fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options to Purchase Shares of Common Stock Total Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase shares of common stock total fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MAIA Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA Biotechnology, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Pretax book loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 1, 2022 to August 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June one two thousand twenty two to august one two thousand twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June One Two Thousand Twenty Two to August One Two Thousand Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Warrants Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Warrants Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments additional paid in capital deemed dividend for shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Additional Paid in Capital Deemed Dividend for Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend for ratchet shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation expense related to accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted common stock under SAFE agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Shares Converted Under S A F E Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common shares converted under S A F E agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares upon exercise of warrants shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares Upon Exercise Of Warrants Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simple Agreement For Future Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreement For Future Equity Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple agreement for future equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfRatchetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ratchet shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfRatchetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Ratchet Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfRatchetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of ratchet shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of issuable upon conversion of exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Issuable Upon Conversion of Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of issuable upon conversion of exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, recognized period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RaduVitocMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mr. Vitoc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RaduVitocMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Radu Vitoc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RaduVitocMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Radu Vitoc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2021 through May 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand Twenty One to May Two Thousand Twenty One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March 2021 through May 2021.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from common stock net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Common Stock Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">THIO Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">T H I O Therapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">THIO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_THIOTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">THIO Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issuable upon Exercise of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity and Information regarding Outstanding and Exercisable Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Standards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage by parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConsultingServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConsultingServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ConsultingServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ForeignCurrencyTranslationAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency translation adjustment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ForeignCurrencyTranslationAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Translation Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ForeignCurrencyTranslationAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (loss) on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of convertible notes and convertible notes, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Overallotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfDirectorsToWhomSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of directors to whom shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfDirectorsToWhomSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Directors to Whom Shares Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfDirectorsToWhomSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of directors to whom shares granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MaiaDrugDevelopmentCorporationMaiaDdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MAIA Drug Development Corporation ("MAIA DD") [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MaiaDrugDevelopmentCorporationMaiaDdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MAIA Drug Development Corporation ("MAIA DD") [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MaiaDrugDevelopmentCorporationMaiaDdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAIA Drug Development Corporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaycheckProtectionProgramTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaycheckProtectionProgramTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PaycheckProtectionProgramTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck protection program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DGD Pharmaceuticals Corporation or THIO Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DGD Pharmaceuticals Corporation or THIO Therapeutics, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DGD or THIO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DissolutionOfFirm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dissolution of firm.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DissolutionOfFirm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dissolution of Firm</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DissolutionOfFirm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dissolution of firm</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares upon exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Shares Upon Exercise Of Warrants Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common shares upon exercise of warrants shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum gross proceeds from equity financing required for conversion of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClaimExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Claim expiration term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClaimExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Claim Expiration Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClaimExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claim expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets before valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority stockholder ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ReceiptOfStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receipt of stock subscription receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ReceiptOfStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receipt Of Stock Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ReceiptOfStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of stock subscription receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probability of default change in control or dissolution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probability Of Default Change In Control Or Dissolution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probability of default change In control Or dissolution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible note for payment on loan to officer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Note For Payment On Loan To Officer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible note for payment on loan to officer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other nondeductible expenses/(nontaxable income)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend on warrant modification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend On Warrant Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend on warrant modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DeemedDividendOnWarrantModification_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend on warrant modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability percentage of convertible notes outstanding at maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Probability Percentage of Convertible Notes Outstanding at Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Probability percentage of convertible notes outstanding at maturity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of derivative liability in connection with debt conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Derivative Liability in Connection with Debt Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishment of derivative liability in connection with debt conversion.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RatchetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratchet.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RatchetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ratchet Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RatchetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratchet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExpirationOfPatentRightsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration of patent rights period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExpirationOfPatentRightsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration of Patent Rights Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ExpirationOfPatentRightsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration of patent rights period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount forgiven</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Decrease, Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Recorded Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancellation of restricted common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancellation of restricted common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued deferred compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Compensation Liability, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off Balance Sheet Credit Exposure Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-Balance Sheet Risk and Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of SAFE.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion of SAFE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of SAFE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with intial public offering, issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from sale of common stock in intial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development incentives receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Incentives Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australia research and development incentives receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business, organization, and principles of consolidation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Business, Organization, and Principles of Consolidation [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Organization, and Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Attributable To Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock upon exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Loss on Extinguishment of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation loss on extinguishment of debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Leases Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Unvested balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Unvested balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares upon cashless exercise of warrants shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon cashless exercise of warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended patent and technology license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Patent and Technology License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Patent and Technology License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RemainingConsultingServicesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining services settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RemainingConsultingServicesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Consulting Services Settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RemainingConsultingServicesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining consulting services settled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Extinguishment of derivative liability in connection with debt conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of derivative liability in connection with debt conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfStockCompensationExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of stock compensation expense recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfStockCompensationExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Stock Compensation Expense Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfStockCompensationExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of stock compensation expense recognized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Offering Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred offering cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible note amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unvested Restricted Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss, including noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price, per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Net Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of unsecured debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probability of equity financing maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probability Of Equity Financing Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probability of equity financing maturity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">U.S. loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RatchetShareExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratchet share expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RatchetShareExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ratchet Share Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_RatchetShareExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratchet share expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Exercised Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Warrant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution to employee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern Considerations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Considerations [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern considerations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of common shares upon exercise of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Options Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate of royalties on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock option plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Stock Option Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DgdPharmaceuticalsCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DGD Pharmaceuticals Corporation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DgdPharmaceuticalsCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DGD Pharmaceuticals Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_DgdPharmaceuticalsCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DGD Pharmaceuticals Corporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UnrelatedThirdPartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrelated Third Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UnrelatedThirdPartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrelated Third Parties [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_UnrelatedThirdPartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrelated third parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total MAIA Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares vesting commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Vesting Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, shares vesting commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares vesting over period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Over Period, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, vesting over period, number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Promissory Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock options to settle accrued bonus balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Stock Options to Settle Accrued Bonus Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock options to settle accrued bonus balance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australian</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Australian Taxation Office [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from unsecured loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MoneyChannelNycIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Channel NYC Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MoneyChannelNycIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Channel NYC Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_MoneyChannelNycIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money channel nyc inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Previously paid issuance costs in connection with the initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously paid issuance costs in connection with the initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible note issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares upon conversion of convertible notes, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_PercentageOfConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of conversion price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of SAFE.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion of SAFE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon conversion of SAFE, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:to="maia_CertainRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" xlink:to="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantDescription" xlink:to="maia_WarrantDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NetSalesUptoOneBillionMember" xlink:to="maia_NetSalesUptoOneBillionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CommonStockConversionPrice" xlink:to="maia_CommonStockConversionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:to="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OperatingLossCarryforwardsExpirationYear" xlink:to="maia_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_SimpleAgreementForFutureEquityIssued" xlink:to="maia_SimpleAgreementForFutureEquityIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RestrictedCommonStockAwardMember" xlink:to="maia_RestrictedCommonStockAwardMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsIssuedForDeferredCompensation" xlink:to="maia_OptionsIssuedForDeferredCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RegeneronPharmaceuticalsIncMember" xlink:to="maia_RegeneronPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:to="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ThioMergerAgreementMember" xlink:to="maia_ThioMergerAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CommonStockWarrantsPolicyTextBlock" xlink:to="maia_CommonStockWarrantsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_UniversityOfTexasEuropeanMember" xlink:to="maia_UniversityOfTexasEuropeanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_THIOMember" xlink:to="maia_THIOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsExercised" xlink:to="maia_ClassOfWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:to="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:to="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" xlink:to="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" xlink:to="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfFoundersTerminated" xlink:to="maia_NumberOfFoundersTerminated_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OfferingAndOverallotmentMember" xlink:to="maia_OfferingAndOverallotmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantValue" xlink:to="maia_WarrantValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyOneWarrantsMember" xlink:to="maia_TwoThousandAndTwentyOneWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantLiabilityNoncurrent" xlink:to="maia_WarrantLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_Debtdiscountandvalueofembeddedputfeature" xlink:to="maia_Debtdiscountandvalueofembeddedputfeature_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsToPurchaseSharesOfCommonStock" xlink:to="maia_OptionsToPurchaseSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MAIADrugDevelopmentCorporationMember" xlink:to="maia_MAIADrugDevelopmentCorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:to="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CashlessExerciseAtFairMarketValuePerShare" xlink:to="maia_CashlessExerciseAtFairMarketValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:to="maia_ProceedsFromCollectionOfSubscriptionReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DGDMember" xlink:to="maia_DGDMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PatentAndTechnologyLicenseAgreementMember" xlink:to="maia_PatentAndTechnologyLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:to="maia_PercentageOfVotingPowerDefiningChangeOfControl_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:to="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DeemedDividendDeclared" xlink:to="maia_DeemedDividendDeclared_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NetSalesUptoOneMillionMember" xlink:to="maia_NetSalesUptoOneMillionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:to="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DefinedContributionPlanEmployerSalary" xlink:to="maia_DefinedContributionPlanEmployerSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionPlansDefinedBenefitMember" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RelatedPartyMember" xlink:to="maia_RelatedPartyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:to="maia_DerivativeLiabilityOnConvertibleNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NetSalesAboveOneBillionMember" xlink:to="maia_NetSalesAboveOneBillionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_UnvestedRestrictedStockAwardsMember" xlink:to="maia_UnvestedRestrictedStockAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_FounderMember" xlink:to="maia_FounderMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsIssued" xlink:to="maia_ClassOfWarrantsIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:to="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:to="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchProgramExpenditures" xlink:to="maia_ResearchProgramExpenditures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:to="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:to="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PppLoanProgramMember" xlink:to="maia_PppLoanProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_UniversityOfTexasSouthwesternMember" xlink:to="maia_UniversityOfTexasSouthwesternMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:to="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MilestonePayment" xlink:to="maia_MilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CombinedMilestonePaymentsMaximum" xlink:to="maia_CombinedMilestonePaymentsMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PaymentsDueRelatedToMilestones" xlink:to="maia_PaymentsDueRelatedToMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantOneMember" xlink:to="maia_WarrantOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:to="maia_TransactionCostsIncurredInConnectionWithEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CashPaidForServicesProvided" xlink:to="maia_CashPaidForServicesProvided_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertiblePromissoryNotesToRelatedParties" xlink:to="maia_ConvertiblePromissoryNotesToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_LeighAnnDurantMember" xlink:to="maia_LeighAnnDurantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfFoundersToWhomSharesGranted" xlink:to="maia_NumberOfFoundersToWhomSharesGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsExpired" xlink:to="maia_ClassOfWarrantsExpired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" xlink:to="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertiblePromissoryNotesToSettleLoan" xlink:to="maia_ConvertiblePromissoryNotesToSettleLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantModificationValue" xlink:to="maia_WarrantModificationValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:to="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_SubscriptionReceivableForIssuanceOfCommonStock" xlink:to="maia_SubscriptionReceivableForIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ChangeInFairValueOfEmbeddedFeatures" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_LiquidityPolicyTextBlock" xlink:to="maia_LiquidityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:to="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ModificationOfWarrantInEquity" xlink:to="maia_ModificationOfWarrantInEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantsExercised" xlink:to="maia_WarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantsExercisedShares" xlink:to="maia_WarrantsExercisedShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:to="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:to="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:to="maia_TwoThousandAndNineteenPromissoryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:to="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ReclassificationOfWarrantLiabilityToEquity" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsIssuedForAccruedBonus" xlink:to="maia_OptionsIssuedForAccruedBonus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantOrRightOutstandingAndExercisable" xlink:to="maia_ClassOfWarrantOrRightOutstandingAndExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_BlackSholesMethodMember" xlink:to="maia_BlackSholesMethodMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" xlink:to="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_The401KPlanMember" xlink:to="maia_The401KPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:to="maia_PaymentOfInitialPublicOfferingTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" xlink:to="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProbabilityPercentageOfEquityFinancing" xlink:to="maia_ProbabilityPercentageOfEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="maia_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:to="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:to="maia_ProceedsFromPaycheckProtectionProgramLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConvertibleNotesOutstanding" xlink:to="maia_ConvertibleNotesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AustralianResearchAndDevelopmentIncentives" xlink:to="maia_AustralianResearchAndDevelopmentIncentives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:to="maia_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:to="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:to="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" xlink:to="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" xlink:to="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" xlink:to="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" xlink:to="maia_SimpleAgreementForFutureEquityDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfRatchetShares" xlink:to="maia_IssuanceOfRatchetShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:to="maia_PercentageOfIssuableUponConversionOfExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TransactionCosts" xlink:to="maia_TransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RaduVitocMember" xlink:to="maia_RaduVitocMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" xlink:to="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:to="maia_ProceedsFromCommonStockNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_THIOTherapeuticsIncMember" xlink:to="maia_THIOTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ConsultingServices" xlink:to="maia_ConsultingServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ForeignCurrencyTranslationAdjustment" xlink:to="maia_ForeignCurrencyTranslationAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="maia_AccruedResearchAndDevelopmentCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfWarrantsIssued" xlink:to="maia_NumberOfWarrantsIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfDirectorsToWhomSharesGranted" xlink:to="maia_NumberOfDirectorsToWhomSharesGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_NumberOfWarrantsExercised" xlink:to="maia_NumberOfWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MaiaDrugDevelopmentCorporationMaiaDdMember" xlink:to="maia_MaiaDrugDevelopmentCorporationMaiaDdMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PaycheckProtectionProgramTextBlock" xlink:to="maia_PaycheckProtectionProgramTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" xlink:to="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DissolutionOfFirm" xlink:to="maia_DissolutionOfFirm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_CommonSharesUponExerciseOfWarrantsShares" xlink:to="maia_CommonSharesUponExerciseOfWarrantsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WarrantTwoMember" xlink:to="maia_WarrantTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:to="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ChangeInFairValueOfWarrantLiability" xlink:to="maia_ChangeInFairValueOfWarrantLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClaimExpirationTerm" xlink:to="maia_ClaimExpirationTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ReceiptOfStockSubscriptionReceivable" xlink:to="maia_ReceiptOfStockSubscriptionReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:to="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" xlink:to="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DeemedDividendOnWarrantModification" xlink:to="maia_DeemedDividendOnWarrantModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" xlink:to="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" xlink:to="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RatchetMember" xlink:to="maia_RatchetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ExpirationOfPatentRightsPeriod" xlink:to="maia_ExpirationOfPatentRightsPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:to="maia_StockIssuedDuringPeriodValueConversionOfSafe_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ResearchAndDevelopmentIncentivesReceivable" xlink:to="maia_ResearchAndDevelopmentIncentivesReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:to="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:to="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:to="maia_AmendedPatentAndTechnologyLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RemainingConsultingServicesSettled" xlink:to="maia_RemainingConsultingServicesSettled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfStockCompensationExpenseRecognized" xlink:to="maia_PercentageOfStockCompensationExpenseRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IncreaseDecreaseInDeferredOfferingCost" xlink:to="maia_IncreaseDecreaseInDeferredOfferingCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TermOfAgreement" xlink:to="maia_TermOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:to="maia_PercentageOfProbabilityOfEquityFinancingMaturity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_RatchetShareExpense" xlink:to="maia_RatchetShareExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ScheduleOfWarrantExercisedTableTextBlock" xlink:to="maia_ScheduleOfWarrantExercisedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_GoingConcernConsiderationsPolicyTextBlock" xlink:to="maia_GoingConcernConsiderationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandEighteenStockOptionPlanMember" xlink:to="maia_TwoThousandEighteenStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_DgdPharmaceuticalsCorporationMember" xlink:to="maia_DgdPharmaceuticalsCorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_UnrelatedThirdPartiesMember" xlink:to="maia_UnrelatedThirdPartiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyWarrantsMember" xlink:to="maia_TwoThousandAndTwentyWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:to="maia_TwoThousandAndTwentyPromissoryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:to="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:to="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_MoneyChannelNycIncMember" xlink:to="maia_MoneyChannelNycIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_WorkingCapital" xlink:to="maia_WorkingCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" xlink:to="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_PercentageOfConversionPrice" xlink:to="maia_PercentageOfConversionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:to="maia_StockIssuedDuringPeriodSharesConversionOfSafe_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>maia-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-24T15:52:26.7381+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureAccruedExpensesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ThioMergerAgreementMember" xlink:label="maia_ThioMergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DGDMember" xlink:label="maia_DGDMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RatchetMember" xlink:label="maia_RatchetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOMember" xlink:label="maia_THIOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReceiptOfStockSubscriptionReceivable" xlink:label="maia_ReceiptOfStockSubscriptionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ModificationOfWarrantInEquity" xlink:label="maia_ModificationOfWarrantInEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" xlink:label="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ForeignCurrencyTranslationAdjustment" xlink:label="maia_ForeignCurrencyTranslationAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DissolutionOfFirm" xlink:label="maia_DissolutionOfFirm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="maia_ThioMergerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_DGDMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="maia_RatchetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodValueConversionOfSafe" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodSharesConversionOfSafe" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReceiptOfStockSubscriptionReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ModificationOfWarrantInEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ForeignCurrencyTranslationAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_DissolutionOfFirm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOTherapeuticsIncMember" xlink:label="maia_THIOTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DgdPharmaceuticalsCorporationMember" xlink:label="maia_DgdPharmaceuticalsCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MAIADrugDevelopmentCorporationMember" xlink:label="maia_MAIADrugDevelopmentCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MaiaDrugDevelopmentCorporationMaiaDdMember" xlink:label="maia_MaiaDrugDevelopmentCorporationMaiaDdMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OfferingAndOverallotmentMember" xlink:label="maia_OfferingAndOverallotmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" xlink:label="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WorkingCapital" xlink:label="maia_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfWarrantsIssued" xlink:label="maia_NumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="maia_THIOTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_DgdPharmaceuticalsCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="maia_MAIADrugDevelopmentCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_MaiaDrugDevelopmentCorporationMaiaDdMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="maia_OfferingAndOverallotmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="maia_WorkingCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="maia_NumberOfWarrantsIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UnvestedRestrictedStockAwardsMember" xlink:label="maia_UnvestedRestrictedStockAwardsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="maia_UnvestedRestrictedStockAwardsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_LeighAnnDurantMember" xlink:label="maia_LeighAnnDurantMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConsultingServices" xlink:label="maia_ConsultingServices"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RaduVitocMember" xlink:label="maia_RaduVitocMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashPaidForServicesProvided" xlink:label="maia_CashPaidForServicesProvided"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsToPurchaseSharesOfCommonStock" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RemainingConsultingServicesSettled" xlink:label="maia_RemainingConsultingServicesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_LeighAnnDurantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_ConsultingServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RaduVitocMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_CashPaidForServicesProvided" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_RemainingConsultingServicesSettled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PppLoanProgramMember" xlink:label="maia_PppLoanProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="maia_PppLoanProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RelatedPartyMember" xlink:label="maia_RelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyWarrantsMember" xlink:label="maia_TwoThousandAndTwentyWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyOneWarrantsMember" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_Debtdiscountandvalueofembeddedputfeature" xlink:label="maia_Debtdiscountandvalueofembeddedputfeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantDescription" xlink:label="maia_WarrantDescription"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertibleNotesOutstanding" xlink:label="maia_ConvertibleNotesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertiblePromissoryNotesToRelatedParties" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertiblePromissoryNotesToSettleLoan" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsExercised" xlink:label="maia_WarrantsExercised"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RelatedPartyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndNineteenPromissoryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyOneWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyPromissoryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_Debtdiscountandvalueofembeddedputfeature" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfVotingPowerDefiningChangeOfControl" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfIssuableUponConversionOfExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleNotesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToSettleLoan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_CommonSharesUponExerciseOfWarrantsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantsExercised" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfWarrantLiability" xlink:label="maia_ChangeInFairValueOfWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" xlink:label="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="maia_ChangeInFairValueOfWarrantLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="maia_DerivativeLiabilityOnConvertibleNotesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" xlink:label="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfEquityFinancing" xlink:label="maia_ProbabilityPercentageOfEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" xlink:label="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_PercentageOfProbabilityOfEquityFinancingMaturity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ProbabilityPercentageOfEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandEighteenStockOptionPlanMember" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_BlackSholesMethodMember" xlink:label="maia_BlackSholesMethodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantOneMember" xlink:label="maia_WarrantOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RestrictedCommonStockAwardMember" xlink:label="maia_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOMember" xlink:label="maia_THIOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_FounderMember" xlink:label="maia_FounderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantTwoMember" xlink:label="maia_WarrantTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UnrelatedThirdPartiesMember" xlink:label="maia_UnrelatedThirdPartiesMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" xlink:label="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendDeclared" xlink:label="maia_DeemedDividendDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfWarrantsExercised" xlink:label="maia_NumberOfWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightOutstandingAndExercisable" xlink:label="maia_ClassOfWarrantOrRightOutstandingAndExercisable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TransactionCosts" xlink:label="maia_TransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfFoundersToWhomSharesGranted" xlink:label="maia_NumberOfFoundersToWhomSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfStockCompensationExpenseRecognized" xlink:label="maia_PercentageOfStockCompensationExpenseRecognized"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfFoundersTerminated" xlink:label="maia_NumberOfFoundersTerminated"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfDirectorsToWhomSharesGranted" xlink:label="maia_NumberOfDirectorsToWhomSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantModificationValue" xlink:label="maia_WarrantModificationValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendOnWarrantModification" xlink:label="maia_DeemedDividendOnWarrantModification"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsExercisedShares" xlink:label="maia_WarrantsExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashlessExerciseAtFairMarketValuePerShare" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantValue" xlink:label="maia_WarrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsIssued" xlink:label="maia_ClassOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandEighteenStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="maia_BlackSholesMethodMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="maia_WarrantOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_RestrictedCommonStockAwardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="maia_FounderMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="maia_WarrantTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="maia_UnrelatedThirdPartiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardDateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_DeemedDividendDeclared" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromCommonStockNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightOutstandingAndExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_TransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RestrictedStockExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfFoundersToWhomSharesGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_PercentageOfStockCompensationExpenseRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfFoundersTerminated" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfDirectorsToWhomSharesGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantModificationValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_DeemedDividendOnWarrantModification" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantsExercisedShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_CashlessExerciseAtFairMarketValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="54" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="55" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="56" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="57" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="58" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="59" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="60" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="61" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantsIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="62" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_The401KPlanMember" xlink:label="maia_The401KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DefinedContributionPlanEmployerSalary" xlink:label="maia_DefinedContributionPlanEmployerSalary"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="maia_The401KPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="maia_DefinedContributionPlanEmployerSalary" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOTherapeuticsIncMember" xlink:label="maia_THIOTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesUptoOneBillionMember" xlink:label="maia_NetSalesUptoOneBillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TermOfAgreement" xlink:label="maia_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UniversityOfTexasSouthwesternMember" xlink:label="maia_UniversityOfTexasSouthwesternMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesUptoOneMillionMember" xlink:label="maia_NetSalesUptoOneMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PatentAndTechnologyLicenseAgreementMember" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MilestonePayment" xlink:label="maia_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UniversityOfTexasEuropeanMember" xlink:label="maia_UniversityOfTexasEuropeanMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesAboveOneBillionMember" xlink:label="maia_NetSalesAboveOneBillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RegeneronPharmaceuticalsIncMember" xlink:label="maia_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CombinedMilestonePaymentsMaximum" xlink:label="maia_CombinedMilestonePaymentsMaximum"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaymentsDueRelatedToMilestones" xlink:label="maia_PaymentsDueRelatedToMilestones"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClaimExpirationTerm" xlink:label="maia_ClaimExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExpirationOfPatentRightsPeriod" xlink:label="maia_ExpirationOfPatentRightsPeriod"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchProgramExpenditures" xlink:label="maia_ResearchProgramExpenditures"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_THIOTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesUptoOneBillionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_AmendedPatentAndTechnologyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_TermOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_UniversityOfTexasSouthwesternMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesUptoOneMillionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_PatentAndTechnologyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_MilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_UniversityOfTexasEuropeanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesAboveOneBillionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_RegeneronPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_CombinedMilestonePaymentsMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PaymentsDueRelatedToMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ClaimExpirationTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ExpirationOfPatentRightsPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ResearchProgramExpenditures" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OperatingLossCarryforwardsExpirationYear" xlink:label="maia_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MoneyChannelNycIncMember" xlink:label="maia_MoneyChannelNycIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TermOfAgreement" xlink:label="maia_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_MoneyChannelNycIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="maia_TermOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>maia-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-24T15:52:27.3060+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.maiabiotechnology.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:maia="http://www.maiabiotechnology.com/20221231">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1" id="DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1">
        <link:definition>100080 - Disclosure - Nature of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransaction1" id="DisclosureRelatedPartyTransaction1">
        <link:definition>100090 - Disclosure - Related Party Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgram1" id="DisclosurePaycheckProtectionProgram1">
        <link:definition>100110 - Disclosure - Paycheck Protection Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayable" id="DisclosureConvertibleNotesPayable">
        <link:definition>100120 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquity1" id="DisclosureSimpleAgreementForFutureEquity1">
        <link:definition>100130 - Disclosure - Simple Agreement For Future Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities" id="DisclosureFairValueOfFinancialLiabilities">
        <link:definition>100140 - Disclosure - Fair Value of Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan" id="DisclosureEmployeeRetirementPlan">
        <link:definition>100160 - Disclosure - Employee Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100220 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables" id="DisclosureFairValueOfFinancialLiabilitiesTables">
        <link:definition>100230 - Disclosure - Fair Value of Financial Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100240 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha" id="DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha">
        <link:definition>100270 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100290 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" id="DisclosureAccruedExpensesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Accrued Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" id="DisclosurePaycheckProtectionProgramAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Paycheck Protection Program - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" id="DisclosureConvertibleNotesPayableAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Convertible Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" id="DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Simple Agreement For Future Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" id="DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
        <link:definition>100340 - Disclosure - Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails" id="DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails">
        <link:definition>100350 - Disclosure - Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" id="DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Fair Value of Financial Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" id="Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails">
        <link:definition>100380 - Disclosure - Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails" id="Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails">
        <link:definition>100390 - Disclosure - Stockholders' Equity - Schedule of Warrants Exercised (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" id="DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails">
        <link:definition>100400 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Warrants Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" id="DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails">
        <link:definition>100410 - Disclosure - Stockholders' Equity - Summary of Activity and Information regarding Outstanding and Exercisable Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" id="DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails">
        <link:definition>100420 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" id="DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100430 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" id="DisclosureEmployeeRetirementPlanAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Employee Retirement Plan (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Commitments And Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Subsequent Events - Additional Information - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="maia_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" name="AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" name="AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_AustralianResearchAndDevelopmentIncentives" name="AustralianResearchAndDevelopmentIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_CashlessExerciseAtFairMarketValuePerShare" name="CashlessExerciseAtFairMarketValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_CashPaidForServicesProvided" name="CashPaidForServicesProvided" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" name="CashPaidToSettleAPortionOfDeferredCompensationBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ChangeInFairValueOfEmbeddedFeatures" name="ChangeInFairValueOfEmbeddedFeatures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ChangeInFairValueOfWarrantLiability" name="ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ClaimExpirationTerm" name="ClaimExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" name="ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" name="ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantOrRightOutstandingAndExercisable" name="ClassOfWarrantOrRightOutstandingAndExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsExercised" name="ClassOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsExpired" name="ClassOfWarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsIssued" name="ClassOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePrice" name="ClassOfWarrantsWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" name="ClassOfWarrantsWeightedAverageExercisePriceExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" name="ClassOfWarrantsWeightedAverageExercisePriceExpired" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" name="ClassOfWarrantsWeightedAverageExercisePriceIssued" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" name="ClassOfWarrantsWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_CombinedMilestonePaymentsMaximum" name="CombinedMilestonePaymentsMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_CommonSharesUponExerciseOfWarrantsShares" name="CommonSharesUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_CommonStockConversionPrice" name="CommonStockConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_ConsultingServices" name="ConsultingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" name="ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" name="ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_ConvertibleNotesOutstanding" name="ConvertibleNotesOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_ConvertiblePromissoryNotesToRelatedParties" name="ConvertiblePromissoryNotesToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_ConvertiblePromissoryNotesToSettleLoan" name="ConvertiblePromissoryNotesToSettleLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_Debtdiscountandvalueofembeddedputfeature" name="Debtdiscountandvalueofembeddedputfeature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_DeemedDividendDeclared" name="DeemedDividendDeclared" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_DeemedDividendOnWarrantModification" name="DeemedDividendOnWarrantModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_DefinedContributionPlanEmployerSalary" name="DefinedContributionPlanEmployerSalary" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_DerivativeLiabilityOnConvertibleNotesPayable" name="DerivativeLiabilityOnConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_DissolutionOfFirm" name="DissolutionOfFirm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" name="EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ExpirationOfPatentRightsPeriod" name="ExpirationOfPatentRightsPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" name="ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" name="ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" name="FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ForeignCurrencyTranslationAdjustment" name="ForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" name="GainLossFromForgivenessOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_IncreaseDecreaseInDeferredOfferingCost" name="IncreaseDecreaseInDeferredOfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" name="IssuanceOfCommonSharesInConnectionWithEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" name="IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" name="IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" name="IssuanceOfCommonSharesUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" name="IssuanceOfCommonSharesUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" name="IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_IssuanceOfRatchetShares" name="IssuanceOfRatchetShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" name="IssuanceOfStockOptionsToSatisfyAccruedBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" name="IssuanceOfStockOptionsToSatisfyDeferredCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" name="IssuanceOfStockOptionsToSettleAccruedBonusBalance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" name="MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ModificationOfWarrantInEquity" name="ModificationOfWarrantInEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" name="NumberOfCommonSharesConvertedUnderSAFEAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_NumberOfDirectorsToWhomSharesGranted" name="NumberOfDirectorsToWhomSharesGranted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_NumberOfFoundersTerminated" name="NumberOfFoundersTerminated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_NumberOfFoundersToWhomSharesGranted" name="NumberOfFoundersToWhomSharesGranted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_NumberOfWarrantsIssued" name="NumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" name="OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_OptionsIssuedForAccruedBonus" name="OptionsIssuedForAccruedBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_OptionsIssuedForDeferredCompensation" name="OptionsIssuedForDeferredCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_OptionsToPurchaseSharesOfCommonStock" name="OptionsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" name="OptionsToPurchaseSharesOfCommonStockTotalFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_PaymentOfInitialPublicOfferingTransactionCosts" name="PaymentOfInitialPublicOfferingTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_PaymentsDueRelatedToMilestones" name="PaymentsDueRelatedToMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_PercentageOfConversionPrice" name="PercentageOfConversionPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfIssuableUponConversionOfExercisePrice" name="PercentageOfIssuableUponConversionOfExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" name="PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfProbabilityOfEquityFinancingMaturity" name="PercentageOfProbabilityOfEquityFinancingMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" name="PercentageOfProbabilityOfTheConvertibleNotesMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfRoyaltyPaymentsOnNetSales" name="PercentageOfRoyaltyPaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" name="PercentageOfRoyaltyPaymentsOnNetSalesDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfStockCompensationExpenseRecognized" name="PercentageOfStockCompensationExpenseRecognized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PercentageOfVotingPowerDefiningChangeOfControl" name="PercentageOfVotingPowerDefiningChangeOfControl" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" name="PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" name="ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" name="ProbabilityPercentageOfDefaultChangeInControlOrDissolution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ProbabilityPercentageOfEquityFinancing" name="ProbabilityPercentageOfEquityFinancing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ProceedsFromCollectionOfSubscriptionReceivable" name="ProceedsFromCollectionOfSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ProceedsFromCommonStockNetOfIssuanceCosts" name="ProceedsFromCommonStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" name="ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ProceedsFromPaycheckProtectionProgramLoan" name="ProceedsFromPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_RatchetShareExpense" name="RatchetShareExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ReceiptOfStockSubscriptionReceivable" name="ReceiptOfStockSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_ReclassificationOfWarrantLiabilityToEquity" name="ReclassificationOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_RemainingConsultingServicesSettled" name="RemainingConsultingServicesSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_ResearchAndDevelopmentIncentivesReceivable" name="ResearchAndDevelopmentIncentivesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" name="ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ResearchProgramExpenditures" name="ResearchProgramExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_SimpleAgreementForFutureEquityIssued" name="SimpleAgreementForFutureEquityIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" name="StockBasedCompensationExpenseRelatedToAccruedBonusBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_StockIssuedDuringPeriodSharesConversionOfSafe" name="StockIssuedDuringPeriodSharesConversionOfSafe" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_StockIssuedDuringPeriodValueConversionOfSafe" name="StockIssuedDuringPeriodValueConversionOfSafe" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" name="StockIssuedDuringPeriodValueWarrantsToUnderwiter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_SubscriptionReceivableForIssuanceOfCommonStock" name="SubscriptionReceivableForIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_TermOfAgreement" name="TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_TransactionCosts" name="TransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" name="TransactionCostsIncurredInConnectionWithEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_WarrantDescription" name="WarrantDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_WarrantLiabilityNoncurrent" name="WarrantLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_WarrantModificationValue" name="WarrantModificationValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_WarrantsExercised" name="WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_WarrantsExercisedShares" name="WarrantsExercisedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" name="WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_WarrantValue" name="WarrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="maia_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" name="AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_AmendedPatentAndTechnologyLicenseAgreementMember" name="AmendedPatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_BlackSholesMethodMember" name="BlackSholesMethodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_DGDMember" name="DGDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_DgdPharmaceuticalsCorporationMember" name="DgdPharmaceuticalsCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" name="DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_FounderMember" name="FounderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" name="JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" name="JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" name="JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" name="JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" name="JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_LeighAnnDurantMember" name="LeighAnnDurantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_MaiaDrugDevelopmentCorporationMaiaDdMember" name="MaiaDrugDevelopmentCorporationMaiaDdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_MAIADrugDevelopmentCorporationMember" name="MAIADrugDevelopmentCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" name="MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" name="MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_MoneyChannelNycIncMember" name="MoneyChannelNycIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_NetSalesAboveOneBillionMember" name="NetSalesAboveOneBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_NetSalesUptoOneBillionMember" name="NetSalesUptoOneBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_NetSalesUptoOneMillionMember" name="NetSalesUptoOneMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_OfferingAndOverallotmentMember" name="OfferingAndOverallotmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_PatentAndTechnologyLicenseAgreementMember" name="PatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_PppLoanProgramMember" name="PppLoanProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_RaduVitocMember" name="RaduVitocMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_RatchetMember" name="RatchetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_RegeneronPharmaceuticalsIncMember" name="RegeneronPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_RelatedPartyMember" name="RelatedPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_RestrictedCommonStockAwardMember" name="RestrictedCommonStockAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_The401KPlanMember" name="The401KPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_THIOMember" name="THIOMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_ThioMergerAgreementMember" name="ThioMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_THIOTherapeuticsIncMember" name="THIOTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandAndNineteenPromissoryNoteMember" name="TwoThousandAndNineteenPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" name="TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandAndTwentyOneWarrantsMember" name="TwoThousandAndTwentyOneWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandAndTwentyPromissoryNoteMember" name="TwoThousandAndTwentyPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandAndTwentyWarrantsMember" name="TwoThousandAndTwentyWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandEighteenStockOptionPlanMember" name="TwoThousandEighteenStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_UniversityOfTexasEuropeanMember" name="UniversityOfTexasEuropeanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_UniversityOfTexasSouthwesternMember" name="UniversityOfTexasSouthwesternMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_UnrelatedThirdPartiesMember" name="UnrelatedThirdPartiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_WarrantOneMember" name="WarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_WarrantTwoMember" name="WarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="maia_CertainRisksAndUncertaintiesPolicyTextBlock" name="CertainRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_CommonStockWarrantsPolicyTextBlock" name="CommonStockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" name="DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_GoingConcernConsiderationsPolicyTextBlock" name="GoingConcernConsiderationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" name="ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_PaycheckProtectionProgramTextBlock" name="PaycheckProtectionProgramTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" name="ResearchAndDevelopmentIncentivePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_ScheduleOfWarrantExercisedTableTextBlock" name="ScheduleOfWarrantExercisedTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" name="SimpleAgreementForFutureEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>maia-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-24T15:52:26.6758+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="maia-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="maia-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="maia-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="maia-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransaction1" xlink:href="maia-20221231.xsd#DisclosureRelatedPartyTransaction1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="maia-20221231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgram1" xlink:href="maia-20221231.xsd#DisclosurePaycheckProtectionProgram1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayable" xlink:href="maia-20221231.xsd#DisclosureConvertibleNotesPayable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquity1" xlink:href="maia-20221231.xsd#DisclosureSimpleAgreementForFutureEquity1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan" xlink:href="maia-20221231.xsd#DisclosureEmployeeRetirementPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="maia-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="maia-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="maia-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="maia-20221231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="maia-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha" xlink:href="maia-20221231.xsd#DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="maia-20221231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureAccruedExpensesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails" xlink:href="maia-20221231.xsd#Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="maia-20221231.xsd#DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:href="maia-20221231.xsd#DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="maia-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:href="maia-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="maia-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantLiabilityNoncurrent" xlink:label="maia_WarrantLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndDevelopmentIncentivesReceivable" xlink:label="maia_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="maia_WarrantLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="maia_ResearchAndDevelopmentIncentivesReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RatchetShareExpense" xlink:label="maia_RatchetShareExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AustralianResearchAndDevelopmentIncentives" xlink:label="maia_AustralianResearchAndDevelopmentIncentives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendOnWarrantModification" xlink:label="maia_DeemedDividendOnWarrantModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="maia_RatchetShareExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="maia_AustralianResearchAndDevelopmentIncentives" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="maia_DeemedDividendOnWarrantModification" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ThioMergerAgreementMember" xlink:label="maia_ThioMergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DGDMember" xlink:label="maia_DGDMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RatchetMember" xlink:label="maia_RatchetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOMember" xlink:label="maia_THIOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrants" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" xlink:label="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" xlink:label="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodValueConversionOfSafe" xlink:label="maia_StockIssuedDuringPeriodValueConversionOfSafe"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodSharesConversionOfSafe" xlink:label="maia_StockIssuedDuringPeriodSharesConversionOfSafe"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" xlink:label="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReceiptOfStockSubscriptionReceivable" xlink:label="maia_ReceiptOfStockSubscriptionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TransactionCostsIncurredInConnectionWithEquityFinancing" xlink:label="maia_TransactionCostsIncurredInConnectionWithEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ModificationOfWarrantInEquity" xlink:label="maia_ModificationOfWarrantInEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" xlink:label="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" xlink:label="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ForeignCurrencyTranslationAdjustment" xlink:label="maia_ForeignCurrencyTranslationAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DissolutionOfFirm" xlink:label="maia_DissolutionOfFirm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_32"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="maia_ThioMergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_DGDMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="maia_RatchetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyAccruedBonus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodValueConversionOfSafe" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodSharesConversionOfSafe" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReceiptOfStockSubscriptionReceivable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_TransactionCostsIncurredInConnectionWithEquityFinancing" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ModificationOfWarrantInEquity" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_ForeignCurrencyTranslationAdjustment" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="maia_DissolutionOfFirm" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_32" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:label="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="maia_ProceedsFromPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IncreaseDecreaseInDeferredOfferingCost" xlink:label="maia_IncreaseDecreaseInDeferredOfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromCollectionOfSubscriptionReceivable" xlink:label="maia_ProceedsFromCollectionOfSubscriptionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_SubscriptionReceivableForIssuanceOfCommonStock" xlink:label="maia_SubscriptionReceivableForIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" xlink:label="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsIssuedForAccruedBonus" xlink:label="maia_OptionsIssuedForAccruedBonus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsIssuedForDeferredCompensation" xlink:label="maia_OptionsIssuedForDeferredCompensation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfRatchetShares" xlink:label="maia_IssuanceOfRatchetShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" xlink:label="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaymentOfInitialPublicOfferingTransactionCosts" xlink:label="maia_PaymentOfInitialPublicOfferingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" xlink:label="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" xlink:label="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="maia_ProceedsFromPaycheckProtectionProgramLoan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="maia_IncreaseDecreaseInDeferredOfferingCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="maia_ProceedsFromCollectionOfSubscriptionReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_SubscriptionReceivableForIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_OptionsIssuedForAccruedBonus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_OptionsIssuedForDeferredCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="maia_IssuanceOfRatchetShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="maia_PaymentOfInitialPublicOfferingTransactionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransaction1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgram1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaycheckProtectionProgramTextBlock" xlink:label="maia_PaycheckProtectionProgramTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="maia_PaycheckProtectionProgramTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquity1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_SimpleAgreementForFutureEquityDisclosureTextBlock" xlink:label="maia_SimpleAgreementForFutureEquityDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_SimpleAgreementForFutureEquityDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_LiquidityPolicyTextBlock" xlink:label="maia_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_GoingConcernConsiderationsPolicyTextBlock" xlink:label="maia_GoingConcernConsiderationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" xlink:label="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:label="maia_CertainRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:label="maia_ResearchAndDevelopmentIncentivePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonStockWarrantsPolicyTextBlock" xlink:label="maia_CommonStockWarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_LiquidityPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_GoingConcernConsiderationsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_CertainRisksAndUncertaintiesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_ResearchAndDevelopmentIncentivePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="maia_CommonStockWarrantsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ScheduleOfWarrantExercisedTableTextBlock" xlink:label="maia_ScheduleOfWarrantExercisedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ScheduleOfWarrantExercisedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOTherapeuticsIncMember" xlink:label="maia_THIOTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DgdPharmaceuticalsCorporationMember" xlink:label="maia_DgdPharmaceuticalsCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MAIADrugDevelopmentCorporationMember" xlink:label="maia_MAIADrugDevelopmentCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MaiaDrugDevelopmentCorporationMaiaDdMember" xlink:label="maia_MaiaDrugDevelopmentCorporationMaiaDdMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OfferingAndOverallotmentMember" xlink:label="maia_OfferingAndOverallotmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" xlink:label="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WorkingCapital" xlink:label="maia_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfWarrantsIssued" xlink:label="maia_NumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="maia_THIOTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_DgdPharmaceuticalsCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="maia_MAIADrugDevelopmentCorporationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_MaiaDrugDevelopmentCorporationMaiaDdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="maia_OfferingAndOverallotmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_OwnershipAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="maia_WorkingCapital" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="maia_NumberOfWarrantsIssued" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UnvestedRestrictedStockAwardsMember" xlink:label="maia_UnvestedRestrictedStockAwardsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="maia_UnvestedRestrictedStockAwardsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_LeighAnnDurantMember" xlink:label="maia_LeighAnnDurantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConsultingServices" xlink:label="maia_ConsultingServices"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RaduVitocMember" xlink:label="maia_RaduVitocMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashPaidForServicesProvided" xlink:label="maia_CashPaidForServicesProvided"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsToPurchaseSharesOfCommonStock" xlink:label="maia_OptionsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" xlink:label="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RemainingConsultingServicesSettled" xlink:label="maia_RemainingConsultingServicesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_LeighAnnDurantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_ConsultingServices" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RaduVitocMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_CashPaidForServicesProvided" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="maia_RemainingConsultingServicesSettled" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnsecuredDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="maia_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="maia_AccruedResearchAndDevelopmentCostsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" xlink:label="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" xlink:label="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" xlink:label="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" xlink:label="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_CashPaidToSettleAPortionOfDeferredCompensationBalance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PppLoanProgramMember" xlink:label="maia_PppLoanProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" xlink:label="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="maia_PppLoanProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RelatedPartyMember" xlink:label="maia_RelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyWarrantsMember" xlink:label="maia_TwoThousandAndTwentyWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndNineteenPromissoryNoteMember" xlink:label="maia_TwoThousandAndNineteenPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyOneWarrantsMember" xlink:label="maia_TwoThousandAndTwentyOneWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyPromissoryNoteMember" xlink:label="maia_TwoThousandAndTwentyPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" xlink:label="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" xlink:label="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_Debtdiscountandvalueofembeddedputfeature" xlink:label="maia_Debtdiscountandvalueofembeddedputfeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" xlink:label="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfVotingPowerDefiningChangeOfControl" xlink:label="maia_PercentageOfVotingPowerDefiningChangeOfControl"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantDescription" xlink:label="maia_WarrantDescription"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfIssuableUponConversionOfExercisePrice" xlink:label="maia_PercentageOfIssuableUponConversionOfExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertibleNotesOutstanding" xlink:label="maia_ConvertibleNotesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertiblePromissoryNotesToRelatedParties" xlink:label="maia_ConvertiblePromissoryNotesToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ConvertiblePromissoryNotesToSettleLoan" xlink:label="maia_ConvertiblePromissoryNotesToSettleLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_CommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsExercised" xlink:label="maia_WarrantsExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndNineteenPromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_TwoThousandAndTwentyOneWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyPromissoryNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_Debtdiscountandvalueofembeddedputfeature" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfVotingPowerDefiningChangeOfControl" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantDescription" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_PercentageOfIssuableUponConversionOfExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertibleNotesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToRelatedParties" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_ConvertiblePromissoryNotesToSettleLoan" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_CommonSharesUponExerciseOfWarrantsShares" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="maia_WarrantsExercised" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_SimpleAgreementForFutureEquityIssued" xlink:label="maia_SimpleAgreementForFutureEquityIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfConversionPrice" xlink:label="maia_PercentageOfConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" xlink:label="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CommonStockConversionPrice" xlink:label="maia_CommonStockConversionPrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_SimpleAgreementForFutureEquityIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_PercentageOfConversionPrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_NumberOfCommonSharesConvertedUnderSAFEAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_CommonStockConversionPrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfWarrantLiability" xlink:label="maia_ChangeInFairValueOfWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DerivativeLiabilityOnConvertibleNotesPayable" xlink:label="maia_DerivativeLiabilityOnConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ReclassificationOfWarrantLiabilityToEquity" xlink:label="maia_ReclassificationOfWarrantLiabilityToEquity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" xlink:label="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="maia_ChangeInFairValueOfWarrantLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="maia_DerivativeLiabilityOnConvertibleNotesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="maia_ReclassificationOfWarrantLiabilityToEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilities_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ChangeInFairValueOfEmbeddedFeatures" xlink:label="maia_ChangeInFairValueOfEmbeddedFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" xlink:label="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" xlink:label="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfEquityFinancingMaturity" xlink:label="maia_PercentageOfProbabilityOfEquityFinancingMaturity"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfEquityFinancing" xlink:label="maia_ProbabilityPercentageOfEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" xlink:label="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" xlink:label="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ChangeInFairValueOfEmbeddedFeatures" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_PercentageOfProbabilityOfEquityFinancingMaturity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ProbabilityPercentageOfEquityFinancing" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandEighteenStockOptionPlanMember" xlink:label="maia_TwoThousandEighteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_BlackSholesMethodMember" xlink:label="maia_BlackSholesMethodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantOneMember" xlink:label="maia_WarrantOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RestrictedCommonStockAwardMember" xlink:label="maia_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOMember" xlink:label="maia_THIOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_FounderMember" xlink:label="maia_FounderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:label="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantTwoMember" xlink:label="maia_WarrantTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="maia_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" xlink:label="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UnrelatedThirdPartiesMember" xlink:label="maia_UnrelatedThirdPartiesMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" xlink:label="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" xlink:label="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" xlink:label="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" xlink:label="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendDeclared" xlink:label="maia_DeemedDividendDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromCommonStockNetOfIssuanceCosts" xlink:label="maia_ProceedsFromCommonStockNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfWarrantsExercised" xlink:label="maia_NumberOfWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightOutstandingAndExercisable" xlink:label="maia_ClassOfWarrantOrRightOutstandingAndExercisable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TransactionCosts" xlink:label="maia_TransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfFoundersToWhomSharesGranted" xlink:label="maia_NumberOfFoundersToWhomSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfStockCompensationExpenseRecognized" xlink:label="maia_PercentageOfStockCompensationExpenseRecognized"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfFoundersTerminated" xlink:label="maia_NumberOfFoundersTerminated"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NumberOfDirectorsToWhomSharesGranted" xlink:label="maia_NumberOfDirectorsToWhomSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantModificationValue" xlink:label="maia_WarrantModificationValue"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DeemedDividendOnWarrantModification" xlink:label="maia_DeemedDividendOnWarrantModification"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantsExercisedShares" xlink:label="maia_WarrantsExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CashlessExerciseAtFairMarketValuePerShare" xlink:label="maia_CashlessExerciseAtFairMarketValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" xlink:label="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" xlink:label="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_WarrantValue" xlink:label="maia_WarrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:label="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" xlink:label="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsIssued" xlink:label="maia_ClassOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandEighteenStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="maia_BlackSholesMethodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="maia_WarrantOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="maia_RestrictedCommonStockAwardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="maia_THIOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="maia_FounderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="maia_WarrantTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="maia_TwoThousandTwentyOneEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="maia_UnrelatedThirdPartiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_PlanNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_RangeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_AwardDateAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_DeemedDividendDeclared" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromCommonStockNetOfIssuanceCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfWarrantsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightOutstandingAndExercisable" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_TransactionCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfFoundersToWhomSharesGranted" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_PercentageOfStockCompensationExpenseRecognized" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfFoundersTerminated" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_NumberOfDirectorsToWhomSharesGranted" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantModificationValue" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_DeemedDividendOnWarrantModification" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantsExercisedShares" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_CashlessExerciseAtFairMarketValuePerShare" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_WarrantValue" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" order="54" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock" order="55" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="56" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="57" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="58" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="59" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="60" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="maia_ClassOfWarrantsIssued" order="61" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="62" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsIssued" xlink:label="maia_ClassOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsExercised" xlink:label="maia_ClassOfWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsExpired" xlink:label="maia_ClassOfWarrantsExpired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_4"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageExercisePrice" xlink:label="maia_ClassOfWarrantsWeightedAverageExercisePrice_9"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" xlink:label="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsExpired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePriceExpired" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageExercisePrice_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_The401KPlanMember" xlink:label="maia_The401KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_DefinedContributionPlanEmployerSalary" xlink:label="maia_DefinedContributionPlanEmployerSalary"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="maia_The401KPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="maia_DefinedContributionPlanEmployerSalary" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_THIOTherapeuticsIncMember" xlink:label="maia_THIOTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesUptoOneBillionMember" xlink:label="maia_NetSalesUptoOneBillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_AmendedPatentAndTechnologyLicenseAgreementMember" xlink:label="maia_AmendedPatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TermOfAgreement" xlink:label="maia_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UniversityOfTexasSouthwesternMember" xlink:label="maia_UniversityOfTexasSouthwesternMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesUptoOneMillionMember" xlink:label="maia_NetSalesUptoOneMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PatentAndTechnologyLicenseAgreementMember" xlink:label="maia_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MilestonePayment" xlink:label="maia_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_UniversityOfTexasEuropeanMember" xlink:label="maia_UniversityOfTexasEuropeanMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_NetSalesAboveOneBillionMember" xlink:label="maia_NetSalesAboveOneBillionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_RegeneronPharmaceuticalsIncMember" xlink:label="maia_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_CombinedMilestonePaymentsMaximum" xlink:label="maia_CombinedMilestonePaymentsMaximum"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PaymentsDueRelatedToMilestones" xlink:label="maia_PaymentsDueRelatedToMilestones"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" xlink:label="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ClaimExpirationTerm" xlink:label="maia_ClaimExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ExpirationOfPatentRightsPeriod" xlink:label="maia_ExpirationOfPatentRightsPeriod"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchProgramExpenditures" xlink:label="maia_ResearchProgramExpenditures"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_THIOTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesUptoOneBillionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_AmendedPatentAndTechnologyLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_TermOfAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_UniversityOfTexasSouthwesternMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesUptoOneMillionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_PatentAndTechnologyLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_MilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_UniversityOfTexasEuropeanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="maia_NetSalesAboveOneBillionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="maia_RegeneronPharmaceuticalsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_CombinedMilestonePaymentsMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PaymentsDueRelatedToMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSales" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ClaimExpirationTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ExpirationOfPatentRightsPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="maia_ResearchProgramExpenditures" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OperatingLossCarryforwardsExpirationYear" xlink:label="maia_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" xlink:label="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" xlink:label="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardsExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" xlink:label="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_MoneyChannelNycIncMember" xlink:label="maia_MoneyChannelNycIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="maia-20221231.xsd#maia_TermOfAgreement" xlink:label="maia_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="maia_MoneyChannelNycIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="maia_TermOfAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000145648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MAIA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MAIA BIOTECHNOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001878313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1495913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">444 West Lake Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Chicago<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">06060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-8592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,996,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">EISNERAMPER LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Charlotte, North Carolina<span></span>
</td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for the annual stockholder meeting to be held in 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K as noted herein. The registrant intends to file its proxy statement within 120 days after its fiscal year end.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885993619776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 10,950,927<span></span>
</td>
<td class="nump">$ 10,574,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">554,321<span></span>
</td>
<td class="nump">54,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ResearchAndDevelopmentIncentivesReceivable', window );">Australia research and development incentives receivable</a></td>
<td class="nump">302,789<span></span>
</td>
<td class="nump">43,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,808,037<span></span>
</td>
<td class="nump">10,672,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">211,203<span></span>
</td>
<td class="nump">651,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,022,040<span></span>
</td>
<td class="nump">11,327,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,165,505<span></span>
</td>
<td class="nump">960,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,103,401<span></span>
</td>
<td class="nump">1,185,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,268,906<span></span>
</td>
<td class="nump">2,145,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,514,247<span></span>
</td>
<td class="nump">2,145,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 30,000,000 and 70,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively,0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 70,000,000 and 30,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively,10,955,904 and 7,584,980 shares issued and outstanding at December 31,2022 and December 31, 2021, respectively</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">52,729,942<span></span>
</td>
<td class="nump">37,618,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(44,207,272)<span></span>
</td>
<td class="num">(28,437,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">8,507,793<span></span>
</td>
<td class="nump">9,181,203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 12,022,040<span></span>
</td>
<td class="nump">$ 11,327,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999897488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">10,955,904<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">10,955,904<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886086199584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 8,933,314<span></span>
</td>
<td class="nump">$ 3,496,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">6,143,527<span></span>
</td>
<td class="nump">4,289,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_RatchetShareExpense', window );">Ratchet share expense</a></td>
<td class="nump">1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,176,201<span></span>
</td>
<td class="nump">7,786,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(16,176,201)<span></span>
</td>
<td class="num">(7,786,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,967)<span></span>
</td>
<td class="num">(827,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_AustralianResearchAndDevelopmentIncentives', window );">Australian research and development incentives</a></td>
<td class="nump">313,625<span></span>
</td>
<td class="nump">43,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan', window );">Paycheck protection program loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">98,394<span></span>
</td>
<td class="num">(1,546,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes and convertible notes, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,322,943)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="nump">406,922<span></span>
</td>
<td class="num">(4,791,584)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,769,279)<span></span>
</td>
<td class="num">(12,578,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="num">(450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to MAIA Biotechnology, Inc. shareholders</a></td>
<td class="num">$ (16,219,857)<span></span>
</td>
<td class="num">$ (12,503,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share basic</a></td>
<td class="num">$ (1.75)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share diluted</a></td>
<td class="num">$ (1.75)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">9,276,761<span></span>
</td>
<td class="nump">5,278,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">9,276,761<span></span>
</td>
<td class="nump">5,278,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_AustralianResearchAndDevelopmentIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Australian research and development incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_AustralianResearchAndDevelopmentIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DeemedDividendOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DeemedDividendOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from forgiveness of Paycheck Protection Program loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_RatchetShareExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratchet share expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_RatchetShareExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000073392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (16,219,857)<span></span>
</td>
<td class="num">$ (12,503,880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,235,830)<span></span>
</td>
<td class="num">$ (12,503,880)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885991132352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Ratchet</div></th>
<th class="th"><div>DGD</div></th>
<th class="th"><div>THIO</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>THIO Merger Agreement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Ratchet</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>THIO Merger Agreement</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Ratchet</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>DGD</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Subscription Receivable</div></th>
<th class="th"><div>Total MAIA Equity</div></th>
<th class="th">
<div>Total MAIA Equity </div>
<div>THIO Merger Agreement</div>
</th>
<th class="th">
<div>Total MAIA Equity </div>
<div>DGD</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>THIO Merger Agreement</div>
</th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>DGD</div>
</th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>THIO</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,616,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,599,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,934,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,002)<span></span>
</td>
<td class="num">$ (3,336,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,719,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,433,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrants', window );">Issuance of common shares upon exercise of warrants</a></td>
<td class="nump">529,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares', window );">Issuance of common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted common shares</a></td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,498<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,278<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted common shares</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,428,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,460<span></span>
</td>
<td class="nump">$ 104,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,460<span></span>
</td>
<td class="nump">$ 104,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfStockOptionsToSatisfyAccruedBonus', window );">Issuance of stock options to satisfy accrued bonus</a></td>
<td class="nump">786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation', window );">Issuance of stock options to satisfy deferred compensation</a></td>
<td class="nump">285,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes</a></td>
<td class="nump">11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,001,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_StockIssuedDuringPeriodValueConversionOfSafe', window );">Issuance of common shares upon conversion of SAFE</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_StockIssuedDuringPeriodSharesConversionOfSafe', window );">Issuance of common shares upon conversion of SAFE, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing', window );">Issuance of common shares in connection with equity financing</a></td>
<td class="nump">5,860,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,180,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
<td class="nump">5,860,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares', window );">Issuance of common shares in connection with equity financing, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReceiptOfStockSubscriptionReceivable', window );">Receipt of stock subscription receivable</a></td>
<td class="nump">322,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,002<span></span>
</td>
<td class="nump">322,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TransactionCostsIncurredInConnectionWithEquityFinancing', window );">Transaction costs incurred in connection with Equity Financing</a></td>
<td class="num">(118,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">1,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DissolutionOfFirm', window );">Dissolution of firm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,805<span></span>
</td>
<td class="nump">$ 1,098,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (813,805)<span></span>
</td>
<td class="num">$ (1,098,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(12,578,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,503,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,503,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (74,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">9,181,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,618,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,437,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,181,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon exercise of stock options, Shares</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrants', window );">Issuance of common shares upon exercise of warrants</a></td>
<td class="nump">$ 385,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares', window );">Issuance of common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,319,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,319,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing', window );">Issuance of common shares in connection with equity financing</a></td>
<td class="nump">2,473,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,473,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares', window );">Issuance of common shares in connection with equity financing, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,750,095<span></span>
</td>
<td class="nump">$ 1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,749,865<span></span>
</td>
<td class="nump">$ 1,099,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">219,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ModificationOfWarrantInEquity', window );">Modification of warrant in equity</a></td>
<td class="nump">450,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant', window );">Deemed dividend on modification of warrant</a></td>
<td class="num">(450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,769,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,769,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 8,507,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,729,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,207,272)<span></span>
</td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,955,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments additional paid in Capital deemed dividend modification of warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DissolutionOfFirm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dissolution of firm.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DissolutionOfFirm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with Equity Financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with Equity Financing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfStockOptionsToSatisfyAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock options to satisfy accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfStockOptionsToSatisfyAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock options to satisfy deferred compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ModificationOfWarrantInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of warrant in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ModificationOfWarrantInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReceiptOfStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReceiptOfStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_StockIssuedDuringPeriodSharesConversionOfSafe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of SAFE.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_StockIssuedDuringPeriodSharesConversionOfSafe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_StockIssuedDuringPeriodValueConversionOfSafe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of SAFE.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_StockIssuedDuringPeriodValueConversionOfSafe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TransactionCostsIncurredInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TransactionCostsIncurredInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998273312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common shares in connection with intial public offering, issuance cost</a></td>
<td class="nump">$ 2,749,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885991059600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss, including noncontrolling interests</a></td>
<td class="num">$ (15,769,279)<span></span>
</td>
<td class="num">$ (12,578,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,319,427<span></span>
</td>
<td class="nump">2,722,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan', window );">Gain from forgiveness of Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfRatchetShares', window );">Issuance of ratchet shares</a></td>
<td class="nump">1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(98,394)<span></span>
</td>
<td class="nump">1,546,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(505,233)<span></span>
</td>
<td class="num">(15,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IncreaseDecreaseInDeferredOfferingCost', window );">Deferred offering costs</a></td>
<td class="nump">440,379<span></span>
</td>
<td class="num">(651,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Australia research and development incentives receivable</a></td>
<td class="num">(269,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">322<span></span>
</td>
<td class="num">(3,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">211,346<span></span>
</td>
<td class="nump">805,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">915,742<span></span>
</td>
<td class="nump">997,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,655,725)<span></span>
</td>
<td class="num">(4,122,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, warrants, and embedded conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,369,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromPaycheckProtectionProgramLoan', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromCollectionOfSubscriptionReceivable', window );">Collections of subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of transaction costs</a></td>
<td class="nump">2,473,560<span></span>
</td>
<td class="nump">5,742,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">385,400<span></span>
</td>
<td class="nump">529,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in intial public offering</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaymentOfInitialPublicOfferingTransactionCosts', window );">Payment of initial public offering transaction costs</a></td>
<td class="num">(2,406,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment on loan payable to officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,036,790<span></span>
</td>
<td class="nump">14,033,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Net effect of foreign currency exchange on cash</a></td>
<td class="num">(4,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">376,635<span></span>
</td>
<td class="nump">9,910,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">10,574,292<span></span>
</td>
<td class="nump">663,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">10,950,927<span></span>
</td>
<td class="nump">10,574,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock', window );">Conversion of convertible notes and accrued interest into MAIA common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of SAFE into MAIA common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsIssuedForAccruedBonus', window );">Options issued for accrued bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsIssuedForDeferredCompensation', window );">Options issued for deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer', window );">Issuance of convertible note for payment on loan to officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering', window );">Previously paid issuance costs in connection with the initial public offering</a></td>
<td class="nump">651,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering', window );">Warrants issued to underwriters in connection with the initial public offering</a></td>
<td class="nump">$ 343,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible notes and accrued interest into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from forgiveness of Paycheck Protection Program loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IncreaseDecreaseInDeferredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IncreaseDecreaseInDeferredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible note for payment on loan to officer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfRatchetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ratchet shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfRatchetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsIssuedForAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options issued for accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsIssuedForAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsIssuedForDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options issued for deferred compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsIssuedForDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PaymentOfInitialPublicOfferingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Initial Public Offering Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PaymentOfInitialPublicOfferingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Previously paid issuance costs in connection with the initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromCollectionOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from collection of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromCollectionOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to underwriters in connection with the initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999124464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business, Organization, and Principles of Consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#8220;the Company&#8221;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#8220;MAIA&#8221;) was incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 3, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Therapeutics, Inc. (&#8220;THIO&#8221;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">minority stockholder of THIO received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> share of MAIA common stock for each share of THIO common stock owned prior to the merger.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DGD Pharmaceuticals Corporation (&#8220;DGD&#8221;), incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2019</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Drug Development Corporation (&#8220;MAIA DD&#8221;) incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Texas</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 10, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</span></div></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company had working capital of&#8201;$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,539,131</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,207,272</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,950,927</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and current liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,268,906</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,729</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,373,561</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before transaction costs and expenses. During May 2022, the company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#8221; The Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the initial public offering. On August 3, 2022, the Company sold an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per the overallotment option for the underwriter. After deducting $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,406,170</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for cash issuance costs, net proceeds from the offering and overallotment were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,093,830</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern Considerations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,207,272</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the Company&#8217;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,951</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,000 million in cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">meet the Company&#8217;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of the COVID-19 Pandemic on our Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221; or &#8220;GAAP&#8221;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s Chief Executive Officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#8217;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">financial statements of the Company&#8217;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">period </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#8217; equity as accumulated other comprehensive loss.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash equivalents as of December 31, 2022 and 2021.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#8220;Accounting Standards Codification (ASC) Topic 820&#8221;, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Incentive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), depending on the specific terms of the warrant agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When warrants are issued for services to non-employees, under ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.772%;"/>
          <td style="width:1.171%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.741%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.171%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.144%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,545,628</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,797,185</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">796,985</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311,117</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Standards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASU No. 2016-02</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> this new standard as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#8217;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886185686832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. RELATED PARTY TRANSACTIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Consulting Services</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leigh-Ann Durant, a former member of the Company&#8217;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,994</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,560</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued her options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,964</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,434</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the year ended December 31, 2021.  Ms. Durant was no longer considered a related party in 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,350</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued him options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,250</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for services provided in fiscal 2021 were settled in March, 2022 for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">226</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options issued to Mr. Vitoc. The Company also issued him a convertible note in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during April 2021, which was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,557</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock on September 30, 2021 at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and also received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,278</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants to purchase shares of common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.  In 2022, Mr. Vitoc provided consulting services to the Company through July 2022 for which the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,900</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for services provided during the year ended December 31, 2022.  The Company paid Mr. Vitoc $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,950</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued him options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,690</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.950</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In August 2022, Mr. Vitoc became an employee of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CEO Loan Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's chief executive officer lent the Company a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in August and September of 2018. These amounts, were unsecured, had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stated interest rate, and no stated repayment terms. The Company repaid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,633</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the loan to the CEO during 2020 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">367</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The convertible note issued to the CEO was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,621</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock on September 30, 2021 at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.  No further notes to the CEO were incurred in the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886152068320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.  ACCRUED EXPENSES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, accrued expenses consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.486%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.15%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.607%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.139%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bonus</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,094,582</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional  fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">332,589</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">380,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516,961</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,140</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred compensation to former officers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,271</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,157</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,103,401</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,185,595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Compensation Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,271</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">193,379</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in deferred compensation. The Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">457,749</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,769</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">296,264</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">743,167</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The fair value of the options issued in excess of the deferred compensation balance settled totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,846</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Bonus</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, the Company accrued $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,094,582</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">713,536</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">786,531</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The fair value of the options issued in excess of the accrued bonus balance totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,531</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August of 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886084682400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaycheckProtectionProgramTextBlock', window );">Paycheck Protection Program</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. PAYCHECK PROTECTION PROGRAM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 31, 2021, the Company received a second PPP Loan in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum. The term of the PPP Loan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and the Company recorded a gain on extinguishment totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PaycheckProtectionProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paycheck protection program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PaycheckProtectionProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998381328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. CONVERTIBLE NOTES PAYABLE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes Payable issued in 2019</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, the Company issued a Convertible Promissory Note totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to one individual (the "2019 Convertible Note"). The 2019 Convertible Note bore interest at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, was unsecured, with a scheduled maturity date of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (before any transaction related expenses and costs). The conversion price will be set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the preferred stock issued in the aforementioned Equity Financing.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Put Feature</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the terms related to the Equity Financing conversion, (the &#8220;Embedded Put Feature&#8221;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense on the 2019 Convertible Note totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">607</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at issuance. The balance of the debt discount was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022 and 2021. During the year ended December 31, 2022 and 2021, amortization of debt discount amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes Payable issued in 2020</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2020, the Company issued Convertible Promissory Notes totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">610,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to various investors or holders, including $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Convertible Promissory Notes to related parties (collectively, the "2020 Convertible Notes") throughout fiscal 2020. The 2020 Convertible Notes bore interest at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, was unsecured, with a scheduled maturity date of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 31, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Prices</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conversion price is set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Put Features</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at issuance of the 2020 Convertible Notes (see Note 8). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maturity Date</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense on the 2020 Convertible Notes totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,375</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,523</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discounts on the 2020 Convertible Notes totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022 and 2021, respectively.  During the year ended December 31, 2021 amortization of debt discounts amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,608</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amortization of debt discounts for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,660</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 8) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes Payable issued in 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the  year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,390,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to various investors or holders, including $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,863,300</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Convertible Promissory Notes to related parties (collectively, the "2021 Convertible Notes") which included a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued on conversion shall be shares of the Company&#8217;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Prices</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conversion price was set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Put Features</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#8220;Embedded Put Features&#8221;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,821,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at issuance of the 2021 Convertible Notes (see Note 6). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maturity Date</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense on the 2021 Convertible Notes totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">199,049</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, amortization of debt discounts amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">513,035</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320,460</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 6) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion of Convertible Notes Upon Equity Financing</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Notes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company converted all $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,010,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its outstanding principal and all accrued and unpaid interest of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the Company&#8217;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,375,228</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock on September 30, 2021 at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million loss on extinguishment, upon conversion, year ended December 31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021 there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Convertible Notes outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">686,489</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expire at various dates throughout fiscal 2028.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,504</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of these warrants have been exercised.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998314672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple Agreement For Future Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_SimpleAgreementForFutureEquityDisclosureTextBlock', window );">Simple Agreement For Future Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. SIMPLE AGREEMENT FOR FUTURE EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, the Company issued a simple agreement for future equity ("SAFE Agreement") for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. 'The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The conversion price will be set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,208</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock on September 30, 2021. The price of the common shares issued in the equity financing was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. 'The conversion price was equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_SimpleAgreementForFutureEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Simple agreement for future equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_SimpleAgreementForFutureEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998442112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  FAIR VALUE OF FINANCIAL LIABILITIES</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.057%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.657%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.041%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d4dbe32f-1df1-43a5-8162-239e9214a75a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, beginning of period</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liability on convertible notes payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,821,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss (Gain) on fair value of embedded features</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extinguishment of derivative liability in connection with debt conversion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,151,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, end of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#8217;s income reflected the volatility in these estimate and assumption changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%; the probability of an equity financing was estimated to be approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%; and the probability of default, change in control or dissolution was estimated to be approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.627%;"/>
        <td style="width:1.225%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.42%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrant liabilities measured at fair value on a recurring basis at December 31, 2021. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, beginning of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">343,735</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320,460</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on fair value of warrant liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98,394</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,546,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,952,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, end of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998319152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.  STOCKHOLDERS&#8217; EQUITY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the Company&#8217;s initial public offering, the Company&#8217;s shareholders agreement terminated pursuant to its terms. In connection with the closing of the Company&#8217;s initial public offering, the Company amended and restated its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;) and amended and restated its Bylaws (the &#8220;Amended and Restated Bylaws&#8221;). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022 and became effective on that date, and among other things, increased the authorized number of common stock to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and decreased the authorized number of preferred stock to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of MAIA Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,729</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,373,561</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transaction costs. During May 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transaction costs. The Company issued these shareholders additional shares upon the closing of the Company's initial public offering such that the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> price per share they paid was equal to the price per share in the Company's initial public offering of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The number of Ratchet Shares were calculated using the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share price in the Company's initial public offering and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">219,872</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were issued on August 1, 2022 to the investors in the Recent Private Rounds. The Ratchet shares were determined to be a freestanding instrument that was classified as a liability when the right was granted and subsequently reclassified to equity when shares were issued. The Ratchet Shares were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,099,360</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> price of the initial public offering and were recorded as expense included in operating expense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 28, 2022 the Company&#8217;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share when the underwriter exercised the overallotment for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to deducting underwriting discounts, commissions, and other offering expenses. After deducting the underwriting discount and other offering expenses payable by the Company, the total net proceeds for the initial public offering and the overallotment were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, MAIA recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">202,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of stock compensation expense related to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of MAIA&#8217;s restricted shares granted to the founders. On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">612,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> fully vested THIO restricted shares were canceled and the founder was issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">612,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> MAIA </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restricted shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in accordance with the founder's original award, the founder was also issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> MAIA restricted shares which vested ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unvested shares as of December 31, 2022 related to the founder's restricted shares. During the 12 months ended December 31, 2022, MAIA recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of expense related to  restricted stock for the year ended 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.072%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.023%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.616%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.131%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the  holders&#8217; warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#8217;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only to be exercisable, in whole or in part, during the exercise period ending on the earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,497</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">450,578</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was treated as a deemed dividend and is reflected as &#8220;Deemed dividend on warrant modification&#8221; in the accompanying statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January 2022, warrants were exercised, resulting in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of MAIA common stock for proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During May 2022, warrants were exercised, resulting in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">275,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Another </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">394,501</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants were exercised with a cashless exercise assuming the fair market value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share resulting in the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">315,601</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the closing of the initial public offering, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,520</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share expired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the closing of the Company&#8217;s initial public offering, the Company issued warrants to purchase an aggregate of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock to the Representative or its designees, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (the &#8220;Representative&#8217;s Warrants&#8221;). The Representative&#8217;s Warrants are exercisable beginning on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 23, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 27, 2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pursuant to the terms and conditions of the Representative&#8217;s Warrants.  On August 3, concurrently with the full exercise of the Underwriter&#8217;s over-allotment option, the Company issued additional warrants to purchase an aggregate of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock to the Representative or its designees on the same terms. The warrants are not indexed to the Company&#8217;s own stock and therefore meet the definition of a derivative liability. The warrants are liability classified instruments and were initially recorded as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">343,735</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was the value determined using the Black-Scholes method using a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.82</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As of December 31, 2022 the Company remeasured the warrant liability resulting in a value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The gain on remeasurement of the warrant liability in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was included in other income. Only the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> warrants issued in 2022 are classified as a liability, all other outstanding warrants are equity classified.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.425%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.994%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311,117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.30</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">608,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,520</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">796,985</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.0%;"/>
        <td style="width:2.0%;"/>
        <td style="width:14.5%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.88%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. Stock Award Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the &#8220;MAIA 2018 Plan&#8221;). MAIA&#8217;s board of directors administers the MAIA Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,924,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding in the plan of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#8220;MAIA 2020 Plan&#8217;&#8217;), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,983,023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding in the plan as of December 31, 2022. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for future issuance in the MAIA 2018 Plan or the MAIA 2020 Plan .</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 1, 2022 the Company approved the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the &#8220;MAIA 2021 Plan&#8217;&#8217;) with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,909,518</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock reserved for issuance. As of December 31, 2022 there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,271,413</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock available for future issuance under the MAIA 2021 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">638,105</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options outstanding in the MAIA 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options are to be granted with an exercise price which is at least equal to the stock&#8217;s estimated fair value at the date of grant, and with a contractual term of no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. In the case of an option granted to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% stockholder, the exercise price shall be generally no less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value per share on the date of grant, and the contractual term shall be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are canceled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are canceled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company&#8217;s exercise repurchase rights and various other features of awards granted under the plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.822%;"/>
        <td style="width:0.96%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.292%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.291%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.972%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.315000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.185%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.991%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,797,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.59</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">811,831</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.77</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled/forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,888</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.82</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,545,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.85</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,773,706</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,449,715</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.24</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.59</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,804,841</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method (&#8220;OPM&#8221;) and the Probability-Weighted Expected Return Method (&#8220;PWERM&#8221;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, the per share values calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share<br/>of the common stock before a discount for lack of marketability is applied. From January 27 to May 31, 2022 the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share based on the sale of common stock from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27, 2022 to May 19, 2022. From June 1, 2022 to August 1, 2022 the fair value of the Company's common stock was estimated for financial reporting purpose at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share based on the price paid in the initial public offering. Following the initial public offering, the fair value of common stock, is based on the closing price of the common stock in the public market.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/>During the year ended December 31, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was used. During the period of March 1, 2021 to June 6, 2021, the fair value of the Company&#8217;s common stock was estimated for financial reporting purposes based on valuations of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share in February and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February and April 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair<br/>value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to<br/>arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value not be necessary to determine the fair value of our common stock.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.458%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair values of stock options issued during the years ended December 31, 2022 and 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ere $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. At December 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,447,367</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which the Company expects to recognize over a weighted average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.26</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.288%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.964%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.243%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,422,799</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,779,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">896,628</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">943,708</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,319,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,722,893</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998296304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Defined Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Retirement Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYEE RETIREMENT PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. The Company will make a safe harbor matching contribution equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of employee salary deferrals that do not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their compensation plus </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their salary deferrals between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2022 Company match is immaterial. The Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 715<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472162&amp;loc=d3e58407-109430<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235042<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998442112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.  COMMITMENTS AND CONTINGENCIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent Licensing, Sponsored Research, and Patent &amp; Technology Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (&#8220;PLA&#8221;) titled &#8220;Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology&#8221; with the University of Texas Southwestern (&#8220;UTSW&#8221;) to license patent families for a specific compound (&#8220;THIO&#8221;) from UTSW to MAIA. The agreement, as amended, has a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, not to exceed a combined milestone payment total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments are due to UTSW related to the milestones. The agreement requires royalties of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on net sales above $1,000,000,000.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also in December 2020, the Company entered into a second license agreement with UTSW titled &#8220;Patent and Technology License Agreement AGT. NO. L3648 &#8212; MAIA Biotechnology&#8221; pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, not to exceed a combined milestone payment total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments are due to UTSW related to the milestones.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The agreement requires royalties of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on net sales above $1,000,000,000.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regeneron - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug cemiplimab representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan in the event that patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of December 31, 2022 neither party has terminated the agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998142384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  INCOME TAXES</span><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's net deferred tax assets consist of the following components:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,294,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,013,721</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,183,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,800,935</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,499,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,724</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102,825</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,229,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,027,154</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,229,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,027,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company has unused U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that may be applied against future taxable income. The state NOL carryforwards begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The U.S. federal NOL carryforwards may be carried forward indefinitely, however are limited to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent of taxable income. The Company has unused Australian NOL carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that may be carried forward indefinitely. The Company has unused U.S. federal research and experimentation (&#8220;R &amp; E&#8221;) tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use of the Company&#8217;s NOL and R &amp; E credit carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#8220;ownership change,&#8221; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#8209;percent stockholders (or certain groups of non&#8209;five&#8209;percent stockholders) over a three&#8209;year period occurs. After such an ownership change, the corporation&#8217;s use of its pre&#8209;change NOL carryforwards and other pre&#8209;change tax attributes to offset its post&#8209;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an ownership change occurs and if the Company earns net taxable income, the Company&#8217;s ability to use its pre&#8209;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#8217;s state income, franchise, or similar taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 740, &#8220;Income Taxes,&#8221; the Company recorded a valuation allowance to fully offset its deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The valuation allowance increased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022 and 2021, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred a pretax book loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022, which consisted of a U.S. loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a foreign loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company incurred a pretax book loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021, which consisted of a U.S. loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a foreign loss of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No provision or benefit for U.S. federal, state, or foreign income taxes has been recorded for the years ended December 31, 2022 and 2021, mainly due to net losses incurred by the Company in all jurisdictions other than Romania, which provides for a tax exemption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.021%;"/>
        <td style="width:1.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.31%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other nondeductible expenses/(nontaxable income)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company files income tax returns in the U.S. federal jurisdiction, several U.S. States, Australia, and Romania. The Company&#8217;s tax returns since inception remain open to examination by the taxing authorities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998482304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUBSEQUENT EVENTS</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 16, 2023, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for investor relations services from January 16, 2023 through July 16, 2023. Per the agreement  an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock will be issued on April 16, 2023 if their services are still in place per the contract.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock on March 8, 2023 and an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock every ninety days after the execution date of the contract until termination of the agreement. The term of the agreement extends for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and renews automatically until we provide written notice prior to the end of the term.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Options</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From January 1 to March 20, 2023 we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">638,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options at a weighted exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to employees and consultants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000289664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Description of Business, Organization, and Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business, Organization, and Principles of Consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#8220;the Company&#8221;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#8220;MAIA&#8221;) was incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 3, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIO Therapeutics, Inc. (&#8220;THIO&#8221;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">minority stockholder of THIO received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> share of MAIA common stock for each share of THIO common stock owned prior to the merger.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DGD Pharmaceuticals Corporation (&#8220;DGD&#8221;), incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2019</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAIA Drug Development Corporation (&#8220;MAIA DD&#8221;) incorporated in the state of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Texas</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 10, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company had working capital of&#8201;$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,539,131</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,207,272</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,950,927</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and current liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,268,906</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During January and February 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,729</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,373,561</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before transaction costs and expenses. During May 2022, the company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#8221; The Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the initial public offering. On August 3, 2022, the Company sold an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per the overallotment option for the underwriter. After deducting $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,406,170</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for cash issuance costs, net proceeds from the offering and overallotment were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,093,830</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_GoingConcernConsiderationsPolicyTextBlock', window );">Going Concern Considerations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern Considerations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,207,272</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the Company&#8217;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,951</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,000 million in cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">meet the Company&#8217;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock', window );">Impact of the COVID-19 Pandemic on our Operations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of the COVID-19 Pandemic on our Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 Outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221; or &#8220;GAAP&#8221;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s Chief Executive Officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#8217;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CertainRisksAndUncertaintiesPolicyTextBlock', window );">Certain Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">financial statements of the Company&#8217;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">period </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#8217; equity as accumulated other comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#8217;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash equivalents as of December 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#8220;Accounting Standards Codification (ASC) Topic 820&#8221;, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s research and development expenses consist primarily of costs associated with the Company&#8217;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#8217;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ResearchAndDevelopmentIncentivePolicyTextBlock', window );">Research And Development Incentive</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Incentive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#8217;s support for Australia&#8217;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#8217;s role at the Company.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), depending on the specific terms of the warrant agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When warrants are issued for services to non-employees, under ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are recorded in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.772%;"/>
          <td style="width:1.171%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.741%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.171%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.144%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,545,628</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,797,185</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">796,985</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311,117</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Standards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASU No. 2016-02</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as amended, Leases (&#8220;Topic 842&#8221;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> this new standard as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#8217;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CertainRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CertainRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business, organization, and principles of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_GoingConcernConsiderationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_GoingConcernConsiderationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of the COVID-19 pandemic on operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ResearchAndDevelopmentIncentivePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ResearchAndDevelopmentIncentivePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998332464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.772%;"/>
          <td style="width:1.171%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.741%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.171%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.144%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,545,628</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,797,185</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issuable upon exercise of warrants</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">796,985</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311,117</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998292880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, accrued expenses consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.486%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.15%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.607%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.139%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bonus</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,094,582</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional  fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">332,589</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">380,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516,961</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,140</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred compensation to former officers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,271</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,157</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,103,401</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,185,595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885998211744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.627%;"/>
        <td style="width:1.225%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.42%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.057%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.657%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.041%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d4dbe32f-1df1-43a5-8162-239e9214a75a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, beginning of period</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liability on convertible notes payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,821,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss (Gain) on fair value of embedded features</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extinguishment of derivative liability in connection with debt conversion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,151,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, end of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, beginning of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">343,735</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320,460</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on fair value of warrant liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98,394</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,546,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,952,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, end of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">245,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886002285680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Unvested Restricted Shares</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.072%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.023%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.616%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.131%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,333</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ScheduleOfWarrantExercisedTableTextBlock', window );">Schedule of Warrant Exercised</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.425%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.994%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311,117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.30</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">608,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,520</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">796,985</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">Assumptions used in Calculating Value of Warrants Granted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.0%;"/>
        <td style="width:2.0%;"/>
        <td style="width:14.5%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.88%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity and Information regarding Outstanding and Exercisable Options</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.822%;"/>
        <td style="width:0.96%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.292%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.291%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.972%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.315000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.185%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.991%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in<br/>Years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,797,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.59</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">811,831</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.77</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled/forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,888</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.82</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,545,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.85</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,773,706</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,449,715</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.24</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.59</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,804,841</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used in Calculating Value of Options Granted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.458%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.113%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation related to the Company&#8217;s stock plans are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.288%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.964%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.243%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,422,799</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,779,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">896,628</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">943,708</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,319,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,722,893</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share-based payment award, warrants, valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ScheduleOfWarrantExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ScheduleOfWarrantExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999763424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Net Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's net deferred tax assets consist of the following components:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,294,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,013,721</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,183,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,800,935</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,499,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,724</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102,825</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,229,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,027,154</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,229,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,027,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.021%;"/>
        <td style="width:1.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.31%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other nondeductible expenses/(nontaxable income)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885988587920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">State of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Common stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,539,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,207,272)<span></span>
</td>
<td class="num">$ (28,437,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,950,927<span></span>
</td>
<td class="nump">10,574,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,268,906<span></span>
</td>
<td class="nump">2,145,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="nump">263,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,999<span></span>
</td>
<td class="nump">$ 2,373,561<span></span>
</td>
<td class="nump">2,473,560<span></span>
</td>
<td class="nump">5,742,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Current cash reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,950,927<span></span>
</td>
<td class="nump">10,574,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,750,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=maia_OfferingAndOverallotmentMember', window );">Offering and Overallotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance cost, net</a></td>
<td class="nump">2,406,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">$ 9,093,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=maia_MAIADrugDevelopmentCorporationMember', window );">MAIA Drug Development Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">State of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 10,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority stockholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">MAIA Biotechnology, Inc. | MAIA Drug Development Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=maia_DgdPharmaceuticalsCorporationMember', window );">DGD Pharmaceuticals Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">State of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=maia_OfferingAndOverallotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=maia_OfferingAndOverallotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=maia_MAIADrugDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=maia_MAIADrugDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=maia_THIOTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=maia_THIOTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=maia_DgdPharmaceuticalsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=maia_DgdPharmaceuticalsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885997432064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Shares Issuable upon Exercise of Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">6,545,628<span></span>
</td>
<td class="nump">5,797,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Shares Issuable upon Exercise of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">796,985<span></span>
</td>
<td class="nump">1,311,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=maia_UnvestedRestrictedStockAwardsMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=maia_UnvestedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=maia_UnvestedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885986119136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,985<span></span>
</td>
<td class="nump">1,311,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_LeighAnnDurantMember', window );">Ms. Durant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConsultingServices', window );">Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashPaidForServicesProvided', window );">Cash paid for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStock', window );">Options to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue', window );">Options to purchase shares of common stock total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RaduVitocMember', window );">Mr. Vitoc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConsultingServices', window );">Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,900<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashPaidForServicesProvided', window );">Cash paid for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,950<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStock', window );">Options to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue', window );">Options to purchase shares of common stock total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.950<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_RemainingConsultingServicesSettled', window );">Remaining services settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Converted shares of common stock</a></td>
<td class="nump">8,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">4,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Converted shares of common stock</a></td>
<td class="nump">3,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayment of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 3,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CashPaidForServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CashPaidForServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares of common stock total fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_RemainingConsultingServicesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining consulting services settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_RemainingConsultingServicesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_LeighAnnDurantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_LeighAnnDurantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RaduVitocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RaduVitocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886002374528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus</a></td>
<td class="nump">$ 1,094,582<span></span>
</td>
<td class="nump">$ 384,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">332,589<span></span>
</td>
<td class="nump">380,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">516,961<span></span>
</td>
<td class="nump">268,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Deferred compensation to former officers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">159,269<span></span>
</td>
<td class="nump">41,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,103,401<span></span>
</td>
<td class="nump">$ 1,185,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885989792352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,271<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashPaidToSettleAPortionOfDeferredCompensationBalance', window );">Cash paid to settle a portion of deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability', window );">Deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,750<span></span>
</td>
<td class="nump">$ 1,094,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance', window );">Issuance of stock options to settle accrued bonus balance</a></td>
<td class="nump">713,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance', window );">Fair value of stock options issued to settle accrued bonus balance</a></td>
<td class="nump">$ 786,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense related to deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance', window );">Stock-based compensation expense related to accrued bonus balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CashPaidToSettleAPortionOfDeferredCompensationBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to settle a portion of deferred compensation balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CashPaidToSettleAPortionOfDeferredCompensationBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options issued to settle accrued bonus balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock options to settle accrued bonus balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense related to accrued bonus balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total fair value of shares issued during the period under a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000121872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program - Additional Information (Details) - P P P Loan Program - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from unsecured loan</a></td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of interest</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount', window );">Extinguishment of outstanding principal and interest written off amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of outstanding principal and interest written off amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=maia_PppLoanProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=maia_PppLoanProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999565824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,967<span></span>
</td>
<td class="nump">827,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantDescription', window );">Warrant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. <span></span>
</td>
<td class="text">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleNotesOutstanding', window );">Convertible notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Share converted</a></td>
<td class="nump">1,375,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,322,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CommonSharesUponExerciseOfWarrantsShares', window );">Common shares upon exercise of warrants, Shares</a></td>
<td class="nump">686,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantsExercised', window );">Class of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyWarrantsMember', window );">2020 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfIssuableUponConversionOfExercisePrice', window );">Percentage of issuable upon conversion of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyOneWarrantsMember', window );">2021 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfIssuableUponConversionOfExercisePrice', window );">Percentage of issuable upon conversion of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndNineteenPromissoryNoteMember', window );">2019 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing', window );">Percentage of the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_Debtdiscountandvalueofembeddedputfeature', window );">Debt discount and value of embedded put feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember', window );">2020 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing', window );">Percentage of the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,375<span></span>
</td>
<td class="nump">$ 11,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt', window );">Minimum gross proceeds from equity financing required for conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfVotingPowerDefiningChangeOfControl', window );">Percentage of voting power defining change of control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Debt discount and derivative liability at the issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember', window );">2020 Promissory Note | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember', window );">2021 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing', window );">Percentage of the conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,049<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">513,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Debt discount and derivative liability at the issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertiblePromissoryNotesToRelatedParties', window );">Convertible promissory notes to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,863,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ConvertiblePromissoryNotesToSettleLoan', window );">Convertible promissory notes to settle loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CommonSharesUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares upon exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CommonSharesUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Conversion Price Percentage Of The Equity Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertibleNotesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertibleNotesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertiblePromissoryNotesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory notes to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertiblePromissoryNotesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ConvertiblePromissoryNotesToSettleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory notes to settle loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ConvertiblePromissoryNotesToSettleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_Debtdiscountandvalueofembeddedputfeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount And Value Of Embedded Put Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_Debtdiscountandvalueofembeddedputfeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfIssuableUponConversionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of issuable upon conversion of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfIssuableUponConversionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfVotingPowerDefiningChangeOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Voting Power Defining Change Of Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfVotingPowerDefiningChangeOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, exercises in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=maia_TwoThousandAndTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndNineteenPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndNineteenPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000328448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Simple Agreement For Future Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_SimpleAgreementForFutureEquityIssued', window );">Simple agreement for future equity issued</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfConversionPrice', window );">Percentage of conversion price</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_NumberOfCommonSharesConvertedUnderSAFEAgreement', window );">Converted common stock under SAFE agreement</a></td>
<td class="nump">5,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CommonStockConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CommonStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CommonStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_NumberOfCommonSharesConvertedUnderSAFEAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares converted under S A F E agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_NumberOfCommonSharesConvertedUnderSAFEAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_SimpleAgreementForFutureEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Simple agreement for future equity issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_SimpleAgreementForFutureEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999868240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885988769616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Loss (Gain) on fair value of embedded features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrant liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">(Gain) loss on fair value of warrant liability</a></td>
<td class="num">$ (98,394)<span></span>
</td>
<td class="nump">1,546,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, end of period</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrant liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, end of period</a></td>
<td class="nump">245,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DerivativeLiabilityOnConvertibleNotesPayable', window );">Derivative liability on convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,821,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Loss (Gain) on fair value of embedded features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion', window );">Extinguishment of derivative liability in connection with debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,151,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrant liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfWarrantLiability', window );">Warrant liability</a></td>
<td class="nump">343,735<span></span>
</td>
<td class="nump">320,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">(Gain) loss on fair value of warrant liability</a></td>
<td class="num">(98,394)<span></span>
</td>
<td class="nump">1,546,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,952,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, end of period</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DerivativeLiabilityOnConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability on convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DerivativeLiabilityOnConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liability in connection with debt conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886002284720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ChangeInFairValueOfEmbeddedFeatures', window );">Change in fair value of embedded features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity', window );">Probability percentage of convertible notes outstanding at maturity</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProbabilityPercentageOfEquityFinancing', window );">Probability percentage of equity financing</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution', window );">Probability percentage of default, change in control or dissolution</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ChangeInFairValueOfEmbeddedFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of embedded features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ChangeInFairValueOfEmbeddedFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probability percentage of convertible notes outstanding at maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probability percentage of default, change in control or dissolution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProbabilityPercentageOfEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probability percentage of equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProbabilityPercentageOfEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885986814192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Aug. 13, 2021</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,955,904<span></span>
</td>
<td class="nump">7,584,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,373,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,473,560<span></span>
</td>
<td class="nump">$ 5,742,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,001,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,319,427<span></span>
</td>
<td class="nump">$ 2,722,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantsExercisedShares', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CashlessExerciseAtFairMarketValuePerShare', window );">Cashless exercise at fair market value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares', window );">Issuance of common shares upon cashless exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,545,628<span></span>
</td>
<td class="nump">5,797,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage', window );">Exercise price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted', window );">Percentage of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants and rights exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire', window );">Class of warrant or right date from which warrants or rights expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 27,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain on remeasurement of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,394)<span></span>
</td>
<td class="nump">$ 1,546,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=maia_BlackSholesMethodMember', window );">Black-Sholes Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">77.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 343,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain on remeasurement of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember', window );">January 1 to January 26, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember', window );">January 27 to May 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember', window );">June 1, 2022 to August 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember', window );">January 1, 2021 to February 28, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember', window );">March 1, 2021 to June 6, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,422,799<span></span>
</td>
<td class="nump">$ 1,779,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=maia_TwoThousandEighteenStockOptionPlanMember', window );">2018 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember', window );">Amended and Restated 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,983,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=maia_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,909,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromCommonStockNetOfIssuanceCosts', window );">Gross proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromCommonStockNetOfIssuanceCosts', window );">Gross proceeds from common stock</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock', window );">Class of warrant or right additional purchase aggregate of common stock</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of common stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon conversion of convertible notes, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares', window );">Issuance of common shares upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">61,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,712<span></span>
</td>
<td class="nump">283,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants', window );">Proceeds from issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,400<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=maia_FounderMember', window );">Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Founders shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">MAIA Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_WarrantModificationValue', window );">Warrant modification, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DeemedDividendOnWarrantModification', window );">Deemed dividend on warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,447,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=maia_THIOMember', window );">T H I O | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=maia_THIOMember', window );">T H I O | Restricted Stock Awards | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Founders shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CashlessExerciseAtFairMarketValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise at fair market value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CashlessExerciseAtFairMarketValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right additional purchase aggregate of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right date from which warrants or rights expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DeemedDividendOnWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DeemedDividendOnWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon cashless exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from common stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantModificationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant modification, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantModificationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=maia_BlackSholesMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=maia_BlackSholesMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=maia_TwoThousandEighteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=maia_TwoThousandEighteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=maia_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=maia_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=maia_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=maia_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=maia_THIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=maia_THIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885993326064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Unvested Restricted Shares (Details) - Restricted Stock Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested balance</a></td>
<td class="nump">58,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(58,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999912048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants Exercised (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Beginning balance</a></td>
<td class="nump">1,311,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsIssued', window );">Warrants Outstanding, Issued</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsExercised', window );">Warrants Outstanding, Exercised</a></td>
<td class="num">(608,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsExpired', window );">Warrants Outstanding, Expired</a></td>
<td class="num">(20,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Ending balance</a></td>
<td class="nump">796,985<span></span>
</td>
<td class="nump">1,311,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePriceIssued', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">$ 6.04<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageExercisePriceIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average exercise price issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageExercisePriceIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885999816112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions used in Calculating Value of Warrants Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">MAIA Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">106.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">MAIA Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">MAIA Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000047776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Activity and Information regarding Outstanding and Exercisable Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning balance</a></td>
<td class="nump">5,797,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options outstanding, granted</a></td>
<td class="nump">811,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="num">(46,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Outstanding, Cancelled/forfeited</a></td>
<td class="num">(16,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending balance</a></td>
<td class="nump">6,545,628<span></span>
</td>
<td class="nump">5,797,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Options exercisable</a></td>
<td class="nump">5,449,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/forfeited</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">2.55<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term in Years, Options exercisable</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 9,773,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">$ 8,804,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885993318848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">71.90%<span></span>
</td>
<td class="nump">71.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">87.90%<span></span>
</td>
<td class="nump">81.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000002368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,319,427<span></span>
</td>
<td class="nump">$ 2,722,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,422,799<span></span>
</td>
<td class="nump">1,779,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 896,628<span></span>
</td>
<td class="nump">$ 943,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886000002240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan (Additional Information) (Details) - 401 (K)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DefinedContributionPlanEmployerSalary', window );">Employee salary deferrals</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Contribution to employee</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DefinedContributionPlanEmployerSalary', window );">Employee salary deferrals</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Contribution to employee</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_DefinedContributionPlanEmployerSalary', window );">Employee salary deferrals</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_DefinedContributionPlanEmployerSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer alary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_DefinedContributionPlanEmployerSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=maia_The401KPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885988467808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember', window );">Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember', window );">THIO | Amended Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CombinedMilestonePaymentsMaximum', window );">Combined milestone payment maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember', window );">UTSW | Amended Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaymentsDueRelatedToMilestones', window );">Payments due related to milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember', window );">UTSW | Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_CombinedMilestonePaymentsMaximum', window );">Combined milestone payment maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PaymentsDueRelatedToMilestones', window );">Payments due related to milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription', window );">Percentage of royalty description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ClaimExpirationTerm', window );">Claim expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | THIO | Amended Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | THIO | Amended Patent and Technology License Agreement | Net sales up to $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | THIO | Amended Patent and Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | UTSW | Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | UTSW | Patent and Technology License Agreement | Net sales up to $1,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | UTSW | Patent and Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | THIO | Amended Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | THIO | Amended Patent and Technology License Agreement | Net sales up to $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | THIO | Amended Patent and Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | UTSW | Patent and Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | UTSW | Patent and Technology License Agreement | Net sales up to $1,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | UTSW | Patent and Technology License Agreement | Net sales above $1,000,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_PercentageOfRoyaltyPaymentsOnNetSales', window );">Rate of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ClaimExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claim expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ClaimExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_CombinedMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined milestone payments maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_CombinedMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PaymentsDueRelatedToMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments due related to milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PaymentsDueRelatedToMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=maia_AmendedPatentAndTechnologyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=maia_AmendedPatentAndTechnologyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=maia_PatentAndTechnologyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=maia_PatentAndTechnologyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesAboveOneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesAboveOneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139886002084736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,294,955<span></span>
</td>
<td class="nump">$ 3,013,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,183,941<span></span>
</td>
<td class="nump">1,800,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">1,499,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">244,848<span></span>
</td>
<td class="nump">109,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,724<span></span>
</td>
<td class="nump">102,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total net deferred tax assets before valuation allowance</a></td>
<td class="nump">6,229,768<span></span>
</td>
<td class="nump">5,027,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (6,229,768)<span></span>
</td>
<td class="num">$ (5,027,154)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885988734304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset, increase in valuation allowance</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax book loss</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. loss</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign loss</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome', window );">Net operating loss carryforward limited percentage of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and experimentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits carryforwards</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear', window );">Tax credits, expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward limited percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Experimentation Tax Credits Carryforwards Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885993293472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other nondeductible expenses/(nontaxable income)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="num">(16.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation loss on extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139885988334816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information - (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2023</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Jan. 16, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options outstanding, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Scenario Forecast | Money Channel NYC Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options outstanding, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Money Channel NYC Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_maia_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock | Money Channel NYC Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_maia_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">maia_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>maia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_MoneyChannelNycIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_MoneyChannelNycIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>maia-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:maia="http://www.maiabiotechnology.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="maia-20221231.xsd" xlink:type="simple"/>
    <context id="C_bd92e2f2-afa8-429c-8e71-c820d8b523b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3dddb3b8-9562-481a-8538-c27da39213ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fdf96b15-9f52-42b0-af98-607e4a595a5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_84f4e80f-cc78-40c3-9fa8-08279e8d87cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:OfferingAndOverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_65e57920-9bea-4275-bd59-c0a66b11eb61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:RatchetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2d323e1e-91fa-4adc-b0b9-fa95c2a916da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_05ed1f6a-7bd5-44e6-a939-0de1e93bb2f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_33263a2e-646d-4256-82aa-1223f29184cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6ed89264-6427-4629-a39a-d1eb18f5c44a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8a3d4bbe-f995-4369-a38d-55c3e19f2acd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_c0d9ded2-a90c-48e6-a41e-23f182621fc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DgdPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ceb3f2a5-5c4a-48e7-96ef-1bd506bd16cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="C_70eeaef3-d979-4694-830c-aa004fc65cad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_cfdd4c68-cf69-49c9-921b-9232d6f85520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="C_ab7d89f5-c0a9-4cc8-988f-dd865cac4e4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_96904691-c19d-41d7-b74c-e304c0e6af45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_18f191ce-f487-4a92-a1ad-96c619694078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5aa0a4a7-169f-471d-837f-b409f7c4b858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="C_514ade27-e387-4d84-83c5-c59113d65690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c9fb6a9b-9be5-47bf-a4da-ec226ccb941f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ee00796c-ffd3-46f4-93c1-8db0ae1a964e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_51ce7740-df5e-458e-9aca-0e98ee73acc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:RatchetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8e7436f3-5354-4afa-bd19-4dded9a9e390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4a905e51-4f6b-438a-9ff9-32f5ff3fbc1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59d4a5fa-7563-4679-8962-c0917ed9d470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_f426df1f-3c59-401e-952f-443722bf8259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e144005c-eb16-4637-a828-601934ff5985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_480dc74f-1404-498f-8b42-20bedaaa1ecf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_ed9fcd67-e733-47c1-804f-2d29703a3a3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7c6a87c-7d18-4cd1-89df-759036b167f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0fdfbd9c-c879-495d-a18d-f5b6252af2fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_46d64219-b005-46b4-9a54-af5112c896b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:LeighAnnDurantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cab8d345-5f87-42f4-95e4-921bbed2dd3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_faeafa90-e78a-4213-beef-48ac41889fed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_77674401-ed32-4efc-bc01-fa0a205bd5c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_704afa9b-4318-432b-94d0-dd9ac96a4003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5e1ca0e3-7225-4c0e-aa21-a8c07456a8d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1491750e-595c-458c-b2bc-3af9c7704855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">maia:RatchetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_79f9be5c-c6c9-4e62-8570-7a5b4ef49378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="C_da576c98-2bde-4e20-b38d-a9c79bec3a95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c5c5e8e4-533d-4dc8-81c1-c4f505de146c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f2dbed72-0d93-4962-be44-54187d716c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_77bae37b-9232-4726-80bf-d4346dbdd5c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_af4145b4-83cc-4b5a-8c80-2f54f89c9863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_68298e68-92ff-4876-a80a-e4764bf1eb5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_25edec4e-51a9-4cf7-a863-6a4423d5e981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_90df5ec5-d2d5-410c-ae2a-6982581d43c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f3cb958a-ca61-46c6-a20f-0990720362c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b89f176d-a5ef-4374-a64e-fbce690b3f42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_093f44a4-068c-4d51-9096-9822ca581146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_24d517c1-101e-49f7-858d-15b0bb2079e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_95ea31ca-fbf2-45cf-921a-af532996efec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_4ac28de6-5d6a-4cc2-ac1f-b7f9d7ebb27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_a998ab06-ea16-418f-8f43-b74df1888ac3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_38807a13-8dd9-4c2d-b8c8-cfc13aebab4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8f949a11-176b-4ad1-9d69-a21194d19325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10dbc5ec-42be-4b85-9613-2d111b13181f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b6fe62fc-f09a-4c0a-822b-9375cd7875df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="C_e4448ed4-2b54-4235-9206-c0b8e343fb1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_60690a56-b071-4f7d-a346-3c1b2b2672ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9685ca74-0b09-41fe-a647-8f730fad5ee4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5c7dbf97-a62c-4354-b7ac-212c85adff76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cbf5e914-0593-48ce-a8d1-7cde11503245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_04cf05b4-4370-4979-8fd8-aad3bb1d1cf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5dff99c3-0b2d-4940-9d28-68bd8d158e84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PppLoanProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_a3f721fc-ed4b-48d0-82bf-0755ef0a4134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_03e3bd00-bb23-45f7-a4b4-e0c48e0a00f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6992df71-0104-43df-abe1-8e43fcfa0c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_60bc5fdb-609a-4b8d-8539-569a6372e484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_08b3f13c-8494-4e8a-bac0-e6e09f3faee0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d8490e1-93cd-41ed-bc23-ad484a70d024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbddc662-f865-4f07-88a7-237f7cbd58b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8de3a275-a1ef-4daa-8115-7bf33cf32d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e6b76190-87b3-4e35-a133-5acf6c22a4fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_bdba1f1c-9953-4f89-8181-9aff72ad45de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_850a921a-9604-4c05-bc2c-f089ad5556e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_1dd9ecfb-e5be-406a-bca6-0d22818e6d05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_e31173a7-a2dc-4f27-be64-82bc649b47d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_6039b578-eeec-4f91-947f-34335f15d319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f14d921e-d893-48a9-b93d-6895d30a125f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_6171e5f5-549d-4e50-9be8-e0a4a67b59bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c3a2c7f8-d558-4863-ba84-7247dacc03ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="C_fed35c89-2357-48b2-9d4e-1962b1feedbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aa57afe6-0ae3-4ae8-8716-1ebfc8bf9e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_8e567c99-be4a-46b9-9a9f-31913733c870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:MAIADrugDevelopmentCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_d418fc52-98ec-47f5-95c9-f00cb3c88d3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b86fb584-5f3d-48eb-bd47-338774b042f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_6dfe66b4-3a5a-4059-86f7-1adc0a69cd08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_84c3fdea-c2ec-4933-8499-ef4172df40e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">maia:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_93dbd88f-ee4a-4a09-9905-9f43b0232942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_7b0c05a1-2ef5-406c-a235-22c40e3c2880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a2369b8a-a97d-441e-a153-ff5a9dd3b27f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="C_e8c711ae-2a67-477b-94f2-7ea7a9761789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8c20c208-c8e0-40af-b818-86f3f673ef3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c40ba4b1-8a23-45d1-b399-8ff938660566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3dc27fee-372c-4000-a17a-fd220345e379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bdce226d-2206-4c50-b8bb-8a3e0648506c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a0c99f8c-3025-49f9-9ce1-af3347da6e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3e133a48-7bca-4524-bf21-ae7de81db87a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">maia:TwoThousandAndTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_549c2a01-f299-4da3-bbae-8c582a89f09f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_460c12ea-f2c0-4902-aaba-b209608b801a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7bfe2412-70aa-498d-b73f-b58ae522d52e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a801211c-4f23-4b06-8cc4-6340d12cffcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_d9c0194e-ae7a-4f5c-a38a-cbedc013e926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:MoneyChannelNycIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-06-05</endDate>
        </period>
    </context>
    <context id="C_0cf26860-1e88-4777-a873-11663c855cc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bda30473-24b2-49f5-aec5-68d7d75fc2b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_d2e664bd-7357-485e-b4fb-bf293169d186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_f508854b-0a5d-48f7-9b76-4f60049b5004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_1d9234a1-5f51-4764-b7e4-a62ca84ba633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ac8db0a5-2d96-4c6b-a190-68c3fc94e6a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_35df104b-b405-4915-a247-efcae1451c3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_123bb045-1787-4e92-86ee-97af8a0fc791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-16</startDate>
            <endDate>2023-01-16</endDate>
        </period>
    </context>
    <context id="C_aca59814-cbfd-4366-be06-42a5a0ba6590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_82d70279-b727-4e18-b4ca-8c7bda2f0d39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">maia:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0f633671-f593-4b41-8b13-f542f6aec2d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bd2957a7-98eb-4f84-87e4-b97ec6293ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_3c664d98-02a0-4f5a-946c-51e9b9611596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_985a2e45-6950-4f45-9fed-bb59ec5581a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bf7f6aa9-8e0b-41e9-900f-25e5d88817a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b2d52605-606c-4298-a0ed-01a4e1641f08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_139f3834-5a5f-48da-b7b6-95728dcce439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8cbd6772-af2d-432e-9e5b-d1b10fd09c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c75159f4-1e2f-4115-964f-af704eb8949f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e4e7d396-2e2a-4ecd-bda9-8259234860d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_07581902-1fc3-4f0d-9e04-a8dbb844ead0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_349fb6e1-da72-4c3d-8eae-a1f0bc375520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7447a51d-1b53-4834-a837-fd4e4d4818a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-16</startDate>
            <endDate>2023-04-16</endDate>
        </period>
    </context>
    <context id="C_7fba4a25-8b91-4e2b-9498-b481e7e735a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">maia:TwoThousandEighteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0ad7911b-4b7a-4316-b95d-e54b9310b0df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PppLoanProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8d11de7f-4020-4686-9774-064ef0b908c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_94951a0e-9218-4969-993f-e925194bc10f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_681b3cde-40ae-48db-9701-970b57fafca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:DGDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_257832a6-de0c-47b0-b609-38c350dcd89a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d3540e61-4c81-4a9e-8519-75d8edfbd550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2703e6a6-9c13-46c2-9da9-deaa17ee8d34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_10e99315-c20f-4d44-875f-39b50152cb08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_13bf0128-a070-4b47-825e-8161c256c563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b7d464db-7209-4119-bc09-50cf74d2d6d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c19f9601-2487-4519-b741-1a2bc336d1b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8b94cac1-12b3-47a8-8cee-4ddd38a0ca14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-13</startDate>
            <endDate>2021-08-13</endDate>
        </period>
    </context>
    <context id="C_b2767d21-f84d-45dc-805e-c26596b84ec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a1c341f2-a782-415b-b128-1db37d526768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_6643c0e3-8b98-4c5e-bc38-a4ac458d4842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_71ce86d1-a364-40dd-8e50-83d2857961c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34634fe2-cf34-4270-bc4d-2bdee5324351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_2fd580ec-da61-4243-8bbe-66e3640f920c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="C_80e5dbc0-3203-4a49-8843-3da9d91fc340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6225085e-6353-4624-b82c-bec3de902a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_daea18c7-8f9f-40db-a949-f62882d10b13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4078271a-c8fb-4d34-a59a-234a262797bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesAboveOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7a095884-7271-41a9-990e-c05d7154216c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c0fc63fe-6219-4ed8-9fd0-353fd3128c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c159ace3-ffb0-4d4d-8a15-d426dd48bb91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2cc4ed46-ee40-4446-afb7-6c466d1a0315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndNineteenPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5e96f6c1-8fcb-4e45-849b-c83a8f2330e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_99f06e4c-f0a7-4618-91e5-f9e6e61a5eb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_75c413f9-8ba4-436c-9bf0-776a3437584a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_49140d15-f3a7-4a2b-a015-cacc8dec9460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_432d777f-5193-4a7a-bc9c-bd381ee50b47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_83947522-5d4a-4233-ab67-fb6efdf06f08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c4856ea2-7771-4d18-b27e-ad041dc17195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_1389048c-24c0-4a62-aaa4-a2b74693dfae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b04addab-578d-403a-ac75-910316d401b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:UniversityOfTexasSouthwesternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a8986a13-566d-41de-a913-47e267f84b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_d07afd76-c668-4a14-b0f2-d16a7a6bc509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0838c5ab-fead-4553-91e0-e9194daa7208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">maia:NetSalesUptoOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:THIOTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">maia:AmendedPatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_538b838f-72d0-42ef-a3b6-35b1fbd33513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4d10bf70-b796-41c1-99f6-677d11e3838c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_ea377e52-e368-402f-8f8d-1865b3d62026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">maia:THIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-13</startDate>
            <endDate>2021-08-13</endDate>
        </period>
    </context>
    <context id="C_b52893ed-19d1-4467-abfb-baf9e1042428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">maia:PppLoanProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_1bfefa67-16ca-409f-bb23-cdd798adfd46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">maia:The401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_af7a9610-410c-4458-b075-3916099f847e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">maia:MAIADrugDevelopmentCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_10935678-cd01-4042-9bb0-148e441856b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">maia:BlackSholesMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_de81be98-77ce-42a7-8aa0-3c3af1588a89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6f7aff38-36bd-4981-a8df-ded8085b1fcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">maia:ThioMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ea85c9c9-8fa4-44f7-9253-844104dacb55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="C_af796981-4cb4-490f-8a9b-07137ac824a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">maia:RaduVitocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ed6afaaf-47e2-4703-8898-9a173c0212f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="C_6c7f2e44-3c3e-49bc-8220-a31f305d9878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fff227d5-244a-4bcb-80ea-d5ce7a3c9fdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">maia:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ba69f1b4-b400-41b9-83cb-6beed2abe583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="C_960ce175-49b7-4d64-b47c-1ecd446c52b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">maia:MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66a04226-000c-48ad-8295-b5d5efd519ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">maia:TwoThousandAndTwentyPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      id="F_32d30681-9f36-4826-9171-c8006f97a233"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_82d70279-b727-4e18-b4ca-8c7bda2f0d39"
      id="F_6762082b-75c3-405b-b2b0-26f82bc658fb"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      id="F_e72148a5-95e0-4c93-8975-0a5b223af98e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="C_de81be98-77ce-42a7-8aa0-3c3af1588a89"
      id="F_d4dbe32f-1df1-43a5-8162-239e9214a75a">http://fasb.org/us-gaap/2022#Liabilities</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_5a7219ee-3121-409b-8a87-233effeb520e">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      id="F_cd9deaf0-1d8f-4cfa-ae75-53003ee3c1ee"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_78eba3d7-e77c-40a4-a35a-d810414a9501">0001878313</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockValue
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      id="F_e8f1a25c-5a33-4074-8478-3135ed3b9513"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e0722739-6efe-43f2-8b8c-82b38a8abf92">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_311a1cb3-a35e-4309-a95b-0e6e22c3377e">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_b4fe6108-af74-46ca-8ef1-45e03a696b6d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_59974d73-9209-4eff-bb9b-a553d5d8b115">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_349cbd3b-b6b4-4e80-964c-68e8a48a5a41">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_9cbbe513-84c1-491b-9108-ec95124609a1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e96c8853-91af-4129-bc25-c10790373a50">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_6f11ffb3-f55a-47e8-bc35-bc9e6ed3837c">001-41455</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_bf19a59a-42f4-4211-a9cf-bf149a980ab6">MAIA BIOTECHNOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_2a44fd53-4be3-41f9-b73b-60231f8e9dff">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_0a70872c-6780-44a2-8330-4d9e59e8b061">83-1495913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_ad2e18e9-9b98-464b-a57f-bd29018e4569">444 West Lake Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_eec1b04c-8f9f-46be-ac8c-5c770c219397">Suite 1700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_4b6c51cc-97b7-4e34-94d5-f37fba65e569">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_1d6361e0-dcd7-4656-84d0-5b3f4d64b9d3">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_908e12dc-763b-4b76-bb8c-da782231b5f6">06060</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e05d6970-7a9e-44d6-9c13-9b3e70e54db9">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_6d74b0ca-6bfa-4340-8ecc-95df2c151f90">416-8592</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_b0e46e08-aafe-4ac2-9789-fdf1e32fafe0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_55d03134-d0cb-4b9c-ac65-9b733248a93a">MAIA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_9e5a4471-2b51-4124-ad55-034e493b819b">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_8a92ad95-3d7b-4058-9012-6d5b033c350c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_315add4e-e167-42a4-be1d-5e46478d7a09">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e3db64c4-932c-47eb-8fe1-8c0c4e2125d0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_571b1345-2737-4aa5-b869-ba2a52adc873">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_9b8e5b93-dec5-4864-bebc-8f0f97a93ccb">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_33181da3-9f92-48e6-94f6-e540497c921e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_358bbcf9-ac21-46e2-9c90-da2c07ce36c3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_c5ca9eb5-49ea-429f-ab63-83e3f1d4c6d9">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_d10ed92c-cb60-48e2-b67b-cdd789a5bd31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_0f92bb62-aedb-47de-bfd1-606021b5e67f">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_4d10bf70-b796-41c1-99f6-677d11e3838c"
      decimals="0"
      id="F_dbf99ce6-0856-4743-a0e6-10f9fa7548ab"
      unitRef="U_USD">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_a2369b8a-a97d-441e-a153-ff5a9dd3b27f"
      decimals="INF"
      id="F_86cf2085-6ca0-4722-a11a-8c55de128a0a"
      unitRef="U_shares">10996404</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_2cb85d0b-a1fd-4c15-8d0e-83205fc6359d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for the annual stockholder meeting to be held in 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K as noted herein. The registrant intends to file its proxy statement within 120 days after its fiscal year end.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_0e42fca6-b08e-4a5f-8555-8a3dab888a42">248</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      id="F_09ebc1ba-8842-4014-8919-683d78a40f58">274</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_21874969-d62c-465f-a206-428a5b2e1dbe">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_4fb6a1f1-99f1-4a3f-a72e-7c693235fb8c">Charlotte, North Carolina</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      id="F_4b9bddd9-2d67-42ca-b28e-9a2ba44e61aa">EISNERAMPER LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      id="F_09bea1fc-ff08-4e45-bb67-54a543c4a1e3">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_14f301cc-d65a-4417-809d-2d17f702482b"
      unitRef="U_USD">10950927</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_7628c8f8-36e1-4cb3-ae66-790f1089dc2a"
      unitRef="U_USD">10574292</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_96bb75f4-3ef9-4bf6-bb80-e9de3fa7966e"
      unitRef="U_USD">554321</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_92105fa0-c2fb-4d36-9093-64b910fc8e0c"
      unitRef="U_USD">54537</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <maia:ResearchAndDevelopmentIncentivesReceivable
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_8392966a-9755-4eb8-9178-db5aef1cb894"
      unitRef="U_USD">302789</maia:ResearchAndDevelopmentIncentivesReceivable>
    <maia:ResearchAndDevelopmentIncentivesReceivable
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_303fd690-be56-4244-a9df-d3728a69cb33"
      unitRef="U_USD">43666</maia:ResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:AssetsCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_72823109-f19c-458a-9538-13adc3965052"
      unitRef="U_USD">11808037</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_49011899-aa86-4d77-9432-cd4f0105743e"
      unitRef="U_USD">10672495</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_5341b6bf-5ad8-4339-a196-7fdd93c3841c"
      unitRef="U_USD">211203</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_75eae16d-bf4a-4c12-ae5c-db987320807c"
      unitRef="U_USD">651582</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_efe8db27-eed6-4e47-9304-acfda0094ca4"
      unitRef="U_USD">2800</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_805482ad-2920-47ee-8273-72b9dd781521"
      unitRef="U_USD">3122</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_4ee5c0d1-5572-4a9f-b83a-d2d7d2fe614c"
      unitRef="U_USD">12022040</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_6b5f0993-aa93-4dba-9c94-d80967059ab1"
      unitRef="U_USD">11327199</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_e5c51c78-e8d7-4f3a-84b0-b7383a1f1ac2"
      unitRef="U_USD">1165505</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_68fbe41d-742c-4189-8529-b67e5d28fc0b"
      unitRef="U_USD">960401</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_6fb7cbce-ed9e-47fc-a3b1-4e4e0a7a86ea"
      unitRef="U_USD">2103401</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_1683486f-43b3-4db6-a7d4-23a516175d59"
      unitRef="U_USD">1185595</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_b79f88cc-1f8c-4cc3-99bb-84b14db75218"
      unitRef="U_USD">3268906</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_db4ff37c-1030-4c30-9480-2e261239d71f"
      unitRef="U_USD">2145996</us-gaap:LiabilitiesCurrent>
    <maia:WarrantLiabilityNoncurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_97c7f475-ff10-4bd9-addd-6074c8e1951b"
      unitRef="U_USD">245341</maia:WarrantLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_769793e7-b39d-45d2-9ddf-19563cf30540"
      unitRef="U_USD">3514247</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_362c739e-c21b-436b-8c23-92e62270287b"
      unitRef="U_USD">2145996</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_7086fd7b-89cb-4774-b59d-599ae6f5b4cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_c3dc6846-0de6-4bb8-96b9-4a5e796255fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_c59099a6-b7a2-49b2-a7d4-d0e835a0bf43"
      unitRef="U_shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_4d351eba-aa6c-4c97-b03d-2ae5ddfa4ae3"
      unitRef="U_shares">70000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_7a79fb31-dfec-43cf-9806-9bd914cc8160"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_4316cc74-04fd-4604-a39e-1722c2231a60"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_fa54f89f-98a8-4537-8286-26488af9cd2f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_ee96ebd2-e862-4140-ac6d-bd3fa5f54154"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_4d3d71ba-6f36-4311-94aa-7495cd25ff63"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_292c9f3a-ca4d-4958-a263-32db50dda459"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_bbc29414-56d5-4634-a80e-49eb6f4fb056"
      unitRef="U_shares">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_bdd7a213-678e-4277-8e52-64ab3b560edf"
      unitRef="U_shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_c06ea33e-1cec-4546-b4ce-37da836a3ab8"
      unitRef="U_shares">10955904</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_421afbd7-3c8f-4b4f-b685-96be7f40b547"
      unitRef="U_shares">10955904</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_856d9fe2-dd7e-421e-960a-e81cb801d4e4"
      unitRef="U_shares">7584980</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_fb472338-c106-4c82-9a58-995af339fb82"
      unitRef="U_shares">7584980</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_fe9fe187-5b68-4a95-9b02-fedf61c7e8fe"
      unitRef="U_USD">1096</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_e8e99eb0-d98a-4a3d-8c13-630ab6d54f57"
      unitRef="U_USD">758</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_5f8d36bc-8368-4bc4-ba5e-0fa59267f04d"
      unitRef="U_USD">52729942</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_2fd19ade-749d-48a0-bd63-642c9ec7ee94"
      unitRef="U_USD">37618438</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_14f30d37-2108-4277-a0b1-a2ec152d3196"
      unitRef="U_USD">-44207272</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_d052c01d-489e-4e92-a104-5999ec3fbc65"
      unitRef="U_USD">-28437993</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_5c6e8d35-3b7d-4ac6-916e-1338fbc1ab72"
      unitRef="U_USD">-15973</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_9fa2fbf4-e64e-4de0-a695-c0191a738d0b"
      unitRef="U_USD">8507793</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_c61f36e0-cabf-463b-9303-9d5f8933d300"
      unitRef="U_USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_4d8328b3-357f-4dfe-bc56-f58828e70423"
      unitRef="U_USD">12022040</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_7224f1d2-95c0-4de0-8d48-8dec0a14c297"
      unitRef="U_USD">11327199</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_f34723b9-00ec-4521-a85f-7d1438d0aa19"
      unitRef="U_USD">8933314</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_b409c12c-4672-41a0-9421-79e0e5d18c35"
      unitRef="U_USD">3496796</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_6404fc98-3717-493c-8364-74464377db29"
      unitRef="U_USD">6143527</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_40079c1b-d068-4eea-97e9-7eecb6b3eb9d"
      unitRef="U_USD">4289831</us-gaap:GeneralAndAdministrativeExpense>
    <maia:RatchetShareExpense
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_13b8b8e3-e8d2-437b-aa4e-607efab8ea3e"
      unitRef="U_USD">1099360</maia:RatchetShareExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_e71719df-5663-4581-a612-ddff68ed89a1"
      unitRef="U_USD">16176201</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_44c45550-f196-46d8-b536-3c7eee219c6d"
      unitRef="U_USD">7786627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_01606826-129c-4128-b4a8-79380f479b4c"
      unitRef="U_USD">-16176201</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_7fa072ad-9843-4475-8b5d-3c7618f798b2"
      unitRef="U_USD">-7786627</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_d517654b-ddfa-414a-bd13-53107b1b300b"
      unitRef="U_USD">6967</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_4e53b2ee-405c-437d-8265-c3a7d4707d2c"
      unitRef="U_USD">827539</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_d63f5966-aead-4d06-b2b0-3dd6fdac8c9d"
      unitRef="U_USD">1870</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_05b52244-30f1-4b3f-b219-2b1994efadd3"
      unitRef="U_USD">2012</us-gaap:InvestmentIncomeInterest>
    <maia:AustralianResearchAndDevelopmentIncentives
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_13776d33-4291-41d1-bf18-d0eac92827ea"
      unitRef="U_USD">313625</maia:AustralianResearchAndDevelopmentIncentives>
    <maia:AustralianResearchAndDevelopmentIncentives
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_d1409e2e-b901-4219-8231-177900a0fab1"
      unitRef="U_USD">43666</maia:AustralianResearchAndDevelopmentIncentives>
    <maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_7cda4f4f-c5b4-49fd-a5a4-6fb910a4d66a"
      unitRef="U_USD">62500</maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_c6803fa8-9851-4f65-9364-d5a9acb3a184"
      unitRef="U_USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_500280db-7292-4385-a684-b4064c4cbccd"
      unitRef="U_USD">-98394</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_1b967a28-d509-478a-b1fc-b450a4cc42da"
      unitRef="U_USD">1546280</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_37c844d9-f610-49c6-b473-f236363a7d69"
      unitRef="U_USD">-2322943</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_fa0a7d1f-920e-484f-82f7-04d5b005c4ef"
      unitRef="U_USD">406922</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_920f8722-0b7f-40ef-895f-c613b5f31c32"
      unitRef="U_USD">-4791584</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:ProfitLoss
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_704b8c81-cc12-464e-af62-37ea75682066"
      unitRef="U_USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_ea13727c-49da-425f-9cb5-f887db58863d"
      unitRef="U_USD">-12578211</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_6ba0f4fe-f009-4b83-8c7a-60c3239550a4"
      unitRef="U_USD">-74331</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <maia:DeemedDividendOnWarrantModification
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_deb7a039-10dc-420b-a39a-50673acc60ca"
      unitRef="U_USD">-450578</maia:DeemedDividendOnWarrantModification>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_e914b60a-9807-438c-9bcb-76ee41f5d766"
      unitRef="U_USD">-16219857</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_83d63238-a6e0-460c-85a3-d8b0ae4e87a3"
      unitRef="U_USD">-12503880</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_6f8917f2-ec6c-46c4-b0df-80c4d50b668c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_1ae67414-266e-4fd3-8868-3d776f837edc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="2"
      id="F_24e0ea83-1506-4f8d-bd30-eaaec0e231f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="2"
      id="F_98e048bc-9347-4500-94f5-5dc35257d6ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_1942f0c2-8fef-4c33-b0d4-bd06d4a000c3"
      unitRef="U_shares">9276761</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_c280a5ac-637a-416e-b82f-014a7ccecb2f"
      unitRef="U_shares">9276761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_baf693da-c476-48f2-9287-2ce8f890aa66"
      unitRef="U_shares">5278435</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_a88819e6-70d1-455a-8fc6-b78ae7740251"
      unitRef="U_shares">5278435</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_709357e7-d504-46be-a8be-272878920bba"
      unitRef="U_USD">-16219857</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_aeb47211-a7ab-49bc-9850-49ee267d4843"
      unitRef="U_USD">-12503880</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_9ba20b2c-5e36-4eef-8082-33ac0cc04160"
      unitRef="U_USD">-15973</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_01bc07eb-0cac-4820-a1f6-f3f308a78c87"
      unitRef="U_USD">-16235830</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_e6752ef7-b801-4d1e-8720-54ddd09c5429"
      unitRef="U_USD">-12503880</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53"
      decimals="INF"
      id="F_77a2ac6e-050c-4e97-b40a-1486eafd4501"
      unitRef="U_shares">7584980</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53"
      decimals="0"
      id="F_d274170f-e0a2-49c5-9993-9240fc3061c0"
      unitRef="U_USD">758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5c7dbf97-a62c-4354-b7ac-212c85adff76"
      decimals="0"
      id="F_913ba90f-88a8-4379-a4a2-0aaaaa2d2cf5"
      unitRef="U_USD">37618438</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_94951a0e-9218-4969-993f-e925194bc10f"
      decimals="0"
      id="F_ef657e56-8f40-4d1f-bf11-3c0a32afb2d2"
      unitRef="U_USD">-28437993</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_833635eb-5d0f-4193-aca7-65a674be8ad6"
      unitRef="U_USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_35df104b-b405-4915-a247-efcae1451c3e"
      decimals="INF"
      id="F_bdfc882b-a00a-410b-bfd6-70a85092f75a"
      unitRef="U_shares">46500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_35df104b-b405-4915-a247-efcae1451c3e"
      decimals="0"
      id="F_35c981b2-3d1d-4a51-9232-f1d923c67383"
      unitRef="U_USD">5</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e"
      decimals="0"
      id="F_522223b3-0dd8-4d63-a45b-792187068ca3"
      unitRef="U_USD">83995</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_bf0afe18-943a-4dcd-9905-0e4dbc399243"
      unitRef="U_USD">84000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_35df104b-b405-4915-a247-efcae1451c3e"
      decimals="INF"
      id="F_4a3e5006-22cc-4e1c-a32f-338bfbb47eb3"
      unitRef="U_shares">529712</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_35df104b-b405-4915-a247-efcae1451c3e"
      decimals="0"
      id="F_b271d5c7-bfa8-4c17-b5dc-591d1cbe1d82"
      unitRef="U_USD">53</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e"
      decimals="0"
      id="F_81480d35-1bd5-4d84-8dcf-23dc191320e1"
      unitRef="U_USD">385347</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_1c0c3e20-f958-4ce2-ad93-4e80c6018231"
      unitRef="U_USD">385400</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e"
      decimals="0"
      id="F_33bd0cbb-301e-46f5-bed0-5b73e36e1801"
      unitRef="U_USD">2319427</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_404329db-f21f-406e-9faf-bf05984612db"
      unitRef="U_USD">2319427</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares
      contextRef="C_35df104b-b405-4915-a247-efcae1451c3e"
      decimals="INF"
      id="F_1956f7d7-5c23-4f64-b5be-a6882a825fd7"
      unitRef="U_shares">274840</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_35df104b-b405-4915-a247-efcae1451c3e"
      decimals="0"
      id="F_859a719e-94e7-4d2d-b9d3-6bcf6e1c3428"
      unitRef="U_USD">28</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e"
      decimals="0"
      id="F_01df092b-dd01-4e9e-a9f3-e1caea97442c"
      unitRef="U_USD">2473532</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_21df3802-f25b-4c22-aa81-83a309393b63"
      unitRef="U_USD">2473560</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_f426df1f-3c59-401e-952f-443722bf8259"
      decimals="0"
      id="F_7f860467-2956-48be-ba9b-cf9e5861311a"
      unitRef="U_USD">2749905</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_460c12ea-f2c0-4902-aaba-b209608b801a"
      decimals="INF"
      id="F_8861ef67-fafd-4d1f-9ada-f44569eb578d"
      unitRef="U_shares">2300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_460c12ea-f2c0-4902-aaba-b209608b801a"
      decimals="0"
      id="F_5aed9066-25dd-4ab2-b3ae-a0478164424d"
      unitRef="U_USD">230</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8de3a275-a1ef-4daa-8115-7bf33cf32d56"
      decimals="0"
      id="F_3949b4b8-b6ee-41a2-87ef-40a06f21fe8a"
      unitRef="U_USD">8749865</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f426df1f-3c59-401e-952f-443722bf8259"
      decimals="0"
      id="F_bf0c0223-5f2c-4985-a549-fdb9465a4c7a"
      unitRef="U_USD">8750095</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1491750e-595c-458c-b2bc-3af9c7704855"
      decimals="INF"
      id="F_0726d7bb-6059-4e75-899a-00fdda1cb299"
      unitRef="U_shares">219872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1491750e-595c-458c-b2bc-3af9c7704855"
      decimals="0"
      id="F_4075a33f-0613-46de-9d7b-6bdc845a3737"
      unitRef="U_USD">22</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_51ce7740-df5e-458e-9aca-0e98ee73acc3"
      decimals="0"
      id="F_47c3ac9b-feea-4424-91e3-a4f838e4e8d8"
      unitRef="U_USD">1099338</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_65e57920-9bea-4275-bd59-c0a66b11eb61"
      decimals="0"
      id="F_aa41890c-43ca-4d73-bb08-af58be90daa6"
      unitRef="U_USD">1099360</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <maia:ModificationOfWarrantInEquity
      contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e"
      decimals="0"
      id="F_5915eecb-083a-44d6-84fb-31e812329e1b"
      unitRef="U_USD">450578</maia:ModificationOfWarrantInEquity>
    <maia:ModificationOfWarrantInEquity
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_9e6a64ed-1dc6-499e-bab9-753784010988"
      unitRef="U_USD">450578</maia:ModificationOfWarrantInEquity>
    <maia:AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant
      contextRef="C_6225085e-6353-4624-b82c-bec3de902a2e"
      decimals="0"
      id="F_3a8ae2dc-661c-4f43-8e39-9d970a623ebd"
      unitRef="U_USD">-450578</maia:AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant>
    <maia:AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_e2bf839d-0cbd-40eb-a0c0-1defb1c5c845"
      unitRef="U_USD">-450578</maia:AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant>
    <maia:ForeignCurrencyTranslationAdjustment
      contextRef="C_b7c6a87c-7d18-4cd1-89df-759036b167f7"
      decimals="0"
      id="F_c6881932-9a13-4633-8904-9bde9ecbd100"
      unitRef="U_USD">-15973</maia:ForeignCurrencyTranslationAdjustment>
    <maia:ForeignCurrencyTranslationAdjustment
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_f890b370-26a7-4933-8d38-292dcabab374"
      unitRef="U_USD">-15973</maia:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss
      contextRef="C_e4448ed4-2b54-4235-9206-c0b8e343fb1b"
      decimals="0"
      id="F_235130d4-fb7c-4638-afea-d013ea2f65c7"
      unitRef="U_USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_ad904153-6935-41e7-9ee3-ef59b16cceed"
      unitRef="U_USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_bd92e2f2-afa8-429c-8e71-c820d8b523b9"
      decimals="INF"
      id="F_1bdfdb74-552c-4f13-8c10-4472ac16a09c"
      unitRef="U_shares">10955904</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bd92e2f2-afa8-429c-8e71-c820d8b523b9"
      decimals="0"
      id="F_ed3decfd-9af3-4b65-a11d-53e3c5718ad1"
      unitRef="U_USD">1096</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_71ce86d1-a364-40dd-8e50-83d2857961c7"
      decimals="0"
      id="F_4b9c2b17-00e0-4f72-bd35-3865759aaa4b"
      unitRef="U_USD">52729942</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4a905e51-4f6b-438a-9ff9-32f5ff3fbc1a"
      decimals="0"
      id="F_a1468ecf-a045-422b-8b9d-4b51a996e457"
      unitRef="U_USD">-44207272</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fed35c89-2357-48b2-9d4e-1962b1feedbe"
      decimals="0"
      id="F_8c9839e6-7c91-4ea6-9f21-8a68e40abf87"
      unitRef="U_USD">-15973</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_f3d235c2-33ba-44dc-b95d-ce5c7e8fd905"
      unitRef="U_USD">8507793</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_c40ba4b1-8a23-45d1-b399-8ff938660566"
      decimals="INF"
      id="F_690af3e6-4ab8-4a6d-b444-e35c5ac9f112"
      unitRef="U_shares">4433644</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c40ba4b1-8a23-45d1-b399-8ff938660566"
      decimals="0"
      id="F_9f663eee-f006-4656-b846-12b4f038cb4d"
      unitRef="U_USD">443</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0fdfbd9c-c879-495d-a18d-f5b6252af2fe"
      decimals="0"
      id="F_8d3e39e0-1502-4ed6-99b7-c008c0da2690"
      unitRef="U_USD">12599585</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_03e3bd00-bb23-45f7-a4b4-e0c48e0a00f2"
      decimals="0"
      id="F_b3aa41aa-4107-419a-8281-d12e224160b2"
      unitRef="U_USD">-15934113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_77674401-ed32-4efc-bc01-fa0a205bd5c3"
      decimals="0"
      id="F_9c0f64fe-dcfa-4ccc-83cf-f0220ddb6fa5"
      unitRef="U_USD">-2002</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b2767d21-f84d-45dc-805e-c26596b84ec5"
      decimals="0"
      id="F_f960c69c-b5d8-417d-a4a6-08b01eeda5bd"
      unitRef="U_USD">-3336087</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6ed89264-6427-4629-a39a-d1eb18f5c44a"
      decimals="0"
      id="F_42da24f7-539e-4e3e-a676-e3a59c41aa4c"
      unitRef="U_USD">1719787</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7bfe2412-70aa-498d-b73f-b58ae522d52e"
      decimals="0"
      id="F_3b387ffe-d5d1-4ff8-ac5d-0526e1afe0ef"
      unitRef="U_USD">-1616300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_335d61ec-2804-4540-a31f-d1b6999f2ea7"
      unitRef="U_shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="0"
      id="F_7ad49371-eda7-4a19-9c98-ea3091ab9dd6"
      unitRef="U_USD">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_99fdaaad-3b34-4d9c-b7f3-9604be2126df"
      unitRef="U_USD">8999</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_4fd67a4f-ad62-4bdc-bb70-beda5758a599"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_ed0619bd-4d3d-49f5-b375-b81c71b4cea3"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_514f39c8-c2fd-41eb-8ee2-d6f37f7a3800"
      unitRef="U_shares">283616</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="0"
      id="F_183577c6-88d9-4ee1-a2e1-be9efcf774f4"
      unitRef="U_USD">28</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_96b891d2-2fc9-4e13-9f23-a3692cc04272"
      unitRef="U_USD">529397</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_e74b59b1-f525-43f7-b29a-81bd64b0036b"
      unitRef="U_USD">529425</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrants
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_aadadf06-bbd9-495e-bdef-840b0b08729f"
      unitRef="U_USD">529425</maia:IssuanceOfCommonSharesUponExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_ece7d5f1-ccf7-4e1d-94ca-9b6794e04037"
      unitRef="U_shares">15278</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="0"
      id="F_ef8ae72d-b8a0-4aa2-b134-c3af6cb7ad1e"
      unitRef="U_USD">2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_7f6a46b4-7457-4226-b6f6-58c733040326"
      unitRef="U_USD">27498</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_95142a14-db07-4257-998e-cba4465055ac"
      unitRef="U_USD">27500</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_cfd39494-6a6d-422a-b566-38df9cc25dd5"
      unitRef="U_USD">27500</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_7469c0b9-e4c1-4b80-b9ba-16c277da5ea1"
      unitRef="U_shares">5557</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="0"
      id="F_2487bb5e-a058-4edc-a9f2-496b015f31bf"
      unitRef="U_USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_2533e7e6-da0a-4e01-b2ec-36ffa0cca281"
      unitRef="U_USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_6af05c6b-c3bc-4ff8-b5a5-a68e77b4640e"
      unitRef="U_USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_26c5028f-4301-4fc6-902f-4ba78e333f03"
      unitRef="U_USD">2428935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_358e0a01-bf0b-4227-9776-03c306d5d40d"
      unitRef="U_USD">2428935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_97eca392-6bd7-4f4f-8a0c-06c86f7e0924"
      unitRef="U_USD">2428935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_514ade27-e387-4d84-83c5-c59113d65690"
      decimals="0"
      id="F_a2454aa8-f346-4893-a597-bda0fff254d5"
      unitRef="U_USD">161460</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_af4145b4-83cc-4b5a-8c80-2f54f89c9863"
      decimals="0"
      id="F_bffe88a1-c697-46a2-83b6-aacb5bef42ba"
      unitRef="U_USD">161460</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_38807a13-8dd9-4c2d-b8c8-cfc13aebab4d"
      decimals="0"
      id="F_04315021-1b39-47ef-9385-7002c54e92a9"
      unitRef="U_USD">104999</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_10e99315-c20f-4d44-875f-39b50152cb08"
      decimals="0"
      id="F_aa82fe00-8620-480b-8b9e-f61b61b941fc"
      unitRef="U_USD">104999</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <maia:IssuanceOfStockOptionsToSatisfyAccruedBonus
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_5b470d4f-9efa-4753-825f-99ddf179c2bf"
      unitRef="U_USD">786531</maia:IssuanceOfStockOptionsToSatisfyAccruedBonus>
    <maia:IssuanceOfStockOptionsToSatisfyAccruedBonus
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_391c523a-372c-4ff8-b0a6-62ec50ae066b"
      unitRef="U_USD">786531</maia:IssuanceOfStockOptionsToSatisfyAccruedBonus>
    <maia:IssuanceOfStockOptionsToSatisfyAccruedBonus
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_3a7c8029-a9af-4550-965d-1f719516c1a2"
      unitRef="U_USD">786531</maia:IssuanceOfStockOptionsToSatisfyAccruedBonus>
    <maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_828ba255-d2b0-486b-afab-e547db3c45a9"
      unitRef="U_USD">285418</maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation>
    <maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_1989d0ff-70e2-4b4d-b413-3f9f33c8b9c9"
      unitRef="U_USD">285418</maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation>
    <maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_5e5d4d40-2dd7-4b5f-bcb1-40b31d8a8751"
      unitRef="U_USD">285418</maia:IssuanceOfStockOptionsToSatisfyDeferredCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_29b31bca-30ed-43f8-b74e-efbf6832694b"
      unitRef="U_shares">1375228</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="0"
      id="F_38d43c41-ba5f-4a14-ac73-7cd7d2f2403f"
      unitRef="U_USD">138</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_b6245257-fad5-4657-82c7-2a928e1cdb1e"
      unitRef="U_USD">11001136</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_b90447d2-aeb4-4579-8e22-31e8cbd6dc51"
      unitRef="U_USD">11001274</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_cba83c85-88f9-496c-96ea-41a22ddd4e65"
      unitRef="U_USD">11001274</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <maia:StockIssuedDuringPeriodSharesConversionOfSafe
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_f19d846c-34d4-4cd5-bff0-63d1cce3822e"
      unitRef="U_shares">5208</maia:StockIssuedDuringPeriodSharesConversionOfSafe>
    <maia:StockIssuedDuringPeriodValueConversionOfSafe
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_2df22ab6-3802-430a-87c8-5c559cd84ff4"
      unitRef="U_USD">25000</maia:StockIssuedDuringPeriodValueConversionOfSafe>
    <maia:StockIssuedDuringPeriodValueConversionOfSafe
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_aee09bff-bafd-4ecb-a7ec-ce1bda78d59a"
      unitRef="U_USD">25000</maia:StockIssuedDuringPeriodValueConversionOfSafe>
    <maia:StockIssuedDuringPeriodValueConversionOfSafe
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_5ef1e64e-4f5b-4a80-93df-9c86985e6966"
      unitRef="U_USD">25000</maia:StockIssuedDuringPeriodValueConversionOfSafe>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="INF"
      id="F_196a921d-3ecb-4439-a92e-42c26016db35"
      unitRef="U_shares">772563</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancingShares>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_f4c1ff31-4e34-4d40-8d8c-0dbb60d4054c"
      decimals="0"
      id="F_e5e31c75-ea66-4a30-98ea-b415b49bcf9d"
      unitRef="U_USD">77</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_9eb611af-8621-4b25-8b16-5ce735a8cd6a"
      unitRef="U_USD">6180426</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_3dc27fee-372c-4000-a17a-fd220345e379"
      decimals="0"
      id="F_9792af37-f592-446a-b2c1-0a901eac4986"
      unitRef="U_USD">-320000</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_a768d15a-4370-4317-b109-5135b85eb8b2"
      unitRef="U_USD">5860503</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_8031fe96-b5f7-4730-83c0-515fd6ad4675"
      unitRef="U_USD">5860503</maia:IssuanceOfCommonSharesInConnectionWithEquityFinancing>
    <maia:ReceiptOfStockSubscriptionReceivable
      contextRef="C_3dc27fee-372c-4000-a17a-fd220345e379"
      decimals="0"
      id="F_b98c692b-b81b-4a5c-85ed-fc36f25f950b"
      unitRef="U_USD">322002</maia:ReceiptOfStockSubscriptionReceivable>
    <maia:ReceiptOfStockSubscriptionReceivable
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_8e02677a-5c28-42d9-9142-01d94183ff05"
      unitRef="U_USD">322002</maia:ReceiptOfStockSubscriptionReceivable>
    <maia:ReceiptOfStockSubscriptionReceivable
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_a348f9ed-1a24-418c-b4f0-88436046e73e"
      unitRef="U_USD">322002</maia:ReceiptOfStockSubscriptionReceivable>
    <maia:TransactionCostsIncurredInConnectionWithEquityFinancing
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_7c88ec77-6f41-4fd3-b362-ca94bd4bf0d8"
      unitRef="U_USD">-118332</maia:TransactionCostsIncurredInConnectionWithEquityFinancing>
    <maia:TransactionCostsIncurredInConnectionWithEquityFinancing
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_d324967f-f41b-40d8-a07f-9afb5074274e"
      unitRef="U_USD">-118332</maia:TransactionCostsIncurredInConnectionWithEquityFinancing>
    <maia:TransactionCostsIncurredInConnectionWithEquityFinancing
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_2b99e091-2e21-48b9-b141-b16916fdeac7"
      unitRef="U_USD">-118332</maia:TransactionCostsIncurredInConnectionWithEquityFinancing>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_8d11de7f-4020-4686-9774-064ef0b908c0"
      decimals="0"
      id="F_0e00fb27-bc66-405a-9695-6edc3035f248"
      unitRef="U_USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_a8548124-0d71-44ec-8c1b-02f3ab71181b"
      unitRef="U_USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_e06a9f18-d35f-4844-8f2d-2dcf9d5b3840"
      unitRef="U_USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_08b3f13c-8494-4e8a-bac0-e6e09f3faee0"
      decimals="INF"
      id="F_55311164-e211-4adf-a2f9-7703a6d7994a"
      unitRef="U_shares">700000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_08b3f13c-8494-4e8a-bac0-e6e09f3faee0"
      decimals="0"
      id="F_545d46b4-ae0d-47a7-9aed-959f4dd5b93f"
      unitRef="U_USD">70</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_07581902-1fc3-4f0d-9e04-a8dbb844ead0"
      decimals="0"
      id="F_84274583-3313-47d3-af87-3930d0a68665"
      unitRef="U_USD">-70</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <maia:DissolutionOfFirm
      contextRef="C_aca59814-cbfd-4366-be06-42a5a0ba6590"
      decimals="0"
      id="F_b2885bd2-578f-4acc-b2de-a47b37237a45"
      unitRef="U_USD">1098110</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_681b3cde-40ae-48db-9701-970b57fafca8"
      decimals="0"
      id="F_4a78933b-20ae-4359-ad30-5e791d0c9d47"
      unitRef="U_USD">1098110</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_514ade27-e387-4d84-83c5-c59113d65690"
      decimals="0"
      id="F_4ca9634e-a0cb-4169-9cbc-9ead0f6feb20"
      unitRef="U_USD">-1098110</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_07581902-1fc3-4f0d-9e04-a8dbb844ead0"
      decimals="0"
      id="F_9e110b48-a767-42a2-bfbc-366003d64ad2"
      unitRef="U_USD">813805</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_25edec4e-51a9-4cf7-a863-6a4423d5e981"
      decimals="0"
      id="F_02f762a4-8aa6-4bb9-9460-0d4cce066801"
      unitRef="U_USD">813805</maia:DissolutionOfFirm>
    <maia:DissolutionOfFirm
      contextRef="C_6f7aff38-36bd-4981-a8df-ded8085b1fcf"
      decimals="0"
      id="F_9887b18b-205a-4403-8c80-4f7baa46abcf"
      unitRef="U_USD">-813805</maia:DissolutionOfFirm>
    <us-gaap:ProfitLoss
      contextRef="C_e8c711ae-2a67-477b-94f2-7ea7a9761789"
      decimals="0"
      id="F_193aac89-c9ad-4bff-bbe9-44a4e477238e"
      unitRef="U_USD">-12503880</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_10dbc5ec-42be-4b85-9613-2d111b13181f"
      decimals="0"
      id="F_44d57f24-82b7-486c-bb27-a65743d13dab"
      unitRef="U_USD">-12503880</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f3cb958a-ca61-46c6-a20f-0990720362c8"
      decimals="0"
      id="F_f3cd41ab-a1a3-4d65-b720-9cbed5832654"
      unitRef="U_USD">-74331</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_9eec3805-b9c5-4913-a6f6-316c93bdc5d3"
      unitRef="U_USD">-12578211</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53"
      decimals="INF"
      id="F_60aed006-e876-49ff-b197-26cd3abc618c"
      unitRef="U_shares">7584980</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_36010f8c-cb65-4fe5-8007-3823f3e1cd53"
      decimals="0"
      id="F_8bdf2cb0-4a94-4bcb-a0fc-a115db45a795"
      unitRef="U_USD">758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5c7dbf97-a62c-4354-b7ac-212c85adff76"
      decimals="0"
      id="F_d60ab972-c7ed-41f3-a455-0344b7dfdd38"
      unitRef="U_USD">37618438</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_94951a0e-9218-4969-993f-e925194bc10f"
      decimals="0"
      id="F_647b97f8-09a9-4b2a-bde6-83117dae3088"
      unitRef="U_USD">-28437993</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f2dbed72-0d93-4962-be44-54187d716c80"
      decimals="0"
      id="F_eaf6c8ec-5315-4092-af38-60ba9cc71bbe"
      unitRef="U_USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_0ce6c939-b492-4913-9869-f89e8096bf5f"
      unitRef="U_USD">9181203</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_40c899f2-c058-4cd8-b61a-65c52ccde4e6"
      unitRef="U_USD">-15769279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_a8017482-efde-4d8f-bba4-bd648ebd9b41"
      unitRef="U_USD">-12578211</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_55179c89-589f-4f2a-80e4-709d5e31da32"
      unitRef="U_USD">2319427</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_be73a2aa-e27f-4d12-b2c7-de294e635ac3"
      unitRef="U_USD">2722893</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_07e5ca9f-c060-4c9a-b60f-6ae7e8416bcf"
      unitRef="U_USD">-2322943</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_43468b6f-ada8-48b8-bfee-6c072ec2484a"
      unitRef="U_USD">62500</maia:GainLossFromForgivenessOfPaycheckProtectionProgramLoan>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_10fb4960-df2a-4d05-a978-4147971190c2"
      unitRef="U_USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <maia:IssuanceOfRatchetShares
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_b9bfeaaa-0a6e-4bac-9d8f-eabfa481d859"
      unitRef="U_USD">1099360</maia:IssuanceOfRatchetShares>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_a4184c83-cbf6-4596-8361-c7a9957673cc"
      unitRef="U_USD">-98394</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_96ab9175-a6c1-42ec-9390-d07cf98bff54"
      unitRef="U_USD">1546280</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_a1992bd7-1968-45b1-ba86-caa95ccd3847"
      unitRef="U_USD">596953</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_d11e4937-eeec-4b0a-9a8c-fe8b2ca88dbe"
      unitRef="U_USD">505233</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_6f33061f-017f-40c5-9240-80f54ca3a8e9"
      unitRef="U_USD">15155</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <maia:IncreaseDecreaseInDeferredOfferingCost
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_32f88675-3933-48ae-bca7-e3ed21890b8e"
      unitRef="U_USD">-440379</maia:IncreaseDecreaseInDeferredOfferingCost>
    <maia:IncreaseDecreaseInDeferredOfferingCost
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_1c4dc9df-69f1-477f-9a25-d8c1ac6b4b8a"
      unitRef="U_USD">651582</maia:IncreaseDecreaseInDeferredOfferingCost>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_7a131682-a7f9-4de8-b5e4-2df8e4fc49b0"
      unitRef="U_USD">269395</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_ba9cb1f8-527a-4e45-a621-db1c5e091699"
      unitRef="U_USD">-322</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_6dd2bf44-ea5b-4fc6-be50-d028a161da8d"
      unitRef="U_USD">3122</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_d707eb39-cb60-4324-bec4-664f605ccf85"
      unitRef="U_USD">211346</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_d9f724dd-821a-4e20-875f-563da6efa209"
      unitRef="U_USD">805516</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_a027e358-2f3c-47ca-8a21-ed4bb7c12796"
      unitRef="U_USD">915742</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_82b24f67-b7ae-4355-925a-d62d6044e42a"
      unitRef="U_USD">997126</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_b8f4d904-b228-4dae-89f7-d4402d1ce64d"
      unitRef="U_USD">-7037</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_f1590181-6d43-4f1b-a67d-1a29f9ce3c91"
      unitRef="U_USD">-11655725</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_c7a9175f-c9f1-44ca-89a4-b994a6bab110"
      unitRef="U_USD">-4122896</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_7196ce5d-bf07-483a-8791-f9c1e0f07cca"
      unitRef="U_USD">7369000</us-gaap:ProceedsFromConvertibleDebt>
    <maia:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_2a5dba36-e006-42bb-9cf3-810f6017142d"
      unitRef="U_USD">62500</maia:ProceedsFromPaycheckProtectionProgramLoan>
    <maia:ProceedsFromCollectionOfSubscriptionReceivable
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_ff77f683-56f2-4ee6-ba78-837e23d7c7c1"
      unitRef="U_USD">322002</maia:ProceedsFromCollectionOfSubscriptionReceivable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_d43e3dff-9b15-4b72-8405-363949b4d298"
      unitRef="U_USD">2473560</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_cfdf0aff-2aae-411b-9abe-22ca7fec0e75"
      unitRef="U_USD">5742171</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_e94b2f38-dbb7-4b19-9cb8-00946d56bfd5"
      unitRef="U_USD">84000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_538d6974-aeb0-42cf-90c3-12002cd990d2"
      unitRef="U_USD">9000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_070ca82b-cf0c-47c8-b4a9-6f3cd8f421ad"
      unitRef="U_USD">385400</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_544fead4-0d44-4cf1-bfeb-f2f8332564ac"
      unitRef="U_USD">529425</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_a1a242a2-8214-41ca-9119-0aed1325cbc2"
      unitRef="U_USD">11500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <maia:PaymentOfInitialPublicOfferingTransactionCosts
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_67f74ede-239c-454c-a094-de3dbe759d24"
      unitRef="U_USD">2406170</maia:PaymentOfInitialPublicOfferingTransactionCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_04b313bd-0a26-47a9-bd2f-8ff68e40e0f1"
      unitRef="U_USD">367</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_6dc56187-582e-4ccb-bdac-4c9d50caba6e"
      unitRef="U_USD">12036790</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_06957346-9542-4028-9752-8be7e1c68234"
      unitRef="U_USD">14033731</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_6e52c1f3-3afe-4feb-a307-a4aecd5d57f2"
      unitRef="U_USD">-4430</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_052d0a4b-b0ed-4a32-9d55-1f8a24de571d"
      unitRef="U_USD">376635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_28e291e2-8510-4a37-a1ea-613ac6eac62a"
      unitRef="U_USD">9910835</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_0414b4dd-7b81-46d8-98a2-81eb0f66625a"
      unitRef="U_USD">10574292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7bfe2412-70aa-498d-b73f-b58ae522d52e"
      decimals="0"
      id="F_6a4d6c18-e697-40c2-a43b-ad5f01c5e948"
      unitRef="U_USD">663457</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_080e43f3-f059-476c-a97c-18a81da6bd24"
      unitRef="U_USD">10950927</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_ae56162a-52bb-4db2-b934-5f994bc50c48"
      unitRef="U_USD">10574292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <maia:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_a63c07fc-8619-44e6-b42d-f7d1bf02a3a0"
      unitRef="U_USD">8249587</maia:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_bd3e1a2a-302a-4787-ac8e-b2fa2aed5e44"
      unitRef="U_USD">25000</us-gaap:ConversionOfStockAmountConverted1>
    <maia:OptionsIssuedForAccruedBonus
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_6a69124a-3a9e-4631-8f69-3c14a5e825b0"
      unitRef="U_USD">786531</maia:OptionsIssuedForAccruedBonus>
    <maia:OptionsIssuedForDeferredCompensation
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_2f304c49-5003-48f9-a253-20a18fd868c7"
      unitRef="U_USD">285418</maia:OptionsIssuedForDeferredCompensation>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_5feb1b64-b6ec-4af6-aea6-25b381195e36"
      unitRef="U_USD">1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <maia:IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_1ddc8dc1-128a-419f-9baf-e1f15d3b8812"
      unitRef="U_USD">-21000</maia:IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer>
    <maia:PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_a1121277-42aa-48b3-aa5d-6eb75600e7e2"
      unitRef="U_USD">651582</maia:PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering>
    <maia:WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_28fd4bf9-18e1-406c-82f0-b9f84fa99126"
      unitRef="U_USD">343735</maia:WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_d7c03aa9-7d7a-4eb7-8cbe-00ec9f4e0600">&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of Business, Organization, and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#x201c;the Company&#x201d;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#x201c;MAIA&#x201d;) was incorporated in the state of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Delaware&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 3, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;THIO Therapeutics, Inc. (&#x201c;THIO&#x201d;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;minority stockholder of THIO received &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; share of MAIA common stock for each share of THIO common stock owned prior to the merger.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DGD Pharmaceuticals Corporation (&#x201c;DGD&#x201d;), incorporated in the state of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Delaware&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Drug Development Corporation (&#x201c;MAIA DD&#x201d;) incorporated in the state of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Texas&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 10, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, the Company had working capital of&#x2009;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,539,131&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,207,272&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,950,927&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and current liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,268,906&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During January and February 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,729&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,373,561&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; before transaction costs and expenses. During May 2022, the company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#x201d; The Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the initial public offering. On August 3, 2022, the Company sold an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per the overallotment option for the underwriter. After deducting $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,406,170&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for cash issuance costs, net proceeds from the offering and overallotment were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,093,830&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Going Concern Considerations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,207,272&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the Company&#x2019;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,951&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,000 million in cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;meet the Company&#x2019;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;issuance &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after these financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impact of the COVID-19 Pandemic on our Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 Outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d; or &#x201c;GAAP&#x201d;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s Chief Executive Officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Certain Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;financial statements of the Company&#x2019;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;period &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#x2019; equity as accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#x2019;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cash equivalents as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#x201c;Accounting Standards Codification (ASC) Topic 820&#x201d;, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;General and Administrative&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s research and development expenses consist primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#x2019;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#x2019;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Incentive&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#x2019;s role at the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), depending on the specific terms of the warrant agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When warrants are issued for services to non-employees, under ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes are recorded in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.772%;"/&gt;
          &lt;td style="width:1.171%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.741%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.171%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.144%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,545,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,797,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares issuable upon exercise of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;796,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,311,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2016, the FASB issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASU No. 2016-02&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as amended, Leases (&#x201c;Topic 842&#x201d;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; this new standard as of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#x2019;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_6941be2b-9b58-46c9-b092-1671953fdc39">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of Business, Organization, and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Biotechnology, Inc. and Subsidiaries (collectively, &#x201c;the Company&#x201d;) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (&#x201c;MAIA&#x201d;) was incorporated in the state of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Delaware&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 3, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;THIO Therapeutics, Inc. (&#x201c;THIO&#x201d;), incorporated in the state of Delaware on November 26, 2018. On August 13, 2021, MAIA and THIO completed a plan of reorganization in which THIO merged with and into MAIA. Prior to the merger, MAIA owned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding shares of THIO common stock, which were canceled in connection with the merger. The remaining &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;minority stockholder of THIO received &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; share of MAIA common stock for each share of THIO common stock owned prior to the merger.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DGD Pharmaceuticals Corporation (&#x201c;DGD&#x201d;), incorporated in the state of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Delaware&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In July 2020, the board of directors approved the dissolution of DGD, and shortly thereafter also approved a special dividend/return of capital to its stockholders. On August 13, 2021, DGD was officially dissolved via a filing of a Certificate of Dissolution with the state of Delaware. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Drug Development Corporation (&#x201c;MAIA DD&#x201d;) incorporated in the state of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Texas&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 10, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% owned by MAIA, until MAIA DD was legally dissolved in July 2021. The operations of MAIA DD were nominal.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd, to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company's product candidates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_712dcaa8-7bcb-48d6-9fe0-6daed58715e8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_fdefd89b-6f29-4b6d-8b60-9aebe38cabac">2018-08-03</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_cfdd4c68-cf69-49c9-921b-9232d6f85520"
      decimals="INF"
      id="F_c00f411a-4f0a-4159-9f81-149c0a5a3646"
      unitRef="U_pure">0.933</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_cfdd4c68-cf69-49c9-921b-9232d6f85520"
      decimals="INF"
      id="F_f504a4f4-eb1e-4944-b9e4-6712990eb177"
      unitRef="U_pure">0.067</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_a08271c3-ef07-41c3-a903-f6781ed82f8c">minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_30e44824-e779-4c3b-b401-7c0c7fdfdeb5"
      unitRef="U_pure">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c0d9ded2-a90c-48e6-a41e-23f182621fc1"
      id="F_42b846dc-8b49-4c95-9fc6-e6a88944b9dc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_c0d9ded2-a90c-48e6-a41e-23f182621fc1"
      id="F_bb50e893-5ea8-4511-a162-e1708256879a">2019-04-01</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_af7a9610-410c-4458-b075-3916099f847e"
      id="F_d0ed3a71-01e9-4c79-b6fd-a8af4bb7fce6">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_af7a9610-410c-4458-b075-3916099f847e"
      id="F_845c26a8-af37-4a83-a12a-4a7c6b1ca8b6">2018-09-10</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_8e567c99-be4a-46b9-9a9f-31913733c870"
      decimals="INF"
      id="F_4443b1ae-845f-47c1-ade2-ca8fbad857ff"
      unitRef="U_pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <maia:LiquidityPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_43888924-a46e-496b-8bfb-6062731fad0b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, the Company had working capital of&#x2009;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,539,131&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,207,272&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,950,927&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and current liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,268,906&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Since inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; revenues and expects to continue to incur operating losses for the foreseeable future, and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During January and February 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,729&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,373,561&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; before transaction costs and expenses. During May 2022, the company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company commenced trading on July 28, 2022on the NYSE American under the ticker symbol "MAIA.&#x201d; The Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the initial public offering. On August 3, 2022, the Company sold an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per the overallotment option for the underwriter. After deducting $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,406,170&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for cash issuance costs, net proceeds from the offering and overallotment were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,093,830&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</maia:LiquidityPolicyTextBlock>
    <maia:WorkingCapital
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_9c8f3d5d-d8ab-4d7c-a7bf-39f9cb6b47b3"
      unitRef="U_USD">8539131</maia:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_95f49ea5-bff2-468f-8661-8cf132a0c5f6"
      unitRef="U_USD">-44207272</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_a9189528-9559-483b-b7c2-8ce44d6ef5e7"
      unitRef="U_USD">10950927</us-gaap:Cash>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_3c45c252-9182-4805-afb1-d4cd73bba61b"
      unitRef="U_USD">3268906</us-gaap:LiabilitiesCurrent>
    <us-gaap:Revenues
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_6a5103a6-faab-418c-bd7d-445db59e44d6"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_850a921a-9604-4c05-bc2c-f089ad5556e7"
      decimals="INF"
      id="F_32aad0c4-10b0-4bcf-a142-e80c85f48323"
      unitRef="U_shares">263729</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c"
      decimals="INF"
      id="F_b0cb5fac-32fd-4204-8468-9660f625fa5d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_850a921a-9604-4c05-bc2c-f089ad5556e7"
      decimals="0"
      id="F_888dc44c-53f0-40f4-9801-51d8654b3a62"
      unitRef="U_USD">2373561</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc"
      decimals="INF"
      id="F_2026c25d-f3bb-4e74-a071-5aeabda71ae2"
      unitRef="U_shares">11111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c"
      decimals="INF"
      id="F_a2da3828-cf79-409f-a685-dd6c8ff84f9b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc"
      decimals="0"
      id="F_fbdf9d8f-83a4-4c35-9f3d-4aac653d1fd6"
      unitRef="U_USD">99999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6"
      decimals="INF"
      id="F_b04d12ae-3164-4d61-b6c9-48843c3a5af0"
      unitRef="U_shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_4ecf3a31-2c04-49e0-8815-9e5e8a1f982f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6"
      decimals="0"
      id="F_ef7cc1c9-e230-4756-b5a3-3c278a86e458"
      unitRef="U_USD">10000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583"
      decimals="INF"
      id="F_ce761fd4-3601-4438-90fb-bba93a7d8f0b"
      unitRef="U_shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5aa0a4a7-169f-471d-837f-b409f7c4b858"
      decimals="INF"
      id="F_3cfd06a0-c677-47dd-ab6d-85b9f1cc1e36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583"
      decimals="0"
      id="F_500adcc1-4ee5-4681-8261-1cbdd45284ce"
      unitRef="U_USD">1500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_84f4e80f-cc78-40c3-9fa8-08279e8d87cf"
      decimals="0"
      id="F_05c83a74-7018-4021-81cc-6fc71745244a"
      unitRef="U_USD">2406170</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_84f4e80f-cc78-40c3-9fa8-08279e8d87cf"
      decimals="0"
      id="F_66b48779-49a8-4fc4-88cf-41e8b9d1ff4e"
      unitRef="U_USD">9093830</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <maia:GoingConcernConsiderationsPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_3b82862f-ffc6-4837-b400-06f61429d2f3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Going Concern Considerations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,207,272&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the Company&#x2019;s inception through December 31, 2022. As of December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,951&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,000 million in cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;meet the Company&#x2019;s future working capital needs, the Company will need to raise additional equity or enter into debt financing. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses in order to satisfy its obligations due within one year from the date of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;issuance &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of these financial statements, the Company cannot guarantee that it will be able to raise additional equity, raise debt, or contain expenses. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after these financial statements are issued.&lt;/span&gt;&lt;/p&gt;</maia:GoingConcernConsiderationsPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_a60f7ff0-023e-4f44-81fb-e0ae9381897a"
      unitRef="U_USD">-44207272</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="-3"
      id="F_73571a4b-6202-46a0-9c43-f32ef89ab338"
      unitRef="U_USD">10951000</us-gaap:Cash>
    <maia:ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_58430710-2f88-4bb4-99c8-a6c467098529">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impact of the COVID-19 Pandemic on our Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 Outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The full impact of the COVID-19 Outbreak continues to evolve as of the date of this report. As a result, we cannot estimate the full magnitude that the pandemic will have on our business. If the COVID-19 Outbreak continues, it may have a material adverse effect on our financial condition, liquidity, and future results of operations for the future. We are actively monitoring the impact of the global pandemic on our financial condition, liquidity, operations, industry, and workforce. Given the daily evolution of the COVID-19 Outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 Outbreak on our results of operations, financial condition, or liquidity for the future. One of our clinical studies is taking place in Australia, which initially imposed one of the strictest COVID-19-related measures, including lock-downs. While we are not currently experiencing any delays or increased costs as a result of these measures, we may do so in the future.&lt;/span&gt;&lt;/p&gt;</maia:ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_39a41108-4351-4189-90df-7962afac4a5b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d; or &#x201c;GAAP&#x201d;). You should read the discussion and analysis together with such consolidated financial statements and the related notes thereto.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company's wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these audited consolidated financial statements have been included.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_da394fec-7fc8-4cc4-911c-f189061995c4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s Chief Executive Officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_859dd0fa-7cbd-4a83-898b-c15275aed45b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <maia:CertainRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_68b08aca-6ac0-4955-909d-8342f00b96c0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Certain Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/span&gt;&lt;/p&gt;</maia:CertainRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_4a6b99e8-e1fe-4d3d-b8a9-8f9a86698991">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;financial statements of the Company&#x2019;s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;period &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for results of operations. The resulting foreign currency translation adjustment, is included in shareholders&#x2019; equity as accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_3d06ce08-c38a-41a8-b513-720534d949ed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. At December 31, 2022 and 2021, substantially all of the Company&#x2019;s cash was deposited in accounts at one financial institution. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution and, accordingly, the Company believes such funds are subject to minimal credit risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_25e38661-c118-47a3-9ac9-1344d3eccc90">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of December 31, 2022 and 2021, cash includes cash in a depository bank account; the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cash equivalents as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_f199ea1c-306d-4f81-b21b-9a3c2855e4c3"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_8b68aced-a961-4909-b17a-a2bac6170c0a"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_c51e4401-2d5d-4e1d-8e98-98932ab7a485">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &#x201c;Accounting Standards Codification (ASC) Topic 820&#x201d;, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2022 and 2021. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes model during the years ended December 31, 2022 and 2021. The estimated fair value of the warrants issued with the convertible notes, warrants issued to underwriters and embedded features, represented Level 3 measurements.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_dc6da17b-9d85-4f5f-a77b-2c0f52bb8153">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;General and Administrative&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, depreciation and amortization, rent, outside legal expenses, insurance costs, and other general and administrative costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_767ac5eb-9c57-41e8-bdd7-5de7c1451d45">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s research and development expenses consist primarily of costs associated with the Company&#x2019;s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#x2019;s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;sheet date in our consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in the Company&#x2019;s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <maia:ResearchAndDevelopmentIncentivePolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_c79ece20-5513-4924-a170-b782eabd4820">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Incentive&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time and it is included in Australian research and development incentives in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</maia:ResearchAndDevelopmentIncentivePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_8448df0d-6e77-4ca8-afc5-eb7b5fbcbcb6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments contain features that qualify as embedded derivatives.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_7415af44-84f1-4029-bfa3-b8ce5e7b0bb1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the offering, in order to estimate the fair value of shares of the common stock, the Company's board of directors considered, among other things, sales of common stock to third party investors and valuations of common stock, business, financial condition and results of operations, including related industry trends affecting operations; the likelihood of achieving a liquidity event, such as an offering, or sale, given prevailing market conditions; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual&#x2019;s role at the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <maia:CommonStockWarrantsPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_ea81fa28-db2d-4e49-857c-a3d0437a30be">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for common stock warrants as either equity instruments or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), depending on the specific terms of the warrant agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When warrants are issued for services to non-employees, under ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;), the warrants shall be classified as a liability if 1) the underlying shares are classified as liabilities or 2) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.&lt;/span&gt;&lt;/p&gt;</maia:CommonStockWarrantsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_3ca6713d-a4da-48b1-8b64-2bddaef2c07a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes are recorded in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_13f26a74-b327-4112-909a-f00e69514791">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2021 balance sheet date that are directly related to the initial public offering and were charged to additional paid-in capital upon the completion of the initial public offering on August 1, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred offering costs were included in other assets and consisted of legal, accounting, underwriting fees and other costs incurred through the December 31, 2022 balance sheet date that are directly related to a planned follow on offering and will be charged to additional paid-in capital upon the completion of the follow on offering.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_5261e74d-24fd-46f2-85e0-9bfa276f53a7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.772%;"/&gt;
          &lt;td style="width:1.171%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.741%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.171%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.144%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,545,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,797,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares issuable upon exercise of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;796,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,311,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_6976f445-af5d-4b10-9648-ed53d5e2baf9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.772%;"/&gt;
          &lt;td style="width:1.171%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.741%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.171%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.144%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,545,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,797,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares issuable upon exercise of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;796,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,311,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_6762082b-75c3-405b-b2b0-26f82bc658fb;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0f633671-f593-4b41-8b13-f542f6aec2d1"
      decimals="0"
      id="F_a84988ea-f6ff-4106-8513-eaeb41369a8b"
      unitRef="U_shares">6545628</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6171e5f5-549d-4e50-9be8-e0a4a67b59bf"
      decimals="0"
      id="F_f2630f16-f119-4e6a-8a1e-82d46fac2f6b"
      unitRef="U_shares">5797185</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_af796981-4cb4-490f-8a9b-07137ac824a9"
      decimals="0"
      id="F_c0f378d0-937d-4f45-b098-b273e33d8da8"
      unitRef="U_shares">796985</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3dddb3b8-9562-481a-8538-c27da39213ed"
      decimals="0"
      id="F_ff3c8f1d-4061-4351-bc43-4cd4587ba5a4"
      unitRef="U_shares">1311117</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_84c3fdea-c2ec-4933-8499-ef4172df40e8"
      decimals="0"
      id="F_2a68dd44-baf0-46ef-8c2e-66037ad67314"
      unitRef="U_shares">58333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_49ee0a3c-1c0c-4bba-a37a-fe2898531064">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_a0b2792f-605a-4763-8395-d49240ea0dd1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2016, the FASB issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_3a3c6a9a-8de5-4162-b84c-7ad9b910ccf3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASU No. 2016-02&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as amended, Leases (&#x201c;Topic 842&#x201d;), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. Topic 842 is effective for public entities for fiscal years beginning after December 15, 2018 and periods beginning after December 15, 2021 for all other entities. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; this new standard as of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the condensed consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less if entered into. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company&#x2019;s operating lease commitments are subject to the new standard as its leases are short-term in nature (i.e., less than twelve months).&lt;/span&gt;&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      id="F_39488108-13a6-4758-a518-3dc778070850">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      id="F_9968103a-0f7a-43e9-ab8c-d4e00fd9c771">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_8e9650a3-2cec-41df-8098-65a46e19b11e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Consulting Services&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leigh-Ann Durant, a former member of the Company&#x2019;s board of directors prior to her stepping down in November 2021, provided consulting services to the Company for which the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,994&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for consulting services provided by Ms. Durant during the year ended December 31, 2021. The Company paid Ms. Durant $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,560&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in cash and issued her options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,964&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,434&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; during the year ended December 31, 2021.  Ms. Durant was no longer considered a related party in 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Radu Vitoc, a shareholder and brother of the CEO, provides consulting services to the Company for which the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for services provided during the year ended December 31, 2021. The Company paid Mr. Vitoc $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,350&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in cash and issued him options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,250&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for services provided in fiscal 2021 were settled in March, 2022 for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options issued to Mr. Vitoc. The Company also issued him a convertible note in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; during April 2021, which was converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,557&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock on September 30, 2021 at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, and also received &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,278&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants to purchase shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.  In 2022, Mr. Vitoc provided consulting services to the Company through July 2022 for which the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,900&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for services provided during the year ended December 31, 2022.  The Company paid Mr. Vitoc $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,950&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in cash and issued him options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,690&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.950&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  In August 2022, Mr. Vitoc became an employee of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;CEO Loan Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's chief executive officer lent the Company a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in August and September of 2018. These amounts, were unsecured, had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stated interest rate, and no stated repayment terms. The Company repaid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,633&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the loan to the CEO during 2020 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;367&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; during 2021. The Company paid these loans in full in March 2021, by issuing the CEO a convertible note in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The convertible note issued to the CEO was converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,621&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock on September 30, 2021 at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.  No further notes to the CEO were incurred in the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <maia:ConsultingServices
      contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86"
      decimals="0"
      id="F_596bfa7f-839a-4b7a-a3ad-eb4ca3126792"
      unitRef="U_USD">88994</maia:ConsultingServices>
    <maia:CashPaidForServicesProvided
      contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86"
      decimals="0"
      id="F_2eab590f-c43c-4b8c-a48c-2605611c5ab2"
      unitRef="U_USD">34560</maia:CashPaidForServicesProvided>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86"
      decimals="INF"
      id="F_3df4509c-7292-4bcd-b730-5a995c7408d7"
      unitRef="U_shares">23964</maia:OptionsToPurchaseSharesOfCommonStock>
    <maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue
      contextRef="C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86"
      decimals="0"
      id="F_ccef2470-a7f6-4310-b7d8-fd2473b2ed4d"
      unitRef="U_USD">54434</maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue>
    <maia:ConsultingServices
      contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938"
      decimals="0"
      id="F_baf60086-991b-4848-8afb-e1cdac24c683"
      unitRef="U_USD">4700</maia:ConsultingServices>
    <maia:CashPaidForServicesProvided
      contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938"
      decimals="0"
      id="F_74fceb7a-ad79-47da-aee8-4d723ed5c886"
      unitRef="U_USD">2350</maia:CashPaidForServicesProvided>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938"
      decimals="INF"
      id="F_f763a464-7ef5-4182-aa57-d129e65e6c56"
      unitRef="U_shares">184</maia:OptionsToPurchaseSharesOfCommonStock>
    <maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue
      contextRef="C_c0cb2884-6b9e-439a-bf3f-7a1e03381938"
      decimals="0"
      id="F_735eae9b-25d2-4043-b5e6-883005a781f2"
      unitRef="U_USD">1100</maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue>
    <maia:RemainingConsultingServicesSettled
      contextRef="C_bf7f6aa9-8e0b-41e9-900f-25e5d88817a5"
      decimals="0"
      id="F_19b5414d-1654-4eb2-9e15-81490ca5a926"
      unitRef="U_USD">1250</maia:RemainingConsultingServicesSettled>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_bf7f6aa9-8e0b-41e9-900f-25e5d88817a5"
      decimals="INF"
      id="F_343e85b5-ca9b-43be-a042-04fa9ee5eb5d"
      unitRef="U_shares">226</maia:OptionsToPurchaseSharesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_bdba1f1c-9953-4f89-8181-9aff72ad45de"
      decimals="0"
      id="F_f016484c-49cd-4a78-8247-38bef33b169b"
      unitRef="U_USD">50000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_a801211c-4f23-4b06-8cc4-6340d12cffcd"
      decimals="INF"
      id="F_f1c58b82-4dba-477d-8579-e071d9be3c45"
      unitRef="U_shares">8557</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088"
      decimals="2"
      id="F_002f7c0f-5448-4aac-b039-c8a4857aeb20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088"
      decimals="INF"
      id="F_be25cb53-cccc-4fc3-9357-82c8040b1952"
      unitRef="U_shares">4278</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_459575dd-b386-4ca9-bf9c-7c0a7fad6088"
      decimals="INF"
      id="F_b9c208ee-3204-4830-8a8f-ee2a0d565e7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <maia:ConsultingServices
      contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db"
      decimals="0"
      id="F_15a91f80-eaff-408e-b636-13e2a749ef0b"
      unitRef="U_USD">36900</maia:ConsultingServices>
    <maia:CashPaidForServicesProvided
      contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db"
      decimals="0"
      id="F_1b1ff8dc-1464-44b3-9d8b-e513d9855736"
      unitRef="U_USD">19950</maia:CashPaidForServicesProvided>
    <maia:OptionsToPurchaseSharesOfCommonStock
      contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db"
      decimals="INF"
      id="F_9c43b786-6e43-4c20-8f72-ffbc326deb78"
      unitRef="U_shares">4690</maia:OptionsToPurchaseSharesOfCommonStock>
    <maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue
      contextRef="C_4df27570-d1a3-4e17-b53a-a2323ee5c6db"
      decimals="3"
      id="F_6520c97a-b06e-4b20-bffa-68d9362b2c96"
      unitRef="U_USD">19.950</maia:OptionsToPurchaseSharesOfCommonStockTotalFairValue>
    <us-gaap:UnsecuredDebt
      contextRef="C_480dc74f-1404-498f-8b42-20bedaaa1ecf"
      decimals="0"
      id="F_73241a87-8d8e-4b5e-bdfa-d71b76f5017d"
      unitRef="U_USD">25000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt
      contextRef="C_bda30473-24b2-49f5-aec5-68d7d75fc2b2"
      decimals="0"
      id="F_13cbd84f-c86e-4564-9422-0ed746867b10"
      unitRef="U_USD">25000</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_480dc74f-1404-498f-8b42-20bedaaa1ecf"
      decimals="2"
      id="F_6aa764c6-5434-4df3-a070-32af21227d3d"
      unitRef="U_pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_bda30473-24b2-49f5-aec5-68d7d75fc2b2"
      decimals="2"
      id="F_c085bd34-a54c-4fd0-8505-8d0f24039517"
      unitRef="U_pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_549c2a01-f299-4da3-bbae-8c582a89f09f"
      decimals="0"
      id="F_a6c8c3fd-82a0-44d3-9330-cc30736772fe"
      unitRef="U_USD">3633</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_77bae37b-9232-4726-80bf-d4346dbdd5c3"
      decimals="0"
      id="F_214a574e-f461-47d8-95f4-815c4f817f05"
      unitRef="U_USD">367</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_34634fe2-cf34-4270-bc4d-2bdee5324351"
      decimals="0"
      id="F_c4f16322-e044-4a21-9ef9-7528a0ef0e6c"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_49140d15-f3a7-4a2b-a015-cacc8dec9460"
      decimals="INF"
      id="F_2af026fb-b2db-4bd8-9149-9bbd2e9b0250"
      unitRef="U_shares">3621</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_a998ab06-ea16-418f-8f43-b74df1888ac3"
      decimals="2"
      id="F_c80ed0e8-af0b-4ca5-822a-f22ce17fe9e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_2b460b92-ee95-4f89-a614-8f8f0433ee5b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.  ACCRUED EXPENSES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.486%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.15%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.607%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.139%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,094,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional  fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;332,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;380,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;516,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;268,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred compensation to former officers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,103,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,185,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Compensation Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and December 31, 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,271&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, of deferred compensation due to certain employees and officers of the Company pursuant to deferred compensation agreements executed during fiscal 2020 and 2019 as part of a non-qualified deferred compensation plan. Pursuant to the deferred compensation agreements, the employees had deferred a portion of their annual base salary to be paid upon a Qualified Fund Raising. The Qualified Fund Raising was achieved during July 2021. Upon this event, the employees' salaries were increased up to the market rates set forth in their respective agreements, and all amounts were paid to the employees. The remaining deferred compensation balance as of December 31, 202l relates to amounts incurred for employees who were no longer with the Company as of the payout date. During the year ended December 31, 2021, the Company accrued $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;193,379&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in deferred compensation. The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;457,749&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in cash and issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;268,769&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;296,264&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; during the year ended December 31, 2021, to settle a portion of the deferred compensation balance totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;743,167&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The fair value of the options issued in excess of the deferred compensation balance settled totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,846&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued Bonus&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022 and 2021, the Company accrued $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,094,582&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, in bonus expense relating to employees and officers of the Company. On April 16, 2021, the 2020 accrued bonus balance was settled by issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;713,536&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;786,531&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The fair value of the options issued in excess of the accrued bonus balance totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,531&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and was recorded as stock-based compensation expense which is presented within general and administrative expenses on the statement of operations for the year ended December 31, 2021. The 2021 accrued bonus was paid in cash in August of 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_15fefff6-2c57-4b19-95e7-59e657eaef30">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.486%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.15%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.607%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.139%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,094,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional  fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;332,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;380,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;516,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;268,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred compensation to former officers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,103,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,185,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_77015284-3df0-4555-9fe0-9d5d2400265c"
      unitRef="U_USD">1094582</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_ffb02229-4b81-42f2-9bf3-232e3eecbeef"
      unitRef="U_USD">384750</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_8fb8b345-0e6e-41c5-916f-e81be8660779"
      unitRef="U_USD">332589</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_573ad3b0-c884-4429-9e21-fe5146310edd"
      unitRef="U_USD">380277</us-gaap:AccruedProfessionalFeesCurrent>
    <maia:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_9286b44d-869c-435a-a995-bb6b0a031a8d"
      unitRef="U_USD">516961</maia:AccruedResearchAndDevelopmentCostsCurrent>
    <maia:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_534b1b7c-45a3-4cd8-801d-f0da631a8523"
      unitRef="U_USD">268140</maia:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_c65f39f6-a573-4dda-a70c-794eec0edcd2"
      unitRef="U_USD">111271</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_3aad42d8-24f9-45f6-9311-8461b883864b"
      unitRef="U_USD">159269</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_f9fa01bb-2913-4369-87a0-e96348a73100"
      unitRef="U_USD">41157</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_848a32a2-46fa-4809-97e5-7d192627eb63"
      unitRef="U_USD">2103401</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_7f471f32-385a-4e82-8c78-92cd19d4b195"
      unitRef="U_USD">1185595</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_de56b5ef-a1e5-4f30-950a-ee22965f2b8f"
      unitRef="U_USD">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_85862c8a-63b2-49b6-b669-ca46cf9c1745"
      unitRef="U_USD">111271</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_c2b8fe5a-a91e-4bf9-ab7f-c3b93692f0cc"
      unitRef="U_USD">193379</us-gaap:DeferredCompensationLiabilityCurrent>
    <maia:CashPaidToSettleAPortionOfDeferredCompensationBalance
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_31ccd9a6-d45d-4e4e-83a1-a9dca5ecc402"
      unitRef="U_USD">457749</maia:CashPaidToSettleAPortionOfDeferredCompensationBalance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="INF"
      id="F_efa5c812-a3f8-44ac-8a7b-9d71d1a69774"
      unitRef="U_shares">268769</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_e6bca42c-fc42-48e0-9114-7f93ccd9b858"
      unitRef="U_USD">296264</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_eb7b9df9-b74d-4010-bcbe-29ea16999b1e"
      unitRef="U_USD">743167</us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e"
      decimals="0"
      id="F_033d5a41-3560-44b2-8eff-f9cbc8eec8ec"
      unitRef="U_USD">10846</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_d433b901-2021-496a-94bc-d0158ceca053"
      unitRef="U_USD">1094582</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_a1824941-ed67-43ac-bd46-216fd07f7c32"
      unitRef="U_USD">384750</us-gaap:AccruedBonusesCurrent>
    <maia:IssuanceOfStockOptionsToSettleAccruedBonusBalance
      contextRef="C_c3a2c7f8-d558-4863-ba84-7247dacc03ae"
      decimals="INF"
      id="F_4603f5ff-e1db-42e2-ae4f-6abe42ebd5b6"
      unitRef="U_shares">713536</maia:IssuanceOfStockOptionsToSettleAccruedBonusBalance>
    <maia:FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance
      contextRef="C_c3a2c7f8-d558-4863-ba84-7247dacc03ae"
      decimals="0"
      id="F_6898de32-58ca-42c3-ae57-9930812119fd"
      unitRef="U_USD">786531</maia:FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance>
    <maia:StockBasedCompensationExpenseRelatedToAccruedBonusBalance
      contextRef="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e"
      decimals="0"
      id="F_befb9f07-e7bf-4948-a593-b9bf9cca0bae"
      unitRef="U_USD">6531</maia:StockBasedCompensationExpenseRelatedToAccruedBonusBalance>
    <maia:PaycheckProtectionProgramTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_01b6bcba-0912-4fca-95d7-438c9db09210">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. PAYCHECK PROTECTION PROGRAM&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 31, 2021, the Company received a second PPP Loan in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under the terms of PPP Loan, interest accrues on the outstanding principal at the rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.98&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum. The term of the PPP Loan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. To the extent that the loan amount is not forgiven by the SBA, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The loan amount may be eligible for forgiveness if used for qualifying expenses and other qualifying criteria are met. The Company used the entire PPP Loan for qualifying expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company received full forgiveness of all outstanding principal and accrued and unpaid interest on the PPP Loan in November 2021. The forgiveness of the PPP Loan qualified for debt extinguishment in accordance with ASC 470-50, Debt Modifications and Extinguishments, and as a result, the outstanding principal and interest was written off in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and the Company recorded a gain on extinguishment totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</maia:PaycheckProtectionProgramTextBlock>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426"
      decimals="0"
      id="F_258780c0-d05b-45fa-87c5-d353825d48ed"
      unitRef="U_USD">62500</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_b52893ed-19d1-4467-abfb-baf9e1042428"
      decimals="4"
      id="F_bb54d257-2b6b-44ae-ac0a-3771ed1ea7c6"
      unitRef="U_pure">0.0098</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426"
      id="F_377cf83d-530d-49a3-b2ea-b972ffe2220a">P2Y</us-gaap:DebtInstrumentTerm>
    <maia:ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount
      contextRef="C_0ad7911b-4b7a-4316-b95d-e54b9310b0df"
      decimals="0"
      id="F_65ba1a34-ba69-4372-826c-91d3af586aa0"
      unitRef="U_USD">62500</maia:ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="C_0ad7911b-4b7a-4316-b95d-e54b9310b0df"
      decimals="0"
      id="F_ce5aed9d-b171-4d20-81f8-181170d1db25"
      unitRef="U_USD">62500</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_11a0579b-95cf-4c7f-8ab8-032d13960127">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. CONVERTIBLE NOTES PAYABLE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Notes Payable issued in 2019&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2019, the Company issued a Convertible Promissory Note totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to one individual (the "2019 Convertible Note"). The 2019 Convertible Note bore interest at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum, was unsecured, with a scheduled maturity date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The 2019 Convertible Note contained an automatic conversion feature, such that in the event the Company consummated an Equity Financing, as defined in the agreement, prior to the 2019 Convertible Note's scheduled maturity, the outstanding principal and interest would automatically converted into Preferred Stock (the shares of a class or series of preferred stock of the Company issued in connection with an Equity Financing) of the Company issued in connection with the Equity Financing. The Equity Financing is defined as a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company receives gross aggregate proceeds of not less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (before any transaction related expenses and costs). The conversion price will be set at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the price of the preferred stock issued in the aforementioned Equity Financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Embedded Put Feature&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the terms related to the Equity Financing conversion, (the &#x201c;Embedded Put Feature&#x201d;) were not clearly and closely related to the 2019 Convertible Note host instrument and meets the definition of a derivative. Therefore, the Embedded Put Feature was bifurcated from the 2019 Convertible Note and separately measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Embedded Put Feature was initially recorded as a debt discount and a related derivative liability at fair value. The debt discount is amortized using the effective interest rate over the original term of the 2019 Convertible Note.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense on the 2019 Convertible Note totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The debt discount and value of the Embedded Put Feature in the 2019 Convertible Note totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at issuance. The balance of the debt discount was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022 and 2021. During the year ended December 31, 2022 and 2021, amortization of debt discount amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Notes Payable issued in 2020&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During 2020, the Company issued Convertible Promissory Notes totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;610,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to various investors or holders, including $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of Convertible Promissory Notes to related parties (collectively, the "2020 Convertible Notes") throughout fiscal 2020. The 2020 Convertible Notes bore interest at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum, was unsecured, with a scheduled maturity date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (before any transaction related expenses and costs). The 2020 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock issued on conversion shall be shares of the Company&#x2019;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Conversion Prices&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The conversion price is set at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the price of the preferred stock issued in the aforementioned Equity Financing. The 2020 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Embedded Put Features&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#x201c;Embedded Put Features&#x201d;) included within the 2020 Convertible Notes were not clearly and closely related to the 2020 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2020 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at issuance of the 2020 Convertible Notes (see Note 8). The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Maturity Date&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The maturity date on the 2020 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) May 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense on the 2020 Convertible Notes totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,375&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,523&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discounts on the 2020 Convertible Notes totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022 and 2021, respectively.  During the year ended December 31, 2021 amortization of debt discounts amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,608&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; amortization of debt discounts for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;       &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,660&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (see Note 8) at issuance of the 2020 Convertible Notes. Subsequent to issuance, the 2020 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2020 Convertible Notes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Notes Payable issued in 2021&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the  year ended December 31, 2021, the Company issued Convertible Promissory Notes totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,390,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to various investors or holders, including $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,863,300&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of Convertible Promissory Notes to related parties (collectively, the "2021 Convertible Notes") which included a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Convertible Promissory Note to settle a loan to the Company's CEO (see Note 2) . The 2021 Convertible Notes bear interest at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum, are unsecured, and have scheduled maturity dates ranging from February 15, 2023 through June 28, 2023.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Convertible Notes are automatically convertible into shares of the Company's Equity Financing Shares (shall mean the shares of any class or series of preferred stock of the Company issued in connection with an Equity Financing), upon the closing of an Equity Financing yielding gross proceeds of in excess of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (before any transaction related expenses and costs). The 2021 Convertible Notes also are convertible into common shares of the Company at the holders' election upon (i) a Change in Control whereby any person or group becomes a beneficial owner of more than 50% of the Company's outstanding voting securities in connection with a merger or reorganization, or (ii) at the time of maturity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock issued on conversion shall be shares of the Company&#x2019;s stock that have substantially the same rights and preferences as the shares issued in such Equity Financing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Conversion Prices&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The conversion price was set at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the price of the common stock issued in the aforementioned Equity Financing. The 2021 Convertible Notes also contain a clause that accelerates their maturity upon a change in control of the Company, as defined above.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Embedded Put Features&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has determined that the terms related to the Equity Financing conversion, Change in Control, and maturity conversion features (collectively, the &#x201c;Embedded Put Features&#x201d;) included within the 2021 Convertible Notes were not clearly and closely related to the 2021 Convertible Note host instrument and meet the definition of a derivative. Therefore, the Embedded Put Features were bifurcated from the 2021 Convertible Notes and measured at fair value. The derivative liability has been subsequently marked-to-market each reporting period with changes in fair value recognized in the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Embedded Put Features were initially recorded as a debt discount and a related derivative liability at fair value in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,821,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at issuance of the 2021 Convertible Notes (see Note 6). The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Maturity Date&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The maturity date on the 2021 Convertible Notes is the earliest occurrence of (i) the closing of a Qualified Equity Financing, or (ii) the date upon which the Convertible Notes are otherwise converted into equity securities, or (iii) maturity dates ranging from February 15, 2023 through June 28, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense on the 2021 Convertible Notes totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;199,049&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022 and 2021, amortization of debt discounts amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;513,035&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Warrants were initially recorded as a debt discount and a related warrant liability at fair value in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320,460&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (see Note 6) at issuance of the 2021 Convertible Notes. Subsequent to issuance, the 2021 Warrants have been marked-to-market each reporting period with changes in fair value recognized in the statement of operations. The debt discount is amortized using the effective interest rate over the original term of the 2021 Convertible Notes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Conversion of Convertible Notes Upon Equity Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Notes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the sale of common stock in fiscal 2021, an Equity Financing of gross proceeds in excess of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, the Company converted all $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,010,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of its outstanding principal and all accrued and unpaid interest of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; related to the Company&#x2019;s 2019 Convertible Note, 2020 Convertible Notes, and 2021 Convertible Notes into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,375,228&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock on September 30, 2021 at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounted for the conversion of the Convertible Notes as an extinguishment. The Company recorded an approximate $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million loss on extinguishment, upon conversion, year ended December 31, 2021. The loss on extinguishment of the Convertible Notes included a write-off of the unamortized debt discount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021 there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Convertible Notes outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 30, 2021, in connection with conversion of the 2020 and 2021 Convertible Notes, the terms of the warrants issued with the 2020 and 2021 Convertible notes became fixed such that the warrants are exercisable for a fixed number of shares of common stock at a fixed exercise price per share based on the amount of shares issuable upon conversion of the Convertible Notes and an exercise price equal to the conversion price per share used in the conversion of the Convertible Notes. The warrants are exercisable for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;686,489&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and expire at various dates throughout fiscal 2028.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,504&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of these warrants have been exercised.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e"
      decimals="0"
      id="F_7b0f6934-a888-48f6-8b8d-b3f8737d1453"
      unitRef="U_USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e"
      decimals="INF"
      id="F_d83ded9f-bf23-4ebf-a0a8-54e2cd6ce22d"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_f14d921e-d893-48a9-b93d-6895d30a125f"
      id="F_9e25f9cc-5f17-4ff8-87b6-c03eaf0dec9e">2021-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_8a3d4bbe-f995-4369-a38d-55c3e19f2acd"
      decimals="0"
      id="F_e5254954-fdd3-451b-9497-440914647f74"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromConvertibleDebt>
    <maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing
      contextRef="C_c568fa76-5ee4-4a28-9ce0-fb60b645fa1e"
      decimals="2"
      id="F_e2ad1b6b-b902-4382-8481-c75fcd47fb02"
      unitRef="U_pure">0.65</maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing>
    <us-gaap:InterestExpense
      contextRef="C_96904691-c19d-41d7-b74c-e304c0e6af45"
      decimals="0"
      id="F_8a4700b7-b634-4827-8a7e-98601e6a7f93"
      unitRef="U_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_2cc4ed46-ee40-4446-afb7-6c466d1a0315"
      decimals="0"
      id="F_6461d2d9-df78-4f12-8150-179cd1e92640"
      unitRef="U_USD">607</us-gaap:InterestExpense>
    <maia:Debtdiscountandvalueofembeddedputfeature
      contextRef="C_a3f721fc-ed4b-48d0-82bf-0755ef0a4134"
      decimals="0"
      id="F_44c276ed-889f-4f85-b44b-1e83411e188c"
      unitRef="U_USD">1000</maia:Debtdiscountandvalueofembeddedputfeature>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_6643c0e3-8b98-4c5e-bc38-a4ac458d4842"
      decimals="0"
      id="F_d61826d7-7692-429b-bb46-18d8fcf73901"
      unitRef="U_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_c159ace3-ffb0-4d4d-8a15-d426dd48bb91"
      decimals="0"
      id="F_c1bab52e-ec9a-4d54-9006-dd870159c8e8"
      unitRef="U_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_96904691-c19d-41d7-b74c-e304c0e6af45"
      decimals="0"
      id="F_371e7ef0-2cc5-4c41-8115-b23365544d92"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_2cc4ed46-ee40-4446-afb7-6c466d1a0315"
      decimals="0"
      id="F_e25abed6-2345-4ad3-acf1-22af00e26a28"
      unitRef="U_USD">310</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"
      decimals="0"
      id="F_73c6c54b-f3c0-42fe-8bcc-e88678edde59"
      unitRef="U_USD">610000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_f508854b-0a5d-48f7-9b76-4f60049b5004"
      decimals="0"
      id="F_c6513fff-a5c9-4f84-a769-3e10974c036f"
      unitRef="U_USD">110000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"
      decimals="INF"
      id="F_0f37ba5b-89ad-468e-a879-35539fef9f2b"
      unitRef="U_pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_fdf96b15-9f52-42b0-af98-607e4a595a5f"
      id="F_a6175bfa-f390-4ad4-a1f3-ac8c8661c875">2022-05-31</us-gaap:DebtInstrumentMaturityDate>
    <maia:MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt
      contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"
      decimals="0"
      id="F_5fbc9350-f7bd-4a6b-934d-c9eb0ecd7bec"
      unitRef="U_USD">5000000</maia:MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt>
    <maia:PercentageOfVotingPowerDefiningChangeOfControl
      contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"
      decimals="2"
      id="F_3986e94a-01ed-417d-8b32-bbf5219ccc85"
      unitRef="U_pure">0.50</maia:PercentageOfVotingPowerDefiningChangeOfControl>
    <maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing
      contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"
      decimals="2"
      id="F_b46fbdd4-2cef-4b2d-9a2a-2ad5b3fc7d81"
      unitRef="U_pure">0.75</maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="C_e193cca7-3e9a-4dbe-94ac-41eeca8b87fc"
      decimals="0"
      id="F_95379e22-0b6e-400d-9b3d-e1cc3c663e98"
      unitRef="U_USD">131000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:InterestExpense
      contextRef="C_b7d464db-7209-4119-bc09-50cf74d2d6d7"
      decimals="0"
      id="F_aec36a74-a4ec-488b-acd2-653f8f184f06"
      unitRef="U_USD">27375</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_fdf96b15-9f52-42b0-af98-607e4a595a5f"
      decimals="0"
      id="F_b17f26ac-d880-4c86-91ec-556c5a9e82fb"
      unitRef="U_USD">11523</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_8c20c208-c8e0-40af-b818-86f3f673ef3b"
      decimals="0"
      id="F_173f4c5f-181c-44a7-8ead-012d9d980fd3"
      unitRef="U_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_ed9fcd67-e733-47c1-804f-2d29703a3a3f"
      decimals="0"
      id="F_4d9d0a37-0090-4756-b9f3-bae3c7e13a69"
      unitRef="U_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_b7d464db-7209-4119-bc09-50cf74d2d6d7"
      decimals="0"
      id="F_b26534d3-634f-425b-96c4-aab4f9a4f73f"
      unitRef="U_USD">83608</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_66a04226-000c-48ad-8295-b5d5efd519ea"
      decimals="0"
      id="F_a2ef0a19-2ddc-4c15-97c8-9643d31b9b8c"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <maia:WarrantDescription
      contextRef="C_3c664d98-02a0-4f5a-946c-51e9b9611596"
      id="F_4fd64e4f-32b4-4735-954d-7ca394fc52bf">In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </maia:WarrantDescription>
    <maia:PercentageOfIssuableUponConversionOfExercisePrice
      contextRef="C_3e133a48-7bca-4524-bf21-ae7de81db87a"
      decimals="0"
      id="F_e44bf063-e1c0-4750-9b67-a31082b1ec5f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">50</maia:PercentageOfIssuableUponConversionOfExercisePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_3e133a48-7bca-4524-bf21-ae7de81db87a"
      decimals="0"
      id="F_9d25ac70-ee25-496e-b6f1-491e67bf2782"
      unitRef="U_USD">65660</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad"
      decimals="0"
      id="F_6d4245de-99b3-4a13-b0c6-7b551b1d2eba"
      unitRef="U_USD">7390000</us-gaap:DebtInstrumentFaceAmount>
    <maia:ConvertiblePromissoryNotesToRelatedParties
      contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4"
      decimals="0"
      id="F_14a1f9f2-89cd-4d1c-ab47-7c01ff679364"
      unitRef="U_USD">1863300</maia:ConvertiblePromissoryNotesToRelatedParties>
    <maia:ConvertiblePromissoryNotesToSettleLoan
      contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4"
      decimals="0"
      id="F_47656c38-12a3-4f8a-af4c-02200049966f"
      unitRef="U_USD">21000</maia:ConvertiblePromissoryNotesToSettleLoan>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad"
      decimals="INF"
      id="F_c023fc70-328e-41ff-88e1-bc73840d7062"
      unitRef="U_pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4"
      decimals="0"
      id="F_f86a5e57-8e4b-46b5-a8e2-7c01aec272eb"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing
      contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad"
      decimals="2"
      id="F_42a18ac7-c67e-47f6-a0ab-235ad00b9c1f"
      unitRef="U_pure">0.75</maia:ConvertibleDebtConversionPricePercentageOfTheEquityFinancing>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="C_d53cc390-bf67-45b1-9a3f-9e59aa8dfaad"
      decimals="0"
      id="F_3717b9c2-ec71-4a56-9612-7a8240ee20ec"
      unitRef="U_USD">2821000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:InterestExpense
      contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4"
      decimals="0"
      id="F_4045dc20-a06e-4970-8e78-a8336a3932ef"
      unitRef="U_USD">199049</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_b2d52605-606c-4298-a0ed-01a4e1641f08"
      decimals="0"
      id="F_4a5348bc-d8d3-4471-8058-1b71981edb7e"
      unitRef="U_USD">0</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_6039b578-eeec-4f91-947f-34335f15d319"
      decimals="0"
      id="F_4ec786bf-4e7d-4a20-a8cb-99b646486aec"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_985a2e45-6950-4f45-9fed-bb59ec5581a4"
      decimals="0"
      id="F_97e3b61c-8fdd-4be2-82e1-dd446ca524e9"
      unitRef="U_USD">513035</us-gaap:AmortizationOfDebtDiscountPremium>
    <maia:WarrantDescription
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      id="F_98ba0428-ae97-41c3-8acc-f7f616f98bd9">In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note. </maia:WarrantDescription>
    <maia:PercentageOfIssuableUponConversionOfExercisePrice
      contextRef="C_6dfe66b4-3a5a-4059-86f7-1adc0a69cd08"
      decimals="0"
      id="F_ad7c2a0a-d882-49e7-9694-350cc5598584"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">50</maia:PercentageOfIssuableUponConversionOfExercisePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6dfe66b4-3a5a-4059-86f7-1adc0a69cd08"
      decimals="0"
      id="F_573565bd-aab0-409f-ac71-4a7398b72156"
      unitRef="U_USD">320460</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="-6"
      id="F_4e833ad2-1809-4525-8fdb-72952b46e545"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_0d7a507d-7072-4f83-b1e6-f120434ac038"
      unitRef="U_USD">8010000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_361ca525-78fd-48ac-83d6-bb7b6dc6b85f"
      unitRef="U_USD">240000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_24d517c1-101e-49f7-858d-15b0bb2079e8"
      decimals="INF"
      id="F_8aa83ae9-fcc3-4c7c-8219-7a1f6ddf7807"
      unitRef="U_shares">1375228</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978"
      decimals="2"
      id="F_3da067bb-e417-4cb5-b869-6b516086f54c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="-5"
      id="F_83321fa2-1934-40f7-bcf7-d8edc7e9af21"
      unitRef="U_USD">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="-5"
      id="F_65eabf8b-fa28-40fd-9454-1bc4c14901ff"
      unitRef="U_USD">3300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <maia:ConvertibleNotesOutstanding
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_afa217b0-648a-46da-a5a7-515b33c99316"
      unitRef="U_USD">0</maia:ConvertibleNotesOutstanding>
    <maia:CommonSharesUponExerciseOfWarrantsShares
      contextRef="C_24d517c1-101e-49f7-858d-15b0bb2079e8"
      decimals="INF"
      id="F_6bdc0945-b31c-48bb-a828-57936537c082"
      unitRef="U_shares">686489</maia:CommonSharesUponExerciseOfWarrantsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978"
      decimals="2"
      id="F_d0aa619c-3604-498e-af3f-4c6ac782d074"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <maia:WarrantsExercised
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="INF"
      id="F_e149df82-4c04-4d39-8812-628d27fcb99f"
      unitRef="U_shares">4504</maia:WarrantsExercised>
    <maia:SimpleAgreementForFutureEquityDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_1c1961a4-ce4f-4d8c-88a0-47265b81fc04">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. SIMPLE AGREEMENT FOR FUTURE EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2019, the Company issued a simple agreement for future equity ("SAFE Agreement") for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. 'The SAFE Agreement requires automatic conversion to preferred stock in the event of an equity financing. If the Company experiences a liquidity event, as defined, the holder may opt for either conversion or repayment in cash, with repayment based upon a valuation at the time of such event. Upon a dissolution event, as defined, the SAFE Agreement requires repayment in cash. The conversion price will be set at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the price of the preferred stock issued in the aforementioned equity financing. The SAFE Agreement shall terminate upon either the issuance of shares or repayment in cash as per the agreement's terms. Due to the contingencies associated with the potential conversion and conversion price as well as the valuation upon a future liquidity event should one occur, no discount associated with these features has been recorded in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the sale of common stock in 2021, an Equity Financing, the SAFE in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,208&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock on September 30, 2021. The price of the common shares issued in the equity financing was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. 'The conversion price was equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, or $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;</maia:SimpleAgreementForFutureEquityDisclosureTextBlock>
    <maia:SimpleAgreementForFutureEquityIssued
      contextRef="C_a8986a13-566d-41de-a913-47e267f84b74"
      decimals="0"
      id="F_f92b655b-1468-425d-bdd9-99cae650ef19"
      unitRef="U_USD">25000</maia:SimpleAgreementForFutureEquityIssued>
    <maia:PercentageOfConversionPrice
      contextRef="C_a8986a13-566d-41de-a913-47e267f84b74"
      decimals="2"
      id="F_c33fc1f8-e5c0-4528-8cae-af07b1d40fc8"
      unitRef="U_pure">0.60</maia:PercentageOfConversionPrice>
    <maia:SimpleAgreementForFutureEquityIssued
      contextRef="C_c4856ea2-7771-4d18-b27e-ad041dc17195"
      decimals="0"
      id="F_163f0547-0830-4853-a137-6d0a93aa5025"
      unitRef="U_USD">25000</maia:SimpleAgreementForFutureEquityIssued>
    <maia:NumberOfCommonSharesConvertedUnderSAFEAgreement
      contextRef="C_c4856ea2-7771-4d18-b27e-ad041dc17195"
      decimals="INF"
      id="F_14fab763-b878-438a-a52c-1c8fa5ca27f3"
      unitRef="U_shares">5208</maia:NumberOfCommonSharesConvertedUnderSAFEAgreement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978"
      decimals="INF"
      id="F_e51fd561-eb05-4f33-b1fe-579fae2c0fef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <maia:PercentageOfConversionPrice
      contextRef="C_c4856ea2-7771-4d18-b27e-ad041dc17195"
      decimals="2"
      id="F_1c11be71-a9a5-4d29-8a4d-02121fac964b"
      unitRef="U_pure">0.60</maia:PercentageOfConversionPrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978"
      decimals="INF"
      id="F_37a3a06d-381d-4f81-9c33-b5a550304ad1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <maia:CommonStockConversionPrice
      contextRef="C_7e7a62fe-eeee-4d2f-be7b-88d85f2eb978"
      decimals="2"
      id="F_7e7c2c1a-08d0-43c2-a9d7-f491391f0cb3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.80</maia:CommonStockConversionPrice>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_8fd4cba7-689d-4b89-8ede-7da17b541f9a">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  FAIR VALUE OF FINANCIAL LIABILITIES&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivative Liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.057%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.041%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_d4dbe32f-1df1-43a5-8162-239e9214a75a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, beginning of period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liability on convertible notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,821,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss (Gain) on fair value of embedded features&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Extinguishment of derivative liability in connection with debt conversion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Embedded Put Features were separately measured at fair value, with changes in fair value recognized in current operations. The scenario-based analysis estimates the fair value of the Convertible Notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the holders, including various settlement, equity financing, and corporate transaction and dissolution scenarios. Estimating fair values of Embedded Put Features required the development of significant and subjective estimates that changed over the duration of the instrument with related changes in internal and external market factors. Because the Embedded Put Features are initially and subsequently carried at fair values, the Company&#x2019;s income reflected the volatility in these estimate and assumption changes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Immediately prior to the conversion of the convertible notes, the derivative liability was marked to fair value resulting in a loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2021. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of the conversion. The probability of the Convertible Notes outstanding at maturity was estimated to be approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%; the probability of an equity financing was estimated to be approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%; and the probability of default, change in control or dissolution was estimated to be approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. On September 30, 2021 the embedded derivative liability was extinguished in connection with the conversion of the convertible notes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.627%;"/&gt;
        &lt;td style="width:1.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.42%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrant liabilities measured at fair value on a recurring basis at December 31, 2021. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;343,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Gain) loss on fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;98,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,546,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reclassification of warrant liability to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,952,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_0a563e2c-0ec7-4039-84ba-5eec71d1cd50">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.057%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.041%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_d4dbe32f-1df1-43a5-8162-239e9214a75a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, beginning of period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liability on convertible notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,821,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss (Gain) on fair value of embedded features&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Extinguishment of derivative liability in connection with debt conversion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;343,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Gain) loss on fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;98,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,546,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reclassification of warrant liability to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,952,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance, end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="C_05ed1f6a-7bd5-44e6-a939-0de1e93bb2f6"
      decimals="0"
      id="F_4cf16a17-3e04-4d91-b2fd-e7dcb77d92ab"
      unitRef="U_USD">127000</us-gaap:DerivativeLiabilities>
    <maia:DerivativeLiabilityOnConvertibleNotesPayable
      contextRef="C_8f949a11-176b-4ad1-9d69-a21194d19325"
      decimals="0"
      id="F_fa2475a4-3536-49a5-be37-478de53ac8fa"
      unitRef="U_USD">2821000</maia:DerivativeLiabilityOnConvertibleNotesPayable>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_8f949a11-176b-4ad1-9d69-a21194d19325"
      decimals="0"
      id="F_e5361efb-c1e3-47f9-b65e-236aacfdb0bb"
      unitRef="U_USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <maia:ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion
      contextRef="C_8f949a11-176b-4ad1-9d69-a21194d19325"
      decimals="0"
      id="F_5deb2e57-de1f-4090-806a-fca38ee6bc1a"
      unitRef="U_USD">-3151000</maia:ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion>
    <maia:ChangeInFairValueOfEmbeddedFeatures
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_14e85319-2096-410b-a276-fcf6b4452342"
      unitRef="U_USD">203000</maia:ChangeInFairValueOfEmbeddedFeatures>
    <maia:ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_c3b13176-d165-469b-af32-b5ac67dc985f"
      unitRef="U_pure">0</maia:ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity>
    <maia:ProbabilityPercentageOfEquityFinancing
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_f5304e90-7c9a-4582-8b15-606030fcdc4b"
      unitRef="U_pure">1</maia:ProbabilityPercentageOfEquityFinancing>
    <maia:ProbabilityPercentageOfDefaultChangeInControlOrDissolution
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_e18cc68d-1175-4b79-a56d-c9a31b0bb228"
      unitRef="U_pure">0</maia:ProbabilityPercentageOfDefaultChangeInControlOrDissolution>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_755c524a-f22b-42e5-a015-02722a5b4722">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.627%;"/&gt;
        &lt;td style="width:1.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.42%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_a0c99f8c-3025-49f9-9ce1-af3347da6e53"
      decimals="0"
      id="F_206b118d-2865-445c-bfd6-783049287951"
      unitRef="U_USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_432d777f-5193-4a7a-bc9c-bd381ee50b47"
      decimals="0"
      id="F_be7fa11e-a4bb-4c82-96cc-a5b5b6e037fc"
      unitRef="U_USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a0c99f8c-3025-49f9-9ce1-af3347da6e53"
      decimals="0"
      id="F_8110ece4-a894-4a7b-80a8-ebd61f8baf2b"
      unitRef="U_USD">245341</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_432d777f-5193-4a7a-bc9c-bd381ee50b47"
      decimals="0"
      id="F_b4f0ef3d-4f26-44ff-ae63-c1a3627054aa"
      unitRef="U_USD">245341</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_349fb6e1-da72-4c3d-8eae-a1f0bc375520"
      decimals="0"
      id="F_1aec52d1-1b5b-4eb9-9585-e8e6314f9de5"
      unitRef="U_USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_e4e7d396-2e2a-4ecd-bda9-8259234860d5"
      decimals="0"
      id="F_fba62493-ef2c-416e-9fe1-5aa9add1d625"
      unitRef="U_USD">85260</us-gaap:WarrantsAndRightsOutstanding>
    <maia:ChangeInFairValueOfWarrantLiability
      contextRef="C_da576c98-2bde-4e20-b38d-a9c79bec3a95"
      decimals="0"
      id="F_9e880d73-9d23-4060-b9b0-55e1345a84cd"
      unitRef="U_USD">343735</maia:ChangeInFairValueOfWarrantLiability>
    <maia:ChangeInFairValueOfWarrantLiability
      contextRef="C_faeafa90-e78a-4213-beef-48ac41889fed"
      decimals="0"
      id="F_f7b5a1a6-71c5-4ed7-b91f-96c813e65fd2"
      unitRef="U_USD">320460</maia:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_da576c98-2bde-4e20-b38d-a9c79bec3a95"
      decimals="0"
      id="F_00f023a6-5d23-4b60-a5b6-9d324db21cc2"
      unitRef="U_USD">-98394</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_faeafa90-e78a-4213-beef-48ac41889fed"
      decimals="0"
      id="F_d4fa1458-27b7-4a94-b904-686d228bd98e"
      unitRef="U_USD">1546280</us-gaap:FairValueAdjustmentOfWarrants>
    <maia:ReclassificationOfWarrantLiabilityToEquity
      contextRef="C_faeafa90-e78a-4213-beef-48ac41889fed"
      decimals="0"
      id="F_d7145722-e27d-45bb-a9dc-0375bb378aea"
      unitRef="U_USD">-1952000</maia:ReclassificationOfWarrantLiabilityToEquity>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_432d777f-5193-4a7a-bc9c-bd381ee50b47"
      decimals="0"
      id="F_fecf7308-7f65-4588-b4fb-f017195eb876"
      unitRef="U_USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_0f482d48-5895-4951-8338-e43510ff1b96">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.  STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon the closing of the Company&#x2019;s initial public offering, the Company&#x2019;s shareholders agreement terminated pursuant to its terms. In connection with the closing of the Company&#x2019;s initial public offering, the Company amended and restated its Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate of Incorporation&#x201d;) and amended and restated its Bylaws (the &#x201c;Amended and Restated Bylaws&#x201d;). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022 and became effective on that date, and among other things, increased the authorized number of common stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and decreased the authorized number of preferred stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales of MAIA Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During January and February 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,729&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,373,561&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transaction costs. During May 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transaction costs. The Company issued these shareholders additional shares upon the closing of the Company's initial public offering such that the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; price per share they paid was equal to the price per share in the Company's initial public offering of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The number of Ratchet Shares were calculated using the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share price in the Company's initial public offering and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;219,872&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were issued on August 1, 2022 to the investors in the Recent Private Rounds. The Ratchet shares were determined to be a freestanding instrument that was classified as a liability when the right was granted and subsequently reclassified to equity when shares were issued. The Ratchet Shares were valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,099,360&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, based on the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; price of the initial public offering and were recorded as expense included in operating expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 28, 2022 the Company&#x2019;s shares of common stock began trading on the NYSE American under the symbol MAIA. On August 1, 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in an initial public offering prior to deducting underwriting discounts, commissions, and other offering expenses. On August 3, 2022, the Company sold an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share when the underwriter exercised the overallotment for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; prior to deducting underwriting discounts, commissions, and other offering expenses. After deducting the underwriting discount and other offering expenses payable by the Company, the total net proceeds for the initial public offering and the overallotment were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Biotechnology, Inc. Restricted Stock Awards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2021, MAIA recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;202,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of stock compensation expense related to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of MAIA&#x2019;s restricted shares granted to the founders. On August 13, 2021, upon the dissolution of THIO and merger into MAIA (see Note 1), a founder&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;612,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; fully vested THIO restricted shares were canceled and the founder was issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;612,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; MAIA &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;restricted shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additionally, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in accordance with the founder's original award, the founder was also issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; MAIA restricted shares which vested ratably each quarter through April 1, 2022 to replace the equivalent number of unvested THIO restricted shares. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unvested shares as of December 31, 2022 related to the founder's restricted shares. During the 12 months ended December 31, 2022, MAIA recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of expense related to  restricted stock for the year ended 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.072%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.023%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.616%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested balance at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2022, the Company and certain warrant holders executed waivers related to the acceptance and approval of an amendment to the  holders&#x2019; warrant agreements originally issued between May 6, 2020 and February 26, 2021 in connection with the Company&#x2019;s issuance of convertible notes. The amendment removed the IPO expiration provision from the warrant agreements, and the warrants are now only to be exercisable, in whole or in part, during the exercise period ending on the earliest to occur of: (a) various dates in 2028 as stated within the warrant agreements; or (b) immediately prior to the closing of a change of control. The value of the warrant modification to the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,497&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants was calculated using the Black-Scholes-Merton option pricing model. The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;450,578&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and was treated as a deemed dividend and is reflected as &#x201c;Deemed dividend on warrant modification&#x201d; in the accompanying statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During January 2022, warrants were exercised, resulting in the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of MAIA common stock for proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During May 2022, warrants were exercised, resulting in the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;153,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock for proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;275,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Another &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;394,501&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants were exercised with a cashless exercise assuming the fair market value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share resulting in the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;315,601&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the closing of the initial public offering, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,520&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share expired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concurrently with the closing of the Company&#x2019;s initial public offering, the Company issued warrants to purchase an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock to the Representative or its designees, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share (the &#x201c;Representative&#x2019;s Warrants&#x201d;). The Representative&#x2019;s Warrants are exercisable beginning on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 23, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and expire on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 27, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, pursuant to the terms and conditions of the Representative&#x2019;s Warrants.  On August 3, concurrently with the full exercise of the Underwriter&#x2019;s over-allotment option, the Company issued additional warrants to purchase an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock to the Representative or its designees on the same terms. The warrants are not indexed to the Company&#x2019;s own stock and therefore meet the definition of a derivative liability. The warrants are liability classified instruments and were initially recorded as $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;343,735&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was the value determined using the Black-Scholes method using a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. As of December 31, 2022 the Company remeasured the warrant liability resulting in a value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;245,341&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The gain on remeasurement of the warrant liability in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;98,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was included in other income. Only the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; warrants issued in 2022 are classified as a liability, all other outstanding warrants are equity classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.425%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,311,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;608,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;796,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.0%;"/&gt;
        &lt;td style="width:2.0%;"/&gt;
        &lt;td style="width:14.5%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.88%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MAIA Biotechnology, Inc. Stock Award Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the &#x201c;MAIA 2018 Plan&#x201d;). MAIA&#x2019;s board of directors administers the MAIA Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,924,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options outstanding in the plan of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#x201c;MAIA 2020 Plan&#x2019;&#x2019;), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,983,023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options outstanding in the plan as of December 31, 2022. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares reserved for future issuance in the MAIA 2018 Plan or the MAIA 2020 Plan .&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 1, 2022 the Company approved the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the &#x201c;MAIA 2021 Plan&#x2019;&#x2019;) with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,909,518&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock reserved for issuance. As of December 31, 2022 there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,271,413&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock available for future issuance under the MAIA 2021 Plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;638,105&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options outstanding in the MAIA 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options are to be granted with an exercise price which is at least equal to the stock&#x2019;s estimated fair value at the date of grant, and with a contractual term of no more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the date of grant. In the case of an option granted to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% stockholder, the exercise price shall be generally no less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair market value per share on the date of grant, and the contractual term shall be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are canceled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are canceled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company&#x2019;s exercise repurchase rights and various other features of awards granted under the plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, only stock options have been awarded pursuant to the MAIA stock award plans.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.822%;"/&gt;
        &lt;td style="width:0.96%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.292%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.291%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.972%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.315000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.185%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,797,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;811,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,545,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,773,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,449,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,804,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes from January 1 to January 26, 2022 based on valuations of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share as of December 31, 2021. For our valuations of common stock performed, we used a hybrid method of the Option Pricing Method (&#x201c;OPM&#x201d;) and the Probability-Weighted Expected Return Method (&#x201c;PWERM&#x201d;). PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario, a scenario assuming continued operation as a private entity, and a dissolution scenario. Under the hybrid OPM and PWERM, the per share values calculated under the OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share&lt;br/&gt;of the common stock before a discount for lack of marketability is applied. From January 27 to May 31, 2022 the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;share based on the sale of common stock from&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27, 2022 to May 19, 2022. From June 1, 2022 to August 1, 2022 the fair value of the Company's common stock was estimated for financial reporting purpose at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share based on the price paid in the initial public offering. Following the initial public offering, the fair value of common stock, is based on the closing price of the common stock in the public market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;During the year ended December 31, 2021, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes based on valuations. From January 1, 2021 to February 28, 2021 a valuation of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was used. During the period of March 1, 2021 to June 6, 2021, the fair value of the Company&#x2019;s common stock was estimated for financial reporting purposes based on valuations of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share in February and April 2021 due to the lack of any single specific event that would have indicated a definitive change in the value of the Company. The February and April 2021 valuations used the income approach and the market approach in estimating the fair value of our common stock. The market approach utilized guideline public companies in estimating fair&lt;br/&gt;value of our stock. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The market approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focused on comparing us to a group of our peer companies. In applying this method, valuation multiples are derived from historical and projected operating data of the peer company group. We then apply the selected multiples to our operating data to&lt;br/&gt;arrive at a range of indicated enterprise values of the Company. We then subtracted the net debt to determine equity value not be necessary to determine the fair value of our common stock.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.458%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.45&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average grant date fair values of stock options issued during the years ended December 31, 2022 and 2021 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;w&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ere $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.55&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. At December 31, 2022, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,447,367&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which the Company expects to recognize over a weighted average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock based compensation related to the Company&#x2019;s stock plans are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.288%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,422,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,779,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;896,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;943,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,319,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,722,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e31173a7-a2dc-4f27-be64-82bc649b47d4"
      decimals="INF"
      id="F_75f9c32b-ef86-4d36-8bcd-6ca63fa5ae0e"
      unitRef="U_shares">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e31173a7-a2dc-4f27-be64-82bc649b47d4"
      decimals="INF"
      id="F_471b72b6-5763-42d6-9f1a-b0f76d271466"
      unitRef="U_shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_93dbd88f-ee4a-4a09-9905-9f43b0232942"
      decimals="INF"
      id="F_a5b67bc1-da9e-49cd-a02b-cba524bca075"
      unitRef="U_shares">263729</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ac8db0a5-2d96-4c6b-a190-68c3fc94e6a5"
      decimals="INF"
      id="F_06eace70-5eec-484d-84a6-c608dd18b139"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_850a921a-9604-4c05-bc2c-f089ad5556e7"
      decimals="0"
      id="F_af156fa3-a944-4462-b091-55e5841941ad"
      unitRef="U_USD">2373561</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <maia:TransactionCosts
      contextRef="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c"
      decimals="INF"
      id="F_9b32ab68-4828-45c4-99d7-6bc121f8af2d"
      unitRef="U_USD">0</maia:TransactionCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_46d64219-b005-46b4-9a54-af5112c896b0"
      decimals="INF"
      id="F_d2219d4b-f7ef-4bb2-8417-fe08b9780fd9"
      unitRef="U_shares">11111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ab7d89f5-c0a9-4cc8-988f-dd865cac4e4b"
      decimals="INF"
      id="F_44a9531d-f4d9-4d83-b3ff-e939c8ef24f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc"
      decimals="0"
      id="F_a79a5eed-015a-4b4f-a66f-5949ff1049fe"
      unitRef="U_USD">99999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <maia:TransactionCosts
      contextRef="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c"
      decimals="INF"
      id="F_114a7c0c-99c7-441a-8edd-bda9003d96b3"
      unitRef="U_USD">0</maia:TransactionCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_5e4b8ae0-ed98-4a91-b036-dc37580f4a4c"
      decimals="INF"
      id="F_f9eccd9e-a8f3-4950-b24c-af6bb882124e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_95ea31ca-fbf2-45cf-921a-af532996efec"
      decimals="INF"
      id="F_e6668fb6-abdc-4845-a20e-37c0699f9d92"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_d3d46989-4d4c-4d97-9060-1f21bdf3e85d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_a92750b0-0d99-4527-98b2-5d7e0f493784"
      unitRef="U_shares">219872</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6"
      decimals="0"
      id="F_10a75e88-1495-4acb-984c-a99a8cea1a93"
      unitRef="U_USD">1099360</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_fd33ea19-8159-404c-8202-b10cfa01c418"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6"
      decimals="INF"
      id="F_cf6eac49-63d0-40c3-8cfb-3ea02a65b0df"
      unitRef="U_shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_b322b08c-a2da-43a6-93a1-42e984605870"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <maia:ProceedsFromCommonStockNetOfIssuanceCosts
      contextRef="C_ed6afaaf-47e2-4703-8898-9a173c0212f6"
      decimals="0"
      id="F_e791bab6-ce7c-47b1-8cbc-b1c6cd7f07a4"
      unitRef="U_USD">10000000</maia:ProceedsFromCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583"
      decimals="INF"
      id="F_84eede3d-1184-42eb-a8f9-f1f11b41bca9"
      unitRef="U_shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_5aa0a4a7-169f-471d-837f-b409f7c4b858"
      decimals="INF"
      id="F_37e509c6-1498-4fa1-a5bb-fd8503a666ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <maia:ProceedsFromCommonStockNetOfIssuanceCosts
      contextRef="C_ba69f1b4-b400-41b9-83cb-6beed2abe583"
      decimals="0"
      id="F_c708fcea-0c8a-450a-84bf-f104de69da28"
      unitRef="U_USD">1500000</maia:ProceedsFromCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a1c341f2-a782-415b-b128-1db37d526768"
      decimals="0"
      id="F_c9bf0a56-f94e-48eb-a07a-09b67028f516"
      unitRef="U_USD">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RestrictedStockExpense
      contextRef="C_fff227d5-244a-4bcb-80ea-d5ce7a3c9fdc"
      decimals="0"
      id="F_cdaf46f7-a5f0-4490-91e5-5697f302865d"
      unitRef="U_USD">202500</us-gaap:RestrictedStockExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_5e1ca0e3-7225-4c0e-aa21-a8c07456a8d9"
      decimals="INF"
      id="F_a02df7bb-deb2-4b6e-9cbe-c589709634db"
      unitRef="U_shares">112500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_8b94cac1-12b3-47a8-8cee-4ddd38a0ca14"
      decimals="INF"
      id="F_426be2c1-0a10-4233-ab8c-bbcc2f336f2d"
      unitRef="U_shares">612500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_ea377e52-e368-402f-8f8d-1865b3d62026"
      decimals="INF"
      id="F_7f89c9d5-5cbb-4a41-87f5-cc0a2e7165d2"
      unitRef="U_shares">612500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_fff227d5-244a-4bcb-80ea-d5ce7a3c9fdc"
      decimals="INF"
      id="F_5ab02fce-7b86-41f4-ac71-36efcd581d35"
      unitRef="U_shares">87500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c0fc63fe-6219-4ed8-9fd0-353fd3128c57"
      decimals="INF"
      id="F_e6a0f1ee-332b-4e5a-9f69-a2a96e9b508b"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_4ac28de6-5d6a-4cc2-ac1f-b7f9d7ebb27a"
      decimals="0"
      id="F_961fd52f-2ab7-499e-890c-158155724a7a"
      unitRef="U_USD">52500</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_0bd47fcb-85d2-4812-b92e-5a8f6d200a6e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.072%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.023%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.616%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested balance at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_cab8d345-5f87-42f4-95e4-921bbed2dd3b"
      decimals="INF"
      id="F_2cdf0774-e42f-4e84-820d-5b58fbf8186f"
      unitRef="U_shares">58333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_cab8d345-5f87-42f4-95e4-921bbed2dd3b"
      decimals="2"
      id="F_fbe2af3b-050a-477f-8bfc-817101b0271c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_8cbd6772-af2d-432e-9e5b-d1b10fd09c8e"
      decimals="INF"
      id="F_5fe48750-be17-4f3f-926f-ca3855a292ab"
      unitRef="U_shares">58333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8cbd6772-af2d-432e-9e5b-d1b10fd09c8e"
      decimals="2"
      id="F_c8875ade-3b35-4aa5-b625-60345b971c7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <maia:WarrantModificationValue
      contextRef="C_139f3834-5a5f-48da-b7b6-95728dcce439"
      decimals="0"
      id="F_30562ac4-269d-4670-ae81-5ba99386c034"
      unitRef="U_USD">144497</maia:WarrantModificationValue>
    <maia:DeemedDividendOnWarrantModification
      contextRef="C_e6b76190-87b3-4e35-a133-5acf6c22a4fb"
      decimals="0"
      id="F_86d07e04-fe0a-4083-b005-242515ca2ab4"
      unitRef="U_USD">450578</maia:DeemedDividendOnWarrantModification>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_1dd9ecfb-e5be-406a-bca6-0d22818e6d05"
      decimals="INF"
      id="F_e1ea0eca-8dd5-4782-9401-989e89e6ef97"
      unitRef="U_shares">61111</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_1dd9ecfb-e5be-406a-bca6-0d22818e6d05"
      decimals="0"
      id="F_6b848203-6e75-44f8-b8ec-1f1a921c37af"
      unitRef="U_USD">110000</maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants>
    <maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares
      contextRef="C_46d64219-b005-46b4-9a54-af5112c896b0"
      decimals="INF"
      id="F_56ea522d-ad69-43f0-8499-eac6dc92aa2e"
      unitRef="U_shares">153000</maia:IssuanceOfCommonSharesUponExerciseOfWarrantsShares>
    <maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_46d64219-b005-46b4-9a54-af5112c896b0"
      decimals="0"
      id="F_30b31cd1-5fe9-4d07-bfb0-36da696b6071"
      unitRef="U_USD">275400</maia:ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants>
    <maia:WarrantsExercisedShares
      contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc"
      decimals="INF"
      id="F_a8c7ac5f-9566-47b2-a17a-26f5d66e528c"
      unitRef="U_shares">394501</maia:WarrantsExercisedShares>
    <maia:CashlessExerciseAtFairMarketValuePerShare
      contextRef="C_863cbba8-59d9-4d51-9cc5-660f99aa7d5c"
      decimals="INF"
      id="F_c0fb0fcb-77e4-454e-9240-a58952575403"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.00</maia:CashlessExerciseAtFairMarketValuePerShare>
    <maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
      contextRef="C_ab0cd34b-a1d8-41d1-bbda-9fcdd53712bc"
      decimals="INF"
      id="F_2fcaf46c-8531-4915-be5f-983d707eeb48"
      unitRef="U_shares">315601</maia:IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares>
    <maia:NumberOfWarrantsExercised
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_eed5ba67-7fc4-4367-a180-5110d493272e"
      unitRef="U_shares">20520</maia:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2fd580ec-da61-4243-8bbe-66e3640f920c"
      decimals="INF"
      id="F_63619d43-2c39-471b-8f95-98e28faf7923"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d2e664bd-7357-485e-b4fb-bf293169d186"
      decimals="INF"
      id="F_587cca78-b107-4c39-91df-9a43e9cfae97"
      unitRef="U_shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e31173a7-a2dc-4f27-be64-82bc649b47d4"
      decimals="INF"
      id="F_d9196cc1-293b-46c5-93e2-13b0150ea8b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_5e96f6c1-8fcb-4e45-849b-c83a8f2330e8"
      id="F_0bbd05bd-748e-4046-96d1-19bfc1376e58">2023-01-23</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <maia:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
      contextRef="C_5e96f6c1-8fcb-4e45-849b-c83a8f2330e8"
      id="F_67762d1d-5cd7-4b4e-a136-414653585ecc">2027-07-27</maia:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire>
    <maia:ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock
      contextRef="C_b86fb584-5f3d-48eb-bd47-338774b042f1"
      decimals="INF"
      id="F_cea7433e-4c33-414e-8b99-6d7e2b822a12"
      unitRef="U_shares">15000</maia:ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_79f9be5c-c6c9-4e62-8570-7a5b4ef49378"
      decimals="0"
      id="F_18652f0d-797c-48aa-8cb3-0010cc526d98"
      unitRef="U_USD">343735</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_10935678-cd01-4042-9bb0-148e441856b3"
      id="F_bd63b4cb-9b62-48b5-b553-49fb1eacb521">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_10935678-cd01-4042-9bb0-148e441856b3"
      decimals="4"
      id="F_a590dcfd-a598-4138-bfa8-ab091f18627b"
      unitRef="U_pure">0.0282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_10935678-cd01-4042-9bb0-148e441856b3"
      decimals="3"
      id="F_1fdcc822-fb28-45e8-ab30-1a81b4168528"
      unitRef="U_pure">0.775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_9a65e813-1f77-4727-b3a4-ed12a2b5363f"
      unitRef="U_USD">245341</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_d3540e61-4c81-4a9e-8519-75d8edfbd550"
      decimals="0"
      id="F_f227a48f-84c4-4a81-8461-88289ee2aba3"
      unitRef="U_USD">98394</us-gaap:FairValueAdjustmentOfWarrants>
    <maia:ClassOfWarrantsIssued
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_6ff5e1d4-076d-402f-b79d-4b9cb74309cf"
      unitRef="U_shares">115000</maia:ClassOfWarrantsIssued>
    <maia:ScheduleOfWarrantExercisedTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_aa1a4e3c-cdf8-40ee-85f6-7af3e47a1e39">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.425%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,311,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;608,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;796,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</maia:ScheduleOfWarrantExercisedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_eb56761c-784f-4978-8cdd-3098c37d720a"
      unitRef="U_shares">1311117</us-gaap:ClassOfWarrantOrRightOutstanding>
    <maia:ClassOfWarrantsWeightedAverageExercisePrice
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="2"
      id="F_8f913669-7c30-4804-8899-a0802ffadb53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.03</maia:ClassOfWarrantsWeightedAverageExercisePrice>
    <maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      id="F_29a49034-3126-4239-b6a1-e71f090d0276">P7Y3M18D</maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm>
    <maia:ClassOfWarrantsIssued
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_b796ca08-e5f5-4cb7-b312-28ae0c02b664"
      unitRef="U_shares">115000</maia:ClassOfWarrantsIssued>
    <maia:ClassOfWarrantsWeightedAverageExercisePriceIssued
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_de8ccaa0-79fb-491f-94d0-43cdce90d3fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.25</maia:ClassOfWarrantsWeightedAverageExercisePriceIssued>
    <maia:ClassOfWarrantsExercised
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_757bc6cc-2c50-4530-9275-90389eb3e1a3"
      unitRef="U_shares">608612</maia:ClassOfWarrantsExercised>
    <maia:ClassOfWarrantsWeightedAverageExercisePriceExercised
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_54710dc8-701b-4c92-a844-4a1e3eb22e58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.80</maia:ClassOfWarrantsWeightedAverageExercisePriceExercised>
    <maia:ClassOfWarrantsExpired
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_30f3b6cb-a053-4fab-be0a-809ddccc75b0"
      unitRef="U_shares">20520</maia:ClassOfWarrantsExpired>
    <maia:ClassOfWarrantsWeightedAverageExercisePriceExpired
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_63755577-5a8c-493b-9406-754e8adfac21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</maia:ClassOfWarrantsWeightedAverageExercisePriceExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_bcb743a9-9c86-46ac-ba34-d43ed285e148"
      unitRef="U_shares">796985</us-gaap:ClassOfWarrantOrRightOutstanding>
    <maia:ClassOfWarrantsWeightedAverageExercisePrice
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="2"
      id="F_3b76e56d-de77-4adb-ad49-9528bca1dbe8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.04</maia:ClassOfWarrantsWeightedAverageExercisePrice>
    <maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_47014a67-b835-4090-9d56-dbef911497fe">P5Y1M28D</maia:ClassOfWarrantsWeightedAverageRemainingContractualTerm>
    <maia:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_bcdc4fd8-9b41-473f-a1ec-19431c7c7ffa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.0%;"/&gt;
        &lt;td style="width:2.0%;"/&gt;
        &lt;td style="width:14.5%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.88%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</maia:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c"
      decimals="3"
      id="F_06b045d2-0144-48d5-84f1-fb03d2f4118f"
      unitRef="U_pure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c"
      decimals="3"
      id="F_02adfaaf-589a-4892-b918-078d546e65e6"
      unitRef="U_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390"
      decimals="3"
      id="F_ff44f904-af7f-4afb-a982-9b09777ded4b"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390"
      decimals="3"
      id="F_e3b98777-4166-4779-af68-60cfdc864e5a"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_33263a2e-646d-4256-82aa-1223f29184cd"
      id="F_73a58959-2fcf-4761-8f2a-0a2eb4644dd7">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_83947522-5d4a-4233-ab67-fb6efdf06f08"
      id="F_43016640-5052-4934-b799-ce72d2163dd1">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_538b838f-72d0-42ef-a3b6-35b1fbd33513"
      id="F_8434b71b-de04-4abf-83f7-43de347a3171">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0cf26860-1e88-4777-a873-11663c855cc6"
      id="F_7d3bbaa0-f31f-4209-b3cd-34da1a979b75">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c"
      decimals="2"
      id="F_378f8421-9d3d-420c-b85a-b6587bf3a7d2"
      unitRef="U_pure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c"
      decimals="2"
      id="F_700da138-b929-420a-94c9-78b5bd9ddbba"
      unitRef="U_pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390"
      decimals="2"
      id="F_2bcf7e38-b7f6-4553-a2d4-e9522c360681"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_8e7436f3-5354-4afa-bd19-4dded9a9e390"
      decimals="2"
      id="F_2d43bee8-f410-4224-a610-eaa6da7effa7"
      unitRef="U_pure">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7fba4a25-8b91-4e2b-9498-b481e7e735a2"
      decimals="INF"
      id="F_bf7f8cb4-43d3-448a-956b-0fb3f8f18d00"
      unitRef="U_shares">1924500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6992df71-0104-43df-abe1-8e43fcfa0c86"
      decimals="INF"
      id="F_9dd597cd-e3f3-487a-8df2-16c9c7676cd5"
      unitRef="U_shares">3983023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6992df71-0104-43df-abe1-8e43fcfa0c86"
      decimals="INF"
      id="F_45de699c-fac0-42fb-aa9b-2defeca9230d"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_70eeaef3-d979-4694-830c-aa004fc65cad"
      decimals="INF"
      id="F_6a3538b8-801d-4560-9607-210f39b03c4f"
      unitRef="U_shares">1909518</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e144005c-eb16-4637-a828-601934ff5985"
      decimals="INF"
      id="F_adb72994-8326-4460-8d80-1f5927d0939d"
      unitRef="U_shares">1271413</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e144005c-eb16-4637-a828-601934ff5985"
      decimals="INF"
      id="F_9dd0227c-e550-41b7-b93e-276ade2d9489"
      unitRef="U_shares">638105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0d8490e1-93cd-41ed-bc23-ad484a70d024"
      id="F_5305b090-9b56-47b8-bfee-0baed9197eb2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_8d2a5729-f502-477b-9b59-964efa6e0f3b"
      unitRef="U_pure">0.10</maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted>
    <maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_5bc6b8e7-1467-46fa-93d4-fcd93e2d1671"
      unitRef="U_pure">1.10</maia:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_def16657-a0a1-4721-9a43-f0b61cf42a05">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_b7c9202b-66f9-4227-aefb-310e7a9526c0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.822%;"/&gt;
        &lt;td style="width:0.96%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.292%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.291%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.972%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.315000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.185%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in&lt;br/&gt;Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,797,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;811,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,545,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,773,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,449,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,804,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="INF"
      id="F_d05b9c90-e4a5-4833-8a6f-88da994de828"
      unitRef="U_shares">5797185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="2"
      id="F_93029763-d655-4cc1-aaa1-7487fe2d7bfb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      id="F_a68eeac7-23b0-4128-b798-dde37c88f3ec">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_d6f0d098-9a8c-482d-8579-720b2b917efd"
      unitRef="U_shares">811831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_62f4a7aa-d395-48f5-8173-b6e16c5a8d52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_d105f066-cd9a-45ca-800a-9bfc9c2da4a0"
      unitRef="U_shares">46500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_d960ee07-929c-4621-8f51-9b51f6a246ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_fe9b3600-467b-4cd0-a247-e65f55e63368"
      unitRef="U_shares">16888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_5f5adfbb-74c2-45a6-a6e6-19362a6e7c25"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_5a380c0e-dee3-4c98-b898-bbdeee8a9cd7"
      unitRef="U_shares">6545628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="2"
      id="F_d8d46f70-10e8-437f-81bd-63d4c8ecfd9b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_f18d9387-775e-4473-aa92-a1d0da653fa4">P7Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_0b7c6e33-0a1e-4fb0-9fe9-1d3bc3e707f6"
      unitRef="U_USD">9773706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="INF"
      id="F_d5fd2c25-bebe-41a6-8666-66fa01d01807"
      unitRef="U_shares">5449715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="2"
      id="F_87f8987e-8ccf-4050-8986-8c9949b819dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_86989026-dbe6-4da6-9a96-4bcf08a0f9f8">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_c1f01b7d-9811-4d87-b954-3e8cbba83363"
      unitRef="U_USD">8804841</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d07afd76-c668-4a14-b0f2-d16a7a6bc509"
      decimals="2"
      id="F_458530a7-bc55-470b-9611-73dd5b4ea6aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.87</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_d418fc52-98ec-47f5-95c9-f00cb3c88d3c"
      decimals="0"
      id="F_8665c73a-c706-4db0-9207-a75f921fd949"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_1d9234a1-5f51-4764-b7e4-a62ca84ba633"
      decimals="0"
      id="F_407dc70b-0238-439c-92c8-75f97479cb41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_90df5ec5-d2d5-410c-ae2a-6982581d43c0"
      decimals="2"
      id="F_07d178e0-83d2-441e-99a8-f2e56563e1af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.80</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_960ce175-49b7-4d64-b47c-1ecd446c52b2"
      decimals="2"
      id="F_0e3f491b-7cc0-4cca-aefd-8d8ac009f53b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_4b5dc57e-799a-45be-88b8-d427de359a24">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.458%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.45&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_13bf0128-a070-4b47-825e-8161c256c563"
      decimals="4"
      id="F_411d535b-1094-4fae-ac16-4c1b2a1f277c"
      unitRef="U_pure">0.0214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_13bf0128-a070-4b47-825e-8161c256c563"
      decimals="4"
      id="F_9067a81f-e59c-4ab6-bfc8-88a11af085bf"
      unitRef="U_pure">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73"
      decimals="4"
      id="F_5c7e56e8-cc31-4ab6-8164-818a3af91726"
      unitRef="U_pure">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73"
      decimals="4"
      id="F_27fcdd10-e0f5-4259-a6f8-110da0bf25f8"
      unitRef="U_pure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1389048c-24c0-4a62-aaa4-a2b74693dfae"
      id="F_288dec63-9171-46ce-83ce-c97b7ac12cf6">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6c7f2e44-3c3e-49bc-8220-a31f305d9878"
      id="F_b202cc94-9c73-4cc8-af85-b4216af6df9a">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_68298e68-92ff-4876-a80a-e4764bf1eb5f"
      id="F_c37858ed-43c3-4011-9f22-18aa27cd59bc">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5dff99c3-0b2d-4940-9d28-68bd8d158e84"
      id="F_c4133148-dd6b-4cf6-a93c-f973384997b2">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_13bf0128-a070-4b47-825e-8161c256c563"
      decimals="3"
      id="F_2726f3ac-b340-46f8-ab79-2c378695edeb"
      unitRef="U_pure">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_13bf0128-a070-4b47-825e-8161c256c563"
      decimals="3"
      id="F_f20cb30f-da61-4444-872f-b47c0832d3ca"
      unitRef="U_pure">0.879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73"
      decimals="3"
      id="F_977942ce-7a01-460a-a9ae-fbbd31dc09cc"
      unitRef="U_pure">0.714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73"
      decimals="3"
      id="F_b5e7dec6-f6e1-43b0-b1da-9ce114725b37"
      unitRef="U_pure">0.815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_13bf0128-a070-4b47-825e-8161c256c563"
      decimals="2"
      id="F_f1f55335-ebfb-46d9-867d-7882d6e5c042"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_83efa49f-5cb0-4cba-a6c0-ab8b23dbea73"
      decimals="2"
      id="F_a66a9c50-3c09-4621-bc0c-baf34e1fad77"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_80e5dbc0-3203-4a49-8843-3da9d91fc340"
      decimals="0"
      id="F_72359bb3-8930-46e8-8973-df87901c8b3b"
      unitRef="U_USD">3447367</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_13bf0128-a070-4b47-825e-8161c256c563"
      id="F_bb272aa7-8305-49d2-831d-301a560f4d83">P3Y3M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_1313009e-c250-4dc1-84b6-f263cf43ffac">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock based compensation related to the Company&#x2019;s stock plans are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.288%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,422,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,779,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;896,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;943,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,319,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,722,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9fb6a9b-9be5-47bf-a4da-ec226ccb941f"
      decimals="0"
      id="F_30ce8a42-a491-4280-9fa4-a35bc2f3850e"
      unitRef="U_USD">1422799</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_74b36063-ab0f-43ae-a3fd-a7c41185eb8e"
      decimals="0"
      id="F_1450a05a-7e62-4970-b1e5-314dea1edcca"
      unitRef="U_USD">1779185</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_daea18c7-8f9f-40db-a949-f62882d10b13"
      decimals="0"
      id="F_38ac0879-00df-4484-bc7b-eb703e774e86"
      unitRef="U_USD">896628</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_60bc5fdb-609a-4b8d-8539-569a6372e484"
      decimals="0"
      id="F_d1177c0d-5daf-4f43-aeb1-9a4080892589"
      unitRef="U_USD">943708</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="0"
      id="F_35376e46-1afb-4c9a-916f-a8b1e24a8638"
      unitRef="U_USD">2319427</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="0"
      id="F_531e8c36-e233-43e6-baa3-c7d28bfde939"
      unitRef="U_USD">2722893</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_a90eb627-3a86-4319-ae91-6fed774530ca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;EMPLOYEE RETIREMENT PLAN&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our eligible employees have been permitted to participate in our 401(k) beginning October 1, 2022. Participation in the 401(k) plan is offered for the benefit of our employees, including our named executive officers, who remain employed with us, and who satisfy certain eligibility requirements. We match employee contributions using a benchmark to industry standards. The Company will make a safe harbor matching contribution equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of employee salary deferrals that do not exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their compensation plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their salary deferrals between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their compensation.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2022 Company match is immaterial. The Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_1bfefa67-16ca-409f-bb23-cdd798adfd46"
      decimals="INF"
      id="F_c5cd50d6-3bc4-4818-acbe-9ea8383af33e"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <maia:DefinedContributionPlanEmployerSalary
      contextRef="C_04cf05b4-4370-4979-8fd8-aad3bb1d1cf7"
      decimals="2"
      id="F_5311da10-a40c-43a8-a424-9fbb4e268b76"
      unitRef="U_pure">0.01</maia:DefinedContributionPlanEmployerSalary>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_704afa9b-4318-432b-94d0-dd9ac96a4003"
      decimals="INF"
      id="F_fb8d3d90-ebb2-407f-9dcd-d27bde915012"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <maia:DefinedContributionPlanEmployerSalary
      contextRef="C_704afa9b-4318-432b-94d0-dd9ac96a4003"
      decimals="2"
      id="F_8fb1ef39-a34f-47be-9e54-64724d1ec428"
      unitRef="U_pure">0.01</maia:DefinedContributionPlanEmployerSalary>
    <maia:DefinedContributionPlanEmployerSalary
      contextRef="C_1bfefa67-16ca-409f-bb23-cdd798adfd46"
      decimals="2"
      id="F_bec7b04f-2e0c-479f-b4c3-12840c005c24"
      unitRef="U_pure">0.06</maia:DefinedContributionPlanEmployerSalary>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e18f516d-40db-4c58-9638-c42dbdec324a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.  COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Legal&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company's financial position, operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patent Licensing, Sponsored Research, and Patent &amp;amp; Technology Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;THIO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; - In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (&#x201c;PLA&#x201d;) titled &#x201c;Patent and Technology License Agreement AGT. NO. L2264 - MAIA Biotechnology&#x201d; with the University of Texas Southwestern (&#x201c;UTSW&#x201d;) to license patent families for a specific compound (&#x201c;THIO&#x201d;) from UTSW to MAIA. The agreement, as amended, has a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, not to exceed a combined milestone payment total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; payments are due to UTSW related to the milestones. The agreement requires royalties of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000,000, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on net sales above $1,000,000,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Also in December 2020, the Company entered into a second license agreement with UTSW titled &#x201c;Patent and Technology License Agreement AGT. NO. L3648 &#x2014; MAIA Biotechnology&#x201d; pursuant to which UTSW is licensing an additional compound to MAIA. The agreement has a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, not to exceed a combined milestone payment total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, no assignment has occurred and none of the defined milestones have been completed and therefore &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; payments are due to UTSW related to the milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The agreement requires royalties of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% (depending on THIO reaching specified sales levels in the respective jurisdictions) royalty payments on net sales up to $1,000,000, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on net sales above $1,000,000,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales of the Company or its sublicensee. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or ten (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Regeneron - In February 2021, the Company reached an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company's compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug cemiplimab representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan in the event that patient screening for the clinical study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial study, or (b) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of December 31, 2022 neither party has terminated the agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <maia:TermOfAgreement
      contextRef="C_c5c5e8e4-533d-4dc8-81c1-c4f505de146c"
      id="F_85f11bb1-31be-4aac-8517-606e11f32141">P20Y</maia:TermOfAgreement>
    <maia:MilestonePayment
      contextRef="C_9685ca74-0b09-41fe-a647-8f730fad5ee4"
      decimals="0"
      id="F_c6dd5ff7-9c2a-45f1-ab12-589504458cad"
      unitRef="U_USD">1000000</maia:MilestonePayment>
    <maia:MilestonePayment
      contextRef="C_99f06e4c-f0a7-4618-91e5-f9e6e61a5eb9"
      decimals="0"
      id="F_06241a4a-46bb-4c8d-8656-c0747d3ea4b4"
      unitRef="U_USD">50000000</maia:MilestonePayment>
    <maia:CombinedMilestonePaymentsMaximum
      contextRef="C_c5c5e8e4-533d-4dc8-81c1-c4f505de146c"
      decimals="0"
      id="F_0228e325-e66d-462d-8cfb-534fa61f0c51"
      unitRef="U_USD">112000000</maia:CombinedMilestonePaymentsMaximum>
    <maia:PaymentsDueRelatedToMilestones
      contextRef="C_7a095884-7271-41a9-990e-c05d7154216c"
      decimals="0"
      id="F_1245889c-fe96-4fda-89d4-366226912ffb"
      unitRef="U_USD">0</maia:PaymentsDueRelatedToMilestones>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_aa57afe6-0ae3-4ae8-8716-1ebfc8bf9e47"
      decimals="2"
      id="F_80927d7a-e2e1-46f4-8849-97ddf1b71d0a"
      unitRef="U_pure">0.02</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0838c5ab-fead-4553-91e0-e9194daa7208"
      decimals="2"
      id="F_84ae2669-899b-473b-9c4e-930783b12b5c"
      unitRef="U_pure">0.04</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_60690a56-b071-4f7d-a346-3c1b2b2672ae"
      decimals="3"
      id="F_1e058eed-e523-4013-b0b3-cf3028b688ae"
      unitRef="U_pure">0.025</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_4078271a-c8fb-4d34-a59a-234a262797bb"
      decimals="2"
      id="F_b282adc6-93b9-4efb-8b89-db2380002a5a"
      unitRef="U_pure">0.05</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:TermOfAgreement
      contextRef="C_b04addab-578d-403a-ac75-910316d401b0"
      id="F_b98ae236-2677-4970-96aa-9b609281d553">P20Y</maia:TermOfAgreement>
    <maia:MilestonePayment
      contextRef="C_093f44a4-068c-4d51-9096-9822ca581146"
      decimals="0"
      id="F_a146a1b7-a9e9-4a64-a9e7-ac3ad07986cc"
      unitRef="U_USD">1000000</maia:MilestonePayment>
    <maia:MilestonePayment
      contextRef="C_c75159f4-1e2f-4115-964f-af704eb8949f"
      decimals="0"
      id="F_33085c93-1e00-488e-967a-b3aa5a93e022"
      unitRef="U_USD">50000000</maia:MilestonePayment>
    <maia:CombinedMilestonePaymentsMaximum
      contextRef="C_b04addab-578d-403a-ac75-910316d401b0"
      decimals="0"
      id="F_c49b255c-4233-447a-81de-d1d86f17ca4c"
      unitRef="U_USD">112000000</maia:CombinedMilestonePaymentsMaximum>
    <maia:PaymentsDueRelatedToMilestones
      contextRef="C_7b0c05a1-2ef5-406c-a235-22c40e3c2880"
      decimals="0"
      id="F_a2865065-1463-4de6-96ff-ac21524f8804"
      unitRef="U_USD">0</maia:PaymentsDueRelatedToMilestones>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_bdce226d-2206-4c50-b8bb-8a3e0648506c"
      decimals="2"
      id="F_48ed8fd1-4476-4a91-b7e6-bf4368d668a5"
      unitRef="U_pure">0.02</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_75c413f9-8ba4-436c-9bf0-776a3437584a"
      decimals="2"
      id="F_82e531e4-aee3-440a-866d-0fdc4da50f84"
      unitRef="U_pure">0.04</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_b89f176d-a5ef-4374-a64e-fbce690b3f42"
      decimals="3"
      id="F_aa92c6f8-9987-445c-95ef-776fac99495f"
      unitRef="U_pure">0.025</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_ee00796c-ffd3-46f4-93c1-8db0ae1a964e"
      decimals="2"
      id="F_30b92c3f-8997-4554-886f-b98d2f24ee2e"
      unitRef="U_pure">0.05</maia:PercentageOfRoyaltyPaymentsOnNetSales>
    <maia:PercentageOfRoyaltyPaymentsOnNetSalesDescription
      contextRef="C_7b0c05a1-2ef5-406c-a235-22c40e3c2880"
      id="F_54daaeaa-6782-47d1-a5bd-738994fe0c32">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).</maia:PercentageOfRoyaltyPaymentsOnNetSalesDescription>
    <maia:ClaimExpirationTerm
      contextRef="C_b04addab-578d-403a-ac75-910316d401b0"
      id="F_f99d982e-029e-4311-8467-7346338e71a0">P10Y</maia:ClaimExpirationTerm>
    <maia:TermOfAgreement
      contextRef="C_59d4a5fa-7563-4679-8962-c0917ed9d470"
      id="F_664e8f86-86b1-45c1-90f2-1e5e885af205">P5Y</maia:TermOfAgreement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_853197f2-7f98-4661-aaf2-7b200d0c52f0">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  INCOME TAXES&lt;/span&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's net deferred tax assets consist of the following components:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,294,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,013,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,183,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,800,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,499,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;244,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;102,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,229,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,027,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,229,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,027,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, the Company has unused U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that may be applied against future taxable income. The state NOL carryforwards begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The U.S. federal NOL carryforwards may be carried forward indefinitely, however are limited to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; percent of taxable income. The Company has unused Australian NOL carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that may be carried forward indefinitely. The Company has unused U.S. federal research and experimentation (&#x201c;R &amp;amp; E&#x201d;) tax credits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The use of the Company&#x2019;s NOL and R &amp;amp; E credit carryforwards may, however, be subject to limitations as a result of an ownership change. A corporation undergoes an &#x201c;ownership change,&#x201d; in general, if a greater than 50% change (by value) in its equity ownership by one or more five&#x2011;percent stockholders (or certain groups of non&#x2011;five&#x2011;percent stockholders) over a three&#x2011;year period occurs. After such an ownership change, the corporation&#x2019;s use of its pre&#x2011;change NOL carryforwards and other pre&#x2011;change tax attributes to offset its post&#x2011;change income is subject to an annual limitation determined by the equity value of the corporation on the date the ownership change occurs multiplied by a rate determined monthly by the Internal Revenue Service.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an ownership change occurs and if the Company earns net taxable income, the Company&#x2019;s ability to use its pre&#x2011;change NOLs to offset U.S. federal and taxable income would be subject to these limitations, which could potentially result in increased future tax liability compared to the tax liability the Company would incur if its use of NOL carryforwards were not so limited. In addition, for state income, franchise and similar tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase the Company&#x2019;s state income, franchise, or similar taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC 740, &#x201c;Income Taxes,&#x201d; the Company recorded a valuation allowance to fully offset its deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The valuation allowance increased by approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended December 31, 2022 and 2021, respectively, mainly due to increases in the NOL carryforward and other deferred tax assets. The Company will continue to assess the realizability of the deferred tax assets at each interim and annual balance sheet date based upon actual and forecasted operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurred a pretax book loss of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022, which consisted of a U.S. loss of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and a foreign loss of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company incurred a pretax book loss of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021, which consisted of a U.S. loss of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and a foreign loss of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No provision or benefit for U.S. federal, state, or foreign income taxes has been recorded for the years ended December 31, 2022 and 2021, mainly due to net losses incurred by the Company in all jurisdictions other than Romania, which provides for a tax exemption.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.021%;"/&gt;
        &lt;td style="width:1.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.357%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.31%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other nondeductible expenses/(nontaxable income)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. The Company did not have any significant unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company files income tax returns in the U.S. federal jurisdiction, several U.S. States, Australia, and Romania. The Company&#x2019;s tax returns since inception remain open to examination by the taxing authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e735d98d-933a-47ea-9be4-a7137214fb2a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's net deferred tax assets consist of the following components:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,294,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,013,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,183,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,800,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,499,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;244,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;102,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,229,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,027,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,229,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,027,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_ce206a4c-a644-4d62-a55f-6321fe433aaa"
      unitRef="U_USD">3294955</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_5a7b116a-dcb2-425a-8ba4-c0ab6456a01d"
      unitRef="U_USD">3013721</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_0177259d-be60-4151-9fd1-f292bdbd428c"
      unitRef="U_USD">1183941</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_a1aa4176-de10-4741-b30b-6b324a43f662"
      unitRef="U_USD">1800935</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_c009c3f0-da0f-4b49-b53d-fd18efeeef1a"
      unitRef="U_USD">1499300</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_197e30d5-4695-4092-8007-e429f3e10483"
      unitRef="U_USD">244848</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_aa7d5eae-8c39-4a2b-bb63-38683e81cdc3"
      unitRef="U_USD">109673</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_c8be65f5-e125-45bb-b313-0f40d9a90adb"
      unitRef="U_USD">6724</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_15a870f8-f61a-43ba-8f3d-c23187b93472"
      unitRef="U_USD">102825</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_d3479c65-f28d-47f5-9946-59ddc643b727"
      unitRef="U_USD">6229768</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_4c1a75af-6e2f-49ac-a1ac-29d948b26c23"
      unitRef="U_USD">5027154</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_18f191ce-f487-4a92-a1ad-96c619694078"
      decimals="0"
      id="F_4d60a8ce-c624-43e0-980e-b33dc1065792"
      unitRef="U_USD">6229768</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_eeb120cc-5b60-4380-b2f8-ba97598b38f1"
      decimals="0"
      id="F_44d0041f-ca81-4917-97ec-29b5f1109893"
      unitRef="U_USD">5027154</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2d323e1e-91fa-4adc-b0b9-fa95c2a916da"
      decimals="-5"
      id="F_9c42f2b9-af41-4558-b0f0-94f66ab0dc6d"
      unitRef="U_USD">15400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_dbddc662-f865-4f07-88a7-237f7cbd58b3"
      decimals="-5"
      id="F_acddcfba-97cb-4310-aa57-2c4d91c9a142"
      unitRef="U_USD">15400000</us-gaap:OperatingLossCarryforwards>
    <maia:OperatingLossCarryforwardsExpirationYear
      contextRef="C_c19f9601-2487-4519-b741-1a2bc336d1b4"
      id="F_2dae785a-86c2-4049-b432-1ce08650e737">2030</maia:OperatingLossCarryforwardsExpirationYear>
    <maia:OperatingLossCarryforwardLimitedPercentageOfTaxableIncome
      contextRef="C_2d323e1e-91fa-4adc-b0b9-fa95c2a916da"
      decimals="2"
      id="F_609bc689-8db4-495c-8250-4305ecb30b84"
      unitRef="U_pure">0.80</maia:OperatingLossCarryforwardLimitedPercentageOfTaxableIncome>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2703e6a6-9c13-46c2-9da9-deaa17ee8d34"
      decimals="-5"
      id="F_bedd9513-1ad8-4802-9e93-18dcf49516cc"
      unitRef="U_USD">100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_257832a6-de0c-47b0-b609-38c350dcd89a"
      decimals="-5"
      id="F_132eac93-77d4-45ff-b064-74daf8b51588"
      unitRef="U_USD">100000</us-gaap:TaxCreditCarryforwardAmount>
    <maia:ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear
      contextRef="C_bd2957a7-98eb-4f84-87e4-b97ec6293ef9"
      id="F_a7bacf7d-a851-46e1-bf81-873cbc2a9fb2">2041</maia:ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="-5"
      id="F_98104366-49b4-40aa-a78d-0fa009c931c4"
      unitRef="U_USD">1200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="-5"
      id="F_9bfa24cd-e9c6-49d8-9706-8f9be4c4ebcc"
      unitRef="U_USD">2100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="-5"
      id="F_0cbf7db3-e939-4733-b6bb-6452acae7a4e"
      unitRef="U_USD">-15800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="-5"
      id="F_12a0f205-d23f-4cf0-9f09-76e0e533fe0f"
      unitRef="U_USD">-15300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="-5"
      id="F_b96c5962-ff3c-4646-9ca6-588d7bee9152"
      unitRef="U_USD">-500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="-5"
      id="F_d1cd2821-ab67-446c-a628-5e558102b562"
      unitRef="U_USD">-12600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="-5"
      id="F_6503fdb3-6edb-4358-a059-b6415618b37d"
      unitRef="U_USD">-12500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="-5"
      id="F_43331c00-d793-4ae3-b1e1-6aed118a2aaa"
      unitRef="U_USD">-100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e2abd603-2514-4a3b-b9bc-0a7947ee208f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.021%;"/&gt;
        &lt;td style="width:1.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.357%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.31%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other nondeductible expenses/(nontaxable income)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="INF"
      id="F_777e94bf-6351-4a80-a0e7-b62d7db2456e"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="INF"
      id="F_ef7cae02-649d-4be9-8050-9d9584fa7f1d"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="3"
      id="F_b04157a4-8353-4c48-a2c2-d11be3bcdc7e"
      unitRef="U_pure">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="3"
      id="F_a6f45932-c319-4b9d-8171-1723b79c4ccf"
      unitRef="U_pure">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="3"
      id="F_09ce149e-b52e-41e9-84de-b4e37ad727d2"
      unitRef="U_pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="3"
      id="F_719e798f-2ccb-44fd-8eb4-ffef92cfbbdd"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="3"
      id="F_ebaaa20d-d3c1-4158-b48f-6df30b0cd649"
      unitRef="U_pure">-0.015</maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt>
    <maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="3"
      id="F_54715b33-7c50-4d4a-ac88-59f411fdd253"
      unitRef="U_pure">-0.039</maia:EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="3"
      id="F_57dd0fcc-0366-4ac2-9007-06c4c19d7aa1"
      unitRef="U_pure">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="3"
      id="F_0bb8ffc9-33d4-46c9-b55a-7da05f611904"
      unitRef="U_pure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="3"
      id="F_d6e0f983-4450-47a0-b92f-06fc57c3bdbf"
      unitRef="U_pure">-0.076</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="3"
      id="F_bdaa0db5-ff34-44be-a891-ee3114864d15"
      unitRef="U_pure">-0.168</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      decimals="2"
      id="F_8832b913-6523-4673-a7a5-0a7e2c2f7c0f"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_cbf5e914-0593-48ce-a8d1-7cde11503245"
      decimals="2"
      id="F_8ff27e45-fc93-4fc2-98dc-174105722b82"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9"
      id="F_e3e6b661-629e-4b40-ba0e-b45c2f085e82">&lt;div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;12.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issuance of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 16, 2023, we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock for investor relations services from January 16, 2023 through July 16, 2023. Per the agreement  an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock will be issued on April 16, 2023 if their services are still in place per the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 8, 2023, we entered into an agreement with The Money Channel NYC Inc. for media services, pursuant to which we agreed to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock on March 8, 2023 and an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock every ninety days after the execution date of the contract until termination of the agreement. The term of the agreement extends for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;180 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and renews automatically until we provide written notice prior to the end of the term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issuance of Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From January 1 to March 20, 2023 we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;638,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options at a weighted exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to employees and consultants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_123bb045-1787-4e92-86ee-97af8a0fc791"
      decimals="INF"
      id="F_4cd52e78-0bc8-4b7f-80fa-16f43dd2268d"
      unitRef="U_shares">18000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_7447a51d-1b53-4834-a837-fd4e4d4818a5"
      decimals="INF"
      id="F_53263e37-9266-49f2-8799-50de51c2f1ed"
      unitRef="U_shares">18000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_b6fe62fc-f09a-4c0a-822b-9375cd7875df"
      decimals="INF"
      id="F_1cc42b37-a446-41d8-a8de-48ab1de8b73c"
      unitRef="U_shares">22500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_d9c0194e-ae7a-4f5c-a38a-cbedc013e926"
      decimals="INF"
      id="F_62121cb7-ff56-4922-bfac-a44e63f692a8"
      unitRef="U_shares">22500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <maia:TermOfAgreement
      contextRef="C_ceb3f2a5-5c4a-48e7-96ef-1bd506bd16cb"
      id="F_5b86be85-622d-48a8-a9e1-bfd5273a975f">P180D</maia:TermOfAgreement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ea85c9c9-8fa4-44f7-9253-844104dacb55"
      decimals="INF"
      id="F_1c9b1537-6ca3-42ee-9d4e-924d52e83550"
      unitRef="U_shares">638710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_ea85c9c9-8fa4-44f7-9253-844104dacb55"
      decimals="2"
      id="F_51f38bf3-4559-4b7a-8f48-d72a9db4d9cc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M29XN6$\O6ARJ.\I[H;7(J\<]HP:Z-3"_[X1I6>H7>^W97'-O_@-02P,$%
M  @ X(9X5I"8,U[C @  X0D  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6RMEEUOFS 4AO^*Q:9ID[I@2 A)ER"UJ:KM8EK4:-O%M L'3H)58S/;2;K]
M^ME 64C(5[5<!-N<\_IYX1A[M!'R4:4 &CUEC*NQDVJ=7[NNBE/(B.J('+BY
MLQ R(]ITY=)5N022%$D9<WV,^VY&*'>B43$VE=%(K#2C'*82J566$?G[%IC8
MC!W/>1YXH,M4VP$W&N5D"3/07_.I-#VW5DEH!EQ1P9&$Q=BY\:XG'K8)1<0W
M"ANUU4;6RER(1]OYE(P=;(F 0:RM!#&7-4R ,:MD.'Y5HDX]ITW<;C^KWQ?F
MC9DY43 1[#M-=#IV!@Y*8$%63#^(S4>H# 56+Q9,%?]H4\8&H8/BE=(BJY(-
M049Y>25/U8/82O!Z!Q+\*L$_-Z%;)70+HR598>N.:!*-I-@@::.-FFT4SZ;(
M-FXHMZ]QIJ6Y2TV>CB:"*\%H0C0DZ)8PPF- ,RNGT-LID<!U"IK&A+U#[]%K
MY"*5FE$U<K69W6JX<373;3F3?V"F.X@[J.M=(1_[?DOZY/QTKYGN&L^U<;\V
M[A=ZW0-Z,VTLFWK4Z,L"W5-NC%/"T%0H6M37CYNYTM)4V<\VJZ5VKUW;+KUK
ME9,8QHY96PKD&ISHS2NOCS^T&?]/8HW'T*T?0_>8>C0UJP:D-"_?E%K\>(5R
M(M&:L!6TV2ZUPD++?B#6$>Y@C,W[6&\;.AG60.W5J+W+4,M*1&2E4R'I'TC:
MD$O-8(NEB\O?#O1^8+@;V, .:NS@1=A4J54[<K!'LLMZ+*(!V:\A^R^"-!]^
MI0E/*%^VD?9/DAZ+:)"&-6EXE'0BLLPLSW.J-3RO6D^&-3@'->?@ LZS2G5P
MN@)+XOW O9IN, ]KYN'ES(?K=+B'X>%A$ QQ;X=W/S ,!KWAX "NA_]M7OAR
MX!,U6TF>@=T2V<[M;NV_]O#SF<@EY0HQ6)A,W F-A"S/$V5'B[S8DN="FPV^
M:*;F# ;2!IC["R'T<\?N\O6I+OH+4$L#!!0    ( ."&>%8./&DAMP4  .L6
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5A=;]LV%/TKA#<,+9#$
M(O6=.0829]T"K%O0K.LS;=$V44GT2-I._OTN)46R)8IHB[S$MG)Y>0XO><\1
M9T<AOZHM8QH]%WFI;B9;K7?7TZE:;5E!U978L1+^LQ:RH!I^RLU4[22C636H
MR*?$\Z)I07DYF<^J9X]R/A-[G?.2/4JD]D5!Y<L=R\7Q9H(GKP\^\<U6FP?3
M^6Q'-^R)Z<^[1PF_IFV6C!>L5%R42++US>067R](9 94$?]R=E0GWY&ALA3B
MJ_GQD-U,/(.(Y6RE30H*'P>V8'EN,@&._YJDDW9.,_#T^VOV#Q5Y(+.DBBU$
M_H5G>GLS228H8VNZS_4G<?R#-81"DV\E<E7]1<<FUIN@U5YI432# 4'!R_J3
M/C<+<3( 1R,#2#. ] <$(P/\9H!?$:V15;3NJ:;SF11')$TT9#-?JK6I1@,;
M7IHR/FD)_^4P3L\7HE0BYQG5+$-/&CZ@1EHAL49_[YBD9JT5ND2?G^[1NY_?
MSZ8:)C5#IZMF@KMZ C(R 2;HHRCU5J'?RHQEYPFF@+:%3%XAWQ%GQGNVND(^
MOD#$(\0":/'MP[$#CM^NH%_E\T?R-<M4;A![AL.EF+JVK5*=)+ G,8?U6NWH
MBMU,X#0J)@]L,O_E)QQYO]H8OE&R,[Y!RS=P99]_@HQ4KK:(EAD<F -T@IW9
M,RU]&_LZ952E-)WE,$]2W_=Q,)L>3HD-X_P@C>(T:N/.,(<MYM")^7=60I'R
M"C+-X!AQI4W1#LR)NDX:GJ")<."').ZA'L8%)$D3']M11RWJR+W25$/7UDAM
MJ6R!VG!&@_FQEZ9^Y/5P.J?[P6T3MV1B)YE_A(8"B,%AL?&)AWPB'$?$PSU"
MP\ X3J+HI$!G6),6:^+$^J=0"JVE*%[Q0@^TX4P&TU^. +5$.I&F+=+4W7ST
MEDG$RY4H&'K7K.E[:P-*W[(!O5&R,\[8ZS3+<];GH=0,\FK7F6A2G"UY!*VD
M5QA;6$+BT$_MA<$GPHJ_#61='2M&/-SH2=P_M98HV&!D!!_I\!$GOMN]Z8$Y
MI\:.C;1T@ X?T":MV[^9X!28C_V(A'T"P[C CZ*1GHX[X<5.G9L_TA?HCZNO
M:">%;FPA?-U(6J!< "]PN1L 7S)EQ_^FFMQD.U,+$GK>",M.;K%;;Q=;6FX8
ME *M*9?H0/,],_:,%4N6@:-":T;U7HZ4R)G[NRD&P\-"/-\;)=GI,W8+]!C)
M(Y62PD:$;;KD.=<O5I)#_07Q3?O>PA)VB<,@(LD8_$ZHL5NI*\& W<>>C;;M
MN=I6QP<(K$1Y8%+S9<Y0";M456=L\/0"SF!>>? =A><CQ7PC_6Z68^@:+HE/
M2!KX(\O123UV:[U=E2Y0R;25UU#& R]*">D7<!AW&<0I#I-@!'$G^-BM^'^!
MS<K%2)NPR7P8 \ X[2.TA9(P3@@>\8*X4WKL%-46(J):2[[<:VIVCQ:P@6"A
M2RU%GAMCQ1O=L7-Y4Q?09#NW-8$_YGM))_#$+?#W#%Y#08KX@6<,S@L<K==.
M4(B,K_FJ,F4VAL0BZ$'H00UZM7)#^$$/0SI[0-SV8+2<'V\?;M$=-XJV+44N
M-B\7Z*&$=];J-6 K\HQ):VV;":.SS1<1G"9AW_580T&L_&2L%Y+.5Q#BM*0M
M,;#.-68K6*<Y^=Z-^%;9SBEW1H2XC<B0LKE:XBLK\3I5<K;T5W'?,]G"R)4_
M\KI .C=!W&[" C7C^5[W;V8:L,&W@;6$.<!VKH"X7<&7ZA(.&@$%M:3@#T!0
M"N@%%6X0W+U6&N34=+WQ];:8 Q)'<=1_1;,$PIM^ N_[(S0Z=T#<[N [:+AJ
M,=3K$2+#0#N1Z<FU8<'DIKI-58!N7^KZ.JY]VM[8WE;WE+WG=_AZ4=^[=FGJ
M:^"/%!QXJ5#.UI#2@ZTS0;*^6:U_:+&K+B>70FM15%^WC$*+,P'P_[6 1MC\
M,!.T]]OS_P%02P,$%     @ X(9X5GQC[32M @  0P<  !@   !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6RM56UOTS 0_BM60 @DMKPU63?22&T'8A*#:=7@
M ^*#FUR:,,<NMMMN_YZSDX:V2BN$^)+XY9[GGKNSS\E&R$=5 FCR5#.N1DZI
M]?+*=5560DW5N5@"QYU"R)IJG,J%JY82:&Y!-7,#SXO=FE;<21.[=B?31*PT
MJSC<2:)6=4WE\P28V(P<W]DNW%>+4IL%-TV6= $ST _+.XDSMV/)JQJXJ@0G
M$HJ1,_:OIK&QMP9?*]BHG3$QD<R%>#23FWSD>$80,,BT8:#X6\,4&#-$*.-7
MR^ET+@UP=[QE_V!CQUCF5,%4L&]5KLN1,W1(#@5=,7TO-A^AC2<R?)E@RG[)
MIK&-8H=D*Z5%W8)105WQYD^?VCSL /QC@* %!(> P1% V )"&VBCS(9U335-
M$RDV1!IK9#,#FQN+QF@J;JHXTQ)W*\3I="JX$JS*J8:<S#3^L$1:$5&0J:CQ
M8)2F8FL@GX12Y(P\S*[)ZY=O$E>C<T/A9JVC2>,H..+(#\BMX+I4Y#W/(=\G
M<%%U)SW82I\$)QFO(3LGH?^6!%X0] B:_CW</R$G[#(96K[P"%^7//*E(#<\
M$S60,<\/TMAN?!_/E99XAG_T9;)Q-.AW9.[UE5K2#$8.$BN0:W#25R_\V'O7
MEX7_1+:7DT&7D\$I]O0SMB&&!Z<OR 896Z3I->OTS(\#_W(8723N>C>"/LL@
M\L+AT.LL]^1%G;SHI#QL!'C-.=XS*8%GSP1+PA6C38/)?^+U,P7M4]\01WN:
MHLN+\$#Z2?__F/RXBRX^&=W^P3M6AKBW#&$T#+V#6/HL^\O@[O2C&N3"MFE%
M,K'BNKG?W6KW$HQM SQ8G^ +T33T/S3-\W)+Y:+BBC HD-([O\!,RZ9E-Q,M
MEK;KS87&'FJ');YR((T![A="Z.W$..C>S?0W4$L#!!0    ( ."&>%:%]?*4
MMA,  '<Y 0 8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULM=UK<]K8FH;A
MOZ+R3,WLJ6JWT8'3GB15W08) 3J@$_!1P;+--$;>2$[2_WX$QB8ZH(CDWE^Z
M[9AUO4)+Z&$!>OGP-=[]E3Q&42I\>]ILDX]7CVGZ_,^;FV3U&#V%R>_Q<[3-
M_G(?[Y["-/MU]W"3/.^B\.XPZ&ES([5:G9NG<+V]^O3A\&_V[M.'^"7=K+>1
MO1.2EZ>G</?WG]$F_OKQ2KQZ^P=G_?"8[O_AYM.'Y_ A<J/4?[9WV6\W[\K=
M^BG:)NMX*^RB^X]7?XC_7"K2?L#A%L$Z^II\][.PORN?X_BO_2_ZW<>KUGZ+
MHDVT2O=$F/WO2W0;;39[*=N.?QW1J_>:^X'?__RFJX<[G]V9SV$2W<:;^?HN
M??QXU;L2[J+[\&63.O'7472\0^V]MXHWR>&_PM?7VW:SBJN7)(V?CH.SWY_6
MV]?_A]^..^*[ :)\9H!T'" U'2 ?!\A-!RC' 4K3 >WC@';3 9WC@$[3 =WC
M@&YA@-P^,Z!W'- K5NB>&= _#N@7!DAG)Z[U-G.MXI!S-<3WR2[.MM(_-^1M
MNL7B?,MG-^QMPL7BC)_=6^+;E(O%.3]?Y6W2Q>*L2ZUS0]ZF72S.N](Y-^1M
MXL7BS$O*N2%O4R^6YKYW;LC;Y(O%V5?.W1?I;?:ETNQ+YX:\S;Y4G/VS]T5Z
M?[ 79__L'I/>9E\JSKYT[NY+;[,O%6=?.G=82F^S+QUF_^;U?'<X60["-/ST
M81=_%7;[VV?>_H?#&?<P/CM'KK?[<'#37?;7=38N_70;;Y-XL[X+T^A.<-/L
M?]F9/TV$^%ZX?0RW#U$BK+?9'^+57X_QYB[:)?\M#/_ULD[_%JX%WQT(__C/
M__EPDV9;LO=N5L>J?[Y6E<Y4]>(TW%0,NZT?IMM6Q:!!_2 G3+-$32L&#NL'
M#K1!Q2#U!_=LI%=MHU8_ZC9^>HJ/N[EB]*CY:&&_ 8(1[1ZBG?#'PRXZS&>%
MJ5]@5N_W\07"^4F8U"M_W-VM]\\BPHU@A^N[:WTKW(;/Z^K#9_JS5N.]9OQT
MA>I]:/ZT=WZ/6C]M5A_Q]@^\U>KEZ65S.($,HOOU:EVU4;/FB)4^9K.0'3[9
ML]W'_=/0+Y&@;U?Q4R3\8QHG2=7YQJGGW9?/R6JW?CX\'W6B5;3^$G[>1!60
MV^#$)1A_Z'\<SX(5A'<AT?C@\R^%J^<SJ&?,.-O7VW07;[*_/&1[/HUV45*U
M/?.?@AK?W<7/\=5W>OGSVYK7;K* ?4]9Z3UEI0.OG.'_##?A=A4)8;9YT>IW
M019_$Z26U*I*SE>I<Y#V2[LOGZ[%CMB16]FMOWR?E;4E]XO*?R;/X2KZ>)4]
MCI)H]R6Z^O1?_R%V6O];E:$D-B0QE<2T\LY5%#F_7T=D09W$QB0V*>\*46KW
M^^U>.[\_IF15@\1,$K-(S*YZ$+?[LB**A:-M1I9U*LI*K9:4+^E6W$J6Y4ZK
MU\W?T".WS2>QH.+@[8K];O$>S,FB"Q);0E@NCN3W.)*;Q-%O@OL89GJC6*H5
M+[SSMR0V(+$AB:DDIKUB[7QTR1U%*<07650GL3&)34AL2F(&B9DD9I&836(S
M$G-(S"4QC\1\$@M(;$YB"Q);0E@N=97WU%5J4U=/DI?#*C"^%U:O+XXEK_G[
M\IS]''V+=JMU<OAS<GC1+#Z\7I%4I;%2"H-^J[1 K-V<2U.6Q(8DII*8II2?
M6!;RE2RGD]B8Q";E(ZS7[_<+2T.RHD%B)HE9)&:3V(S$'!)SFYRA/+*B3V(!
MB<U);$%B2PC+Y6'[/0_;_Y8\?%NV5N5B;<5+5ZDD-B"Q(8FI)*:U2P_[=NEA
M/R(KZB0V)K$)B4U)S" QD\0L$K-);$9B#HFY).:1F$]B 8G-26Q!8DL(RT5R
MYSV2.U0D?PUWNW";5J9PIQP"4E^1"F\LW=9NRZ7Y2F)#$E-)3.N4UJ=2KY"N
M9#V=Q,8D-JD\R.1^X1V@*5G3(#&3Q"P2LTEL1F(.B;G-3E,>6=,GL8#$YB2V
M(+$EA.42L?N>B%TZ$>O6I[7%+EV?DMB Q(8DII*8UBT]YJ6>W!$[A0PE:^HD
M-B:Q"8E-2<P@,9/$+!*S26Q&8@Z)N23FD9A/8@&)S4EL06)+",OE<>\]CWN-
M\SC3T]UZM?_,>"Z:JX*W5S[O=]NE=TQK:U^:J"0V)#&5Q+1>>45:"-/R+;J%
M':^36S0FL4G5@:/T"VON:?DN7A?OHT%NEDEB%HG9)#8C,8?$W$8G%(\LZ9-8
M0&)S$EN0V!+"<EG5?\^J_B]G5=UBL5:_=+%(8@,2&Y*82F):O_08%]M2M_AZ
M:_E6W5:K]*:G3F[9F,0F)#8E,8/$3!*S2,PFL1F).23FDIA'8CZ)!20V)[$%
MB2TA+)>L8NL]6O==/FJR]78?K)M->+BB]\*UX)'^_HQ]7?B4YVU]^4OS$M6&
MJ*:BFG;4.C7[=H16U%%MC&H35)NBFH%J)JI9J&:CV@S5'%1S&YS9/+2BCVH!
MJLU1;8%J2TK+Q^=W77]$)#[KEJ?U)2Y=GZ+: -6&J*:BFG;4<@_Y=KO=+68N
M651'M3&J35!MBFH&JIFH9J&:C6HS5'-0S44U#]5\5 M0;8YJ"U1;4EH^G:53
M.M>W"SKT3+O>]SP]Q/%SM$U>DSKZMO^YJF_5GT<R]X:$(O7Z<O%3M_6U+PY:
MM'&06-'7HR,JG<)KJ6K5[5I*Z?I$#=VZ$:KIJ#9&M4G3@VF*EC50S40U"]5L
M5)NAFH-J;M-#R4/+^J@6H-H<U18-SYG+'Y\S\VEU:B8DUG<3^OYMSMR%FD(:
M"_O@2N[_%L+5:O>2Q=GG>/M2O9HL][?I]CIMN?3"+-H["-6&J*:BFH9J(U33
M46V,:I.&Q^44K6J@FHEJ%JK9J#9#-0?5W(9'DH=6]5$M0+4YJBU0;4EI^5 ]
M]0K:=_[_U5"]B^ZCW:ZP2*P,5Z7\)*S75L1>,5QK-^KB<"6U(:JIJ*:AV@C5
M=%0;H]JDX7$Y1:L:J&:BFH5J-JK-4,U!-;?AD>2A57U4"U!MCFH+5%M26CY<
M3XV'Q%_J/+2*MU^B77)\:_3UMW3]>1,)VS@]\UYHN>^-*+9:HM15BA&+=A5"
MM2&JJ:BF';7<RQ=R\:.X:$D=U<:H-CEWP(ERIYB=:.<@5#-1S4(U&]5FJ.:@
MFMOXY.6A=7U4"U!MCFH+5%M26CX]3SV"Q%]J$O2#]*S]1!'9-N(6U0:H-D0U
M%=4TL=P7192[;:G4: @MJZ/:&-4FJ#9%-0/53%2S4,U&M1FJ.:CFHIJ':CZJ
M!:@V1[4%JBTI+9_:ISY&XB\U,LJGMON'.JP,Z(KV.>7^KK?UFW)Q\J*MB5!-
M134-U4:HIJ/:&-4FS0[+*5K40#43U2Q4LU%MAFH.JKG-#B0/+>JC6H!J<U1;
MH-J2TO*!>FI$)#;O1-0H4&M7OF33BUM4&Z#:$-545-/$<E.7MM0J+7O)FCJJ
MC5%M@FI35#-0S40U"]5L5)NAFH-J+JIYJ.:C6H!J<U1;H-J2TO(I?6K!)#;O
MP91/Z?4AH[?1ZG!ES==U^BA$KU^;?K_>9D/6VX?*I"ZW^VGW.JUV2RXN@M&.
M2Z@V1#45U;2CEFL76+J:E:RHH]H8U285AUM'[+44J?0V+]IX"=5,5+-0S4:U
M&:HY%9-_+4OEWF)NTY.2AVZ?CVH!JLU1;8%J2TK+9:)TZITDU?=.^J5,K%O%
MUM>]=!6+:@-4&Z*:BFJ:5&X"T^U*[4[A7#!"J^JH-D:U":I-4<U -1/5+%2S
M46V&:@ZJN:CFH9J/:@&JS5%M@6I+2LMG]JEADU3?L,F)5M'Z.3U=#I2\?$Y6
MN_7AHB!AM__KE_#SIK(UA%1N$21+V=/(0I_VV_I-N#APT19,J*:BFH9J(U33
M46V,:A-4FZ*:@6HFJEFH9J/:#-6<H];YP9G+;7B&\]"M\U$M0+4YJBU0;4EI
M^2B53E%:WUW)VX7;)'Q=XJ[B)-TO>U<OA^MH*]:_P]?UKUKWFK!4[G%R+8H]
M62XE+-I["=6&J*:BFH9J(U3346V,:I.F!^84+6N@FHEJ%JK9J#9#-0?5W*:'
MDH>6]5$M0+4YJBU0;4EI^8P]]822ZGM"9<O539@DZ_OUZKW'\/'[487-.OR\
MWNQ#-8V/+R]7AFJY78K8;TOE3QO7;\K%H8IVA$(U%=4T5!NAFHYJ8U2;-#TP
MIVA9 ]5,5+-0S4:U&:HYJ.8V/90\M*R/:@&JS5%M@6I+2LN'ZJDG5/9C7:@.
MUDD2;U[>\O1^O7NJ#,Y:Y>)W84EM@&I#5%-134.U$:KIJ#9&M0FJ38_:]R\@
M]D2YURHTGS70JB:J617W06SU>Z)8" D;+3M#-0?57%3S&AXD?M.)"-#-FU>4
MO:[:OD75#2LW<$EM8#[(3OV7I/K^2V:4K0+CI/HS1.5F)->BU.[V)+'8"KB^
MRL71A+920C45U314&Z&:CFIC5)N@VA35#%0S4<U"-?O,":(E]WJ%T]P,+>R@
MFMO\;GAH81_5 JG<ENVZJ\C%IL9SM.H"U9:4ED_#4S\EJ;Z?TI_AYO!IW# 5
M!M'J=T$6?Q.DEB16IF.Y-T]?[(E2Z>J3^IH79R/:_ C55%33CEKNZI-V\0I0
MM*2.:F-4FU0<;W*W(_:48NO%*5K70#43U2Q4LROV\+64[=]NOR\7XPSM6(1J
M;L7CIO+$Y*%E?50+4&V.:@M46U):/O).S8BD^F9$Q\A[NY:D6?21S2-N46V
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MCL#Z #HOC,&=X1.,#USV%U!+ P04    " #@AGA6D88<R< (  #L*   &
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M"S4FCIO7 V,A8<8"L6_?%^,-]\%[VYXA'@:"DSA#^2G@L$(_"GB@-"1,:7K
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M0_OAW2"F_0[P"Y5 &U54LP6(C-_G $"VG]:U-UIL[-=I<Z&U6-O+%:-@7#,
M_K\0L,6Z&_."_@/'N_\!4$L#!!0    ( ."&>%9Q.QSI&B8  !-T   8
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M,3TG]KZJD[\-U1;G?YSR:[,F:PL\6I2$>=^T).EKEE&1S*+L2!0&JY0(#-%
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MXRX@CFIR=.9M4\D.MK9CE^;L0HN>>^N>@VN(*G9RJ.40$UE-TDW20!Z\S%%
MV/;&?6TLCXO#>/&SD^1CF!\-F^;'$E 'DZF.2)8TGEB.2"20#5 ,CW\OO+*E
MTQ[9.82D%*=*&L(2L,]N\2OZX9JM066G)F?'HLTI8O4*.,%3=T)4"B;:A6OS
M%1>:YQLX:4R1AVO%;VII:CF,[)P6V:-=^(0BW#KN84_,-K&15U-L^+P()]%M
MW#'9-(5PMY-;<<HT=VC]5I]HO"^Q'4/ 'J54!/D!"5VDH"KU(:B%UC\G /GR
MF74*V2N#BK?2S2V64G616HA5'_>6.^+(<R?8<05][J!&?M^$C<*?X O;K?4
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M)9K6ECFCX;_#"DU*PYI)9Y_*J;B8XCC!+NSM#"$&/)*? D@ZF!$Q5T#WSH?
M+.&B\F59^!WKH46K)R-Z2-$$?1\6;>84.U3T3R%\MSJ:[.3\X3=:U-"DL&A-
MT'D99/1JLR"-H>[&ACLP4%"SN+C66?QLIV&T'ZA$I(&Y&VO.9("'06FE,6AF
M./\H4N1F49WUXQ@B%BN'EZ4<6\$@";JK9#LK*86Z6!:V3&S2-DQM!56&@X?
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M_=9G\;3.+*BQ+8UJ?=SXV/=ZL8BEY6SKNAY;N5>E6_H>KV T+&I)=+>8' 6
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M<!R"3PR%8)&FUO1MPQ5>H&#3)!Q#%\%%VDHU&?>^Y:FE5J)W)IG^\1=W46L
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M3*U4.T^:=J;O)(M@+R_V]&43@A;'[:#[?$$[EO:H!R8&Q4M#X/^9&'W:A5#
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M(#5X$SFI^5 >O*5=27Y^LA!;.N?L"1;6^#93-%Q9H4:QIP!L%F<MV*P!2X^
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M< $\7RCP@+] !LU;8^?_!5!+ P04    " #@AGA63)HCTU $   5"@  &0
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M%N&*HA@L0J6)7B4II?##U@@7!15</'@#2RM=O+/5RF('02R]0T1MT<':1JH
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M,1N,IBU%M)ND7:JUM#Y9=QNE7QFL=-')'H24DRQS^:!V5BFIQTJRD>P*#V!
M/N>W<[QMM[P9WU#+6PJ$/),JUOK=^@IG1U@T.FL 5(<WZG.$?VE094V5T-+C
M!BY)?#]K""UH^STV,?UC3,)G84MM97=@\.DT^9>P[1ARU[GDV/3S0PW I7Q
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M\X=3N9G58Z'K=:VYK>6%N[1VMMX\"CE4;O29R$[#4U95J0 K8H(, 7?RC_#
MRE"!V$& 2>8:@X#,5-F#)2GM^>3Z#-F5$7N0@.64CG$L2+7Z.T(H-Q.Y;CR+
M"+6M 6.R8U!$?ZT<%":E)]:T0AZ*2;KG]1DU^.9+G-S'*-R*$2/!1#]2#FF<
MR<Y$B/ID$GM@!-BP 8!DLV+;:>I#'61E@_ 3ZSN\X,-"?_W+XZJL3M!-?@[\
MN41 3#9I^AL6;+<(D^\D3P[<NIU&\2;2E35/G0WY%K[36E)$U<YR:]Z*D[AV
M,79*^$EUO=-Q0KT54C"0+!2^$DA!LQ#U]NYR%.><.(\$*@[XOA:M"*Q065/?
MO9 JCK-S*ZL=(]S:90M38W.^+R'6Y9O5(LW::(JL4EM)LO91H7$@8L_VAO5
M^NV=?*ZV^I9\"%;J_?&X \)>Z6(]UZANE4^=:E_ZQG)M./F'L:ZO"JU1>N..
M;2;7D^6F\ :4N(<)ZC]V0[\T:!IW]JQV49U#:4X7/77 DXOW;O()<%/7O@=R
M'X2;!O/E/ @92HT&>+ 83)>^IK_XB]N!!6#>8AP"1\SG'2PWF7')R5 NO'@E
M1F?B*VAB;1(Y\PIGP6*QD#&C^V$=J %[ST8+YF8Z!:!DSI;!?#X.YL-9+6Y;
M?V=)38/)!--")]@$I"#8 [4(%L-)L "\_[;C<W>2ULJ4/:W,[I4FW4FS5#C
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M3^GCE Z9&OB1WO')=4\))C<QJZQUQ:MS:[%U;ZF^C.:Q%Z^8Y=GC^D%;K&/
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M)[VP0\+GJBW8$2]H41,*'S!O^<PSC\S1DMVZ,M1*N%EMT04=.%]!2XM"%\'
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M8-)CB*.4W,#J'5MM:M::0&=H1.'JN,&P8A>:.8^Z-4=M]%+[+G3,9\WFWX@
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M;+BA#5^\J?A6-#;>FX(?,R5396D!WB\,#A;-%S+079.?_@]02P,$%     @
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M2?4#8";%1>&(Q$Z!BD?0MX5R1>2,G6 837 ->MJ2W=YF(+QF,V+.47(:LZ?
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MA\$> BITW<JZ0$!'085*)(AR N0[VK_6FRH)$%R@BQX>("VE? 6+#KQN6(=
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M?#S=*%J.6F97CCNNCI+UK5FPO_^ZEC*4 [SQAQ>QAA:2<?*IV)3P[7!/)!+
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M/BZS,OVR*=@9,DK4T%NR=K"=;WGY 2Y7,DE.F+_4C'!(^7UH>FF9R-5J1NN
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M5*"5?MQ$("EAR9!:\?I@$C2.6^PX@Z[ZBGN$D/4S82O,3_ 5[-9Z@5@ N7
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M\V_+F?9%RZP.][;.%;!"792M\>,/ZH$O/(JF1+N'WQ04E\$0 9<50^4@\8<
MT#XT-K/E4#:>9N$X.0S'R+X%]N-6"!WMN0-KV!1\&.XTM+E\K+#7L-J)K"6Q
M:7_&G?.9>^EA3K5ATQ7.B4IW;?W!'- H20(>1>P(D0"'>&@<GCY9V!GY'#%T
MHT=&7&,[+)<V+5N+%]?.B0#=B<-:(:%QQ&+LC9TFWW&G?N.\TST#M:FK;>CD
MN.5\W;S>H0WG<!!X+)FR/UQ#"A<[M64T9Q$MX!-)\DTAH<'$ \@]]=F2/U_5
M%Q=K\0Q=C0X58Z1K@>4;SG2229?9^F7?L2FL)M\@Z>RUW9*3<+2#0QK/\M&9
M6USK&^P8D*]UG8*1BO>J#UPJW/*7"D6WQ0ZE2E/90\3QY6?_X"KU;_9:OCYC
M10"-^]FM4"K/!^>REG68:MK+ SY+GSYYFCZ;7B9/TXNKBW1R^?3A)1QE7UP]
M2Z\NGY*Z/.>O[KCX[&?+,0?X1"(BT^?)T\OT_/S\:&[;M_U/CS?KOS>YB;]Q
MTC6VCRJ&3UXM^98O%B4V,%;HWY1G'T5#3!L9G[T[=MR*]V^O;U_ZJ$BG2W,\
M!>_/FL*-O^&!4LVZWR_%\A-V-+QE"J4=%B+<GOUSS8,@?%^%:](\,''#U_LY
M>=@R+E#()F?H'":BCEHT=/CMG2.W._79KEOOU+,XA^'0&!\A0<8%1ID<(QK?
M+3@]WN#W _K!Q^GC8UY$)77P33N39ZF_7476]>W/R8_-*7]Z<H:O84+D;L6U
MSVFBR[CO-)1I"T^FNY$95EL2<X,#7?%KMN3/O86"OY;K$YKY"91-$*OAQG?_
M#0-A':<$D>;JG,O:J7,6_3S-I@V^N,@_9K\-X5 9"^^D;<T*ARVPX &(_IN:
M!!F[S8R2^K5^7OCJ+C2G'A7<4>N($0^KG<]!3AMN"KYO"AIZ4=:<C9/O$7"R
M=?)4OXA.NY1963WP-+D]%J'"XW;?4Y+<O5?:8;L8WQAJ*H256].W#1=+X @V
MQ,;QER+X*AW%FHP+N><FTU8B/XPR_>Y)]]4( > J/.CPH*W>YG-X.U7[1P)I
M.U$9%5$\_T*^"T!EFD@I^YT$UE_A*DEQP^RWG' [=SBQ*1)0SA3LHC!&^'C9
M!=]'P>%Q)K8H6A>'L-7BD$23(E('&'&Z=8&9KW;L@?^:B;B$QWD^F&XG6:H@
M?10[9H2,?08E+A)(=T:?<1 N-%A1!WS"@.T]OY\*MDESCL U'N  WD-0AIAP
M"1,Z_@D?WPX7(N!"$CL5838V;+/D7F<97B\9TGT<Q!'MZ,[TEGP^64[OL@"N
M LL7*\B8#UL#LYNZ1QD)OHJ'J%N>]!U/J&W9KK7E+1P"ZN)I/.S%33T)271
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M*O0$^+[D7.T[VD#W/)_^#5!+ P04    " #@AGA6)AUV(!P$  !U"0  &0
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M0&EB+1M=+1O*6O[$GWBZ/E+ RJ&]"QBI.5#-A6JTU7;K4MLO7>0*?:C&H%J
MTL3Z[D)<71EK7?^Z7CYL#G4)AZF*+)F1/X_G[[=JMG?M0V/95A->Q.LOL<9<
MR6+&V)P8MK@<A4[.@VH^5&-0+4!I8F5WB:I^(E(-$[Y?UV_J(Z\1)ZNJY#<'
M:?_<.=U$6N?0O!6J.:VVNZ=E[]?XR44H=$X>5/.A&H-J 4H3R[O+3G5U@N?E
M65%4Y9Q%G,\*\IAG2U)(2EY:U*/#JM"U^DNLC3OU''K7JV2U]==^S1XN9I@3
M<S36]RMW=/@$;M4+'FQ-'"Y8[]/I$WU_0QB:4T*U *6)]=9%E?J)K++=J8O"
M8D':%<B?,:'I)%1SH)H+U6BKG7.00K:D_" %-/.#:D&K[;;Y>&Q:H^[6BI7:
M!7JZ.M&3/3/&:5S&84)6ZX<DCJKGR$>>Q^E<6K_0? ^J.5#-A6I4EV1\^DCR
MJN)!U^M#-0;5 I0F=D*7]^GJP*\^CDSX'^OXJ=HP2$OYTS4T\H-J#E1SH1K5
M#V._@SH_N8@/G1.#:@%*$XNWB_)T=99WMZA/%Z^>N85+3:IG[2A>)?S-[F_O
MRS"=A7GU9/]E-0O+^H^S;%6'@+^7^9J3QS IN/3<<O4<>E<_- N$:BY4HR<>
MN_I>E^X=(B?A0S4&U0*4)EYAU"6(QHD$\2\W3WT*5'V"KJQKU"OOVS50S8%J
M+E2C)QZT($SKDW+UYJ1<PY U$'0^/E1C4"U :6(#=1FFH<XP%0U"?G>_E?5E
MP0\))VZZ7O+-F>O2%QCU:GJW"C3DA&HN5*,G'IYU\78>AJMWW<.T?90V#Y*A
M5;+QGM?IAK21D+/UH1J#:@%*$QNI"U -=8#*/GZ0]@4T.X5J#E1SH1J%:AY4
M\Z$:@VH!2A.[H(M9C5=RL:P!S66AF@/57*A&H9H'U7RHQJ!:@-+$ONI"7D,=
M\K[T] 4UV[M-K,,@2I,<^72@JW6A&H5J'E3SH1J#:@%*$SN@RX$-=0Z,.<U!
MO9+>_7"8X([V.P%ZY2Q4HU#-@VH^5&-0+4!I8B=T";6A3JA94:S#-!*ZX7C!
M0U-JXS#+U#7;-O?/1'"@JW6A&I7<B.EDI&GV7N]ZT-7Z4(U!M0"EB17=)=G&
MWYIDJ_7>-3Z1U+A\*P>:4D,U"M4\J.9#-0;5 I0F=D*79!OJ)/O#$\_#),G*
M9H_XP]%W1E SO4L>FF9#-1>J4:CF034?JC&H%J TL2VZC-RP7\EA)6A.#M4<
MJ.9"-0K5/*CF0S4&U0*4)KZS81>?F^HD]J6'E<S#RT=-V7G5ZM7W;0"HYD(U
M"M4\J.9#-0;5 I0F-D 7?YOJ?!5S5*E=B>(XT)UZ'KT[ 9IH0S4*U3RHYD,U
M!M4"E"9V0I=?F^K\^B_N@[>ZL-<L.RGZ3CV-WHT C;"A&H5J'E3SH1J#:@%*
M$QMAY^V>U5<*?VBKO'E3>&%_7%KWV'=MQKYM,_9]F[%OW(Q]YV;L6S=CW[L9
M^^;-?T<.;78YM&F]CAUQ$QI<0S4'JKE0C4(U#ZKY4(U!M0"EB7W5I=NF.MUN
MKF"*?P1[45:4;TC*Y:\XLJN!M;$^.=C2@E[4#-5<J$:AF@?5?*C&H%J TL2B
M[X)L$QADFX>IK:W9YM0\*'OHE=10S85J%*IY4,V':@RJ!2A-+/LN[3;5:7?S
MAMI.OIX3AS_Q)%LU6T=WZH\&4)N]MX>@5VM#-1>J4:CF034?JC&H%J TL4>Z
M'-R<OI+]#&B0#M4<J.9"-0K5/*CF0S4&U0*4)O95%Z2;Z@N6S__\)374NS&@
M23A4<Z$:/?$ ?/ZOM/ZA@3=48U M0&GBIX]U@;>E#KS/_B@FM=.W_*&: ]5<
MJ$9/W/_W?'5!=$WQ<4S0Z?A0C4&U *6)K=!%WY8Z^FYV0V[CK.31(LV2;/[]
M#6%I=$'^W'R<S^<%S\,57Y=Q5&S^(NT3Z'7?4,V!:BY4HU#-@VH^5&-0+4!I
M8M-T*;EEO([]$@MZW3A4<Z":"]4H5/.@F@_5&%0+4)K85UWH;IT(W9]3GA>+
M>%6?=155W1+..7GX3E9A?B1X5X.]&P0:O$,U%ZI1J.9!-;_5[)UC_-J%;9K:
MSM?>6]DRZ P"E":VP<ZG(RMCQNOWTH]GE/2&M".@D3E4<Z":"]4H5/.@FM]J
M8D=HX\E^$T"S<)0F-D&7A5OJ+%RQ8_*BZ$2]NMY] 4W5H9H+U2A4\Z":#]48
M5 M0FM@^7:INC5_)+@KTTG*HYD U%ZI1J.9!-1^J,:@6H#2QK[K8WE+']B_8
M18%F]E#-@6HN5*-0S8-J/E1CK59_CN%V^VYO!R= K5$L^RZ)M]17I#N>0SXN
MPGQ9K:(^%APFQ<D-+FBF#M4<J.9"-0K5/*CF0S4&U0*4)G9(EZE;K^3B= L:
MR4,U!ZJY4(U"-0^J^5"-0;4 I0E]->JR^M&)K/CL<U744-_&@&H.5'.A&CWQ
M #BNK/ZA4_"A&H-J 4H3Z[\+Z$?J@/[L<U743N_RAV;P4,V%:O3$_7^SRKN/
M*=!M:2] <W>HQJ!:@-(VO3 L%IR758&'UY=+GL_Y'4^J_8KF/>ZO!G4:O_TM
MR?EC_2$Z[VZ,P?#@]U1_Y^GU[X<=<WVYJG;-WX?Y/*XVJA+^6)':Q60T('D\
M7VQ_*+-5M><U( ]966;+YML%#V<\KQ>H_OZ89>6/'^H5/&?YUV;:U_\'4$L#
M!!0    ( ."&>%;EA\(A? ,  .D-   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;,U7VV[;.!#]%4(%BEV@C6Z^9FT#MI.B 7HQ8K1]6.P#0XUM(A2I
M)2D[_?N2E*Q(L6QLL0):/UB\S!S-.>10P\E!R$>U ]#H*65<3;V=UMFU[RNR
M@Q2K*Y$!-S,;(5.L35=N?95)P(ES2ID?!<' 3S'EWFSBQE9R-A&Y9I3#2B*5
MIRF6WQ? Q&'JA=YQX)YN=]H.^+-)AK>P!OTE6TG3\RN4A*; %14<2=A,O7EX
MO0R=@[/X2N&@:FUDJ3P(\6@[=\G4"VQ$P(!H"X'-8P]+8,PBF3C^+4&]ZIW6
ML=X^HK]SY V9!ZQ@*=@WFNC=U!MY*($-SIF^%X?W4!+J6SPBF'+_Z%#:!AXB
MN=(B+9U-!"GEQ1,_E4+4',+!&8>H=(A>.O3..,2E0^R(%I$Y6C=8X]E$B@.2
MUMJ@V8;3QGD;-I3;95QK:6:I\=.S3UCG$I#8H$6NS)Q2"/,$K8M5M>-KNN5T
M0PGF&LT)$3G7E&_12C!**"CTMFX\-Y,)9;E=&[3>86D,;I\(RQ-(T$:*%"TQ
M(SG#;@V-P\W1^(,PKUZ!++S0'S>@,67J3X.O',[$UX:OC=HG);=%P2TZPRV,
MT$?!]<Z$P,W[FP"^$:I2*SJJM8@N(MX N4)Q^ 9%012U!+3\[^[AA7#B:O%B
MA]<[@U<*?*=4CA\8H#PSHMX^@214N35=:T$>T>?,JMTJX$5\>X1<JPP3F'KF
MC% @]^#-7K\*!\%?;>0[ FM(T:NDZ#GT^(P4S8T'))=4T]/-)](LU]7FN\62
MF[U<WW=_?S# Z$Y#JOYI$ZS7I6 =@34$ZU>"]2_NG89@ZEDP: A&FH+!4;#,
M".;2\@W"J3T2VK0J NB[ .SG9#\;]'O]032:^/NZ#*=V_>%X&([ZE5V#X:!B
M./A_V?$-2VE.M=;$N C]L^O<$5A#A6&EPO"W2(QAEX)U!-80;%0)-OK5B3$Z
MV?##\6!<V^^%"J=F81R:W[ ]+\85P?%%@E_X'I0V1.[-0U)BF\6'8G[ ,FE-
MAXN(/[NZ'8$UR(?!<\$3_!8)48;1D69=H35%JU6)X:].BLL1M#-$K5*%I]^3
M41S'+[+&KQ7-*<BMNTLHY K<HB*L1JO[RMQ5Z2_&%_8>XXKQ9YCB$O01RRWE
M"C'8&,C@:FABDL6]HNAHD;G2_$%H4^B[YL[<Q4!: S._$4(?._8%U>UN]@-0
M2P,$%     @ X(9X5APOTHKF"   FVP  !D   !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&ULM=U=<Z-&%@;@O]*EW4HE55D+&GUZ;56-Q3=Q9<JSDURD]@)+
M;8L:! JT[)E_GT9@H0;<$I,WN<A(,N=I9/$:T1R)F]<T^Y)O&./DZS9.\MO!
MAO/=]7"8KS9L&^97Z8XEXB=/:;8-N;B;/0_S7<;"]:%H&P^IIDV&VS!*!HN;
MPV,?L\5-NN=QE+"/&<GWVVV8?;MC<?IZ.] ';P\\1,\;7CPP7-SLPF?VB?'/
MNX^9N#<\*NMHRY(\2A.2L:?;P0?].C",HN"PQ&\1>\U/;I/BJ3RFZ9?BCK>^
M'6C%&K&8K7A!A.*?%[9D<5Q(8CW^K-#!<<RB\/3VFVX?GKQX,H]ASI9I_'NT
MYIO;P6Q UNPIW,?\(7UU6?6$QH6W2N/\\'_R6BX[I0.RVN<\W5;%8@VV45+^
M&WZM?A$G!?KHG0):%=!FP?B= J,J,"X=8505C"XM&%<%XV;!Y)V"254PN72$
M:54PO;1@5A7,+BV85P7S2PMT[>V5TRXN.;[8Y497;B6'3<P,>;BXR=)7DA7+
M"Z^X<=A.#_5BRXJ2(E*?>"9^&HDZOGA@<<C9FGP,,_Z-_"\+DSP\;.PY^0_Y
ML%Y'Q>TP)EY2QK>(P8\FXV$4YS^)13Y_,LF/__[I9LC%RA3D<%4-O"P'IN\,
MK)/[-.&;G%C)FJT[ZNTS]50!#,5OX?BKH&^_BCNJ%#^QW14QM)\)U:C>]834
MY?=A)LKU0SGM*#?5Y1]VF7)TZ_+1N\IM=;G)5LJ5=RXO[QK=O;Q<ZRCWSOSJ
M]L]71'M_Y?V+7W=]UE$>7#!ZN?+-<FDS-(Z)- Z>T3>1Y(]?Q*+$XVR;_[]C
M/>]*=]3M%OOFZWP7KMCM0.Q\<Y:]L,'BAW_I$^V_71L[$C.1F(7$;"3F(#$7
MB7E(S$=B 0B3HC8Z1FVDTA?+-'EA&8\>8T:2E#,2Y?F^<V=TIX3Z9@N)F4C,
M0F(V$G-*;'+ BN.$EX6N:YI.IZ.;X<MI;I"C>DC,1V(!")-R,S[F9GQ!;@Y'
M5;LL6K&NP(Q;K]=$?J&6RC'ZI@")64C,1F(.$G.1F(?$?"06@# I*9-C4B;*
MI/P>9N(-',\)3\ENGZTVXNB?Y)M0C$32)[)*MUL1(G&<M_K2%2(EWG>O@\1,
M)&8A,;O$QB=_>*;SR7PVEO_Z..W%=$,7_TT;NQ/DNGE(S$=B 0B30C(]AF1Z
M64C85Y:M(I&0PU[E9[)C61F6KFQ,S^Y@E*/VW>"1F(7$;"3F(#$7B7DE-CM]
MO:]H(]4^<L0 A$F9F!TS,5-FXCZ_(N:^B$77MJ^L[;M?0&(F$K.0F(W$'"3F
M(C$/B?E(+ !A4ISFQSC-_Z%)M3DR:DC,1&(6$K.1F(/$7"3F(3$?B04@3(J:
MKM6GE+1STP/Y/N91\DP*7+R5R[N2I5;Z1@NJF5#-@FHV5',J[?1]]&PVGS=G
MU:"#>E#-AVH!2I/#<W(^5E>')\PW9!=&:_*49L?\B".B]"7J/E%ZIQ9[!PFI
MF5#-@FHV5',J[31(QF@\T9I!0@[J034?J@4H30X2K8-$E4'Z=5>V,7S?S)L:
M[YTII&9"-0NJV5#-J;3363IJS">MG1-R4 ^J^5 M0&ERINK6!%UY.K9'IL0B
M/(S)4QAEY"6,]YU3>.K1>H<,VK( U2RH9D,UI]).=USCT<AHA0S:D #5?*@6
MH#0Y9'53@J[N2KC/KLAOD0A19V2@C0A0S81J%E2SH9H#U5RHYD$U'ZH%*$U.
M5MVVH(__H5E '7E&>@G53*AF034;JCE0S85J'E3SH5J TN38U3T0NKH)XM+Y
M0&BW U0SH9H%U>Q*DR8>)G.M,?'@Z.V.A]&TN90+734/JOE0+4!I<BCJG@==
MW?3P/?-\R+/;2ZAF0C4+JMEZNU5$G\_'K8"T%Z-&<RD7NFH>5/.A6H#2Y(#4
M#1"ZN@/B;\[?05LD*DV:AZ*-=B,3.J0%U>R.)S 2^XAF MI+Z;/6/ "T70&J
M^5 M0&ER .J6!5UYFA8^V0;M9(!J)E2SH)I=:;HN[3ZNYLV&TFJYYB<4FNF!
M=B! -1^J!2A-_BQGW81 U4T(#ZSX0/GI,8>XP7G<_=9*C?4-!VV?4]=I\YV$
M"1W3@FHV5'.@F@O5/*CF0[4 I<D1JEL1Z)E6A,L_'J>6>N<'VH) VR?FQYK6
M_,ML00>UH9H#U5RHYD$U'ZH%*$T.4-V"0-4M"%6 V+K'@0MMG_*>C<>-3Z4L
MU0/W3@BTH0"JV5#-@6HN5/.@F@_5 I0F!ZGN.Z#JOH-+/G!*VZ>QFQ\(4H_2
M.S70#@&H9D,U!ZJY4,V#:CY4"U":G)JZD8"J&PG^YH=/*UV:,Z+363-3T!8"
MJ&9!-1NJ.5#-A6H>5/.A6H#2Y$S5+014_=4'W_=957K^VQ#4X_;.$;0G *K9
M4,V!:BY4\Z":#]4"E";GJ.X)H&=Z JQ?.X,"[0& :B94LZ":#=4<J.9"-0^J
M^5 M0&ERINJ6 EJ>D<6WMU%H9P%4,Z&:!=5LJ.9 -1>J>5#-AVH!2I-C5S<J
M4'6C0I]I<FA7 E0SH9I5:5(SC=Z:=+>A@SI0S85J'E3SH5J TN0 U8T.5-WH
M\%W3Y//6Y(0Q*;Y[5CZH@G8I0#4+JME0S8%J+E3SH)H/U0*4)G]Q<-WS8)S]
MXH6ST^1&NS>A.16A'J5O:J":!=5LJ.9 -1>J>5#-AVH!2I-34[<Y&.HVA\])
MSE;[3.Q^UNRQ\^NVU$#?MVU0S81J%E2SH9H#U5RHYD$UWVAWK-!QZ\US<'8Q
M.1!UVX*A;EOP$L[$6G*2A;Q['P+]<@2H9D(U"ZK94,V!:BY4\Z":7VG%-_,<
MM_16&)3+R$DXN12#NN_@@>W";UN6\.*09']^/X&] @/V$@S8:S!@+\* O0I#
MNQ'$F#2_UK=S(<.0E_*@*^9#M0"EE=$8GEQ":,NRY\-5KG)Q&+Y/>'GMDN.C
MQRMI?3A</ZKQ^%*_MO2.QVW]VBTO653SY66[[L/L.4IR$K,G,91V-14']5EY
M):SR#D]WAPL8/::<I]O#S0T+URPK%A _?TI3_G:G&.!X/;+%7U!+ P04
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M@KEL9M4M6M&.ZFA'VFB/GWYX:]1:N;Y1EV*C9M03Q_$G9U$/Y+,%R*L!>5I
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M-%BEW7"%?10H:X#O4XD5M9K8#>K.+/H-4$L#!!0    ( ."&>%9Y"<".PPT
M /F:   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;.V=6W/;N!F&_PI&
M/65GO)9XE)0ZGDE,@$RGZ7@VW>Y%IQ>T!%N<\* E*7O=Z8\O2-&"0,*0V+R^
MZUYL+(G? Y!\A</[0>#54U%^JS:<U^2W+,VK#Y--76_?3Z?5:L.SN+HLMCP7
MG]P791;7XF7Y,*VV)8_7;5"63NW9S)]F<9)/KJ_:]V[+ZZMB5Z=)SF]+4NVR
M+"Z?/_&T>/HPL28O;_R4/&SJYHWI]=4V?N!?>?WS]K84KZ8'RCK)>%XE14Y*
M?O]A\M%Z'_E.$] >\8^$/U5'?Y/F5.Z*XEOSXO/ZPV36U(BG?%4WB%C\\\AO
M>)HV)%&/7SOHY%!F$WC\]PN=M2<O3N8NKOA-D?Z2K.O-A\EB0M;\/MZE]4_%
M4\2[$_(:WJI(J_;_Y&E_['P^(:M=51=9%RQJD"7Y_M_XM^Y"' 4(CC[ [@+L
M<P.<+L Y-\#M MQ^@/]*@-<%>+V Q>R5 +\+\,\-F'<!\WZ5W%<"%EW HKV[
M^]O1WLL@KN/KJ[)X(F5SM* U?[2":*/%+4SR1KM?ZU)\FHBX^OJFR!]Y62=W
M*2=_*VI>D=OX.6Y>_4@^KM=)([ X)9_S_=>DD=N[@-=QDE8_B$-^_AJ0=[__
MX6I:B[HTQ.FJ*_?3OES[E7(M\J7(ZTU%:+[F:TU\8(Z?GXJG)\JW#8"IN(B'
M*VF_7,E/MI'XE6\OB3.[(/;,MC05NC&'_V67BG"K";>6NNOQ?>'4'![PU4NX
M;6O"V?GANG,/SP^?:<(C<_C'W<,EF6DKK]Q)Y_"=<%J>\]J=W!1E_>/?>9F1
M@-_5Y)]_%0>0SS7/JG_IE+ZGN7I:T_F\K[;QBG^8B-ZEXN4CGUS_\7>6/_NS
M3B5(6("$422,(6$A$A:!8(KRW(/R7!/]^K9,\E6R%0UNG!6[O-:IS4@8JS8D
M+$#"*!+&]C"_A36CN<?KQ<R:B?^NIH_'0D(6&H%@BI"\@Y \HY"^Q/6N3.IG
MLHYKKE.1,7RLBLQU.;3NK_4. ;(R% EC2%B(A$4@F*(N_Z N_T0S5:PX7U?D
MOBPRLCH:0JY%?ZF3FY$W5FY(6("$422,[6'>4:,U=_SEL-%"%AJ!8(JLY@=9
MS8VR^IS77%!KPG\34_-*VVX9"6.%A(0%2!B=#SHL?^G/U1O/Y@.!+.RYYRQ[
M^D!6+ +!%'TL#OI8G.A(Q&!\G52KUX9&QO"QXD#" B2,(F%L,1"1X\PT0R-D
MH1$(IJAH>5#1TJBBCYF8W27_WGL9Q7W;91E59<2-5142%B!A% ECRT'[Y2W]
MI>?T1(4L,P+!%%%9,^FCS8RR^B4NRS@72N+5JDRVC;JTKIB1,E9-4%H I5$H
MC?TOM,]Y,S;-.Y?\*:DWA,>K3?.EKS>\G8V0@?]YT7YV4V3;.'\F257M^'H?
MMBG2-2_)T_Y&5^3= =+=^^H'4A<D7OVZ2TI.8NF>5IM85*HI=U5DF:A+51>K
M;R_UZ,JZ)/2H%/%9K*\A*?F*)X^B5O%+79IBM[MRM8DK+I!Q3?)==K>GO%)V
M7 FEBN%6)B[DFMP]DVR7ULDV?4[RA[96DD#%^8B9)$OR.%\U'W_=(Y\VB:BO
M^+.]2JUGO-L6>3<?J+KFM6'MS^E/U?!<1,'>[ \71%0YSL6XCY>K1)S#MDQ6
MG/!?=^+BB7-K&$?4_:=;4;OVY,BN$J>0Y/W##I=7+?.2Z.9F;Z.O&4)?L[?4
MU["&_]?7&^@K0K6&:N]TE.6QC+W3<27S-LU3[.JJCO.UN.#:?LK(&]U/(6D!
ME$:A--;1CD<^_9$TM, (15.%94MAV2.L(+[_*M^_?)6URC("1RL+20N@- JE
ML8YV/%/S9KJ9&K38"$53]253<98QW[*?\\M&]X(49?*0-)U>,V^[,.1)S.#1
M.H/FY: T"J6QCG:L,]O5R0R:=4/15)G)O)ME3KRU0XX7)UN[GN!31SB^+I8S
M]VQ[H5Z8&W-1HZ4"S:I!:0Q*"Z&T"$53!27S;Y8YZ773'TZ^$P/(=9&F<5G)
MH:5^X8PW-'_[$D.FD@(HC4)I#$H+H;0(15,E)I-PECD+%\9"4N_2HA+SPJ*9
MW-1BQ+5+JDW&Q92M<S:U H-FXZ"T $JC4!KK:,=?S!]MQ[:7;M_7A)8;H6BJ
MSF16SC*GY6ZZ>?U^5MY.P0\3::&R%[_BHINW:Q4W3%7Y"]]=+/OM&C0C!Z51
M*(U!:2&4%J%HJMYDEL\RI_E>W*Z>77,ANTVMQ!:G>TUH2@]*HU :@])"*"WJ
M:(OC&W5I>X=[I:I&9O4L<UKO)HVKZK@].LA'/YJ'9O6@M !*HU :ZVC'+;GK
MS=Q^_P=-[*%HZK)NF=FSS9F]UB5_495.2^;XL5J"T@(HC4)I#$H+H;0(15,U
M)_UZ>V_;HI:@VU"['DH+H#0*I3$H+832(A1-E:!T]NU3SO[IM>AFQ&C90;U\
M*(U":0Q*"SN:,O3U?+]GV$:H0E4]22??-COYMV(TQO,Z?FAGC::4KCKNU^H.
MZNU#:0&41J$T!J6%'4U9Y340W5OX^K;T]6VSK]^NH#&.W9"F\PV4%D!I%$IC
M4%H(I44HFJHY:?W;'G;L!OTM#I060&D42F-06@BE12B:*D&9&K!/_4#GC+$;
M- L I050&H72F#W, CCVS.T/MT)HJ1&*I@I*Y@!L<PX .GB#_H8'2@N@- JE
M,7OXHZ#^<"N$EABA:*KH9"+ -B<"FJT,R&U99$)O1?G<KJ[4"@KZNQ\H+8#2
M*)3&H+002HM0-%5Z,IM@+[%C.&@Z 4H+H#0*I3$H+832(A1-W8-$IAT<<]KA
MG#&<&3%6=AWMN(/1;)(0G'<8A=:-06DAE!:A:*I09*[ ,:_M/_QLNGQEKP=S
M_&B5=!M*S8[N_^QRMNBKY*S#*+1N#$H+H;0(15-5(NU\9\Q"_7/V;# #1\MF
M:%)KEZ\'T&(IE,:@M!!*BU T55]'>V:-L?=UOZC2:@R[=Y:C:W-\KZ^PLPZC
MT+HQ*"V$TB(4396.-.D=LTE_SKX?9L1HH4!]>BB-=K3C%3:])I)UAR@)OUEO
M=Y 06JL(15,E(CUUY]0>4D>;-) X7Y/'.-VU30W/[OAZS==DNZO)/6\VOM(K
M"&JS0VF!,USR;VE&U%#['$H+H;0(15/5)NUSQVR?G]QHQAP_6DM0[QQ*H\YP
M%ZI!:W3RD!!:IPA%4]4AO7#'[(6/WD#&S!NM%JCA#:519[C.?Z"6X2&.-= +
MU,9&T52]2!O;.65CV[-S;&PS9K1,H#8VE$:A- :EA5!:A**ITI,VMH.UL1VH
MC0VE!5 :A=(8E!9":1&*IFYH+&UL]_MM;#-BK.R@M !*HU :@])"=^CK^QIC
M/T*5J@I*VMVNV>X^N;6Q.7ZTFJ!KX:$T"J4Q*"T\>1>?#WM"ZQXX$*%JHZI,
MVN6NV2X_F50QQX]6&73I.Y1&H30&I84=K9]E\OM-UEMXXZ[TQMVW\,;-T-$*
M@RYRA](HE,:@M-#5)@OF7E]A;_+8B*/G1GR_A6Y&C-83U$*'TBB4QMRA(6_/
MG;X"0G=HREN69SM]H;R%D>Y*(]T=8:1K50*UR:&T $JC'<UD5IT^)(36*4+1
M5'5(X]LU&]^CK4TS;[1:H$8XE$;=TT:XYI"%X_>7O(30>D4HFJH8:8:[9C/\
M2Y(GV2XC#V5156(L8]H-DI2\W;IV3>Z+LK=L_+5%*.;B1PL,ZIU#:11*8U!:
MZ.J6GFL6[T2H8E4U2JO=-5OMZD#[L6AVQ"+;XHF7S?,LA53%R]4FSO>?"P76
M99%J90?UXJ&T $JC4!J#TL*.UAM[#X;>;^&QN])C=\T;SPR7)JQYF3S&S3-9
M29K$=TG:M()QW4[\VI_.Y"O^NGL%M>"AM !*HU :@])"=_@ "\L9+LF(4*6J
M#WF3YKIWQM8TO=0B^0_YB:="76MR&Y?ULTYD9NQ8D4%I 91&H30&I8506H2B
MJ5*4MKR'W;'&@[KT4%H I5$HC4%I(906H6BJ!*5G[WW_CC5FQ&C906U[*(U"
M:0Q*"[WA7O:6+M6(*E45E/3M/;-OW^X><L;*'3-FM*B@3CV41J$T!J6%4%J$
MHJG2DX:^YV*[4ZBY#Z4%4!J%TAB4%D)I$8JF2O#H$=+F5,%9W2GV.=+0; &4
M1J$TY@T7_,^=I>8I&]!B(Q1-591,+WCF],+)117F^-%R@J83H#0*I;&.=F(9
M1 @M-$+15#')S(,W9DN:<Q=5F*&C%0;-)T!I%$IC'>W$,H@06FB$HJD*D]D$
MSYQ-.&=1A1DQ6D_01 &41J$TY@VWZ[>6RYG;?WBYYKC!)/$M_']/^O\>^'G2
M9MYHR4 =?BB->D,7O9\S]X;[R7N6,W,&#0MT33R*IDC&E[:];[;MP2DC<VEC
M!06E!5 :A=)81U,6=BWL898GA!8;H6BJ^*11[Y__*-BM]+;V3X6M"U)VR:-M
M+ [2/\['7,)HP4&]>RB-0FFLHRFVY\)WG*'@H+8\BJ8*3MKROMF6/R6XBM>U
M^"@MXEPK-JAC#Z4%4!J%TI@_]-BU;1MT$QH4396:-.S]$POM1S^-V P<K2ZH
M=0^E42B-^;J]WW5/(X86&Z%H>WU-JPWG=1#7\?55QLL'?L/3M"+ML*RQYH_>
M%=WB??,0JO<?[<ET\/XGZ_V-I7F?6N_#]OVIQ%]?;>,'_B4N'Y*\(BF_%T4U
M,^D)*9.'S>%%76S%='M"[HJZ+K+VSPV/Q3BQ.4!\?E^(]K-[T13P5)3?VM.Y
M_B]02P,$%     @ X(9X5CH15:\E P  UPH  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&ULK59=;]HP%/TK5C9-G;21#S[; 1*%HO6A&BKJ]C#MP207
ML)K$J>U ^^]W;8<4*$2TX@7BY)YS[SF^MFYWS<6C7 (H\IS$J>PY2Z6R*]>5
MX1(2*FL\@Q2_S+E(J,*E6+@R$T C TIB-_"\EIM0ECK]KGDW$?TNSU7,4I@(
M(O,DH>+E&F*^[CF^LWEQSQ9+I5^X_6Y&%S %]9!-!*[<DB5B":22\90(F/><
M@7\UZNAX$_";P5IN/1.M9,;YHU[<1CW'TP5!#*'2#!3_5C"$.-9$6,93P>F4
M*35P^WG#/C;:4<N,2ACR^ ^+U++G=!P2P9SFL;KGZY]0Z&EJOI#'TOR2=1'K
M.23,I>)) <8*$I;:?_I<^+ %\!M' $$!"/8!S2. >@&HGYJA40 :QADKQ?@P
MHHKVNX*OB=#1R*8?C)D&C?)9JK=]J@1^98A3_2E+LAC(8"$ <#<503?).%>Y
M '+SE#/U0KZ3010QO4LT)K>I;36]9Q<C4)3%\BN&/$Q'Y.+SUZZKL"A-[89%
M 4-;0'"D )_<\50M);E)(XAV\2Z**14%&T77027A%+(:J7O?2. %_J%ZJN&_
M0H5P7\/]RP/P435\#+,:"3HF>U"AIE[N3]WPU8_P%7OP=S"32N A^7>@I&M+
MT3A,H2^.*YG1$'H.W@P2Q J<_I=/?LO[<<B><Y*-SD2V8UVCM*Y1Q;YI;5JV
M-G8NF=O6!FLKDS+?;SIKJ:5N&6I]=:[Z0=/SO*Z[VO;JI*A199D?-*%9FM"L
M-&$"(D3M>(,3/B<A3U<@S)6="1;"(>66S_>V1'FUUI[P4X)&E95]4'>KU-VJ
MU#TT2A5$J#E)4"_>I.$CR?&2$60Z&-^\]L4A$RQY<TM>,_ Z>R945O#>DW(F
MLAVSVJ59[>J38KPQ'4$R]$<NJ3C8&^TW_;[O266B]WKR-MUEF6Y':*<4VCFA
M*ZK[WS)TMI(V:OLJ*[.\5^69R*PA[M8HD(!8F)%*XB'(4V6G@O)M.;4-S+#B
MOH;;D>^.B@5+)8EACE"OUL;C(.P891>*9V:PF'&%8XIY7.+D"4('X/<YYVJS
MT G*6;;_'U!+ P04    " #@AGA650J97$,#  !9$   &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6S-6%U/VS 4_2M6-DT@,?+1] /61@(R-"28$!WP
M,.W!36Y;"R?N;*<%:3]^=I*FB1;2=N2!ES;^.,<^Y]JWN1VN&'\2<P")GB,:
MBY$QEW)Q:IHBF$.$Q3%;0*Q&IHQ'6*HFGYEBP0&'*2BBIF-9/3/")#:\8=IW
MR[TA2R0E,=QR))(HPOSE'"A;C0S;6'?<D=E<Z@[3&R[P#,8@[Q>W7+7,@B4D
M$<2"L!AQF(Z,,_O4MU- .N.!P$J4GI&6,F'L23>NPI%AZ1T!A4!J"JR^EG !
ME&HFM8_?.:E1K*F!Y><U^V4J7HF98 $7C#Z24,Y'QL! (4QQ0N4=6WV#7%!7
M\P6,BO03K?*YEH&"1$@6Y6"U@XC$V3=^SHTH 6SW%8"3 YQ= 9T<T-D5X.8
M-W4FDY+ZX&.)O2%G*\3U;,6F'U(S4[223V(=]['D:I0HG/0N,>'H =,$$)NB
M2Q+C.""8HFN")X0224"@SVBLCEN8T&S.!G$#6"0<U#&00@]]C280AA B'SA9
M8AW1"A&.0_2(.<>QK/0?^" QH>)0+74_]M'!Q\.A*94ZO4<SR)6<9TJ<5Y3X
M$!RCCGV$',MQ:N 7N\/M&KB_.]RJPDT5DB(N3A$7)^7K;(W+$3H3 F3F7MFU
MW/T0J>MS!T'".8EGZ:SO+.9%QSD61*"?UVH!="4A$K_JO,UVX];O1B>?4['
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MP?H(-1WT[PNN%5'Y8@:HOL!,_@-02P,$%     @ X(9X5A^T+DUT P  D0P
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M]+LWJ-<8I*]?Q:/H?9=5+P2V8]RP-6[8AY[.EDPN$+B$PEFX?LA2+.>84ZI
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MZ[=]T_@(4S?K-TPON#0@L"#(Z/B4[@==][_UP*J5;R'GRE)#ZA^7])\!M5M
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MSC?QOF;IKNMT)D;?1T)I=LCJ^D#@K@^(^W.YAXK9/-L4Z77G)9/;ZITJM%2
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M#4_W^XYE-OS3DJ1"WYU&-8-J,:HEE&:'J.X^S"YT'QI3L=Z_O#.K,KN1WK%
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MMV72GWD?MT6Q7>\_O,G2,LK5"\K_?K7=%O>?5 -\WN[^V'\YK_\?4$L#!!0
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M^'*!BA14?M4IS54#"J,U$9D<^$K+-&1^NI4T=I+"5R1U0[CA3.42+EF&V;\
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M:G_B>4<JOY!L9YHZ]TQ*EIC3+=(0N0Y0]]>,R:<+_8"R+SC_#U!+ P04
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MO;&]PE35["O!R+QLL$MI;+LNAYE]((%R&^SZ2DJS$YR!YLD5_P-02P,$%
M  @ X(9X5D+6;.LB"0  T%L  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULM9QK;]LV%(;_"N%=T )=;%V<IET2( DY+$"S!4V[?1CV@9%H6YLD>J(<
M-\!^_$A9,4U7H2WG78$TEB,^I,XK'?&\NIPN9?6WF@E1DR]%7JJSP:RNY^^'
M0Y7,1,'5D9R+4O]E(JN"UWJQF@[5O!(\;1H5^3 <C8Z'!<_*P?EI\]UM=7XJ
M%W6>E>*V(FI1%+QZO!2Y7)X-@L'3%Q^SZ:PV7PS/3^=\*NY$_7E^6^FEX9J2
M9H4H529+4HG)V> B>,_&8].@6>.W3"S5QF=B-N5>RK_-PG5Z-AB9$8E<)+5!
M</WK05R)/#<D/8Y_6NA@W:=IN/GYB?Y3L_%Z8^ZY$E<R_SU+Z]G9X&1 4C'A
MB[S^*)<_BW:#F@$F,E?-_V39KCL:D&2A:EFTC?4(BJQ<_>9?VD!L--"<[@9A
MVR#<;A _TR!J&T3[-HC;!O%6@V>W8=PV:#9]N-KV)G"4U_S\M))+4IFU-<U\
M:*+?M-;QRDJSH]S5E?YKIMO5YU>R*+):*U\K<E&FY$J6=59.19ED0I$?R$6:
M9D91GI/K<K5?&GU?45'S+%>O]2J?[RAY]>WKTV&MQV.HPZ3M^W+5=_A,WP&Y
MT;W-%&%E*M*.]FQ'^] #&.I K*,1/D7C,O02?Q+W1R0\>4/"41AT#.C*WYR*
MY(A$0=-\U-&<^IO_(A]T\Y%I'IQTA6/_WD-/,*+UKA$UO/@9WD>A=P-1R;)+
M66]3D]W>JSE/Q-E IR\EJ@<Q./_^F^!X]&-75)$PBH0Q$,R)?[R.?]S0HV?B
M_T$JM74\_O%!KT.N:U&H/[M4B9&J(&$4"6,@F*/*>*W*V'M4?!)50>2$\&DE
MA,F;73KX$6/R*'BENF+N;=@WYD@8 \&<F!^O8W[LC_G/U[^2?\F%#K?.\^26
MUSKNA.O3U2>1S$J9R^DC^9 E>OXBR(5/&&\_?0\0)(PB80P$<\1ZNQ;K+3IM
MO46J@H11)(R!8(XJ)VM53EZ>MKR(OCKXQQ..GDV"%#D,!H(Y07^W#OH[[T;J
MR?6]_BK5$_=<Z*F\/@CF_-%$WTSALV)1=*G@9?95804[;F"F:'PX#P)=1)I_
MI\.'S:@CNV4@F!/U8&1KFI$W[I\_W?V..5_X.^HK!I1&H32&HKF2;92A ?JL
MT1)1VB!I%$IC*)JK36BU";V'T^TJ9RF2+@2I1*X/IY34TF:UKBQ^Z8?VE@=)
MHU ::VF;2=8F5S?FMO8._,5WF\)>DKJ@)3J41J$TAJ*Y4MDR/8#7Z0&T4(?2
M*)3&4#17&UNL!X!JW<_HK89_1+Z)+W0@#$5S0V]K]L!?M!\V^?5#>VMQO/?T
M%]HQ0]'<V-L2//#6DH>>L:%U.)1&H336TO8Y8]L"._!7M+>BTF?EFD^%23B5
M?.1Y_4A2H9(JFYN+)ITAAY;<4!J%TMB.Z'V:B4H0KG^4/HWF@J39-*O78:ST
M'JS(1%8D7\U]4C*O9+I(]#YN)D?K;\TX]&=%$OF@B2FY?R2<_,;S+"57.<\*
M\HHK<R6Q24U92>J9L&>'UPTL%7-3..I$)4NRG F]2D5^$36YX_KP:0:I&^@1
M5;HU+XD9E=!S +,P%/\L>&Z.M6^#-SK+K'_(,JMGFY1[/4#31,_N"KG0G26R
M*'3W>O/UB%5NKG#FCV2F?^N.YNN]ZXA<ET3P9$82KL2;9@.>PF37(IDBN5SJ
MEO="A\WDWF8FF2FUX&4BS*8WD+\65:;2K+ELVZ -3SR8=9O!F<7MF)--'=J(
MFPY+63\;]W:@B[(T&^CJ:B*JVRR25;M)-K';0EZ-1]^]/O*E16O'!#O\F&8'
M$%_F6;6ZC*G[R&37E<=+/ZGW@>D?5^";$T!]&13-O;IJC9G0;\S<9*4Y\>O"
M!F?I^[OLJQ241J$TAJ*YXEF+)H1;-"'4HH'2*)3&4#17&VO1A'Z+YF9[CMVI
M!M21";]V/8+.F36T6X:BN8&VODSH]V5>FL%T"S,'4,T<8#'_>J+0*1S4RH'2
M*)3&4#1776OEA' K)X1:.5 :A=(8BN9J8ZV<T&^<?-0'F*VLC#1Z E<^'4N=
MTD!]'2B-MC1SU<66H$>CT,V=#-6I&W/KX81^#P>:[585SQ[9#FH!06D42F,H
MFJNN=8E"^)T:(=0B@M(HE,90-%<;ZR:%?C_D@&P'M9):VKNM]#3>GMM!/2(4
MS8VYM0="?QENL]W+K[[YN^JM!I)&H32&HKGW*%M+(1JADU@$=0R@- JE,13-
MU<8Z!I&WZMVO*O4S>JL1[%F50KME*)H;:%O^1[O*_\,RE[<:[10+:B% :11*
M8RB:J^C&LQ<1/*UAG\G /I2!?2KC_W )(NL21-Y*]X"YF1_86YIXG]J10CME
M*)H;<UO]1_[J'Y+A]JU _6/I+1?4.(#2&(KFJFK]A>@8GN6@[@"41J$TAJ*Y
MVEAW(/+?0W) EH.: RUM5P4*[92A:&[,;=4?^:O^F]6-4=#KH_XN>ZL"O<4$
M2F,HFBN>M0^B=_!D!G4)H#0*I3$4S7V2UKH$\:X;#_:H1/V,OFJTM,U*=#SJ
M+$6A_3(4S8VTK?GC'37_"U/801=(_6/JK1ST/@,HC:%HKKK6:(A#=(Z+H98!
ME$:A-(:BN=I8RR#>\;Z&WA,V/["W-%#'H*5M%[GQU@525*=NS#=>T>"W J#9
M;M_RU#^FWK)!;SF TAB*YJIK38=X#,]V4.L 2J-0&D/17&VL=1#[;TTX(-M!
MG8.6MIV?MLM3:*<,17-C;BV!V&\)V&SW\@ND_JYZJP&]DP!*8RB:*YKU%.(3
M>!*#6@90&H72&(KF:F,M@WC7'0?[E*50DR#^^HT0SY6E4 , 17-?VF0-@/$.
M ^# U-7["JE_''W5@M(HE,90-%=1:S2,X8\CC*$V 91&H32&HKG:6)M@[+\?
MH?_DS _L+4VX3_%(H9TR%,V-N2W_QSN>3$!DN'U+4/]8>LL%=0Z@-(:BN:I:
M@V$<P[,<U!Z TBB4QE T5YN--T&BGTCP WM+T_T,P78)"NV4H6BKF \WWEQ<
MB&K:O#+:/+R]*.O5:WO7WZY?2WW1O(QYZ_O+X#U=O5S:8E;ONK[AU30K%<G%
M1"-'1V_U!E2KUT>O%FHY;]Z/?"_K6A;-QYG@J:C,"OKO$RGKIP73P?HEWN?_
M 5!+ P04    " #@AGA6BMN'R \#   ]"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6RM5EUOFS 4_2L6FZ966@N8[RQ!:A--Z\.VJFFW9P=N$E3
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M2I(DR_P(8'X'28(A\#3B".8 /&!(DMCWX,[[*%J_IZ+-?W!'OP%02P,$%
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[;L) %(7AK2 O(,-]F(0(J-+01MF
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M/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%     @ X(9X5H"$^)W  0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ X(9X5IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #@AGA6+.I]0S8)   L0@  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ X(9X5M5N&PQ^!0  \A8  !@
M             ("!>1$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( ."&>%:0F#->XP(  .$)   8              " @2T7  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #@AGA6#CQI(;<%  #K
M%@  &               @(%&&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ X(9X5GQC[32M @  0P<  !@              ("!,R
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ."&>%:%]?*4
MMA,  '<Y 0 8              " @18C  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #@AGA6MJ^&F%,"  #L!   &
M@($"-P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ X(9X
M5I&&',G "   ["@  !@              ("!BSD  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( ."&>%9Q.QSI&B8  !-T   8
M      " @8%"  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ."&>%9,FB/34 0  !4*   9              "
M@6V$  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ X(9X
M5O&P/YEQ!@  2Q$  !D              ("!](@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #@AGA6Y#G$RE,3  #&.@  &0
M        @(&<CP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( ."&>%;P=.H()00  )<)   9              " @2:C  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ X(9X5B+EGK2Y"   ,A<
M !D              ("!@J<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #@AGA6?P0SD,4)   -&@  &0              @(%RL
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ."&>%8APYSR
MJ ,  %,(   9              " @6ZZ  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ X(9X5N]ZUH]N)P  7H   !D
M ("!3;X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #@
MAGA6D^8G)%D#   #!P  &0              @('RY0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ."&>%:(\O/"X (  !8&   9
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M970R-RYX;6Q02P$"% ,4    " #@AGA6Y8?"(7P#  #I#0  &0
M    @(%=" $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M ."&>%8<+]**Y@@  )ML   9              " @1 , 0!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ X(9X5F>E>+WL @  1P@  !D
M             ("!+14! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #@AGA6I4;GW%L$  !K%0  &0              @(%0& $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ."&>%8'49%9&@,
M *4)   9              " @>(< 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ X(9X5GD)P([##0  ^9H  !D              ("!
M,R ! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #@AGA6
M.A%5KR4#  #7"@  &0              @($M+@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( ."&>%95"IE<0P,  %D0   9
M      " @8DQ 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ X(9X5D6'&EKY!   C1D  !D              ("! S4! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #@AGA6'[0N370#  "1#
M&0              @($S.@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( ."&>%;_.^T#7!P  !W! 0 9              " @=X] 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ X(9X5F^2J4/)
M @  7P<  !D              ("!<5H! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #@AGA6R5>$YJ<#  !W#@  &0
M@(%Q70$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ."&
M>%9P^5R)_ ,  ",4   9              " @4]A 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ X(9X5I=I_EUE!   >!,  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( ."&>%:*VX?(#P,  #T)   9
M  " @?I] 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
MX(9X5D[/)*19!   S14  !D              ("!0($! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #@AGA6=-BLN&<#  "Q"@  &0
M            @('0A0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( ."&>%9ST@#KD04  &XU   9              " @6Z) 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ X(9X5KJI4+=/ P
MSA4   T              ( !-H\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #@AGA6EXJ[',     3 @  "P              @ &PD@$ 7W)E;',O+G)E
M;'-02P$"% ,4    " #@AGA6-#P:=D$$  "Y(0  #P              @ &9
MDP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ X(9X5CB#;R;$ 0  #1X
M !H              ( !!Y@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ X(9X5H"$^)W  0   !X  !,              ( ! YH!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-#P  ])L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>359</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Related Party Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransaction1</Role>
      <ShortName>Related Party Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Paycheck Protection Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgram1</Role>
      <ShortName>Paycheck Protection Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Simple Agreement For Future Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquity1</Role>
      <ShortName>Simple Agreement For Future Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Fair Value of Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities</Role>
      <ShortName>Fair Value of Financial Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Employee Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan</Role>
      <ShortName>Employee Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value of Financial Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha</Role>
      <ShortName>Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails</Role>
      <ShortName>Accrued Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Paycheck Protection Program - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails</Role>
      <ShortName>Paycheck Protection Program - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Convertible Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails</Role>
      <ShortName>Convertible Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Simple Agreement For Future Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails</Role>
      <ShortName>Simple Agreement For Future Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value of Financial Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stockholders' Equity - Schedule of Warrants Exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants Exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Warrants Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions used in Calculating Value of Warrants Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stockholders' Equity - Summary of Activity and Information regarding Outstanding and Exercisable Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Activity and Information regarding Outstanding and Exercisable Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Employee Retirement Plan (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Retirement Plan (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Commitments And Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments And Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="maia-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Subsequent Events - Additional Information - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorFirmId must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorFirmId fact are Context: C_cbf5e914-0593-48ce-a8d1-7cde11503245, Unit: (none), Rule Element Id: 2. maia-20221231.htm 4022</Log>
    <Log type="Warning">[dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorLocation must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorLocation fact are Context: C_cbf5e914-0593-48ce-a8d1-7cde11503245, Unit: (none), Rule Element Id: 2. maia-20221231.htm 4112</Log>
    <Log type="Warning">[dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorName must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorName fact are Context: C_cbf5e914-0593-48ce-a8d1-7cde11503245, Unit: (none), Rule Element Id: 2. maia-20221231.htm 4111</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="maia-20221231.htm">maia-20221231.htm</File>
    <File>maia-20221231.xsd</File>
    <File>maia-20221231_cal.xml</File>
    <File>maia-20221231_def.xml</File>
    <File>maia-20221231_lab.xml</File>
    <File>maia-20221231_pre.xml</File>
    <File>maia-ex31_1.htm</File>
    <File>maia-ex31_2.htm</File>
    <File>maia-ex32_1.htm</File>
    <File>maia-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img118615358_0.jpg</File>
    <File>img118615358_1.jpg</File>
    <File>img118615358_10.jpg</File>
    <File>img118615358_11.jpg</File>
    <File>img118615358_12.jpg</File>
    <File>img118615358_13.jpg</File>
    <File>img118615358_14.jpg</File>
    <File>img118615358_15.jpg</File>
    <File>img118615358_2.jpg</File>
    <File>img118615358_3.jpg</File>
    <File>img118615358_4.jpg</File>
    <File>img118615358_5.jpg</File>
    <File>img118615358_6.jpg</File>
    <File>img118615358_7.jpg</File>
    <File>img118615358_8.jpg</File>
    <File>img118615358_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="511">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "maia-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 511,
    "http://xbrl.sec.gov/dei/2022": 48
   },
   "contextCount": 202,
   "dts": {
    "calculationLink": {
     "local": [
      "maia-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "maia-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "maia-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "maia-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "maia-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "maia-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 584,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 10
   },
   "keyCustom": 109,
   "keyStandard": 250,
   "memberCustom": 37,
   "memberStandard": 26,
   "nsprefix": "maia",
   "nsuri": "http://www.maiabiotechnology.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Related Party Transaction",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransaction1",
     "shortName": "Related Party Transaction",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:PaycheckProtectionProgramTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Paycheck Protection Program",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgram1",
     "shortName": "Paycheck Protection Program",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:PaycheckProtectionProgramTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Convertible Notes Payable",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayable",
     "shortName": "Convertible Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Simple Agreement For Future Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquity1",
     "shortName": "Simple Agreement For Future Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Fair Value of Financial Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities",
     "shortName": "Fair Value of Financial Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Employee Retirement Plan",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan",
     "shortName": "Employee Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Fair Value of Financial Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables",
     "shortName": "Fair Value of Financial Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "maia:DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_0f633671-f593-4b41-8b13-f542f6aec2d1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies - Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_0f633671-f593-4b41-8b13-f542f6aec2d1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_cbf5e914-0593-48ce-a8d1-7cde11503245",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_e094d0a6-8fd0-4c2b-8554-eca1e94d5b86",
      "decimals": "0",
      "lang": null,
      "name": "maia:ConsultingServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_eeb120cc-5b60-4380-b2f8-ba97598b38f1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Expenses - Additional Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
     "shortName": "Accrued Expenses - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_eeb120cc-5b60-4380-b2f8-ba97598b38f1",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredCompensationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "maia:PaycheckProtectionProgramTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Paycheck Protection Program - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails",
     "shortName": "Paycheck Protection Program - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "maia:PaycheckProtectionProgramTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_047a8a4f-efd4-4cbc-bd34-b5f08ef4a426",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_eeb120cc-5b60-4380-b2f8-ba97598b38f1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Convertible Notes Payable - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
     "shortName": "Convertible Notes Payable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_f14d921e-d893-48a9-b93d-6895d30a125f",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_c4856ea2-7771-4d18-b27e-ad041dc17195",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:SimpleAgreementForFutureEquityIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Simple Agreement For Future Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails",
     "shortName": "Simple Agreement For Future Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "maia:SimpleAgreementForFutureEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_c4856ea2-7771-4d18-b27e-ad041dc17195",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:SimpleAgreementForFutureEquityIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
     "shortName": "Fair Value of Financial Liabilities - Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_a0c99f8c-3025-49f9-9ce1-af3347da6e53",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_cbf5e914-0593-48ce-a8d1-7cde11503245",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:ChangeInFairValueOfEmbeddedFeatures",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
     "shortName": "Fair Value of Financial Liabilities - Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_05ed1f6a-7bd5-44e6-a939-0de1e93bb2f6",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_cbf5e914-0593-48ce-a8d1-7cde11503245",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "maia:ChangeInFairValueOfEmbeddedFeatures",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value of Financial Liabilities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
     "shortName": "Fair Value of Financial Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "2",
      "lang": null,
      "name": "maia:ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_e31173a7-a2dc-4f27-be64-82bc649b47d4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_e31173a7-a2dc-4f27-be64-82bc649b47d4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_cab8d345-5f87-42f4-95e4-921bbed2dd3b",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails",
     "shortName": "Stockholders' Equity - Schedule of Unvested Restricted Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_cab8d345-5f87-42f4-95e4-921bbed2dd3b",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "maia:ScheduleOfWarrantExercisedTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_eeb120cc-5b60-4380-b2f8-ba97598b38f1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stockholders' Equity - Schedule of Warrants Exercised (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails",
     "shortName": "Stockholders' Equity - Schedule of Warrants Exercised (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "maia:ScheduleOfWarrantExercisedTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "INF",
      "lang": null,
      "name": "maia:ClassOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Warrants Granted (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
     "shortName": "Stockholders' Equity - Assumptions used in Calculating Value of Warrants Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "maia:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_1aaa2a7a-c357-4fc8-a215-712ae1861d5c",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_eeb120cc-5b60-4380-b2f8-ba97598b38f1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stockholders' Equity - Summary of Activity and Information regarding Outstanding and Exercisable Options (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
     "shortName": "Stockholders' Equity - Summary of Activity and Information regarding Outstanding and Exercisable Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
     "shortName": "Stockholders' Equity - Assumptions used in Calculating Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_13bf0128-a070-4b47-825e-8161c256c563",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_daea18c7-8f9f-40db-a949-f62882d10b13",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_04cf05b4-4370-4979-8fd8-aad3bb1d1cf7",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "maia:DefinedContributionPlanEmployerSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Employee Retirement Plan (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
     "shortName": "Employee Retirement Plan (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_04cf05b4-4370-4979-8fd8-aad3bb1d1cf7",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "maia:DefinedContributionPlanEmployerSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_59d4a5fa-7563-4679-8962-c0917ed9d470",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:TermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Commitments And Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments And Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_59d4a5fa-7563-4679-8962-c0917ed9d470",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "maia:TermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_18f191ce-f487-4a92-a1ad-96c619694078",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails",
     "shortName": "Income Taxes - Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Subsequent Events - Additional Information - (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_7447a51d-1b53-4834-a837-fd4e4d4818a5",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_7bfe2412-70aa-498d-b73f-b58ae522d52e",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_7bfe2412-70aa-498d-b73f-b58ae522d52e",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_f426df1f-3c59-401e-952f-443722bf8259",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_f426df1f-3c59-401e-952f-443722bf8259",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1",
     "shortName": "Nature of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "maia-20221231.htm",
      "contextRef": "C_243cc501-d8c0-4aa7-be9e-402dc3edd4e9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address Address Line1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "verboseLabel": "State of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "maia_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments additional paid in capital deemed dividend for shares.",
        "label": "Adjustments Additional Paid in Capital Deemed Dividend for Shares",
        "terseLabel": "Deemed dividend for ratchet shares"
       }
      }
     },
     "localname": "AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments additional paid in Capital deemed dividend modification of warrant",
        "label": "Adjustments Additional Paid In Capital Deemed Dividend Modification Of Warrant",
        "terseLabel": "Deemed dividend on modification of warrant"
       }
      }
     },
     "localname": "AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated two thousand twenty equity incentive plan.",
        "label": "Amended And Restated Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "Amended and Restated 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_AmendedPatentAndTechnologyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended patent and technology license agreement.",
        "label": "Amended Patent and Technology License Agreement [Member]",
        "terseLabel": "Amended Patent and Technology License Agreement"
       }
      }
     },
     "localname": "AmendedPatentAndTechnologyLicenseAgreementMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_AustralianResearchAndDevelopmentIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Australian research and development incentives.",
        "label": "Australian Research And Development Incentives",
        "terseLabel": "Australian research and development incentives"
       }
      }
     },
     "localname": "AustralianResearchAndDevelopmentIncentives",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_BlackSholesMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black sholes method.",
        "label": "Black Sholes Method [Member]",
        "terseLabel": "Black-Sholes Method"
       }
      }
     },
     "localname": "BlackSholesMethodMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_CashPaidForServicesProvided": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for services provided.",
        "label": "Cash Paid for Services Provided",
        "terseLabel": "Cash paid for services provided"
       }
      }
     },
     "localname": "CashPaidForServicesProvided",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_CashPaidToSettleAPortionOfDeferredCompensationBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid to settle a portion of deferred compensation balance.",
        "label": "Cash Paid to settle a Portion of Deferred Compensation Balance",
        "terseLabel": "Cash paid to settle a portion of deferred compensation balance"
       }
      }
     },
     "localname": "CashPaidToSettleAPortionOfDeferredCompensationBalance",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_CashlessExerciseAtFairMarketValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise at fair market value per share.",
        "label": "Cashless Exercise At Fair Market Value Per Share",
        "terseLabel": "Cashless exercise at fair market value per share"
       }
      }
     },
     "localname": "CashlessExerciseAtFairMarketValuePerShare",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_CertainRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain risks and uncertainties.",
        "label": "Certain Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Certain Risks and Uncertainties"
       }
      }
     },
     "localname": "CertainRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ChangeInFairValueOfEmbeddedFeatures": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of embedded features.",
        "label": "Change In Fair Value Of Embedded Features",
        "negatedLabel": "Change in fair value of embedded features",
        "negatedTerseLabel": "Loss (Gain) on fair value of embedded features",
        "terseLabel": "Change in fair value of embedded features",
        "verboseLabel": "Loss (Gain) on fair value of embedded features"
       }
      }
     },
     "localname": "ChangeInFairValueOfEmbeddedFeatures",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ChangeInFairValueOfWarrantLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of warrant liability.",
        "label": "Change In Fair Value Of Warrant Liability",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiability",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ClaimExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claim expiration term.",
        "label": "Claim Expiration Term",
        "terseLabel": "Claim expiration period"
       }
      }
     },
     "localname": "ClaimExpirationTerm",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "maia_ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right additional purchase aggregate of common stock.",
        "label": "Class of Warrant or Right Additional Purchase Aggregate of Common Stock",
        "terseLabel": "Class of warrant or right additional purchase aggregate of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalPurchaseAggregateOfCommonStock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right date from which warrants or rights expire.",
        "label": "Class of Warrant or Right Date from which Warrants or Rights Expire",
        "terseLabel": "Class of warrant or right date from which warrants or rights expire"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "maia_ClassOfWarrantOrRightOutstandingAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right outstanding and exercisable.",
        "label": "Class of Warrant or Right Outstanding and Exercisable",
        "terseLabel": "Warrant outstanding and exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingAndExercisable",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants exercised.",
        "label": "Class Of Warrants Exercised",
        "negatedLabel": "Warrants Outstanding, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsExercised",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants expired.",
        "label": "Class of Warrants Expired",
        "negatedLabel": "Warrants Outstanding, Expired"
       }
      }
     },
     "localname": "ClassOfWarrantsExpired",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants issued.",
        "label": "Class Of Warrants Issued",
        "terseLabel": "Warrants Outstanding, Issued",
        "verboseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantsIssued",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price.",
        "label": "Class Of Warrants Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePrice",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price, exercised.",
        "label": "Class Of Warrants Weighted Average Exercise Price Exercised",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePriceExercised",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePriceExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price expired.",
        "label": "Class Of Warrants Weighted Average Exercise Price Expired",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePriceExpired",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageExercisePriceIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average exercise price issued.",
        "label": "Class Of Warrants Weighted Average Exercise Price Issued",
        "terseLabel": "Weighted Average Exercise Price, Issued"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageExercisePriceIssued",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_ClassOfWarrantsWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants weighted average remaining contractual term.",
        "label": "Class Of Warrants Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "ClassOfWarrantsWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "maia_CombinedMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined milestone payments maximum.",
        "label": "Combined Milestone Payments Maximum",
        "terseLabel": "Combined milestone payment maximum"
       }
      }
     },
     "localname": "CombinedMilestonePaymentsMaximum",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_CommonSharesUponExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares upon exercise of warrants shares.",
        "label": "Common Shares Upon Exercise Of Warrants Shares",
        "terseLabel": "Common shares upon exercise of warrants, Shares"
       }
      }
     },
     "localname": "CommonSharesUponExerciseOfWarrantsShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_CommonStockConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock conversion price.",
        "label": "Common Stock Conversion Price",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "CommonStockConversionPrice",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_CommonStockWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants Policy [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsPolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ConsultingServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services.",
        "label": "Consulting Services",
        "terseLabel": "Consulting services"
       }
      }
     },
     "localname": "ConsultingServices",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible notes and accrued interest into common stock.",
        "label": "Conversion of Convertible Notes and Accrued interest into Common Stock",
        "terseLabel": "Conversion of convertible notes and accrued interest into MAIA common stock"
       }
      }
     },
     "localname": "ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConvertibleDebtConversionPricePercentageOfTheEquityFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt Conversion Price Percentage Of The Equity Financing",
        "label": "Convertible Debt Conversion Price Percentage Of The Equity Financing",
        "terseLabel": "Percentage of the conversion price"
       }
      }
     },
     "localname": "ConvertibleDebtConversionPricePercentageOfTheEquityFinancing",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ConvertibleNotesOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes outstanding.",
        "label": "Convertible Notes Outstanding",
        "terseLabel": "Convertible notes outstanding"
       }
      }
     },
     "localname": "ConvertibleNotesOutstanding",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConvertiblePromissoryNotesToRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory notes to related parties.",
        "label": "Convertible Promissory Notes To Related Parties",
        "terseLabel": "Convertible promissory notes to related parties"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesToRelatedParties",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ConvertiblePromissoryNotesToSettleLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory notes to settle loan.",
        "label": "Convertible Promissory Notes To Settle Loan",
        "terseLabel": "Convertible promissory notes to settle loan"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesToSettleLoan",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DGDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DGD.",
        "label": "D G D [Member]",
        "terseLabel": "D G D",
        "verboseLabel": "DGD"
       }
      }
     },
     "localname": "DGDMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_Debtdiscountandvalueofembeddedputfeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Discount And Value Of Embedded Put Feature",
        "label": "DebtDiscountAndValueOfEmbeddedPutFeature",
        "terseLabel": "Debt discount and value of embedded put feature"
       }
      }
     },
     "localname": "Debtdiscountandvalueofembeddedputfeature",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DeemedDividendDeclared": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend declared.",
        "label": "Deemed Dividend Declared",
        "terseLabel": "Deemed dividend declared"
       }
      }
     },
     "localname": "DeemedDividendDeclared",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DeemedDividendOnWarrantModification": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on warrant modification.",
        "label": "Deemed Dividend On Warrant Modification",
        "negatedLabel": "Deemed dividend on warrant modification",
        "terseLabel": "Deemed dividend on warrant modification"
       }
      }
     },
     "localname": "DeemedDividendOnWarrantModification",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DefinedContributionPlanEmployerSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer alary.",
        "label": "Defined Contribution Plan Employer Salary",
        "terseLabel": "Employee salary deferrals"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerSalary",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "maia_DerivativeLiabilityOnConvertibleNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability on convertible notes payable.",
        "label": "Derivative Liability on Convertible Notes Payable",
        "terseLabel": "Derivative liability on convertible notes payable"
       }
      }
     },
     "localname": "DerivativeLiabilityOnConvertibleNotesPayable",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business, organization, and principles of consolidation.",
        "label": "Description of Business, Organization, and Principles of Consolidation [Policy Text Block]",
        "terseLabel": "Description of Business, Organization, and Principles of Consolidation"
       }
      }
     },
     "localname": "DescriptionOfBusinessOrganizationAndPrinciplesOfConsolidationPolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_DgdPharmaceuticalsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DGD Pharmaceuticals Corporation.",
        "label": "DGD Pharmaceuticals Corporation [Member]",
        "terseLabel": "DGD Pharmaceuticals Corporation"
       }
      }
     },
     "localname": "DgdPharmaceuticalsCorporationMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DGD Pharmaceuticals Corporation or THIO Therapeutics, Inc.",
        "label": "DGD Pharmaceuticals Corporation or THIO Therapeutics, Inc. [Member]",
        "terseLabel": "DGD or THIO"
       }
      }
     },
     "localname": "DgdPharmaceuticalsCorporationOrThioTherapeuticsIncMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_DissolutionOfFirm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dissolution of firm.",
        "label": "Dissolution of Firm",
        "terseLabel": "Dissolution of firm"
       }
      }
     },
     "localname": "DissolutionOfFirm",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation loss on extinguishment of debt.",
        "label": "Effective Income Tax Rate Reconciliation Loss on Extinguishment of Debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ExpirationOfPatentRightsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration of patent rights period.",
        "label": "Expiration of Patent Rights Period",
        "terseLabel": "Expiration of patent rights period"
       }
      }
     },
     "localname": "ExpirationOfPatentRightsPeriod",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "maia_ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of derivative liability in connection with debt conversion.",
        "label": "Extinguishment of Derivative Liability in Connection with Debt Conversion",
        "terseLabel": "Extinguishment of derivative liability in connection with debt conversion"
       }
      }
     },
     "localname": "ExtinguishmentOfDerivativeLiabilityInConnectionWithDebtConversion",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of outstanding principal and interest written off amount.",
        "label": "Extinguishment of Outstanding Principal and Interest Written Off Amount",
        "terseLabel": "Extinguishment of outstanding principal and interest written off amount"
       }
      }
     },
     "localname": "ExtinguishmentOfOutstandingPrincipalAndInterestWrittenOffAmount",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of stock options issued to settle accrued bonus balance.",
        "label": "Fair Value of Stock Options Issued to Settle Accrued Bonus Balance",
        "terseLabel": "Fair value of stock options issued to settle accrued bonus balance"
       }
      }
     },
     "localname": "FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ForeignCurrencyTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency translation adjustment.",
        "label": "Foreign Currency Translation Adjustment",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAdjustment",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_FounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder.",
        "label": "Founder [Member]",
        "terseLabel": "Founder"
       }
      }
     },
     "localname": "FounderMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_GainLossFromForgivenessOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from forgiveness of Paycheck Protection Program loan.",
        "label": "Gain Loss from Forgiveness of Paycheck Protection Program Loan",
        "negatedLabel": "Gain from forgiveness of Paycheck Protection Program loan",
        "terseLabel": "Paycheck protection program loan forgiveness"
       }
      }
     },
     "localname": "GainLossFromForgivenessOfPaycheckProtectionProgramLoan",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_GoingConcernConsiderationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern considerations.",
        "label": "Going Concern Considerations [Policy Text Block]",
        "terseLabel": "Going Concern Considerations"
       }
      }
     },
     "localname": "GoingConcernConsiderationsPolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of the COVID-19 pandemic on operations.",
        "label": "Impact of the COVID-19 Pandemic on Operations [Policy Text Block]",
        "terseLabel": "Impact of the COVID-19 Pandemic on our Operations"
       }
      }
     },
     "localname": "ImpactOfTheCovid19PandemicOnOperationsPolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_IncreaseDecreaseInDeferredOfferingCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deferred offering cost.",
        "label": "Increase Decrease In Deferred Offering Cost",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredOfferingCost",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesInConnectionWithEquityFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares in connection with Equity Financing.",
        "label": "Issuance Of Common Shares In Connection With Equity Financing",
        "terseLabel": "Issuance of common shares in connection with equity financing"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesInConnectionWithEquityFinancing",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesInConnectionWithEquityFinancingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares in connection with Equity Financing shares.",
        "label": "Issuance Of Common Shares In Connection With Equity Financing Shares",
        "terseLabel": "Issuance of common shares in connection with equity financing, Shares"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesInConnectionWithEquityFinancingShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares upon cashless exercise of warrants shares.",
        "label": "Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares",
        "terseLabel": "Issuance of common shares upon cashless exercise of warrants, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfCommonSharesUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares upon exercise of warrants.",
        "label": "Issuance Of Common Shares Upon Exercise Of Warrants",
        "terseLabel": "Issuance of common shares upon exercise of warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponExerciseOfWarrants",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfCommonSharesUponExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares upon exercise of warrants shares.",
        "label": "Issuance Of Common Shares Upon Exercise Of Warrants Shares",
        "terseLabel": "Issuance of common shares upon exercise of warrants, Shares"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponExerciseOfWarrantsShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible note for payment on loan to officer.",
        "label": "Issuance Of Convertible Note For Payment On Loan To Officer",
        "terseLabel": "Issuance of convertible note for payment on loan to officer"
       }
      }
     },
     "localname": "IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfRatchetShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ratchet shares.",
        "label": "Issuance of Ratchet Shares",
        "terseLabel": "Issuance of ratchet shares"
       }
      }
     },
     "localname": "IssuanceOfRatchetShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfStockOptionsToSatisfyAccruedBonus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock options to satisfy accrued bonus.",
        "label": "Issuance Of Stock Options To Satisfy Accrued Bonus",
        "terseLabel": "Issuance of stock options to satisfy accrued bonus"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsToSatisfyAccruedBonus",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfStockOptionsToSatisfyDeferredCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock options to satisfy deferred compensation.",
        "label": "Issuance Of Stock Options To Satisfy Deferred Compensation",
        "terseLabel": "Issuance of stock options to satisfy deferred compensation"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsToSatisfyDeferredCompensation",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_IssuanceOfStockOptionsToSettleAccruedBonusBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock options to settle accrued bonus balance.",
        "label": "Issuance of Stock Options to Settle Accrued Bonus Balance",
        "terseLabel": "Issuance of stock options to settle accrued bonus balance"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsToSettleAccruedBonusBalance",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January one to january twenty six two thousand twenty two.",
        "label": "January One To January Twenty Six Two Thousand Twenty Two [Member]",
        "terseLabel": "January 1 to January 26, 2022"
       }
      }
     },
     "localname": "JanuaryOneToJanuaryTwentySixTwoThousandTwentyTwoMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January one two thousand twenty one to february twenty eight two thousand twenty one.",
        "label": "January One Two Thousand Twenty One To February Twenty Eight Two Thousand Twenty One [Member]",
        "terseLabel": "January 1, 2021 to February 28, 2021"
       }
      }
     },
     "localname": "JanuaryOneTwoThousandTwentyOneToFebruaryTwentyEightTwoThousandTwentyOneMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January twenty seven to june thirty two thousand twenty two.",
        "label": "January Twenty Seven To June Thirty Two Thousand Twenty Two [Member]",
        "terseLabel": "January 27 to June 30, 2022"
       }
      }
     },
     "localname": "JanuaryTwentySevenToJuneThirtyTwoThousandTwentyTwoMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January twenty seven to may thirty one two thousand twenty two.",
        "label": "January Twenty Seven To May Thirty One Two Thousand Twenty Two [Member]",
        "terseLabel": "January 27 to May 31, 2022"
       }
      }
     },
     "localname": "JanuaryTwentySevenToMayThirtyOneTwoThousandTwentyTwoMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June one two thousand twenty two to august one two thousand twenty two.",
        "label": "June One Two Thousand Twenty Two to August One Two Thousand Twenty Two [Member]",
        "terseLabel": "June 1, 2022 to August 1, 2022"
       }
      }
     },
     "localname": "JuneOneTwoThousandTwentyTwoToAugustOneTwoThousandTwentyTwoMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_LeighAnnDurantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leigh-Ann Durant.",
        "label": "Leigh-Ann Durant [Member]",
        "terseLabel": "Ms. Durant"
       }
      }
     },
     "localname": "LeighAnnDurantMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_MAIADrugDevelopmentCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MAIA Drug Development Corporation.",
        "label": "M A I A Drug Development Corporation [Member]",
        "terseLabel": "MAIA DD",
        "verboseLabel": "MAIA Drug Development Corporation"
       }
      }
     },
     "localname": "MAIADrugDevelopmentCorporationMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MaiaDrugDevelopmentCorporationMaiaDdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MAIA Drug Development Corporation (\"MAIA DD\") [Member]",
        "label": "MAIA Drug Development Corporation (\"MAIA DD\") [Member]",
        "terseLabel": "MAIA Drug Development Corporation"
       }
      }
     },
     "localname": "MaiaDrugDevelopmentCorporationMaiaDdMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March one two thousand twenty one to june six two thousand twenty one.",
        "label": "March One Two Thousand Twenty One To June Six Two Thousand Twenty One [Member]",
        "terseLabel": "March 1, 2021 to June 6, 2021"
       }
      }
     },
     "localname": "MarchOneTwoThousandTwentyOneToJuneSixTwoThousandTwentyOneMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2021 through May 2021.",
        "label": "March Two Thousand Twenty One to May Two Thousand Twenty One [Member]",
        "terseLabel": "March 2021 through May 2021"
       }
      }
     },
     "localname": "MarchTwoThousandTwentyOneToMayTwoThousandTwentyOneMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt",
        "label": "Minimum Gross Proceeds From Equity Financing Required For Conversion Of Debt",
        "terseLabel": "Minimum gross proceeds from equity financing required for conversion of debt"
       }
      }
     },
     "localname": "MinimumGrossProceedsFromEquityFinancingRequiredForConversionOfDebt",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ModificationOfWarrantInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of warrant in equity.",
        "label": "Modification Of Warrant In Equity",
        "terseLabel": "Modification of warrant in equity"
       }
      }
     },
     "localname": "ModificationOfWarrantInEquity",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_MoneyChannelNycIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money channel nyc inc.",
        "label": "Money Channel NYC Inc [Member]",
        "terseLabel": "Money Channel NYC Inc"
       }
      }
     },
     "localname": "MoneyChannelNycIncMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NetSalesAboveOneBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales above one billion.",
        "label": "Net Sales Above One Billion [Member]",
        "terseLabel": "Net sales above $1,000,000,000"
       }
      }
     },
     "localname": "NetSalesAboveOneBillionMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NetSalesUptoOneBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales upto one billion.",
        "label": "Net Sales Upto One Billion [Member]",
        "terseLabel": "Net sales up to $1,000,000,000"
       }
      }
     },
     "localname": "NetSalesUptoOneBillionMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NetSalesUptoOneMillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales upto one million.",
        "label": "Net Sales Upto One Million [Member]",
        "terseLabel": "Net sales up to $1,000,000"
       }
      }
     },
     "localname": "NetSalesUptoOneMillionMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_NumberOfCommonSharesConvertedUnderSAFEAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares converted under S A F E agreement.",
        "label": "Number Of Common Shares Converted Under S A F E Agreement",
        "terseLabel": "Converted common stock under SAFE agreement"
       }
      }
     },
     "localname": "NumberOfCommonSharesConvertedUnderSAFEAgreement",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_NumberOfDirectorsToWhomSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors to whom shares granted.",
        "label": "Number of Directors to Whom Shares Granted",
        "terseLabel": "Number of directors to whom shares granted"
       }
      }
     },
     "localname": "NumberOfDirectorsToWhomSharesGranted",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "maia_NumberOfFoundersTerminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of founders terminated.",
        "label": "Number of Founders Terminated",
        "terseLabel": "Number of founders terminated"
       }
      }
     },
     "localname": "NumberOfFoundersTerminated",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "maia_NumberOfFoundersToWhomSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of founders to whom shares granted.",
        "label": "Number of Founders to Whom Shares Granted",
        "terseLabel": "Number of founders to whom shares granted"
       }
      }
     },
     "localname": "NumberOfFoundersToWhomSharesGranted",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "maia_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_NumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Number of warrants issued"
       }
      }
     },
     "localname": "NumberOfWarrantsIssued",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_OfferingAndOverallotmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering and overallotment.",
        "label": "Offering and Overallotment Member",
        "terseLabel": "Offering and Overallotment"
       }
      }
     },
     "localname": "OfferingAndOverallotmentMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_OperatingLossCarryforwardLimitedPercentageOfTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforward limited percentage of taxable income.",
        "label": "Operating Loss Carryforward Limited Percentage of Taxable Income",
        "terseLabel": "Net operating loss carryforward limited percentage of taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryforwardLimitedPercentageOfTaxableIncome",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "maia_OptionsIssuedForAccruedBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued for accrued bonus.",
        "label": "Options Issued For Accrued Bonus",
        "terseLabel": "Options issued for accrued bonus"
       }
      }
     },
     "localname": "OptionsIssuedForAccruedBonus",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_OptionsIssuedForDeferredCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued for deferred compensation.",
        "label": "Options Issued For Deferred Compensation",
        "terseLabel": "Options issued for deferred compensation"
       }
      }
     },
     "localname": "OptionsIssuedForDeferredCompensation",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_OptionsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares of common stock.",
        "label": "Options to Purchase Shares of Common Stock",
        "terseLabel": "Options to purchase shares of common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseSharesOfCommonStock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_OptionsToPurchaseSharesOfCommonStockTotalFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares of common stock total fair value.",
        "label": "Options to Purchase Shares of Common Stock Total Fair Value",
        "terseLabel": "Options to purchase shares of common stock total fair value"
       }
      }
     },
     "localname": "OptionsToPurchaseSharesOfCommonStockTotalFairValue",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_PatentAndTechnologyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and technology license agreement.",
        "label": "Patent And Technology License Agreement [Member]",
        "terseLabel": "Patent and Technology License Agreement"
       }
      }
     },
     "localname": "PatentAndTechnologyLicenseAgreementMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_PaycheckProtectionProgramTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program.",
        "label": "Paycheck Protection Program [Text Block]",
        "terseLabel": "Paycheck Protection Program"
       }
      }
     },
     "localname": "PaycheckProtectionProgramTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgram1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_PaymentOfInitialPublicOfferingTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Initial Public Offering Transaction Costs",
        "label": "Payment Of Initial Public Offering Transaction Costs",
        "negatedLabel": "Payment of initial public offering transaction costs",
        "verboseLabel": "Payment of initial public offering transaction costs"
       }
      }
     },
     "localname": "PaymentOfInitialPublicOfferingTransactionCosts",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_PaymentsDueRelatedToMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due related to milestones.",
        "label": "Payments Due Related To Milestones",
        "terseLabel": "Payments due related to milestones"
       }
      }
     },
     "localname": "PaymentsDueRelatedToMilestones",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_PercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of conversion price.",
        "label": "Percentage Of Conversion Price",
        "terseLabel": "Percentage of conversion price"
       }
      }
     },
     "localname": "PercentageOfConversionPrice",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfIssuableUponConversionOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of issuable upon conversion of exercise price.",
        "label": "Percentage of Issuable Upon Conversion of Exercise Price",
        "terseLabel": "Percentage of issuable upon conversion of exercise price"
       }
      }
     },
     "localname": "PercentageOfIssuableUponConversionOfExercisePrice",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "maia_PercentageOfProbabilityOfDefaultChangeInControlOrDissolution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of probability of default change In control Or dissolution.",
        "label": "Percentage Of Probability Of Default Change In Control Or Dissolution",
        "terseLabel": "Percentage of probability of default change in control or dissolution"
       }
      }
     },
     "localname": "PercentageOfProbabilityOfDefaultChangeInControlOrDissolution",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfProbabilityOfEquityFinancingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of probability of equity financing maturity.",
        "label": "Percentage Of Probability Of Equity Financing Maturity",
        "terseLabel": "Percentage of probability of equity financing maturity"
       }
      }
     },
     "localname": "PercentageOfProbabilityOfEquityFinancingMaturity",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfProbabilityOfTheConvertibleNotesMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of probability of the convertible notes maturity.",
        "label": "Percentage Of Probability Of The Convertible Notes Maturity",
        "terseLabel": "Percentage of probability of the convertible notes maturity"
       }
      }
     },
     "localname": "PercentageOfProbabilityOfTheConvertibleNotesMaturity",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfRoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales.",
        "label": "Percentage Of Royalty Payments On Net Sales",
        "terseLabel": "Rate of royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales description.",
        "label": "Percentage Of Royalty Payments On Net Sales Description",
        "terseLabel": "Percentage of royalty description"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSalesDescription",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "maia_PercentageOfStockCompensationExpenseRecognized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock compensation expense recognized.",
        "label": "Percentage of Stock Compensation Expense Recognized",
        "terseLabel": "Percentage of stock compensation expense recognized"
       }
      }
     },
     "localname": "PercentageOfStockCompensationExpenseRecognized",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PercentageOfVotingPowerDefiningChangeOfControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Voting Power Defining Change Of Control",
        "label": "Percentage Of Voting Power Defining Change Of Control",
        "terseLabel": "Percentage of voting power defining change of control"
       }
      }
     },
     "localname": "PercentageOfVotingPowerDefiningChangeOfControl",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_PppLoanProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP loan program.",
        "label": "PPP Loan Program [Member]",
        "terseLabel": "P P P Loan Program"
       }
      }
     },
     "localname": "PppLoanProgramMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously paid issuance costs in connection with the initial public offering",
        "label": "Previously paid issuance costs in connection with the initial public offering"
       }
      }
     },
     "localname": "PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability percentage of convertible notes outstanding at maturity.",
        "label": "Probability Percentage of Convertible Notes Outstanding at Maturity",
        "terseLabel": "Probability percentage of convertible notes outstanding at maturity"
       }
      }
     },
     "localname": "ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ProbabilityPercentageOfDefaultChangeInControlOrDissolution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability percentage of default, change in control or dissolution.",
        "label": "Probability Percentage of Default, Change in Control or Dissolution",
        "terseLabel": "Probability percentage of default, change in control or dissolution"
       }
      }
     },
     "localname": "ProbabilityPercentageOfDefaultChangeInControlOrDissolution",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ProbabilityPercentageOfEquityFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability percentage of equity financing.",
        "label": "Probability Percentage of Equity Financing",
        "terseLabel": "Probability percentage of equity financing"
       }
      }
     },
     "localname": "ProbabilityPercentageOfEquityFinancing",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ProceedsFromCollectionOfSubscriptionReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from collection of subscription receivable.",
        "label": "Proceeds From Collection Of Subscription Receivable",
        "terseLabel": "Collections of subscriptions receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfSubscriptionReceivable",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from common stock net of issuance costs.",
        "label": "Proceeds From Common Stock Net Of Issuance Costs",
        "terseLabel": "Gross proceeds from common stock"
       }
      }
     },
     "localname": "ProceedsFromCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock upon exercise of warrants.",
        "label": "Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ProceedsFromPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from paycheck protection program loan.",
        "label": "Proceeds From Paycheck Protection Program Loan",
        "terseLabel": "Proceeds from Paycheck Protection Program loan"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgramLoan",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_RaduVitocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Radu Vitoc.",
        "label": "Radu Vitoc [Member]",
        "terseLabel": "Mr. Vitoc"
       }
      }
     },
     "localname": "RaduVitocMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RatchetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratchet.",
        "label": "Ratchet Member",
        "terseLabel": "Ratchet"
       }
      }
     },
     "localname": "RatchetMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RatchetShareExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratchet share expense.",
        "label": "Ratchet Share Expense",
        "terseLabel": "Ratchet share expense"
       }
      }
     },
     "localname": "RatchetShareExpense",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ReceiptOfStockSubscriptionReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of stock subscription receivable.",
        "label": "Receipt Of Stock Subscription Receivable",
        "terseLabel": "Receipt of stock subscription receivable"
       }
      }
     },
     "localname": "ReceiptOfStockSubscriptionReceivable",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ReclassificationOfWarrantLiabilityToEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrant liability to equity.",
        "label": "Reclassification Of Warrant Liability To Equity",
        "terseLabel": "Reclassification of warrant liability to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilityToEquity",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_RegeneronPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron pharmaceuticals inc.",
        "label": "Regeneron Pharmaceuticals Inc [Member]",
        "terseLabel": "Regeneron"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party [Member]",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_RemainingConsultingServicesSettled": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining consulting services settled.",
        "label": "Remaining Consulting Services Settled",
        "terseLabel": "Remaining services settled"
       }
      }
     },
     "localname": "RemainingConsultingServicesSettled",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ResearchAndDevelopmentIncentivePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentive.",
        "label": "Research And Development Incentive Policy [Text Block]",
        "terseLabel": "Research And Development Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentivePolicyTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ResearchAndDevelopmentIncentivesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentives receivable.",
        "label": "Research And Development Incentives Receivable",
        "terseLabel": "Australia research and development incentives receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentivesReceivable",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Experimentation Tax Credits Carryforwards Expiration Year",
        "label": "Research And Experimentation Tax Credits Carryforwards Expiration Year",
        "verboseLabel": "Tax credits, expiration year"
       }
      }
     },
     "localname": "ResearchAndExperimentationTaxCreditsCarryforwardsExpirationYear",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "maia_ResearchProgramExpenditures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research program expenditures.",
        "label": "Research Program Expenditures",
        "terseLabel": "Research program expenditures"
       }
      }
     },
     "localname": "ResearchProgramExpenditures",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_RestrictedCommonStockAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted common stock award.",
        "label": "Restricted Common Stock Award [Member]",
        "terseLabel": "Restricted Common Stock Awards"
       }
      }
     },
     "localname": "RestrictedCommonStockAwardMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share-based payment award, warrants, valuation assumptions.",
        "label": "Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions used in Calculating Value of Warrants Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ScheduleOfWarrantExercisedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of warrant exercised.",
        "label": "Schedule Of Warrant Exercised Table [Text Block]",
        "terseLabel": "Schedule of Warrant Exercised"
       }
      }
     },
     "localname": "ScheduleOfWarrantExercisedTableTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage",
        "terseLabel": "Exercise price percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted",
        "terseLabel": "Percentage of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, shares vesting commencement date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Vesting Commencement Date",
        "terseLabel": "Shares vesting commencement date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesVestingCommencementDate",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, vesting over period, number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Over Period, Number",
        "terseLabel": "Shares vesting over period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingOverPeriodNumber",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, vesting quarterly instalments, number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Quarterly Instalments, Number",
        "terseLabel": "Number of shares vesting quarterly instalments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingQuarterlyInstalmentsNumber",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "maia_SimpleAgreementForFutureEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simple agreement for future equity",
        "label": "Simple Agreement For Future Equity Disclosure [Text Block]",
        "terseLabel": "Simple Agreement For Future Equity"
       }
      }
     },
     "localname": "SimpleAgreementForFutureEquityDisclosureTextBlock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquity1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "maia_SimpleAgreementForFutureEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simple agreement for future equity issued.",
        "label": "Simple Agreement for Future Equity Issued",
        "terseLabel": "Simple agreement for future equity issued"
       }
      }
     },
     "localname": "SimpleAgreementForFutureEquityIssued",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_StockBasedCompensationExpenseRelatedToAccruedBonusBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense related to accrued bonus balance.",
        "label": "Stock-based Compensation Expense Related to Accrued Bonus Balance",
        "terseLabel": "Stock-based compensation expense related to accrued bonus balance"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseRelatedToAccruedBonusBalance",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_StockIssuedDuringPeriodSharesConversionOfSafe": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of SAFE.",
        "label": "Stock Issued During Period Shares Conversion of SAFE",
        "terseLabel": "Issuance of common shares upon conversion of SAFE, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfSafe",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_StockIssuedDuringPeriodValueConversionOfSafe": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value conversion of SAFE.",
        "label": "Stock Issued During Period Value Conversion of SAFE",
        "terseLabel": "Issuance of common shares upon conversion of SAFE"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfSafe",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_StockIssuedDuringPeriodValueWarrantsToUnderwiter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Warrants to Underwiter",
        "label": "Stock Issued During Period Value Warrants to Underwiter",
        "terseLabel": "Issuance of warrants to underwriter in connection with initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsToUnderwiter",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_SubscriptionReceivableForIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription receivable for issuance of common stock.",
        "label": "Subscription Receivable for Issuance of common stock",
        "terseLabel": "Subscription receivable for issuance of MAIA common stock"
       }
      }
     },
     "localname": "SubscriptionReceivableForIssuanceOfCommonStock",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_THIOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "THIO.",
        "label": "T H I O [Member]",
        "terseLabel": "T H I O",
        "verboseLabel": "THIO"
       }
      }
     },
     "localname": "THIOMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_THIOTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "THIO Therapeutics, Inc.",
        "label": "T H I O Therapeutics Inc [Member]",
        "terseLabel": "THIO",
        "verboseLabel": "THIO Therapeutics, Inc."
       }
      }
     },
     "localname": "THIOTherapeuticsIncMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "maia_The401KPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The401 K Plan.",
        "label": "The401 K Plan Member",
        "terseLabel": "401 (K)"
       }
      }
     },
     "localname": "The401KPlanMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_ThioMergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "THIO Merger Agreement.",
        "label": "THIO Merger Agreement [Member]",
        "terseLabel": "THIO Merger Agreement"
       }
      }
     },
     "localname": "ThioMergerAgreementMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs.",
        "label": "Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_TransactionCostsIncurredInConnectionWithEquityFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs incurred in connection with equity financing.",
        "label": "Transaction Costs Incurred in Connection With Equity Financing",
        "terseLabel": "Transaction costs incurred in connection with Equity Financing"
       }
      }
     },
     "localname": "TransactionCostsIncurredInConnectionWithEquityFinancing",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_TwoThousandAndNineteenPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Nineteen Promissory Note [Member]",
        "label": "Two Thousand And Nineteen Promissory Note [Member]",
        "terseLabel": "2019 Promissory Note"
       }
      }
     },
     "localname": "TwoThousandAndNineteenPromissoryNoteMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyOneConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one convertible promissory note.",
        "label": "Two Thousand And Twenty One Convertible Promissory Note [Member]",
        "terseLabel": "2021 Promissory Note"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneConvertiblePromissoryNoteMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyOneWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one warrants.",
        "label": "Two Thousand And Twenty One Warrants [Member]",
        "terseLabel": "2021 warrants"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneWarrantsMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty Promissory Note [Member]",
        "label": "Two Thousand And Twenty Promissory Note [Member]",
        "terseLabel": "2020 Promissory Note"
       }
      }
     },
     "localname": "TwoThousandAndTwentyPromissoryNoteMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandAndTwentyWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty Warrants [Member]",
        "label": "Two Thousand And Twenty Warrants [Member]",
        "terseLabel": "2020 warrants"
       }
      }
     },
     "localname": "TwoThousandAndTwentyWarrantsMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandEighteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock option plan.",
        "label": "Two Thousand Eighteen Stock Option Plan [Member]",
        "terseLabel": "2018 Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockOptionPlanMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_UniversityOfTexasEuropeanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of texas european.",
        "label": "University Of Texas European [Member]",
        "terseLabel": "University Of Texas European"
       }
      }
     },
     "localname": "UniversityOfTexasEuropeanMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_UniversityOfTexasSouthwesternMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of texas southwestern.",
        "label": "University Of Texas Southwestern [Member]",
        "terseLabel": "UTSW"
       }
      }
     },
     "localname": "UniversityOfTexasSouthwesternMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_UnrelatedThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrelated third parties.",
        "label": "Unrelated Third Parties [Member]",
        "terseLabel": "Unrelated Third Parties"
       }
      }
     },
     "localname": "UnrelatedThirdPartiesMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_UnvestedRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock awards.",
        "label": "Unvested Restricted Stock Awards [Member]",
        "terseLabel": "Unvested Restricted Stock Awards"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAwardsMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_WarrantDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Description",
        "label": "Warrant Description",
        "terseLabel": "Warrant description"
       }
      }
     },
     "localname": "WarrantDescription",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "maia_WarrantLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability noncurrent.",
        "label": "Warrant Liability Noncurrent",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityNoncurrent",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WarrantModificationValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant modification, value.",
        "label": "Warrant Modification Value",
        "terseLabel": "Warrant modification, value"
       }
      }
     },
     "localname": "WarrantModificationValue",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant one.",
        "label": "Warrant One [Member]",
        "terseLabel": "Warrant One"
       }
      }
     },
     "localname": "WarrantOneMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_WarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant two.",
        "label": "Warrant Two [Member]",
        "terseLabel": "Warrant Two"
       }
      }
     },
     "localname": "WarrantTwoMember",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "maia_WarrantValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant value.",
        "label": "Warrant Value",
        "terseLabel": "Warrant value"
       }
      }
     },
     "localname": "WarrantValue",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, exercises in period.",
        "label": "Warrants Exercised",
        "terseLabel": "Class of warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_WarrantsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised, shares.",
        "label": "Warrants Exercised Shares",
        "terseLabel": "Warrants exercised, shares"
       }
      }
     },
     "localname": "WarrantsExercisedShares",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "maia_WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued to underwriters in connection with the initial public offering",
        "label": "Warrants issued to underwriters in connection with the initial public offering"
       }
      }
     },
     "localname": "WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "maia_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.maiabiotechnology.com/20221231",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "CEO"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r196",
      "r451",
      "r452",
      "r455",
      "r456",
      "r522",
      "r571",
      "r636",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r196",
      "r451",
      "r452",
      "r455",
      "r456",
      "r522",
      "r571",
      "r636",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r386",
      "r530",
      "r553",
      "r572",
      "r573",
      "r585",
      "r596",
      "r601",
      "r641",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r386",
      "r530",
      "r553",
      "r572",
      "r573",
      "r585",
      "r596",
      "r601",
      "r641",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "MAIA Biotechnology, Inc."
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r345",
      "r386",
      "r414",
      "r415",
      "r416",
      "r529",
      "r530",
      "r553",
      "r572",
      "r573",
      "r585",
      "r596",
      "r601",
      "r632",
      "r641",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r345",
      "r386",
      "r414",
      "r415",
      "r416",
      "r529",
      "r530",
      "r553",
      "r572",
      "r573",
      "r585",
      "r596",
      "r601",
      "r632",
      "r641",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r387",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r212",
      "r387",
      "r613",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r212",
      "r387",
      "r613",
      "r614",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r630",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r201",
      "r202",
      "r203",
      "r250",
      "r251",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r421",
      "r422",
      "r423",
      "r437",
      "r438",
      "r447",
      "r448",
      "r449",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r498",
      "r499",
      "r503",
      "r504",
      "r505",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r600"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonus",
        "verboseLabel": "Accrued bonus expense"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r171",
      "r550",
      "r561",
      "r565"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r116",
      "r515",
      "r556",
      "r557",
      "r618",
      "r619",
      "r620",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r600"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r624",
      "r625",
      "r626",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r98",
      "r99",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "verboseLabel": "Stock-based compensation expense - MAIA"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance of common shares in connection with intial public offering, issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expense related to accrued bonus balance",
        "terseLabel": "Stock compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r31",
      "r39",
      "r135",
      "r303"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r143",
      "r152",
      "r170",
      "r192",
      "r232",
      "r241",
      "r245",
      "r252",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r451",
      "r455",
      "r480",
      "r600",
      "r637",
      "r638",
      "r681"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r166",
      "r172",
      "r192",
      "r252",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r451",
      "r455",
      "r480",
      "r600",
      "r637",
      "r638",
      "r681"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r446",
      "r590",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r108",
      "r109",
      "r446",
      "r590",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units, Authorized",
        "terseLabel": "Capital shares, authorized"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r567",
      "r568",
      "r600",
      "r615"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r168",
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period",
        "terseLabel": "Current cash reserves",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r134"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r160",
      "r161",
      "r200",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r436",
      "r447",
      "r448",
      "r458",
      "r460",
      "r461",
      "r471",
      "r481",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r510",
      "r511",
      "r533",
      "r534",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r160",
      "r161",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r436",
      "r447",
      "r448",
      "r449",
      "r458",
      "r460",
      "r461",
      "r462",
      "r465",
      "r471",
      "r481",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r510",
      "r511",
      "r533",
      "r534",
      "r554",
      "r555",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants and rights exercisable period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r71",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price, per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "periodEndLabel": "Warrants Outstanding, Ending balance",
        "periodStartLabel": "Warrants Outstanding, Beginning balance",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsExercisedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r147",
      "r156"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r265",
      "r266",
      "r570",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r624",
      "r625",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "MAIA Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r600"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value, 70,000,000 and 30,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively,10,955,904 and 7,584,980 shares issued and outstanding at December 31,2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r26",
      "r177",
      "r179",
      "r186",
      "r547",
      "r551"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r132",
      "r133",
      "r249",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r50",
      "r51",
      "r132",
      "r133",
      "r249",
      "r566",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of SAFE into MAIA common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Share converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r190",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r297",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r144",
      "r145",
      "r150",
      "r196",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r501",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r61",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)",
        "verboseLabel": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Principal amount forgiven"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r136",
      "r138",
      "r281",
      "r501",
      "r581",
      "r582"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Convertible note amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r16",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Percentage of interest"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r173",
      "r580",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r17",
      "r196",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r501",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r135",
      "r138",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense related to deferred compensation balance"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.",
        "label": "Deferred Compensation Arrangement with Individual, Recorded Liability",
        "terseLabel": "Deferred compensation balance"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRecordedLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Shares Issued",
        "terseLabel": "Options issued"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued deferred compensation",
        "totalLabel": "Deferred Compensation Liability, Current, Total"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r142",
      "r151",
      "r616"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs",
        "totalLabel": "Deferred Costs, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r107",
      "r672"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r671"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r107",
      "r672"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r107",
      "r672"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": {
     "auth_ref": [
      "r107",
      "r672"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r107",
      "r672"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Deferred compensation",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r107",
      "r672"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "auth_ref": [
      "r382",
      "r531",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined benefit plan.",
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Employee Retirement Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Contribution to employee"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r174",
      "r175",
      "r479",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Derivative liability, bifurcated put contained in convertible notes payable",
        "totalLabel": "Derivative Liability, Total"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative liabilities:"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r126",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r187",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r213",
      "r216",
      "r218",
      "r219",
      "r220",
      "r222",
      "r469",
      "r470",
      "r548",
      "r552",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "Net loss per share basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r187",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r216",
      "r218",
      "r219",
      "r220",
      "r222",
      "r469",
      "r470",
      "r548",
      "r552",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Net loss per share diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r678"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Net effect of foreign currency exchange on cash",
        "totalLabel": "Net effect of foreign currency exchange on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r194",
      "r426",
      "r441"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r670",
      "r673"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r670",
      "r673"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other nondeductible expenses/(nontaxable income)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r670",
      "r673"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r670",
      "r673"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Debt discount and derivative liability at the issuance date",
        "verboseLabel": "Derivative liability on convertible notes payable"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized compensation expense, recognized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r669"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r669"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Shares Issuable upon Exercise of Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r66",
      "r162",
      "r181",
      "r182",
      "r183",
      "r197",
      "r198",
      "r199",
      "r202",
      "r209",
      "r211",
      "r223",
      "r259",
      "r321",
      "r421",
      "r422",
      "r423",
      "r437",
      "r438",
      "r468",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r515",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "negatedLabel": "Extinguishment of derivative liability in connection with debt conversion",
        "terseLabel": "Extinguishment of derivative liability in connection with debt conversion",
        "verboseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r39",
      "r65"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Gain on remeasurement of warrant liability",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability",
        "verboseLabel": "(Gain) loss on fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r472",
      "r473",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r295",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r473",
      "r526",
      "r527",
      "r528",
      "r581",
      "r582",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r295",
      "r347",
      "r352",
      "r473",
      "r526",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r295",
      "r347",
      "r352",
      "r473",
      "r527",
      "r581",
      "r582",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r295",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r473",
      "r528",
      "r581",
      "r582",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r295",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r526",
      "r527",
      "r528",
      "r581",
      "r582",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r39",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (loss) on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of convertible notes",
        "terseLabel": "Loss on extinguishment of convertible notes and convertible notes, related parties",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "verboseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r193",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "negatedLabel": "U.S. loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r27",
      "r141",
      "r148",
      "r157",
      "r232",
      "r240",
      "r244",
      "r246",
      "r549",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Pretax book loss",
        "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r193",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "Foreign loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r194",
      "r427",
      "r428",
      "r434",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r180",
      "r424",
      "r425",
      "r428",
      "r429",
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Due to related parties",
        "totalLabel": "Increase (Decrease) in Due to Related Parties, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Australia research and development incentives receivable",
        "terseLabel": "Australia research and development incentives receivable",
        "totalLabel": "Increase (Decrease) in Receivables, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r137",
      "r149",
      "r184",
      "r231",
      "r500"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r30",
      "r230"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r192",
      "r252",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r452",
      "r455",
      "r456",
      "r480",
      "r578",
      "r637",
      "r681",
      "r682"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r146",
      "r155",
      "r600",
      "r623",
      "r631",
      "r677"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r167",
      "r192",
      "r252",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r452",
      "r455",
      "r456",
      "r480",
      "r600",
      "r637",
      "r681",
      "r682"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r11",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r17",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r267",
      "r268",
      "r269",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Minority stockholder ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Minority Interest Ownership Percentage By Parent",
        "terseLabel": "Ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r114",
      "r118",
      "r176",
      "r178",
      "r210",
      "r211",
      "r620"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income Loss Attributable To Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r213",
      "r214",
      "r217",
      "r220",
      "r232",
      "r240",
      "r244",
      "r246",
      "r579"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to MAIA Biotechnology, Inc. shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r110",
      "r321",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Schedule of Unvested Restricted Shares"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Off Balance Sheet Credit Exposure Policy Policy [Text Block]",
        "terseLabel": "Off-Balance Sheet Risk and Concentrations of Credit Risk"
       }
      }
     },
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r232",
      "r240",
      "r244",
      "r246",
      "r579"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r47",
      "r55",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r112",
      "r113",
      "r115"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent",
        "negatedLabel": "Foreign currency translation adjustment",
        "terseLabel": "Foreign currency translation adjustment",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income Expense Net",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Overallotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total MAIA Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Cash issuance cost, net"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r2",
      "r322",
      "r323",
      "r344",
      "r588"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "terseLabel": "Deferred compensation to former officers",
        "verboseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r77",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r388",
      "r588",
      "r589",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r600"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value, 30,000,000 and 70,000,000 shares authorized at December 31, 2022 and December 31, 2021 respectively,0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds From Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, warrants, and embedded conversion features",
        "verboseLabel": "Proceeds from convertible debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from initial public offering",
        "verboseLabel": "Proceeds from sale of common stock in intial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of transaction costs",
        "verboseLabel": "Gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.",
        "label": "Proceeds from Issuance of Unsecured Debt",
        "terseLabel": "Proceeds from unsecured loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosurePaycheckProtectionProgramAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from equity financing",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r97"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds From Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r165",
      "r176",
      "r178",
      "r188",
      "r192",
      "r201",
      "r210",
      "r211",
      "r232",
      "r240",
      "r244",
      "r246",
      "r252",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r450",
      "r453",
      "r454",
      "r470",
      "r480",
      "r549",
      "r579",
      "r598",
      "r599",
      "r620",
      "r637"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss, including noncontrolling interests",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.",
        "label": "Receivables From Stockholder [Member]",
        "terseLabel": "Receivables from Stockholder",
        "verboseLabel": "Subscription Receivable"
       }
      }
     },
     "localname": "ReceivablesFromStockholderMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r369",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r369",
      "r518",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r516",
      "r517",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransaction1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments Of Related Party Debt",
        "negatedLabel": "Payment on loan payable to officer"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayment of unsecured debt"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r101",
      "r159",
      "r689"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development expenses",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and experimentation"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r68",
      "r154",
      "r560",
      "r565",
      "r600"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r162",
      "r197",
      "r198",
      "r199",
      "r202",
      "r209",
      "r211",
      "r259",
      "r421",
      "r422",
      "r423",
      "r437",
      "r438",
      "r468",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r77",
      "r78",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r388",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r77",
      "r78",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r388",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r185",
      "r192",
      "r228",
      "r229",
      "r239",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r252",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r480",
      "r549",
      "r637"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net sales",
        "totalLabel": "Revenues, Total"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Stock price per share",
        "terseLabel": "Common stock per share",
        "verboseLabel": "Sale of common stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSimpleAgreementForFutureEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "auth_ref": [
      "r74",
      "r76",
      "r85",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of derivative liabilities related to convertible notes"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Tax Rate of Income Tax Benefit Differs from Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r88",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Activity and Information regarding Outstanding and Exercisable Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Assumptions used in Calculating Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule Of Subsidiary Or Equity Method Investee [Table]",
        "terseLabel": "Schedule Of Subsidiary Or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Shares vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "terseLabel": "Founders shares cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Shares, Unvested balance",
        "periodStartLabel": "Shares, Unvested balance",
        "terseLabel": "Unvested shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Shares, Vested",
        "terseLabel": "Founders shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options Outstanding, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options Outstanding, Cancelled/forfeited",
        "terseLabel": "Cancelled/forfeited, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options outstanding, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options Outstanding, Ending balance",
        "periodStartLabel": "Options Outstanding, Beginning balance",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Additional incremental stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfUnvestedRestrictedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Shares vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Fair value assumptions, contractual term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfOptionsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Sale of common stock, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r66",
      "r162",
      "r181",
      "r182",
      "r183",
      "r197",
      "r198",
      "r199",
      "r202",
      "r209",
      "r211",
      "r223",
      "r259",
      "r321",
      "r421",
      "r422",
      "r423",
      "r437",
      "r438",
      "r468",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r515",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r223",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r66",
      "r67",
      "r68",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common shares upon conversion of convertible notes, Shares",
        "verboseLabel": "Converted shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of common stock sold",
        "verboseLabel": "Issuance of common shares, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Forfeited",
        "negatedLabel": "Cancellation of restricted common shares, Shares",
        "terseLabel": "Cancellation of restricted common shares, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Issuance of restricted common shares, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r68",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Issuance of common shares upon exercise of stock options, Shares",
        "negatedTerseLabel": "Options Outstanding, Exercised",
        "terseLabel": "Issuance of common shares upon exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityAndInformationRegardingOutstandingAndExercisableOptionsDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Convertible note issued",
        "terseLabel": "Issuance of common shares upon conversion of convertible notes",
        "verboseLabel": "Issuance of common shares upon conversion of convertible notes, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares",
        "verboseLabel": "Issuance of common shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Forfeitures",
        "negatedLabel": "Cancellation of restricted common shares",
        "terseLabel": "Cancellation of restricted common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Issuance of restricted common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r66",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common shares upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r110",
      "r111",
      "r117",
      "r162",
      "r163",
      "r182",
      "r197",
      "r198",
      "r199",
      "r202",
      "r209",
      "r259",
      "r321",
      "r421",
      "r422",
      "r423",
      "r437",
      "r438",
      "r468",
      "r490",
      "r491",
      "r495",
      "r515",
      "r557",
      "r558",
      "r623",
      "r631",
      "r677"
     ],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r191",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Common stock, conversion description"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Common stock, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r496",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r496",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r496",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r496",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r523",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary Or Equity Method Investee [Line Items]",
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebt": {
     "auth_ref": [
      "r3",
      "r145",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Unsecured Debt",
        "terseLabel": "Unsecured debt",
        "totalLabel": "Unsecured Debt, Total"
       }
      }
     },
     "localname": "UnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r224",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Deferred tax asset, increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "MAIA Stock Warrants",
        "verboseLabel": "Shares Issuable upon Exercise of Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSharesExcludedFromCalculationOfDilutiveLossPerSha",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInCalculatingValueOfWarrantsGrantedDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Warrant liabilities:"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Warrants",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesAdditionalInformationDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfChangesInFairValueOfTheDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialLiabilitiesScheduleOfFairValueMeasurementsOfEmbeddedDerivativeLiabilitiesAndWarrantLiabilitiesDetails",
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "terseLabel": "Weighted average common shares outstanding diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r213",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted average common shares outstanding basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.maiabiotechnology.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235042",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472162&loc=d3e58407-109430",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0000950170-23-009766-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-009766-xbrl.zip
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MTA'VSFV0J.V((8:MT=&X20%'-YAJIR%QVVL)=4$+Z*H5I.4^!6#"(2CQ@"Q
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M*]@()4_F'&LN7<^$4U35,GNP=A>-CS;>%4&1Q.WX> ^D@%GLE=T:P)%ES]]
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MQXN)B4AZ)IKZRXZ4W'*H>;0.NJ6^(R(5*R,!<#]S:\!A%).;8PAW.7]7O7N
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M*6F:/GM=.W 6D%]LR^^TO58<Q(^+F?X/4$L#!!0    ( ."&>%9-N:_C[!T
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M$H,+"P<'&P?_-UP@+(_?%"AQ<&\*X%')/<$W=:)F$WQ#0",?^ZFBG9!=2/.
MULQYE.@:A_ *Y^%OT/X=V3\'+.!_A.R_@/T5URQ @@W"! ^;$H  )QIX"+%.
MNG2"$0<''\F<KTZB&3AQ#SG37@[UB'#$*:ER-=NC@0[B%=8+VA-')"@<#81F
MM[4>:2#%T<#S0<>K:["1Q_@0-$# _Q:ZJ3O:>H#'C[H5C9#S84<#\BV1:,!?
M 'HH,O)$E@D-(&^T4**!3R9*:*"-OA61 EG!/8B^(KH00P'=:* +7K2M$[OM
MM/65_T([MKJ(A7P>'^=[GO>0S.UJPE<]PT\6B 'V2QZ'!.K(/DBH[R86Y)=3
MA*%_M+.DCROJVZ+XJOUHWZ>$2\8X?XS)?_*7TH PX#L:^*-=H[^@:R "8V>@
M@;=T'9 3GLTE!#8=&J!6_A7<)CB3#(JB,"%  R-EV=!E$A.D&NM! $(9%>1[
M'0T 9FA@U2XSZ^\8)1+F([(R7KBHK[RB!HJL?N;@U\EB@>-3>&\Y<&I;VJZA
M,&.FYG6M%_''H1F.(\-]JRG(RI8LBYOCRI7H69L7"^O(C<8HM\BO4R'W_1SV
M_-GO\D1KJMMN+(6<@$52W[$=U+SAN$U,L,:H:9D[%R,UW!@'#63H%2^%#RJ-
MGR T>:Q%LU0LKW],VY,^ZHI_E-IY8=F3^?-HSK'.=5HUMF9MRL']^Q+#STPR
MRB8Q3&80(.^P!KJ*3B*O:@FOXO%N/J*.:WDQW@.);E6?G)1;SB!0PW$N"Q;6
M9%; /B/H<4$\/5Y9N%.]64S:F.J9ZDTN_A,;A=KM/13Y##PE H!70"8)^?^'
M$/T?,$I&$5%DC_?^D$>W<GPE:@PN=*WOQN-W]:&$'5%XJER'63F(?C3 :6)X
MT8D&LLPQ^DD'_,AX-$ &G1:<0P.*):ZT70BKKA2'Z.4,$L-G(B-)QGS3F<%#
M-H%^FQZ*[%(L$E.&IKZ.!3.*7K8_1E0(-?OZ/.^)ZP!1<MM@K*\T3V1I<V$V
M_)EU)$"H$6VOT1J2)R-$]9"QY,OQ@DV<B5?C\OO!>(=%)3C#,JZ4>:OT3D&6
M_[T21^7:.GC3G9S%O?0YR_Y8[$K\YV%RDBI[:FYG2>73LXIV#JDW0^6SUM-
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MF+;+]J)X=$>&JE54ERZNVD,\;%2[RI(NAOY-=&^SNWM5:JI>GC6G?T.PP"/
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M]5?'T] R"KHV;C1I.O%RUV%LV,5P/YDM\L@$!YEW#SMSUDM\-7\:D6&2LCW
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M:_QO_<"'CN'\L&&(,NQ29WC^ZK/N'(Q6XEP!XB$M.2K+BI[Y-U!+ P04
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M -%$V; G_V<9@>R 0%S]BJ5I(=3PY7 /B"^,4+PNODO&:[L-G%E3&'-:\-%
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M[V?=QWY)CXN2,^D*':1"FJ=_X:D1EBQFE5@%C$(06</JTX5@JSM_4:LQDO!
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MFM_R/X;#Q1"X-3;05GBO[F Z"R$PGB-<ELT:S".;A"5INJGF(Q=K#!D7LF2
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MEXD3+\;!X8G!+Y64W*=B;5VIC(CIUQ<.RZ:72ELVRB,V D.F6<H>/I_=>ZS
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M $R5 &7,"=.+*V7R)K>@*J/VTX<B-OPH6Z$1% 137&;QSHV>X9'U6J (8?C
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MU(P044%N$0X>7NY_+H* @8&!C85-BH-#RDU+0<O]_]J>NP "=& >X242 AV
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M.)>+FMR0D*8L]+7MW"RDGKA630SV0T."RFNS$]NA1<N0W,#J>U.&(N)Q0)$
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M%^PW\L<FNBL#G!1-(*W$'YHP#=#7# M:-K<LX/IDJ&BE;=C+93?'=0S!R[4
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M>ZKD;X,"]SR]-+X3-DT)F<=#;(I/PGZ71/-?TGB7WO?H-$\_SL->24VH(@X
MV!*3Q6<!<T6EKT^(:7R^[C839'(H9H:.7P+Q\*6"6G/+?#GD<9(=1*-(1YA.
MEXC_15B\\BR#$3N7EVN%1<!50!K6;MQJ$P/D3A;8GIES3W+>EGV3Q=A2%SJ[
M64>8W8BEGR_.(I=4UTSI?4^M=9)^Q7)!:HY?E"C"HHF>)T? !3"S)W &!!/A
MPD7+I\N9CR&.1!HRDK0R1.H(_T]0-Z4;M@,[[R+%M@9/\,@0(7QZS_@B/OU<
M%C1T)X.Q^4:_YT_-I/C%F"6E6S13V9[9ZT>Z'U]'7,",JW)$)[<RN5CAS5Y
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MO+0H74EF%3C@6A5_HUX,Y$4P_W>"F*  5N[2Y0,YL/3A]W';&<:\-:[.V!4
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MK/:O8I(^1^X?Y7,^[FS"SH4ZN)9^]8HB^@+]6-B2.!2MIMA=G9T4Q_K>'A7
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M=NW$/D1,=-9K<2P4%K5BP$VO3(;84+S^/6H?=,%$1^AEQ]TQG=/$+0?EZ6(
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M.GH/84IUU7>OKRA?RQ-G.MYM)5HAPNK=!/I%AW7^#S_OP.?_!5!+ P04
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MSE8-:@XK1CS%KYB:8,DG&5.^YVFL7UACD%/<OH*ESD[)[,@Y))63F=O,Z04
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M0Z<-)Y^*T]C#R6K/%'S9HO+ZC"7@OHQ.+)*$KZ:Z 5(MA;\#V680.6I@JD)
MW@C?O/PX#[UZ0'V?NW2?R(CX9J$?V^N@!TY\+GL\P'B=HJH!?[>GI1/Z]-"
M7G)>8D['SKMS34SPBFGOMV;G8VP7)C?+H[,W].;]L;]]8-"N@YI%.F(.^"]G
MWH X(OQO7;&,O8N<% ,99V29AX1=TV:4!ZT-Y$\$S(8_KJ0.V"FK(Y['!OL
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MQL<I!D;+WEN>HB/H1'!+^IP\^X=Q;-&,\@/)Y!HT&EU!%:]8V5X5ES/%3W>
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MS\*'/90M3+;NA^=\A236T\U'RT[>2H<6D[6&>:FJ;QODBOJ]F=><.K3B=-W
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M>B3O*%&0(.9J#*=OM/;)F\LFHK;PVAMIE.#6'KS8>>C U]D_$LG<%!U $BW
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M*SOJZ.:_8C0COL,G?@&PQ!XIGG%?;0D3?[7EYPMP5VSS[U@WC:NH-.]!6;R
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M"\<YQBA 6)#\//VL'\7\5/#8:ZOBC7[,X(@HZ7*UWUJ4LL))P*?!GHS5A\E
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M1$**Q%*DC&:2M:;Y2>F'_TT;/SA6+4TO5@2IE/='\7'>?FD,N=E-/JG59%&
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M%G2*W"L)]\-; %4/[-?=PZ9Z,0B;73:^I:5VC\!3.MD8(Y;9:+"C>7W45B5
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M3,S@>*'NE0)S=.!;:(.F'>G>$V)(-V8L;X_V5(F6XZS[]=G;YW)0M/OSS'8
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M;;(LE:R#X_._+./Z5T/ORZ__ 5!+ P04    " #@AGA6[X$][PCH  #&'@$
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M=N0)BW_0J:B5[*M\HZ<5#O8U*X;E)8T<?VN\IXVA*+"T1P;E(#M3P%0_^!5
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M#1[P&]UY\I!+C!0/]H=FAF>RW!E<T=V!#&:+6Z!F@ZO.!!SV9YDACC,%1$+
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MF&F3A_$] = 62KG4NU&KF@!_5>-?BITC"+<Z^=EQIY7\7+[ZL1TTHBED//Q
MA-PGHMUR<CQ=J*$9;FBLIW)*G_)Y4520CE:U>4]A>+;+A DKK&EI;CKD412A
MQZ9WK.O6R? 0W!F$XLJU^AVN"4@DILZHQ!5$Q]=EQ=<EF8\7"6* 9H.E6-%\
M'VO+M/U3XU+2940FFR9?["USJ!MQ(JD/5EM+E!IN/7?&V;;;9I7?M\#^U)>I
MM\[( BGXF%UE[+2C G+R_1CVNYDA]8TCT4$/K:$] OQ5)4&(TRT,-9H7GH5Y
M/0\+?7(%&E^T3MO#4@:R4W):U8GEFV;622=L7Z?OF"QF' 4<6PYIGR$2?DFR
M9/<U1#/ZSGKKIVO^YQ0W+P)?FRR)"4:DR20\^2PO3_QZ("I-"5Z_ "/%9'?H
M3+2(VWLQ&CBVLLJ3^&3I=MW\_EU+^YB%3[;G#I)_W3_-HZFJ=D.=,3X\>G*_
M.=Y (:1.FPDDE80P.9\&_;)KXG"H7E)S2>&(9^7J)9FIVWC B['9WVQ+<^I<
MJ6%GZ^[HRTP7U"]RTK9][RZ;->U>O1 G>+EG[M(#F"YZ1.D"&AH&\X1A-*,R
M:PA!#"$4>?8-@PROF>X,VLE]^EM\%7O//?*^V.-1=GBVUN-<U8]2Z=7K:^-N
M&1$!.KF<5-]]0&WH*8B=Z9=Q:29#=89MVQ8B1/0+ZH^KT#RMSF;/>>#;I/)-
M;]PU"(VC^/TP;\<Q.JW<T;L[=Z$O;A-S3!#BV[\+";2WJZJ*P;A)WN-U<WF'
M8<T26\T"GZ+6F:MHSU2FPR35-H-DO_7$/6=!"=.@'TO44!C'!YE^!K_Q=CG@
M&P7I8A,33--.N^N,<8_=^91#8ZMH0L2U.[XJP[SZ<EPRZ?> NSL$KXVB1Z_7
M^HOXSEI:JMHM^\<+E\_/LOH8/J@8ES0<@(-YE/K8^R=,?+:OX1BN^9*ZR)T>
M]+,=17*AI@L=#M,YXT"KP31(.+]^-A.E&M?SYT&/9#D71[9^JW370U=OW5M%
ME#;V,E\22[^<>1Q/HFYAB1?:49"W<;L+LUN)8IV'1UY86[54-]F==]3RBVP&
MO1C3SVYF+'J=E<J.6NCG2+,\?<MMI]/Z%XLR77#@;P*Y+*V4)+&$L%Q5!JUD
MJ(!"#]A__4C"PC+<0-I"KJZ^KNJC@KSK$^2=-^S#/+7,T^.)_8K:) >%Y-D^
M%,JF*;4-]X!O#SM;J9189<$:M7.,[_:)L:N9EG\;B>2-) Z5-Z*'+!MR<K9G
M&D7VL%\G(9>0DU@)<RG9+XYA)10CD8(NK]CK*R,#MR?Z/)2NQ[<T7Y+4WIK
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M-&HA3=P,Q3 >@KWC?NA0W)^1,U/U_)3&)WJPG@Q-", K2$5^,Z7.::F%:9H
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M4N$!:]K#D)W7.,*D"EAI O- 34('&LS@#MEVP)?97ZFR<02N86=4",NC7CP
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MPVNBGL/[^,S !E_TIT/VQE1HZ&YQD712+S1$ASH[4^2"OP;!Y&7=P1L!QW@
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M%)2$SR"DU&"^D2UAEL-!1-3=-JE!1 9A$D=&%L+G614X^U%9'V% PDQ7@D/
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M@/^+O/>.:FKK^D:CJ*B *$@O00%!JDJ3EHA($R%B 04A*ET$1*0'0I$B541
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MQLTFN._0]O!X>63$-5G/>]HA-7Z'46J^"F>.>"2\]%[/AW!0NBC>V>.R\)+
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M]^[EIT.Y2>FME")=]W!.6O>("Q.T5P'94I[-(:Z-9.EH&1?'7S]2+1_HWAE
M2TGXL0$+TS#L0K#8.BFZ>G$DG-[1>QEAF':.NZ%^]L=.])*5$*R[6C&<"0*\
MX%/5G@7!2]L\%;.J/W^5EN9^?VRZY*?%4.FO%!M F56J#J[?.O^1^)ZG2[$#
M?WV:$ E=N5H'A&\XH,3,;+01^CSU$72<Z+OS![U.MHDS89"F'\EN*O;#7\>-
MXX_?\E7$6<97YW5,WKIUL:==7TWX"(^.5JDP2*GM9)T+4:W1"AR5P=^O946B
MBPY<[T/<$ZM;D;H0U/: CW=6R$NW>/KQ\Y^R28GFF%,'J&T4JRM4'Y C>2IF
M<@XC\8A?(JXAM/<MDM>'1^KY8_7+FV?>ZX.:/9?P5F/1QIY3L"$AW0HR/@JR
MWYE7)SP](H\GZZ3^K^%CA<F/ Q_M#W2V8=FYA#A!46N:1QVR\;5A@DQ[T$\T
M7RL\K0D[OV=5X.([_;&Q]SN-U<M4P.D[H[:E,X29H'H@!&\=J4B'.O-GM65:
M_6R_TS87"-5# )9P$+6H!-@H-PY%Y0!\ZXFN?[W4#S='?HM'%[5NP==7(:@/
MF+N #F ;KX$0_XR(IQU(8(*>S_R;2]NE##NP=>0*=GXJ(+4Y82^Z"1VIL1RI
M13AI]1/JH3K^7NJ:Z"D)]L4CS]X>">[3EC*"'BM#'G#9GLQ>2BB8O9;64BP[
MN:]Z953@6)B"I5;IHCWTS.'ZYRXM2"(W/0<Y\\$70))[,@'GK ']ERL0@#&\
M9AVPI:&WMS+:*"YC^$B,DK,WK^5,U;,"-TB7NX_#U](6V.C5;W$K%7SBPHOP
MRTN1PA;?H.1GC![HFIF6.A,4#,AB103\KU<LD-_"YHL9%G0$/G<^K8MVZ-X'
MWYXF&ZE0EU3L@'A%_)2ZP!5#,?,;TJH37/S3$ANS-H?^(T%WK?O0OD)J.2>!
M0+F&Y0G":T"?E2\:7P=@]3.:1LU[CH^WG/Q3!Q?="&[=RZ*XU7/!N?S?M1\_
MP#?AV3OMR9\56:@PTQ?[^GB4SU\Y*W"_I/S1I>ZO3;$RC9\131/5.FTJD\C_
M8?>RE=,5!G2[%]:&^?6^I&>==M]G_.+8<="[@+O^?35;88QCT"%'1K14))0L
M"&7H9O[]?&YYZWF@-[B="4*_7J/SK++23B++\/3CL"/(,64D+=+@[^=]J%6Q
M[05H,C!:E6:W_SHS@1;\5QN;B_]")FS$4E1C K/F;+3)D]]1 6Q6>,[G,5_X
MCW94/VP0V+>F8H:K:H/87:(DOK0T R0+.>8<I-J'M<<>Q(W)WV_5Z]?KPQEY
M!(4\;U104),^H#8M"8TLR8,26>G9V)GWO@#*V@- H^?S?4$'J$>8("*JD<Z'
M\\^JZ"$,;HW:I<1W'B,H5378LP:3*@M]7LY)GJ[T?//R[=WDA!>8D]!%3C*^
M82CRF0I4U"GIYVV_(#OOE!+E7$0,_Y#@#Y904MXBW!"AUE]49T3>Q F6K\J.
M$F93*J]_EKYJ/6Y^'S1SSN01MKR2ED:(9J3LH@\O[ 'DQ'-?,*/>&[YMFORF
M6[^[[+TG&OU5;:=S'3VP30O>35!\S]7-9.N]+/VA1+/Q3Q_VV#TXN_"#0@R3
MU4:"%98N\^9+1%W8!A"TD@+(E?V @[R<@[Y?5+60P)7;TG+3^CI#IQ*UW@Q@
M^/SRZS< (;@2Z![(B0?]$[<HRU0I%"V1'L# K2)GM;\$&L'EF: & ))-),P3
M-L  B#):G)^[/-F$Y#7("V>P7XR6+CCR[A]?%?GSL4<S>I)QF@EJ4Z+XT$,5
M@$!E/&#VRT*1<IUAA(K!+AP#@O8'FT^:'Z3(I=/+/TD,P[A(>N O(/#B; @V
MDCM Z&OC+ 9,K!9%YW?Y)=N=1U&JSR6?2%[%+PK\F2NB/[A,)PQI,HS5ZI>@
M4^>A:X'EQS?MC7,[5B&8[*QLM-PVZ$.=;1-8N.XJBHMF0.1D0ZBG-C^><7ZX
MJ69<T.  >B,VN]*.-6O0UK0P&H,*^<XW6?8,49.(=1E</4UR\XCMOO(QYSU7
MQ0?YQ,5*1GHF-]]QZOZELU4)L2BN)"(?[LOU9O?<BH\ID*NJ^8HOX8A\\.B0
M1]S6C+^%BY"[WD-;<670G.QSJ@5IG9H^E@8[FOVL)V7<)0KSO7OKJ=_U-EZ?
MNUZG,]+GT8!*3TOO<2JR@44)VB&Y3I+UA\,*VK)52ZK$5E+V2,>D?/?AU0)I
ML'PE:>N!I H1+CL00%HXFBL %PJPV]>U Y/GX4)!>-2*!U@(N2"KR'B)M_8-
MS/*KZAP+! ,8N9=4W$X+1]&?H);!TW!T^=9^Z/8L=!3ZO3COQW+CNL NIO']
M-UAFSQIR01(0OBT FXNU4-L:@CLU&"[Z4^1$P1QV@Q4 _@:Z<%\+$^C3E1(P
M_^XD8J3*[_#<S!C@:ET?5=ZO&/SO20/ '^-Z&;+KD-0:*BS'-Y\H^N8)'=(_
M8*EZYI>!![MT@ESH&>]2C_1!K:0&L0T@ZK.\&WPPJHXI[2LX46M88'>*K4HW
MW$/"=JEX+-Z@4F7&?SKN%!D<%B3RP#FE<N5>])0**/79>^OZ)]/!!J87%JT5
M(L<Z I!1G>.+TEEO' IS2A(SZ\U..PW>\E^^DY%^(ZF_3O*:V=.7%0'@;&-6
M?<RIY,O&H^'5J4_Z8RGX,"QGV;* +_ZF1NQ]:RA,$M-^Z.K"K7!AY$$0A;'L
M)NO?,:X8XE9W90CR?LQ*1*8K6W5JSLG6('9:P.NGZMUUS:HBV7J?4:DNVKV\
M!S:"/82KOI:7JA,ZY,+9N,/B(R>_MJJ#P_VU$UK<#U"WQX=:FS)$;YUZ]>I2
MS\GOB=-B".J1:JF/PH[J(BX?"NRFAONL,G^N%"ME"\H<>\#U&'G<+;MH8,8/
M&:<%SC4@S3Q!L8T.S_'ZX,&#=7E/\[DU7:6_*?U8G2^+G<Y;<^<R&$.'5GC[
M7ZG99R/5[Q!KHISJ5-5B.)+"SB<A+!,?@[_OTCF6KDE$M7)RI/F<SK8IY;]V
M\5;+0D&(4F_LY[LH^,,!I9U+MSM=*:?\[)@@"P_WXXF>J)=[JVB]#*_+-D-7
MP_RMEI72U4(RX<?X):^_&>DVQV3D3#_[0 ;'U[%Z%#AW#5)=K,K-AYVG)/3U
MS:IR&H+'PG![WI)^1,,B;$2ZU\%A$#E,34^AF_O='8MD3SF9;H,8+W%V?7U.
M+8O7SABV_O*X ZNW2XN=UX;/-?KA/@Z6ZXHJ)07KC'\)("K2GJ-VESL1&$F2
M&OF#C5W)ZU(L9N,E6NO.TAB#'J120WXW@YVF4D;)[ES*+CAKP@=C^;95<<@J
M;W^MM'"&@9F-L\TFV8:W%W.$VM@XO%GY0BC<\ :MU:LFG/0K;$MPMLFH)2,=
M!I9Z;XI1Z.-92*L,.!D+/1XDBBFK,!G+/[^6XBZ[H_,N]BNKR:3JM,AJ[?G%
M#-EG5#0QG1,WM.9*'-$?VC2MOM;(K["ODR76WO10O5BL8P8FN5D_3E;F9*JW
MYL6/;1)O0:QY*B7C"0=<;-@S#I;'\)8ZORR[5/.YF)]UOY%(ZY2VGO2U./5\
MXT?HN/SH]RK7WCAK2R17(\J6[@^4,/#0?Q)L=9NV'2U'A@P[L@?+Z/O4A.1(
M>@$0!]WI+=%FN#3U<L<XM@7V#,ZUR]VH]#)-*.>#[@O/?RD8I/28?LP/G_F@
MP/B 00^YX*"VA"U9E"@3M' >M6T68',Y*592(BCC7>ZU,\C^IU R'BR"G2D$
MB!2AXO?= Q&^NXL4]!X0&/3*W3T=%EUW"+?S)C=%(WMG_>@+6[H, 1*IDLZ3
MC]S9^&WCPE]KD)W;EM[^1L.,;:<K0K^@I)$X+80W$$+*@4@>-/S;A^K^\GP@
M7 ]\&Y7Z"WP]>WJS=)*3ZI@03U@S!QC3\O#N!P+__C@Z?R9S7FEE)VSN21UC
M _&>"6*G4(89T7U8^LYOR_O_\CS/>N#Q0(<@^*- TU34*/XEE)@!T41V60(]
MP[K^OJW@+X]CT!\2"O =2YQYW:L[@RN1-*765O=M67,F:'/QM]T,?WW<HF_-
M;/WU5F##NH8-,@!R]5^D9_"W"K8QT9!2J&(5)-<8O^S8_G?A_5OQ&_0[3FZR
M_B9\JL^-F/'41GCLZ)X?" -2Q8"K5WZVHC#;4VGAT^;MF_@':\M#/0P3)J@9
M_OL4>S]X41M%=8:%P==_ B&[KQ _U /H'//[=+ML1*VM@IL1=/YZ1QX/ZS79
M[1_K^!  A/YIXGUK=2,]LEYWXRDY"\OMOB1)+ODQ>;.XTKF$H_7-I-U+?;6%
M1Y<9"TLC7&Z-Z]O<8^ZT1/<]MHQ@7C  CZ:@91;1R.*ZV[FZ3-!A109ORKP8
M$S2$NK=*2TAO3:I=Z";E+-@%+B7C3(;RMS*R;_K+,&P<SY(!"TE@\)YZ!D!T
M&"T.XAD8QKB(1-HZTMW;-GT"EV3G:K:$B.[-(AJKX_C()Z>ACBYPECF?V!7=
M/)4/..6#GX:SKKH>)7UXP6_K%>A)F[4P40F@C73@E,<7W5^4$$65*<@6;5:3
M/LO^CL;^S23?J-M.,1_O%+AXVC5:!T^9O7YV"W-51]T]M2>ZK\YU1]_7O,75
MX%J7UJ&LVQ-^E3X6I]G]I.*^]X2@T(4F.SI!WR$0"CI6F6Z!"SK7F]4CV2]?
MI)^J@GO8S<^"63JY$KN@]=0LL2Y\S%PJ"FN/YYE_<Z4?(TM=]_1Z1Y'LM0@?
M.O=)IX,5Y;8'M%I?KYW_0?CMI\7 ;Y.HLBEGJ=PWD :;OA7'%O 6Q#T2OL$"
MW0F$6PS5IU10=,''6M[S26GM"8%+_2.YXO5'<J65DX+5=X]A"*X;>%'F&4:=
M!+I/#!"U>>89^P$L*85C@C:.5.[NS+31I<Q#R45NJTR0]C@3]*/9?S,$.6%$
M9H+^D;+HOZFF=X_![0V Q_CZ?P,>_PDB.1^0T5&$%8]1;@!PV#)!LM&;UX?J
M9,?5:&^1N^M%^7?7BQ8)96J@6!1H &U^X9-//PDT(<\FACR\^WG+"*"0"##&
M/_37+8^3@4:M([8!8)QY[0LWL7+W@Y8<_\SG>/4QN-:UV,$[-(!:8U4?,T$\
M6*+-LS& G]2VJ6%L3@Y.^0T_]F"@TZN_*[5XVNC<K1D8>MB*RZ:<+Y/[J389
M] U622M=I!D,?;$=K\1I2S4)O@TZT;N^V<75OS_8:.4CO\-=7>X!>9O 7.<@
MGCY%WB'.9]LOVG]QJF<]@]$.D:&6,Q_&\Y8(HUVD*>4Y/%>/6?1,SV78%&$F
M !D,K30(+X02)66\$M(Z94MS2)6:D#LD$=E,AB".C(Q,:ZQA%_2$X_/X.]2&
MW(Y8?S::V''DJ? 77#W5D^2THW',(Y._(\"KCTZ'@:@> (+C;"6L _W<UK <
MII90C@P0?4*\Y(/&Y$HO8:RS2^YR-.,\A&W?OLTP53_,OU$  \2X<I46"! X
M/" \^R(;$8(01KVLVEE+9$R]0FRKT7JN-:_ES"6Q0!U0;/Y ID6@%E9\^MQ$
MNE30"FVP'\%&]?0< [.6U31P4_-OORZ7=Y@(_S5PQ/AX.^4IJWN[1WI3X-S:
M ^N<N)S/ED[^'-6:* U&_YN,+T<*R<N7?]3I?/3U6W>]:&SD6%S]0K'NQZ?2
M??>J3M]_!//<W2-S<W<60J_5AK:$W#KU>N?&-(,;'P80RG<S@"54K*_S.%\K
MR&O4RGROSY.MX#D%IMK#H[!K=[R6OT\#%N/RLA?"9S/+US,(#^J-L?=C>355
M6=7W1EW\KA][SK)8@@?<;J"=4 %NP+,Z >8"# >^VS.)#>/JRR=>&!/EPE]G
M7!5>E*]\#G-;QZ]'H[H-W'MG-FBWPW-I4KWE]K4NBD/!H_)9I\:)A>OZSW6/
MUI^#*#!N[DMX1<&KE( 7YDD"9;H%K3LZ<X^=]W)[T-]5<@LAI?=>R7 <\EX$
M<;\EA5DQQ*B:@!'N#<('2?:OR7-I0V]\(>,,/!Y]_MK<EVG^,.*^NCUKB WR
M ^U1;R'2X9F6,D28^MG%ECBXP 159);8VI>_MU=R;_TE\'UA[4!"P0W&"[[?
MFI@IU6#M+7\2?Q,Y9/FD>]ENQ16==O6YCE;P<S/P8L#MSX7UZELF=RBL"UOC
M^$,_"Z<J=W3G!+4SH2FEA!'CO;SB)W15?@B<UV(9JEN^ [@* ZHF$V0+#-29
MG3=KZ<8X<Y0@\J&K^R6*#=U A]R2*MRO80OY:?RYWG2]]1O;Y:;5I(HSCS./
M!][/77O.R#6H'&^W$:8*C2OR"T2$[1A:SSNP"^BC N2FM*:%0D>$GV@'SGLR
M!"S&%>E\(@&KU0 C?=-.71T;$1]#-BU'!BF17=]:'A]X\ZZD5^X)F4OSU:MW
M,B6D!Y,^82%]+]<%T 56/BG>)._S>%CKT&\RX,SK6J263FJB!@=:S/W+,U(]
M "4\>N 3\J:_W?A9BG-CZ*T/0@4576WUI /O*'SU<&ZJ_GF) :13QPC/*8E+
M0^$3Q:SB H=M9NQB$[I+GL#9J?DX>(5/,))XCG+8-\;F2X]438K3=3M5TM=:
MG>.Z+)-"2HU%QFH";6J,\TC'6XP>+AL;JC<L.L,A9!+9J&3/U@EY]5CU:_NQ
M5!<W";NEZZH+G$D>NP:ELZZAC>5]V+RC1)USU58D43<+C.YV^<T_^?S]OM/7
MKX\:IX4\OGO>T(*2N9M%Y8T(NO1,Q?+DD-#VH<")TJ@V/,?G&9+6^IK*U)N<
M/$\BZF?** %&V6?Y5@,;]91/E;P,':2\&KKNO#H6P<E57=^P*B04\FLTTWTL
M4'P,N^@QIJW4R-N9[?RF)5'9HC]?MOU4X[=!R39MVR@*'>]IT"^#-&+]S9JR
M <B33^%CQ,1_V0)H_(H)F-R./8:<J9HGI -.0V) VYTR3V*-!XPSM7G(@B;N
M#WE-K.V_'6WUM7M49K]#E&QIL&KQ?=R^"9"!2J94*SBZQAH;7.>3?^J9^]CR
M,1NKV>5,*_W.<W*1)^]/+/UJ+[K 40:J%N@$W\JC2X"O9PY3'")IY]!-\&T%
MC<UI3X 0*R-Q,C3 V7\@H8-\H+0D*YM3U$2*4"M84,7]  V",NQ^B% 35N/;
M''KK*EV3^/+,TS&NXTNM[7NVA)>%#X_0,R"*U+3QB/<D8T7NV:&@UW[O"#&*
M)YOADW?OG'=PU(PZW;MG]$^F%/6;*XKY+U=47.>YHTV[1(:'>14&8I3G-\-,
MRE(6ZB6J=4\URU?Z#!U12KB\O50%CR>LZ". &'4W $4_[F)X7T9=@@D25R>>
MUI?/II;&TU]YQ>G"J6!B+?W:]O0US,M?6ZD62<J?(0KV9M6O)L9 &AL\<UX3
MT,^&NPL>>;='D+,W^N9W3*QA<3_'<LF9K4R0"W)+#<M#ET>N?1*<#V)'MHF1
MH?3@!>Q:NFP2O; !:'@ Q280N%TD.(]AWUU,B:P'HCG+Y]T5D068KAXF2('A
M> _^G',S;1Y>S*]"93!!?ICR=--(?;Z/+\W@!D$=2 XMU=%CE-1F3D'GDKEM
M< 1IT#GW.ZZ]NIJM+A^-_,(57)]W+N-\@>GJM*#L?$($%DR3I^2W] <=I%3B
M4(<'G2Q+TXR%XB"].)6LN":7.KO)J!OM#R?B?YE/UT-#M^&A=4A*YH6^.O5<
M7PP)UT\QSM'-NVW@W7W R"YJO\RCI1RM\.5F$,)"+W"6[(UC\.8^4Z!IDV"#
MPT;DB@25M_%>AFN\Q6>?7S@L87<]J38NEM]6/#:Q*>B;#3MYP1_6\KH0H9Y-
MTTVZ^$C9O=*YS=LME)[IT"R&&GUHRI?4+ :Y^ &S0K4B[L!BS:@)ERC+]86*
MQ*7G-0%7:M8K$NEI$@K\C^(I86^Y=D+J#^KN%<0<><3SBJ7*,>S*/@#'L*P%
M_#T=AQ:E/_]-\.0*;3< $WUZL"&?4Y/Y6<L2)<25_P"UPE['!!4ITN(LAQX4
M?>3<L/\]1]?UFH0BPZ!;XMN;],@I0#T!_MLO, #.#_4#+!X\@%V JC&2A@=Z
MDSNC&'()U]EH_.''S6Z)Z.@A2BGSXU*Q=8=V+CFG;K-O^M0<22 F]Y7'<4AZ
MQX\/++H?[Y:XL'CN4TV5;>S!K?/[1#M(E?%9->2!QD);G&5GDZI@:\S:2S5>
MI;J+4T,Z)\YBSEP^TW(STDWOC'9W].45$=V-V!XOX[8R LC)']7D:JKJ^WKM
MZ;%9\E?0"?NZI&,?Q<_+P-]OM+,,S!1 67^Y#-B(E*<U]5>8:_2F#;FX0LQ3
M^$,\2WR*A5Z=^M'$[L8J?+\:%HLZBJX3SQYV%A4-=Z/9%AXZT7/B\=Z+/)[R
MO5FQ!\?AKV*Y6A\$>UX03=#SLVB B3QX@P5"7B8UWW+'H3:/"7(T]M$8;"ST
M>/SUSD*\"HCOQ 60K11/&#EU7"J.=I.2UC3D&/V0&[=Q==9[T]Q?\.N++S5U
M\6K&)^/M[E;7GV=A^:B\9^F)F1Y(RN,.MAFV=2I( 4"A>@3&,_^YW>RF#/)/
MR<T^@R>7&+R^G O 0): POY(7 [/-T%M$:B0[2#H]!( -_0%-SERO@BBN+4$
MD8>Y,+[T3.Q$*>T(4"_ H[HV^M;T>^":C"X:PI$JP@3= RPD<]&YAS!QHP:!
M59J?L[QLN8)';-DCB0 XQ\%H%DQ0.!+@,ZVO)YRA#P&DFKIXOG40 U-L6]XL
M16VX#"#V<S8;IU]> D>=I2I8\QH[7$K C2^T=W,= '_?\G8=R=AJ]K21H'*3
M!().49-:1(_M;K ^F#2?]S!5%?7SS"AEWT65K0GD9L)AC<WFA[XPXF8S!Y_%
MCGDIY0'TF.5!NYLE:3C5C1D[F8N:RF[\X?>/_-#WB(V="M:2-7.];D)-88)*
M?XF>,M0ZB_17[-]2L%JLZ+]2J.1<K;5T'V(NGQ[Y-F+0NC4&P^\<!*%G<3=N
MOTP]1)2%']21J)%/[QDV\*R8NA0'[SA15_Y]X33X7.M;$D]OPF"J21(Q>R/$
MH^".T;A+!Q.TF*=EGKBO1O#Y_;;'GX0FV38O[H5<>Z2CF?^4XAB.@*&#^BP#
M4UZ3>,F;485U["^,"BQG9^6NGZD;(A9.. @)>9PP1F2=;FL^HTSC=N=L1!U#
MW"9KV9RHZZ:)Y#J;/7@3V/2B'#<3(_?XT$7N%+$S1SX9S?XJD6I$^&<<(T\'
M3U L0NM.D*A:%O?EBWK&>=^+-/%6VGV-[E$R/LLN.;)YT;/*NS/0*(O1N7'-
MUZ#%W^?9>@>:VP6C<%.PJ((B7ZN6<I8UE2O]HWB]F-W$.NFPNONQH [&.0HV
M=)+<^BQ(D?# TK)5<%C'_4/#PY ?<3F!Z!I[4& W;NIPJ\35_4@^WU,=X\A%
M;1_B2%# ($UCE"=T:?I*9<V+@TM9MP>O&EZ-D%%+&3K8L5\JV_.ZRP !I"5.
M(>F2)_O:NFFJ_=><?ORZW%V>,"QNTB#P3/,J9G)?AKZID<3.>@*.MXSZ13$>
M=8-+^8V,T^)]^8W8@EK:CQV\39HW0\6$P?;S@:@8-<[GTT@@UI3R5O6'B>W$
M4]7YXZ+FNA-+4LLL9:YB7O.&G"#Z!Z0CE!.A3=U?Z#)D,IJE,FEEWN<^]>7-
M]7RW#!5W=9'VZ8!#YT -</^=(YSK9YF@&F@R8GH\81#>C#E'?IK!TP]1F..K
MV7<26CR$23CHVWYF</IKD> C[D<-LBDG\"/-@2*""W$610>D62;0H>#2G!"*
M$O&*?\L7OX_X/)61;6<EG(\<=!!D?5GMTD?B[=B0K Z6WB.AQ5X)L8(#,0PN
MFF!Q_[L!%1?H,2.D:*D[,=NAUXM_H4U/9W7OI;?*56)CJF=MTC*#O@4ID(O"
M/=[/0'G1:X6B#*/L7GD+PXB+4Q:NH[JE2V$3,G7<JWM)^TNLD=%0QR^R5\GP
M\#)WS@=JHCR]=3+S"G$%EOH)<IR5+EO1%[CDTN_8N6O#KEK7K\">RB$4*6$Z
MG\F<P5H^8\L''UR]@RL8\GW1[F%_/$; UTU<7B+-3A)1^F+/_@M3=2O3N&V?
MT&NW(:=\D2U!O)1?%O<(X]XHN<W^*F<?5DF[@WLNB@_Q1.'%U7G6F* PR%'?
M-ZW-QD74GG%))B@VI[(BP,7X_,.!*^6QT"-XX2N7"@Q8?%A^A<M^!=S).6H%
ME+.3*(V1G].M_YSRK"SO28R? N/;-V.]C<\^=A/!P[ZL_*W'][S^Z,N-RSA%
M+U/>F7WO\F.4*\8JWK=H\F; JZ7^\]E"M_;6\@3!J_R?&W4&*MG "A&<56 N
MK;/C>';?1-JY)^D:VH+CN(6SOUI][B;)80SE=*+>'JNS6VLYXSE_/-@1W8TY
M3T=!)\8AJ@ S-X?33V=@6M>W+5JAI:.P14Y*)7B-!W!1EQV+OD&ZU[1^.9#7
M(8D?4G>7)_5.<&'%<ID@:ZF=UJV!^8T>^',E((8FT4FT><'T(PN*9B_-].[[
MA/,L,D&?.1L#%<=;FT/<BRXY=JW5ZF,S]AYI>WW[IJV;3H-\+<%!<\"?4"D;
MY^3TF<J&<R0._?)SS68[V1.8=GX&WCX2/WQV.+YLSTHZST9?9(,U"[%U$4T<
M43,MB[9FL>B9ZGU?7!5K^-Q!_67KJN,C]O#(=W<U'2K+"#RTBP.0,T;$ 'RH
MH @^#%DV49ZRC>1LVYNF<P*N]CVYKN+$(^KPJBW(TY S9 9='<1)!3?ZPQ?+
M29W<1I]+:GX4KN6)R'MG_6@XZV)[4KKA\,W! 7<RR?U!+1G5C#P:=!)QH?1'
MW3TR]&()N6GT7FU-%;FW/U\P7-/0N4U?LR+N'9=G:R$((:3G#150#@3CF" >
MK9LYU,"7,QLUL5U6,NI>-]@?O7^F&;KVW=3CCM>9W17]D.?_,K\#1*7B2%IR
MH06C?@4Y,^.R+))3<YHFE1I%;?I-$X4JZD^!'Q_B+B"W9G?W49N416Q ='^;
MZH'^,=5C*2K&!#W? /0%/P=P1H?2^9E,<B8E&MN4FC<3I$5]EDO-KV<(=;F^
MJXF?OA*ODCRI=[#ITO%%'/? 3_/E1F3\45]9G52C_A,UM95QFY;EG_./<[QH
M]SE#THK_ C.5;9TI$!4](AR[]O[-N/,XI(1OV9(@7DOUH6C ]_A^V*#<=4E7
MW:)XN-<CW"1OPS:#;5L>/?:;,8"[DI;#S?UK'OR@WM]23(&I7S K@?>>2+W;
M,)V[SW^\SCQ:,O)I^O+]CP[),PT7V[*6BI(JW_?3+E$CO4@$KIR\R33^L9O&
M3EUM3O6:86Z,#;\QC]8[#K510<HSHK(_B"64[\';R<U5>Q0*0>R,W.73NHW3
MS@W3(=UU#Z+=G@J:+>AI]7";9LVI!04N%:&^KL.$:0X5O75J0$R>CE#&9<[N
M]_YJ=7BANLWDD^^^=76)B9T>##_"[(>6U-@([&)_@;N[..:-OE<%6UD+Y=-1
MTW4Q6F%/?UU.--PB4NJ$1V<)A##/9U%>T3U2X#] DT =!-SMR1PT:GN!0 NJ
M3CA$TTNJA\ACL%UB[@MY4_<V#OV,^[&DN4>+&*SM-^<_(*"GHG]:>:1GZ=*J
M3)'96W'^JO5HP\U]U%+RALC-\J\TR4<J7VHW'\(4OWU?)"!!2PSM6FRR7VJ"
MED<@B>ZW+O2C1"9!@>V)^JU,/-M2X*WXP C0M'3NX:.Y"G9RIO9P'DY'64E,
M]$#0/9N.'0TFZ!M@9P TWC&O>_ %M?%$ ( WD;^O"Y2#D5]7&#/HL.DMT5:&
MO\53!D!R5BPPVH#+\("N?=CX,NWJJ[8 ("/) -(T/9(/<!B*+LW(QM3U7OIE
M<&LD?@7RJ0 F8#6?&L33=X+<UUF>@2&?^5Q5MZ_Q!1-TR"."1(9>'OY0MSH,
M4<!2*A=Y<FGP'HRP$>#$1!XSFN:.W9$O<GUZU^AYYX3;R$[%S)=F?[YHS F$
M =5G'!9J(SQ0[JJQ?(-RX+V/>V&'[=Y7N3=3%.5.V%VKBK\B+#U52@/PH12=
MR+G#F\6PN&F\T4;^DA"'.8TX]L/KA+CS=OQ[/]?SSRI*]%VN/O)HR&%UV=&A
MF5-V/T;T#'50V95W3EI.RR _35M/(OQ.&SC]P:O]$3?&+2;\HPNS: _Z%K'.
M[L]$!?H5B3$-H\(_!F[<7#FN?#YZR.#^F%VPQ'.2]GPS1(ZVCYS;P!F' K@>
MD3]^";H(.]JZD5 . RC%I^JRX?CS3- M0O:3%5]O4C.A/+6U\'!7HMLZ]$#Y
M2_D36[IM+@[1L&(YZ;V$<)HC!=!(2&E:<Q![7QET']4Z]X40F_&,N9$"#W_H
M0HN TO<;B67VIJP"D-<[:K2'_4$ N6TT(*+Y9KMF@U3(G?656,,S)].-[+FD
MVZ:E=>\F3UY^J\KZBM$!+5,+98C0Q!,:&(J]">'K3!!'IQ=/7\Y[[OPJI;83
M,GO?%BM8.(ZV9VB8)RQ\J@0?PYQ#7*$6BA1L^/-FGYS==D[VCGEJ?@>CU&<N
MO=IZF]]N47G/'!,DHG631#^"O]2#$9TQF],H*GSBFMU;E.E8T6-;+_HPQ-1
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M(<P>B^Q(4#4:Q]=^.1V 2IF?NI! H\HSHT97LK-)Q:K#R-HB<D92!')7\!B
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M277\"@T5*GM%9%F"50D&P@6_VC9Q_CI^I]RKTG/P.E^MH83#*PVA$FS;^5C
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M^49J0/&*A6G)V]4<8UK[!Q-!-\>D#FI:+T]]W@_O!^&WK1@MEE&L%*85"&N
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M4\C#QMK#:_)L:#F(:Y6WI:JX2Q3_9RKHPJ$(7U [5A1I!,;D&( NH5D3X9L
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M8#^29Q(@0=#S]8Z[TFBN\/),1[JH$/ +\)IU^&IS5 D1B8M^43=!R(S1 GV
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M_R62NMB/\TZ8>%[;W?\,4D4YB; H#+2\0VN";V* *26%!=56M"<&-S;N(\(
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MHVV1#]Y!I"$8#OK)I<$AG_'UEZ5ISJ+C$81S;J)Q+T4DOM3E6!Q29^HZ*?D
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MV)8.NS=C63X)JEO185%=6DBK.P;Z7\@Y890KH% _]+SGO@R2)86I=R"6Z5A
M8W<#AO( XDR4D3/$@1$:OMD0?YR';/*T!6<J-P94U:0JE^+!X H<P0A.7MWD
MOV%3!260-"C%K:A"9F@ I)0W/X>DA4<?I*ZO*8&,I*[[-UDPT9R;E/53>T@X
M]",W]D.,]XTQQ-Z[7 M)T6J2Z;5=?VG_\V2CC/9WBC7>1O1A_]0!4%_E"$QY
M0^HM(V0+H_^NON_\$.XZ?%VR#T?SA^RSC@[$8/?0(!/.YJ0?"[ERUBR\X25J
MVTAKWH?=U@>992*KU*QN]WX2FAW M5_J/"VM:XI),OUAS!G:?3?QGDC!'04=
M[+,KSCIF.$ISF?W2?Z'/5+Q\1VED<;'^+4[&;^E#1_H4.SLT7NL4.V:FA]]-
MMN_7UN!E4NPH30B3V?)?TZS:C?1:F!A5*TV'E>G1) -J8JJ323F=LJN+=U/%
MBSY)O5 0[/5[/]YO>K;S';DR-(K[@BY,S/]S3QRV-B*'RE%FA2,+ "/O?T](
MU$_!-ZNQT+*HWD.XK6@ ,N8(&50-+UI\5O]G6H9[G5>MV<WD4EK<J+);1&H-
MR@T4Y&S&K:A7GZ/#@!?P=8YTXSN1-7 NQUU71;F2J?RKYMQ+651%60PP%8@.
M!NDP,V!)5)CPF0%5E;Y[1)A"<X',Q+C:@BME(^$;7_<S,/MRTVL-H8/42%RD
M[7'>0X<-SF+ \QF@(.]/ SWLGO&@7O9UP@!OL%<1[X2Y<6,4D/%^:C<N?E6;
M#ML=.CJX<6#@$!V&PPM30\UL@T?T>'W,:#E4SI%YO6%2R;"DI. I*6N*(:?*
MN;U?"CVBT\_(V>QD(JV^'HCD_^1D8,[?BMRKFV=H^?6V7:5?!S,H'3FY&=9^
MCGOZ>UC[X/<H<@M/XJ1.57>MT-=KG_O:O6[9AH3DC]HY\5D/L=WU-MH62*QO
MZ),)SH*$!R'?W0%L<1;")59>_5H$:U-)E<>8CL54?5S(*LWZR(4(!NK5T0_!
MT/N060W80-3,]><";AY;O&9YAX40](A;1Y ;1P3*:+2'=%B$_E\*;'G_NU;T
MQH>@9T%=*T@X?[\]\!2BJ "B(L25=]8;0301 Q##)E>^NID3)YL6V5!EJ5Q=
M)R11UQRD'[?%R &YC^[+6)E9E_,U&EZI?=J2*U]-[L(1?UO%/H5OG)(L_'&+
M /LCK5%!XZQDI.;P0($SZI<R);9#_5SBYE&B9V_!YICF/^./#N/"4T4(#'B2
M>7F0&\R$?YX?#6S]$%YU,ZA-)2,JOG]NW"!&?\&GO^%3W>CCG+F12J5NDF;U
MLJ;"*)Q04ZU%AYV?-:##:L>@_3\!U)&(8C3.?&V0 CU91(^P46X_4=.3U,2^
MC@6999=4'R8)*NN@\5199PZ@XW07;K$"3FYE&2T+A4^EW$2N?<%2;;'=.23J
M95P) 8!$$X$?B,82'@.-#>0 ^/0Z;N5VR:P@JJ5V5_^, 3JYL3(>?.C^;/=9
MR].:+ISB@JD7#G!L<RE'Y!MUUTK>V9=H1ZF9KP(>;3(I2[=N-3M&7F\$=AM\
M3O5;II^;D-Y3U^E.24$.U^:GH3T-B((. A%E,?W3/9V7_(R"XHYK.%;T77#Y
MW 40N@;W %,!Y&1PHQS25"]-Q9\RO.?U:[91T-%V[-L-T[#U7% @>82=M@?)
M"0PBH&.M2550:A#>.%![!%H>!ELHVJC1F\[(FKWM#>[:,/H;#3"Y76"2,%Y\
MC<H_ R_F#7:'<_J(X/-7;#ANELYRTXIM3,JJ.9[VG_6/,;YPAKF"*VD"*]N
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M[%@.R-Z)_UHVEW&R_=>P\LM),<[+%]R/&SXVU2/898'-&>!Q?%WP  -^?:+
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M)HB2&('8L'\J_%/A_\,*#,P!=GKO?P!02P,$%     @ X(9X5DIHD4PB(P
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ML&4H'8$QZWL_EY$A1X9KEK;,ZJH873*N'[D-/3(9GDTNB1[]<A*]QY@Z?JJ
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M30DT,\;1<<4\31PBX6 O FF85E:9DY8LA<O6E/XN)047TXMF.<BCAP+I_DA
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MXLYB*'(% :T_\?+.9G("99 S_P=02P,$%     @ X(9X5A2UUJHHU0  ?.4
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M<:/BVMH6TU4HO8LO_"?L;*)T?<0_*A9),TJ@*'[&.*=4&A[@@?$:4TPVI3^
M02_IE==>)O(*W+\JQ4_*%JFTY=NGBX5A(CCE<^=R/!PD'D,I5P 8H5/;_V1%
M9 4M.;\.5W'*FC#YZH>!B]T*:#JJJTG@A+Q4\\<%E#_@:0S 8TM072$F_B'^
M^JN95H"(6/4#TT%)*+XF<Z0?NOJD!(9';ASI))B<'WTCN@='(IB'68A)S5\E
MQX\D)L_DLXRJ;S.G,E07$VS0V 2BL@=>G2HLOC95 GRDK)P":BFV0H!.-DT^
M&QX,<8/_5S9T\XR\HD*BB?[M(\-O?<N.4?E"H4 DT<L&]:KO,8$SU/X/Q6*C
M,(*O^C-O9!1E %F3D/8+7((QYSJ+##Q8>3B&XJO\'#_2:JY^TX<U[\@._=?!
M F/J/!I/0W\,>LE7O^,@/! V^O34U7)1+%5$%^"GHHZDK\\(DX]7OY%5SYGF
M'&K2X(?]FC- B#PG_Y]C-#&KVD@JG8P++7D9E\!.I@P>\#U48&$!1ROMQ!21
MGR*9IZ^NP9?;!8?_F[28)OEW%X9Y(GQ>/" \=$\MGJNJ"_Z#C$Z22FT&XT;*
M% I-^%O\37C&Z\M2'E5X-&O[Q+X%DQ )6?2WLLL^S$27$7Q,!/)';#$SVWJF
M0."ACE46HB*>\_=)A3#:]Z^&>JAFQ8\,6<U(7 O)Q9TZUG7VLF!#&;/@4?'>
M2L!5XN&K2S*CD*.0,UEEP3.707\CT=#DHY;X!:G""/[\$Z<?R680IQ[XS7(N
M4BNVP5==9.^:XR6X?VO6J<+;.:!Q6@1SJ:AK:LQJX3'[ 7L %#T-WQDG;0\Q
M0S'S?P8<59\1R%ML:; CK0[?3(.*198PD08D#S 0) WS,!K[H-H1/\O8=6F2
MF5&YY?^UXQ^;D)7*FU+'7KU^]]?YA:UJ@U%<O.]=EKFA@2&*D:/XV#CK/&_5
M2SLA\Z'%XBNML9RJ#$@&X,4Q4PW)UG1!?84@%,H(Y/S_;:6,!N3.;*1+(."I
M_9>E3@#7!K#AK6S$^4( L= (<SKG7O8+":R<Y-;)U@FXO0*'Z_RU8PG,G.A7
MHOM6_Y+VYF'+V\*/ !I1V/^VF$H6W"CB@8/_XQ^>O/'QAB4>H$Y-!L#[GRX=
M&I]-<"F<T]2ML<XY%5NS3UA5269;VF7G*-=\/[].=0\K!?X<!?$';2T99LG3
MM,LLS+[0@2_?L4<W4B/@):E2D F<F6BLD1HJ/$M)YHHION8:VJCWG<O9IRZ\
M(!9_,X%PQT*H.K\Z+@.9R9HZ.25PU>'LA+&:J3A*RPC,USZ;#Q-?IZ-;GW)@
M.U8@ ">['9EB\@5@&9]E84:&[O)&$2[M-X=,L[%60-BD[:\;( :_S6:C;*+>
M_$K3T<_SLL@O6+76B4/O;F#F&SXJ$YY 4I'!'UKS:#_OV]C&"KKR-/7_YKD7
M5NWW1.4\Y2=4PA)>]^NX]['5G2"#8(X^0*6)F3F!1N PY<A_%!HK;<I@W@77
M0]N%=_[4?#=.8+^\M*!^\7+ 7@U:\/_'DA_!5Z3P,Y\59=&JFZN[;*]V.A-\
MJ5M,CHF%Z,<^^=\HOS,GB@*C&E.N8"5;E<B[WN&E 7EM9LF?/\^L8(_QDW+7
M; @KO3@NI\VKEGD^Q-ZW;I&3+D+^E5WAD_]**(M0P.QQZQGPOB/QX7PZ]VU[
MQ!"#9D")4LDB?56*FO-U@]\RPJ)C%9DE] 7?(J?PUE?!01_P=%Q*L3:U9BR@
MRHF']58_X@$6F>X1V"?W); +E_$.7#S.^S=5.B_SN)B9#5#?H)K(R8#JO-3?
MXR&_PSO^,A<=(*P*$$T'1CYH,&:A6.<^6M^AOH-Y!CR<]YC0$T,E)/<5_WO:
M<XK/@:XHAS+?J%S5^,B=9R%-_F]NT_#=KGQ 3%=Z!A([SD@ U_]6,_]OBZB=
M_1F($==]!BH%Q2]?O#FS?/C:K/+HS0;:^*D2>.6'J+) ^PQ,*'%W944A[E,%
M8"TDE0-.[HLC7I2]2E(;BN#2Z&O.@B6KFZH])[E"O#4"C[DU];.*7(L4[5(T
M11PUVKDE-4]R98]R,)7ONH.-)1+EPN1%I%#HU*\]AL[F3B!NBP)I1A6AQ?CW
M"ZIGH,KK&=AK[KLU?@:H\:/NIWSW+,H-;0GT^0/>9US+2O+FO/XFM6!&J2SD
M4A85U Q)O77#(!-^K,<^!Q%+ >I/;<*A0.W9L<R(T%@A%>+.H5J\L'OW&=)4
MP6T";"9RV\\-;\'<%$)RK0:81UNA8545&%NAA(Q"],%\(P/25'#1)FLH^)3&
MK( I9:>6,E(? TE*SZ+>,^&4_1H_@D8C#=8K3H+"_X5#$/1T@QNHY>K[&W;M
M&9AOS;Q#*0V%+8++(BI)Z7CP=W@&#E=5'N$G$!EZ.GYCNV3>[:S=D6KS$'I%
MA7%45A!^9\NSGKNH(_C5J2H2Y,'Z_?JR//.+7Q2,M40 5N(RY<UBXY(H1_<B
M?:YOX6VM<@3=Q2K8MDDM5/$%F1_RB1!T1NQ M24LU)D1$2]:E?/F32FK6JF
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M5IVFL96*[U#<,>?]DZ:N#GU.]OT;W^-/FCX%XM<=S*R$]#E9]YI_-TK^V6"
M;A@80S<R;<,>*X?"$(;QM'SK99[FM^66H(."[7E.EU,O/OBXVA?R6^WZA^_B
M0U&50:TN2?S\?/.#OE+^YH)LXC-@G6(UJ;?$!M%RAT624J%(*/]+68JE9IMJ
M9\]FU+V\\@SD/F9X^W0151P/#:D0#PHBIDC%D7YRM>-66(*:GO%I"55&0+6&
MYUT\]BW1.*WC8L5PB>0[]S)%V@;V^FC:J=<2BZ5UF7'MRH*C%D;IQNI3YMP]
MJ"K7107!L\8GU%4"EGNZ/S.^D3/-UR<1,AB]DT%\FJ3^3/!$588L%LA0KM42
M]ZDO(;CM>OBJ)J-[9PQDRBUAL?CQ.]'@SS2<F*Z2N;NC#]9N+/9)*4&S78[H
M#G7RZR#T$0]5I,K&0A%EUW+V(YAM,'@0.J>BV?4A?0JN*3\ZK1NX+&TL[QV9
M"Q-Q6BKUTS.W6U#WH#7YX#@71M7"[]M :PN?PL;\^T1?FG!! <&DIT(W/=OC
M?J%KH\C8MM(]7X:W,67*XXK(KO#KKR;,J^5",FS) V&2RF)0B0W!7.SRP@L2
MY5'>B+:Q/O/^P<0!^,!!XOYM3:II5^3+I8'$/H$%"./IVZACX9JL8F;=2W$.
M8R\\U;3D11O^LWVOC_.U)^?9AB-XYIEO]9Z!LV@1 OXDG3O#E2Q(U(C)DJ[0
M,U S]$$% BH>OTYGMLJ%A&[(O2%B$)"[4O^47&'#QG[B(ZX#"24N8ZLH;VVT
MJV!'_Y&45B4HK)/5YW/&1-N<P"2\YSI>_#HE ?)5Y\*>QAI[TX^0>'Q7CV^5
M-7+=[@0SU1,_Z'L 7K-/BWOB(E?6%JS'F/"LMYXKVCBV[IJA+IH\6_G65_]O
MPMSUJ[+B7R([\LWW#GU*/8Q5IH)2^FVFOE+LC;PRTU,TP6R)Y-Q?X_FMHVZ0
M/&EXFSK0TAJ P7Z]IX=SG13"CHV_$A.7*' D6+0UIW*]H8(>JV3N4M^,4_CK
MH0<>RT"+J,)5P+4#N[]P_]#%/!G?8 1;]DG]O!,ZRRDG\SHK3[*[E,N]8<8%
M6_% _:'X\B,^56":.Q*>WLN56B774CU2)=V& 5<$#@(D&;3&N/T9K.)RYLW6
ME^\B%%6_R<<NZK7H+7"1100U-&S)&]]BN.&SZ240++8(KA%Y%'!@6&?'LR;5
MFDL2[Y_T_] )63->L7%W</<6'A?.T(M2>;LG6FK6MYAJD\':YK00B7A.0^YG
MA'68,CH5G&B?>F]8T=L^)C:$5W]T?WUHZ/(SE_1*P&9T3'M//:=%=DJ$+(76
MJSI5_UXD[AOPW;L!)B,C(?5MOM5=>X,K0GQ2SA"+((,&W^1+5W),@5X=(9J%
MMDBW>)<\E51[[XUF<F.%J3H5/$C$3%)$89[-R.0QUU:!QSBY36K]YZ+Z"A,U
M0X[0NG(T618[,[;[57R02GK#\(_.C.7=?(YKOH@\W27%2@-#R,J(J69='2JZ
ME1<APUQANOZV@/"/'1DV!YL4WB_7\G,\X.2"&ESD@LAUB5@"4>Y(9-Y S?2!
M> -W@L0Z'A^"7;WT.7KYK!#[C WISU]]0$\)WM\7Q3+S,824^#:L?[8$CF*Q
M(WKV271VYFU5FFQ];.W#8'MOY273=L3O?A=^BIAN@90RZ6?XXU)KW OBF+=/
M>"<Z^_25;7'0 D[%P;4N]O.F4\Q#D1/HAPU&:=I93OVE'0K[<:KZ3 %?BJ8E
MHH28)_@^1#C3Z\MW+W,AL0[GM_9COV0:K*,#EHM$-@_EN-J^?K 1Z3/)QYOZ
MD'>G?1K"@S>Y]?5XA[NSDZ::+"]5&E_<'U[#SJA;S<Z@-[\TN!?1CY?\N./8
M B.]NM;M$\0-S,;R!D?ZTWS<BH@B"YI3274PX)^(Y-A%$=\4[<1-Y%JHM<!*
MG:0>//^F\5XWTRJ\YLA$Y:SJ2.ZCH_8J!N*J!21QXTY' W+R%FT[< W5\^UI
M3(I@T,!(J/YLW>24G>/E39.<3,2R$@S\*V1=LW,RM[($054?&<+&%%O'&4@)
MJ\L]F@?MS.H.:%>2>FGI6#W$B\ L0\7 +%^G'5(7*F#/6O&F:CA:70(^YM51
MYZ?/KMD@E*Z<= $-Z^YD='W]Q!^+7\1M]18X^V,E!!]L]6V5*,CYYBXC),I[
MY+/YZ74L1%MVXMQ((F9'U)3QO5@8V5E=21L7M<!VP;SO<:7)G-6LYX:]B_47
M:_'U"G0'R248\ PR= J3C?SU]0TCRN?J>.Z#OZ'0<=+TR2'1FN_DWI,8VN2,
M=9G_SC2Y"!F3=0*1(WE][-[RCB^64YBQNF3,>T5\FM_5U13.J%(D/4@9H=51
MXR.VUSU6PZ3Z:Z"-'(LJ%+1,AY@PM)$86V$=9G(3FA(V2M[BN/-:5O4N+5*&
M[TA*QXUY.LAXCL?STCLK\G4TZ$):Z'&!\,$F"*6P2H&=?41?3?ND+'9-N:I)
MQW2>>=M_[]6/C>SZ5RA8BS2QKQ<_T+PGVPR\S/>!WYBNI2%GLMERJZ[_PC8)
M/]( PNXZTHSKG]&2RH.V[DL:O!,&@L_YI80$ZF#PTIL%:A=VQ"F^]9"NAQ($
M;9;H,HD31!G"-TD$Z=]0]26$-Z/T/Q#O82G =X>JEO4PETE<$N?A?6>##46
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M J,JN&^G(%?I$Q&G=G2>LU*UO8QJ5'!P-$A(Y+U:+<W>PW'<S%F=6C)[)8@
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M9IZ+-531V*[ =(A?WLXT A+_J_LFHP'PP#F-H$2YV;_Z/TL_\ Q%D4./\)4
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M K9#3![[V%,G0HFUP\'MGLO*%TB \=5!^A+J]L'90-U7_QZ+9D#:8Q+.XLN
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M=7!J.UOOP@591V)G]JG^[3*,'QC?+\<';RG:BIV/VE<W<>2ZQ#@\LSH38F\
M>#M*Q941!$'7G3[7-.7/EH>)JCI@U]9]#95,))QV*RH*C\$J+%8[3U<*_MUA
MN=0B4*("5>4WSW&E[G-C3A=4P**OF15.TILYY$ZV-G>T=<W?(Q4\P%F2$>:]
M+/]M2YKDKDVO6O55;5)UZ9Q?7[E"T7/-1G RIL1QYE2.N/8>L-@+M_OP/J^^
M!T0MF'Q"*+O>]:6J7P9-0$S<?/"2U=RO7)*)^3[K)5N1>QJCG/L\]G3ZR9_*
M8CTP&NDCYS1Y"'1G!/*22W3TPZQXHIN[B==,HY6P:;I&8N(ZMZ;M7ZM-RJ71
MC6;$/S($_JAUUO<K6K16/)97-I)M>Z6I3&(-FS'^9 _EPM#1MF6/34U4D8/S
M*2KH/S7@+$N,8K-!A)E27Q^2W8F?P4[S[#UP8_V%U?#;5\!<H%@V^DVZ= 7I
MR]\Y<B^+Q%XF]C LACXBC$QXVTWL7NP&(UPT[",)J([.TQ']0*<Q>.>3$'4;
MI7X+]UZGT%J:P)$9(V=T8V.,B#F( I;O6B%:-LD^,O'!BS237@9A(%?)7DEA
M\?(^_BNSL1F+6*>%Q\&]5JIFH69/N_B*X$W!LBQI(@^J&Z*<1';- K!_A[JZ
M"M9ZC6YK"S*+X,!KXDCNM;MU_?)5\?(_#VVO'-GG67ZJ+]4JX!.^YH?KF ;:
MY)T;49-DY=\-_;RD33^\G\?GZ9B-;48@AW@#U?H.]!;JPDJ+8QNJ(7&AD2=V
MY60B+(1@EAD+4=</>KWOC@2Y\76P%@LF^4RDKR5__*:K[6(?2:WC_IU*,W=(
M@)D]B_B80O#CJR)&AO*Y7\Y0Z6'1F)822_=<DL),:RS-AD1]AP0J);FG'T0"
M8IJ)4LR<+\>M3OKJ6IY94S;W/IUE5,LP%>9*,5WD=^:8$F8RNXJ3YM)O&.7>
M7=)=>_DD?G9=EKXQ<%..Y6X.1*8MGG5=1^/EX47H/GU1W*HK2SE69/7>I]4X
MZ)L(+I"C'5=.EG""+8DVU2H) UW@27Z/I2/5\(M#:(RYEO0@HZ!R+MG+HTH"
M)9+68OL%NA;)^VK2UK;TG67I;%:C% S;.$7OMI_%=E<L6D^T,]-1<(UU'EY%
MOO,-SO]2I^C.9RTKW_ LP9FFE#N5,M%<AH[@&T/9ODFD-<MHF5W&\;QJ%EYU
MLQ-'D'@(5JB[C#WAKF8W]59[H]!;GNR#,?K%W:+1/I8O XR>9NSU%"R1<%>2
M1$]++VY.*',P272V1D@O1\B=C[>CWBDY#S Q3JOEC#1(J(T?9BTN5> FJ(#"
MY9H.GL,;!J0=-I  2\-J1YFA]P':YG=B8\-IL@_R7609]..LVVMRAID4"3F^
MKWD&S=7M3SZZ%?"$;[*<VJ:BKKE!0>@#6S_G 11 )@%BO$S#;Z'J"<QE:GCE
MFIL_*\DTMG.?HV%6B*)+,O92HQ8F2/:PNKN(7KVZ>X\$='+[E'\OFJIT-_2D
MAFN@9,+94[U3]0![@RYP*$"(OMP:QY9PP-L;.QX[M//AF05PZ):5?>\2N2"W
M87BO7MKEV+2Q\ENE]W5TM*I3")UBX%3=LM0C64HA(=RCHMB3GO5(,VZ084XH
M<59>9.^Z0GZ-COZ@1$>V*(%_K+IXG$=4<Q[_ZT!N0FD+U3V, 3+)'I:A0FG=
MVJ\-C6']P5S=M"9VWP".:<Y#IBV<7JYCE7V4].DL^[6GV&T'G,MAF:R@$PY5
M+;/1O3?QK&F\B1\)OK[6A"B1.ZJ2F^GVW\%/HK58N*H*5TEBZB@=^JZ@%:O4
MZ)[X@O5(_VWXKUN%)STK B3C.; /G#UU3GMJV(]#"A@"I8<NF&RGWK"YXXI,
M?+ B<"OXK=$8P+ZC_4@#0/($T'40^KK0?G/FR9K=(UM[0)7<24TB8\2]GIJJ
MV,FH=VP02QLN8[X<FP2E )D[88"[SS45DG_0?ZL T1>]*/C!>#]\/6GT\:C6
MG*5'7'H^.1UN;_^.<V2[@01LM)DGHM<K,F1H?,>A<J[!WTY#IH+4^I/(=TSA
MP5>6H<4^SPT61"LVK.^%A[L P/)5Z],^T:\C/4UO8[(=51I<.X_.A'R5Z56:
M?3A+?YVT;JGBEB$]>/8%"0BV62M1'2#5Z^9JS)Q_!YK#IO:ZA'5H)ISIN39+
M''-0Z&\-@\LWU&=!UG;T<XQ'*6QW;[4H/2<:)4Y4K;1^&B/"P)%-8BY\VTU@
M:LM]T:'Z^!'-FR4#?&.]%2SYF8/57 >FL*H\\$.KI$8>/$&*V>SG>E(*<K:8
M(\2NQ-6!!;G\]]GR4A4S;L7$Q_CCO$(PG!!?6A[29N1A*A)3LC[,2[+N3++"
MP&,2&K7V^SRJE)<$D"\L4!"E=!V;Z"T5=223-HF2H^C0SXO">1RL$4ZPS?K"
M@FBG\EEVGBPA@[Y!9P3'[YC<XZ^8IUBE(-*&JT2+>.8HL='OME3W&M;NC9V>
M8@W=UWQDC&_T/6MAMJK=?GIRMP1GIIBB7V+\\PAW*==)X6N"/E<+<OGP*RW%
ME0VZE3+/XO=YME\J9ZY#];I$+OI:U;$2U@AWZ&['L0L/DI!/W':?+'^W+B+$
M99IR]]73O5].SS?R26Y3"DPU!.PILYG;298S2[__H$ZA@M'%DI\KHC;"O6]?
M0\OYD[ZQ1FY\ND%;IONV%ZV>V/""E/9/O.M"NOA[8=YR)>'[5%^7CILH:+*I
MBQ5K%*2;8\:ZWT_]OI(""$UOXX-S52+;+_>UO8NO/.B#=@>J&)WV&6-CIQP'
M+-+Q;+CR,JSI!#OZG;Z^P? K>(4Y!05<6U5+>S*8NWJ[>NXQ-M)/<YG6'_7K
ML)>F4)TR7FKPVEH8:C!&]]F^K86(ACG23) SX)UT6@M0D]KV"& 0T<N*E:B^
M5+:0X>H^01]9YA5<+CK@347:PQ0[NRRL$/4S,"TP/)0S^"+BD9C>H^D/XHH_
M'_2LR[! ')+2%XS[O4?ZBO5^%.*)?DI;#;(KI'B-28C!Z$*EY1N1W9*ZK,P5
M_J3YW>=CTJTU3B4^OSG6Y7(I2WY?^L8VD?>)=BN?WGGVQK- ?JI5UH^Z<<SN
M\)9&%).E7=H&@SFE -JO\V/KA  ^GD7%RQ2YS5\]H.9/#*3X/C+< E$5 [!/
M]J-GJM9KTQ4AH&KKQY%[)$F*ZSO=CQ1,,;H94*N!ZP=$8K_2W6_CX-4D*;_=
M9CH6Y#47B:LXQ@QPUC2+ZVZR[R@4E2+EW^+*2+(JF_\,#5][]T &V(R]=5H,
M*I9F.M9G:AEE!ZWQ[Y"::B.V@)/D)5/\R5?Z(OA<KV.\;1LLS)Z^)G&:?_#<
M;VS+I;ASXLYX,X$^T3L:A8]E^F?19W@T3W1.!E?DNXN[%[-"V?'0WZ(F*4VL
M@O%O/YC1,X+W\Y/&(WY&!U/CF6GND/8^O:1\E:./<I 755Y6+)X][[36WYM[
M&</6E3$CNW4YR49[N8D$+-#^:DE?Q@K.F73Y7%^M.%F;:*XZ(2VFO3,'/MWI
MZ-3\WDFA+#45NIO+T=F5KL?-US#B<8:0Y5@\,T4"ANX85XVOCXC3ZO3=)ZVB
MX%E3XS8AQ#C:\/.B7#OEDM_0:HN!0>/RHP =VIC^_AWX!7.M<:1)_6T6H5J)
M,@ON!($#XOHYB:(PN^SJ@\%/W#7Z33O6=OSGL;M\SS:Y @0Q)T<J1&_)PID(
M\"_=DI$ "0%(OHW[<XT119O><D9%(GL#>.E$J17B<<O04!ACS1Q(W"R*H[[[
M.P9$");Y0]:D*,&Z+Q/\C4\FC268Y76;5; <"<2"H^NHS-?*K+8^9L&,C?^M
M:E2D)'61=]]%.8_TM%SF9U-:RW"9N\\?8DGI@U8BM*VL3;ZF;4G<<^>J3-2F
M%D8"=M2KE#:3.XJ?*2P[PA3P\:;F9*]VO!6/I5,>4E157SHF%1;8)-WI^!RM
MZ^%9ROWH$;/@VRO/$S%;^NV]Y<MMA>)"/=U587?3GH("U3TV)>A42Q8!:C-Z
M-W40WB*+!&3BIG=@(=A3]2>A:N#GL<J'8HA$.V+20UT"@M[F^-[!E(U]&JNQ
M9@6?8DE&;=49W\- OB[[HE74+ETXV\@V:*7/-J'9]JIO_MFA9_"*\L=L-\;[
M!.DVAKJ4/'<]O/J+*=9B=,<!&[94#\2.-:H7B8VM)VPMWM0TU;[0$RI;(L3N
MV6N-4U 9YQ'0WZ\U[#=Z"\C!RP1L$C\(B D;=J/*I39V5GYU2%JZ5-A1)(5;
MK>0NS8_IJZR:WG(YVFQNBA?RB5GGGETBJ9NL77_X#R;4WEK,^O!\4D-#G5-+
MD(P5H%!8^D.^?NL8'&$R;ZCL[<HTT%_*.4+]"SJ61.A>G\O4UYLZX( '>6XH
M,^ 9O]WY,MSKZX_7WJEY%<-ZNH3\:K]V231<&6%9;#04:CJI,2]%XC[_+J3^
M7JJ^K"CK+9<WS6(2^%R?OF?/'>/[V8ZF1=H'0_Y81BNCV?:ZJ*?01 $2A;A!
MB8=0K%FW;8M4)(!^O9)67.5(_M(S.1)(95^DI1<T\"'RX#GBP"Z:465[Y3K#
M@_^J16T;1OX[JC-*1H%3I9. ;UMBVV> @_>8JR_I@NOZ"SZ=]2$ W[[&ZWC]
MD/G#0,\SV,O8N4,=03)U0T\CY[M'V03,=Y]D9Q32JC3$K"^LI5#83?!_A%+=
MOFK3$Y;^53:@^ 1CV7L!:[X1=2?I97R"P.F?EBE-M+Z"&,\GY9*<',RWC+V]
M78EUWRTP]5OPRB'_>/UGW62)'SU/<=Q6SOVZC'.I&L-2]??Y,Q@]7IQC^CF8
MW/:"0V1@- 1'/ZA#5'J,NLY<T^K4N5+B_4-BCCC#Z[>_/12&*_+,F%_13@OB
ML_0?H\)4A&]LR;*)+D874UDXX+SPNX4$S.@S#-KU((0*H;\KJ@\%FN_J3^]E
M-6IX.F508+Y>$18:,+W7@/@!$T,"ZH_?0^LW?'E3KME7=NI&@%]>T;^__^NQ
MZN.N*YV=?86X@!07[JWOLI]J (!OH?M(@*1-J:G_4JJZY>(Q'5YDT]-I.%_=
M28%,N9L 7P$FX=S3.+L*5C7L[[TK6,)Y'84&/[S.',E'9,G-=<88\%^T\$*E
MOZ2L7""86E@<8/;5M.+&TQJ'H[ZGL^>GU]:7/2Q*0V,I!97=U%4M1:F_\IU=
M ?[-!4MX]5WW33 <U"-KB,_4#;H<J$IPO],FD&.2&\1>*_*G[BDDK:W)_'S6
M-OM,SX3E"],5)W2+=E$+&+QTKFYG+[WQ,7\LQ7<;<(:A;*[Z@?82N^-IK]:H
MB\*T[S#IU9B.Z2<J4DP69P*XJ./YN XW0R"HZ2/O\1X%$< E_'W7L0B876LN
MG[$4;'S$:?4A.7G"M*<B)18)P"@YI_=.S Y@XF$,)]'T9$R*Z879XL#/<1W8
M5?8EO@6./;19L9U<HU#YCF$2,"0172OV]*[U]**42$>'8=(9X6R?SS)97R4G
M;U<CO>##DJ*I07MA6$F??K*(M_=X'6HE\6PN.X1=TY/<U']JN0I:9E&5:N$/
M$[KMTDUW>ILF8SRQ1B2Q=.:^-+&2T\Y]2<%+2VK?SPTRV_GE:IY^2, 'HSY_
M)(#6&;S)IAV+ #;S(@$&RTC \(!.\+)6=>18W9[JC+2!RQN *.)6#MGD+05=
MP8B)#&REX:/?>[1&BN)JFM(7OG=V2$V6ZU.(FJ AZ><$A?08+A'O,/R8/V(@
M 9@V?9'K.GL=(U^)L(XQN@XMQ=B6CQSQ?DH&]P7CT76IX3!L3800L'_B:6X0
MHCT(USD KFP;7]^QL0V+KS)\L"9^HK74U<IHSQY@0T8P)?#E:.:6@DGV?8VT
M'*+N+=4^1\[#]I@G'+AO)<-?FZ6O*U)E;'-83_O>[:_=R:.67Q<GE*"O >YV
M"Q**AW6MO&J^(A_ESZ1KF%[EI=%5::JCGO>>>%M71T9ZH-][E>5'0-XE>6VC
MX//"VX/RSM$"X6QS@XH0UIAE9F[O]_'(PK<*WH[W&WT^\TH)Z=1!8]0>K+%D
M=&46.Y>FMB98FCN=W7J!U_<Q3J[/9V[U= 9K0]==4-U(CL8"RVJFB/B.ZB;@
M-RXWMWE3O?6ZW8CX4\?(0,P+3:>H;2ZC]> 2^OKJJE;_'/-9F.=]/_NY5)RN
MHI6CG$-F<%U9W0:0FV^K^DW!O4]:X]! W[4Y837@1Q?Q\8JB[1'F<F&_V0'R
MUZ;N$69=F)D"SZP_KU%(U^5UY')=-W^P/VZK<IK::>I%N,8M(0$7#_3 +A7X
M6W58PK .H$*3 Q149IGRB9("%)U\NT(]TL>&J&B>GX?\*/OX[J35LJ8%]7?Z
M,#&5N64HSS/Y!Z+/?M-^7@B'&,=\\CA8JUT(WE8\/YVI']R!=!9^6B5MLY@3
M+458\,)UNHX*N<HMJQ]4Q+$Q"V87F+]U^7V6;PJT2KLNT0U#2$\?=W+']L%$
ME!PO+0^*S[7:#"VMCA"#L&#JYN&C%<3E]Q+OY)ZR=AS<#\KU'S,UP1CR/"Q7
M.%6+5P%7L)6VB4@M 2T.I<4DEDAL)* *,>[.V6'VN8C1X^++_7CAK<D=M45/
M\)06\V,ZY:<JHNTXT*V9HME%18=[[:WZ/[L<00^?#!8,2BDEJS;4USV15^EJ
M>G?KR;,KGHR5C*Q?R^H0KN:PF4^8!@TT1>F7V/GZ$BR6>'01JO?BZ=*PD("R
MJC*>C<88P2^9+N3W'][RS7'=TM-S[>5)9>GIYP0X1BG)DN>,RHT0AN?I*  6
MG_;3\!%UEV2<&F4$JMSS[+_K>.]"ZAQVJ%5JWU]5V7O8V?HR.@/ 'B![6JQE
M<=N?O(=4#RN\JM^I1/+"#49S2F:UJ1)>RQ=4^CWDUT.Y-YWNT!7B0MMWAQ1:
M.)1/^.IYR(NC#>AKTLP!3%7%SM]8W&E[PZR'C17N2I"*7@2*WJ_8.5=UPR78
MO[;2T*'X8*37U)S8'G1R<IKKP?RI'4243>,7J6A4D\88_S.1^#;AWL;>AE!.
M9<)9TKO[]Q@:7GM^ ZZ.-%%^,#;>>5%26S6;53W\]*[0H\;T]AI180K;+<;=
M:"3@>:%+Z-#+VI\@W 9 R-PLQ#YPI)&+^>?4=!SXM#P8[&"3J##_+%OY+.EM
MV%AP?-0$2P;K-ILUEJJ"1'NR@MR?#RJ\4,=? $HJ%PPN B5?W>;'Q6/=DO ;
M510:502PV*!/$,-1Y-^VSKNE[IWD*MB0@<U=SO4VF]#00/H6435_.#'1UH"H
M M'#VQ]!ABOWQ??+1Q<J'6IG/0(X^I*M+6NN>#_==Z1X7S<?&_7_B'O+@#B6
M;EUX"$E(( 0([@1W"!IT( 0/P=V#0X#@SB#!!H< ">X2' 9WA^#N'MQ]@&&X
M0_;>YWW/^;Y[SKV_[H^>F:Y>]:RGUJKIJNJN6L5O0T!X6>1@!++(L3A"AS1[
M9EJ9BBM\4/S5F6$X0W\PSZU3$/5[="IDE3&,)BSH<<$+80/^Z#W%-B\+!\Z.
M)Q,<OWSPWG^10MG1N0A,X<)/P O$QYMSQ*8IQ%WM3 [/F[$#>S6G47_9)I.K
M QM7QO"1T/)@8[;:RB=--Y'DZPPL!UZ.K;E1^.T2TD8>=4>@L4VH:G(G*7I9
M6SPN_W@Z9!A%[?,]6&DAL@-WR$++NI\FC-:J]K X/?I=$DTXU:<<MUAHX$=)
MG8M"/"G"1H$7[H['_1:OL2M%5.@.9TAJ/%//KQ7J?C1Y_!0S=+-ZL:'$UQF0
MXS*';8"25F(YH,[^H1RBW+TFOA"@0=HQX0[NGVR5,Y*NC9F3S@@=8E6BHFU7
M 4CAQNS1IN5)%W=945M8>U"?B/17-280:QB<]UV7RR:(UFFF&,2A-C ]G8UR
M3EZ)R-K3Y('3EM>.F$RV1K\.?9WUV;9W6S@OS,MR*,%T2HOK2]_ 0,"&<,E"
MS:X5VL?CRP/:H5U12G[--(Z)$MY?.%__1 S[$S(L04SO3+G2^BFIA >G'4X&
MT5M4)DZ\;8"@:8I+D9A1EE@^@M#EP,]6,8BU<I@3U32)FFIQ28:@%FFC%,4M
M;OJ/N;57_9M8$%8./F27L<*%G,F\0#9(@?56HL;6+)H8,JXC]5LJPE:2R/:4
MJ+H?+?E[SW,M1A>'K?G,*)YA/VGKEO?\@D0+H8HV":%^1T@JQD#:]EL-=\ E
ML:3\<7RKJ*VM;2UQ/D&@Q5LJ&\G7DJN)#T'#:L;@78YY Y#HC)>B2!/D<8$>
M!I&_8F6Z: \M1\5Q:1[>0_O]U_VO2S5*J$PON#^^G5-'S=KU8E+CPDI7W6;@
MB"$5QU'Y1F.W1 ?U,BF1N7*.8#[2CC>HD\8HQ-"WTXW#F4C6'>4 QU0*"A^M
M'H6P: 14R@8,(8M1\,%>HJLA6FZZSK3SYTEG^B>E;IE5EZ=O7,W)T.\!S^1#
M@-O8O)LMZS*"N&OR-X\'KTNATXV*DC51S<5D6_[W@/;_2'Z8KZ'^C[C>B3C9
MDNB%>2K6OZ<^S*/0#[X'_"US\$=&PT60#H[9@A <H;4=!'4G_'W"^'#2- 46
M:O3?+3MT58>]?@A:D*ZRG'@/"&>#O4[]UYE'#HZ'&\JDX<)Q"U1,4!PQVBMH
MX;X'$.G_I[,K?OK+4_P'J=6592S07PHBH6*>_R9"A!#!^"E6AVCBCH-<@^"^
M#MY6<"Y0.^D:^<V3/X6O?2B\EQ+I,(+C5X%.X#G:@]4>7C("'TX2SLC7]>81
M!7MWDRV02H,H,"@8N(W/M@E$% P+ Q,TPJH_  KW,'E@/+&Z<"(/?2\HBB#0
M!WH#YVHY#G;UA_O&P(U@5G/Y6?.]^LI!SJZUQQ$M_TB VJE*$<;A^ ,B_@<D
M8S&5$Z$GOND?F:QVK:L[9!-8#W2Z8O3!53DO]T]:H.\OCFZ>]E]'GF3!L80\
MX+X5#UIFZ1%:A+/D&P0=$*DN?Z5:@%9QID';Q ^LF\ (#P1<H'K-KB\?@ZU:
MSM$?BOC@R9(ZA,(=A$+N?1S%@]_D"GF+J:+_GHX@,K=UAYSS0*14Q=@@\6^@
MW\O'H7N@\Y?_ %77_ .T>\&FY;TD>I>&X!/EJJ_= _/?0.1^V!6/K1A1;.&'
M8KM/XC0U^M\*ISF[L<$H;Y;OD/^1>5,,^EMD$&$9M%M^A @OC(I_9"^O#U'N
M!R>9:2%JC6?+=X2S+]2W6XY0B8L1E? N!:&P$(Z58@7W/?W+ $13H&WR/P:0
M 7LOO8,/(4JGC2 [5(4@>PW\XZRP/> Y1NR#Q_-;G%,0E@:9CA\.,R+46&D^
MJ$E[4 -<)9X";;7_H57,$6E+X68MO']Z!)6X2+L^?L@L":-R'X9!I1$,2Q4S
M(VU?@\R4#X<?@C_8:MP#TI[_I2M\C_QLE6Z3:4)21DNH,>@N2;9!$.+JH$%%
MV?[!2YP-1I78\X !/I\!36)T9R.\"JRT<#%+ +7S%8&&OZ9]S\L+NOCVN?B;
MSYTD=#I/4?:/P)59<DET$0@OY?4-ECR\;Q+A=-Y-II'MG(.T3_ ,C$V0[U;+
MK'O>'7(NK(O\SP]36)?+N?)ED;Y2I/,7,;E)X$,.QL74\$+!_+7E?:B@0"\'
M$$DW3E#)2=.NK4M@\1L+UQ&5U2!#HNJVC _^-LI9X7O/P7-<%@GO,Z\G9AXI
M,@Q,KVNSN_C!3RGTORM?DFN)W[9GIS^#5>Y)QGN)2XN_CG:3G%#<(%=4&A7!
MO*:;4)'@W"SK74&M4>WY>SK4)^+?:8H?\;;(757\8QAE'G6!*M..,'[%[@_>
MK:J9YWRI8+R+:VD$,@KW+B^1QVD]3'^2K^"]"MJ0ON2!0PN_*3KC,=R%M#0#
M&<UF9AK0UWT$5&\^(?IHH'0X1#<@6GF?+>W"_S1KG^WN O8GVA$8: @Z*MV0
MG-&_W;M6W7V8L>3=?@]8UA+^\]GT,!<I<D8?[H[Q*[U^E+))13NJ@O'ME^<4
MQHY#&,!PQ.U]QCXS\D]NQ4O\>T!JZ+^AG(V"&!]PSD:\5=T?)CJ1E[5<3?]+
MO6X &&CPEWKR?ZEO12C6_Q59!D2(%DX@2H3(!OR3#>.?;-&2?W[GWR+? [Q
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M.UHW4]$6I1;X_+K'SE5UNA6/[?,(4?SX2)F"RI& YBSJYLC> 82?,1H]6SE
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M*$]5%:9/8%#B>^1%!I2Q*<U>S@O9FGP]SE)E;AQ@=$KSA8@M7;C*0I#06'C
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M+$5^AO$0GID>WC8&VB9'N3N3W\/:)U=/<!@,D&(:;2F#E%X?^\.O<^ =8_>
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MAQY9<DFK+]'P>7N$];KTTH%N0_T4<5$K;;&77;8<HI,%+75"C0*/YR,-VJ4
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M3#!2Q L:5-C*D,)# 0HP7V8DO&/HH,NY1WQ'PXMX^S;^H:GUZ051AO*;1_>
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M2!HV&5@UDOFV[RKK%@/*8E++&W58'.Q/XN@>I=K9/L>/-N3X;*,ZQ)29=YP
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MI\$N5@1;VX.[W\UR;Q%5!!XUQYRMY-$, "4?6W-&?=M&'0^7 !F($U-'@OS
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MGTS8ZNGC4A2H[_XCCJFU%#W=3IWE5%@9SO7A 3N;<H-7;.LNZ/K="/X D[]
M*V1_G"F+),(72^"M1AA]"_1%0TN,C1\%/\/LY.4TL66ZL4J,4;69E<O4!\_2
M!8M4;9O+SL::)%X"_O[ %']@QL4\OO#=]QLHY3VVY%SL]CL+&XCR,A#VJU?1
M==-(?>0\['ZTBUUM);-[<=>C N0DDRFQ0[OB]AJTD.M.NLVZ\;,OP._1W$+>
MEAC3&E2PRF]A4TJ-#X_C7+8#^][&:O3+,8>GJE2*;F0_@])W29P9;#(SM(V6
M1K[^J6^0+=!T@8R"ZR? @A(X ]!Z!&3'ZG%A%)>&3Q@UM^5*WGH")W;$ G6(
MO$>PRD*]*-E915W]AH?J9C+^GDP_Y7]IU)&>"<RS45IP)"WH+7RL%WF_5K E
M+UI%5G55I!T4D2J;UD95G+903%%=,;2=P:!6^ZEUAG)P84]XW>#JF=VXV/#T
M!7"O[MS=5X$(9N#LWRLZ4,55]F+!P.+'6H(,PQ"O6[V0;-G$9,>3<*!TB+:O
MBM1XEX4@><&IUHDAKT0ZF:9.Q]RC48<ZTVRXSILJ1OOMT>K:FI$,C8YG<DUW
M&^> \NT#.('@JQNC0*.Z-U,_HW&WPZ%\+=V,9>\_$>W>E-!?#:MC*[!CY<1(
M:6 Q1#!106!Y0J6ZON0WPZ7(Z$A) Y!8RS6 \4)YS_0X.==HO<:DU&2ZQY[:
ME4%&%U%Q@-3\5BS4QYJP<@WXY,<'-_K@GIQ_U#!,'@5E61Z1"*I6M#7.R),L
M@C7$+<X'%[IIB)XQD8%W-+22MQ@1M-G;8L^(A?(\U#V+/#NO 3>/D/2P5,ZZ
MBBIT^+SVX*-AG(JF<@S]0U ES2"\M6F.JP0O$'2AA^4H:1@]3)$\%\*UG/Y1
MX+#T77+$/AIV,(THK3;?/ [>BVJ(2]]XD+S9,9H1.S75,7?SY([MU865SXN"
M?+:IY&;4QXII^_P,/@^1TQV.LB>23+%.[%^/S6%B3=< (O<!"D)R"VKEIZ?-
MT[ZB=*]<.\'FE#P,T6?D>JJ&D.,G[Z4Y8CPDNI(V:U<?_WK3J<3B]VL._5:?
M!5V?V?!RS5H3PCG6E*XM#DI%.CD\9Q5PH(/^B,[,*(S*V_?@8E]'U;)U:#">
M= P3K%L&WH[LV"\;VM24A?C6/:3\PGPI.9YB-W_G L92'"[%E5F1R/49H8&H
M3&3\NJ/0E_-4+0>$DQ4@GDO#401"GE41@K+F;6G')&CJ,[X4H(X*#S+&7SSY
MJ&VH]&?KU09T3LXVQ>OR1]U3L;#&TL&Y9&?/8Z)"W^^7GTUL6+7\3?"Z1P-3
ML.8KEMKZ +=1CG+,SE6[CS]9N@AMG(>!(R+2%Q8+"H  38$7I+PU.G!6#1.[
M$'W])VM<22M>$+.3L@N]RCP$Q>@N@@A7?Y,GPJIJ%#UQ]-+H6SPES_-6'ZQM
M7<"0! O7XC4@2&!A?+E&#,5US,LCW>8=*:-3Y^ 4^VR'?H_'N*F1IMR,#6(*
M/88Z6^2".\KJH[;>/[5-WNE*KP(V(XPN4XME.&%7/+4^.7S;[BS<8V-#AFQ'
M>R4?7K*UN(+9;EW1;K"2C3D<:>BT@A6#7([S[9Z6U?HD977J5#=LG.L]5V:,
M*I?V!SP_,U![?PU@=?;E27[?S (OBOOO;_L"=_^$_,?QG3+4]L?=[P[:Q+>B
MT4N-C V B8NW%2%:9=57[7BKT&N _*BY2<(U(,L%N2A_9E!DGV$UD^%6P#T<
M9+BO84K#H$J!$M Y.-<U^H"&UCU=K&<1Z3/X0NO>AUZXNJ"X4LZ'D,;I$81Q
M.>@!,D/Y_ GY>P&^G,O(5+FE.FTVW-E1<3D"NK?[BO#I5W<F(5 S1!O-OGQ
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M'^$89C@>(RF7U+5QB"_.5.9[*#1+!G 1$P0I_,D&>^.B\2AAQ0.[J$N[T,@
MIL8#Z'GW,6_X6<9HKU9( 4$P$LB5H_2V0T<PXW]"D>77A#1@!@*[^MLEOM^8
M&B:U'5+'U$)'KT.@TRS4X]LG=6XSS+)S#@S%A]^A*/\G[+#M4$SA04(M80@0
MLN0Y^$]6.:H29Q0,/.OPVA8 'H7Q5*]?3:1=^(9A1MRF!G/B+ .@(-;4<AG
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M81*.*('GO.?BNVUTZH<JV[YSQ6P5XB182#+%*\G.Y$H.(9M;RUDTV>GT=(9
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M0&2@HE")$8 63K;B?<92XKM+<]J"KW*A[&LVW(-S,)G?C4C=2Z:$?%UBQ#S
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M0KEW7\/NKQ<)V)<:6_.(*6%=ZO*'GT;9(@^UZDJ^V:LK<47H_]#W6HD(W*=
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MBT@X3'C%:6')/$*P)/UU_)IL'9OD;CK*6=YP20TK.@<VYS7_![XWU#'=F_B
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M0UV%,+)/GLSA\G1\RH^][T@<%.4_B1I84V!MHSH:-5_>[PER@-# 6KM<O !
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MF@,C_AH6,>=S!>HU]%4S&HO7M>%++<W&\GXSD1, /GE!N-81NN(_U%W L1
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M5EUVWX5V;.&IE>3DN\F3X!#*S1E_;A\+)D+2'Y?&M-L<NS4.2AB *G.E';K
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M*4B%?UA&FV[_AAI?9EW$M;0KK)M]O%#D<XN!^[,!&[RP'FT>:'KR[MOW_Q^
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MS;]I; W.W:QHUOJSNB#I;28*?=DQJOM<=@'JDJ_I1(H @&ML[NR4W\\D=7;
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M7!9&71:??[3[OS*%B\87*ASB*X'#JCH&CL"8YH7^&TD28PM@B1H\1Z-ESD<
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MU+GWRK<=E3VCTM_^C*=M,DA$=)G/]=?PK\9,KL@LN.W!3&)^AD7I#M>%1DL
M/XLKL,<PH]_@_5J<Q\,FP.7MVW(^;I\XHO +=-9([ER>3/L!94_N%5RRVY1
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M&/$+*VZRY6RCYA>BUE'Q4LJ*CSE@I':@HPRZXE]GB9BII:#QF!71SFJ^ZM5
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M'NX\@/25:^6K+L< C0%(BCBF00:HEXY&_U%98=]U[^?*X*@2QH_]G:^KZ,C
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MVCT7MS&J7^*OR-8LR"NI5G/2*<6TRXQWY_S)1Q)L!TV4:FV4SS)"@NN#7:3
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MMHFP]H$K6I0.&.JHDN#\:QG 7Y#O#'971X9XJPV$ADJ_(&_%P>3H!Y[#<^B
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MZ@^G/U[OT.B?JJRPYR7W-B&Z-56*.>RVG9V%/P_B?RM],?>^I(JR/L VDU[
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MH&JZSLM@@[$MWMKG[81G_.\-YB*"DR5H)MVK($0_PG3XVG??F^B[/@)B#KM
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M[H/;M@ 7@E\E9&4X4EJ^[?$DCSLY(@*[%V"E^VQ[ZW+/:UL3O=X#L7'>*85
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MEYJ9F 5S!I/]FX@ <K,T%;9^W!KJR<5U\N(60K'IIG.VJ4"K2OAI 20GXIT
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MSS:BO @YX??.5BZI-.0X$!UZI.T.#F3)A6VE+=0+1[X)I4&J+B-]6X!RE[W
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M%D[WOV$ 2H71=_/%H/N J1Q1\&R"@<$ #+\$?-ND@2".,\#'N0G75HT PMX
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M,G.G,(.7X]W9,06UNUF1)+6GTE/9VT57--%D(J^]76J"0^"Y0@>W(N1BDO&
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M=:_W)4>-A?>P<L6T\)N1C7TQT%;YL:]C;=B:J!,G<\79=D]Y]:>/T1/MO0(
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MXOW "XPS//: 1U+S^!%OGJ.V-B+XOF7A@5M^3F!&03.EQ(%!RMR/@(W)#W
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ME[DQF06:F[O0D\GL3RJ?EWW_EMJSTN["Y;R$B._E2KF3$FG?P8@2MY-4A8;
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MU&[S<;2TUW)U? +MO,&/@A/#7$9VZX 6[_J.IOA.^9T+HX;77\\5]Q@\U=\
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MM#<:$'7H-P.(5A8Z)>6=C.FJ2A[P@>]LVCT&4^D&@F5Z=7(H"PT!'*$.HCA
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M-S;-I[-G !:H,I;E\JR'*B;&1G]"(<20SVQLH/)FRQL?@)<9E;X0@L S$-5
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M4K?KB@D%00>'Y9Q#$^>^#,FVJ?/CSQE@_^*YE4+XG0&&]9Q+5<VH[]^@MQ>
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M;WL^W6I4(S/ID+Q3CK-+5[F@QG'EV996.F4**)_CK7WG%%+-!M,<CL<)^'*
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M)QZU(LCSI'IZA\]*!XD[Z'T2<0*(P<>&]=W[!YK>4[+>;\B2^(IL=(SF10Z
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M ^=1;>7]5J_%O(1@,6O/)O1VR?O?PJ<5+4S*-;:-W[R_=G\.8=^VOL<NX";
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MBB%O <9F\;5Z6_1%676+&<0MC(=SQ;6J3-^4R"AL#5@JF&<*/RZ= K+ NSO
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M X/62VRE?_7'BHE\6.:4^\G.)1(#J6$TXZW$#2Q>))QV&S2'FZGFE)R9F>E
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M;A@[M',P]YS-8RV#4:9.A4%#PQ%?^VKH4/P*C,'.VRCH[9"IT>??P_+1 M(
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MY4Y,RV9:4%"$Q<</%>KAZ5+JW*<?X3D4@*I=[D76#746AS>.%[0F+B;LK-H
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MB(UXG>BD^)EQ?UWE*L5A,39<1.Z8'V<UE9<6(7ZW-G7%5[_'4+1LNPKA*W^
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MV'[9C&=07^V *N^R38KP,#_?$)^=-GK%O I]6=OI%7SO)#M0,O=89*S!HV!
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M]W.1P(+'7*TR>V<&_PALGGT]52E#;K)*&RG0F]^)5ZI(ZP[ZT&>0':_Z]D'
M-1?[1WRY"]M1X9T(9@SZFG:^6%)C$?3OIJ:=>.H[9+66!@?':X\!@QI*"G[
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MSQFBAD[N9#10\28=J@3J@*1H5<<O;V7!*;.I-0\MV]\<O:+;(;41 AF7P7O
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MZ+!M)6U7 2R#()(M.TM5^C'>M\/:_!1P?9?3?YB?HWK(;)?3PAQJT_!ZX?U
MC :OHQE0],)@MA6]:CO]WH4 ?Q,D!83W:<;S+U Y[2NQ8[1>7R_\2R(R<OB?
M>@WRJ^>/^#&>&=R4X3*YV+TO0+/&2>]OQONN"2"*QL1$VPQ/V1_Q\ &)X2-\
M4I1*##L#5XTHZ1_.G@O?:I5!*,.&2;&_2]4QZT>*VFE=.Z_-; &]?]A!\-0=
M2&;$G !V>&7XF&I,JJ"\<]P02LCRLXN.4OGI]272UF=&I)"2A(?,TV]8GL=4
M)?#SY:.>N7G:AMC>U3SW3I2Q34^GIE,EA0%Y"N"!ZXYVX^CK9+-AA6"P%K6
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MZQ$X<<-"Z[LDVVQV*T<K/S#6_&6"2+%&M5/=9O[2I.P$.-J$G<W3S\2C\ZV
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MA>)/W)(F5ESZ?^AZSX"F@F=O.!9$141%I!.5HG3ITH*("(@8BO02!:2%(CU
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MF9ZQZ;@5.?FHAR?6]MOK&F4YZHU77JA ;@GUE:+@#RGQO!T,*?(CG.H.$V=
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M^(7YB\%+C8./][XH'5SM#(*\;SEC4 A9+\ZE]!@3E^+PK(2"U0"B1)'C"^Q
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M@&I@M5:_[IY </I8J\U%9+Y;LU*4 C0.- =.,VM)!M>$$K&]JD$O+P]_"%!
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M1=Z>6@X-SH9U N[L[FAL3&4C1A;H@+;0,CK@\OW56F!7()#&0D!0HG?G*([
MTW3 8!5B?X4.(#U%=%RGW**%YM !:$;#T3EK03I4"J?B<\:,@.5I@_6,-G[2
M 40(]%\8V#'2C\$RH!L# -(!4?^A;I?"&%#$?*G&<!KMF X@,PC>@(DS'W,C
MMAC?O- 9JT <$/G^T &,\7T:V60TL:E!Y61 7=)5!G?6WQRE>2>DT5[_AU_F
M5%GI</3R#-MQ!>.W0@W<!SA'(TT];7T107X:"K[-Z,N)_D^(P='?Z H&I>4U
MX/^@5*6:NJF&^ /"T 'ORQ[1 >_N$\VI1[>.#_^10OPC10>HL=..@32QA,)%
MX,Z\,@.%,;@EO7%4>\)N4P-!2?L/+<6TEZO5I3C$_NX1A';S']N9&6PG<-,!
M-?\8Q& \Z/R6.SH6<9RB4>C((/'?A [2>6V=YW=XS=XMFQ,]EURD2JHH^76C
MM: E,S/;?B#)$])H6_H:SZK1-?%]00>SH<"%CMD@IS)6&%%X\E]H6%G91N)\
MZ[4'M29["< CA6=ND!^U':&N3;WR@Y5]C<?^7UTRZ !^MX54%NDW]5_U/^V#
MJB5L/*(S<S26HA@RX#1#JOA?K.5HA15W@:X1GZ1)93>D8?>"K$[;*HZ;64=9
MVB(6/T+\BQ@SM9$_#V&CNH\TW2JS6:OEN?6^Y//N]Y!56/VK,-H9[%P7NZ#T
M48+=#FYN4A"'?I<7[J&J_4[I[81I$&=_Z,] Z=_CS=Q&'3LZK/H?37_ 7+;[
MV,U,P\;">I.)';CO90O@JZO(RVK>7F3QXK-6_,P=O2)[HPM>S1(HJB_Z>+MZ
M5^/L)SL#+6>7U&NTQY .8X*7]*WE/*[M3_;BOYI*+;Y%BW[Z?P--Y,$I!M \
MI['+;EPC9[C.M_J_+Z4KS=XL!*P<(O?K"MVN#NQM=1GH17&;SY'(<YK4HGRN
MO>+ .=+N7.1V$?*1UH6]O!QL?(COO7,Z"S9*\2TR+J#3WJS3A" $'0"J6:_'
M'&]M8MB\CDQ</6X=/HGT^T '!-TR"R;DO^Z<B%2[[M/'<5]V\6."]_IH'E#A
M&46G6P4<)Q$V_MT6U5X,7ZV%:M.V)_:;?1[)QM8[^CTTR@SZ)DT'%$7?+KQ]
M>UT'=9YE_D3RRFW ,K'KJM_"U]POI^@ C+[.2%9?0!= Z?5@,*C)^)4UX$)R
M:]<)_4N /K^>8,#CW=P-W:6TKX+Y$UESKUQ.1";@\&EKOD]H?ADAAJ<0[XTF
MHB'+]YBIYQ.L'I\/N/?E= ZFFFNF)T\<D6EXTNC0>$&Y]2=?IG'(T,F7=7GR
M1O=.?$EX9)CO>?^#:J:QTZN+MQ=&$FQVOVHZ,5JE#)V@)&L#$^2==[^<C&^^
M[;G0S,<#4 TQ&C!@/I6/TZ/XWF/IH0QC$Q&S>?V 6ZOZ<]'J")1 %>"E=_H=
MEX55'3CC:U."$ )U. YT&QIIV<BN!TZ\DA[^'WEN<7,U"&I&0@Q#\2/_ZXH6
MVR+D.V-Y1?Y[JT'X;Y/-Q&Z F>(\N 3DX5C)'PMM+AY1:PO9ZPK@^4$'Q&CA
MPAABKCZ.V'V893O8AIR$= $Y"?;C KJ[K$PM!,*8]2SD<)&3A&C>QK2L(7\,
M(/WG,_C/L''8:*G'$?KQMM71%94#/Z3Z,]"KX8@Y_RZSJJ#XP[O!20GM<-&$
M]JB[93J4#J)@%_",%X>_BW9WABHAPKCZX(L7&3'I188.J&(>O^ ^6I;(N0W7
M F5&(T"?"GK;"JB=&^M(E-P-6I5AKH#F:6-<NO:#ATD/[SZ-TW,"O0J[&G>:
M,/$Y/82C[YV/T%23M/) $/-AM!?U]*FQ!36@)F'ORVD@K<'A:59AD^%INTB4
M=+#_=</BY"1UB]2M;-J>\.6 +O'@T<_1'U"7HPWI -G?):BJ^(OJZJQR3&$V
MR?&R'<CN#RP]P4[JA90M ^S75[0JP%Q[VL%([<QJOT+0_I<SU4KH/-WAXH#O
M-5?)P#@FF]MNX*%1G:_?95P%LJJ,=,\:R&;=)"PT"S.]%0;&\:\",/V2LM%)
M/>;U89T+--F(MM"Z)CI@1'2]?7"VS/OX?0^5H?XB[C*F\=_)P;>R#ME5.N#*
MK76.JT9VYW9O/-U%')RV8(CW?\H/V?S/%.2OI/Y_DB#_?R9&QB.J>L(AG0*G
MTJS+;1OH@+>+MM#'R0%SLUH[\AZTON^+=,!K\QR*:J=9MBQQ(@7/<GW.85SR
M1E-$,'7*4DEZ!\5J-L!_'VNMMW!%RR>!M\S)Q.[R$3_E)P2N,48%>DL=Z[19
MQ6(%&Q%\1HT2!G0 /$?ZN+(4$9Y/27@DD^)^ZS@DC?8QE.F4G)3%W["GO>'3
MBIQ+Q^*#30C20AN0!?>"Q/F>(+%9OOTG)R@-3-N [IASYE(]2)A.%HA2FP9K
M*;[<_F=Z;8Q4&CAA<H+)/ 5#.UF=7Q45>R<E3R ,$OA[__U,X)7\US9I\2!1
MF FN.7R&DFQ7.?PM>?']=.^.'FWM>.E?<A( F@4D2&EU[D)<V920_ ML&FT2
M=>!(9SORNI4A?;S=:]W"?YS1 J28'?ASP>4NYA05SAWG%3_:KPU!-R_]LBQH
M:NE]E"V0<?RW'MVN1YQBV <186)NF&"G"(1:VE![K9U!?^X/^0]*ORJZFLU]
M$-5VGW^DJEHG')]I8ED@(]DBO)HD24_:!-\MWV^*GS)*]N0)E77>SC/;V\::
MIB :RXMG[5-L@K)C'@A+5QD$OUR,>Z1Q(:;*2-O%^^W_UN )_\=5R-JV'*&'
M0OP4.*+5Z=$!7](_)B9&YY[" *6_;ZT:C^DG+1]O6:5^2$P.ZN_,-'7?_T^]
M^&DRAWFV=[H6^ZD/XFF4!'P $1FA8/!$@0[0C9?\X07!.U1#"^B U*!!JYVY
M!!Z;AMH.#P/!@_1+E0RSY05DZ9^YYR[Q7(442UZZT_G(*$<4*.%20Z9=)\G?
M,D4?R0>:7*NO#V@U#!)"/MJ;X<25O5*#BN3DNYC7]OM#S_D&^#Q_>?>G^MG^
M(.";W=MPO1+KU5K.]E_*F;?2>PHV?"'Z, TMC+R!JN$P7)L_G.+#:YN*??OU
MG* OU93\^:VKB7><LL7!8SY!H[[/0!"%I8N=PMQS>>9<K76/3&T]RP"E[2 N
MM#!S)^%7RR4#(;=9H5#5)Q^FJS!.9WMM_K)''U5@97\(/?*N#D#!)CM-"P>L
M_Y!]IO*-69ZGI9856/=#^7^3OUO\.B[Z0TB5H_66,5,0^"Q(*X*%ZHU'@:TG
MFJQ!R:$^'ZS=TI19^81UN?EE[9KQA]#WA$78C?BE-7E)K]-)[I;61WGO[W+,
M8S4Z&,;&'%68A'F[9\L.'M[C?X)?"I$6?+J3\OO+<_!FM\R/,/^=GMJA=35I
M$J33!):C,T(UP>F'GAFTJ95=30O A(61IQH=RHB9/']!U^%F)/,8$)"29CC4
M)**!N_1 D;0F:T=H^)#[,W[U[%KC:VZRPDIP?KB_.$$?]W>X&3VY*\NZ&MA[
M]U[NK04;5@RC-U$\7J\5-$ZX!CLE(W+T)"JLH.:<WZ^9!E'G)-JO_@VW<-9X
M^[@T]36+OSJPHT5Q"A_*WOZNLS8K1R=,:A$N,W"F'=2\?AX2KPJ7+' K_J8^
MOA'\NT$1Z<"2.2A;?^]WB#0)Z 9FAUEWJP"CX IX#5:+U<.NO>^9Z?ZTC, 0
MLJ/[LZ@K!K$^;/;*JUW/7-%GX1#@:^>=Y8IJTE/0#:1-]5N;JBOBNA:=8'L=
M;L*AX=20473<Y*ATEP&TO>$BJH"RWU[\%>'46:&MB/0FQP2-QY]D5N=*M@2Q
M4$A2Y?@8=4Z[JF%WZZ<@@]AT4!D_R>RH73G%XM. !LH2TW1C 1&3?7FB"LWQ
M9Q7$&XXSV0@.;9IS/_/  Y?K<]5=R">#(?&%Q(56E>:$:%29 C#2[APQULS%
M3+]98.*<IQ<OEZRHQ5!7IE^?@%O$QB?$I3 Q&+)KEIFDO?D:IY#6SL)7TV%R
MY)P"VXCE^&P_**C.&LP<YY_AP3EO2\XI<%VVK(XTB,JO3/P55/^"5_]BW,]E
M;!VK%FZK,TZZ]7#PE5^<QL.Q76B],#34:7/UBY\E,"@.U9Z9C59<VT6\SV89
M4S,@!IH19Q(^^"MO)#%9 L]RR;)/%8BY.?(_"3&F%.+O4G6<<9#SE$>C3QM4
M^((S%!:7D_F,X*\>@ O8,-AD4\JRMS/Q.QN'%F[4M^BXV6]R-R#MI&C,L[=>
MFE8MO,2+J.]4PQK,+0OM:%@PJTRZLMRM]#)NM6?>;]26ZN/,<6SO%:0C [$W
M)7-K?6"?UF*."!V]LIY'4P\GR, LQ30QQYF=*C\:)R6QS #?-W<15M9AN,I3
M4!.R+E3></1H]N&;6,^-XS/JZ\Q:%%(A>$%?DM-RQ ]J'?K$P<OC.*-$Q]?W
M:OYF"3'\D>@*V![ZC53[:H^-';:Z)P[]6%.>]J!IE&FD7E9'_@O3]0M\%P($
MU^U,OE%Y20&?O7&B7RF(^6.QG?LML8,%V"??MDRT!25>;->*!V*[*H_7S%]
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M7%[#"?GAPDF7B4.IDG6.V,.P<CZ,RV\EZ:Q+]D\=E!>:_07N4*!!^"WN=8:
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MA!:#HM]3B'FQL06KS)I$CCM<?[2R_?+Z:-P"E=I7S7JR_U>0D,F$QE_V$#K
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M"-Z%S6[56LW9*D=FM^3+MWCOY"PQ8SAV).R42/?AMX@[MG9SJ_MDFGS-*)#
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M_X>4U[IGA L*@9I-HM?-1#^?P9*B1"MDF=?7R&/)N7F"E<ONS4/I( ZS<^<
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MC2<&7WQ>1=/+VEXLO7&T<I _K8_B];=#Q]<"17?/ :T/J$AJ0+-[L!?[E%_
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M(!I+F7P*"]M@H+)_AK?TMNIEZ:N>V9_GF,27JV'C\$8G3NYVR^%4VJ[[XGB
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MRTDKQ+X:8OTP^QQ'NICK.5,S4\<EY<]-<BF5LJR^K"4_\')'V\4=1'!0+1)
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MKHH[(N7XYRR='^*HR8H0RPV7D+NC2-^#73)S6S/Z9@W?36:5&DNKKA2V_AY
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M0O PT.FI1;_<C%WDQ>6QUI!<9!K"KHCI*8HV.-/>D$40./%,3:;T]H[\2GB
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M/5UP-POTU@M$<665VCZ->C: _C;"*Q?H -!?%2+%R[\]'&0:"DU**]U*5P-
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MIP+/.CXF*HVVLQN5XQ-QN[^_A/% ]O /<*UB!\#/U]06>%E&+6-+;_VH@"K
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ME.-*>:L:J"LMD^58?K# 2$ZF?69PTJ)XA,RF8#P\DA@7*FP#-<$AT"6('G.
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M!]W/3;9<'65:964Q$("6#JUKD\3;^5D&0(N0C7=UX0&X\Q_+#_;"@1LF+"Q
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M2[C(TI+=B<Z'T>6Q<LU4X8GO3]P/(?^<^1S6I0\*5(H0]1IGW?M$D@5'T50
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MEY/T1*71O,T2"UC4@=</2W&\D)\KOMF9F# I6K$-L-M=MEW_XN$R[K56O-)
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M23?V^NE\"5?]56PQ_P=SD*945$':\2#?,)KD@AQE3F5$$66D6A"]811Q?K,
MBA(,V&63B.=D\3W(:O").GWE=A(=\Q/@VTM?&'7S.OC!T;QD.<?I.TXRM/+0
M]]=CQU@'"D.C [=.MS!W^Q-0)WR+DO;1&9BXS_YD-+SJ0[J(L7QV(2!>W?,^
M>G=+WAPJ>:C#.D#Q<\3.:H?DVB-^/]92,5L5ZM4"NB->K;D)$9.]8  :GA2C
M+]>G!3/H.A[]26\8N?:/ 7->N=':"=J4H_>A_5=]*5K[?)2G6<BFOCV<E8*%
M-]$^Q4[?Z#^HDMH1,X8>+C-%[P7 5+!N7HR;/>5EVJGG='SJ0VQBVIH9C\J8
MZXE>06H*BX#*XLLMP9^+-\8/J0@O/>EV(RPO#W\2J6M"1OO$<KD:#./O]"&'
M%]3(P(QS \D^[J@WZA(E.OWMI^"+&Z?6'8,$81-#3R'8'5)B6%?#^'937MR"
M3'7S"*BM18=]J32=WP_$\*QK7I;:W<W P]%:9G+6'7E"OX7"D(E9FYZ]&AS5
MUB?C"EV#M6[[PZU<OA4)9 Y6MMPHZ0^F@.[5PC2-46F\7;-EQ!Z;P<DKG6F>
M5YV?%]C0>!X2IR*8P(K:W4["DARE,C_"Q8(^J;8D CA5]80?!0 S_.M81:76
MT\9):1I%G/=YP_M]WC,_\5V\"]+DZ:;.2 -<YP3I$;]GESZ+=J^@/7AE0?JM
MR0]:F8M_R_L+11 L)ZDC#>%M5!GFFND,[=EK0L[MB>%"]*DXE996@ 37*5'T
MG.NTA$,MQ?BIOXUO)"Q4GX]J; 8!$+K=??7'KQQRZ5_^X@CG'USRI@O-S;#A
MF3>"3M#>P*@1SG?2;Z39X[?Q"H,])*#XMY [QY>+3\"X5GQ$\,N!W]0K=;ID
M$4+FL\B![W+&F"&K!KEK\ZYE5GW<[W8!_'M[L\2,I%3%[N.2[^K2F;!9<0?$
M8U'V#6;@:;NB O*$U 3" S?.=3]Z;]+KL?6F4-8&\JM:SF<_9E7;IB>KT  R
MNO/7A 2E/7W<OQ^GAF'U_!4J9M=$ZX+D+C9#].P8VW0PI+:=<8%][S:G:%*<
MM_QDHY+ [A?UM3%<S,-XLBQ10OP@<N<XFY8[,3E)P3&R&FD1V6#0AR"%\%F6
MK1,'8TY;L+G=@W":+;E\!&6R-(JN:4Z>XG*%68P?*ADH"?6V,@W F$*_:+.?
MES\FA0=+C5D]_'446I'WRU%1HHP\5)16%QHY]BEM(PT2JH^)PZT(-?E*B:=R
MOWLIC'A8VS51T1U&8\@]S#]E\.'E]VZI"">IJC!V8OA3T514 E,=B89#V0I0
M&$7SWP-J6$ "+WW@0WA2^M&^)M\]QGPR.-OYR:T:/-?WXUH>B,=7:34D%TO%
MWAP470.ZN#AVPINAWSQOEB-0T'Q4"6-KVCF['0W0I&,A(&Z_U)K\]@5+GUAZ
M3%>X;G#@/8!;@'TTBR.+[<EG2U_)/I] *\G:_*M\Z6'0X4/NNF"716[EMN':
MD^O0B_N2ZX[^A+%PJF< 58SKH]:D?C(3:PPP]4)"(]V6AGPN"J$*3398BIR\
M! D[?/:Q:6=J3PEE1Z:R4?9%[?O\*=KDW.1F/-S)Y/0H;\TK@33JL".L36=M
MKJ>ULV?Q&:26)SW?5>78JH//!R?X0]U<[-FVF?!G'$0Q$*L]%&07.ZGEDH/U
M'Z>8]9^Z^]6WH7]K#VYP\8U]Z9M8P/0#.-$F\"0C!70_[5T6>::[<U^"X-%G
M9&HD0I5J6?3DS+$I_: [@/M=U<496/S(.63[@N3IS)8R;FS@):!57U[7P&:@
M]-6#-!A%T$;[F&= 0+.U;F\SFIM4<B:D "OB1X+0XLTK,?UIA4:HA%<3CIN!
M7ON\XFQF)>4M54!NH&RDJ?2,H03)14[6SKR L'_-[X9-L>NA-Y?Z40D)FZOB
MCFQ\A?0WJ&*9BJ?2G=U@^W,SS2T?#&0?RY%8HGLCE._7D&9M+KNH^56&A//V
MS7)>]C5S3D.NGJ8&V$VX:;CS8>K)B4;,1MC'1ANU8=V=VL]A; A0R8D#Q&'%
M.E?.46=^1KL=9PYF?8N%S% WUW'YJU@_YYRVEZXD_(F0OM.+<MRSV0S7#HR!
MY-GL<*&H4JAAK7A*-%2"SV!O.1>*T_9;)AA-J-UND,A<IWV4!OWIE-ID*B>+
M\60V\V2/_/CWLFL<]MDI[(F!*(I>VX93!1LC%M=#"*'?]0'T0[\;;'8F^;-&
M"#]*PU8-TXSV/'DY';@WG'AQJS9J"O4GV.H_R$.T ^S2& \5X57F@^J(D3E-
M8I6=YQ9UQ7<*HO:YC5('9GMDJ,@!72C^?P_1!A%)'.YUGQ_I^G/20%=E@ONF
M9H'L#XC32I86 ]W/'0EW#\5G8;82\-&#=?CW@$\ WW%A^F1. 05%'MN[/WW5
M!DHHJ= G8*8CNLJI1Y1^"7UM(:8%<BW9^+A$'J$=*RD]%AMCSY/9$K+Y1Q+>
M5Q?I]D?.XJ*E[R7JQ*GH$B(+K !471FFW>A+'J'^@V7ZS-@Q)"[QD^U*U=9=
MKK7F] F6TP6ZLO99JAZ8]AJ^/]RLTD-62%SQHEGG-OH=&?]4/6;8_\*I2\Y7
MF.:!4%1!#1F$'24V^=79N UOQJL4;U\=Q5RDK @;EP."$@L72!8Z7*[L_F,(
M,L=,0N%PB?HQ<C^(%HRCHG/B.LO&/QIDKE9QU.%:9\V,QVSO41$G0S_B1DP)
M\2;H?GMND'^\2=9M:[BZ,H]E3% LS, :J*;(<<BK@X-94[&T ][!$3EW=_2*
M?#]RQZMEUEP-()HB35@'XU#SO$_H(QPSU_0N:1Y=>*1Y'!3\%0K.)&:T*[5*
M)' : .776<2AU[68\FJ?<?08[37R6-E=(N5M9R9HF9<^+0[%[*\S7-2X#L+0
M0?G#U<'IT5R:FX#;R$EI*D@[?$E-&6XVB1%8GU->*@I[H5L\+F@FW(5^&6%;
M1P9"]ZTYBG=7!ATZP?/ GAA0M7@CYP<I8#;"4J R$_K;COH15<9*?DQ.[BLL
MCM )L+5=U^X-/-:I7H\68&>6C'G2[L'WW_/4X;L=PD[.EW6YI%7LVW^5;V7;
M+@:/(28F&[I6>U7U<Y_-NA?9R%$Y9^1"<(Z?XI<\1G!2,<E6N9N.J_REO1YP
MM'I"I\@)^KUU:QA'@K!;YR^=)%FP]/:E$L_M#_JY8$B)0<,U\] F? A3?)7T
M:>!A4\4[?5;:H:+Z,-;/,2SDY68M *RR]RYQ7Z['9$QQ#2V_3]3XPSO.R ?1
MTGG@W(\.I)!W&3I<S?#P-PW3BJ?(YG$[QV^9Y,R]^O:D_O3'T=X.S?0-'.R$
MD$(_ BY;? .'NL#V#O?NI( .;5D>K .MH<F<NKEY2M/"]J4E@RWR#9+$\=G,
MU9V&>U0,'3%9SO2,(O[(=$! JMKP2Y;NUC;5/L!$._[POAI96-QW.>Y63:SA
M_:!5$'"FM[3*\;6WQ*5PRJM,(4V5T2TZ,\/]QHSG[5HE#U,2QWTVG!-N*=#'
M1.JFQI$5XQNF"EG\1?DH746WN4D&+VR)&TTX'8DQB)%Q$\WZ$T #?KV06C)I
MN?233WNP.%I5Y*:#<3XV?=%B]"_5L6&M,A-W&3M,8\(E*7-6OYMZ/N/$J>_&
M=5X"'28$>FFZAFSQJIS@8_>ZYT'W%C_ 0'6DC]^RSX%JQ*E*;!K2TK93G3\!
M@G0SN9@L7FP:$1#$.NW_\<.X<IYOZ.FA[O \B_X->1UM<%16D9_+-ES<<YFV
M)87-O^W\P"UEZD&*T/TSU.8"M6V$]T[GBTR\,PY#?ZQ/TD,?D^#?0R]R7 96
MX J?C#'>)Z#!?"^2!*[WF 4("VB !;64,H=:FG+>%X\N2"9KN%8)#,29"PXT
MB3ZBOC%[EB$7NSP\/^O[Q(N+VU\PJ1MV79NNV7BD@20M9"RDAX&!\@GL"_\Z
M>9M,%I%,S?>@5BI-_?LOQ*FGZM\S*?ZI^DJ*_ZJ= ^J8GKJJ=?#<C% ,$=-;
MNO+.<2;L8BX/J.V8!5J%Z>[Q"SG\!=U+5Z K ZTX#$7;CSU^'SLN<E2S3W H
M2,FN"F&]YPUS/RKK_&WK59\GK$YGK7A?LN/A_2$RUJ)DOW=.K?#D6GV*_Y&3
M9#T_\YC&IZ;?])Z"!OG-W*$81"Y@T8.H<24<UM)1EJVR0-J>Y*&9TD#NK1)*
M#5L.D[38OX/7L%"V<-X<0=[0GFB6AJ9=U9@3[.(?*GC!-)9VNH,1/;0#?S6:
M, ]_<8_\75]?NWN4QM+D5\;Z[4UE7)YLB&A;T]+=)P#I+WYSS(;.$G/:Z?H1
M&4<BKW3(\9'&+.&MX7R-5Z#,-59$X_+9M^XV3:0*TK_^4L[J)5=*865S1?,4
M\S6*V02.<O[M&HXJ?S@NVPD]PPZ] Y!_U[#+(+%-8V+PFV6DF>#DR2,%8!U<
MS/I6* 0R@7 I34"E]-M^WH[$T5=#*FT+]A@\Y[L:87"C ()PR&X2A=RBUJ!)
MD9B#U#HE"(+MT G@'B[,%KS%J#]=]6U^^*0A[_$?3J*S KA7O@/L&5CYEV7/
M9!8 RPSJD>W&+X9:BS4Q+H=$]IM6N).\$@DZJ-?!,6=!5M7-KN<N/5+T8,")
M:C-%&$W-SS]$@8,I/[\^F5CO7RMFXR<5&TA.W3% 8('S"'(7)1<]OH:P!_=V
M(]SP0R<MC@!)G"=LQ]/SQ 9[]$")PL9S_0($Z;,']&-U!%J15C=/!:]T4L1"
M3MS$OHN6KDR'B$V]4O*+&Z*W. C.8QWEGOW5"RY?<<G_K/30B'^GFJBIV<V$
M2VUM)_VYM1\Y;&2E$8O'MKXUEIS%8(Z#\;/#N2UI*@8X6#WA]?N,$H!M7XGP
MOH7@$IN!=1!%&T+1L(=I;T$$?U_;MCL]1!U=UG +#P]U8%I'#M/!-2K*V)XX
M6#[XKN N#*\H1*5?_M<NT@X%?KQ60-]1H:'(4^W7SM/,$2W;_.;X(MN#0X"*
M;E+DE\HC_XK%*1#6%W/A/;I5F<-? U("B5&MWUVX6=..!5;C8A._L-(F7(I@
MQD1%/5":$^O%#J6-E5BEJ23GY+B=1TUZANFU)K$A!0%$</N/:ZP56D=5$4Y/
M-1Y2!47*WT1MF#BNRR6[+)N_C?*E?GQ3G>[R6H/7/%>=8!/*=JFY14>$[,WQ
MK+$D8H)5*I6MN]K043Z4-GV)&KFZHY*C95J/\$V2Q>#5($1HV1M+4@JYP2;A
M3MN%N*_B\ZFT?I@@YHH84RIQFK:AT):@"\)0A*5X+(/><EW(X05+N:JRX>%@
M+O$2^;B5R3NA^-.5=/&:)OZ)*B$"_$:+)L'6(WTVZ3)W@A7IC_EP/[T_\DF?
MKOC[&V*':;7-YFX2_3^>F<S_TGB+&\"V0C+T@;+L+OT)6-G<;(AY8=T+5*5/
MC-:_)BI.$\*>,VGI6+)W^WO)[-""1V#K\($>YZ+H_9>^[1HED;AG;UM<-B&H
M39GC!W X#G77R3;+$4+/*T1ND8FSKV4=C/U09<_QP$U%Y4Z(1>&NMA(/OD4%
MWWP"@BW6_92MB0<_'G;H[>EN9ES3J-VTE)-[$-U(?XX1+@LJ[3-UE3RY*O5T
M^^//W-A*=GM1,_>*)FERBKB4.;"-Q62![TD 7KYJ5X? $,;,N,'IY3WI;&M5
MP??7EP4P\9<%SNSUVA+;<@K@ZIDKHK=')-E96<BB8(/XS1?7*Z^QX<X_D><<
MV\2;BF'P;N7N>(9_^=D<3XN^6+:5,&6";-\#&+_*WOR(5^E.VF=4P&2YP6"H
M2CTF39*$KTV7O0K++;2!+]<E"&^/&^2'OC4;9RVCWZSK<?W N!HM,MTG0?>J
M4EG,;^WK>_[1$F7PI$$DY\$@,HVOCW6FUKSDP*GTR_/JS[AY9U.2'*V9:=(A
MQ0:\X RK(;M%[_=5[(4]L\@(97_ZG>H[> [FL$;M/\87Q=N"$VHYXY?MMW_P
MQO8,^?=K$*P<A#9M?T?Q?@+L_>GG^U=4\NA1]*IRSG^'L;90;&D?)*H,BUTD
MCN&!.,9<.8ROBI#4XTZMIZ Z?TV0\T[[GLINX&ZJ_$B98H+<A9KARUIM53M,
MU1&K>.YU."K@6M"U/J>)U4"%SJZ8%=?!X<M;7YT,>DYNW_RY"-:1U9*OB17$
M.^R]OD@FA/(1=R?P%S+.NN^+BSB66B@6S6.RI+[!FGKCOII;-&]==EQ])[/6
ML@&N<Y[V"BSL+=_]:LZ&<J;4FUL--4+'T9$KY%#Q$ K$@323U- DD(**^@6/
M%^E',\I+9.U0U#G'B=W8*?^=@,9Y<:<X?:K#+('P%PF3<%1/I<97V>$>Z)OS
MW2!>0/DN:*5\VT!V)DXGZ(/$IO7A!FN(J KH3RLKC@^=$(X[3IRGVU5ZCZ&%
M,7/@#:DI->-MW#_B_@F (><FYNWNQ5O[X4XB'[6;>]3;(8=(\]C%S>\3@'7^
M"4#F\.*@39K;W>JF_$-4-3VF&6.RWYF*^4BSW;GF=7J>9R/E<BAZ9PS630KB
M(S2-L:P1WS^G=:>MQ6=OM=I*D#+APY^8O[]D[1TJ-^%//?/A;O\$(-P47=(7
MF=F=.S*C#"'_]<;2O?[%(L,@7?L:<.&D1WQOH1JQ"=2@STN F+S>J<I0/9&K
M:N4+AK59P&=-*=!A(H]L-8[8VME9SJP0Q\XKW?$633M]#PYE!"H1^OQPU?-<
M?7A1J$^>D8!CD<]5V@-KK[ HU)X*;W@&C=F3O*0(AE<\5J;*&=7'@<2:L?^@
M('?W>28^F6DZ1'_3UIW?9--KD'PDBG585R*:#:8RU\]GR$<UU5_T3M2/SI"T
MD!C*_P2D17^0M1_2-Y#G@P14^L$:=A?[G=%^3'B^<:%*!425<Z1Q-G8JFL?'
M!)+."F&"58D;U:VL"?3T*DMIJ%MZ/RF7<J!A?ST*I=KH:B,LR#WD8>J2M4W8
M@=L?MJ1!-W5J=63UB-#;M0],TTZA&9\  FS"U=IY%ZI_VYA2D?^UH>9_!XQ1
M1'[6L6AGU+]2U&\/'1Q7U%&+]<9=KB_5*.>E35PTJRBL>]ZMAIL^E&XEZ5(4
M/ZR5I238DX(R A(K.C+=B!B9E)%RE>[Z/K72B[.]/6X(MX>Z5OVW['G%31CE
M3:),3S$BC4T@0@S^0LU)L.'6O9Q90.0E-G6\42-*6LCD'(\)U"M(G]"!81.*
M+\Z_Y5U@:DE"%G+JJ]43/K3JW,890\E35! 8!N3N352]'8]B^)'LB0=UA6P0
M&!: *54,X2Z<[.W&2]*C6G1?)V1K;S&D'+?!'Y;#%L8?)D+\7*/'C [ATU"!
M?2N>JASRZ*J^S[*\Y0FGR-W%GRLN<2WP\I'SH_F7KI0K :]>^2@FRRQ!QWX/
MU C:CM(#JS7".%3K^P+=[@\?H.WO9L_6E3H&AUV1I#%7DFQL7O'V@-23 $;I
MMVAK2B@[N^E_"Q05:V\R.]K9-[MGD;=';^ 3L*D9QK]I=</'D^HB3+B::_C&
MNL)0:EJRK3N9.8/\V_2Y1?DZ/:ZXR[-AD:=-5:-8;8KX?E1G37 3.O.W;P3O
M_5%/##%&8^B_CG)4ZP.3NV>$N[X5LVD]RO[X-C6>$?A7 [,/J>5=]FW"T]T<
M"6D+]\+TY&1(B\BS<$W"PS[U@ D".3$Y42,N^XC!:2W=B?<'*&ALH<L0OVDU
M^^I? Y%JENH\,82RAQPG0+0JS28!XYN![Z>UKS13]^$$;"F/RI"L[>S7)3=_
MN>;$.,%S'@()KG]MV.];K_8_0QVZN^8-:]5X<<NWQ8^(*[<BF*:MUTMU8.V9
ME"^5"0>J>36#"JHX<VYLN,TOJH,S952.;@0CJL_U!A^T$D.<W<V_ F./3&^*
MEW?H!27/QPTNO_6/N*0;;?@TQ=>G_,"%]88%>([UN(H:_#4L>?6'^<!]U/:*
M5TPB=4)*AB4!T@WC.W2KI"D$2DG 5MNQT<6&A]G7Q.RXB9X_FC 6QP"?B3JJ
M//FPTTQ>V<D&%][RJ]!D'FK3;==949NN-"IW_ LOM5JZ,FZ0DLT^L$SUY^L^
MAHV;>Q=)%4/\7@-+3!0*]-<JDJ8WW!2_L)'D$4^K;A@,5.B] P]=X.FXX]1?
M\$>+#4%+8 'F4OT-/YZDZ4N&PXRN/#[>-JFI0)\JB8*='.]T30H4%ZJ#@-1
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M%(9VY\:%/&@VW'^HA)X .OW'EK-3W+L9X<4Y-GA9BS(*&."HURPKCP7 >EF
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M4=3DHF?)$@/^BWK1_^\SK_Z_A/8T]S\ 4$L#!!0    ( ."&>%;P635K+28
M #$H   2    :6UG,3$X-C$U,S4X7S@N:G!GI7D%4%Q=EVTW[A8@0#?N[I:F
MD1 \! G62$*"2^/N$MP]. 0([M)H@. >W$EP=PL2&+[O_3/SS[R9J2?[UJJZ
M5>?4K;/NWF?O=?9YG'O\!2!0E%60!0"1  #@TP-X7 1( S#0T-#14#'0T=$Q
M,3&P<(AQ<;"Q<<B)GN$34U)04U%2@,$T#%S,-'0<]& PBS K!P^O@(  -;,H
M5(1/C(M?@.^OCP Q,3%QL''(<'')^&C!M'S_U_;8 2#$ &0#OR$#Z0!(A$!D
M0N!C-X#Z:9VHP+\-\ \#(B&CH**A8V!B83]-J"< ( &1D9%0D%%145">1KV?
MQ@$HA*A$M+Q2:,_4/J#3V1/S^<?E8M"_K.XD41\_8>#_Z!" B47ZG(R<@I&)
MF86534!02%A$](7T*QE9.7D%Q;<:FEK:.C!=(V,34S-S"TM')V<75S=WC\!/
M0<$AH6'A\0F)2<DIGU/3ON3E%WPM+"HNJ:FMJV] -#8U?^_J[NGMZQ\8G)B<
MFIZ9G9M?6%U;W]C<VM[9W3L].[^XO+K^?7/[%R\@ !GXK_9?\B)\XH6$@H*,
M@OX7+R"2ZU\3"%%0:7G1B*34T#_8/Z/C\\<@?AF76]V)2<^O?D+RT6$<BY1!
M8)7Q]"]J?S/[/R,6\/_$[-^(_3NO!0 .,O#)><B$  G ]6V_+;%Y& J_>!Y6
MC]C6@I H,!\=U??%;"5G1-=SW>24@MWKF>>LV):NY;PL4E$ZXGU7VR@4^0E+
MH_GYWX@]-)[/((2%A7X,5PK6HJ:B:S 8(__6M#T\Y-!Y]QXTUU.?7N=*!'XX
M3"F"GH\X9@'K9VBR=;TME]>;+/)B1C[X\[Q:;*6ZZ1"4UOY1CW[JM.!$&B\4
M4ZJ"NCD\*"X_[+Z2_PBHKS>O:0N[BM]4IB]K.A6/L  ?0V_I%IOE6!?ZC/B.
M5-V.1(N>]V91>O*[-.?+ FDB?&8V0QF ?6+(&@+[H,9+";*61<52ASU#1K>$
M:Y$;;_>UZD6Y:883V\!RNN"ME3WLSZ_+Z(;T5O4X.D[[VB"THF.WEQ#JW_(7
MM@>^A[:'9.*=&>Z+C:/V,?IWSL5.Y;;*,VOQ!B^.($%1#=^6 @I_!/97B@?*
M3QU<I&,R3AS9,$XZ%W-Q$VHS[8 ?;H"_+M&1)^K6&[(>[KK3EII-"^$FCF9@
M3!2KS:5A;5$3\GZQ7VJ#_AHI&JYU&EH=V#J2>&@]:RJM(L?'ZE.@V$YG6X=)
MCF<,42A9&KEZ$&K H7@("G6WQO0VD5!MWO[U;-S\GK(15[&#L9*Y4JJP[G<Z
M>%[)L1:H&7DF-X";V)U@[_ESBN\J<*J4N_AN>ALV+J7*4P+,Y:S/(P /.,E6
M.ZZ@THCB \R9\N7I$7.U0EY#FIQ3G%*#J7Y4"9X&_-WGZTK%'*1PEG]'C4VK
MC)&%MZ<92\IP;=V=<3Z37,J8RMO.M?K2V.D+2ME]O5F;#T&OM3TDYC\P=BPS
MZ<78Y*59+LNG6YB;[SYP3]2+U UPZFH9R*R(.'QFZ\<T7#KM*!TKT^VKE,EK
M_XQ0[S"+3+J!274";F,4UP_$J(LM5C@FN&DT*!P*,YVI3N]*8YB'/J+;+3F5
M^Y+O4A0<: G?4N19NCCP2!X0$SNS=3&?2 1!V&,+Q+46YA!6:X<OSO1T?BDE
M"RO;565SAYSYG((OH&T6XVZ5RMFO)[G7S].@BB8!*)CGQZ*CLFZ]>-Z\L)D5
MBL;)2PEL;">M^DG.K^&N2\"E?C3[G\R"2@HG7W.MU@9>[P7*UL=[1E"689XS
M]:Y&+_I8>YO7X%EFSPX]8!:).>>#@@Q2LDTL'D81O<A7CDSV48^ =_R1VO(U
M]!"ZYF255N"&M]48_<EQ:'97P\.S^-YECK5&]870#()QCO3?;UIB5!0/ZNZT
M0G2F35\X::V91D8D)3CJK]HG4W=%)PHTXQ$E+$U^"6=3?OG/COG_ (;R<LVH
MH3 A9L Q;PHHX':] KJ7M^]"=ZR"B)827ER>(*>C36 IB)87]YNE+7:#O&V&
M^RQS"LQ+U#%9A59NQMXTTDK8==F\S Q2P(TJ+'CY@#9MLW!D0NH!:XEW(="3
MA\$1"S? Q"#]:MO/O_"[?Z ;&9'Z%\I 1[/2X'76&\H<0 )2\&KH\6SY>Z4A
M"R:>@FY.%LE-DDY:%>D8%8_S_GMT3U=[%(2N:8*%#8)45H^,K-6F"E-8=-!/
M824'Q^F=LHSSR=[#VK5V9R0HN-E3K]J^CB;)CM[MNPT;VO/C7P ,<K(<O(O]
M!?G6^KJ'\0;^Y1 >MG[\5 2H2@YLK*Y<,2?#&<\P)+%PI%PC@$.I^;V6H)M*
MY*U^W3?RJ:^M$\X8 E"B0:NG/-X1U40@'TKZ^@ 4RGIM)P*U3 EI?5X!VXM=
M^>D=Q>ML*Q"&'>ESA&GT$:FWA,_ CO>'@UL.OOR7<!; /Z.(N?&L/YKWF^E.
M'J*IV"" 7G0'S1);0!R6^@B843I_=CBGBF*HC')RG)31+V_H@5]@4()XSS$S
M-B>.OZY5](_/O'P9H..'[BB)+:-Y]SHAGC,6?DSO= \UOZ-Z,$O:$$_MN"]"
MTFH,$K\HDJ P6RQOWRZZCWK[S>VPFICW2S4Y9[1DV2E]J0V.U.4(>_K+B/BF
M9D3RX83)_1LV$Y,/230Q1AK6V]%;=$P:2_E(\N#M DA_;6QQL*:65Q)O^TJ?
MOL<D7Z*^0:I+^."W*9!"=6M+W,P:NXBNA9K\.5))\NX%R<<^C?KV@!7Y#:SS
M[IJR-Y+>^68%2%SCKV%&9G,UK%YFYF+K!4CFGQN):%FO.SZ<_?%F 5YH^'A)
MG,](M-4>X[?M7EX5G!N=>U7RBG7PU[J*7/8 Q/^[ ,Y+<RN?]*H@<8Q,BT]G
ML& [C$/FSB7/P?JYX.)[ON0C&W,(X;XYDJ#7J"NBB2=_79U'2(ML=ZA+;5SW
M",CB]7GI1P2Y@QEC)""-_# \U[)BE@OG8W0(AQG3OGFA50\@5I/Y&XZ5ZU A
MZ(>+[> 3XJ8[D#Z9KP/3')CIX))-KL'MB"W>2V;"N"9ZEZ->&M1A<WKUM@G>
M*^$EZUA; <D X[$@3E12*_8H@OY<'.,TQRP:UD7U)9*]JBZM8L_L"!9!IW:Z
M*JX0P_P@6%]'^.[G(H:U;":]-%T@M/$!?3#;1QL]800@7>+V,#KV9IKKP-JF
MLC=C)Y[LJJ26]QUPU$-$E!Z]P;*W<-W*@'>%W.ENU0&^D4:V3.Q>%I>*A1PO
MM8 OTH>.,N7J YSD-FV+MTJOO(AX7T.C'+'1UZ2#2NM@IV;?XB)*.2+@)3X)
MTH++>K;,;SD<TSA\=G%[S:& !4J"\ONY U21C7Y'Y',(H9VQ1\!L/@3#U!()
M;1CAQ:W;N5 >?'"&]GO]@D)_CH,C3B[Z*6Z<'])@O#,.+E/Y 180:R<@+JF3
MOE)L5EL2E5CM?X'DW8-9PV1%80SJ6MBRXR0-$7OL^#>&76TJRNB[M\*DYWV%
M<M[B^]HR<7:Y*QPQJ=)"(I=4=<#%<?VI%:')\IR&QJ;::4-$NHUI<J^,?*!X
M#Y?\C8/];X(W;)AB]D:&IGHS\19ZJFF#*^P0&.5RG#2\3]3:%:R*KN!E;\(]
M25VNT$87Y<I7A-Q4U@91B^E.TQ>>48D !0W6LN+9V4FAYZ(0R-6_4"BG<4 Q
M=:6$19NS\3J,DQ8V-:0Q10YD7+!A=N8'/$AP/Q.: 9NAHZ]$Z/TV_4#UDS-&
M:F[Z.W /%>FOW8'1BH RJ8PF5?R22F#+SAV1AK K;'01"106L_&TZ\:O3(B@
M2>+\F0M'X:T,GE#'U)O<["A:1;HX2I.T?P1PA "\O2W_:#<A5L3Z'V IL5WM
MU3F8'0!#'."<^I2=TK9DO!$Y.#S>CT]0)]4,9G]6U>N]%^14$;ZGF4@"E2KI
M>M. F\U]PK"6(/>:O0#$GWA*%6%?[J;K*0^/?'">KMBYAB]3C$;>;_AB"$9^
M0[7BU+)JP:5@H>(FU!NS/H6_YYJT=$]WO]%(8-(P$A6C8I^4Q'I2OA L7=-G
M*0(5;@^9OT9T&::T]D;O]P(F'OCMPI"Z7$QP$4[^K7VC&GY=F_15)$)YJVT>
M^]T4"@:$1J3QNP>(JCZ\/Z'$2M_4%SNI>>;R4#RVVBS#,<5J7Y\D;:5X%ZQP
M934@#HLM<1T],)8WY6O=34;=#7KYGB-RMHKGW90T'T8(%MW<+_8;!2 MD-W(
MZNQ#]A!)X@"RE)M H>U.4/7^NTI':*NENBDZ_=%E2<-U7 ]-Q/ RX5W^Y7LC
MR1N#2J.12_P0*7C]^ZH=-8[VN9E]4]4BND,EFP]C1';9$F_W9RJ4<_<3[N7J
MIR2JX\ERIA#IC72A[LE;1"U9RBM&O$8!GQ=XV">+<J1DB%6!_PW02+,+NUS!
M,;1VTG%G&9KM!U9JTQN/@&\AOS4HG ?U8*/#LL<\JXX#NZJU2^\-XNEWT##$
ML&2KOFZ6CC\74 O]2A7_L6Z?^Q6*%(]1/'6";N+P9S498L 3@%M7#XQ3 F/$
M>U68AUR<)K.HE?.9GY>8]HWA0Z-(2$V]$JT.;(3KE<0@;Q'&X&SH\DJ6("U8
MLH2/"!#*W]BYIW2&)C>TTH9_QZWR_.N%CNZ?L@"<!\6;3X2!YT905N8)I\6B
MW/!UE;HT$8FI_-A2C$? ,HK]9#W _GD69"K%H'GR8J?L&&\HR9_RM9YIB(UJ
MBQ HF>8DCP;@.1V%WNT17;G60D*15*NC7 AI19OK/F135*O")L*@1S&.QB\2
MG'IGL0!&\AP: J&>5R4H<;">']%*?I03%0'?:7Z:N/B=-I]7W2!;CZ*7%"27
MB*_:ZM5TE8/M](_,^Q>D76VO6E@/(^#G1N;71B+]/7:!JVU+M]ISMI>G]AN[
MV?/)-LD?)=B@_4H\2ZZ\9U,NOSS2+B@JQ0[ TABXK/>)'FF M7NC7ZEB<J6I
ML^J:YW3A@L%ZO@+?U8:.(H^ PG9DO[+0V%\.=?J:SN1.K?QNZ2M:^GGC\Y[Z
M6XSI\#9"_[HB#=OY$]&;7= Q[YZE):!GO"YP]2>NKUG9EB-(F2;!9NDX+ONK
MBO+</5NF4SX2!CW-S.M;XY*-KN W'1F$"IG$3$F3+,;1<FIZD\.[UNERQ]18
MT+ 2K06C&__"#K71'XYI/QI#1F/,(3K@X@L!6NVTI'@BLO@%KF\'?4V%?0(.
M@9N-ULX]VF=,F2$+,!?N$VY9\:]^)8(T!,#0!VMOMZ^&>E\5UT12%[]$3@X
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M_KALF18XF$+AN&2*+? 6N>#[*]XL'FGCY'ZRL3<LR-,L%;8=MVU;M3D*T(,
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MQKJ8WT;OMU7KIT8C?[QT\<\<Z_4)**(QM:<G';5KFX^"614GKUMG&!K+9BI
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M)@;J+@Q+G?/;>AF"G4C8.@),4\A=CCPU$O]'-_^/(? X_R]02P,$%     @
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M=-ZSV9JN0R![9O!4?"DMP1)L59HY<U1F'.]DU("'07..9Z\;9=LYIBY!][Q
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M<GM1)GMPG:87K)>YG4M]UPT<5D,Q#4&)F&BM)!,*Z6*015';NJJ0R@XQ;'%
MHLKV_6\B6:GKXZ?<1?.#W#&7$J\N-2',1)\%L 0,# >OK/G\'[M7[ UZY-C#
MREL%67M88@11&'ICFK\:KL9TLI%P]T,AX&<BH!/<VHQ9XEVW$AXKL(<&]M"D
MOAMG8,<0&,)A[0AQX"Y3D&9Z*X/;&IXK^GW;R_!A#8M!\J9KHS'R5@4/<8[0
M<815T]U=_(U0!#X^4?LV5#?1+K[-_ !.;@8ZV?-<8P=7=K/VD(=)6+R1VK&]
M/['F*[)=.)^[0!' NF]3%E76Q-$9M\;J^CKK\SB[1U:*>27^$.PIXB"K^42O
M!E_6M7>U.<:PE:%+MGR4^D^C7["&&)RD&TW(%4')\3GY0W#75:;3 WIH&::3
MFBRF9!%*L0X^;%)O?3QRH<:I-4F@]\$:\Q,FQ6I/Y7/W&X>T/\7/H&CUD,+:
M+R)DU(.'+C/1!O?CD4OH?_RR117,9(=>RDCL1V/W9%8WZ%\AL.!.J9LCM7"W
M;'<(*17R3V6745I[[(E 9XUZAFM/Z+/8,&.M9,6T"]_.!0UA(#[61R+L#,%%
M:AE&H(KDW,+?2$^S+E+.TCVV20Z5@2)6<,5SR!DN)'%)7S<:*9J?=6:B[IQE
M!.%RBWEJP&F.Z]*6LJ,NVMGQR;>$I4);]$, ,V)6?G3O7Z\Z+BDJ/I\A^)ZP
MNM86T=5QT.D,@[GMV6-6S(]TI4 T*/YAEIXCJP05S$^Y$8ZRZ"3W>NS/WVJA
MUO_8TX+#F[=4KTB@M]"80SGN&XBO>^K59J8SI50=<13BJL"HW(.RY>Z(PV56
M?L^3L+$S3\:A^"K*-8BW^UY)4KZ^Y>M'TQSCI,^''-OM)P5N\802QG4QA@$+
M(-TW@I/V/]^D?:1;QN*T)%,2O]YA<&:\(D^OTW112QF)_L%L3^P"6HG;KBH)
MR,S#K7CR%H\THYO8,3LG&R#Z6IV3H%7M8Y=ZR?EXF]^$'E[XR6!GE[,$:\CL
M6GPSA/T"&.$&^*PV]Y06?\J%&:8MEZJ&B/DI);/1D#$8@0I!647TY;OMS?'[
M^Z(QKC([]C/)P9HHR*B=:(&Q8>[3U6V'8M2KA6G-+ZRYD^8%&(U7FS9D'YPA
M #AN+>[$N\9ZZ04^6R# D21P8X;-P_2!T/\#K 'G9C[->#O^GG7^JKFO93YN
M-]4D9?+LFO[#4K7><O  T=F\4_F#G'OBY1YX''\G]=TB48VKI*?=+;?+!$<%
MWZUJ7CB3IP !F377"D'6*[;#[KZ0>I[:<1DO*XGK8Z@5<_!X1I;:4XU"(X9@
MX_NCO&"#= !([WW&B2T:(WJF/4VMXFJUOBY002A.9$+?5GF471_QQMXC6?BE
M.(2B+TAJJ/PU"G%;#4.,LN*3/[BZ_#*%CK_?"S<&40S,T_)=9[TI1D0<($QI
M6I-#T/ZO,.)/DY]EM> E7C!IBXXFJ*>?':+<4P4YQK-$HVTYHA3,$/\ ]O^Q
M42A?BM9&^'R,3 P+>ORXD]IW)L8-"?#$>6$1K^A](8#@$0T$@#%X@= B[W7R
MG]Z_N5] 8LW0^U&9FX'E(.,7CZ"[07%7WI[;5]6&2 N*S>!R8<0J$'4J&_JH
ME&TJU-+LY(8T;!1\2UZ,NV<U_UEIF^XM32\98_&7/3P^<=V"H^%<&L]M"C6L
M AAJ%X[L47K5IK/2TWT\.(<\2_KQ<V3"$G\[GMEXN42PCU[<Y^^O)G@V\U2F
MGM^QU92T1YKE9YM+44PA[B865_?:1" JGC>,,D<@1:L:!G7&[D_N6SKF$#:&
M,.BY^=KY(_;!6%*( ='1"HL=?J4GEB>D[9.;3;Y&F)(?%:DI]%\D"6D597H2
M1Q^NKNZ2AV1KS>E.;,GRGI,<?>XT-KK#-DA\)K5*;6B(-")Q;TRKZ>QI1J5&
M1RR+I&9^07/%7(IU4.(=EI]0]EH@*;2,^(1,70[A[7L:=RJL!]'SK_'"#9_<
MOI$-(MKZ+?F](MHI:L\X/18T)=X5U;-X(X+!Y0/2)\JN7+T(X/%9>&G?X<W[
MJJ?J9G]$GBP33[J"E?&GQ+NVFO2X JVVTG2DJEF3F:,Z;2::IN5TE3>)X-%5
MEQ^K#92_<(I>1HP]Z$5:\N9YKWU]&2!25JK2CEN)5OZ_CF(A!/B6\L*.+HFG
M.D[9^)^I?5BI"ND^TEFO7Y269S:%<GL,DJ,U70YRC"GP4?S$CG)<IL7L@K_^
M6\7_H]M1$]8F'5&H49Y3+,;%ZEIV^*[-DOQO+_,M,+%/C.QU6^(RCK5MLLYK
MJVQL=GP)-3C*I&&G D,WG'E\5#-)\L3'R*9;%JSN]=]Q?"1>.1FD<^H"$S"L
M4][=(NNC4$\-N;HHZ)>-C<1I9NC?/=B4BN9J[4H9Q, ;7<2/,PMI$$ SYX7S
M)ER>@,%T;%?HJ/NO]]W$P/1O*8R2Q6-<?IF/A_32^C@-/M+H5 <%>_!D0I7O
MD:(!>-$OE#E2 0)T2Z]#@'MTLR^WA"00 $?)5BGFQU)V:5*1B-&_%8H]DJ^\
M?&=>QT$ WZH7&JN$82ZO[GT:Z^+][ ]6?88?>*'&RB6\LK(SSD^!SW,GQNQ/
MZ4:Q5FXF9AR_36$D_TSN?7JN.,OV(>!?)9&\("%P8=>>Y9%GR\GE$,==X9X?
M2,9S?"10\X5]FBH;VNMS<_AS0^HXCZ+K1L 9W%%[*&^WOB6'YK&0WNX8$[3M
MC<P,ZEX?8#)R>O_4REVJQON#'6LD5Z/OJV&TC%7"*!,#Y7'JH)>U6\W&%UCS
M7ZI<?K]3+&DU96O]N-5:ZR22WIL8<6X#")SXXV;Q,1;WX['K(XNA;7;=[F,Z
M+O1KX</XF<O,5%8<_3-R*XE7A;05'@9X(59;3%]8:VO,&<&TO:T*S29#85ER
MH+>('E&=!FV 6PY1%6@NIO7;_OWMI#7QA/ROW3 U<-O6+]S#ZL5E@I_B51X^
M3]UW2(@ BDI<>TNI&EW>T=AX&=OWY( E^26IKT>TE8EB,89R+=\OV.'(T?Q9
MH/9^J":JF[\YU]K#/'!.?FK=&>XKRZEM6*%_K^\! ;BW^\6 0!!,])BBMFHO
M_ID9^WW0XCNIDRHAE*WR.3YU9<;#AQP__-@!;*@#QXN3(Q $>/</1%8^%9D]
M&MG/.G9$;F,D#SU4Q3N+BPN.9/)M4HI##</BCM91_B/3-2C;LWK5;?WTRA2F
MI]C")<;$R'6*]@-I(P>Y Y';#*OQ+#2/\^O%I+(8P9WW1RU!MM&#1;$_S>E6
M>A&S<I6-D5YU&?Q4W&5,LL4G5 WOX;#V,KNQ^T37&VF-%XO,C1W*74_O0L!K
M)@D.)0JT=U!SI_IR(/G E.4JLGC_W!J:  X(N$ZQP#*K!&MKYO?'8WE['W>F
MPER6_B828ZJ2ZVED-8="F8, !E*4\5=+KG;]3Y[UF\F&#+FFY](8"82Q(RB?
M/AP.G!W)$ZL58)G06])51%O(SJ:(S\(=A3$RQ<WKIK&70'/".N.DMVNVU$3Y
MQV"C3^5-G[R?KC!H;3!4S^*.=0LDN">F;FF1 G';C4IPX&_-4FE(5]!)!+70
MS#O(U78-;VX11O(6X812]XHK+Z=NYFG&C'-[<DBQA"58DD(OY.AZ5#>AIR>R
M:FDUUELX(H&,4;SD9,0Z-,PNOIIQ]Y$W'!1EN5];LG&'\WVLUDF@/G EEI /
MB\-)U(\2):<:(22")UU[9AENO$FXT?CJ5$%>K:X1,YQX9T"W>I:;O9&@L_.!
MXSE/B$%\W/-@I>/_F2C\K%E.-6;''U<Z"]L-N>@(=#*>5ISM-?>(I*909/]!
M+D10[6L0?>I?N6:83O-S!ZS[@\WIT'+^<H"U_Y&[X>?Z]- DZZVCN ;B&7X@
MXE: ZPNUH_MDTC"V)_"VS!X\\1C!AP<!W$X@@/"O3UK7-1  %!D  59>FIYD
M@?HY^9?DQ%\,*F C36%$NB;HJ-E[T2#Z5@A^%M3TOJZT'/>X'_E;>(Z$ 4IA
M#YS@6QH8G=FZ1=Y/@Y53(GWUG<*!3'>\]PY]9K_9DP.NTXUF2I]'&.R@U\)'
M#ORG?%A^__T] 4+_&@F4RS?B()D,_INNLOVNLZX!'P]A[WU"_F<?L[*N#'QL
MJ.NB)6Y,U15D1S]<+.J)[7AJ5;N&@DVEL)"S[&_*1ILV)U>9S!\&#5+U6V8X
M8XP5I&,UP<@I@YD2!I&CNC"#B\J>0T>?;;?']]ID7L$E9-TK*1$W\JA$A\H*
MU+1O3LYJ,8:KH0WD40]WPH$3QV64[*6[=1WS;UBVX=S;Q R[1>$6*N%E;!"@
ML]^7:8!'7#D"L5&V7H=M^C"9OR.^!A?;JRF%QH^ALE:A8F_D$IN6ZXBF):F^
MQHXCXZ*UHQ%I2B'4=&*# .%,<;'(&?)>$Q#@7!H"'+_[^.P7=_'VY-%[R?N7
MRK/CY<DA!(  Y*O/&U@O,/KA"Z,.!!AX&GARM-XQAQ<4H?^@+$6$5-C78 BM
MGX%-QU+RQL">""45J<K2*M_H0CF)>7RE+L>(>F&)F^S[B.@PS^P@Y^9I>>-Z
M2XC6,,_@(-L4PH)O"T<GBX0EBW3=II&U$(U\;GT$%0[=4%.$] 251TF%7DB3
M(VM]#L^Y9ZKP.$+\ITT2WR,-R0"6*YG5=_84TO5/!WG6,[M(#/L%Y_D;+6\-
MN@MD_0;+LRQI$QCA:8A2ZDE$+UD#Z%KZ\!8TQ.?A:85\Q+^ZW:LP%,B4I5%Z
M*Q2+*AVNE(S<KPZ.9)?BOR:@"_'QHZ:6?\$! XL_N7/+RY)P^G-)U)U\^<N2
MV#4U^?EO[YQ4*9TW88PV[AP^?-UBK&P0MXK]@35*#JZVCWHET_GP2_T/T!I/
MD)@N:'G0JI?C';]='3.Z:Q!+"^(K::JZ8H'J'=OTQ@3O)3@SJYE52Q&7-TM2
M=*1NI_ S6Q)%3P/V\A89F([AN.Z$SM.6*V:E4\[AF^E,X]/X<XS1#ZUG(VO&
M+9H5Z*:_ZF/ 6GOQ4XMCG$TQ;#IO#!Y-GBK<]&\-A#15ZM](%_FN/3"_^^R/
MN['(>=08>Y6)I)(\WL0>?L+BFC4]-SZW3._1:\8S%8.G3)P$QWDT@3-YS#DN
MXVE>J\)6N<P[XW16UM-;69OI,1H:4RR;.?2XWP?0R_*DFRZM%%SD9OM@Q[BE
M_IK(J(U\_/;("P&TWD. G_'M?A49WF8D=Z]NW9\;7Z99%AW@XFBZM#^E9:;2
M[!J"'8'R.-F+L\J_PGO 5;H8^H5:M<D5V9+F#26"$P=Y='A.XX$\2UJ*)@[!
M\(>%8P&9G1'G U]QVW0N][F(!#T3=X>S+^;1:KU%+6,.)@CS4./F!7&O6WTI
ME)6T_.[NGG]\*%FL8I=@G:_BPE'J:'B%E I\'Z"VC6"6UUS65F-(QJ,Z&K1"
M;Y",W[?@#B6D.BK3H2F<C;<CI*'D87@;6:8<CFP5N8UZS%D4TNJY?7/-5KVC
M,Z0IY3S7E_91J7'*NOV7515+"@%B/,,F"B+/"Z?:*TAR& F7P3>*(705DGY'
M79S7OH.@TU]#X,1(@+"DDOO&<VF%H*5=\Q9KCB"*MT0VR(F70/&VZ@"<GRU_
M$Q^^X-WY$@!Q'.ZRY5O:FSNBR5O2=@P%W^!Q@G,RB;LS!T92(]H^=.$7Q_KD
M;E+6F9>%IZJ\29:R_WHA!#(E%Z5TI=Q1/G3A?:)>RH&-^=3!TE(=JE.C]LEL
MJQN7DIZ(<GSA4-96+C[*$)Y4PD]@[0VYF'3I,* 7'7$921OS#>VP"\]\:Q?F
MI[LR>3/"1XJ-G\,W'0L-QRZQS\L0X#K/A<)]]7#QAD<" EA!@ >%0K$6<=O7
M:8LVN<?]M@-:SA7LM\J.A=)\N<T!O6$:5#L^$IB*+%_'@GT[.SGZ5^8KQ*-\
M7\?D^2A(^L:(<JFF/_(G=#?7%]@[YKC(T-%KFL[F- %&/49JMM.P##==F6BA
M_=,'IRXZN\^8+28I<KH"IL,GP3821BA>QFL [\4X==A144>8QP>*M0!2TP(:
MW.E=\@P30O_4.)[=S/+NIB.39S$29 C0]H)HV:8P6=DA5,"_6K%&^-%V<K\E
M2](5=.\QIC21.U_+O G?K%,*>55O2UXTIIO1/-3]3X3D_>:!R$-0\K4VDXNE
MQZPR,F_38EMW8;^G&M+<Y,FCK:7]NUD'PM!$R75EJS)?U/0.%UOU#@R6HO(C
M*VN]7]D8M7/KNA=>)R=RMOYA,&..&G -U\*O!YS+/CE-\6V/9GY[''?-1"UQ
M)4\&<U+X9D;_P U.9/ST6WR0/T!"3#YZ\#]T:>?9Q&,L!,"$ /-LWD_ W).N
MR^[SRUA\AP"'?\"2*<Q&IUD/^9JBN3 ^?+-IW]AB9A(9V68%2XY)8M9% S\C
M<?H, H7F-D+F\IX4Z../X*I/*&G[KE^O^26/T\0+"_L(EJK<ZM,]PHW)U5X]
MS?_P6_0\6TFY-EO_QO[CK<EG/U')L$V^68IAS=QN=XYRW 4?1"/0NTZ"H;<U
M,H%2I3(*)K*<3D/^SS4'\I*O2Q-J9N^2\@_+;N,4>&,+U=FB9[^OO9&*Q3=2
M"R;].&H_VY+L3O.)[$0P(DO-1H3-C.=.*LJY"DJ4HT]90ROF_&/9X*1S>$Y%
M4?[$C=^A"!5;6MK92AZQYX]=.^ROF(%OP]E,5$'F1P(,>)Q]QE/%Y2S+)S_+
M0CYL*:+:CA.%3>W.>+_0B,=8[X?O4B^"(\]CP!T"D-R07,UV)%44\)M @+N7
MP'2#\:+H!27O(FZ>^8_Y#TJ\F=7+^H7@I;6#WZGHX_^0XXJ0%K&$<C09#F_/
M;X:MCU0)ML(RU=BG% ?_%!5+Y&^+8H!S_+C4)WV%JM"B\4*G90=^QHJU5DY>
M%<WWX&:AQ!]^9QYF_HAZ!5_R@B1#GM[61+"RK//<H$_QJ+]%M*9K%[FGW>&+
M."H=[+?@@' (L'S%66K/TZS]T\+9(9EM>+@ I6!^+M%=1B'&ZRJ^PK(6 O@;
MF#MFU-0FL+Q>?49(E+:VSU_BK1N5A2VV&18C#8E")+F)883![Z97.SM1^&10
M9.%66-LP=C63^AC>6,7SS K3/>?\'KS^V4YT2UR,W*">IIGUPU@AN[-5QI;]
M;/;A5FW(R9WI1S YFP5T;W#0$CE/TU'8O0*T_-CH(1/4@(R:4Q^U=N^4USV3
MP%[M1L6RSMXO#=96LF&.\J.A]RY=HS[7U@5EU#,YJ!_V4V:O6?QW0W]L5T]Z
MKHB*[#U(G[ELDC*@-EAQ'MO*+VF,]/"AB<*@;VO6&[L3?IM)7]+1[*H=SC6T
M_\F>61I:)/SK7 +%2TF1\<.;=)_K<DFW(5$P6FU"[8^O#Y<-2^5&T?XA-Q5_
M#4R?-[%255N\QE;M>S.N7YAD'4U$+2?Y9#+O\W^*QBK\_V9?R.XJ6.Q9R(L8
M I2_]OXM]450=:+CGT',AX?#QMPT_SQ?P@#*4 SEVSD\7QTB 4=)&?JUT7)M
MS%/ZMB1M'LX-/?II/1>)>1)KY>&=9MW  9ZS:L.)LUMT\#&.(04VE!\'*5JJ
MHN7V]&9EG$F@&;T6QC>,XJ#P@M5VL:FL%C$\<A;1]P8MPV#1T7,$_@!9DZ?4
MZQOC9\UO2?K0"WKAXB\SUS3=?T]]@8J\?EK7?RLB=+!JO>S-B?8<5G__!OC5
M,'-04ZR^+DJZIP63,-46<Q$G)]C^,ZUD0.>&'W"2D:<1UK1H+7M0I+5R\D$O
M*X2*&73L+#?Y35<  KC_?%#,K@NXO+,BWF>)4Z/N&=_9K)C*B@"UEARK(#>B
MML:"4\^$ZR<E*56CAU Q8+$O.6]R'[3,<Q4EY<\/;AZ_?Y!A[K<]D771P'5(
M9+&CYQ/5>A-1QIU$)P*+LF42P5M$E9W8W79R;?F03@X!&KR?BG1>Z=P\L#U-
M8'DO=CS/9**KG^76+-Y*7EN8:7S8-$TB^(0E'BVS]!(LIB,UQD^)\RIT-)<6
M+9QB^O7NILPL\X-SEPYM'SJ9:S'@N9%6SN##2;ZS2%PVY;GDI&:9R+9"-UKQ
M<AGP%K&D0?<(NZ8/+L<R0+5/NM(^\;)7#>C,0!7\B]1@M>[ENO0BGMYL<E<O
M3U?W*%S_YC/J5$.LYL-0/'!:JAENWJ-TEA&@,J5BPBAKHY2# NHD<'V1[K]-
M82K_Q),F:?<-XJ#U9?G+@XDZUFXJ$TR!47A1,8[=D)[VVX7U4/QX,7\YF[$&
M:(R.>TQLJ-4O7\![]?T;YT8AM)NVQYYP4K!GVIJYI^+5(J1+Y6V(%: 9+_9;
M2L5:MIMDISQ:]24 $9$O!UUAT</YU#&MUNGZWBN'B#&\.,M@S7O5 >K 035=
MT\/X=&RV^7/E/A)AE3]_X6!Y:(\.\Y2',D6OAC<8-HK*1%V?IHMCD#($^&WZ
M,NMW65-:EOD.[&_CIX8))!@_O<_888!9]>;70MIQC*31$E>YZ(^?_Q[3KA,O
M]N5+>CV/6*F+G;0P>%\E=H*U8:2)H]^UWXY9;>.F*R@_P<U[[<M3'&"W0OK3
MX7>ML\.9@SU["N(\RU/3:#%SVG+S,T[ARMMI=I+;,GT(T&4- 8PD-C0KD-B"
M2!NF/V+)<J'@&H2Y%F5L7(Y]9=WU=R:YC=.Y^N.UZT8A]')^X;53U*+(IA0_
M/3EB2VVV#,(C6G,9]O+(5Y/&6=T9L@1XRL#%(< ^8X/SB3%D_7EYK3UC(2'C
M9O6E%>W(P"M>MN>NK&DR%[WZ=QX-;YDGM%)O,E&3_UM([?@[HG8I[,)@]Q*P
MZF.K4PH[(>6NQ6I?XF1N":?Y*6,<(I-Q.*((Q?H>>NZ%%':=/X@_Y+R5YEK'
M_1!B(WX0D1' 8 FV0[.?*[.TB*DG5]=^;;Q9P[F8SJSRKL5H$^9@3WG+-X&<
MJ]H'3?#JN;9O,R*(]Z $-=C&:[/2]/HM-][7&-FY&$;:\F ,8SN;+%?R!X4)
MD@1FL1U0 ,=2$.G3!\O\^*D=[N]:N=%IPSV%?-G5A4LG5&4]^0%UFM9D.S2[
MJ=K]MAB@[7'7Y701Q>7$6;:*H=@H3M8/$1:[3<WQCBM0T<DF=[F<1_NNQ8OB
MROJBZ)([>33\C"*N_O:I*$C?9T:])+]-ADBH39+(/_^S0*3XNT T;D]YRH
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M-@KUOOD$J;WH^_4F%%->:?'B2]KG'5+O9?&0M9BTUG1R_Z;-X<EQD,R(.V"
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M&/IL!UYX&SB+A/I(82K8BZ(%L&"N@X;-F5*:RSMX#;\_-0BWM\@.1M7D[ #
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M\NLU)%>I*I4Y7BYH=%*CG<)!SJ+@)=YKXW1A1)[W%D@?PJ3J* E]+)=-R:,
MN/>W.WA?;IWO$;.A:/[P]HT,U)D\<%(R!MJSRP,Q!AB#42XOA02SUO?6L[H2
M47TGA/B(A>SVX][85Z>5GYK1$NZ]J:?CM?" 'G!U*C0M)>"$U-+AO;;#<G&.
M8,$T5P([ 36]K]BQ<MOJ[C-_QW?9I8X8'N:(*YP&/:!@8,J5.2F-M* 5",W7
M'^;ZK1B#*EL*:DDQ0Q5H=DM ^W5DW!\'(.]#^UN8'-5^4R(\O9$EP$(19GT
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MZ1P$;Q3<YHPSW=]JMQON75_5!4EI<Y=+0PD+H#&)O'"8M",)8PZHF3NF^MO
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M$J4TF/VI0"IQB47\0Q$\5[QT]Y5*NRES #?8[6_3H99C:1DJI/Q*TV*XXM_
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M?L'\@0K=W%-1OBDWVJH@K>;$!R>)4 6&@5OL0Y9'71K-G;MW;G07II"BOW?
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M)KL9D3YUI'!L_@A)PHZ0'7300A2\&QKA)F^D/%^U;MJV2]K3%W  UX)PJAU
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M@51[@C<#J3Z^5#RW\E*@U:?Q$KFE("OC<"P2DZ^/,?'28:K'(._Z M&!B'I
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MN<!O(G29NAG #& &, .8Y?.V [^)T&7J9@ S@!G #. 6RV?.,6#J9@ S@!G
M#.#-!C#+YRT&?A.AR]3- &8 ,X 9P.V5S_W&W2[/N22< ]A0L+>0PJL<P %3
M^N93.H.3P<E*6+M8=+^WUX[\[,8#OXG09>IF #. &< ,X/;*YV.^:I"IFP',
M &8 ,X W&\"ME,_[G&3 U,T 9@ S@!G FPW@5LIG+J)CZF8 ,X 9P S@#0=P
M*^7SX5XK@,^Y))P$^/1@;R&%UY( N>7GYE,Z@Y/!R4I8NUATOW?,00PVL1C
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MFP,2*W(8N[.FK=%SXP3/4_P+X(ZOPT!XVCWVC[(#8LMYXFF43Y-B,K5:7):
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M>PB;.^IM>:;>6PUGS8FY6T+N#%0&*BMG+6;7WQ^@8+IFNF:@,E 9J%L#5);
MCY(FS^WTF*X9J Q4!BH#E27P4]C W$F Z9J!RD!EH#)060*S#<QTO75TS4!E
MH#)0VP!4EL!\J0O3=3-R]#A!LXW$?@6#1^),P8^W13P19S(.OCMICU&@;?3/
M0&6@LK+68O[=[^VU" 68KC>0KAFH#%0&:AN RA*8)3#3]>;1-0.5@<I ;0-0
M60*S!&:ZWCRZ9J R4!FH;0 J2^!&E8XS73-=,U 9J S4K0$J2^!'0(/A9MK
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MD>\:2!BKT8UMJ91F>H8T3$^R&[MA^,(D^@0D^JX(IMU:TX4;-1>)NQS-MF]
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M73\Y3*"I?X;<2^:F]/,ZMB6NKT]?OWZ-SC&-5:7D.W;N87EOD#V ]FC_15<
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M$2A6VZSL45*@(CD1B*Q)")IJ?J<4JB_P8LD3[P&Z;$M+EPO:Y(J2$3I <YM
MUL@:KY$]JJ/VW"<:669^ZCD_4)0M:"D[::ENE<!_BEFB#T8[CUO3W5QD8<II
MMRY&>70[A]U\JI/NT.KK)R^ZH4H^S2>%C,%LC\D8<8^$KW>M]];,T.!V/C=5
M:4PUS7U"^7LH$@NC?'L*\MXMF4;H4[&ZOQ6%<!!>$23/2]T/2'T^7 %'#_,C
MK.*!9U>J!"8O0HU.*]R=WY-9N<::>VT$IINZ)8$.O]<[;Y.ZTRU5-+VHN5K7
MFC.ARHUUQ*C(22%9LL]JB\8ZO,I9EJE;#< #KI46([ 'HGE7WDH=D3FH8]2
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M4U21_=ETJO'</]\?C4Z.3>77GZE2M*."7CL>-D]CK18>\=&0'@2+SEFQ:6(
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M9=K>&U$UKOT65?_:P[A0[?9;X 60)VJYU*HP)3VXBSRL[;+O'D^ _S0$^$.
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M*I.LA"]*$Y@799*2&36T0&RRHYO#BXU8YBR6J32Y7'2ET:!+P0O![=*<"((
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M N8>-6]C*-(6)!/4.K'6*5K)?8='&,$\Y+LCFW$)9P7!03,R/QLRI1$C+<@
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M$&,,_+=*^F4%HZ, I<&.-71T03XWI?"- GB)T3M/42H$1.$[ZAN!1'A'C@R
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MMC8E(VRI+70$T-@U25)_Y"(>23ZA:BD3CCVF%$VR9.7+C%!_-_5FPJ0J-K:
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M$?(6!5$G/33#@4LO!.71$'*D!G.+BX)?2,\B#2ECNQC3VYT8P=G%#:)6=*:
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MAM6M7(I'"$DN:'A6S1$L0K@ GVABW4E(K O7P4/O0D;+BX/&^? &$09[6LY
MZZRRX1X3X5D@<G>LG2UG./0:J3%OL,0Y"L-713V+SF-,.3<F!]D);UZ=]XS/
M*#'Q';AD9I3!P[+5);HT&R=/Y<JPG]A*\:9HCV^(8CAX]7WO:=3\P4LM *J>
M[E&\5S.@N9MO- H"T"J<D.T\(?=\6;WK-%*(L>S5N;4P2HQ8M:XNJW0[QM,W
M @_&6ZE'5Q(;,A=YN= 8FSF?5);)]!.#AG[1*JV(H)QI^N 1NK@^_7)YWC-Z
M/KN_/.\G1JJ"GRL<WZ=R?/G[V,W;*LV?&XOZDZGALFW'Y/O'$@Y..#CW-*5?
M"%A )\2Q>8NQ@S>?F#(JBM&P@OL(+D",QW@WGS%R;C:BF,PJI8JJ5WEZ)722
MMO[HB^U=UH??XW%RU556]&AP/#K[Z>7:#,5)N4S5ZL4TU=_69P=S89/IRKR3
MGL+89U&]I#GHPV@7Y0O,-DJ33'?.F.L]].'P]*='=S(:<VHG-,EP1OHTKS>^
MM[WK;IAS?RI/CT?#T[.3H^>CP].CT]'Q3[0AOHT.1B.[);R]T.S6SL\YI_ZD
MVB0N^.  B:*CDP6]]@3-3!88;J[JV !Y?2(]^_<).N4E4_ MNHE^=4U]XDIH
M/A>ESV_K=&QW(&'ZY?_#P0P'\ZD<S,MZO$A*HH"5)&6"#"*X.GJ776$<;2:$
M2-0TNV%==5\R9?'9#Z\LN),=NX2QMYAMHV_,:^A:&R<BB@;L^7 <MV5KA./X
M$,?QDRZH7JDD1F E-_0W+><*B[#AL8RQV(($U!%:U9=H=HI,)9V'JW%1R@GW
MZJU(?LL,;U#[U:6Y/^E\O[WXA#ZSW,'#!&)M$SI,EH=E-BER9$B+UZP+@HDE
M%5/V4C9^7>IPZK=E!X93OUV7\(UW[@<,?3+=$&:ZT5$3TYT?B7Z64U<:GNCU
M9J*??VVTLNX&"*=S6W9*.)T/<CKAM)0((D/#<M(P9!5GV"09$X Y9J\&&AX3
MUR65J# _<[E7+3R$:[=D4@HJG<^@U&1#9W>Y1M)S\Y7>[(FYUQ&5E\6*B@\B
M;OOM^T\]>45=:$<^Z'IKJZ";!$YFWJ<<':.3(!NCT,+:8;EN>>-S?TQP,R=(
M=516T.E9-7<X/<Z\+^#'((*VY3@$$?0@9D&./V 2!HH;5<=)94NGYIG5VNED
M=B5MT'F6JA/:EHY65)^M7AJ4*95YXH1!4 I>8G/AW&W)'@CG[B'.'4-$KA+X
M%K&WF=#SVF$9;#@H(=BUG9&_7=R+*DE)-^,<P'3EM#\OM$%T?DW:02XS2 6]
M8]8"Q4-#,5Z_6D!>N"TNL6,V$KG.G\V60'>M(4U4F7F]U$'V(+I75"WH=[BN
MI.9S-N$4_#$E459^/-J@IEYIS+?D[DRCOZ.<0D(I:.?5Q[_W7#BGP=:D+0&^
MI,3Z">F4\ZJP'("F*Y%2-DKCFV;23I./Z;K(WQ6B@Q?;!C$)@)(0;-\!J16T
MEH<0 H6>UB479);DBF@I=5:5<_^5+Z.@W6_)FH5S\A#G!/6GN%#7K- KQVP3
M3L;6K%(X&0]Q,ICEWGJYG5-ICEE X71LRTJ%T_$@]X8JB%X';-$:#4^$7J0:
MB\T%G6I[UBF<C8<X&Z5._DWTLN@V:KJ"8DU!# ,!9FQ!."_;LG;AO#P(ET*.
M_DLDL$>6.722UB56 VL>$_JM:/#+O,0_A,.S)0L9#L^#F"G9[[7XZWO(7XD!
M !CD+"]F4LX/L2W)54(G;%(DT!"&-G3&A?0&FPY0<)MO9PQA!_<HYF&F!&Q:
MV7Q,0G;KKUZ%L+A%=<J4KL@(4.-3F992KVWLEQ?Y0YZUVK#:^+7"Y!7,J?^-
M/,'(AT:]J,<(!*L:K*^F&,%$(1ESE.6FL%FU8B")ZRJ16\,SLP(:"75BPS&Z
MMRG]B%M>=;!T.(*IQ* )B?%VZ@I(\E7 Q<NQ,"R'OUT*(E<X;],5,ROO(/K0
M^JCTV.]MOJ&&XU";*I!6;8LF<[U G6V%X,IOR<2@&KU\Q@9';C/U$0FU,+$J
M*I?0+O22,JM*!(M7AOVP3EU1^?8@*&=CIBE<SD3Z#2QHDE&JB2T2I>!67/&D
M(CBLYV/154D*JGD3=&H046W0KHECPFD27ES-6@ $\DU<*!X$BHSH'7P<Q^QL
MK/)6.=$;1BB3U+/-.J9]LT!8;3&O<MC/:'RJA!D>-W%)Y@1H2*ZT?5T32]>3
MFKV%6FC>1X30K4O.C/<('KW$&"F!XA4N 36$@ CR==DYV :_=)H4L,J4\8,7
M1UQBNHQ.IQ3.RURF#9K3MA(YERW 65 UB %%RYB:4C>EEX=W> "KNRIE2> 4
MZ&3I S%Z49VEV$_[.VX=R?P_/.C#EQE+@L6^D 4'5,J)Y/SC^_.LZ2VF!::*
M-!,8D5LMLZ?-).$NH_V-]U"*B U$<M05 96)C1I+PQ8('N%,PG::$U]7( KA
MV#2[P,4+)A,L:-,-ADF3J39)CSB'&7_'5,+)",="W-P(]"8:;9.&C$-(7;:R
M4)S;4K?FM 0 2;C"G_@5?M$ZL$(7P@BV!K&CD;\=U"0>GV0>S8E::Q5A441X
M"\ID\J00.WV)P"]SP,$JI')28\TW.QY6_XB6]1+YN8S;Q1'G)S8'FFH!.+*3
MY7Q5(JP-!%*6@VH!>GF^8HH5B@N8E@6&S=+.R]'(*8%B$+5G!1,JVD+$W&+E
MW5QC,5>P)FLD1F=MSZ+YX**11!;F(J:ZPBC2Y=+J67G=?0_"CW(/NB;I,AQ$
MK]5D[NYCP_YI%8';M(WV/)D&W%Q1@0%,=;TA-69#EFL#,1ED]5-E5SX-[,KA
MFGSH7?BF+E"F]R*- K.5SF.D'B<EZ-A+2Y!"P1G6.M/HY4$(M5><EEP\E,HP
MSE41DV_TW>>?B; ?Q37Q4^*]0._UOH@/,)YZ_3*Q'B KAMEH_?RS*6,\@WZ1
M+$;1KR>V/AN8O%-*'D1O%5>M1W%/C7+%G036L;+IAB78]H40X%/$@>SFN3;5
M)Z&1\FO)%F2<7"5QC;>$;:EBB[=C"'SEHOJQH&K+-*-8 0T4!I@UJ0]::*$?
M(BM,VL0I!X4 UD_JQN&XR0*5)6&SB UMS</ 5<%?I1RIK*>41:9;L&O=S64*
M"X6F%/Z#I4&1?1I+"6#2959)+2(T7K!9<Q%WK!K"%E+TB"2F^LYV>^]V\!C_
MTLG%L02;N7# 7,Q&0,_L:BGV>D.;J>:%!@T)5!-)_OO$-""VD"VF0*1J22HR
MU;<:)YF.VX1[=Q0-/ G1P! -W-XY_]M_T>F(ABR)NS+JX2CB,2*FRLKDU<./
MSI!D AT1MA*) ?-/W,ELR9#]A/7:JCP%6Y#+W8_!N%NR.Q>,(C7.TZ1<- O"
M&(NJT.RP$V+JB50Y+M&;VBCC3.0_Y'E"]U0?I0%<.80\$W,6R^600XH&!9=A
MUDCM$OK.*L<[$4,Z5.^/'-%TSX#5R%+'6-^ZZ+:J>W*-T?3))!EG+]Y&H!%G
M3='598-;UYGT?E/.9)!705X]'7DUVBROO-  2 ^0 @OBW375%Y?YLG9*J82^
M5EAVJDQ0:VWF.;(TD\@$Z<H]X>M("191P&CL&QN5VSU.+ZX@C[+)G&4NNHQ$
M7R*26&CF-CRA.\1E#J(2XUSR"=4299]4.9GKN$ZI!DL0(CNUH8,0>3@A<MCM
M1R;O<:6^:I(04W8LN$/.QZ_GC!1[XCU1@:(G0]R((K:^#N%#U")8F75I] F<
M910]W6PD)M=ZK5@L.QGJLO;9Q"7L9E0RJO.+57,35%9,E5FLR63X!-=H"G/B
M4$Q)Z#T3>SVB0$-;LA'A$%OBE YF>(W@8">LDYDG3;W 0?361 3(D9*"3*JB
MZCJ_F:A15JW3$]%%UC[U,_,Y3AFX)X)/\L=)F48I2XN\P"HVM)./U@^S&!_.
M*F# @3$BVK6\56HI& R_=^%B2EC2W*)$4%!A37*00Q-0%(I\(8$V,(\,;X15
M'<3EYZ0#2$"U)/ 0.0HG#O\B/>XZ?ZV 5)LD8XL]9^'D[?C)PYKG7,,#:;J\
M"' 7/FJ-5WLMRFKO*)5E?,_Z<5>\J@I\4'!G8BW(JV^,V<II:<3+Q8U1)'G-
M=D&=X<EE<6"LDRLZIX0$6B&(F\ ^?*H%;><#[1@A)S[0LI[-Z!D%FL4L0[L
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MFW<-N1.3W. #KS1?GN4<D=$8'PGR-LC;OSBE_/WOJ=M(+(N?'3'HYIJ4V[<
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M5-N"35GU:96#,>!:(KE;"8KS Z%:H>/?J+JPXY5M^&9\LC=\N3]V,!4QL<Q
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M-Y2S)F#R0W)96N)\Q2=]N LN_"AII/L J8AEBJ1XL%65[WI+G<%LMBH:6H^
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M>/$*9+KZT9\Q=Q)GA#" U&+,V)3#=WV^=ATT%%?IKP2ND3SXA^;U+F@%/+]
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M Q%91F7R,-+@@[8LDA!Z0:7=AU$:F.E6>]33HWK4P$Z],N<Y\/3)#?&^]'$
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M*>MJ#402RPU%X28)W,(M&6AZNV,,:1B[(H2VVAXI.&GHN&30=/SIP@34X&>
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M4I=%/B-[K:]5/JA#KYQLQ9ORB_ 'C8P*0Y<& Y MZNN <26@!GH[W0M&3NN
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M[MIKQ%G6329FL6;L_;[2R5.!I^&[91@2P4]H%6<L12#:L)<%Z*C,-P%)*]S
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M?*QJY<9:@0H\T@^282U'.'*W-!@Y8VI8*85&165-@VVBL!8B8I56HT<%^0A
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M)B#%-0IL[=AWTSM_S1H]G%&0V)^6AV+;%0T<=P+2T+SPU4+?-)V WV4+&N]
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M$6$YJV22)XQXD6"6> VV>;XH(YOC2S#]N/7/*25?^&O,[,1J;G0Q<:8ND#'
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M)>RZ9EUR=INS@Z#ET 0@TG+<-AXR<.DV%V>Q<ZGU(U<Y4"-=ET<69BEN3<J
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MBR]#.-:;Q?<44C1>G,2G8]4/*F'^*0XMYK.C,V[N9O%./#,GCN(_A:V5<8(
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M15 OD2?'5=&+A'9:YH76)+X'P6RCS[*>$XUX@0XZ":U_I">!8?V88H)>;;<
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MH%W=%;'^:QDVC*5V7TX(;(1Q4,<'&%(&;$B"TP_7S>(;;!QBY8714TW:"#D
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M=+_FQF4PE9%>>,!IRZ3HK6'BQ_$LZS+ %N]_C.+'T+W6Z<YHP6I:* K+Z@Q
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M\F$776Z!GY<AJ^!EWS9>''"I?A$<C7HY=+W&2:V__?!7Z)"%DE47Q$'A1"4
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MTK"9,X83T0[OQ%!QMJS><*L*9R/U_+,]"%O0DY4=0]0P,K>UAK"KG6?6$<\
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MG48'S'4:+ W+\*&H\9XMI?=O:R5[<3ID)+T02W/0J=[&,DT>NB1FA-5?&.G
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M<M:9^P-9\N3$[9?/3IZ??*[ RPR-X%W'><57Q:Z7U/;#XV/5HA?2#=M-)U9
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M3KG50D4@4)"1[@?L/IWJ:+C5Q7[%_10W-8[8&$A%ZY;/J1AB=X")+4*]S\/
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MGBR O&5)-29G ^Y%I2EO"3-GO5S 1TWN0V<Z[/C/=.7PB5#1FGPRXXY>-\P
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MPEG:T-@W;NIIU=<=NHAJ\O#R(0<S0'8D6!*QZJJ"QT%UW6]&ZRPOS_4UR\K
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MS[2?B+.'9P#<*MR@"\U<35,E%-/W3)-L<+(K"QC"]PE&4];^I**%(P>5;/D
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M2=ZONG=:*3>2D3JTUE0(_)>R>Y/\P$KJ=ZN_?NFFOQV5"2JV=ZJU/CFN*&_
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M0/G2UE56;B-I!O<;H0NE7BH-IIB*S"T:O<EZ< ?SMB"YH%XPO=Q+Z3^Q!_J
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M ?Y.WWWR6?;Y9X\^#W:.QQ%_G1F)()H.3\)J4 (KP'NL8"Z>P-9%5 LLR]9
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M@BFC7NV+-MBBD:J/D'[ZTU7G]O.WKT]?%-U?SN,%#@F0%[Z6@U;U5>>O7[]
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M\8'X<"<^T"FT7OPBN3&(#T]V"M4NRX)N_46*%?"^QU9/=G1R,4ZJ[L;!ZNN
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MHAHJ3MOJC,=6=]"I@9!NM@XE::4\+T(X0KBG9@PAG+D(]^<_?7<Z=J\.,DH
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M.-:XUZV!E!H/A<T,9A&6&B"HA*6$I82E1F,I02E)*R%APY"0HFE4S$3%3(_
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M71+P7^PW?A23)!Y],.=Y42)_NBTAGFC^X W^5L^)DC-I=_3EMUB8URS<U+N
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M]07HI6]]RMIV6+VU6+"<_3DH]M-IEJ0Q*!"X/!8)R)RK?)UZJI6<X ;WPG^
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M.5-JSWUY^PHL=:GW$I>"M<$8 YBAW8U^I(397=ZR^\_%"WF?W??TW\J>.Q=
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MGE2J:\%5_%%G/L%>6&,<KD>O3D:O99 ];\X'0'N5RY'T)WKL,L+F<DIZ@55
M"K094'CTNXL>6<G+LG2_HGE4=I2+&0 @=Q[P!04,?L)U:XY*'7GYK )J/(&.
M(]UR8(&#=/+>@457JF@%:62C-8$!UPAW>9N]*E^E@B,S%9TN]62B&Z6K)6MV
M@1SZ2<6IJML)B#C&PE",.O-,9:Q%6"<I:8\B@ZI2I+I!VJMJEP^Q<81YB(6Q
MQ<12J0[:/)(/VF$Z286 J.')36'IM\CD"Q7%ON/JY,@/F1J0&U"ZHE0M92N6
MJX0%3<XB-'XM^#<TOM1&\#$3+%0=V"1/Y,XJ%7<112.G(#D%#T32:J,@C*"
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MLV;)#)UX-QW6\AEO&(^&@TTY]&YS#%;>"UFG.? LG46Q;NFIOD0.? 9$GV2
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M7G4<GUYC@%BN@@Z]9NWY!L!QE^"8U#O!<>/X=1 X=K[:1^!RSN$8,[5$F'!
MY"7[P$-^J;*YMJ!SF>I%.&V@,#0 IWN$TZ3W":<;QZ^#X'3WJVT?$TZ'21;(
M25<$S77;_PV YCY!,ZEZ@N;&\>L@T-R#(_01U$CGV*SZC0E!R%R[[=\ 9!X<
M(S(/"9D)F9O-KP<@<V?<[]A#F4X]''2')3)_[1T/*I<PNC/23!E>3Z^*:HJZ
M0T)=TN*$NHWCUT%0]PB*A'/4Q>:>_\Z IE,?CK6$O(9M[P8@[XB0ES0Y(6_C
M^'40Y#V"^J6-Q&ILNJ7#Q3Q,"9'-WO8-0.3Q$0*R38!,@-QL?NVKI+A?]O.P
MOPZ;#\B_XQNN8U\F:Y7QW^K\J;]EP9(Y0S5ZZH;.F7[X34&RQ=Z_/R,<)AS>
MB<.#MGV$,#PB&"88;C:_]C,&<F3;G0*&!_;7WA&<C-^+%!M!3^-HSM[X22CB
MT_D"?O#^_2<6"R 8\ENBKCOCX:5@OL+@S^+23](8#L]__M-WIV./7R;,Q3TS
M7>(-W'6!1'BVSH=*?HRN=)-I-73*H2,S0?7.;>G81PG5U &3H+KA_-I_!TP'
MNX-TC@"J 7#E8.9LDOB>SV-?R(/R*AS7'%;A(<9NW;IC:K=M_\4\?547CA.X
MU(A9-11/#$>B#Q0T^J^HR-F7612':13B60S;+7IB(211M;87,1RK/F63P'?9
MJ3IOX='KK1_/V]MV#@' D>\P  "' (  X!B854/QK # FB>.M#]MKP=OKZY-
MYO\#.&XB2QFAQ/T=4-I[U+6_'D&+G#,9F@$.R9Q&0)A/L1^Z_H('[,UWX68R
MD?%\"E< XGS*XB3#$T@:L<]9 &^SN[QE]Y[S%S+GPNY[^F\J+1(=4!?P$$SG
M@(O??->AHE-7@ID][O8L3.HX]:)%*E&K?#[<)Y?4[3BY+^N"QQ,>BJ1U_CT0
MR_PI3J=3]Y"1R5)1?W"CHPV!V]$S=1/<CJ!/ZPW@]M8/.?P1_D3@=KQ247=P
M<^CD1N!&3%T'-X=.;C><W.P1^[U]T3YK%S!D=_N=6[%JW!D05AFBN>J)5700
M(ZPZ>J9N8A4=Q'8?Q BK:KG):XY5=L=NO_MX08J-T(J86F=!?A<BK+'_^^KS
M>_8N3%) &L%>1VXFBXI5@5+WI<0)/_^UE__:B^"%890ROE@('N<%3N_@X3%W
MY?'J-4\Y(%@@V$2X/$OTJU)^F3 >"X:%31YVK+[VTUEQ?[FF_%V4F$&[=SL,
M79S]1AJ+$O..@%DU%-"J*O_"OT=A-%^R-]_AMPF>0B[<F9CS F](Q],6VJKC
MST[?D]H@'7\$S*JA@-ZBX\]XX&:!\FN]]\-O$YX(TOBTH6[6^*_?O"4E0AK_
M")A50P&]1>._%E,_]$GATW[Z 87__O05Z1!2^$? K!H*Z"T*_SV?B(!T/6VE
M.^KZ3Y_?D/H@77\$S*JA@-ZBZS_% DOMR9]#.^KN*K]'&H34_1$PJX;">19=
M848IO]R5M_/\KBDZ6QNPYLH?_LLG@9!_W,6QGPL>:YK;!^+B!/:=B,N?]1<I
M2Z+ ]_*KU1X;#=J#P?#G!TKHX* ">C,];R+=YKJ.4P#^(K>YQV8B%KC#VWNA
M+JF78I(1*_^G*,T3!M\DOL_\B2^3TE&CQ%NZHI]E<:S:-BVB.&5@<,II9*/6
MW]E4/@GYI7+8WYSAKT^SRRQ)V4:;]"?E) X[$W$#>#EVU@@Z*^SY!>"'@O86
MG\+7GO#@FB^3E\_8+Z8)T=,:5(81HX:[\+GSF!KE0BS27<,7B)M[X&;W =S,
M6W=+7\1%RE,U"BOGZD7+WL'5#WS)NL3/0_"S]Q3\/%W$?L!LXN@A.-H_)$='
M=;+DFL+1P5/(Z-^R4#!G3 P] $.'#V#H_V8\!HL]6*X;17:G];\W2Z?C$#</
MP,W18QJXY7 Q\YE)1[=Z[^S_@\VXL<<!W HW\4N%'7@!^IU9%,.?YPL1)CR-
MXB5;K(R')P[L95-W>R]7.D*\ P1G@X[]?/+BN=UY@;T? ./SC/V+UM\M.9V0
M^R%#E0(_U*.3_*102#-^A06^(F31W$^QY\1S7W/:8Y.EKB-V7_Y_?_G+7_Y_
M]1?OY8NB)'AU#!,\+6&> $R"KX#[TQE/=0'R%*DCU^6KPF/X&WPO#V3_0?@9
M7I8N%Z*\J?+<-!8\35"7PG'A"NY4&RZ<^KB)X"D&[S43-]-FOP B&A&-B$9$
M(Z(1T2C<]M!P6Y?";34^LVW?AT2.@XOE) J\@Y'TXMVO'T^__/[YS8499&W(
MN50[NZKG4N7A^G?FQ])+( ^=98M#/+K9_>?>B[R+X?;N\JMN,B:/FYXZN\;*
M0P9OF@B6 "WA%WBPA#=-Q(P'4SRXXOVR^:.Z0#XP%ED(=WE9L&0\2V=1#/3P
M##X['JW.:8APO$8WR@G[P&-WQIR>=--V#=YO)M)PNXDJ<U+S9>LOQ2\Z ;F.
M\C117+0?7IYT7LK+6P%?1ED*S_\NO)?J779'4EK? -\?\$4B3A*QX#$P;S6M
M5#[[V7I%Q)6?^!,_\-/E27[_EKH(];K>N-WOC']&NF_+SU87#=J=_N"6:^QV
MQ[[M.;UNNV</5R[:7T5'(7</RPTW+ V\'@*PRG-8,_[FK\^ZSXZ1936$A0^G
M[T[9JW?G7]Z<_?;Q_/WYK_^TV+N/9P?NE-E,]IO(7Y+8)K&,)+!1[#Q6-M40
M)U\M3XB#)&BWL6EG42!;I95A[*RA0/Z2_,+^$7"/_<-/(Y? DF2XH6RJH6Q^
MY'-!<$FB5C<VU5#4" ))+AO/IAK*Y1<_#0@#2=9JQZ8:RMK9S!?3+=.8,9W_
M;,9]>'GX\+9")#"F)6G^*TM2?[ILP Z^8^:2K+B#71[[J0\OV96M5.8E81&,
MK*C1J4D3$437>4K2- K@;WYXR18B3F1%3IAG+>F75;*>9&V,ZMOE<DQFD$O
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MI='+211[(I8+],/+D\Y+>7DKX,LH2^'QWX7W4KW*[D@*ZALPHY,O$G&2X$
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M?G.Z0@O&P"L'J+@V;O#!*[L!8N(]*P>(*<04*@>(A4$8?/"Q,$!^P<B.+U5
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M4T%3G2^$WSAE<@@QVCP=HM4+Y:/]>?WSX_1H^AJ\GL%5F^WG#(ULHHYIU.0
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M^_=D;WG'7M?#ZU4N>;7:)JHU'VTC/ \VH_10JZ*A" ?.MN %X.PCP]G=L!J
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MD7FAVKS[R?=/]),^-_R^Z?Z!<U/VY,G>LIZ]KH?7JUSR:K5-DVLVW$9XWGI
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M4)+)Q%HGB)NT0(33U$*^A-N_%3(76'(J'N/LODC(]UE?M#X*C>.7D-+C$1O
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M4*4UC2JMH#@[ZEZXCH<'HSNK&S)=O;WE?P6*I=>;@V9L5[!LE+ R XW9)Y&
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M/XP46YR$2O)023ZQ0[EJ^N' Y[+^AHZ<@Q_5]6[T2GG<:C'Z8P&1FZY[Y=
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M[JS<MJ_7<*+_]:ASK*^P6!'$7]XWIEI/E1U!KVO(;84O7ONA]:##X2^G\TI
M7P6[GNK<PE*7Z\DOP+VTN=1@M;] 27,\G]]2ICY4C@\.)"N";FG X2<WWE:&
M_CVQ^G%3*[C))3[,77GOJEQ^E)5104[<VM"R243[-:?8\(0B)1(82D$8HEDA
M$4]53-*"I['0#\X8?N.$B',,_[USC 2G_--.RO)BW&U!U.]!D%2/XE\<.LCY
M+D4C(#(T38-8>>F02S?9=1QFAYE8UWO+@H!SJM89N##%@=!X!C,> $,LRP8
M4/3SZ#87^GWGG[XV_L'>.(Q_F'5!6(=#NO!G[R4:ET;U*U\52.T@K/\H9V>*
MAR,*^9"[)>C?(:*S8B:7>[[93Q&J]M9#6SXY$9B@P'2V%IWLIK&DKSL9N?:[
M-?ZQMX[X9\0<SMGE4]OEG#>-=_("/!]/J3 1_O-UP-#91/ AZW>.Y8#]M,3?
M":F%D+W=Y[QWW4O\USE/X5J%LYNDT;9SO<;)XFH8H^&\?,YQ-;25]FVINZ8=
MHQD7X 5V,@6-%CJF\IK#;RA@+)L>F%FSP)1?M\8-'62K]<C(6P&^RCE>5^-%
M[.J[O?@&%#4A9ILB-VT13T\P'ESRO,"I0IPHC@@5&%&1$Y0(I;@VB8R+C<%[
M]TD*\941O_&OCP,X]T8B/S'>7!6DZ  S=\>J'5E=8[<-TW<;2BR(18GCS;BF
MR\@8"W95YSX\ZN&K@NB+:XWE;O:AI6$6T7AJP95OE,SEV7KX9%1L-G[838,/
M^NC4$)_I>KC!+: 8K/;13JN!)KK40^GOJH1WG*O?KA7[CTWYVCVQUO;A$/!Y
M^PU+ WIO&^KD(FU=K;74P[2I&][M8[?V+5UJB[GI=9[6>L%]F I6VS?]T,YY
M.- *^C^ON@:L+V?5V4YVF3^U)5L-5?I#HWM(!JV^\.'JOD_ #-#*-3>'/^=N
MV4/]A';1+ICQY:LESJM1>0B,WH!8F9^.!><0\I%6\]6W'0I7(0@W.7AC.?A_
M^DJ^K3;6<M%W%8=G],';K9935]EV63:]Q[=C@Z/(@<J;'J6_6DMKO:Q_=+!=
MQ0ALJ6^PZ#YM[?8AZ.@R*8:"R/YZ/_%K*]E&%/!9'[[1@I4D"[]W76F=?9]C
MS65[YCJL>7+UQ[7;9K>0+V>Z\YFO+]H1_<XUE!N.KU;+,]^)$O3[JEYR3 %X
M]1<WS6WEPQ^2@WW60W^8;NC3<Z-0<3W\^A"R;R&_X'//L$,;G*')R7(Q2@P;
M?7W3=9WLI.O0RF(*+CJ<FB3G!4$B3:!=+TX0BQE')HYUSC),"K:3_-E>!K[Q
M_3^#A^Z)BW(Z.7C217(BE[P<P-/.P-- X3Y6UGG]O[CB]1%J&)O ?<LBEP7G
M(G*N&_AL- MSMII\X*:C:CWNC=5'%KI*Z+[T&83>]5D-N.\C&8TZG0T)43X*
M.K\:BS.?F&3?:Z6O#[NM/LZE*<&G^7Z^[GJN?#@-+N>E0M"PJXNX#?(<;.ZY
M'@OGF]Y003'D*92?=+,F0JW/"SJMR7>?5AY=V!L6SD\'B-.-;%L[KEUGB >?
MV,WG3Z+Q?I;D6!=$H808A4AN$D0S'2,F#$^*W&0I+W:AR=_Q&M+?FH^Z_@SN
MN*#*GU25_VJYX>>J:2)+_\AM0)"+.Y.+/UJS649S(.^%)6^7]GTMXZ=L^FQ9
MYRIVX7@0,@N[,^Y6WK9U*99MWR%@?/>9/2U0^=)95OZSP/SJ,K,72R<&UW*9
MUMX.<T/ZOFGK_<*.HK?EW*UJ6,GJ(V#1JVQ:T3>.ZU-P^W6@F]>QY;T*WN?&
MJGB?P?6UKA)[M]_OUST;.SY6^<5MEXF+_+-\/OOJ&Z]]7Y=_!\.CW+#VH<6@
MMZLO*MAA5Y5LC3R_U+7""M!<D+D%21D#X<'LLP+69VK Q3[)>-9IPFW!5Z$E
M7_IIV67=TV480 XYO6B@FO+I]) )U>_84?03+Q<NM;>/I5SW$E6+?FB-#V,,
MCUL-%NCVL$^F<HGCVPHP1CG8?3<,U^*QZ1P*79W#V@-6Q2>?R\6UUNEGW![D
MU>GKFR.N^A^N=[6;.3>5S\U2VXYNOUBWPZ[_'L20K38*R<TAN?F.Y&82DIMW
MG]S\^/ZHG%FH2DAF=R6S*%9@"V!S0I%66:HRG0ANV$[&X\DSK99S?6*.K4SN
M9>AG+;N2CG?^D]7[NCI_X[2]<RF>F.OP]^4"WR?(>O*FEM-1#DPURW.H!NO=
MXAOMJ08U[SK4=GJQ&39UYIN(CY3*"*'T(:I5L*<[]J-.%SV$ZJS!X177P(B?
MWGF7_G\UT9R=Y^WFULOJZ#^Z+=^<#\Z7;?5:N'H MTQ[/E[%K]WE:,ZO+-)\
MY=) 7OL7XMC1L;O!'O4YOVCTJ[ZE24^BVAUJ]^P?5JNPRQAT!@1V?#CR5?^4
MM4OMM6H@HGMU7AP510+CKO_C+ZVZ]5)\A O\C5?&WW9=<E20'3]R]XM,CS A
M#WBD_6>]?;O.O)CJSNM-&[5=,B99-NO_![+0GAV/%EYYS  _V"XAW2Q;*R<Z
M!O.,]_H6==#STLMA\5MV.NS&)';#TAY^_]<?\A^>=F<Z(3U0+[N N/Z\5-$Z
M.-E"T>?:T:>S_7;B:;SI7/S#33I[MS'G>TI\>\?I&+_.TF8?CLFD6#^HTH,0
MWF$WIK0;@RI-@BI](:H4XM=3XM&@-H/0#4)W"JP6A.YC"ET\)1X-0G<?;96X
MF"4DMKN2/.P0V&V8FI3>PQ#09Y^) ?6W+A;@DO*&M(3K*1P/XOY=;7S0T+O
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MW3 >P$Q7'I6KF;Z$E//8;F3Z[#<S36FV*6:3;U $8%^$G[.@A!7(I6D=G-F
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M5<I?BP8PWV<S K /"*DH^;T"("TXNM2AZ#AXORJ-$R; VW74+*E_"^[QLPO
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M+03@IKEMPC_F\#[I-FD,CP>V1=U GF# SYJ&W&@ZN<!PJTG;!J%RYZG/:AJ
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MX!(W?YE,?9/Z+XTGQ\K&MVGLNPR*.IS0>_N__GI^O=RTXBX_P^GQ?YCIU(#
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MJ?Z:0JZ;[%U-0^Y(VU1F#CK"S,!>KT5O4^_8:8AAFL:$+WLGY/Y8G[NTUA3
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M"U8!* (T_9POFYT;P/CP_4&W 9-$6KCK%#X"LC4#("@\V#2PEO0P,Y^=3Z;
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M%#E-B$?-<V/I@(03.KFDB98[_1R]=3HP+I!(6B$XCR,C(L]#=9R+@8; KA_
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MCEW;PMK=W<+:76UAO>X]_2K7^[5=JP'ZEAV?[V&]R"7&0TWT+\)RGELV-<>
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M1PE9#$%I?HP#2KA=3FQPBIK"Z50BSD%.=- 8D20,50$;9G900B2<8RP\BH[
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M\O1'9N_@C>W;P<H< I/T3>P'%=P?6@PJ^-FIX'^5>\30ZN!70![[(;9_K#*
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MP3 PQDJ)B#A7#-G6+ <<K!0L6;ZWXJEAONZ>!$V-M.CY?-T!4!R*ENS9L@^
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MOGW_%\;'.O7RVRS_FTFQ=FQ!ED($53&'I0%%8;-[54VF"U !/H*$#Z)Q>R"
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M']OZ+*/5NF1F.S^C?6C0:\MYD[/%E<N)V]@TH^H7.P&+79"Z P<GGL><88J
M=EO$F[TDL)P- -X:O*62NRUI<ENMG*;*AO.8+QQ3RJ[0=++]S/_=5*F>6-!]
M<.1LVM2M%S2=Q;EMGQL\&V^;TRJ-IQ^;41^8Z5BD\YW-'ZJ_UP!_,C^<5+_/
M8,6GN>9@U;6O]7ZZ(__+GLU>5N^C/YW RWRXJ%Y]F,>V&&!OKLS#-D7K _L\
MLBXJ=P;P,FT%ZD7QWL<@WP\72OF_;]X>B2M3H>K-I/IU>A[/<OD.Q42WXV=
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M*G/2HNO ^W,]!\[._?1 9>064EG#7M7S&8O033'<]U>Y_S#[L/:H"^ P[.R
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M313OY)>$"=R*9)$2.=<M\Y F(RGRV! 5 _RJ[E_ N\Y%'[K4IQS_+A0_;L@
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MZN-G%(ICO.+GF_+E)-R@&\P;9+@]IA?>X;YTWK'X/G+ZQ!: .V8\'T2CZLJ
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M<.1??Y25GO_T'W_]<=1.QC_]/U!+ P04    " #@AGA6W)P4XKL7  !S' $
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MU4.+!;6: \M1Z<L&$H>4[V8VS0<CV]-;..IE\WUU,IX3N)!!'^0:*&P=TVC
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M5%U3(]P;4M<Y\;"26N<H'1BL!7VUW@C"^%[?1^*=_C(3$SN\)NXTB#]K4:^
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M#&J4@9D8J 9X=T>M-%N86]3_"S2U[-S%G8J:HK.2M9K&K\)FDSIP/:\-1NB
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MN#5CM$-:RH)6UF]KKK1YBJ6,:K1Y6S.G:>3:>#CY7/QX!-'[Z?]02P,$%
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M'[NMC41K/;8:&CNV)8/$HX%T2(_8.(;^<Q(3Q?,INH^PJ1G&V"[ 5"QOPAA
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M$$NFFX5W8%7K'NS[KVH.;^,S_ 4W0$<XH2OV0>LA8#R8K.L2AJ)I\0VC,>2
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M,P@!= *\HR?>V@]]<EV!W$*X>B6B@:TU=.MKBC(F8!M^>U.([ZM)FF4X"I:
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MJLOA4BO?.G__H,"M)\6.C&WM\P<%[8YO)(Q'72S=3MI!+4F5W<Q;EZ[T*2F
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M9*Z[O"OHK)9Z"6XGU' +4 !^I:Y<><H]Y4KV9_)_SUBR__W_ U!+ P04
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M+#W]7)8QT5F>,;R0LT,^Y,XYP(^6KT[LR8-[2?;>;D\_,GAY+K$W+GP0.?1
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MBENNVS,&\2,8X8LL1UJ27+565,L3$S"N6S.%:\>/ GT8D.E1I+$7K-@.X,<
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M#!(!FTH=-@^R08TS4]-/C>89G,$HSCB9I]G47ZHR;)0(4>H CHT CU*N'^@
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MSS.#T&W@.R&Y,7G !%J2-VK>+0^-&H&J:X!P=BC\IE.@Z1A:8ZG=-0:<?MQ
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M U4<@0=*%";VD&6,2\;WOB(1]%BA$JG$[2/+&)>L@"RS?O@R%*3TG1.O8IK
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MME^ K!@!\*UC(]F3JUC(Q %-8LL@W[:$X=\,]<CG'!8Y4LL]395C;!07_3
M9DU'GRU\N==RITCA>6!QJH'QYRRL@/!&4,E7"C9=RX4P+':=!<&/NORL ]PI
MR,&'BX@LP:FH"BH(,K&(&2VKR3U])UY,YU%F;Q\SOT8M@W9&UZ'GO_A>1BS\
M@-CO3JIV"E.?X_:^C6HWT55-[3?NZ;H+H"?;8'036#%Y.?$%J#5V*1A,/IL%
MDO-!M<:RM>9*29S^7;;&?"#WI4.T^![!/$'"6N!.&B_N%GM90 LN>C?Q[E/%
M("8"MY.Y/MZV2R#&7[[""3.K-:0:@+2CP (Z)WK @=B=8!O?^#N_H.6N-FOG
M#:;"+*Y>+D:<"CN+6(P!V%ZNPAH%C#?$+]4,)L8>*N(B&_&"8=>C8CA3$U3E
MB#A+5#3C.%=N:,]]&4JFP:KGKK!E(>1U<6KWL'7T0":;; X<BN L"K.^\6\U
MJ94EZO+8/D6Q8NR0PT$7GH#A#&7FFU_*NMH4N\I18#(NJP"8H(SF)VH=XEZW
M=VM)7@4K"*Y'/\0IQF$1G:U_U<#']Q]^*F/.S4X@OE4+\$;T N<\R@+:;EYB
M3])RJ^ )2*RD4<"1SQRS]W[RZQD.W>W.B7_M9<47R"*@BR3A 8QZ?JR0Y=S@
M!-(XG. *]T7E$<>E2A4!6?NH/&;E*>(F*<)LL-5$I()+;!7?@\^JWRXK-:1
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M^1LD^@JT\/Z_RZB/>(V^C.!AO."W#P@>Q7NHD,#>V>$>2I+(-,PH.Y()4KD
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M[BM!DO7&$NDBDNH\9"D5I3&!*&Z<1*Q2<*TL:@#,951R%)F!!):^RXK#<E
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MG*M2N8R>*%]1>$XY+Q#G/6J=/<R<)B>1.9G*UH]H59-;*+FW^^(M"QI496R
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MV.56 H>76+Q/<!79C,I>X*<TAW.[==(L)O<@H!#TD5/000#B,H?)2V7T*56
M^A9("G)A59![_(+#[.3R8_'X]"98MF(2<H!.<9H%T"Y&P_Z)KDV(,)RX,/7I
M5WHQ: KZ)B^#LGM846+I5LQ]%*P).%4G!"" [5TFX,6@#A>"M307JQ(P[@D
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M;\3>O:RL!S"PWM'*G(A:3/XCWK8]&5>$$3@ Z2''G#:]@@) #TF"W TT0(C
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M&6YU):E-5N5$DN=8-E69DSAU>7DY8"HV\:.+FJZ+GS!9>D7EW)" J@A9I2Q
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MWZ1A35$<V&5I3\Q?2OH>L(=AY ,SA- BM##E?.N*:;4T18WN8[6&UMM[NIE
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MC9(9W-KPNPZ'0;VHJ$1 )YB$&Q+LDC1./XZ/40#20E_VU^">F.S]3-4$")"
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MDC]!\'8C.OIL(@MP3]Q'.950N#1V3__6"IFV-L2585BL'S-V@$D+W%/TE11
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M5"IN3ODXM4(U4+X\^DB8(R@IM!JV $ >]1@FYYX#\I)_27*0/B%&RHR>4&N
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M4$N1ZM8@#-N=S2[&P5XZ%;S;56^UW0HW:;;SB/5!@9[6?0%YC)OTI:3S]07
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M2*,)%=6KR2XO(_C$X,[8EMH*B&^32O4$[ ,58O$FG0!SW,4XZ%=BX4,VG41
MZKH%32V7&-3878VEIPLNW@,#-+*B/6B_+M+4<&. !!]N5S#UQE5PI,=ZO7VA
M\TL*#I3-D7,,VDM7\T4] Q*3FKY4'_0K),3F^^[IM 2IYQR<'O9?OU#Q H)R
MY$<2FK=5Q)EZ(/0WTXA8:W[VC$W1/9Y,2/3917+K%[XA$KRO[1)?+[MOL*,Y
M^O5R@GX(@E,65G'Y1_/=,X8B^M9\*=_C*+B/4]^R'[4&Z!)@#(C.+WY6U"(X
M!Z9AG]!]N7#G-3N.)0?U9 H+_:Y="DY?'^P''P*?^.+>EN#4Y;(5,R)4Y3A8
M*VYA2+,MB0#QU%*>\&QR"[QOU>77D1$UI!^V$7V[O?9C"(=XVQ%2\ >/RM;L
M*AF,6W0Z%52DWXZ-J$>*O_G;=EC@*9W194[-?F*1*C5VK-!Y4]!#7@H]34#.
MZP%06.GTF6A =S#)+'A!@SLCRD$LV^MEER:$8P4TQ:#F[XLT:-1#'5;%/0G!
M)PW.M;)(LV.M\;D1%#UD<>.4NZM2=T8K#^V*&RBB@JC7V^LRC\"LH;M;F8<U
MHA_K$//RMYKWM:]B\)3$L26O<YT\N@6$/TQ&3\.4]-%E,QV7JKL$KJDE.FJD
MYLU8%50(?B\+%A>9#J\4>3*1I:#WMLJ7@/1@3IPU!?*<0^=23_9C9^7WT521
MEX6%"Z^W&OCI4-5C6$]4Q\8 H00.;C\VX@3D+G7[M[%?VG*NLT&6 :==U8Z%
M",5A;][ KL@,/KRL[8YP]2-B1$HE*I*0&90AHJ 1N-[5#CN!E0K":?8([L0A
M. ,=S2_\^OB9PQDF7'2U9B$[& 9[X5H(.7 1\,S60QQI0;VOP*M9:3B1!KIB
MT IG5E&Z6N3N2YI'O)AF03\TRZI(RKT(B#"K$>/I8M^W3')0LP;;$,S*'L33
MV0%[:Y][6/D>KB(N<I9'L]GYB3C&JLZ3 U'CU,&7L,A]N.I+ 5/7=FVC)OQ+
M1@Y^%$J_C(@IIL(16WV..&'9_V=06DJ>;!V3"@(F8_K"3U!CM(\4]J;M*2FB
M'=/<=DX'%$@821P5>)Q.)80Y0?P<8$B18)>D<?IQ?(P"MJ%E,4M+D.2I!- C
M1> E4["- ":QWM;^9 MGZNZ%[<25\<Z]N17FEK@^CZI&7Z.&RALIBM@0&M+?
M!?OBF2X#RIV5HS7(4O+$NRMY\]+=@Q +3B&$KJSHL;_=$?6VMHAWZVT:L,G<
M1WG@QW\C?G9/_Y(W+U-+,VQ?M,%,:H\*M;?&KDQ1"YA;9\S>9T-7L#9>"L -
M,ROH%YMXL*J*NFV'T$G=%Z>;"/ALE8JG'/;/Q+@13Z. ?<8:%=_A\@V,Q\O4
M$#N.BFESG9EJM19+W5K:>WC2AM+ZH:JTK?E)[5O&7T&D65M]'=3M4B7&X3!
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MQ>;__6/%);T-?_N/_R'_0O_KG1[W__C_4$L#!!0    ( ."&>%9-)!UY%%8
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M?_*X')%6H#J*"044":,8DX>.H/#Z!<O.U(\WV0I<@2?>EF[O9\I.K&GV^4F
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MD7GF4GG$SPX//A>8[NKQQ55QHT<E[@/,7>:(2AR8C -289PYOQRKY4<>[X%
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MCZ0/_LYCC76YB%:-K(R(9-S)FARS>,SQ1E,6/@L^V 4^M[A@6[<13N42!UG
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M+>QN@F;IS2,QB GZ53:=W#AF9B&[665&.4'>__K+4%0_ .Q+)EG"0W+$IDZ
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M7<*&&U"4_X#_\X38_]__/U!+ P04    " #@AGA6N[^0?:T(  #!3   #P
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M0.VAL;:!W[A&*AF.?<\YF&PY+4\#N^.Y6VUR;$RV;E"UL1V;' ,A"&X^<&
MW/C#+<2 ,\!KL8J8;S9,&;W&90'3Y;SNMBWLR61Y?/ _L4"Q+^!V0]=,\C2$
MAIK-Y_@UC.%SP8T5!O!+!51E5R4:EB0Z3P!"X#$[C**&6GO$4JTX-BHI-X@#
MMF/_80 +BTC!9%L#1#);' "F[1E_ ?Z:J]1Y.I%BPK!<3^FX>%5!%?4$2S(A
M9PR>3F/I*@AZAUJ "IZX<MF[!Z1KWVBL0TP[G]Z7K[G/<=MNO_";I^M >'^(
MG16K+U<^(9Z__K7YH=%;>@D13Y?8.BK#3P7T?.!.IJR!^)& 1L^*UR'-90Z0
MX3<L[+FNF@U+=$4#2&=!,\T\C=NXD"VE<^PK_4ZW_6@!&*#*WG%;VQ&W5[8O
MA$ JG+O, ;.[U_G01C#V]TUXCU!WK^$*^@=DVH^0Z7Q8Z0S^4,OVQPZ51>JL
M6KZ> EK=;JW\#Z OT[)(N29/>U/P:=V'J?#:LS_K>&,].TRP>(>E=I%R+A7G
M.IWS"ZTPF/O>^"U3[F<BX17RXS'DM4>^4 7%2JM3(ZU&J[V KK4)5>7  SFP
MB4$F*ZRY(7$%):\BJ*\0V)]GWN;%N\!Q,<'.(]#J9N!J/+<E=YVX-C?6Q.K/
MRI6?]T&<%\Z6?;U/RG1Y)4-Q[=%,CQL(1W#OX%8^TK(.&%4Q5$V$55RKN#YO
M7!,>AH*]W;B^Z.=#-S:J#Z%U*ZN3%TV#:OI^-72PK31?Q;6*ZVN,:S5]5]/W
MBW_!3<Q91$[F)U[G[H6<Q;2H//PD#^]\51Q\FX%S5]R\^U"Q!+_Q*.S/_"J;
M_^= \5F=M_9 ,9[7D!D=,\<R=1I!LGA43.E,VVJROX_?1';X2W_??H/9?P%0
M2P,$%     @ X(9X5OB0N[]_!0  A2T   \   !M86EA+65X,S)?,2YH=&WM
M6FMSVC@4_=Y?<;>==)(9#-A 'C:;&4KH;&:WH1-HI_M1V#+65I9<60ZPOWZO
M_" /2-I9FC8T3!*(K2OIZMQSKJX?W4C'_/0%="-* OR&KF::T]/!)ZOE=!O%
M 38WRO;N1 8+2/6"T]]?QD1-F7"!9%K^QN)$*DV$]A(2!$Q,73A.YM[+?-"D
MZJ+I7%M,!%1HMUEO[GFA%-I*V;_4M?$XT5XQJ*5EXA8G<HN0Q(POW#&+:0H7
M= :7,B:B,IY(K65<VN=3$,ZFPE5L&FETH6O&J%R8$/_S5,E,!)8ON52NFD[(
M?K.6_QQX*^?L V\6,4VM-"$^=1-%K9DB2>'7C)HIW(GDP>I2;GK^^DLFM7?'
M_^)D#5*J6.C%N)(9"W3DADRC;T(C2NC]8!ZQ"=/0<NIVMV$&/>TVD@UPM8\W
M!=;'>:C:>F3[@\OQ^=OS?F]\/KR ]Q\N1Q]Z%V,8#[\+S!O3]Q=!V3Z&#_51
MO5^'T:"?(VVW.LT:]$;0.QN^'P_.=M _$O05X"?-0QB^A?$? QCU+M_T+@8C
M:_CIK\'?T.N/38O3;#K?@GR[WFFUOI)=G$W!YS3\(5E;2!43_FC@GPO  T%]
MS:2 &=,1Z(A"3XB,<+BD9K\$&<*[WGD/WC"IJ1\)7,=T48-SX==AWYB_?C5W
MFK;O]66<$+$H#@/O '#,M[@ L)O6GQ!*E0^>H$<R "K,#@QGU*?QA"IHV34,
ML>/4@*00,DZ#:W]&U,\4TPP72$0 @[D?$3&E@!/&+$V-[_AK+ .B*414473Z
MEF_%6I:NH?O@4Z59B"M),I5F6!: EG"="5Z_L@^/O#(1H$\DD(E&KVY:ES:&
MNSAA[BI1$R)H:@WGG"Z@Y^?X&>[6L)UH]PZ% W9UNU:Q#+4,B9WC/6\EHP0L
M33A9N"&G\S6,_B=+S9*J".=F5JJ)TE[.6POI%J?NA*24,T'7LOR:*T9)1WN_
M'.UO@;I$E F#B)4#^^"\=S/% YC?A/*HX]A'QX?M$Z=UU#YR.GN(X[Y]4-'A
M!@]N>[3U<+\\':,NREP29IPO,.?$"3=J7BI<T2\94S3&#JD13%JF)+NU3S"/
M*+ [^\'!4F37^6"9"TJEV2>MMF>RQ%)GB&SYN=/;<]>;\VSTQD1H)LE%9%H(
M+BW L[E^*C$2IE"-Z&)J=%<SS81SP&XX/A8 V)"@$--:WBMD@@C?G,<! Y8/
M;;9CM,IX+CZ)>WL^95HIM2P)ZO>H<6T!9V'PVB=[U47Z4J!?J^HVKJC7J>W^
M6!9>K%:2&P3.E!--[TZ%H,F$TW4YR]S3\"92!53E#IH;&DTO-[>0SS)#;; Y
M#;QB*KN99[2R _*6DR2E;DH3@D%;YJ;\AD0Q=GYC!!U0U>Q7+,7+?,[TPJWZ
MET9H%2PA*Q38J;</6T9UW88.[C'JU)LFXSUHT_H&F_;ARF3XC[KK?U3(KZ3.
MJN?KM>YT.K7J#]5=T;*DG,V$-T-,K8FBY+.;?UKFQ/HT<&6*3I_PDG(%%9=C
M%N"7H^)B[KNTK"CW(Y6PA8GP#'GMPCNB_ B<=GY]T;JAKK6$VG'@ 0X\Q2##
M2M9\(G'%0;8BJ%LH[#<+]^G%N]1QN<$N(^!T$H1:<H:5TBT0UW)C3:Q^%E=^
MW W&1V9+(VU 19<M64K1W[CI,HWA\.]=W$=. OC(M/37*6)7!>UVP%U<=W']
MOG&-61!P^NO&]5$?>#W9J#ZDUF=9ECPJ#7;[]M// \\UO^_BNHOK-L9UMV_O
M]NU'?R$O(@RS1_'HJQ\Q&L)@3OU,LRL*PS!D/E4W.;*#>R.X]]\K)GR6$+X*
M\\%#E1-^FR=A/_,-O?_S//&[@K?V>6*T+"@3,J5%RK%(B&1Q"9^119J7EMV&
M>8WZ]$6WD;]^_1]02P,$%     @ X(9X5F*R(+9\!0  ART   \   !M86EA
M+65X,S)?,BYH=&WM6FMSVC@4_=Y?<;>==)(9#-A 'C:;&9J0W>QN0R?0F>Y'
M8<M86UER91%@?_U>^4$>D+0SE&YH/$D@MJZDJW//N;I^=",=\]-7T(TH"? ;
MNIII3D_[GZR6TVWD!]C<*-J[8QDL(-4+3G]]'1,U8<(%,M7R%Q8G4FDBM)>0
M(&!BXL)Q,O=>9X,F91=-Y]IB(J!"N\UZ<\\+I=!6ROZEKHW'B?;R02TM$S<_
MD5F$)&9\X8Y83%.XHC.XEC$1I?%8:BWCPCZ;@G V$:YBDTBC"UTS1NG"F/B?
M)TI.16#YDDOEJLF8[#=KV<^!MW+./O!F$=/42A/B4S=1U)HIDN1^S:B9PAU+
M'JPNY:[G;[],I?8>^)^?K$%*%0N]&%<R8X&.W)!I]$UH1 F][\\C-F8:6DX=
M0V(&/>TVD@UPM8\W!=;'>:C:>63/^M>CRXO+L][H<G %'SY>#S_VKD8P&GP7
MF#>F[T^"LGT,'^O#^ED=AOVS#&F[U6G6H#>$WOG@PZA_7D&_)>A+P$^:AS"X
M@-'O?1CVKM_UKOI#:_#IK_[?T#L;F1:GV?RFW-*N=UJMKV079U/P.0U_2-86
M4L6$;PW\2P%X(*BOF10P8SH"'5'H"3$E'*ZIV2]!AO"^=]F#=TQJZD<"US%9
MU.!2^'78-^9OW\R=INU[9S).B%CDAX%W #CF!2X [*;U)X1298,GZ)$,@ JS
M \,Y]6D\I@I:=@U#[#@U("F$C-/@UI\A]:>*:88+)"* _MR/B)A0P ECEJ;&
M=_PUE@'1%"*J*#I]S[=\+4O7T'WPJ=(LQ)4D4Y5.L2P +>$V$[Q]8Q\>>44B
M0)]((!.-7MVU+FP,=W'"S%6BQD30U!K,.5U S\_P,]RM83O1[@,*!^SF?JUB
M&6H9$CO'>]Y*1@E8FG"R<$-.YVL8_<\T-4LJ(YR96:DF2GL9;RVD6YRZ8Y)2
MS@1=R_);KA@E'>W]=+2_!^H2428,(E8&[)/S/LP43V!^%\JCCF,?'1^V3YS6
M4?O(Z>PACOOV04F'.SRX[]'.P_WZ=(2Z*'))..5\@3DG3KA1\U+ABGZ9,D5C
M[) :P:1%2K);^P3SB *[LQ\<+$5VFP^6N:!0FGW2:GLF2RQUAL@6GY7>7KK>
MG!>C-R9",TDF(M-"<&D!GLWT4XJ1,(5J1!=3H[N::2:< W;#\;$ P(8$A9C6
MLEXA$T3XYCP.&+!L:+,=H]649^*3N+=G4Z:E4HN2H/Z(&M<6<!8&KWVR5UZD
M+P7ZM:INXXIZG=H>CV7NQ6HEN4'@3#G1]!Y4")J,.5V7L\P]#6\L54!5YJ"Y
MH='T,G,+^2RGJ TVIX&73V4WLXQ6=$#><I*DU$UI0C!HR]R4W9#(Q\YNC* #
MJIS]AJ5XF<^97KAE_\((K8(E9+D"._7V8<NHKMO0P2-&G7K39+PG;5K?8-,^
M7)D,_U$/_8]R^1746?5\O=:=3J=6_J&Z2UH6E+.9\&:(J356E'QVLT_+G%B?
M!FY,T>D37E NI^)RS!S\8E1<S&.7EB7E?J02=C 1GB.O77A/E!^!T\ZN+UIW
MU+664!4'GN# <PPRK&3-9Q)7'&0G@KJ#PGZW<)]?O L=%QOL,@).)T&H)6=8
M*=T#<2TWUL3J_^+*C[O!N&6V--(&E'39D:7D_8V;+M,8#O_1Q?TAL8*+X*(.
M[_W?S#7T.F%4Q5"U$59QK>+Z?>,:LR#@].>-ZU:?>SW;J#ZEUA=9G6R5!M7V
MO3/IX*6F^2JN55QW,:[5]EUMWUM_/2]B-(2+Y9.Q01@RGZJ[M*@0W@CA_0^*
M(;8)@KL"\\%3Q1)^FT=AF[R$NI77Q+[V1/&[HK?VB6*T+"(3,J%YFK%(B&QQ
M"9^119J5D]V&>9'Z]%6WD;V _1]02P$"% ,4    " #@AGA6-9/RXU$>  "A
M)   $@              @ $     :6UG,3$X-C$U,S4X7S N:G!G4$L! A0#
M%     @ X(9X5DVYK^/L'0  B20  !(              ( !@1X  &EM9S$Q
M.#8Q-3,U.%\Q+FIP9U!+ 0(4 Q0    ( ."&>%:LF0J6KUX  .EB   3
M          "  9T\  !I;6<Q,3@V,34S-3A?,3 N:G!G4$L! A0#%     @
MX(9X5HH49Y<6-0  3S<  !,              ( !?9L  &EM9S$Q.#8Q-3,U
M.%\Q,2YJ<&=02P$"% ,4    " #@AGA6ZZ\E)\$D  "#)P  $P
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M;6<Q,3@V,34S-3A?,BYJ<&=02P$"% ,4    " #@AGA6%+76JBC5  !\Y0
M$@              @ 'E: ( :6UG,3$X-C$U,S4X7S,N:G!G4$L! A0#%
M  @ X(9X5J6"*J.^O0  B\8  !(              ( !/3X# &EM9S$Q.#8Q
M-3,U.%\T+FIP9U!+ 0(4 Q0    ( ."&>%;2]3,5D#<! 'E8 0 2
M      "  2O\ P!I;6<Q,3@V,34S-3A?-2YJ<&=02P$"% ,4    " #@AGA6
M:\/X"HKP 0!Y @( $@              @ 'K,P4 :6UG,3$X-C$U,S4X7S8N
M:G!G4$L! A0#%     @ X(9X5N70N-T%;   ?&X  !(              ( !
MI20' &EM9S$Q.#8Q-3,U.%\W+FIP9U!+ 0(4 Q0    ( ."&>%;P635K+28
M #$H   2              "  =J0!P!I;6<Q,3@V,34S-3A?."YJ<&=02P$"
M% ,4    " #@AGA66Z0(,2U5  "J7P  $@              @ $WMP< :6UG
M,3$X-C$U,S4X7SDN:G!G4$L! A0#%     @ X(9X5A3HFGYQ>@0 MRT^ !$
M             ( !E P( &UA:6$M,C R,C$R,S$N:'1M4$L! A0#%     @
MX(9X5MR<%.*[%P  <QP! !$              ( !-(<, &UA:6$M,C R,C$R
M,S$N>'-D4$L! A0#%     @ X(9X5I:":,+N#0  Z+,  !4
M ( !'I\, &UA:6$M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( ."&>%9A
M7'LD_C8  /#E P 5              "  3^M# !M86EA+3(P,C(Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " #@AGA62#V^](3"  "+L0@ %0
M@ %PY P ;6%I82TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ X(9X5DTD
M'7D45@  YW$& !4              ( !)Z<- &UA:6$M,C R,C$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( ."&>%:[OY!]K0@  ,%,   /              "
M 6[]#0!M86EA+65X,S%?,2YH=&U02P$"% ,4    " #@AGA6!;O;Z*D(  #(
M3   #P              @ %(!@X ;6%I82UE>#,Q7S(N:'1M4$L! A0#%
M  @ X(9X5OB0N[]_!0  A2T   \              ( !'@\. &UA:6$M97@S
M,E\Q+FAT;5!+ 0(4 Q0    ( ."&>%9BLB"V? 4  (<M   /
M  "  <H4#@!M86EA+65X,S)?,BYH=&U02P4&     !H &@"$!@  <QH.

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
